Evidence Report/Technology Assessment Number 130

Management of Adnexal Mass

Prepared for:

Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov

Contract No. 290-02-0025

Prepared by: Duke Evidence-based Practice Center Durham, North Carolina

Investigators Evan R. Myers, MD, MPH Lori A. Bastian, MD, MPH Laura J. Havrilesky, MD Shalini L. Kulasingam, PhD Mishka S. Terplan, MD Kathryn E. Cline, MHS Rebecca N. Gray, DPhil Douglas C. McCrory, MD, MHS

AHRQ Publication No. 06-E004 February 2006

This report is based on research conducted by the Duke Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0025). The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

Suggested Citation:

Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, Gray RN, McCrory DC. Management of Adnexal Mass. Evidence Report/Technology Assessment No. 130 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 06-E004. Rockville, MD: Agency for Healthcare Research and Quality. February 2006.

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-Based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. This report was requested and funded by the Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion at the Centers for Disease Control and Prevention (CDC). The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.

To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation. The reports undergo peer review prior to their release.

AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality.

We welcome comments on this evidence report. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by e-mail to **epc@ahrq.gov.**

Carolyn M. Clancy, M.D. Director Agency for Healthcare Research and Quality	Jean Slutsky, P.A., M.S.P.H. Director, Center for Outcomes and Evidence Agency for Healthcare Research and Quality
Eddie Reed, M.D. Director, Division of Cancer Prevention and Control National Center for Chronic Disease Prevention and Promotion	Beth A. Collins Sharp, R.N., Ph.D. Acting Director, EPC Program Agency for Healthcare Research and Quality
Centers for Disease Control and Prevention	Susan Meikle, M.D., M.S.P.H. EPC Program Task Order Officer Agency for Healthcare Research and Quality

Acknowledgments

The authors gratefully acknowledge Jane Kolimaga and Alison Lee for assistance in study initiation; Margaret Jamison, PhD, for assistance with analysis of the Nationwide Inpatient Sample data set; and Karen Hoffman, MD, for initial work on developing the ovarian cancer natural history model. They also thank Mona Saraiya, MD, MPH, and Christie Eheman, PhD, from the Centers for Disease Control and Prevention for their valuable input.

Structured Abstract

Objectives: To assess diagnostic strategies for distinguishing benign from malignant adnexal masses.

Data Sources: MEDLINE® and reference lists of recent reviews; discharge data from the Nationwide Inpatient Sample.

Review Methods: The major diagnostic methods evaluated were bimanual pelvic examination, ultrasound (morphology and Doppler velocimetry), MRI, CT, FDG-PET, CA-125, and scoring systems that incorporated multiple clinical, laboratory, and radiologic findings. Meta-analysis using a random-effects model was used to estimate pooled sensitivity and specificity for discriminating benign from malignant. We reviewed evidence for followup strategies for masses considered benign, and for adverse outcomes of diagnostic surgery. We also reviewed published models of the natural history of ovarian cancer and compared the impact of assumptions about natural history on outcomes.

Results: The majority of studies did not describe whether patients presented with asymptomatic masses detected through screening or with symptoms. Prevalence of malignant masses in a U.S. postmenopausal screening population was approximately 0.1 percent, while benign masses were found in 0.8 to 1.8 percent of women. Pooled (a) sensitivity and (b) specificity were: bimanual exam (a) 0.45, (b) 0.90; ultrasound morphology scores (a) 0.86 to 0.91, (b) 0.68 to 0.83; Doppler resistive index (a) 0.72, (b) 0.90; pulsatility index (a) 0.80, (b) 0.73; maximum systolic velocity (a) 0.74, (b) 0.81; presence of vessels (a) 0.88, (b) 0.78; combined morphology and Doppler (a) 0.86, (b) 0.91; MRI (a) 0.91, (b) 0.88; CT (a) 0.90, (b) 0.75; FDG-PET (a) 0.67, (b) 0.79; and CA-125 (a) 0.78, (b) 0.78. Both sensitivity and specificity of CA-125 were better in postmenopausal than in premenopausal women. In modeled outcomes, combinations of imaging and CA-125 were both more sensitive and more specific than either alone. Performance of scoring systems in validation studies was consistently worse than in development studies; the highest demonstrated specificity observed was 0.91, with a concurrent sensitivity of 0.74. Evidence on followup strategies was sparse, although one large study provided good evidence for safely following unilocular cysts less than 10 cm in diameter. Overall complication rates in studies of surgically managed adnexal masses were low, but important clinical information was not reported.

Conclusions: All diagnostic modalities showed trade-offs between sensitivity and specificity, but the available literature does not provide sufficient detail on relevant characteristics of study populations to allow confident estimation of the results of alternative diagnostic strategies. Although modeling studies may prove useful in evaluating diagnostic algorithms, further work is needed to explore the implications of uncertainty about the natural history of ovarian cancer.

Contents

Executive Summary	1
Evidence Report	7
Chapter 1. Introduction	9
Ovarian Tumors	9
Definition of an Adnexal Mass	11
Detection of an Adnexal Mass	11
Types of Adnexal Mass	12
Management of the Adnexal Mass	12
Importance of Discriminating Benign from Malignant Masses	13
Significance of Clinical Presentation in Evaluation of Management Strategies	13
Summary	15
Chapter 2. Methods	
Topic Assessment and Refinement	17
Analytic Framework	
Literature Search and Review	21
Sources	21
Search Strategies	21
Abstract and Full-text Screening	21
Full-text Screening Criteria	
Data Abstraction and Development of Evidence Tables	24
Quality Assessment Criteria	
Additional Analyses	
Test Characteristics and Confidence Intervals	
Prevalence and Event Rates and Confidence Intervals	
Estimation of Pooled Sensitivity and Specificity	
Estimates of National Rates of Surgery for Adnexal Mass	
Model of Natural History of Ovarian Cancer	
Peer Review Process	
Chapter 3. Results	
Question 1: Prevalence of Tumor Types	
Approach	
Results	
Discussion	
Summary	
Question 2: Bimanual Pelvic Examination	
Approach	
Results of Literature Search and Screening	
Study Characteristics	
Results	

Discussion	41
Question 3: Single Modality Tests	42
Approach	42
Results of Literature Search and Screening	43
Ultrasound Morphology	
Ultrasound Doppler Studies	53
Combined Ultrasound Morphology and Doppler	61
3D Versus 2D Ultrasound	63
Other Imaging Modalities	64
Serum Markers: CA-125	66
Other Serum Markers	69
Population-based Studies	70
Methodological Issues	72
Summary	74
Question 4: Explicit Scoring Systems	75
Approach	75
Results of Literature Search and Screening	76
Study Characteristics	
Diagnostic Accuracy of Scoring Systems	77
Discussion	86
Question 5: Monitoring Women with Suspected Benign Masses	
Approach	
Results	
Discussion	91
Question 6: Surgical Morbidity and Mortality	92
Approach	92
Results of Literature Search and Screening	93
Methodological Quality of Included Studies	93
Results	93
Nationwide Inpatient Sample	95
Other Outcomes	97
Discussion	
Summary	
Question 7: Modeling Diagnostic Strategies	99
Approach	
Predicting Outcomes of Management Strategies	
Models of Ovarian Cancer: Literature Review	
Discussion	107
Summary	111
Charten A. Diamarian	110
Chapter 4. Discussion	
Limitations of the Report	
Methodological Issues in the Literature	
Description of the Patient Population	
Sample Size	115

Blinding	115
Observer Variability	115
Natural History of Ovarian Cancer	115
Implications of Findings	115
Question 1	
Question 2	
Question 3	116
Question 4	116
Question 5	
Question 6	116
Question 7	
Chapter 5. Future Research	119
Minimal Data Reporting	
Prevalence of Different Types of Adnexal Masses	
Diagnostic Testing	119
Scoring Systems	
Followup Studies	
Adverse Outcomes of Surgery	120
Sensitivity and Specificity of the Pelvic Examination	121
Modeling the Outcomes of Different Screening Strategies	122
Modeling the Natural History of Ovarian Cancer	
Chapter 6. Conclusions	123
References and Included Studies	
List of Acronyms/Abbreviations	145
-	

Figures

Figure 1. U.S. ovarian cancer incidence by age and race, 1992-2002	9
Figure 2. Analytic framework for evidence report	19
Figure 3. Schematic of natural history model	30
Figure 4. Performance of bimanual pelvic examination for detecting the presence of	
an adnexal mass	39
Figure 5. Performance of bimanual pelvic exam for distinguishing benign from malignant	
adnexal masses	41
Figure 6. Performance of ultrasound scoring according to Sassone's criteria (1991)	47
Figure 7. Performance of ultrasound scoring according to DePriest's criteria (1993)	48
Figure 8. Performance of ultrasound scoring according to Ferrazzi's criteria (1997)	49
Figure 9. Performance of ultrasound scoring according to Finkler's criteria (1988)	50
Figure 10. Performance of ultrasound scoring according to various other unvalidated	
criteria	51
Figure 11. Performance of Doppler ultrasound resistance index	56

Figure 12. Performance of Doppler ultrasound pulsatility index	57
Figure 13. Performance of Doppler ultrasound velocity indices	58
Figure 14. Performance of Doppler ultrasound for intratumoral blood flow	60
Figure 15. Performance of combined ultrasound morphology and color Doppler	62
Figure 16. Performance of CA-125	68
Figure 17. Performance of RMI model of Jacobs et al. (1990) in development set and	
subsequent validation studies using cutoff score of 200	79
Figure 18. Performance of RMI2 model of Tingulstad et al. (1996) in development	
set and subsequent validation studies using cutoff score of 200	80
Figure 19. Performance of model of Tailor et al. (1999) in development set and	
subsequent validation studies	81
Figure 20. Performance of various other scoring systems in development and validation	
studies in separate populations	83
Figure 21. Performance of various other unvalidated models	84
Figure 22. Performance of unvalidated simple combination rules in postmenopausal	
women only	85
Figure 23. Performance of unvalidated simple combination rules in mixed pre- and	
postmenopausal populations	86
Figure 24. Schematic of Markov or stochastic model of ovarian cancer natural history	119
Figure 25. Alternative model of ovarian cancer history	119
Figure 26. Model predictions of ovarian cancer incidence (black triangles) compared	
to SEER incidence rates	119

Tables

Table 1. Age-adjusted annual U.S. incidence and mortality per 100,000 women	
by race and ethnicity, 1992-2002	10
Table 2. Results of abstract screening and full-text review	
Table 3. Included full-text articles by research question	24
Table 4. Model variables	31
Table 5. Prevalence of tumor types in screening studies	34
Table 6. Case series and retrospective medical record reviews	34
Table 7. Sensitivity and specificity of pelvic examination in detecting the presence	
of an adnexal mass	38
Table 8. Sensitivity and specificity of pelvic examination in discriminating benign from	
malignant adnexal masses	40
Table 9. Detailed description of ultrasound scoring systems	44
Table 10. Sensitivity and specificity of ultrasound morphology	46
Table 11. Ultrasound morphology assessment comparing pre- and postmenopausal	
status	52
Table 12. Sensitivity and specificity of Doppler studies	55
Table 13. Study characteristics of simple Doppler visualization	59
Table 14. Doppler studies stratified by menopausal status	61
Table 15. 3D versus 2D ultrasound.	63
Table 16. Sensitivity and specificity of other imaging modalities	65

Table 17.	Comparison of MRI, CT, FDG-PET, and ultrasound	65
Table 18.	CA-125 results stratified by menopausal status	69
Table 19.	Population-based screening studies	71
Table 20.	Effect of classification of LMP tumors as malignant or benign on diagnostic	
test ch	aracteristics	73
Table 21.	Pooled sensitivity and specificity estimates	74
Table 22.	Performance of other scoring systems at initial derivation and subsequent	
replica	tion in another population	82
Table 23.	Studies of followup regimens for benign-appearing lesions	88
Table 24.	Morbidity in series of patients undergoing surgical management of adnexal	
masse	S	94
Table 25.	Estimated U.S. discharges for exploratory laparotomy and diagnostic	
laparo	scopy with discharge diagnoses consistent with adnexal mass, with mortality	
and co	mplication rates	96
	Estimates for key model parameters1	
Table 26. Table 27.	Estimates for key model parameters	00
Table 26. Table 27. surgica	Estimates for key model parameters	00
Table 26. Table 27. surgica Table 28.	Estimates for key model parameters	00
Table 26. Table 27. surgica Table 28.	Estimates for key model parameters	00
Table 26. Table 27. surgica Table 28. Doppl	Estimates for key model parameters	00
Table 26. Table 27. surgica Table 28. Doppl cohort Table 29.	Estimates for key model parameters	00 01 02
Table 26. Table 27. surgic: Table 28. Doppl cohort Table 29. Table 30.	Estimates for key model parameters	00 01 02
Table 26. Table 27. surgic: Table 28. Doppl cohort Table 29. Table 30.	Estimates for key model parameters	00 01 02
Table 26. Table 27. surgica Table 28. Doppl cohort Table 29. Table 30. in 1,10 cancer	Estimates for key model parameters	100 101 102 103
Table 26. Table 27. surgica Table 28. Doppl cohort Table 29. Table 30. in 1,10 cancer	Estimates for key model parameters	100 101 102 103
Table 26. Table 27. surgic: Table 28. Doppl cohort Table 29. Table 30. in 1,10 cancer Table 31. Table 32.	Estimates for key model parameters	100 101 102 103
Table 26. Table 27. surgic: Table 28. Doppl cohort Table 29. Table 30. in 1,10 cancer Table 31. Table 32. the Ur	Estimates for key model parameters	100 101 102 103 103 105

Appendixes

Appendix B: List of Excluded Studies

Appendix C: Sample Data Abstraction Forms

Appendix D: Evidence Tables

Appendix E: Peer Reviewers

The Appendixes and Evidence Tables cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/adnexal/adnexal.pdf

Executive Summary

Introduction

Ovarian cancer is the leading cause of cancer death from gynecologic malignancies in the United States, with an annual incidence of over 25,000 and an annual mortality of approximately 14,000. Cancer incidence increases dramatically with age.

The high case-fatality rate has largely been attributed to the fact that most ovarian cancers are diagnosed in advanced stages (Stage III, where the cancer has spread beyond the pelvis to organs of the upper abdominal cavity, and Stage IV, where the cancer has spread outside of the peritoneal cavity), when survival is poor. Stage I cancer (limited to the ovaries) has a survival rate of over 90 percent. Thus, there has long been an emphasis on early detection of ovarian cancer in the belief that detection in early stages will lead to decreases in morbidity and mortality. The detection of a mass in the area of the ovaries and fallopian tubes (the uterine adnexae) raises the possibility of ovarian cancer, which necessitates further study to rule out malignancy.

There are two main clinical routes by which an adnexal mass may be detected: (1) women with symptoms may have an adnexal mass detected as part of their evaluation for those symptoms, either by physical exam or radiographic imaging; (2) the mass may be detected during bimanual pelvic examination or radiologic imaging as part of a routine health maintenance examination.

For the purposes of this evidence report, we define an adnexal mass as an enlarged structure in the uterine adnexa that can either be palpated on a bimanual pelvic examination or visualized using radiographic imaging.

There are a number of conditions that can be associated with an adnexal mass. These include malignancies arising from the ovary and fallopian tube, or metastatic disease from another site (such as the breast or gastrointestinal tract), as well as a wide range of benign conditions. For the purposes of this evidence report, "management" of the adnexal mass refers to the process by which a mass is ultimately classified as benign or malignant.

The clinical significance of discriminating benign from malignant masses differs depending on the clinical setting in which the mass is initially detected. For women with symptoms, in whom surgical management may be appropriate whether or not the mass is malignant, the main reason to discriminate between benign and malignant lesions is to facilitate referral and management by clinicians who have specialized training and experience in managing ovarian malignancy, with improved outcomes. For asymptomatic women, discriminating benign from malignant disease is important both to ensure appropriate management in the setting of malignancy, but also to avoid unnecessary diagnostic procedures, including surgery, in women with asymptomatic, nonmalignant conditions.

The prevalence of malignancy may differ between women with symptomatic and asymptomatic masses, which may in turn affect the positive and negative predictive value of a test, and, potentially, sensitivity and specificity as well. Prevalence also varies with age and with family history.

This report focuses on the evidence relevant to establishing the most appropriate way to distinguish benign from malignant adnexal masses in both symptomatic and asymptomatic women. A key consideration throughout the report will be the underlying likelihood of

malignancy in the populations studied, and the impact of this prevalence on the interpretation of the results of the reviewed studies. The results of this report are intended primarily to (a) provide a resource for clinicians and policymakers developing guidelines on management of adnexal masses, and (b) provide a resource for researchers and funding agencies in identifying gaps in our knowledge and research priorities.

Methods

Working with the Agency for Healthcare Research and Quality (AHRQ), the Centers for Disease Control and Prevention (CDC), and members of the technical expert panel, we developed seven questions to be addressed, using an analytic framework which incorporated prior probability of disease, test results, and outcomes of diagnostic surgery.

We searched MEDLINE[®] (1966-September 2004) and the Cochrane Database of Systematic Reviews. Searches of these databases were supplemented by reviews of reference lists contained in all included articles and in relevant review articles and meta-analyses. The searches yielded a total of 1,023 citations. Pairs of readers reviewed each abstract and selected 445 articles for full text review. Specific inclusion criteria were developed for each question, and both readers were required to agree on inclusion.

We developed tables to abstract each article, and quality criteria for each question. For studies of diagnostic tests, 2-by-2 tables were constructed for each included article, and sensitivity, specificity, and positive and negative predictive values, with 95 percent confidence intervals (CIs) for each, were calculated. If not provided, we also calculated 95% CIs for articles about prevalence and adverse event rates during diagnostic surgery. For diagnostic tests, pooled estimates of sensitivity and specificity were calculated using a random-effects model.

We performed three supplemental analyses. First, we used the Nationwide Inpatient Sample (NIS), a nationally representative database containing discharge data from approximately 20 percent of U.S. hospitals. Using *International Classification of Diseases, Ninth Revision* (ICD-9) codes and the provided corrections for sample weighting, we estimated the number of cases of women 15 and older undergoing diagnostic laparoscopy and exploratory laparotomy in 2000 and 2001 for diagnoses consistent with an adnexal mass. Mortality and morbidity rates for each type of procedure within each diagnosis were also estimated.

Second, we performed a simple decision model based on serial or parallel testing using the pooled sensitivity and specificity of various tests to predict outcomes.

Finally, we used a previously developed Markov model of the natural history of ovarian cancer to explore the implications of alternative possible pathways in the development of advanced disease – specifically, that some cancers limited to the ovaries (Stage I) may spread to the upper abdomen (Stage III) without first spreading to other pelvic organs (Stage II).

Results

Question 1: What is the prevalence of various tumor types among women with an adnexal mass, stratified by cancer status (malignant vs. benign), age, menopausal status, and size of tumor?

In a large screening study in Kentucky the prevalence of malignant masses was 0.09 to 0.18 percent, and of benign masses 0.8 to 1.8 percent. In 16 case series, the prevalence of malignancy

ranged from 0 to 57 percent, reflecting differences in the referral patterns of the centers where the surgery was performed. The prevalences of specific types of masses also varied widely within studies. Six studies did not report the proportion of women who were postmenopausal, and none of them described whether patients were symptomatic or asymptomatic, or the type of evaluation they had undergone prior to surgery.

Question 2: What are the sensitivity, specificity, and reliability of the bimanual pelvic examination?

Pooled sensitivity in five studies for detection of an adnexal mass was 0.45, and pooled specificity 0.90. For distinguishing a benign from a malignant mass, pooled sensitivity in 10 studies was 0.72, specificity 0.92. When only screening studies were included, pooled sensitivity was 0.58, specificity 0.98.

Question 3: Among women with a palpable adnexal mass on exam or a mass identified by ultrasound/imaging, what is the sensitivity/specificity of various evaluation modalities including ultrasound (transvaginal ultrasound, transabdominal ultrasound, color Doppler, twodimensional [2D] vs. three-dimensional [3D] ultrasound), computer tomography (CT) scan, magnetic resonance imaging (MRI) scan, and CA-125 levels for distinguishing benign from malignant masses?

A total of 153 articles were included. For morphologic appearance on ultrasound, pooled sensitivities for specific scoring systems ranged from 0.82 to 0.91, and specificities from 0.68 to 0.81. For Doppler ovarian blood flow studies, pooled (a) sensitivity and (b) specificity were: resistive index (a) 0.72, (b) 0.90; pulsatility index (a) 0.80, (b) 0.73; maximum systolic velocity (a) 0.74, (b) 0.81; presence of vessels (a) 0.88, (b) 0.78. The combination of morphology and Doppler had pooled sensitivity of 0.86 and specificity of 0.91.

Pooled (a) sensitivities and (b) specificities of other imaging modalities were: MRI (a) 0.91, (b) 0.88; CT (a) 0.90, (b) 0.75; and positron emission tomography using an 18-Fluorodeoxyglucose tracer (FDG-PET) (a) 0.67, (b) 0.79.

Pooled sensitivity and specificity for CA-125 at a threshold of 35 U/mL were 0.78 and 0.78, respectively. In studies that compared performance by menopausal status, both sensitivity and specificity were substantially better in postmenopausal women.

Characterization of the patient population with respect to presence or absence of symptoms, or previously performed tests, was uniformly poor among studies.

Question 4: What is the accuracy of explicit scoring systems which incorporate various combinations of imaging findings, patient risk factors, and/or CA-125 levels for detecting malignancy? Have these scoring systems been applied to a population of women before laparoscopy or laparotomy?

We identified 36 studies. Existing validated scoring systems were all developed in mixed pre- and postmenopausal populations. The highest demonstrated specificity obtained with these scoring systems appears to be in the range of 90 to 95 percent, and, at this range of specificity, the sensitivity appears to be in the range of 65 to 80 percent. Performance was consistently worse in validation studies (done to confirm the performance of the scoring system) than in development studies. Many of the studies were applied to patients immediately prior to surgery, but the clinical presentation and prior testing were not described.

Question 5: Among women with suspected benign masses on initial investigation, what are the sensitivity and specificity of monitoring with periodic CA-125 and/or interval ultrasound examinations for detecting malignant masses? How does the interval of testing/definition of change affect sensitivity and predictive value? Nine studies were identified, and, because of variable definitions and methods, no definitive conclusions could be drawn. In one large study of over 15,000 postmenopausal women, no cancers were ultimately diagnosed in a unilocular cyst less than 10 cm (2,763 women) over a mean followup of 6.3 years, although three cancers developed after resolution of the cyst or in the contralateral ovary.

Question 6: Among women with adnexal masses, what are the morbidity and mortality from diagnostic surgery (laparoscopy or laparotomy)? At what point does the risk of surgery outweigh the risk of detecting malignancy?

In 15 series totaling 4,915 patients, there were three deaths. Morbidity rates were also low. Comparative studies suggest lower morbidity with laparoscopy, but there is potential confounding, even in randomized studies. None of the included studies provided sufficient clinical detail to determine whether risks differed based on ultimate diagnosis.

In the NIS, both morbidity and mortality were highest in cases with a cancer diagnosis, but available codes prevented direct comparisons. In addition, because outpatient laparoscopic procedures were not included, both numerators and denominators are likely to be underestimated.

Question 7: What are the estimated trade-offs resulting from various strategies for evaluation of the adnexal mass?

Given the summary findings, we were unable to construct comprehensive models to estimate the likely outcomes of different strategies. In a preliminary model, serial testing with the best imaging study (morphology plus Doppler), followed by CA-125, resulted in fewer missed cancers and fewer surgeries than either test alone in postmenopausal women. Parallel testing incorporated into a scoring system resulted in slightly fewer missed cancers, but more surgeries and twice as many tests.

Because comprehensive models should ultimately include the natural history of ovarian cancer and the possible effects of screening, we identified three articles that simulated this natural history. All three assumed that ovarian cancer necessarily progresses through all four stages. Using a similarly structured model, we were able to generate estimated incidence and stage distribution similar to reported data by allowing some Stage I cancers to progress directly to Stage III. By reducing the available detection time for Stage I cancers, this would adversely affect the potential effectiveness of screening.

Discussion

Limitations of the Literature

The main limitation in the literature was the failure to adequately describe relevant patient characteristics, including the presence or absence of symptoms, and variable reporting of menopausal status. Inadequate sample size, lack of blinding, and failure to account for observer variability were also common limitations.

Limitations of the Report

The report did not include non-English publications. We did not include non-U.S. studies in our review of the prevalence of different types of adnexal mass. Given the heterogeneity of

studies, pooled estimation of sensitivity and specificity may not be appropriate. The NIS does not include outpatient procedures, and our coding algorithm may have missed some complications.

Future Research

Research priorities include: a minimal consensus data set on key patient characteristics (with results presented stratified by those characteristics); better estimates of prevalence and surgical outcomes using data sources that capture inpatient and outpatient encounters, such as Medicare or health maintenance organizations; better characterization of patient characteristics in all studies; better evidence on the value of the pelvic exam as part of routine health maintenance; and development of additional models for simulating the natural history of ovarian cancer and evaluating screening, diagnosis, and treatment strategies.

Conclusions

Developing an effective and efficient algorithm for the evaluation of any condition requires good evidence on the prevalence of the condition at the first diagnostic encounter, and the sensitivity and specificity of the potential diagnostic tests to be used. Unfortunately, the overwhelming majority of the literature we reviewed did not provide sufficient detail on important patient characteristics to allow estimation of the outcomes of different diagnostic strategies, either in the context of detecting adnexal masses or distinguishing benign from malignant masses.

All of the diagnostic tests and scoring systems we evaluated exhibited a trade-off between sensitivity and specificity – studies of a given test that reported higher sensitivity had lower specificity, and vice versa. The bimanual pelvic examination has low sensitivity for both detection of adnexal masses and discriminating benign from malignant masses, raising doubts about its utility as a screening test in asymptomatic women. In pooled analysis, the combination of ultrasound morphology and Doppler blood flow had the best combination of sensitivity and specificity, with MRI comparable. In a preliminary model, serial testing with imaging followed by CA-125 was both more sensitive and more specific than either test alone; parallel testing using both tests incorporated into the Risk of Malignancy Index resulted in fewer missed cancers (greater sensitivity) but more surgeries (lower specificity), with twice as many tests.

Studies of surgical management suffered from the same limitations in terms of description of patient characteristics, making estimation of the risks of false positive diagnostic testing impossible.


Ultimately, evaluation of potential strategies for reducing morbidity and mortality from ovarian cancer may require use of simulation models, a technique that has proven helpful in evaluating prevention strategies for other cancers. Because the natural history of ovarian cancer is relatively unknown, testing of alternative models is critical. Although a few sophisticated models exist, development of additional models would be helpful, especially in the context of evaluating results from ongoing trials of screening. If any of these trials show a benefit from screening, then the need for better evidence on the diagnostic evaluation of adnexal masses will become even more critical.


EVIDENCE REPORT

Chapter 1. Introduction

Ovarian Tumors

Cancer of the ovaries is the leading cause of cancer death from gynecologic malignancies in the United States, with an annual incidence of over 25,000 and an annual mortality of approximately 14,000.¹ Cancer incidence increases dramatically with age, being relatively rare prior to age 50 (Figure 1).





Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov).²

Ovarian cancer incidence varies by race and ethnicity. Both incidence and mortality are highest for white women (Table 1).

Table 1. Age-adjusted annual U.S. incidence and mortality per 100,000 women by race and ethnicity, 1992-2002 †

	White	African- American	Asian/Pacific Islander	Native American	Hispanic
Incidence	15.1	10.3	10.4	8.9	11.9
Mortality	9.3	7.6	4.8	5.1	6.2

[†]Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov).²

Malignant tumors of the ovary can either arise in the ovary (primary ovarian cancer) or be the result of metastasis from another site, such as the breast or colon. Primary ovarian tumors, whether benign or malignant, can arise from three broad types of cells: the cells on the surface (epithelial cells); the cells that form eggs (germ cells); and the cells surrounding the eggs, including the cells that produce ovarian hormones (sex cord-stromal cells). Epithelial tumors are the most common type, accounting for 60 percent of all ovarian tumors and up to 90 percent of primary cancers. Sex-cord-stromal tumors account for 10 to 15 percent of all tumors, while germ cell tumors are relatively more common in younger premenopausal women. Thus, although ovarian cancer is relatively rare in younger women, when it does occur it is more likely to be a non-epithelial cancer than cancers in postmenopausal women.³

Within the broad classification of epithelial, sex cord-stromal, and germ cell tumors, tumors are further classified by the individual cell types from which they are derived. For example, the most common epithelial tumors are serous and mucinous tumors, the most common sex-cord stromal tumors are fibromas (arising from the connective tissue surrounding eggs), and the most common germ cell tumors are teratomas. Within each histological class, tumors can be benign or malignant, based on their ability to metastasize.³

Some epithelial tumors are classified as "borderline" or "low malignant potential" (LMP) tumors. These are tumors in which there is no invasion into the ovarian stroma, but for which histologic evidence of proliferation exists (increased cell division, changes in the appearance of the cell nucleus). There is controversy over whether these tumors represent pre-invasive cancer, and, if untreated, would go on to become a cancer, or whether they represent a subtype of tumor that has a relatively small chance of becoming a cancer.³ In estimating the diagnostic accuracy of tests for determining whether a mass is benign or malignant, whether LMP tumors are classified as benign or malignant can have an effect on the estimates of test performance, as we will discuss later in the report.

Ovarian cancer spreads primarily by dissemination throughout the peritoneal cavity; common sites of metastasis are the small and large bowel, the omentum, the liver, and the diaphragm. Spread to retroperitoneal lymph nodes is also common.

Treatment for ovarian cancer consists of surgical removal of the ovaries, fallopian tubes, and uterus (if present), along with as much metastatic disease as possible; if there is no obvious spread beyond the ovaries, the lymph nodes are sampled to determine if there has been lymphatic metastasis. Surgery is followed by chemotherapy, with responsiveness to chemotherapy depending on the amount of tumor left after surgical removal and the cell type of tumor, among other factors.³

The high case-fatality rate observed in ovarian cancer has largely been attributed to the fact that most ovarian cancers are diagnosed in advanced stages (Stage III, where the cancer has spread beyond the pelvis to organs of the upper abdominal cavity, and Stage IV, where the cancer has spread outside of the peritoneal cavity), when survival is poor. Stage I cancer (limited to the ovaries) has a survival rate of over 90 percent. Thus, there has long been an emphasis on early detection of ovarian cancer, in the belief that detection in early stages will lead to decreases in morbidity and mortality, just as cervical cancer. The detection of a mass in the area of the ovaries and fallopian tubes (the uterine adnexae) raises the possibility of ovarian cancer, which necessitates further study to rule out malignancy.

This evidence report was prepared by the Duke Evidence-based Practice Center, in partnership with the Centers for Disease Control and Prevention (CDC) and the Agency for Healthcare Research and Quality (AHRQ). The purpose of the report is to provide followup data regarding key issues identified at two conferences sponsored by CDC, one in November 2000 on broad issues in preventing morbidity and mortality from ovarian cancer,⁴ and one in May 2002 on the use of ultrasound in the diagnosis of ovarian cancer.⁵

Definition of an Adnexal Mass

For the purposes of this report, we define an adnexal mass as an enlarged structure in the uterine adnexa which can either be palpated on a bimanual pelvic examination or visualized using radiographic imaging. The normal ovary is approximately 3 cm in length, decreasing in size after menopause.⁶ In terms of physical examination, the precise size definition used in the literature is quite variable and, in practice, may also vary depending on the ease with which the examination is performed, the patient's body habitus, the examiner's experience, the time taken during the exam, and the presence of other abnormalities such as uterine fibroids. Historically, because of the decrease in size after menopause, any palpable mass in a postmenopausal woman has been considered abnormal (the "palpable postmenopausal ovary syndrome").⁷ As discussed below, some masses may ultimately prove to not be ovarian in origin.

The definition of an abnormal structure on radiologic imaging is also quite variable. Small fluid-filled cysts are quite common in both pre- and postmenopausal women. For the purposes of this report, we consider any structure observed during radiologic imaging that prompts additional evaluation (such as measurement of serologic markers or further imaging) as a mass.

Detection of an Adnexal Mass

There are three main clinical routes by which an adnexal mass may be detected. First, women with symptoms may have an adnexal mass detected as part of their evaluation for those symptoms, either by physical exam or radiographic imaging. Because ovarian cancer often presents with vague abdominal symptoms, we would consider any evaluation for symptoms to be in symptomatic women. Second, the mass may be detected as part of a routine health maintenance examination. Finally, it is possible that an asymptomatic mass could be detected during imaging done for another indication. In premenopausal women, the most likely scenario where this would occur would be during ultrasound evaluation during pregnancy. Another common scenario in peri- or postmenopausal women would be evaluation for uterine bleeding;

because uterine bleeding is not a common symptom of ovarian cancer, a finding of an adnexal mass during evaluation for bleeding could be considered as an incidental finding. Because malignancy is rare during pregnancy, and because the technical considerations for both diagnosis and management are different, the most appropriate management of masses detected during pregnancy, especially if detected serendipitously by ultrasound, is outside of the scope of this report.

We did not identify any literature that would allow an estimate of the proportions of women with adnexal masses presenting by each route; as we will discuss, this is a major deficiency of the literature. The proportions are likely to vary by setting, referral patterns, patient thresholds for seeking care, physician thresholds for diagnostic tests, and other factors. For example, one gynecologic oncologist estimated that well over half of the referrals for evaluation in a large health maintenance organization were for incidentally detected masses (W. Kinney, personal communication).

Types of Adnexal Mass

Conditions that can present as an adnexal mass include:

- Benign primary ovarian tumors epithelial, sex cord-stromal, and germ cell;
- Borderline and malignant ovarian tumors epithelial, sex cord-stromal, and germ cell;
- Metastatic malignant tumors most commonly breast and gastrointestinal tract;
- Masses arising from the fallopian tube most commonly benign, including hydrosalpinx (a large, fluid-filled fallopian tube) and pyosalpinx (an infected, pus-filled fallopian tube); primary fallopian tube malignancies can occur, but are relatively rare.
- Masses arising from the uterus most commonly benign leiomyomas (fibroids);
- Masses arising from the gastrointestinal tract diverticula of the colon, large colonic tumors, tumors of the appendix;
- Masses arising from the urinary tract pelvic kidneys, diverticula of the ureter;
- Masses arising from remnants of embryological development;
- Endometriosis;
- Pelvic inflammatory disease;
- Cysts arising from normal ovarian functions, such as development of eggs (follicular cysts) and ovulation (corpus luteum cysts).

Management of the Adnexal Mass

With such a wide range of potential causes, and with a wide range of appropriate therapeutic options, precise diagnosis of a mass, especially in symptomatic women, is important. Once diagnosed, a mass may be managed in a variety of ways, ranging from observation to surgical removal and chemotherapy. However, a review of the test characteristics of various methods for obtaining precise diagnoses of specific conditions, and of the range of medical and surgical treatment options for each condition, is beyond the scope of this report. For our purposes, "management" of the adnexal mass refers to the process by which a mass is ultimately classified as benign or malignant.

Importance of Discriminating Benign from Malignant Masses

The clinical significance of discriminating benign from malignant masses differs depending on the clinical setting in which the mass is initially detected.

In women who initially present with symptoms, diagnosis of the underlying cause of the mass is important since it may help define available treatment options. Although medical therapy may relieve symptoms in some cases, surgical management is the treatment of choice for many conditions. Because surgery may ultimately be the most appropriate management for symptomatic adnexal masses, the main reason to discriminate between benign and malignant lesions is to facilitate referral and management by clinicians with specialized training and experience in managing ovarian malignancy, with improved outcomes.⁸⁻¹⁰

The other main group of women with adnexal masses consists of those without symptoms who have a mass detected through either physical examination or imaging. No organization currently recommends routine screening with serum markers or imaging for ovarian cancer.^{11,12} The U.S. Preventive Services Task Force gives screening (including serum markers, imaging, or pelvic examination) a "D" recommendation (fair evidence against screening).¹³ However, because an annual pelvic examination continues to be recommended by professional organizations such as the American College of Obstetricians and Gynecologists (ACOG),^{11,14} many asymptomatic women may have an adnexal mass detected during a periodic health maintenance examination. In this setting, discriminating benign from malignant disease is important not only to ensure appropriate management in the setting of malignancy, but also to avoid unnecessary diagnostic procedures, including surgery, and anxiety in women with asymptomatic, nonmalignant conditions. In some cases, there may be a rationale for removing certain asymptomatic benign lesions, including prevention of malignant transformation; prevention of ovarian torsion (a condition where the ovary twists and occludes its blood supply, causing abdominal pain and possibly resulting in loss of ovarian function); prevention of rupture, which might lead to acute symptoms or a worse prognosis (for example, in the case of endometriosis); prevention of more advanced or complicated surgery for a larger mass or more extensive pathologic process after the development of symptoms; and, for premenopausal women, possible enhancement of fertility. A review of the evidence (or lack of evidence) supporting these rationales is beyond the scope of this report.

Significance of Clinical Presentation in Evaluation of Management Strategies

As discussed above, the results of tests used to distinguish benign from malignant disease have different implications depending on whether the patient is symptomatic or asymptomatic. However, clinical presentation also has implications for interpretation of test results.

Diagnostic or screening tests are most commonly characterized by their sensitivity and specificity. The sensitivity of a test is the probability that, given the underlying presence of the disease, the test result will be positive; 100 percent minus the sensitivity is commonly called the false negative rate. The specificity of the test is the probability that, given the underlying absence of disease, the test result will be negative; 100 percent minus the specificity is

commonly called the false positive rate. In an ideal evaluation, the sensitivity and specificity of the test are independent of the underlying probability, or prevalence, of disease.

Clinically, the more common scenario is that the clinician is aware of the test result and needs to know the probability of the presence or absence of disease. In this setting, the positive and negative predictive values of the test are more important.

The negative predictive value of a test is the probability that, given a negative test result, the patient truly does not have disease. It is a function of three parameters: the pretest probability of the disease, the sensitivity of the test, and the specificity of test:

(1 - Prevalence) * Specificity [(1 - Prevalence) * Specificity] + [Prevalence * (1 - Sensitivity)]

As can be seen in the equation, the negative predictive value is much more dependent on test sensitivity than test specificity. Negative predictive value will be high when test sensitivity is high, and when prevalence is low (i.e., disease is rare).

Similarly, the positive predictive value is the probability that, given a positive test result, the patient actually has the disease. It is also a function of prevalence, sensitivity, and specificity:

Positive predictive value is high when a test has high specificity, or when prevalence is high (disease is common).

For any given test, the positive predictive value will be higher and the negative predictive value lower when used in populations where the disease is common compared to populations where the disease is rare, while the positive predictive value will decrease and the negative predictive value increase as the disease becomes less common. This effect of prevalence on predictive values is independent of test sensitivity and specificity. The significance of the prevalence of disease in the population in which test characteristics are being evaluated is even more critical because, under some types of study design, disease prevalence can also affect estimates of sensitivity and specificity.¹⁵

Therefore, variations in the prevalence of malignancy among women with different clinical presentations will affect at least predictive values, and possibly sensitivity and specificity estimates. The prevalence of ovarian cancer clearly rises with age, so age and/or menopausal status are important considerations in evaluating management strategies in both the symptomatic and asymptomatic patient with an adnexal mass.

The prevalence of malignancy among asymptomatic women with an adnexal mass will be a function of the underlying prevalence or incidence of malignancy and the test characteristics of the initial test used to detect the mass. Evaluation of the different screening tests and strategies for early detection of ovarian cancer is beyond the scope of this report, especially since there are at least three large trials still ongoing.¹⁶⁻¹⁸ However, in order to properly interpret the results of tests performed in asymptomatic women with pelvic masses, some estimate of the underlying probability of malignancy among these women is needed. Since many of these women are likely identified through a bimanual pelvic examination, deriving this estimate requires an assessment of the sensitivity and specificity of the pelvic examination. Symptomatic patients may be more likely to have an underlying adnexal malignancy, especially among postmenopausal women.¹⁹

In any series of women with adnexal masses, the proportion of women who are symptomatic and asymptomatic will likely determine the prevalence, and thus the predictive values of the diagnostic tests used to evaluate the mass.

Summary

In summary, this report focuses on the evidence relevant to establishing the most appropriate way to distinguish benign from malignant adnexal masses in both symptomatic and asymptomatic women. A key consideration throughout the report will be the underlying likelihood of malignancy in the populations studied, and the impact of this prevalence on the interpretation of the results of the reviewed studies. The results of this report are intended primarily to (a) provide a resource for clinicians and policymakers developing guidelines on management of adnexal masses, and (b) provide a resource for researchers and funding agencies in identifying gaps in our knowledge and research priorities.

Chapter 2. Methods

This section of the report describes the basic methodology used to develop the evidence report, including topic assessment and refinement, analytic framework, literature search strategies and results, literature screening and grading process and criteria, data abstraction and analysis methods, and quality control procedures.

Topic Assessment and Refinement

The Centers for Disease Control and Prevention (CDC) and the Agency for Healthcare Research and Quality (AHRQ) originally identified five key questions to be addressed by the report, focused on management of adnexal masses in peri- and postmenopausal women. The Duke research team clarified and refined the overall research objectives and key questions by first consulting with the two study sponsors, AHRQ and CDC, at which time two questions were added, and then by convening a panel of national experts who would serve as advisors to the project. These experts were selected to represent relevant specialties including radiology, obstetrics-gynecology, and gynecologic oncology, as well as national professional societies, including the American College of Obstetricians and Gynecologists (ACOG), the Society of Gynecologic Oncologists (SGO) and the American College of Radiology (ACR). Members of the technical expert panel were:

Susan Ascher, MD; Department of Radiology, Georgetown University Hospital; Washington, DC (ACR)

Michael L. Berman, MD; Division of Gynecologic Oncology, UCI Medical Center; Orange, CA (SGO)

Barry B. Goldberg, MD; Department of Radiology, Thomas Jefferson University Hospital; Philadelphia., PA (ACR)

Edward E. Partridge, MD; Department of Obstetrics and Gynecology, University of Alabama, Birmingham; Birmingham, AL (American Cancer Society)

George F. Sawaya, MD; Department of Obstetrics and Gynecology, University of California, San Francisco; San Francisco, CA

Howard T. Sharp, MD; University of Utah Hospitals and Clinics; Salt Lake City, UT (ACOG)

Stanley Zinberg, MD, MS; ACOG; Washington, DC

As a result of an initial conference call with the technical experts, AHRQ, and CDC, the Duke research team modified the key research questions originally proposed in the Task Order in two fundamental ways: (1) The questions were expanded to include women of all ages, and (2) Question 6 would include laparotomy data, where available. After review of a draft version of

the report by the technical experts and additional reviewers, the order of the questions was also changed to allow a more logical flow.

The key questions addressed by this report are:

Question 1: What is the prevalence of various tumor types among women with an adnexal mass, stratified by cancer status (malignant vs. benign), age, menopausal status, and size of tumor?

Question 2: What are the sensitivity, specificity, and reproducibility of the bimanual pelvic examination?

Question 3: Among women with a palpable adnexal mass on exam or a mass identified by ultrasound/imaging, what is the sensitivity/specificity of various evaluation modalities including ultrasound (transvaginal ultrasound, transabdominal ultrasound, color Doppler, two-dimensional [2D] vs. three-dimensional [3D] ultrasound), computer tomography (CT) scan, magnetic resonance imaging (MRI) scan, and cancer antigen 125 (CA-125) levels for diagnosing malignant masses?

Question 4: What is the accuracy of explicit scoring systems which incorporate various combinations of imaging findings, patient risk factors, and/or CA-125 levels for detecting malignancy? Have these scoring systems been applied to a population of women before laparoscopy or laparotomy?

Question 5: Among women with suspected benign masses on initial investigation, what are the sensitivity and specificity of monitoring with periodic CA-125 and/or interval ultrasound examinations for detecting malignant masses? How does the interval of testing/definition of change affect sensitivity and predictive value?

Question 6: Among women with adnexal masses, what are the morbidity and mortality from diagnostic surgery (laparoscopy or laparotomy)? At what point does the risk of surgery outweigh the risk of detecting malignancy?

Question 7: What are the estimated trade-offs resulting from various strategies for evaluation of the adnexal mass?

Analytic Framework

Based on the original proposal and discussions with CDC, AHRQ, and the technical expert panel, we developed the following analytic framework to structure our review and synthesis (Figure 2).




Figure 2. Analytic framework for evidence report (numbers refer to key questions)

Comments on this analytic framework are as follows:

- Separate consideration of age or menopausal status is important, since several factors that may affect the probability that a given adnexal mass is malignant may vary with age and/or menopausal status: the underlying incidence of various conditions that result in an adnexal mass, the frequency of contact with clinicians, the type and length of followup, and the prevalence of other conditions that may cause symptoms similar to those caused by ovarian malignancy or other symptomatic pelvic pathology. Race/ethnicity may also play a role, both in the relative likelihood of malignancy and the likelihood of other conditions.
- A variety of conditions, both benign and malignant, can cause a mass in the adnexa. The underlying prevalence of each type of condition, along with the sensitivity and specificity of the initial diagnostic test, will determine the proportion of patients with a given test result who are truly disease-free, or who truly have disease. The evidence on the prevalence of these conditions is reviewed in Question 1.
- Women can present with an adnexal mass in one of two ways through presentation with symptoms and subsequent detection of a mass through a physical examination, or through detection of a mass in an asymptomatic woman during physical examination or an imaging study. The ultimate probability of malignancy may vary based on how an adnexal mass is initially detected, since the prevalence of malignancy at this stage will drive the positive and negative predictive values of all subsequent tests. Because many women will initially have their masses detected through a bimanual pelvic examination, we review the evidence on the sensitivity and specificity of this component of the physical examination in Question 2.
- After the initial diagnosis of an adnexal mass, the choice of the next test will provide a revised estimate of the probability of a given disease. Although determining this probability is important in the symptomatic patient so that she may receive appropriate therapy, it is even more important in the asymptomatic patient, who runs the risk of undergoing unnecessary surgery for a benign condition if the test is falsely positive. Question 3 addresses the sensitivity and specificity of tests commonly used as "next step" diagnostic procedures.
- Frequently, a combination of various test results and patient characteristics can provide better discrimination between diseased and non-diseased, or benign and malignant, than any single test parameter. Question 4 addresses the performance of various multivariate scoring systems in discriminating benign from malignant masses.
- Because 100 percent sensitivity is difficult to achieve, some tests will be falsely negative. One strategy to minimize the consequences of a false negative test would be to monitor the patient with a specified test or tests, at a specified frequency, for a specified duration. Question 5 addresses the evidence for the effectiveness of such an approach, and which combination of test, test frequency, and duration of followup offers optimal performance.
- The ultimate diagnosis of ovarian malignancy requires surgical exploration, either through laparoscopy or laparotomy. Although an adverse outcome of surgery is not desirable under any circumstances, patients who undergo surgery because of a symptomatic mass have the possibility of improvement in symptoms, while, for patients who ultimately prove to have an ovarian malignancy, surgical management with adequate staging and reduction in tumor bulk appears to improve outcomes. However, for patients

with some asymptomatic benign masses, the benefits of surgery may be less clear while providing substantial risks. Question 6 addresses the risks of diagnostic surgery, both laparoscopy and laparotomy, for women with adnexal masses.

• Finally, estimating the benefits, harms, and costs of various management strategies, including screening, for ovarian cancer is complex. Synthesizing the wide range of data and incorporating uncertainty, as well as missing data, can often be done using simulation models. Question 7 presents an initial attempt at summarizing the likely outcomes of several different diagnostic strategies. Because modeling the natural history of ovarian cancer will ultimately be important for comprehensive analyses of different screening and diagnostic strategies, we also review existing models for the natural history of ovarian cancer with special attention paid to underlying assumptions.

Literature Search and Review

Sources

The primary sources of literature were MEDLINE[®] (1966-September 2004) and the Cochrane Database of Systematic Reviews. Searches of these databases were supplemented by reviews of reference lists contained in all included articles and in relevant review articles and meta-analyses.

Search Strategies

The basic search strategy used the National Library of Medicine's Medical Subject Headings (MeSH) key word nomenclature developed for MEDLINE[®] and was adapted for use in the other databases. The searches were limited to the English language. The texts of the three major search strategies are given in Appendix A.^{*} The searches yielded a total of 677 citations, whose records are maintained in a ProCite²⁰ database.

Abstract and Full-text Screening

Paired researchers from the Duke research team independently reviewed a set of abstracts and classified each as "include" or "exclude" according to study-specific criteria, which they developed. An abstract was included if at least one of the paired reviewers recommended that it be included. A total of 445 abstracts were included for the further "full-text review" stage. Interrater reliability for include/exclude decisions was tested by having 10 pairs of readers review 138 abstracts. Agreement was good to excellent (kappa 0.66 to 0.95).

At the full-text review stage, the paired researchers independently reviewed a set of the articles, and indicated a decision to "include" or "exclude" the article for the data abstraction stage. When a pair of reviewers arrived at a different opinion about whether to include an article, they were asked to reconcile the difference. Detailed inclusion and exclusion screening criteria were developed by research question and are listed below.

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/adnexal/adnexal.pdf.

Full-text Screening Criteria

Initially, the patient population was limited to peri- and postmenopausal women, and only articles that provided data specifically by age or menopausal status were included. After initial discussion with the expert panel, the search was expanded to include premenopausal women.

Question 1. Background clarifications were as follows:

- (1) The search should be limited to (a) screening studies and (b) case series of women with an undiagnosed mass (not just women who went to laparoscopy/path diagnosis).
- (2) Pathology list:
 - a. Benign
 - i. Uterine leiomyoma
 - ii. Nonneoplastic cysts, such as:
 - 1. Follicular (functional) cysts
 - 2. Corpus luteal (functional) cysts
 - 3. Theca lutein cysts
 - 4. Simple cysts
 - 5. Peritoneal inclusion cysts
 - 6. Paraovarian cysts
 - 7. Hemorrhagic cysts
 - 8. Endometrial cyst
 - iii. Polycystic ovary disease
 - iv. Cystic teratoma (dermoid cyst)
 - v. Hydrosalpinx,
 - vi. Cystadenoma
 - vii. Fibroma
 - b. Malignant ovarian neoplasms
 - i. Adenocarcinoma
 - ii. Others
 - c. Tumors of low malignant potential

Screening criteria for Question 1 were:

- (1) undiagnosed mass (regardless of whether symptomatic or asymptomatic; detected by palpation or ultrasound imaging);
- (2) exclude if n < 50; if $n \ge 50$, write n on decision sheets;
- (3) histology diagnosis;
- (4) screened women without mass (case series or cohort) or women with adnexal mass (case series).

Question 2. Screening criteria were as follows:

(1) comparison of bimanual pelvic examination to a reference standard;

(2) $n \ge 20;$

(3) able to construct 2-by-2 table for test characteristics.

Question 3. Screening criteria were as follows:

- (1) undiagnosed mass (regardless of whether symptomatic or asymptomatic; detected by palpation or ultrasound imaging) or screening population;
- (2) disease status distinguishes malignant from non-malignant;
- (3) must have 20 or more subjects;

- (4) disease status must be verified by histology or negative surgery (laparoscopy/laparotomy);
- (5) test is ultrasound, CT, MRI, PET, serum CA-125, or bimanual pelvic exam;
- (6) able to construct 2-by-2 table for test characteristics.

Question 4. Screening criteria were as follows:

- (1) patients with cancer;
- (2) studies with scoring, risk score, combined modality approach;
- (3) assesses predictive value of two or more variables (radiographic, patient characteristics or CA-125) using multivariable model;
- (4) screening studies;
- (5) $n \ge 50$.

Question 5. Screening criteria were as follows:

- (1) $n \ge 50;$
- (2) histology or followup interval = at least 9 months;
- (3) outcome = continued negative test with no clinical evidence of developing ovarian cancer.

Question 6. Screening criteria were as follows:

- (1) procedure = operative laparoscopy for adnexal mass, with or without biopsy;
- (2) addresses complications of procedure (morbidity or mortality);
- (3) $n \ge 100$ for morbidity.

Question 7. Screening criterion was as follows: article described mathematical or computer model of natural history of ovarian cancer.

Summaries of the results of the abstract screening and full-text review are provided in Tables 2 and 3. A list of excluded articles by reason for exclusion is found in Appendix B.^{*}

Table 2. Results of abstract screening and full-text review

Articles identified	1,023
Abstracts reviewed	1,023
Included	445
Excluded	578
Full-text articles reviewed	445 [†]
Included	204
Excluded	269

[†]The combined number of included (204) and excluded (269) articles exceeds the total 445 reviewed at the full-text level because 28 articles were considered excluded for one question, but included for another question.

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

Table 3. Included full-text articles by research question

Question	Number of articles
Question 1: Prevalence of tumor types	20
Question 2: Bimanual pelvic examination	14
Question 3: Single modality tests	153
Question 4: Explicit scoring systems	36
Question 5: Monitoring women with suspected benign masses	9
Question 6: Surgical morbidity and mortality	24
Question 7: Modeling diagnostic strategies	4
Total number of included articles	204 [†]

[†]Some articles were included for more than one question.

Data Abstraction and Development of Evidence Tables

The Duke research team developed and piloted evidence table formats for abstracting data to answer each of the seven research questions (see Appendix C^*). Based on clinical expertise, a pair of researchers was assigned to one of the seven research questions to abstract the data from the eligible articles. One of the paired researchers abstracted the data into the evidence tables, and the second researcher over-read the article and accompanying evidence table to check for accuracy and completeness. The completed evidence tables are provided in Appendix D.^{*}

Quality Assessment Criteria

At the data abstraction stage, the researcher was asked to evaluate each included article for factors affecting internal and external validity. The quality assessment criteria varied by question and are listed below. Researchers were instructed to assign a + or - to each item, and provide a brief rationale for each decision.

Quality criteria were as follows:

Question 1: What is the prevalence of various tumor types among women with an adnexal mass, stratified by cancer status (malignant vs. benign), age, menopausal status, and size of tumor?

- Size of population from which sample drawn. Rationale: Ideally, data on prevalence would come from population-based studies; alternatively, a precise description of the population served by a given center (for case series) allows comparison to other studies. Credit given for description.
- Number of cases. Rationale: Small numbers, especially in the denominator, decrease the precision of the estimate of proportion/prevalence.
- Patient selection. Rationale: The process by which patients come to undergo surgery may affect the prevalence of underlying disease, or the proportion of different types. For example, if one group of patients was more likely to undergo medical treatment for certain types of adnexal findings (such as oral contraceptives for possible functional

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

cysts), the distribution of types of masses would be different than in a group less likely to undergo medical therapy prior to surgery. Studies were given credit if this process were described.

• Application of reference standard. Rationale: If either all or a random sample of test negative subjects do not undergo the reference standard test, significant overestimation of test sensitivity can occur. Studies given credit if all patients underwent reference standard; alternative standards (such as pre-defined followup) were allowed for screening studies.^{15,21}

Question 2: What are the sensitivity, specificity, and reliability of the bimanual pelvic examination?

- Reference standard. Rationale: Histology or, at the least, intraoperative visualization, is the recognized reference standard for ovarian or other adnexal pathology. Studies given credit if all subjects underwent this reference standard (documented followup acceptable in screening studies).
- Verification bias. Rationale: If either all or a random sample of test negative subjects do not undergo the reference standard test, significant overestimation of test sensitivity can occur. Studies given credit if all patients underwent reference standard; alternative standards (such as predefined followup) were allowed for screening studies.
- Test reliability/variability. Rationale: Inter- and intraobserver variability can, at least, affect the precision of estimates of test characteristics (if random), or can bias results in one direction or the other (if systematic). Studies given credit if test reliability/variability were measured, other studies measuring it were referenced, or if it was discussed as an issue.
- Sample size. Rationale: Small sample sizes limit the precision of estimates, particularly for test characteristics, which are proportions. Studies given credit if sample size discussed, or if study over 100 subjects.
- Statistical tests. Rationale: Inappropriate use of statistical tests (e.g., use of parametric tests for nonparametric data) or inappropriate interpretation of results (concluding no difference for underpowered studies) can lead to invalid conclusions about a study. Studies given credit if no examples of inappropriate use identified.
- Blinding. Rationale: Awareness of other relevant information (such as clinical history or, in the case of retrospective studies where images are reviewed outside of the clinical setting, the ultimate diagnosis) can lead to biased interpretation of results. Studies given credit if blinding explicitly described.
- Definition of +/- on screening test. Rationale: The ability to replicate a study, or to compare results between studies, depends on a description of the criteria for defining a positive test. Studies given credit if definition provided, or reference for definition provided.

Question 3: Among women with a palpable adnexal mass on exam or a mass identified by ultrasound/imaging, what is the sensitivity/specificity of various evaluation modalities including ultrasound (transvaginal ultrasound, transabdominal ultrasound, color Doppler, 2D vs. 3D ultrasound), CT scan, MRI scan, and CA-125 levels for diagnosing malignant masses?

- Reference standard
- Verification bias
- Test reliability/variability
- Sample size

- Statistical tests
- Blinding
- Definition of +/- on screening test

Rationale for these criteria is the same as for Question 2.

Question 4: What is the accuracy of explicit scoring systems which incorporate various combinations of imaging findings, patient risk factors, and/or CA-125 levels for detecting malignancy? Have these scoring systems been applied to a population of women before laparoscopy or laparotomy?

- Reference standard. Rationale: Histology or, at the least, intraoperative visualization, is the recognized reference standard for ovarian or other adnexal pathology. Studies given credit if all subjects underwent this reference standard (documented followup acceptable in screening studies).
- Verification bias. Rationale: If either all or a random sample of test negative subjects do not undergo the reference standard test, significant overestimation of test sensitivity can occur. Studies given credit if all patients underwent reference standard; alternative standards (such as pre-defined followup) were allowed for screening studies.
- Test reliability/variability. Rationale: Inter- and intra-observer variability can, at least, affect the precision of estimates of test characteristics (if random), or can bias results in one direction or the other (if systematic). Studies given credit if test reliability/variability were measured, other studies measuring it were referenced, or if it was discussed as an issue.
- Sample size. Rationale: Small sample sizes limit the precision of estimates, particularly for test characteristics, which are proportions. In the setting of multivariate models, study power is limited by the number of cases in the data set. Studies given credit if sample size discussed.
- Statistical tests. Rationale: Inappropriate use of statistical tests (e.g., use of parametric tests for nonparametric data) or inappropriate interpretation of results (concluding no difference for underpowered studies) can lead to invalid conclusions about a study. Studies given credit if no examples of inappropriate use identified.
- Blinding. Rationale: Awareness of other relevant information (such as clinical history or, in the case of retrospective studies where images are reviewed outside of the clinical setting, the ultimate diagnosis) can lead to biased interpretation of results. Studies given credit if blinding explicitly described.
- Definition of +/- on screening test. Rationale: The ability to replicate a study, or to compare results between studies, depends on a description of the criteria for defining a positive test. Studies given credit if definition provided, or reference for definition provided.
- Explicit validation method. Rationale: A scoring system will often perform differently when tested in a data set other than the one in which it was developed. Studies given credit if the method for validating the system was explicitly described or referenced.

Question 5: Among women with suspected benign masses on initial investigation, what are the sensitivity and specificity of monitoring with periodic CA-125 and/or interval ultrasound examinations for detecting malignant masses? How does the interval of testing/definition of change affect sensitivity and predictive value?

- Reference standard
- Verification bias

- Test reliability/variability
- Sample size
- Statistical tests
- Blinding
- Definition of +/- on screening test

Rationale for these criteria is the same as for Question 2.

Question 6: Among women with adnexal masses, what are the morbidity and mortality from diagnostic surgery (laparoscopy or laparotomy)? At what point does the risk of surgery outweigh the risk of detecting malignancy?

- Size of population from which sample drawn
- Number of cases
- Patient selection
- Application of reference standard

Rationale for these criteria is the same as for Question 1.

Question 7: What are the estimated trade-offs resulting from various strategies for evaluation of the adnexal mass?

For this question, we examined published models of ovarian cancer and qualitatively assessed the underlying assumptions and evidence for them.

Additional Analyses

Test Characteristics and Confidence Intervals

For test characteristics, a Microsoft Excel® spreadsheet was developed which calculated appropriate test characteristics (sensitivity, specificity, negative predictive value, positive predictive value) for individual studies if studies provided enough data to input (a) values for individual cells of a 2-by-2 table, (b) the prevalence of disease and values for sensitivity and specificity, or (c) sufficient data to solve for two equations involving sensitivity, specificity, or predictive values. Ninety-five percent confidence intervals were automatically estimated using the approximate formula for proportions:

 $p \pm 1.96^* \sqrt{p^*(1-p)/N}$, where p = point estimate of proportion, N = total sample size.

Prevalence and Event Rates and Confidence Intervals

For Questions 3 and 6, prevalence of different mass types, and morbidity and mortality rates, were also calculated using the above formula. For studies where the numerator of a particular proportion was 0, the upper bound was estimated using the formula:

$$p + 2.56^* \sqrt{p^*(1-p)/N}$$
, where $p = 2/(N+2)$.

Estimation of Pooled Sensitivity and Specificity

For Questions 2, 3, and 4, we used two complementary methods for assessing diagnostic test performance: (1) summary receiver operating characteristic (ROC) analysis; and (2) independently combined sensitivity and specificity values. We calculated pooled sensitivity and specificity estimates, along with 95 percent confidence intervals and summary ROC curves, using Meta-Stat 0.6, a shareware program for performing meta-analyses of diagnostic tests.²² In this software, logits of sensitivity and specificity values are pooled, using a random-effects model weighted by the inverse of the variance.²³

We combined the sensitivity and specificity values of the tests across studies using a randomeffects model to estimate the average values. A random-effects model incorporates both the within-study variation (sampling error) and between-study variation (true treatment-effect differences) into the overall treatment estimate. It gives a wider confidence interval than the fixed-effect model (which considers only within-study variability) when estimates are based on heterogeneous results.

When each is combined separately, sensitivity and specificity tend to underestimate the true test sensitivity and specificity; however, they can provide an indication of the approximate test operating point for most of the studies.

Summary ROC curves are a potentially useful graphical summary of the diagnostic test performance data. In brief, each study provides a pair of sensitivity and specificity values to the analysis. After logistic transformation of data, a linear model is fitted to the observed studies using regression analysis. This best-fit model can then be transformed back to ROC space and plotted as curve. A summary ROC curve can be thought of as an ROC curve that describes joint changes in sensitivity and specificity with changes in cutoff values. The ideal position of an ROC curve is near the upper left corner. The area under the curve (AUC) is another summary measure of the degree of discrimination of a test.

The summary ROC method assumes that the variability in the reported sensitivity and specificity values from different studies is due to different cutoff values (explicit or implicit) being applied.²⁴ However, the summary ROC curve can summarize studies whose variability may be due to other sources of variation, since the summary ROC curve no longer ties specific cutoff values to specific intervals of the curve. One can think of a summary ROC curve as an overall estimate of the discrimination ability of a test.

When there is little variability in the test results – i.e., when studies appear to be operating at similar thresholds and report similar results – summary ROC analysis provides little additional information. In this case, separately averaged sensitivity and specificity values across studies will give similarly useful summary information. However, where there is substantial variability in test results, the separately averaged sensitivity and specificity values tend to have wide confidence intervals and have means that do not characterize any of the studies. In this case, SROC curves provide a more suitable analysis framework.

Estimates of National Rates of Surgery for Adnexal Mass

The Nationwide Inpatient Sample (NIS) is a public access database maintained by AHRQ. The NIS represents a stratified sample of approximately 20 percent of all discharges from U.S. hospitals; data for the year 2000 contain administrative discharge data from hospitals in 28 states, while 2001 contains data from 33 states.²⁵ Weights are provided in order to allow

estimation of national data based on this sample. We used data from 2000 and 2001 to provide supplemental data on the frequency of diagnostic laparoscopy and exploratory laparotomy for Question 6. Because previous work has shown that administrative data may lack sufficient clinical detail to compare outcomes,²⁶ we did not attempt to directly compare complication rates between these procedures, or between diagnoses.

The search was limited to women 15 years and older, who had one of the following *International Classification of Diseases, Ninth Revision* (ICD-9) diagnostic codes: 183.x (malignant neoplasm of the ovary and other uterine adnexa), 220.x (benign neoplasms of the ovary); 620.x (ovarian cysts); 752.11 (para-ovarian cysts); 614.0, 614.1, 614.2, 614.6 (adnexal masses secondary to pelvic inflammatory disease); 789.33, 789.34, 789.39 (abdominal masses arising in the left or right lower quadrant, or other nonspecified site); and V655 (normal findings after diagnostic evaluation).

In order to avoid overestimation of complication rates due to other procedures, we then excluded patients who had an ICD-9 diagnosis code for hysterectomy (68.x). Procedures were then classified as laparoscopy only (54.21), laparoscopy with conservative ovarian surgery (65.3x, 65.4x, 65.5x, 65.6x), laparoscopy with oophorectomy (65.0x, 65.2x), or laparotomy (54.11) alone, with conservative ovarian surgery (same codes), or with oophorectomy (same codes).


A discharge status of "Dead" indicated in-hospital mortality. Complications of surgery or hospitalization were indicated by diagnosis codes of E870 through E876.

Model of Natural History of Ovarian Cancer

We used a Markov state-transition model to explore the impact of alternate assumptions about the natural history of ovarian cancer. The original model was developed as a graduate school project by Karen Hoffman, MD, and further refined in collaboration with two of the authors of this report (Drs. Kulasingam and Myers).

The model simulates a cohort beginning at age 40 distributed across cancer stages. Subjects progress from no cancer through the stages of ovarian cancer to death. Each cycle is 12 months long. The original model design is illustrated in Figure 3; subsequent modifications include removal from the at-risk population by undergoing oophorectomy for another cause, and allowing some Stage I cancers the possibility of progressing directly to Stage III. Model variables and the ranges over which they were varied are outlined in Table 4. Probability of progressing from no cancer to Stage I cancer varies by age and is based on age-adjusted ovarian cancer incidence rates. Because the probability of progression (or duration of time within a stage) is unknown, probability of progression from Stage I to II, from Stage II to III, and from Stage III to Stage IV was adjusted to reflect incidence distribution across stages. Within the model, subjects may die from causes other than ovarian cancer. The probability of dying from a cause other than ovarian cancer varies by age and was constructed from CDC National Vital Statistics reports and Surveillance, Epidemiology, and End Results (SEER) data.^{27,28} Probability of clinical diagnosis is based on the annual report of the International Federation of Gynecology and Obstetrics (FIGO).²⁹ Five-year survival rates gathered by SEER 1992-98 were used to predict probability of dying from ovarian cancer.²⁷ SEER localized disease corresponds to Stage I cancer, regional disease corresponds to Stage II cancer, and distant disease corresponds to Stage III/IV ovarian cancer. The model was constructed in DATA 4.0.³⁰

Figure 3. Schematic of natural history model



Abbreviations for probabilities are described in Table 4, below.

Table 4. Model variables

Variable description	Model abbreviation of variable	Value	Range varied
Probability of clinical diagnosis for each stage (I, II, III, or IV) if	pClinDxStagel	0.261	Calibrated
no screening test or if screening produces a false negative	pClinDxStageII	0.446	
	pClinDxStageIII	0.837	
	pClinDxStageIV	0.950	
Probability of dying from diagnostic exploratory laporotomy	pLapDeath	0.00023	0.00 to 0.0010
Probability of dying from each stage of cancer, based on 5-	pDieStagel		Not varied
year survival rates		0.051	
	pDieStagell		Not varied
		0.187	
	pDieStageIII		Not varied
		0.691	
	pDieStageIV		Not varied
		0.691	
Probability of developing Stage I cancer, based on ovarian	tCompInc		Varies with
cancer incidence rates			age
Probability of dying from a cause other than ovarian cancer	tMortCaAdj		Varies with
			age

Peer Review Process

We employed internal and external quality-monitoring checks through every phase of the study to reduce bias, enhance consistency, and verify accuracy. Examples of internal monitoring procedures include: three progressively stricter screening opportunities for each article (abstract screening, full-text article review, data abstraction review); involvement of three individuals (two clinicians and copy editor) in each data abstraction; agreement of at least two clinicians on all included studies.

Our principle external quality-monitoring device was the peer-review process. Nominations for peer reviewers were solicited from several sources, including a technical expert panel and interested federal agencies. The list of nominees was forwarded to the Agency for Healthcare Research and Quality (AHRQ) for vetting and approval. A final list of peer reviewers is provided in Appendix E.^{*}

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

Chapter 3. Results

Question 1: Prevalence of Tumor Types

Question 1 is: What is the prevalence of various tumor types among women with an adnexal mass, stratified by cancer status (malignant vs. benign), age, menopausal status, and size of tumor?

Approach

We included studies in the U.S. population with more than 50 women and limited the literature search to screening studies and case series where results were provided for all women with an undiagnosed mass, not just those with subsequent positive additional tests.²¹ Studies of adnexal mass in which the gold standard is applied only to those with positive tests results would underestimate the prevalence of disease and cause a substantial bias.

Results

Twenty articles met the inclusion criteria and are described in the Evidence Table 1 (Appendix D^*).³¹⁻⁵⁰

Detailed prevalences for specific tumor types are provided in Evidence Table 1. The included studies can be divided into two groups. The first group includes four reports from a large screening study in Kentucky (Table 5). The prevalence of malignancy ranged from 0.09 to 0.18 percent. In postmenopausal women, the prevalence of malignancy was 0.09 to 0.18 percent, borderline tumors were not reported, and the prevalence of benign tumors was 0.08 to 1.3 percent. In a population that included either postmenopausal women or those with a family history of breast, ovarian, or colorectal cancer, the prevalence of malignancy was 0.10 to 0.11 percent, of borderline tumors 0.02 percent, and of benign tumors 1.1 to 1.2 percent.

The most common malignant tumor types include primary ovarian carcinoma, such as serous and mucinous cystadenocarcinoma, granulosa cell tumors, and undifferentiated adenocarcinoma. Borderline tumors were less common, such as serous low malignant potential (0.02 percent). The most common benign tumors were serous cystadenoma (0.4 to 0.7 percent), paratubal cyst (0.1 to 0.16 percent), endometrioma (0.03 to 0.3 percent), and mature teratoma (0.02 to 0.08 percent).

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

Table 5.	Prevalence	of tumor types	in screening	g studies*
----------	------------	----------------	--------------	------------

Study	N	% Menopausal	Malignant	Borderline	Benign
DePriest et al.,1993 ³⁶	3,220	100; most had positive family history of breast, ovarian, or colorectal cancer	0.09%	Not reported	1.3%
DePriest et al.,1997 ³⁴	6,470	Either menopausal or had positive family history of breast (30%), ovarian (24%), or colorectal cancer (15%)	0.11%	Not reported	1.2%
Modesitt et al., 2003 ⁴⁰	15,106	100	0.18%	Not reported	0.8%
Van Nagell et al., 2000 ⁴⁹	14,469	Either menopausal or had positive family history of breast (34%), ovarian (23%), or colorectal cancer (23%)	0.1%	0.02%	1.1%

*Note: All four publications represent the same screening study at different times.

The majority of U.S. studies with histological diagnosis of all masses (n = 16) were case series of women with undiagnosed adnexal mass undergoing laparotomy (Table 6). The prevalence of malignancy ranged from 5.7 to 57.5 percent, the range of borderline tumors was 1.4 to 11.2 percent, and the prevalence of benign tumors was 40 to 100 percent. All tumor types were over-represented because patients had an undiagnosed adnexal mass, and the clinical presentation was not well described in the majority of studies. Most studies included both premenopausal women and postmenopausal women and did not provide results separately. The one study that included only postmenopausal women⁴¹ found only benign tumors.

Table 6. Case series and retrospective medical record reviews

Study	Denominator	Location	Age, menopausal status, race	Malignant	Borderline	Benign
Childers et al.,1996 ³²	138	AZ	52	13.8%	Not reported	86.2%
Dottino et al.,1999 ³⁷	160	NY	52.2 53% post 91% white	8.1%	5%	86.9%
Fleischer et al., 1996 ³⁸	62	TN	50 >50% post	50%	Not reported	50%
Lin et al., 1993 ³⁹	80	NY	56 76% post 90% white	57.5%	2.5%	40%
Parker et al., 1994 ⁴¹	61	Multi-site	65 100% post	None	None	100%
Roman et al., 1997 ⁴²	226	CA	20% post	11.5%	7.5%	81%
Schneider et al., 1993 ⁴³	55	AZ	53 60% post	25.5%	3.6%	70.9%

Study	Denominator	Location	Age, menopausal status, race	Malignant	Borderline	Benign
Scoutt et al., 1994 ⁴⁴	109	СТ	40	20.2%	Not reported	79.8%
Shen-Gunther et al., 200245	125	OK/NV	58 82% white	44.8%	9.6%	45.6%
Smikle et al., 1995 ⁴⁶	195	ТХ	40% post	13.3%	Not reported	86.7%
*Chalas et al., 1992 ³¹	241	NY	Not reported	50.2%	7.5%	42.3%
Cohen et al., 2001 ³³	71	IL	22-80 44% post	18.3%	1.4%	80.3%
DePriest et al., 1993 ³⁵	121	KY	3-74 49% post	10.7%	Not reported	89.3%
Troiano, 199747	144	СТ	45 29% post	11.8%	2.1%	86.1%
Twickler et al., 1999 ⁴⁸	244	ТХ	38.6	5.7%	6.6%	87.7%
Vasilev et al., 1988 ⁵⁰	182	CA	Not reported	8.2%	1.6%	90.1%

*Retrospective chart review

Discussion

Estimating the age-specific prevalence of specific adnexal tumor types from the available literature is difficult. The best data come from a series of reports from a large screening study; overall prevalence of masses was 1 to 2 percent, with benign masses outnumbering malignant by 4- to 10-fold. Because patients with negative screening test results did not undergo definitive diagnostic procedures in these studies, the prevalence estimates are dependent on the sensitivity of the screening tests used (and the completeness of followup among test negatives). In addition, there is a potential bias in that premenopausal women enrolling in the screening study were at higher risk than average because of family history; in addition, postmenopausal women may have been more likely to enroll because of concerns based on family history, vague symptoms, or other reasons which would affect relative prevalence compared to the general population.

Estimates of prevalence in studies with 100 percent histologic diagnosis are inevitably biased by the clinical factors that determine which patients ultimately undergo surgery. These can include the presence and nature of symptoms (patients with symptoms referable to a mass would likely undergo surgery sooner than those with asymptomatic masses, all other things being equal); other findings (for example, the presence of ascites); patient anxiety; the diagnostic algorithms used (for example, the duration of followup for persistence); and the nature of the practice (malignancies will be more frequent in a gynecologic oncology practice compared to a general gynecology practice).

As mentioned previously, we did not include studies from outside the United States. Given differences in ethnic backgrounds (affecting genetic risks), observed differences in cancer incidence, and differences in clinical practice between countries, and the almost universal failure of studies to describe the clinical history leading to the diagnosis of adnexal mass, inclusion of these studies would not have allowed a more precise estimate of prevalence of different types of adnexal masses in the U.S. population.

Summary

In four reports from a large U.S. screening study, the prevalence of adnexal masses detected by ultrasound among postmenopausal women was 0.8 to 1.3 percent, and the prevalence of malignancy 0.09 to 0.18 percent (i.e., 9 to 18 per 10,000). Prevalence of different pathologies varies widely among case series. There are no data on the relative prevalence of different pathologies among women with asymptomatic masses compared to women with symptomatic masses.

Question 2: Bimanual Pelvic Examination

Question 2 is: What are the sensitivity, specificity, and reliability of the bimanual pelvic examination?

Approach

Articles were sought which evaluated the ability of the bimanual examination to detect adnexal masses, and/or to discriminate benign from malignant masses. Preference was given to studies where there was histological confirmation of the diagnosis, but an alternative reference standard (such as followup) was allowed for screening studies. Data allowing calculation of sensitivity and specificity had to be provided.

Our rationale for including the pelvic examination was based on its role in the initial evaluation of adnexal masses. Some asymptomatic women will have a mass detected as part of a "routine" physical examination; others will have a mass detected as part of an examination performed because of symptoms. The postexamination probability of malignancy is a function of the prevalence of cancer and the sensitivity and specificity of the bimanual examination; these probabilities, in turn, will affect the positive and negative predictive values of additional tests such as cancer antigen 125 (CA-125) and imaging studies. Because the pelvic examination will be the first test performed, either as a screening test or as a diagnostic test, knowledge of its test characteristics is important for evaluating subsequent diagnostic tests.

Results of Literature Search and Screening

We identified 14 studies that met the inclusion criteria.^{42,51-63} Nine studies provided data on discrimination between benign and malignant masses, ^{42,51,53-57,62,63}, four on the ability of the bimanual examination to detect any adnexal mass, ^{52,59-61} and one provided data on both discrimination between benign and malignant and ability to detect masses. ⁵⁸ All 14 studies are summarized in Evidence Table 2 (Appendix D^{*}).

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

Study Characteristics

Types of data incorporated. Two of the studies^{54,56} included history or clinical impression as part of the "test;" results were not provided separately for examination alone.

Types of study population. Ten of the 14 studies were performed prior to surgery for an adnexal mass, while four were from screening studies.^{51,52,57,58}

Reporting of study populations. Of the screening studies, Andolf et al.⁵² was performed in women over 40 considered at high risk of ovarian cancer because of symptoms or risk factors; Grover and Quinn⁵⁷ was performed in asymptomatic volunteers 25 and older, but described menopausal status; Adonakis et al.⁵¹ was performed in women over 45; and Jacobs et al.⁵⁸ was done entirely in a postmenopausal population.

Seven of the 11 preoperative studies reported menopausal status, but only two reported on test characteristics specifically by menopausal status.^{55,56} None reported race/ethnicity, and none reported the clinical route by which patients had come to surgery (detection of an asymptomatic mass, symptoms, etc.).

Methodology. The methodological quality of the included studies was as follows:

Reference standard. Of the preoperative studies, all but one⁴² had operative confirmation of findings. Ultrasound was used as the reference standard in the four screening studies, with 12-month followup examinations or questionnaires.

Verification bias. In the study by Roman et al.,⁴² 26 women with non-palpable masses did not undergo definitive diagnosis.

Test reliability. Only one study⁶⁰ provided direct data on test reliability. Grover and Quinn,⁵⁷ Ong et al.,⁵⁹ Schutter et al.,⁶³ and Buckshee et al.⁵⁴ used a single examiner. The other studies did not address the issue of test reliability.

Sample size. None of the reports had a priori sample size calculations.

Use of appropriate statistical tests. All reports used appropriate techniques for calculating test characteristics.

Blinding. Only two studies^{54,60} explicitly stated whether examiners were blinded to prior history or other findings.

Definition of positive and negative test. Nine of 14 studies reported their definitions of a positive test, although the precision of the definitions was quite variable (from "a mass 5 cm or more in diameter" to "larger than normal"); others relied on "clinical impression."

Results

Table 7 and Figure 4 present the results of studies that evaluated the sensitivity of the bimanual examination for detecting an adnexal mass. The studies of Padilla et al.^{60,61} are particularly striking for the low sensitivity, since the examinations were performed under anesthesia, when, presumably, patient discomfort would not be a limiting factor. Both studies suggested a relationship between experience and accuracy; medical students performed worse than residents, who performed worse than attending physicians. Although these differences were not statistically significant, the studies were underpowered to detect significant differences. Obesity, defined as a body mass index greater than 30, had a significant negative impact on sensitivity, while increasing uterine size increased sensitivity, possibly by elevating the adnexae out of the pelvis.

When sensitivity and specificity were combined separately using a random-effects model, the pooled sensitivity was 0.45 (95% confidence interval [CI], 0.28 to 0.68), and the pooled specificity was 0.90 (0.80 to 0.96).

Study	N	Sensitivity (95% CI)	Specificity (95% CI)	% with confirmed	Notes
Jacobs et al., 1988 ⁵⁸	1,010	84.6% (65.0 to 100%)	98.3% (97.5 to 99.1%)	mass 1.3% (0.1% malignant)	Reference standard: ultrasound Screening study
Andolf et al., 1990 ⁵²	801	33.7% (26.5 to 41.0%)	92.0% (89.9 to 94.1%)	20% (0.1% malignant)	Reference standard: ultrasound by midwife Screening in women considered at high risk for ovarian cancer; no ovarian
					cancers detected: 2 endometrial cancers, 1 LMP detected
Padilla et al., 2005 ⁶¹	252	15.6% (8.1 to 23.0%)	93.8% (90.1 to 97.5%)	35.7% (unclear if any malignancies)	Exam under anesthesia prior to surgery for pelvic mass; examiners blinded to radiology findings
				maignatices	Likelihood of not detecting an adnexal mass increased with less experience (OR for resident 1.13, student 1.36 compared to attending, although 95% CIs cross 1).
					Statistically significant increase in missed diagnosis if subject with BMI > 30 (OR 2.57; 95% CI, 1.36 to 4.87), and significant decrease in presence of enlarged uterus (OR 0.48; 95% CI, 0.25 to 0.93).
					Final diagnoses not presented, reasons for surgery not systematically presented
Padilla et al., 2000 ⁶⁰	140 (82 masses)	Left adnexa (attending exam): 32.7% (19.5 to 45.8%)	Left adnexa (attending exam): 88.5% (81.4 to 95.6%)	58% (0 malignancies)	Exam under anesthesia prior to surgery for pelvic mass; examiners blinded to radiology findings; no clear relationship to experience
		Right adnexa (attending exam): 21.2% (7.3 to 35.2%)	Right adnexa (attending exam): 78.7% (70.4 to 87.0%)		
Ong et al., 1996 ⁵⁹	86	71.9% (60.9 to 82.9%)	59.1% (38.5 to 78.6%)	74.4% (0 malignant)	Pre-surgical exam

Abbreviations: BMI = body mass index; CI = confidence interval; LMP = low malignant potential tumor; OR = odds ratio




Figure 4. Performance of bimanual pelvic examination for detecting the presence of an adnexal mass

Key to Figure 4: $1 = \text{Jacobs et al.}, 1988;^{58} 2 = \text{Andolf et al.}, 1990;^{52} 3 = \text{Padilla et al.}, 2005;^{61} 4 = \text{Roman et al.}, 1997;^{42} 5 = \text{Padilla et al.}, 2000;^{60} 6 = \text{Ong et al.}, 1996^{59}$

Table 8 and Figure 5 show the test characteristics for discriminating benign from malignant masses. Using a random-effects model, pooled sensitivity was 0.72 (95% CI, 0.49 to 0.88) and specificity was 0.92 (0.80 to 0.97). When only the three screening studies were included, pooled sensitivity was 0.58 (95% CI, 0.21 to 0.88), pooled specificity 0.98 (0.97 to 0.98).

 Table 8. Sensitivity and specificity of pelvic examination in discriminating benign from malignant adnexal masses

Study	N	Sensitivity (95% CI)	Specificity (95% CI)	% Malignant	Notes
Adonakis et al., 1996 ⁵¹	2,000	66.7% (13.3 to 100%)	97.2% (96.5 to 97.9%)	0.15%	Screening study; threshold of "abnormal or ambiguous exam;" CA-125 used in conjunction to proceed to ultrasound
Grover et al., 1995 ⁵⁷	2,623	0% (0 to 100%)	98.5% (98.0 to 98.9%)	0.05%	Screening study; ultrasound and clinical followup
Jacobs et al., 1988 ⁵⁸	1,010	100% (0 to 100%)	97.3% (96.3 to 98.3%)	0.1%	Screening study; followup with ultrasound
Roman et al., 1997 ⁴²	200	51.2% (36.3 to 66.1%)	83.6% (77.8 to 89.4%)	21%	Results for 26 patients with non-palpable masses not included; no substantial difference based on menopausal status
Buckshee et al., 1998 ⁵⁴	34	77.8 % (50.6 to 100%)	88.9% (77.0 to 100%)	25%	One examiner; non- consecutive patients prior to surgery
Balbi et al., 2001 ⁵³	72	90% (77.5 to 100%)	74% (61.8 to 86.2%)	31%	18 patients with "clearly benign masses" and 2 with "clearly malignant" excluded; clinical impression
Finkler et al., 1988 ⁵⁶	106	43.2% (27.3 to 59.2%)	90.8% (83.7 to 97.8%)	36%	"Clinical impression" included exam plus history; results not calculated for
		Premenopausal: 16.7% (0 to 33.9%)	Premenopausal: 92.3% (85.1 to 99.6%)	Premenopausal: 26%	exam alone
		Postmenopausal: 68.4% (47.5 to 89.3%)	Postmenopausal: 84.6% (65.0 to 100%)	Postmenopausal: 59%	
Schutter et al., 1998 ⁶³	155	91.5% (84.4 to 98.6%)	73.9% (64.9 to 82.9%)	39%	All postmenopausal; high prevalence of cancer; single examiner; inclusion/exclusion criteria not described
Schutter et al., 1994 ⁶²	222	92.6% (87.4 to 97.9%)	63.0% (54.6 to 71.4%)	43%	Preoperative patients
Dowd et al., 1993 ⁵⁵	225	51.0% (41.7 to 60.3%)	87.0% (80.8 to 93.2%)	49%	Preoperative patients
		Premenopausal: 31%	Premenopausal: 95%		
		Postmenopausal 59%	Postmenopausal: 75%		

Abbreviations: CA-125 = cancer antigen 125; CI = confidence interval




Figure 5. Performance of bimanual pelvic exam for distinguishing benign from malignant adnexal masses

Key to Figure 5: 1 = Grover and Quinn, 1995;⁵⁷ 2 = Adonakis et al., 1996;⁵¹ 3 = Jacobs et al., 1988;⁵⁸ 4 = Dowd et al., 1993;⁵⁵ 5 = Schutter et al., 1994;⁶² 6 = Finkler et al., 1988;⁵⁶ 7 = Balbi et al., 2001;⁵³ 8 = Buckshee et al., 1998;⁵⁴

For both types of studies, there appears to be a trend towards decreased specificity as prevalence increases, although the number of studies is small and the confidence intervals are wide. The extreme differences in sensitivity in the two largest studies (0 and 100 percent) prevent even a qualitative assessment of any relationship between prevalence and sensitivity.

The two studies that stratified results by menopausal status^{55,56} found lower sensitivity and higher specificity for discriminating benign from malignant masses in premenopausal women compared to postmenopausal women (Table 8).

Discussion

Despite the common recommendation for routine pelvic examination, we found surprisingly little literature on its accuracy. Based on the literature we did identify, its sensitivity for detecting adnexal masses appears fairly low. Sensitivity for detecting normal adnexa is also low, as demonstrated in a recent study of examinations under anesthesia.⁶⁴ Although sensitivity for

distinguishing a malignant mass from a benign one is somewhat better, these results need to be interpreted with caution, since most of the studies were done in preoperative patients, who would already have a higher probability of having a malignancy. In the four large screening studies, there was a total of only five malignancies, with the bimanual detecting 0 percent, 66 percent, and 100 percent in the three individual studies where ovarian cancer was detected; the fourth had one case of a low malignant potential tumor and two endometrial cancers. Pooled sensitivity for the three screening studies that addressed discrimination between benign and malignant masses was considerably lower than for all studies combined (and was similar to the pooled sensitivity of the studies that examined the ability to detect any adnexal mass).

Both types of studies show a trend toward decreased specificity as the prevalence of abnormality increases – this may reflect a greater degree of suspicion on the part of the examiner, based on other findings, and a greater likelihood of calling an examination abnormal. This is supported by the finding of the two studies which stratified results by menopausal status, which found higher sensitivity and lower specificity in postmenopausal women compared to premenopausal women.^{55,56} Because examiners were unblinded, and were likely aware of the higher prevalence of malignancy among postmenopausal women, they may have been more likely to assign a diagnosis of malignancy among those patients. Future studies need to pay stricter attention to blinding examiners to other information. In theory, this bias should also result in higher sensitivity as prevalence increases, although, because of the small number of studies, the small numbers of subjects in most studies, and the diametrically opposed findings of the two largest studies, we were unable to recognize any relationship.

In the two studies that addressed the effect of experience on test characteristics,^{60,61} there appeared to be a relationship between increasing experience and increased sensitivity (specificity did not change); however, even attending physicians achieved a sensitivity of only 28 percent. Based upon the available literature, the bimanual examination does not appear to be a sensitive test for detecting the presence of adnexal masses and appears to have limited ability to discriminate benign from malignant masses. Although specificity was somewhat better, positive predictive values will still be quite low in low prevalence settings, as discussed under Question 7. This will, in turn, lower the positive predictive value of diagnostic tests performed in patients referred on the basis of a pelvic examination. These tests are discussed in detail in the next section.

Question 3: Single Modality Tests

Question 3 is: Among women with a palpable adnexal mass on exam or a mass identified by ultrasound/imaging, what is the sensitivity/specificity of various evaluation modalities including ultrasound (transvaginal ultrasound [TVUS], transabdominal ultrasound, color Doppler, twodimensional [2D] versus three-dimensional [3D] ultrasound), computer tomography (CT) scan, magnetic resonance imaging (MRI) scan, and CA-125 levels for distinguishing benign from malignant masses?

Approach

This section considers the various evaluation modalities that are described in the literature and would be available to a clinician to aid in the work-up of an adnexal mass after it has been diagnosed. We focused our search on articles whose primary reference standard was histopathology. Ideally this reference standard would be applied to all test negatives. However, we accepted a repeat negative test (such as imaging) conducted at least 6 months later as an acceptable alternative. We did include some studies that were from population-based screening samples, and these will be considered in a separate section below. The evaluation modalities investigated can be divided into several general categories. Imaging studies will be divided by technological mode (ultrasound, MRI, etc.). Ultrasound studies will be divided into those that evaluate adnexal morphology (either by an explicit scoring system or by descriptive standards), those that measure vascular flow in the mass (Doppler), and those that evaluate these modalities in combination. Serum studies will focus primarily on CA-125, as this is the most common marker in both the literature and in clinical practice. However, other serum markers will be discussed as well. Finally, the studies for which it was possible to stratify by menopausal status will be discussed where appropriate.

Results of Literature Search and Screening

Two hundred and five articles were identified for abstraction. Of these, 153 met the inclusion criteria and were abstracted into Evidence Table 2 (Appendix D^{*}).^{31,33-36,39,42-44,46,47,49-56,58,62,63,65-195}

Ultrasound Morphology

Conventional grey scale ultrasonography is the most common imaging modality used to differentiate benign from malignant adnexal masses. Especially with the advent of high-frequency transvaginal probes, the quality of the images allows description of the gross anatomic features of the lesion. This is, however, limited by the great variability of macroscopic characteristics of both benign and malignant masses. Furthermore, the technique is operator dependent. To overcome these limitations, morphologic scoring systems have been developed. Such scoring systems are based on specific ultrasound parameters each with several scores according to determined features and with a cutoff value to categorize masses as either malignant or benign.

Table 9 describes the details of the most commonly used scoring systems. Briefly, the following scores are suggestive of malignancy: Sassone¹⁵⁹ greater than 9, DePriest³⁶ greater than or equal to 5, Ferrazzi⁹³ greater than 9, and for Lerner¹³¹ greater than or equal to 3. Although the development of all the scoring systems was motivated to improve the reproducibility of morphological measurements, only the scoring system by Lerner et al. based the categories on a multivariate logistic analysis.

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

Scoring system			Score		
Sassone et al., 1991 ¹⁵⁹					
Morphology	1	2	3	4	5
Inner wall	Smooth	Irregularities ≤	Papillarities > 3	Not applicable,	-
structure		3 mm	mm	mostly solid	
Wall thickness (mm)	Thin (≤ 3)	Thick (> 3)	Not applicable, mostly solid	-	-
Septa (mm)	None	Thin (≤ 3)	Thick (> 3)	-	
Echogenicity	Sonolucent	Low echogenicity	Low echogenicity with ochogenic core; mixed echogenicity	-	High echogenicity
DePriest et al., 1993 ³⁶					
Morphology	0	1	2	3	4
Cystic wall structure	Smooth (< 3 mm thick)	Smooth (> 3 mm thick)	Papillary projection (< 3 mm)	Papillary projection (≥ 3 mm)	Predominately solid
Volume (cm3)	< 10	10-50	> 50-200	> 200-500	> 500
Septum structure	No septa	Thin septa (< 3 mm)	Thick septa (3 mm to 1 cm)	Solid area (≥ 1 cm)	Predominately solid
Ferrazzi et al., 1997 ⁹³					
Morphology	1	2	3	4	5
Wall	≤ 3 mm	> 3 mm	-	Irregular, mostly solid	Irregular, not applicable
Septa	None	≤ 3 mm	> 3 mm		
Vegetations	None	-	-	≤ 3 mm	> 3 mm
Echogenicity	Sonolucent	Low echogenicity	-	With echogenic areas	With heterogeneous echogenic areas, solid
Lerner et al., 1994 ¹³¹					
Morphology	0	1	2	3	
Wall structure	Smooth or small irregularities < 3 mm	-	Solid or not applicable	Papillarities ≥ 3 mm	
Shadowing	Yes	No	-	-	
Septa	None or thin (< 3 mm)	Thick (≥ 3 mm)	-	-	
Echogenicity	Sonolucent or low-level echo or echogenic core	-	-	Mixed or high	

Table 9. Detailed description of ultrasound scoring systems

Reproducibility of tests. Timmerman et al.¹⁹⁶ evaluated the subjective assessment of ultrasonographic images for discriminating between malignant and benign masses. Three hundred consecutive patients were evaluated with TVUS by six different operators, and both

diagnostic accuracy and interassessor agreement were calculated. The operators had varied experience in TVUS – from approximately 300 to 15,000 scans. The two most experienced operators agreed 92 percent of the time. The accuracy of the least experienced operators ranged from 82 to 87 percent (p = 0.0001). Overall, 65 percent of all the masses were correctly classified by all six operators. Interassessor agreement was greater between the most experienced operators as well (kappa = 0.852). When comparing experienced with less experienced operators, the kappa ranged from 0.581 to 0.737. This is similar to the kappa reported by Yamashita et al.¹⁹² among five operators, 0.62 (± 0.02) with TVUS. Interassessor agreement was not calculated between the less experienced operators. None of the included articles described operator experience, and only a few addressed interobserver variability. Although operator experience appears to correlate with accuracy, the specialty training of the unltrasonographer does not. In a meta-analysis of both morphologic and color Doppler tests in the evaluation of adnexal masses, Kinkel et al.¹⁹⁷ found no difference between radiologists and gynecologists in the performance of ultrasound.

TVUS versus abdominal ultrasound. Of the 122 articles that evaluated adnexal masses via ultrasound (through either ultrasound morphology or Doppler measurements), only five articles exclusively used transabdominal imaging.^{52,58,116,133,198} Fifty-nine articles used TVUS exclusively and 51 used a combination of TVUS and abdominal ultrasound. There were seven articles for which the ultrasound modality was unknown. In the majority of the articles that used a combination of TVUS and abdominal ultrasound were patient refusal of transvaginal scans, virginity, poor image quality, and very large masses. Although a few articles reported how many women had which type of ultrasound, none of the articles reported their results such as to permit a stratification by TVUS or abdominal ultrasound. We therefore elected to group all ultrasound studies together regardless of TVUS or abdominal imaging.

Trials identified. We identified 69 articles comprising 73 ultrasound morphology assessments. Despite the availability of published scoring systems, most of the studies based their diagnoses on either descriptive assessments of adnexal masses or used a modified or unique scoring system. Only 13 studies explicitly used Sassone's criteria, six used DePriest's, and three used Ferrazzi's, Finkler's, Lerner's, and Valentin's respectively. When a scoring system other than an established criterion was used, it was not always clear how it had been developed or modified. Details of the tests and their evaluative performance are provided in Table 10. Assessments of adnexal morphology by ultrasound which were either a unique or modified or unclear scoring system are labeled "other" with a brief description when possible. It is also important to note that not all of the established scoring systems were employed using the original cutpoints. For example, Caruso et al.⁸³ and Itakure et al.¹¹⁵ both used a cutpoint of > 7 for the DePriest scoring system, where the original description used ≥ 5 .


Scoring system	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Range of sensitivity in individual studies	Range of specificity in individual studies	References
Sassone	0.86 (0.79 to 0.91)	0.77 (0.73 to 0.81)	0.65 to 1.00	0.65 to 0.93	43,54,68,69,83,93,130,131,1 54,159,160,163,179,193,199
DePriest	0.91 (0.84 to 0.95)	0.68 (0.49 to 0.82)	0.88 to 1.00	0.40 to 0.81	35,36,69,83,93,115
Ferrazzi	0.87 (0.80 to 0.92)	0.81 (0.62 to 0.91)	0.84 to 0.87	0.67 to 0.88	69,75,93
Finkler	0.82 (0.65 to 0.91)	0.78 (0.59 to 0.91)	0.52 to 0.88	0.55 to 0.70	56,62,63
Other (note: significant heterogeneity in criteria used for diagnosis – see ROC curve)	0.86 (0.82 to 0.89)	0.83 (0.76 to 0.88)	0.43 to 1.00	0.29 to 1.00	33,34,39,42,43,67,69,74,76- 80,87,90,95,97,101,102,104, 106,108,112,117,118,122,12 4-127,133-135,138- 140,142,144,146,147,155,16 1,166,168,169,171,180,181,1 85,187,188,192,195

Table 10. Sensitivity and specificity of ultrasound morphology

Abbreviations: CI = confidence interval; ROC = receiver operating characteristic


Results. The results of pooled sensitivity and specificity using a random-effects model, along with the range of sensitivity and specificity reported in individual studies, are shown in Table 10. Included studies are shown in Figures 6-10. There was a great range in test results, especially in the studies not using established scoring systems. This most likely reflects the heterogeneity of the tests themselves. There was little concrete difference among the established scoring systems. Overall the tests achieved relatively higher levels of sensitivity and negative predictive value (NPV) in the diagnosis of malignancy than specificity or positive predictive value (PPV). With the exception of four studies, the NPV was above 0.80, with the majority of tests above 0.90. The PPV in the majority of studies was below 0.50. In general, there was a trade-off between sensitivity and specificity, both in the individual studies of a specific scoring system, and in pooled results of all studies of a scoring system – as sensitivity increases, specificity decreases.





Key to Figure 6: 1 = Lerner et al., 1994;¹³¹ 2 = Ferrazzi et al., 1997;⁹³ 3 = Sawicki et al., 2001;¹⁶⁰ 4 = Rehn et al., 1996;¹⁵⁴ 5 = Sassone et al., 1991;¹⁵⁹ 6 = Caruso et al., 1996;⁸³ 7 = Leeners et al., 1996;¹³⁰ 8 = Alcazar and Lopez-Garcia, 2001;⁶⁶ 9 = Alcazar et al., 2003;⁶⁹ 10 = Timor-Tritsch et al., 1993;¹⁷⁹ 11 = Zanetta et al., 1994;¹⁹³ 12 = Alcazar et al., 1996;¹⁵⁴ 13 = Schneider et al., 1993;⁴³ 14 = Buckshee et al., 1998;⁵⁴ 15 = Sengoku et al., 1994;¹⁶³

Figure 7. Performance of ultrasound scoring according to DePriest's criteria (1993)



Key to Figure 7: 1 = Ferrazi et al., 1997;⁹³ 2 = Caruso et al., 1996;⁸³ 3 = DePriest et al., 1993;³⁵ 4 = Alcazar et al., 2003;⁶⁹ 5 = Itakura et al., 2003;¹¹⁵ 6 = DePriest et al., 1993³⁶




Figure 8. Performance of ultrasound scoring according to Ferrazzi's criteria (1997)

Key to Figure 8: 1 = Ferrazzi et al., 1997;⁹³ 2 = Berlanda et al., 2002;⁷⁵ 3 = Alcazar et al., 2003⁶⁹




Figure 9. Performance of ultrasound scoring according to Finkler's criteria (1988)

Key to Figure 9: 1 = Schutter et al., 1994;⁶² 2 = Schutter et al., 1998;⁶³ 3 = Finkler et al., 1988⁵⁶




Figure 10. Performance of ultrasound scoring according to various other unvalidated criteria

Key to Figure 10: 1 = DePriest et al., 1997;³⁴ 2 = Marchetti et al., 2002;¹⁴⁰ 3 = Tailor et al., 2003;¹⁷¹ 4 = Ekerhovd et al., 2001;⁹⁰ 5 = Canis et al., 1997;⁸⁰ 6 = Wakahara et al., 2001;¹⁸⁷ 7 = Maggino et al., 1994;¹³⁵ 8 = Schelling et al., 2000;¹⁶¹ 9 = Roman et al., 1997;⁴² 10 = Brown et al., 1998;⁷⁷ 11 = Granberg et al., 1990;¹⁰¹ 12 = Hermann et al., 1987;¹⁰⁸ 13 = Kurjak and Predanic, 1992;¹²⁵ 14 = Tingulstad et al., 1996;¹⁸⁰ 15 = Stein et al., 1995;¹⁶⁸ 16 = Torres et al., 2002;¹⁸¹ 17 = Manjunath et al., 2001;¹³⁹ 18 = Ma et al., 2003;¹³⁴ 19 = Valentin et al., 2001;¹⁸⁵ 20 = Franchi et al., 1995;⁹⁵ 21 = Merce et al., 1998;¹⁴⁶ 22 = Davies et al., 1993;⁸⁷ 23 = Morgante et al., 1999;¹⁴⁷ 24 = Benjapibal et al., 2003;⁷⁴ 25 = Gadducci et al., 1988;⁹⁷ 26 = Buy et al., 1996;⁷⁹ 27 = Strigini et al., 1996;¹⁶⁹ 28 = Luxman et al., 1991;¹³³ 29 = Kurjak et al., 1994;¹²⁷ 30 = Huber et al., 2002;¹¹² 21 = Reles et al., 1997;¹⁵⁵ 32 = Mancuso et al., 2004;¹³⁸ 33 = Kurjak et al., 2000;¹²⁴ 34 = Alcazar et al., 2003;⁶⁹ 35 = Kurjak et al., 1992;¹²⁶ 36 = Komatsu et al., 1996;¹²² 37 = Yamashita et al., 1995;¹⁹² 38 = Sohaib et al., 2005¹⁶⁶ 39 = Cohen et al., 2001;³³ 40 = Medl et al., 1995;¹⁴⁴ 41 = Hata et al., 1992;¹⁰⁶ 42 = Schneider et al., 1993;⁴³ 43 = Weiner et al., 1992;¹⁸⁸ 44 = Jain = 1994¹¹⁷ 45 = Buist et al., 1994⁷⁸ 46 = Alcazar et al., 2003⁶⁷ 47 = Lin et al., 1993³⁹ 48 = Jain et al., 1993;¹¹⁸ = Bromley et al., 1994;⁷⁶ 50 = Zimmer et al., 2003¹⁹⁵

Comparing the figures, studies using the Sassone criteria show greater variability in sensitivity compared to variability in specificity (Figure 6), while those using the DePriest criteria (Figure 7) show greater variability in specificity and a relatively narrow range of sensitivity. Figure 10, which depicts a variety of other studies, suggests trade-offs between sensitivity and specificity; different morphology methods for discriminating benign from malignant have different thresholds, resulting in the sensitivity/specificity trade-off.

Three articles compared different scoring systems within the same study population. Caruso et al.⁸³ examined 112 women with adnexal masses comparing Sassone, DePriest, and Valentin scores. All performed similarly, displaying a sensitivity and NPV of 1.00, a range of specificity of 0.61 to 0.75, and a range of PPV of 0.35 to 0.48. Alcazar et al.⁶⁹ also compared the performance of Sassone, DePriest, and Ferrazzi. There were no significant differences between these scoring systems when receiver operating characteristic (ROC) curves were compared. The area under the curve (AUC) was 0.89 for Sassone, 0.92 for DePriest, and 0.90 for Ferrazzi. Ferrazzi et al.⁹³ evaluated 261 masses collected in three different centers. They compared ROC curves for scores based on Sassone, Granberg, DePriest, and Lerner's criteria and compared it with a scoring systems. Their new scoring system (Ferrazzi) performed better, with an AUC of 0.84 (p < 0.0001). However, subsequent comparisons have not reaffirmed its superior functioning. When the Ferrazzi scoring system was compared to both Sassone and DePriest, ⁶⁹ its performance was almost identical.

In spite of different designs, all the scoring systems performed similarly when compared within the same study population. It has been suggested that the poor performance of scoring systems with regard to their PPV is due to the misclassification of dermoid tumors.¹⁹⁷ Dermoids share many of the features that are characterized as "malignant" in scoring systems. The Alcazar study proposes a scoring system that was developed in part to correct this. Although this scoring system does perform well in its initial application, it has not been independently verified. The authors conclude, "a completely reliable differentiation of malignant masses cannot be obtained by sonographic imaging alone."⁶⁹

Stratification by menopausal status. Of the 69 articles identified that addressed the assessment of adnexal morphology by ultrasound, only 13 contained data that either directly reported test characteristics by menopausal status or contained enough information to enable the stratification of results. Six were studies in a 100 percent postmenopausal patient population. Seven were studies that allowed comparison by menopausal status within the study population. They are presented in Table 11. The only significant difference in test performance appears to be in regards to the PPV. With the exception of Roman et al.,⁴² the PPV is slightly higher in postmenopausal women. This likely reflects the higher prevalence of ovarian malignancy after menopause. Aside from the PPV, the performance of ultrasound in the morphological assessment of adnexal masses does not appear to be significantly changed by menopausal status.

Study	Scoring System	Premenopausal				Postmenopausal			
		Sens	Spec	PPV	NPV	Sens	Spec	PPV	NPV
Finkler et al., 1988 ⁵⁶	Finkler	0.50	0.96	0.50	0.77	0.78	0.92	0.94	0.75
Franchi et al., 1995 ⁹⁵	Descriptive	0.73	0.86	0.44	0.95	0.89	0.75	0.82	0.83
Guerriero et al., 2002 ¹⁰⁵	Descriptive	0.98	0.89	0.44	1.00	1.00	0.51	0.52	1.00
Reles et al., 1997 ¹⁵⁵	Modified score	1.00	0.79	0.46	1.00	0.87	0.89	0.77	0.94
Roman et al., 1997 ⁴²	Descriptive	0.93	0.92	0.66	0.99	0.81	0.62	0.54	0.86
Schelling et al., 2000 ¹⁶¹	Descriptive	0.91	0.84	0.29	0.99	1.00	0.73	0.62	1.00

Study	Scoring System	Premenopausal				Postmenopausal			
		Sens	Spec	PPV	NPV	Sens	Spec	PPV	NPV
Alcazar et al., 2003 ⁶⁹	Sassone DePriest Ferrazzi Alcazar	1.00 1.00 1.00 1.00	0.88 0.80 0.84 0.96	0.50 0.38 0.43 0.75	1.00 1.00 1.00 1.00	0.61 1.00 0.82 1.00	0.88 0.82 0.82 0.94	0.81 0.82 0.79 0.93	0.73 1.00 0.85 1.00
Menon et al., 2000 ¹⁴⁵	Descriptive	-	-	-	-	1.00	0.94	0.24	1.00
Schutter et al., 1994 ⁶²	Finkler	-	-	-	-	0.88	0.64	0.65	0.88
Bromley et al., 1994 ⁷⁶	Unique scoring	-	-	-	-	0.91	0.52	0.52	0.92
Schutter et al., 1998 ⁶³	Finkler	-	-	-	-	0.86	0.70	0.65	0.89
Luxman et al., 1991 ¹³³	Descriptive	-	-	-	-	0.93	0.55	0.45	0.95
Kuriak et al., 1992 ¹²⁶	Unique scoring	-	-	-	-	0.48	0.98	0.93	0.78

Abbreviations: NPV = negative predictive value; PPV = positive predictive value; Sens = sensitivity; Spec = specificity

Ultrasound Doppler Studies

Color Doppler scanning allows the assessment of tumor vascularity. Malignant neoplasms have active blood vessel creation (angiogenesis) compared to normal or benign neoplasms due, in part, to their increased metabolic activity. Overall, malignancies display an increased vascularity with decreased peripheral blood flow resistance and increased blood flow velocity compared with benign tissue.^{152,200} Doppler signal analysis can separate high-resistance and low-resistance vessels and has therefore been investigated as a separate test modality, as well as in combination with ultrasound morphological evaluation in the evaluation of adnexal masses.

The most common flow criteria are the resistance index (RI), the pulsatility index (PI), and the maximum systolic velocity. RI is defined as the difference between peak systolic and maximum enddiastolic flow velocity, divided by peak systolic flow velocity. Usually the lowest measured RI from a series of measurements is reported from different arteries. PI is defined as the difference between peak systolic and enddiastolic flow velocity, divided by the time-averaged flow velocity. The maximum systolic velocity is the maximum flow recorded in any visualized artery.

In order to make a measurement of either RI or PI or maximum systolic velocity, an artery must be identified on ultrasound. The inability to identify an artery in the mass means that the test cannot be performed. Therefore, not every individual included in the study population is captured with the assessment of these color Doppler modalities. Another limitation of these measurements is that the range observed in malignant masses overlaps with that observed in benign masses. For example, in Lin et al.,¹³² discussed in more detail below, the RI for malignant masses ranged from 0.23 to 0.82. Although they did not report a range for the benign masses, there were eight benign tumors with a RI < 0.4. This overlap limits the effectiveness of any threshold and, perhaps, contributes to the different thresholds reported in the literature.

Reproducibility of tests. Timmerman et al.¹⁹⁶ (discussed above under ultrasound morphology) included Doppler measurements in its analysis of interobserver variability and experience. In short, operators with more experience (300 versus 15,000 scans) had greater

accuracy (92 percent versus 82 to 87 percent, p = 0.0001). Interassessor agreement was also greater between the most experienced operators (kappa = 0.852) compared with the less experienced operators (range 0.581 to 0.737). None of the articles evaluating color Doppler described operator experience, nor did any address interobserver variability specifically in regards to Doppler measurement.

Trials identified. Fifty-six articles were identified that described color Doppler analysis, comprising a description of 65 tests. Thirty-two articles evaluated RI, 20 PI, and six the maximum systolic velocity. These are the most common flow criteria measured in the literature and presumably in clinical practice as well. Other Doppler parameters were described in the literature sometimes in conjunction with either RI or PI or maximum systolic velocity but were not included in this table. The other articles included 10 that involved the visualization of flow within the mass, 70,71,104,105,119,137,160,161,168,182 two that involved counting the total number of arteries (either > 4¹⁵² or > 3¹⁹⁹), and one that measured the absence of a diastolic notch.¹³⁷


Results. Table 12 details the test characteristics of RI, PI, and the maximum systolic velocity in the evaluation of an adnexal mass, again using pooled values from a random-effects model. For RI the range reported was from ≤ 0.8 to < 0.4, with < 0.4 being the most common. For PI the range was relatively narrower from < 1.5 to < 1.0 with the majority of studies using either ≤ 1.0 or < 1.0. The reported range was greatest in the assessment of maximum systolic velocity, where there were also the fewest studies from > 30 cm/second to > 10 cm/second. As the threshold for RI decreases from ≤ 0.8 to < 0.4, the sensitivity and NPV decrease, and the specificity and PPV increase. This is seen most clearly in studies that evaluated a series of RI cutpoints with the same study population.^{132,176}

Lin et al.¹³² evaluated 370 women with adnexal masses who were scheduled for surgery at a single institution. They reported outcomes based on RI cutpoints of 0.4, 0.5, and 0.6. For RI < 0.4, the sensitivity, specificity, PPV, and NPV were 0.69, 0.97, 0.89, and 0.91, respectively. For RI < 0.5, they were 0.79, 0.92, 0.77, and 0.93. And for < 0.6, they were 0.91, 0.86, 0.68, and 0.98. The authors conclude that the 0.4 cutpoint yields the highest concordance rate between Doppler prediction and histopathologic diagnosis. This conclusion, however, is based more on clinical impression, as ROC curve analysis was not performed.

The range of Doppler study performance is listed in Table 12 and shown in Figures 11-13. Overall there was great heterogeneity of performance results. The range of sensitivity was largest for RI. This range did not appear to be secondary to differences in RI thresholds; however, the < 0.4 threshold did appear to narrow specificity results. In spite of the large variation in thresholds described for maximum systolic velocity, the range of test characteristics was somewhat narrower than that for RI, probably because there were fewer studies identified that used this measurement. Again, there is a trade-off between sensitivity and specificity, although this appears greatest for maximum velocity.


Doppler method	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Range of sensitivity in individual studies	Range of specificity in individual studies	References
Resistance index	0.76 (0.68 to 0.73)	0.89 (0.84 to 0.92)	0.19 to 1.00	0.53 to 1.00	43,68,70,75,76,79,81,86,88,95,106,107,1 17,124- 126,128,130,132,141,146,152,168,172,1 75,176,179,184,190,193,199,201
Pulsatility index	0.79 (0.73 to 0.83)	0.74 (0.64 to 0.81)	0.57 to 0.95	0.32 to 0.97	73,79,81,94,103,109,115,120,154,155,15 8,163,168,169,179,182,184,188,199,201
Maximum systolic velocity	0.76 (0.61 to 0.86)	0.83 (0.66 to 0.93)	0.48 to 0.94	0.43 to 0.97	68,79,107,109,152,199






Key to Figure 11: $1 = Kurjak et al., 1991;^{128} 2 = Wu et al., 1994;^{190} 3 = Lin et al., 1993;^{132} 4 = DePriest et al., 1994;^{88} 5 = Prompeler et al., 1996;^{152} 6 = Tepper et al., 1995;^{176} 7 = Kurjak and Predanic, 1992;^{125} 8 = Valentin, 2000;^{184} 9 = Stein et al., 1995;^{168} 10 = Anandakumar et al., 1996;^{70} 11 = Valentin, 1996^{201} 12 = Franchi et al., 1995;^{95} 13 = Merce et al., 1998;^{146} 14 = Carter et al., 1995;^{81} 15 = Takac, 1998;^{172} 16 = Buy et al., 1996;^{79} 17 = Leeners et al., 1996;^{130} 18 = Chou et al., 1994;^{86} 19 = Hata et al., 1995;^{107} 20 = Marret et al., 2004;^{141} 21 = Kurjak et al., 2000;^{124} 22 = Kurjak et al., 1992;^{126} 23 = Timor-Tritsch et al., 1993;^{179} 24 = Zanetta et al., 1994;^{193} 25 = Tekay and Jouppila, 1992;^{175} 26 = Alcazar et al., 1996;^{199} 27 = Hata et al., 1992;^{106} 28 = Schneider et al., 1993;^{43} 29 = Berland et al., 2002;^{75} 30 = Alcazar and Lopez-Garcia, 2001;^{68} 31 = Jain, 1994;^{117} 32 = Bromley et al., 1994^{76}$





Key to Figure 12: 1 = Rehn et al., 1996;¹⁵⁴ 2 = Guerriero et al., 1998;¹⁰³ 3 = Valentin, 2000;¹⁸⁴ 4 = Stein et al., 1995;¹⁶⁸ 5 = Itakure et al., 2003;¹¹⁵ 6 = Valentin, 1999;²⁰¹ 7 = Valentin, 1997^{182} 8 = Carter et al., 1995^{81} 9 = Buy et al., 1996;⁷⁹ 10 = Benjapibal et al., 2002;⁷³ 11 = Kawai et al., 1994;¹²⁰ 12 = Strigini et al., 1996;¹⁶⁹ 13 = Hillaby et al., 2004;¹⁰⁹ 14 = Salem et al., 1994;¹⁵⁸ 15 = Timor-Tritsch et al., 1993;¹⁷⁹ 16 = Reles et al., 1997;¹⁵⁵ 17 = Alcazar et al., 1996;¹⁹⁹ 18 = Fleischer et al., 1992;⁹⁴ 19 = Weiner et al., 1992;¹⁸⁸ 20 = Sengoku et al., 1994^{163}





Key to Figure 13: 1 = Prompeler et al., 1996;¹⁵² 2 = Buy et al., 1996;⁷⁹ 3 = Hillaby et al., 2004;¹⁰⁹ 4 = Alcazar et al., 1996;¹⁹⁹ 5 = Alcazar and Lopez-Garcia, 2001^{68}


Table 13 compares the characteristics of Doppler studies that did not use measurement or calculation of Doppler waveforms. They relied instead on either the presence of vascularity within the mass (yes/no) or on a direct count of vessels seen. These tests seem to perform as well as the RI or PI in terms of sensitivity, although specificity varies quite widely (Figure 13). Valentin¹⁸² measured both the PI (< 1.0) and the presence of color lakes visible on Doppler in the same study population. Of 151 patients, PI was measured in 135, indicating that for 16 individuals, no artery was visualized within the mass. The sensitivity reported for the PI was 0.83, specificity 0.34, PPV 0.20, and NPV 0.91. Simply documenting the presence or absence of visible color lakes on Doppler yielded a sensitivity of 0.88, a specificity of 0.67, a PPV of 0.33, and a NPV of 0.97. Not only did the direct visualization test perform better, but because its outcome was a simple binary outcome (present or absent), the results included the entire study population (n = 151). Prompeler et al.¹⁵² measured RI, maximum systolic velocity, as well as the number of arteries visualized in the mass. Their data for the simple counting of arteries also performs as well if not better than the calculated tests such as RI or PI. In a random-effects

model, pooled sensitivity for the presence or absence of blood flow within a mass was 0.88 (95% CI, 0.80 to 0.92) and pooled specificity 0.78 (95% CI, 0.65 to 0.87)

Study (N)	Test	Sensitivity	Specificity
Prompeler et al., 1996 ¹⁵² (212)	Total number of arteries > 4 (postmenopausal women only)	0.82	0.92
Valentin, 1997 ¹⁸² (151)	Color lakes visible on Doppler	0.88	0.67
Maly et al., 1995 ¹³⁷ (102)	Demonstrable blood vessels	0.95	0.30
Schelling et al., 2000 ¹⁶¹ (257)	Central vascularity on Doppler in solid component	0.93	0.94
Stein et al., 1995 ¹⁶⁸ (170 masses)	Internal flow within solid component or septation	0.77	0.69
Guerriero et al., 2002 ¹⁰⁵ (826 masses)	Arterial flow visualized in an echogenic structure or irregular solid portion	0.95	0.92
Anandakumar et al., 1996 ⁷⁰ (146)	"Continuously fluctuating" vessels with turbulent flow	0.77	0.68
Antonic and Rakar, 1995 ⁷¹ (71)	Color flow present	0.89	0.47
Guerriero et al., 2005 ¹⁰⁴ (424)	Color flow present in "echogenic structure"	1.00	0.91
Juhasz et al., 1990 ¹¹⁹ (147)	Color flow present in mass	0.96	0.84

Table 13.	Study characteristics	of simple Doppler visualization
-----------	------------------------------	---------------------------------





Key to Figure 14: 1 = Guerriero et al., 2005;¹⁰⁴ 2 = Schelling et al., 2000;¹⁶¹ 3 = Prompeler et al., 1996;¹⁵² 4 = Stein et al., 1995;¹⁶⁸ 5 = Valentin, 1997;¹⁸² 6 = Maly et al., 1995;¹³⁷ 7 = Anandakumar et al., 1996;⁷⁰ 8 = Antonic and Rakar, 1995^{71}

Stratification by menopausal status. Out of a total of 56 studies identified that evaluated color Doppler, only 11 contained data that either directly reported test characteristics by menopausal status or contained enough information to enable the stratification of results. Two of these studies were in a 100 percent postmenopausal population, and nine enabled comparison by menopausal status within the same study population (Table 14). When comparing test performance within the same study population stratified by menopausal status, the PPV of the test is significantly increased in the postmenopausal group. In Salem et al.,¹⁵⁸ the PPV increased only from 0.20 in the premenopausal group to only 0.47 in the peri- and postmenopausal group. This may be a reflection of how they defined peri- and postmenopause (which was not clearly stated by the authors). After stratifying the reported results by age (> 45), the PPV is 0.73. This increase in PPV among postmenopausal women appears to be greater in the context of Doppler studies than that observed with ultrasound morphology. This finding differs from the one meta-analysis on the subject. Kinkel et al.¹⁹⁷ did a systematic review of both ultrasound morphology and Doppler in the detection of malignant masses. Although they noted a difference in outcomes

dependent on menopausal status, this difference did not reach statistical significance. Interestingly, there was a difference in terms of Doppler test performance by year of publication with better results demonstrated by earlier studies (p = 0.005), a result that was independent of sample size.

Study	Test		Premer	opausa	I	P	ostmen	opausal	
(N)		Sens	Spec	PPV	NPV	Sens	Spec	PPV	NPV
Franchi et al., 1995 ⁹⁵ (129)	RI < 0.65	0.82	0.72	0.31	0.96	0.86	0.75	0.82	0.83
Guerriero et al., 2002 ¹⁰⁵ (826 masses)	Arterial flow visualized in echogenic structure or irregular solid portion	0.94	0.96	0.67	1.00	0.96	0.77	0.69	0.97
Reles et al., 1997 ¹⁵⁵ (98)	PI ≤ 1.1	0.80	0.67	0.36	0.93	0.93	0.83	0.76	0.91
Schelling et al., 2000 ¹⁶¹ (257)	Presence of central vascularization on Doppler	0.91	0.94	0.53	0.99	0.93	0.92	0.84	0.97
Prompeler et al., 1996 ¹⁵² (212)	Total number of arteries > 4 RI > 0.5 Maximum systolic velocity > 30cm/s	0.85 0.84 0.92	0.71 0.47 0.65	0.36 0.23 0.33	0.96 0.94 0.98	0.82 0.82 0.76	0.82 0.69 0.88	0.76 0.66 0.82	0.86 0.84 0.84
Strigini et al., 1996 ¹⁶⁹ (109)	PI < 1	0.83	0.73	0.21	0.98	0.85	0.81	0.73	0.90
Salem et al., 1994 ¹⁵⁸ (109 masses)	PI < 1	1.00	0.84	0.20	1.00	0.73	0.71	0.47	0.88
Szpurek et al., 2004 ¹⁷⁰ (464)	Doppler subjective index ≥ 4	0.82	0.93	0.79	0.94	0.92	1.00	1.00	0.82
Kurjak et al., 1992 ¹²⁶ (83)	RI < 0.41 randomly separate vessels	-	-	-	-	0.96 0.90	0.95 0.98	0.90 0.96	0.98 0.95
Bromley et al., 1994 ⁷⁶ (33)	RI < 0.6	-	-	-	-	0.66	0.81	0.67	0.81
Antonic and Rakar, 1995 ⁷¹ (71)	Presence of color flow	1.00	0.36	0.11	1.00	0.87	0.79	0.81	0.85
Guerriero et al., 1998 ¹⁰³ (192 masses)	PI ≤ 1	0.86	0.46	0.08	0.98	0.88	0.52	0.66	0.81

Table 14. Doppler studies stratified by menopausal status

Abbreviations: NPV = negative predictive value; PI = pulsatility index; PPV = positive predictive value; RI = resistance index; Sens = sensitivity; Spec = specificity


Combined Ultrasound Morphology and Doppler

A limiting feature of ultrasound morphologic assessments has been felt to be the high rate of false positive test results.¹⁹⁶ Color Doppler, in contrast, has displayed a slightly higher PPV, especially in the earlier studies.¹⁹⁷ There have, therefore, been attempts to combine ultrasound morphology and Doppler studies in a single test.

Trials identified. Of all the articles that investigated the use of either ultrasound morphology or color Doppler in the evaluation of an adnexal mass, nine articles containing a total of 13 tests described a combination ultrasound morphology and Doppler modality.^{65,79,91,100,123-125,130,201}

Results. There is a large range in the reported study performance (sensitivity ranges from 0.71 to 0.98, specificity from 0.6 to 1.0. The relevant studies are shown in Figure 15; all but two had both sensitivity and specificity above 0.80. Pooled sensitivity in a random-effects model was 0.89 (95% CI, 0.81 to 0.93) and pooled specificity 0.91 (0.80 to 0.96). Both of these values were higher than the pooled values for any morphology or Doppler method alone.

Figure 15. Performance of combined ultrasound morphology and color Doppler



Key to Figure 15: 1 =Kurjak and Predanic, 1992;¹²⁵ 2 =Valentin, 1999;²⁰¹ 3 =Kurjak and Kupesic, 1999;¹²³ 4 =Buy et al., 1996;⁷⁹ 5 =Leeners et al., 1996;¹³⁰ 6 =Grab et al., 2000;¹⁰⁰ 7 =Fenchel et al., 2002;⁹¹ 8 =Kurjak et al., 2000;¹²⁴ 9 = Alcazar and Castillo, 2005⁶⁵

Stratification by menopausal status. There were two studies that analyzed combined ultrasound morphology and Doppler in 100 percent post menopausal patient populations. Kurjak et al.¹²⁶ reported a combined sensitivity, specificity, PPV, and NPV of 0.90, 0.94, 0.90, and 0.94, respectively. Their combined test consisted of RI < 0.41 and an ultrasound morphology scoring

system unique to them. Veunto et al.¹⁸⁶ in a population-based screening study reported a sensitivity, specificity, PPV, and NPV of 1.00, 0.83, 0.006, and 1.00, respectively. Given that these two studies are of greatly different design, it is hard to compare them directly. Comparing Kurjak et al. to the range of combined ultrasound and Dopper studies, it appears that in the postmenopausal group, the test has a better performance. However, this test performance may reflect patient selection criteria for the study that was not clearly explained. Combination modalities as a screening tool for ovarian cancer had a high false positive rate (as seen in the PPV of 0.006^{186}).

3D Versus 2D Ultrasound

We identified five studies that analyzed 3D ultrasound. Four are listed in Table 15. The fifth, by Cohen et al.,³³ was not included because it compared 2D ultrasound with 2D plus some component of a 3D exam (possibly 3D Doppler) that was not clearly stated in the article. Overall, 3D ultrasound appears superior to 2D especially in regards to sensitivity and PPV performance. We were unable to stratify these results by menopausal status. Test reliability and variability were not addressed specifically in terms of 3D ultrasound.

Study	Test	Sensitivity	Specificity	PPV	NPV
(number of persons)					
Alcazar et al., 2003 ⁶⁷	2D 3D	0.90	0.61 0.78	0.68 0.81	0.88
(41 masses)	Presence of one of the following fulfilled criteria for mass: > 3 mm wall, > 3 mm septum, > 3 mm papillary projections, solid areas or echogenicity				
Kurjak and	2D	0.91	0.97	0.77	0.99
Kupesic, 1999 ¹²³ (120)	3D Both used a unique scoring system that included Doppler measurements	1.00	0.99	0.92	1.00
Kurjak et al.,	2D morphology	0.67	0.94	0.55	0.96
2000 ¹²⁴	2D Doppler	0.89	0.95	0.67	0.99
(90)	2D combined	0.89	0.98	0.80	0.99
	3D morphology	0.78	0.98	0.78	0.98
	3D Doppler	0.89	0.98	0.80	0.99
	3D combined Both used a unique scoring system for morphological assessment. Doppler for 2D was RI ≤ 0.42, for 3D it was "complex" "chaotic" vessel arrangement	1.00	0.99	0.90	1.00
Alcazar and	2D	0.98	0.88	0.94	0.96
Castillo, 2005 ⁶⁵	3D	0.98	0.79	0.90	0.95
(69 masses)	Presence of at least one of the following fulfilled criteria for "complex mass": >3mm wall, > 3 mm papillary projection, solid areas or purely solid echogenicity Doppler flow in mass also used in test but unclear how				

Table 15. 3D versus 2D ultrasound

Abbreviations: 2D = two-dimensional; 3D = three-dimensional; NPV = negative predictive value; PPV = positive predictive value

Other Imaging Modalities

Although ultrasound remains the most common imaging modality in the evaluation and diagnosis of adnexal masses, newer technologies such as MRI, CT, and positron emission tomography (PET) have been studied as well. These modalities may not be as readily available to the clinician as ultrasound, and there is less literature devoted to them than to ultrasound; however, they are included in this review because of growing interest both clinical and research in their use. Further, despite refinements in ultrasound morphology scoring systems or Doppler measurements, the overall performance of ultrasound in the evaluation of the adnexal mass may be relatively fixed by the technology itself. Therefore it is necessary to investigate other imaging modalities and see how they compare with ultrasound.

Reproducibility of tests. Unlike ultrasound, MRI, CT, and PET images are not operator dependent in terms of obtaining the images. There is, however, the potential for interobserver variability in their analysis. There are no standardized morphological scoring systems for any imaging modality other than ultrasound. We identified two articles that directly addressed the issue of test reproducibility for either MRI and/or CT in the evaluation of adnexal masses. Buist et al.,⁷⁸ however, reported a series of 64 women who were evaluated by both MRI and CT and reviewed by two different radiologists. They reported a kappa value for the interobserver reliability for distinguishing between benign and malignant disease of 0.28 for CT and 0.41 for MRI. Yamashita et al.¹⁹² also calculated kappa values for interobserver variability among five radiologists. They showed far greater agreement: for precontrast MRI, kappa = 0.71 (\pm 0.02); for contrast-enhanced MRI, kappa = 0.73 (\pm 0.02).

Trials identified. We identified 17 articles comprising 22 tests. There were 15 articles for MRI, three for CT, and three for PET and one that used a combined CT/MRI test. There were two articles that investigated nuclear medicine technologies in the evaluation of adnexal masses. These, however, were not included in the review given the experimental nature of such tests at this time. The PET studies were all performed also using tracer 18-Fluorodeoxyglucose (FDG) with the test measuring uptake of FDG in the lesion.

Results. The results of MRI, CT, and PET modalities are summarized in Table 16. All of the articles describing CT and PET and most of the articles describing MRI either used descriptive criteria for differentiating malignant from benign appearing lesions or did not report the criteria used. Only two articles for MRI used a scoring system, slightly different from each other, which increases the difficulty in comparing studies. To date, there are no standardized scoring systems for any imaging modality other than ultrasound.

The range of test performance of MRI, CT, and PET are shown in Table 16. Table 17 includes, for comparison, the test performance for ultrasound morphology, color Doppler (all the modalities), and ultrasound morphology and Doppler combined. Tian et al.¹⁷⁷ was excluded from this table because there was no description how CT and MRI were combined for a single test result (in series versus in parallel). Overall the sensitivity for MRI, CT, and PET are similar to that of combined ultrasound morphology and Doppler and less heterogenous than either modality separate. The specificity, however, is equivalent to either test separate and wider than the tests combined, with the exception of FDG-PET. However, the comparatively narrow range of both CT and PET results could be secondary to the relatively few studies that use these modalities. There is a large range of results for PET PPVs and a small range for CT, again possibly reflecting the paucity of studies. The range of NPVs for MRI is comparable to that for combined ultrasound morphology and Doppler and better than either CT or PET. Overall MRI

appears similar in performance to combined ultrasound. More research is needed to accurately assess the performance range of CT and PET.

Imaging modality	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Range of sensitivity in individual studies	Range of specificity in individual studies	References
MRI	0.91 (0.86 to 0.94)	0.87 (0.83 to 0.90)	0.67 to 1.00	0.77 to 1.00	44,78,91,100,106,111,112,118,121,122 ,129,144,156,166,192
СТ	0.90 (0.83 to 0.94)	0.75 (0.36 to 0.94)	0.86 to 0.96	0.35 to 0.89	39,78,129
FDG-PET	0.67 (0.52 to 0.79)	0.79 (0.70 to 0.85)	0.58 to 0.78	0.76 to 1.00	91,100,121

Table 16. Sensitivity and specificity of other imaging modalities

Abbreviations: CI = confidence interval; CT = computed tomography; FDG = 18-Fluorodeoxyglucose; MRI = magnetic resonance imaging; PET = positron emission tomography

Another way to compare imaging modalities is by looking at studies that compare imaging modalities within the same study population. These are listed in Table 17. There may be a small benefit in performance of MRI over ultrasound, especially in terms of PPV. There is no evidence to support the superiority of any single modality, although FDG-PET appears inferior to the rest.

Study	Test	Sensitivity	Specificity	PPV	NPV
(N)					
Medl et al.,	Ultrasound morphology (descriptive)	0.81	0.73	0.79	0.76
1995 ¹⁴⁴	MRI descriptive	0.97	0.83	0.88	0.96
(73)					
Yamashita et al.,	Ultrasound morphology (unique score)	0.89	0.84	0.63	0.96
1995 ¹⁹²	MRI precontrast	0.78	0.93	0.79	0.93
(72 women 80	MRI contrast enhanced	0.91	0.93	0.81	0.97
masses)					
Fenchel et al.,	Ultrasound combined morphology and	0.92	0.60	0.24	0.98
2002 ⁹¹	Doppler	0.83	0.83	0.40	0.97
(99)	MRI	0.58	0.76	0.25	0.93
. ,	FDG-PET				
Jain et al.,	Ultrasound morphology (descriptive)	1.00	0.60	0.18	1.00
1993 ¹¹⁸	MRI	0.67	1.00	1.00	0.97
(32)					
Kawahara et al.,	MRI descriptive	0.91	0.87	0.91	0.87
2004 ¹²¹	FDG-PET	0.78	1.00	1.00	0.75
(38)					
Komatsu et al.,	Ultrasound morphology (unique score)	1.00	0.46	0.57	1.00
1996 ¹²²	MRI descriptive (n = 59)	0.91	0.88	0.91	0.88
(82)					
Lin et al., 1993 ³⁹	Ultrasound morphology (descriptive)	0.83	0.50	0.58	0.79
(80)	CT descriptive	0.86	0.36	0.74	0.56
Buist et al.,	CT reviewer a	0.96	0.44	0.72	0.89
1994 ⁷⁸	CT reviewer b	0.89	0.83	0.89	0.83
(64)	MRI reviewer a	0.96	0.33	0.68	0.86
	MRI reviewer b	0.96	0.94	0.96	0.94
	Ultrasound morphology (NR)	0.89	0.44	0.71	0.73
Grab et al.,	Ultrasound combination morphology	0.92	0.60	0.23	0.98
2000 ¹⁰⁰	and Doppler	0.83	0.84	0.42	0.97

Table 17. Comparison of MRI, CT, FDG-PET, and ultrasound

Study (N)	Test	Sensitivity	Specificity	PPV	NPV
(101)	MRI descriptive FDG-PET	0.58	0.80	0.28	0.93
Hata et al., 1992 ¹⁰⁶ (63)	Ultrasound (NR) MRI score	0.85 0.67	0.69 0.97	0.68 0.95	0.86 0.80
Huber et al., 2002 ¹¹² (93)	Ultrasound morphology (descriptive) MRI descriptive	0.85 0.89	0.73 0.86	0.87 0.93	0.71 0.79
Reuter et al., 1998 ¹⁵⁶ (65)	Ultrasound morphology (descriptive) MRI descriptive	1.00 1.00	0.66 0.78	0.40 0.50	1.00 1.00
Sohaib et al., 2005 ¹⁶⁶ (72)	Ultrasound morphology (descriptive) MRI descriptive	1.00 0.97	0.40 0.84	0.53 0.80	1.00 0.97

Abbreviations: CT = computed tomography; FDG = 18-Fluorodeoxyglucose; MRI = magnetic resonance imaging; NR = not reported; PET = positron emission tomography

Only two studies compared pre- and postcontrast enhancement with MRI.^{111,192} Contrast enhancement improved evaluative performance in both studies, particularly sensitivity. In Hricak et al. the sensitivity increased from 0.87 to 0.95, specificity from 0.75 to 0.79, PPV from 0.78 to 0.83, and NPV 0.84 to 0.94.¹¹¹ These results are similar to those of Yamashita et al.¹⁹² in Table 17.

Stratification by menopausal status. None of the studies describing MRI, CT, or PET reported results either by menopausal status or in data that would allow menopausal status to be stratified.

Serum Markers: CA-125

The concept of using tumor markers as either screening or diagnostic tests for ovarian cancer is dependent upon identifying an abnormal level of a particular marker in serum, reflecting a systemic effect of disease in the ovary. The most extensively investigated ovarian cancer associated antigen is CA-125. This antigen is recognized by a murine monoclonal antibody produced using an ovarian cancer cell line as an immunogen. Elevated levels are detected in approximately 80 percent of ovarian carcinomas at the time of diagnosis;^{136,167} however, elevated serum levels have also been reported in a variety of benign conditions, potentially affecting specificity. In addition, CA-125 is not as commonly elevated in non-epithelial ovarian cancers. Because these stromal and germ cell tumors are proportionately more common in premenopausal women, the sensitivity of CA-125 may it is not as sensitive in premenopausal women.³


Reproducibility of tests. Only one study included specific information regarding the interand intra-assay coefficients of variation.⁶⁶ They were < 7.5 percent and < 5.3 percent, respectively. The sensitivity of the assay in this study was < 5 U/ml.

Trials identified. We identified 66 studies that investigated the use of CA-125 as a serum marker in the evaluation of an adnexal mass. One study was a population-based screening study that employed CA-125 as part of the screening triage.⁵¹ Forty-six studies in total used 35 U/ml as a threshold – in 37 it was the only threshold used, whereas in five, both 35 U/ml and another threshold were reported for the same patient population. There were 24 studies that reported a threshold other than 35 U/ml ranging from >20 U/ml to >100 U/ml. In addition to the five

studies that reported 35 U/ml and an additional level, there were four other studies that reported two threshold levels within the same study population. All but one of the studies were case series. Although there were a few studies that compared CA-125 results from operative cases with normal controls, only the data from the operative series were included in the 2-by-2 tables. The clinical presentation of the cases was rarely described. Some of the series were drawn from oncology clinics

Results. At the most commonly used threshold of 35 U/mL, the pooled sensitivity of CA-125 for discriminating benign from malignant lesions was 0.78 (95% CI, 0.75 to 0.81), and the pooled specificity 0.78 (95% CI, 0.71 to 0.82). Individual study sensitivities ranged from 0.45 to 1.0, and specificities from 0.46 to 0.99; see Figure 16, where the trade-off between sensitivity and specificity resulting from different thresholds is clearly seen. Not including the one screening study in this series,⁵¹ the studies ranged in size from 52 to 429 individuals. Unlike ultrasound morphology assessments, the range of CA-125 performance is not influenced by the heterogeneity of evaluative modalities. However, the results of performance have, overall, a similarly broad range. This most likely reflects heterogeneity of study populations. As very few studies actually reported how patients were diagnosed with masses, it is impossible to accurately stratify these results by patient characteristics. As with ultrasound measurements (both morphology and Doppler), the narrowest range of CA-125 test performance was with NPV, making this, perhaps, the most reliable part of the test itself.

Figure 16. Performance of CA-125



Key to Figure 16: 1 = Adonakis et al., 1996;⁵¹ 2 = Woolas et al., 1995;¹⁸⁹ 3 = Gadducci et al., 1992;⁹⁸ 4 = Wakahara et al., 2001;¹⁸⁷ 5 = Maggino et al., 1994;¹³⁵ 6 = Dowd et al., 1993;⁵⁵ 7 = Schutter et al., 2002;¹⁶² 8 = Patsner and Mann, 1988;¹⁵¹ 9 = Roman et al., 1997;⁴² 10 = Schutter et al., 1994;⁶² 11 = Gadducci et al., 1991;⁹⁹ 12 = Chen et al., 1988;⁸⁵ 13 = Vasilev et al., 1988;⁵⁰ 14 = Timmerman et al., 1999;¹⁷⁸ 15 = Hogdall et al., 2000;¹¹⁰ 16 = Malkasian et al., 1988;¹³⁶ 17 = Torres et al., 2002;¹⁸¹ 18 = Schutter et al., 1998;⁶³ 19 = Manjunath et al., 2001;¹³⁹ 20 = Troiano et al., 1997;⁴⁷ 21 = Chalas et al., 1992;³¹ 22 = Mancuso et al., 2004;¹³⁸ 23 = Gadducci et al., 1988;⁹⁷ 24 = Finkler et al., 1988;⁵⁶ 5 = Tay and Chua, 1994;¹⁷⁴ 26 = Soper et al., 1990;¹⁶⁷ 27 = Smikle et al., 1995;⁴⁶ 28 = Hurteau et al., 1995;¹¹³ 29 = Asif et al., 2004;⁷² 30 = Einhorn et al., 1986;⁸⁹ 31 = Hillaby et al., 2004;¹⁰⁹ 32 = Alcazar et al., 1999;⁶⁶ 33 = Balbi et al., 2001;⁵³ 34 = Antoni and Rakar, 1995;⁷¹ 35 = Hata et al., 1992;¹⁰⁶ 36 = O'Connell et al., 1987;¹⁴⁸ 37 = Schneider et al., 1993;⁴³ 38 = Weiner et al., 1992;¹⁸⁸ 39 = Tian et al., 2000;¹⁷⁷ 40 = Berlanda et al., 2002;⁷⁵ 41 = Sengoku et al., 1994;¹⁶³

The only screening study identified for CA-125 in our literature search⁵¹ included 2000 women. The sensitivity in this study was 1.00, specificity 0.99, PPV 0.17, and NPV 1.00. Few of the other studies achieved this degree of sensitivity, specificity, or NPV, although overall the PPV was higher. In the presence of an adnexal mass, the false negative rate increases compared with a screened population reflecting the fact that benign gynecologic disease can cause elevation of CA-125.

The most common threshold other than 35 U/ml was 65 U/ml. Most of the studies using 65 U/ml as a threshold were from Asia. The probable heterogeneity of study populations makes

comparisons between these levels limited. Looking at the studies that reported results for different levels of CA-125 for within the same study population,^{87,98,134,136,147,148,162,167,180} in the higher threshold measurement, the specificity and PPV are higher, the sensitivity is lower, and the NPV is only slightly lower.

Stratification by menopausal status. Of the 59 studies we identified that examined CA-125, only nine contained data that either directly reported test characteristic by menopausal status or contained enough information to enable the stratification of results. One study was conducted exclusively in a postmenopausal population.⁶³ The studies are listed in Table 18.

The incidence of ovarian cancer is higher in postmenopausal women relative to benign gynecologic conditions, which also increase CA-125 levels. This should translate into a greater accuracy of CA-125 test performance in this population. Indeed, all test parameters except NPV are both higher and the range narrower in postmenopausal women. The lowest PPV was 0.73, with the remaining above 0.85, which is significantly higher than the range of PPV observed in studies that did not stratify their results by menopausal status. The NPV is lower in the postmenopausal population, despite the higher sensitivity, because of a greater prevalence of cancer in this population. CA-125 is consistently more helpful in discriminating benign from malignant lesions in postmenopausal women compared with premenopausal women.

Study	Threshold		Premen	opausal			Postmer	nopausal	
-		Sens	Spec	PPV	NPV	Sens	Spec	PPV	NPV
Malkasian et al.,	> 100	0.60	0.95	0.67	0.93	0.77	0.97	0.98	0.72
1988 ¹³⁶	> 35	0.60	0.73	0.29	0.91	0.81	0.91	0.94	0.74
Gadducci et al., 1996 ⁹⁶	> 65	0.67	0.91	0.67	0.91	0.80	1.00	1.00	0.69
Gadducci et al., 1992 ⁹⁸	> 64	0.50	0.26	0.05	0.86	0.81	0.86	0.88	0.78
Franchi et al., 1995 ⁹⁵	> 39	0.73	0.64	0.24	0.94	0.77	0.85	0.87	0.74
Patsner and Mann, 1988 ¹⁵¹	> 35	0.63	0.78	0.66	0.76	0.77	0.81	0.85	0.72
Dowd et al., 1993 ⁵⁵	> 35	0.74	0.73	0.60	0.84	0.86	0.82	0.90	0.76
Finkler et al., 1988 ⁵⁶	> 35	0.50	0.69	0.35	0.81	0.84	0.92	0.94	0.80
Schutter et al., 1998 ⁶³	> 35					0.69	0.84	0.73	0.81
Antonic and Rakar, 1995 ⁷¹	> 35	0.67	0.92	0.40	0.97	0.87	0.93	0.93	0.87

Table 18. CA-125 results stratified by menopausal status

Abbreviations: CA-125 = cancer antigen 125; NPV = negative predictive value; PPV = positive predictive value; Sens = sensitivity; Spec = specificity

Other Serum Markers

The fact that CA-125 is < 35 U/ml in 20 percent of women with early stage ovarian cancer, has motivated research into other serum based tests. We identified 13 articles that described a total of 17 different sera studies in women with an adnexal mass. Some studies investigated the performance of other tumor-associated antigens such as tumor-associated glycoprotein 72 (TAG-72) or CA-19-9. Although most of the tumor-associated antigens achieved specificities of

approximately 0.82 to 0.92, the sensitivity, PPV, and NPV were overall lower than those reported for CA-125. Two studies investigated carcinoembryonic antigen (CEA),^{114,157} and although they employed slightly different thresholds, the sensitivity reported in both (0.16 and 0.22) are so poor as to lead both authors to conclude that assessment of CEA in the evaluation of an adnexal mass is not helpful. Roman et al.⁴² investigated whether the addition of human chorionic gonadotropin (hCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) to CA-125 improved the test performance. In their series the sensitivity of CA-125 alone was 0.67, the specificity was 0.71, PPV 0.35, and NPV 0.90. The addition of the other three tests did not change the test results very much. The combined test (defined as any of the markers positive) sensitivity was 0.72, its specificity was 0.70, PPV 0.36, and NPV 0.94. AFP, hCG, and LDH do not appear to improve the diagnostic performance of CA-125.

Gadducci et al. investigated the role of D-Dimer in a series of 121 women with adnexal masses.⁹⁶ The sensitivity for D-Dimer alone was 0.91, the specificity was 0.83, the PPV 0.82, and the NPV 0.92 – making D-Dimer one of the best performing tests identified in our review. Stratifying by menopausal status showed a greater performance in premenopausal women where the sensitivity, specificity, PPV and NPV were 1.00, 0.91, 0.75, and 1.00 respectively (n = 57). For postmenopausal women they were 0.89, 0.65, 0.85, and 0.72, respectively. Chalas et al. investigated the role of elevated platelets in 241 women.³¹ The specificity and PPV were similar to that reported for D-Dimer (0.84 and 0.83, respectively), but the sensitivity and NPV were significantly lower (0.56 and 0.59). These two studies are intriguing, but the results need to be established in future studies to better assess their possible contribution to the evaluation of adnexal masses.

Aside from D-Dimer, none of the studies contained information making stratification by menopausal status possible. In conclusion, none of the sera markers investigated in this review appears to perform better than CA-125, with the possible exception of D-Dimer in the premenopausal population.

Population-based Studies

Almost all of the studies identified were case series. There were, however, 13 populationbased screening studies included in this review. They are listed in Table 19. Although all of the women included in these studies did not have a diagnosis of an adnexal mass at the time of enrollment, these studies are included here because they highlight some important issues about test performance. The strongest studies from a methodological perspective were those by Marchetti et al.,¹⁴⁰ Vuento et al.,¹⁸⁶ DePriest et al.,³⁴ Adonakis et al.,⁵¹ and Tailor et al.¹⁷¹ Marchetti, Vuento, Tailor and DePriest all used ultrasound as a screening modality. In all of these studies, the PPV was low, ranging between 0.006 to 0.07. Screening with CA-125 yielded a slightly higher PPV of 0.17.⁵¹ Tailor et al.¹⁷¹ offered followup screening within the same populations. In the first screening episode, which captured the total study population of 2,500 women, the test characteristics were similar to those reported in the other screening studies. The test characteristics improved, however, with subsequent screening. Women who had a negative screen were offered either a 12- or 6-month repeat ultrasound (depending on individual risk factors). Nine hundred and ninety-eight women received a second ultrasound screening. For this subset, the PPV improved to 0.21. For women screened greater than two times, the PPV was 0.25. However, not all women offered additional screening returned for the ultrasound. This potential bias was not discussed by the authors, and it is unclear how it may have influenced the

performance of repeat screening. The three studies by Kurjak et al. each had various biases that could have accounted for their markedly different reported test performances. One did not report followup on test negatives and therefore included no false negative in the series, ¹²⁶ another study population was an undescribed subset of a larger still incomplete screening series, ¹²⁷ and the last study did not describe inclusion criteria.¹²⁸ Van Nagell et al.⁴⁹ screened 14,469 women with ultrasound. They reported their results 12 months from the time of screening. However they note that four women were diagnosed with cancer greater than 12 months after screening. These women had all screened negative and were included in their analysis as true negatives. Reclassifying these individuals as false negatives changes the sensitivity from 0.81 to 0.68.

Study	N	Test	Sensitivity	Specificity	PPV	NPV
Marchetti et al., 2002 ¹⁴⁰	4350	Ultrasound screening: criteria	1.00	0.37	0.07	1.00
2002		Operative cases only $(n = 45)$		0.01	0.01	
	Assuming truly negative		1.00	0.96	0.01	1.00
Menon et al.,	1027	Ultrasound				
2000 ¹⁴⁵	_	Volume > 8.8 ml	0.90	0.94	0.21	1.00
		Abnormal morphology	1.00	0.94	0.24	1.00
		Complex morphology	0.84	0.97	0.37	0.98
Vuento et al.,	1364	Combined ultrasound				
1995 ¹⁸⁶		morphology and Doppler (PI < 1.0)	1.00	0.88	0.006	1.00
DePriest et al.,	24/3220	Ultrasound morphology				
1993 ³⁶		(DePriest)	1.00	0.71	0.33	1.00
		Operative cases only (n = 24)				
Kurjak et al.,	83/1000	RI < 0.41	0.96	0.95	0.90	0.98
1992 ¹²⁶		Ultrasound morphology (unique score)	0.48	0.98	0.93	0.78
		Presence of random vessels	0.90	0.98	0.96	0.95
		Combined ultrasound and Doppler	0.90	0.94	0.90	0.94
Kurjak et al., 1994 ¹²⁷	32/5013	Ultrasound "persistent mass" Ultrasound assuming all test	1.00	0.97	0.80	1.00
		negatives true negatives	1.00	0.99	0.80	1.00
Kurjak et al., 1991 ¹²⁸	680/ 8620	RI < 0.4	0.96	0.99	0.98	1.00
DePriest et al., 1997 ³⁴	90/6470	Ultrasound morphology (DePriest) (n = 90)	1.00	0.59	0.17	1.00
		Assuming all test negatives				
		true negatives (n = 6470)	0.86	0.99	0.07	1.00
Adonakis et al.,	2000/	CA-125 > 35	1.00	0.99	0.17	1.00
1996 ⁵¹	2000	PE "palpable mass"	0.67	0.97	0.03	1.00
Andolf et al., 1990 ⁵²	801	Combined ultrasound and BME (both positive for test to	1.00	0.94	0.11	1.00
		be positive) Ultrasound and BME criteria not well described				
Jacobs et al.,	1010	CA-125 > 30 U/ml	1.00	0.97	0.03	1.00
1988 ⁵⁸	1010	BME	1.00	0.97	0.03	1.00
1900		Ultrasound (ovarian volume > 8.8ml) (n = 58 for ultrasound)	1.00	0.74	0.04	1.00
Tailor et al., 2003 ¹⁷¹	2500	Ultrasound morphology (descriptive)	0.86	0.97	0.07	1.00

Table 19. Population-based screening studies

Study	N	Test	Sensitivity	Specificity	PPV	NPV
		N = 2500 Ultrasound for second	1.00	0.99	0.21	1.00
		screening episode (n = 998) Ultrasound for >= third screening episode (n = 733)	1.00	0.99	0.25	1.00
van Nagell et al., 2000 ⁴⁹	14469	Ultrasound (ovarian volume > 20 cm ³ for premenopausal women, > 10 cm ³ for postmenopausal women)	0.81	0.99	0.09	1.00

Abbreviations: BME = bimanual examination; CA-125 = cancer antigen 125; NR = not reported; PE = pelvic examination; PI = pulsatility index

Methodological Issues

In reviewing the literature on evaluation modalities, numerous methodological problems consistently reduced our ability to draw conclusions about the performance of various tests both individually and in comparison with each other. Some of these problems concerned study design, others related to statistical issues.

Patient population. With the exception of the 13 population-based screening studies, all of the articles were case series. Some were consecutive and others non-consecutive. Some were based on operative cases within a specific time frame at one or several institutions, whereas others were referral series, often located in oncology clinics. The path to diagnosis was almost never described, making it difficult to asses the generalizability of the results. Further, age was the only patient characteristic that was reliably documented. Other characteristics, such as family history, were almost never included. This has several implications. The overrepresentation of operative cases especially from academic facilities, likely overrepresents the prevalence of malignancy in the study populations when compared with the population of women with adnexal masses in general. It also exaggerates the performance of the evaluative modalities, especially in regards to sensitivity and PPV. Finally, it limits the generalizability of the evidence.

Definition of malignant. There was inconsistency between studies regarding whether the malignant classification included any malignancy or whether it included only ovarian malignancies. The inclusion of all malignancies would exaggerate the test's specificity and PPV at the expense of its sensitivity and NPV. From a practical standpoint, this difference may not be that problematic, as all malignancies are important. However, this classification bias increased the heterogeneity of test performance and limits generalizability. Finally, almost all of the articles that reported series containing tumors of low malignant potential (LMP) (also called borderline) classified these tumors as malignant. This changes the reported performance of the various evaluative modalities in these studies. There were three studies identified where stratification by LMP was possible. These are listed in Table 20. Classifying LMP tumors as malignant increases the specificity and PPV relative to classifying them as benign, while decreasing the specificity and NPV. Overall, PPV tended be somewhat low (even in populations with high prevalences of disease). The inclusion of LMP tumors into the malignant category inflated this measurement somewhat. Obviously, because of uncertainty about the natural history of LMP tumors, the most appropriate way of classifying them as part of diagnostic test

evaluation is also uncertain. Given this uncertainty, ideally investigators would report results using alternative methods of classifying LMP tumors.

Study	Test	LMP	LMP classified as malignant				LMP classified as benign			
		Sens	Spec	PPV	NPV	Sens	Spec	PPV	NPV	
Roman et al., 1998 ¹⁵⁷	CEA	0.16	0.93	0.35	0.83	0.19	0.93	0.25	0.90	
Wakahara et al., 2001 ¹⁸⁷	Ultrasound morphology CA-125	0.82 0.45	0.82 0.86	0.65 0.74	0.92 0.63	0.86 0.77	0.78 0.61	0.54 0.37	0.95 0.90	
Timmerman et al., 1999 ¹⁷⁸	CA-125	0.80	0.82	0.63	0.91	0.77	0.79	0.56	0.91	

Table 20. Effect of classification of LMP tumors as malignant or benign on diagnostic test characteristics

Abbreviations: CA-125 = cancer antigen 125; CEA = carcinoembryonic antigen; LMP = low malignant potential (tumors); NPV = negative predictive value; PPV = positive predictive value; Sens = sensitivity; Spec = specificity

Variability in test criteria. Of the 69 articles that evaluated ultrasound morphology, only 31 used established scoring criteria; 38 used a novel method. This resulted in a great heterogeneity of tests for ultrasound morphology and contributed to the range in performance noted. Many of the studies employed purely descriptive analysis to arrive at a benign versus malignant diagnosis. This limits the reproducibility of those results. Many of the scoring systems and descriptive categories had never been independently verified, and the paucity of details regarding what constituted a positive test makes such verification impossible. In terms of ultrasound evaluation by color Doppler, there was also a range of reported thresholds. Some of the variability in test criteria reflects the limitations of ultrasound technology. However, such differences limited the comparability between studies.

Masses as numerator. While most studies examined persons as the unit of 2-by-2 analysis, there were many studies that analyzed their data by masses. Even though the number of persons in the study was usually reported, it was often impossible to reconfigure the 2-by-2 table to refer to persons not masses. This was especially true in the radiology literature. This influenced the comparability between studies.

Menopausal status. Most of the studies did describe the patient population in terms of age. We were able to calculate the proportion of menopausal patients in most studies. However, the results were rarely reported in a way that allowed stratification by menopausal status. Where stratification was possible, a difference in test performance was seen. The heterogeneity in test performances was magnified by the different proportions of pre- and postmenopause in the different study populations.

Sample size. Few studies discussed sample size issues, potentially leading to inappropriate conclusions, especially regarding comparability of test characteristics.

Failure to account for observer variability. No studies attempted to account for the effects of observer variation on the precision of estimates, although a few did calculate interobserver coefficients. For tests where the thresholds for normal and abnormal were based on either qualitative assessments (such as descriptions of ultrasound morphology) or quantitative measures (such as ultrasound morphology scores), this variability will have implications for the precision of sensitivity and specificity.

Prevalence and predictive value. We did not limit our analysis of test characteristics to studies from the United States. As the incidence of ovarian cancer is different in different countries, this influences the range of predictive values reported in the literature. Locations with low disease prevalence will have low PPVs compared with higher prevalence areas. The heterogeneity of study locations influenced the range of reported test characteristics and somewhat limits the comparability of the results.

Summary

Table 21 summarizes the pooled sensitivity and specificity estimates for CA-125 and the various imaging modalities.

Diagnostic Test	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)
ULTRASOUND: MORPHOLOGY		
Scoring system: Sassone	0.86	0.77
	(0.79 to 0.91)	(0.73 to 0.81)
Scoring system: DePriest	0.91	0.68
	(0.84 to 0.95)	(0.49 to 0.82)
Scoring system: Ferrazzi	0.87	0.81
	(0.80 to 0.92)	(0.62 to 0.91)
Scoring system: Finkler	0.82	0.78
	(0.65 to 0.91)	(0.59 to 0.91)
Other	0.86	0.83
	(0.82 to 0.89)	(0.76 to 0.88)
ULTRASOUND: DOPPLER		
Resistive index	0.72	0.90
	(0.61 to 0.82)	(0.84 to 0.94)
Pulsatility index	0.80	0.73
	(0.74 to 0.85)	(0.62 to 0.81)
Maximum systolic velocity	0.74	0.81
	(0.56 to 0.86)	(0.59 to 0.83)
Presence of vessels	0.88	0.78
	(0.80 to 0.92)	(0.65 to 0.87)
MORPHOLOGY PLUS DOPPLER	0.86	0.91
	(0.79 to 0.91)	(0.80 to 0.97)
MRI	0.91	0.87
	(0.86 to 0.94)	(0.83 to 0.90)
СТ	0.90	0.75
	(0.83 to 0.94)	(0.36 to 0.94)
FDG-PET	0.67	0.79
	(0.52 to 0.79)	(0.70 to 0.85)
CA-125	0.78	0.78
(threshold > 35)	(0.75 to 0.81)	(0.71 to 0.82)

Table 21. Pooled sensitivity and specificity estimates

Abbreviations: CA-125 = cancer antigen 125; CI = confidence interval; CT = computed tomography; FDG = 18-Fluorodeoxyglucose; MRI = magnetic resonance imaging; PET = positron emission tomography

The use of established scoring systems in the evaluation of an adnexal mass by ultrasound morphology appears to perform slightly better than simple descriptive assessment. However, there does not appear to be a benefit of one scoring system over another. Based on small numbers of studies, 3D ultrasound shows some improvement over 2D. Although the pooled

sensitivity and specificity of MRI was the highest of any imaging modality, its performance was less consistent in studies where it was directly compared to other modalities such as CT and ultrasound.

Color Doppler assessment by RI, PI, and maximum systolic velocity are not superior to the more simple assessment of the presence or absence of arterial vessels within the mass. The efficacy of RI, PI, and maximum systolic velocity are hampered by the overlap in values of these measurements between benign and malignant masses.

Combined ultrasound morphology and color Doppler assessments have higher sensitivity and specificity compared to either alone. Although ultrasound morphologic evaluation by a gynecologist appears to be as reliable as that performed by a radiologist, there was no evidence of Doppler measurements done outside of the context of a radiology referral.

In postmenopausal women, an elevated CA-125 is useful for helping rule in ovarian cancer. Qualitatively, there was a consistent trade-off across all tests between sensitivity and specificity.

The relatively low PPVs in all of the tests are particularly striking given that many of the included studies were done in preoperative patients; the likely "screening" done prior to a decision for surgery suggests that the PPV of a particular test in the initial evaluation of an adnexal mass is likely to be even lower.

Question 4: Explicit Scoring Systems

Question 4 is: What is the accuracy of explicit scoring systems which incorporate various combinations of imaging findings, patient risk factors, and/or CA-125 levels for detecting malignancy? Have these scoring systems been applied to a population of women before laparoscopy or laparotomy?

Approach

Explicit scoring systems were sought in the medical literature from among all studies of diagnostic assessment of adnexal or pelvic masses. We considered only scoring systems that combined data from more than one category of the following types of information: (1) imaging findings; (2) patient risk factors; and (3) laboratory data. Clinical prediction rules that utilized data entirely from only one category (for example, ultrasound based morphological indices⁵⁶) are described as part of Question 3.

Imaging findings could include: (1) ultrasound based tests, such as transabdominal or transvaginal 2D ultrasound or Doppler ultrasound; (2) radiographic tests, such as CT; or (3) other imaging studies, such as MRI or PET scans.

Patient risk factors include menopausal status, age, or other risk factors.

Laboratory data was primarily CA-125, but we recorded data on other serum tumor markers as well.

Results of Literature Search and Screening

We identified 36 studies that met the inclusion criteria.^{42,48,51-} 53,55,62,63,66,72,86,87,97,103,105,116,134,135,138,139,147,169,178,180,181,185,202-211 These are described in Evidence Table 4 (Appendix D^{*}).

Study Characteristics

Scoring systems identified. The scoring systems were of several types. The most common were models developed using statistical modeling techniques such as logistic regression (or artificial neural networks) to develop estimates for predicted probability of malignancy. Such estimates were then used to construct clinical prediction rules (e.g., the Risk of Malignancy Index [RMI], which calculates a numeric score based on CA-125 level multiplied by a menopausal score and an ultrasound morphology score) and decision thresholds (e.g., for RMI, the most common threshold is 200). Other scoring systems used simple combinations of criteria based on individual modalities, which were then combined using Boolean *and* or *or* (e.g. CA-125 > 65 U/ml *and* ultrasound morphology score > 10 points). Some models were validated in separate populations from the data set used to develop the scoring systems either described as part of its initial development, or in subsequent publications by the original developers or others.

Types of data incorporated. The most common scoring systems used ultrasound, CA-125 and menopausal status. Some type of ultrasound data was used in all 36 publications; studies varied with regard to the type of ultrasound technology that was used. All used 2D ultrasound to evaluate morphology, some using transabdominal and many using transvaginal probes. Studies that used Doppler ultrasound used a variety of parameters, including measures as simple as detection of flow, or as complex as specific indices derived from Doppler-measured flow rates, such as the RI or PI. Many described scoring rules based on combinations of features of morphology (Finkler score) or combined morphology and blood flow.

CA-125 was a component of the scoring system in 30 reports; other serum tumor markers included CA-72-4, incorporated into two reports,^{53,63} and the markers AFP, LDH, and hCG, were used in one report.⁴² All studies that used these other serum markers also used CA-125.

Menopausal status was incorporated into scoring systems of 19 reports. The definition of menopausal status varied across studies, and in a few cases age was used as a proxy for clinically determined menopausal status. Three studies included only postmenopausal women,^{62,63,135} and thus could not use this variable in the scoring system.

Physical examination was a component of scoring systems in six reports.^{42,51-53,62,63}

Type of study populations. Most study populations were case series assembled at the time of referral for surgery and collected either at the point of preoperative ultrasound imaging or preoperative surgical evaluation. No studies were based in primary care clinical populations. One study described evaluation of adnexal masses detected during an ovarian cancer screening program.⁵¹

Reporting of study populations. Menopausal status of the study populations was described in 28 of the 36 reports; three reports included only postmenopausal women.^{62,63,135}

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

Age was reported for the study population as a mean or median in 18 of 36 studies; it was reported in categories in one additional study. Symptom status was seldom described in the candidate reports.

Race/ethnicity was not reported in any of the studies.

Risk factors for ovarian cancer (besides menopausal status and age, describe above) were not reported, except in one study that reported the proportion of the study population that was nulliparous versus multiparous.¹³⁸

Methodology. The methodological quality of the included studies may be described as follows:

Reference standard (handling of borderline). Some studies, particularly those assembled at the time of ultrasound investigation rather than surgery, encountered women with masses due to simple cysts with low risk of malignancy. Two studies allowed use of an operative report in lieu of histopathology as a reference standard,^{87,116} and one used clinical followup without surgery as an alternate reference standard.⁴⁸

Verification bias. Fourteen studies failed to verify disease status for all or a significant sample of test-negative women.

Test reliability. Only nine studies provided data on the reliability of test assessments.

Sample size. Only 11 of the reports described a priori recruitment targets or sample size calculations. We excluded studies with fewer than 50 women; however, some studies report subgroup analyses with fewer than 50 women, for example, the subset of postmenopausal women in Strigini et al.¹⁶⁹

Use of appropriate statistical tests. The majority of reports (n = 28) used appropriate statistical analysis of the diagnostic data; however seven reports reported inadequate analyses.

Blinding. None of the reports described the use of techniques to blind investigators to the disease status of study patients.

Definition of positive and negative test. Most studies (n = 24) provided a priori definitions of a positive and negative test result; studies failed to meet this criterion most often when no explicit threshold was set a priori, but it was set based on study data.

Explicit validation method. Half of the reports (18/36) used some explicit validation method; many of the reports replicated previously described scoring systems in a new population. In many cases, these studies described new scoring systems which were not always validated.

The most common validation method was replication in a separate population. Two studies used validation techniques within a single study population: one split-sample,²⁰⁹ and one bootstrap.²⁰⁵

Diagnostic Accuracy of Scoring Systems

This section considers the diagnostic accuracy of the RMI (Jacobs 1990) and subsequent replications and refinements (RMI2, RMI3, Jacobs 1993, and Timmerman models).

RMI. The first scoring system based on a statistical model was published in 1990;¹¹⁶ it has been replicated in 11 subsequent clinical populations.^{55,72,87,139,147,180,204,206-208,210} The diagnostic performance in these 12 studies is shown in Figure 17.

The RMI is a clinical prediction rule based on ultrasound, CA-125, and menopausal status data defined as follows:

 $RMI = U \times M \times CA-125$

where ultrasound (transabdominal) is scored 1 point for each of the following characteristics: multilocular cyst, evidence of solid areas, evidence of metastases, presence of ascites, and bilateral lesions.

U = 0 for ultrasound score of 0

= 1 for ultrasound score of 1

= 3 for ultrasound score ≥ 2


CA-125 = Serum CA-125 in U/ml


Menopausal status M = 1 if premenopausal

= 3 if postmenopausal

In the initial report, Jacobs et al.¹¹⁶ used the cutoff value of 200. At this cutpoint, sensitivity was 85 percent and specificity was 97 percent among a population of 143 women undergoing surgical investigation for an adnexal mass. The performance of the initial model (study 6 in Figure 17) has, in most studies, failed to be equaled in subsequent attempts at validation. Three of the subsequent 11 studies have similar performance (studies 7, 9, 10 in Figure 17).^{72,87,208} It is notable that these three studies have fewer quality features ($n \le 4$) than the other eight studies ($n \ge 5$ of 7 quality features).

When sensitivity and specificity are combined separately using a random-effects model, the pooled sensitivity is 0.78 (95% CI, 0.72 to 0.84) and the pooled specificity is 0.90 (0.81 to 0.95).





Key to Figure 17: 1 = Tingulstad et al., 1996;¹⁸⁰ 2 = Timmerman et al., 1999;²¹⁰ 3 = Mol et al., 2001;²⁰⁷ 4 = Lu et al., 2003;²⁰⁶ 5 = Manjunath et al., 2001;¹³⁹ 6 = Jacobs et al., 1990;¹¹⁶ 7 = Davies et al., 1993;⁸⁷ 8 = Morgante et al., 1999;¹⁴⁷ 9 = Obeidat et al., 2004;²⁰⁸ 10 = Asif et al., 2004;⁷² 11 = Aslam et al., 2000;²⁰³ 12 = Dowd et al., 1993⁵⁵


RMI2. In 1996, Tingulstad et al.¹⁸⁰ reported a refinement to the original RMI scoring system, commonly referred to as RMI2. RMI2 is defined identically to RMI except that new weights were used for the ultrasound and menopause components as follows:


U = 1 for ultrasound score of 0-1 = 4 for ultrasound score ≥ 2

M = 1 if premenopausal = 4 if postmenopausal

A cutoff value of 200 was also recommended for RMI2. Like the RMI, the RMI2 scoring system has been replicated.^{134,139,147,207} The original report of RMI2 found sensitivity of 0.8 and specificity of 0.92. Subsequent validation studies have performed no better. These validation

studies all exhibited five or more quality features. The pooled sensitivity of all five studies is 0.77 (0.71 to 0.82), and pooled specificity 0.89 (0.85 to 0.91). The summary ROC curve is shown in Figure 18.





Key to Figure 18: 1 = Andersen et al., 2003;²⁰² 2 = Tingulstad et al., 1996;¹⁸⁰ 3 = Manjunath et al., 2001;¹³⁹ 4 = Ma et al., 2003;¹³⁴ 5 = Morgante et al., 1999;¹⁴⁷ 6 = Aslam et al., 2000^{203}

RMI3. Subsequently, a further refinement to the RMI and RMI2 was reported by Tingulstad et al.²¹¹ This third scoring system is defined identically to RMI and RMI2 except that new weights were used for the ultrasound and menopause components as follows:

U = 1 for ultrasound score of 0-1 = 3 for ultrasound score ≥ 2

M = 1 if premenopausal

= 3 if postmenopausal

A cutoff value of 200 was also recommended for RMI3. The RMI3 scoring system has been replicated in one additional study.¹³⁹ The original report of RMI3 found sensitivity of 0.71 and specificity of 0.92, while the validation study reported very similar performance, with sensitivity of 0.74 (0.65 to 0.83) and specificity of 0.91 (0.83 to 0.99).

Tailor and subsequent replications. Tailor et al.²⁰⁹ reported a scoring system based on an artificial neural network method that was based on a small population of 67 women total, 15 of whom had malignancies. Unlike the RMI family of systems described above, this system did not include CA-125, but considered age, menopausal status, and a variety of ultrasound morphological features and Doppler indices. While this system reported using 52 cases as a training set and 15 cases as a test set, the performance of the system was reported only for the study population as a whole: sensitivity 0.93 (95% CI, 0.81 to 1.0) and specificity 1.0 (0.94 to 1.0). Subsequently four studies have replicated this system showing markedly poorer diagnostic performance (Figure 19) when applied to separate populations, consistent with over-fitting in the initial model development.^{185,203,204,207}




Figure 19. Performance of model of Tailor et al. (1999)²⁰⁹ in development set (4) and subsequent validation studies

Key to Figure 19: 1 = Mol et al., 2001;²⁰⁷ 2 = Valentin et al., 2001;¹⁸⁵ 3 = Aslam et al., 2000;²⁰³ 4 = Tailor et al., 1999;²⁰⁹ 5 = Aslam et al., 2000²⁰⁴


Twenty other scoring systems have been described, none of which has been as extensively replicated as the systems described above. Five of these other scoring systems have been validated in one other population as shown in Table 22; each of the systems was based on ultrasound morphology, CA-125, Doppler, and menopausal status. The models were: Timmerman LR1,^{178,210} Timmerman AAN1,^{178,207} Timmerman AAN2,^{178,207} Timmerman LR2,^{178,207} and Jacobs 1993.^{207,212}

Table 22. Performance of other scoring systems at initial derivation and subsequent replication in another
population

Initial	Subsequent	Sensitivit	y (95% CI)	Specificity	y (95% CI)
description	validation	Initial development	Replication	Initial estimate	Replication
Timmerman LR1 ²¹⁰	Valentin 2001 ¹⁸⁵	0.87 (0.79 to 0.97)	0.62 (0.44 to 0.80)	0.92 (0.87 to 0.97)	0.79 (0.68 to 0.90)
Timmerman AAN1 ¹⁷⁸	Mol et al. 2001 ²⁰⁷	0.94 (0.87 to 1.0)	0.90 (0.79 to 1.0)	0.90 (0.85 to 0.96)	0.60 (0.52 to 0.68)
Timmerman AAN2 ¹⁷⁸	Mol et al. 2001 ²⁰⁷	0.96 (0.90 to 1.0) (0.91	0.90 (0.79 to 1.0)	0.94 (0.89 to 0.98)	0.46 (0.38 to 0.54)
Timmerman LR2 ¹⁷⁸	Mol et al. 2001 ²⁰⁷	0.96 (0.90 to 1.0)	0.90 (0.79 to 1.0)	0.86 (0.79 to 0.92)	0.56 (0.48 to 0.64)
Jacobs 1993 ²¹²	Mol et al. 2001 ²⁰⁷	0.85 (0.74 to 0.96)	0.90 (0.79 to 1.0)	0.97 (0.94 to 1.0)	0.61 (0.53 to 0.69)

In each case, the initial diagnostic performance described by the system significantly degrades on replication in another population (Figure 20).

Figure 20. Performance of various other scoring systems in development and validation studies in separate populations




Arrows indicate change in performance estimate from development (start of arrow) to validation (end of arrow) for paired studies of each scoring system.

Key to Figure 20: 1-4 = Timmerman et al., 1999;²¹⁰ 5-8 = Mol et al., 2001;²⁰⁷ 9 = Jacobs et al., 1993;²¹² 10 = Valentin et al., 2001^{185}

Ten additional systems were described in seven reports.^{42,48,53,63,181,203,205} Most of these studies used logistic regression or artificial neural network modeling methods to derive a new model. One used bootstrap validation techniques,²⁰⁵ but none was validated in another study population. One of these studies²⁰³ reported on newly fitted logistic regression models created by forcing variables that were include in previously described scoring systems.^{178,209,213} Aslam et al.²⁰⁴ constructed three separate models based on each possible pairwise combination of the three previously described models. The diagnostic performance of these miscellaneous unvalidated models is shown in Figure 21.





Key to Figure 21: 1 = Twickler et al., 1999;⁴⁸ 2-3 = Biagiotti et al., 1999;²⁰⁵ 4 = Torres et al., 2002;¹⁸¹ 5 = Schutter et al., 1998;⁵³ 6 = Balbi et al., 2001;⁵³ 7 = Roman et al., 1997⁴²

Thirteen further reports describe the diagnostic performance of simple rules for combining single test or single modalities into a decision rule.^{42,51,52,62,63,66,86,97,103,105,135,138,169} None of these criteria has been validated in another population. Each of these studies used dichotomous rules for two or more tests (or modalities) and then combined them using a simple rule like "malignant if any test positive" (Boolean *or*) or "malignant if all tests positive" (Boolean *and*). Some of the studies reported diagnostic performance of several different simple rules.

Twelve of these studies used ultrasound and CA-125, five incorporated physical exam, two included other serum tumor markers^{42,63} and one used age over 50 years.¹³⁸

Six of these studies reported results for postmenopausal women separately: in three studies, the entire study population was postmenopausal^{62,63,135} while three studies reported diagnostic performance for the postmenopausal subgroup separately.^{103,105,169} The diagnostic performance of 18 simple combination rules in these six studies is shown in Figure 22.




Figure 22. Performance of unvalidated simple combination rules in postmenopausal women only

Key to Figure 22: 1-4 = Maggino et al., 1994;¹³⁵ 5-8 = Schutter et al., 1998;⁶³ 9-11 = Schutter et al., 1994;⁶² 12-13 = Strigini et al., 1996;¹⁶⁹ 14-17 = Guerriero et al., 1998;¹⁰³ 18-19 = Guerriero et al., 2002^{105}

In contrast, the diagnostic performances of 17 simple combination rules in studies that include both premenopausal and postmenopausal women in the study population are shown in Figure 23.




Figure 23. Performance of unvalidated simple combination rules in mixed pre- and postmenopausal populations

Key to Figure 23: 1-2 = Andolf et al., 1990;⁵² 3-4 = Adonakis et al., 1996;⁵¹ 5-9 = Mancuso et al., 2004;¹³⁸ 10 = Gadducci et al., 1988;⁹⁷ 11-12 = Chou et al., 1994;⁸⁶ 13 = Alcazar et al., 1999;⁶⁶ 14-15 = Roman et al., 1997;⁴² 16-17 = Strigini et al., 1996

The results show a wide range of sensitivity and specificity. This variation reflects differences in decision thresholds (e.g., CA-125 > 35 U/ml versus CA-125 > 65 U/ml) and in the rules for combining tests (e.g., use of Boolean *or* versus *and* when combining results of two or more tests).

Discussion

No scoring systems were both developed and validated expressly for evaluating adnexal masses in postmenopausal women. Existing scoring systems that have been validated have all been developed in mixed pre- and postmenopausal populations. Those scoring systems that have been described in populations of postmenopausal women were neither rigorously developed (they consist of simple combination rules) nor validated in other populations.

The highest demonstrated specificity obtained with these scoring systems appears to be in the range of 90 to 95 percent and, at this range of specificity, the sensitivity appears to be in the range of 65 to 80 percent. However, as suggested by the performance in the few populations of postmenopausal women studied, the same degree of sensitivity and specificity is unlikely to be possible. Reliable estimates of the diagnostic performance of scoring systems cannot be determined from these studies.

This review of scoring systems demonstrates several important limitations of predictive models and has important implications for the clinical usefulness of these models and the future research in this area of inquiry. First, validation in an external population is critical to obtain accurate estimates of diagnostic performance, because all modeling techniques lead to overestimation of diagnostic performance in the data from which it was derived. This overestimation of diagnostic performance is clearly demonstrated by comparing the development and validation studies described for RMI, Tailor, and other scoring systems (Figures 17-20). The studies described here suffer from being relatively small for modeling; reliable variable selection and parameter estimation requires at least 10 to 15 cases (in this case, ovarian malignancies) for every term selected in a predictive model. Few, if any, met this statistical rule of thumb. This limitation is particularly apparent in the case of the Tailor model, where subsequent studies demonstrated a high degree of overestimation of the original model. Third, these studies used populations that were identified following referral for surgery in most cases, after some filtering had already occurred. Furthermore, these studies failed to describe the initial presentation (symptomatic or asymptomatic, palpable or non-palpable mass) of women eventually enrolled. Thus, the applicability of these studies to women in primary care, where an adnexal mass is often first noted, is uncertain.

Question 5: Monitoring Women with Suspected Benign Masses

Question 5 is: Among women with suspected benign masses on initial investigation, what are the sensitivity and specificity of monitoring with periodic CA-125 and/or interval ultrasound examinations for detecting malignant masses? How does the interval of testing/definition of change affect sensitivity and predictive value?

Approach

For each study we sought to identify a population of patients with a screening abnormality which was "probably benign" and which the authors felt did not meet criteria for immediate surgical intervention. We then attempted to define the outcomes of further testing in the defined population, including the results of subsequent testing and final clinical outcome as defined by a pathology report or extended clinical followup. The interpretation of results is limited by the narrow scope of Question 5. Specifically, it is often difficult to identify a subgroup of patients with a screening abnormality which could be defined as a "suspected benign lesion" within larger screening studies. Often, results are not stratified with respect to these sub-populations, making it difficult to calculate sensitivity and specificity of the followup regimen. We assumed

that this refers to detection of cancer as part of the followup regimen, and that women with cancer diagnosed outside of the followup were "false negatives."

Results

We identified nine articles meeting the criteria for this question;^{40,127,135,145,214-218} these are summarized in Table 23, with details in Evidence Table 5 (Appendix D^{*}). Five were population-based screening studies of asymptomatic, postmenopausal patients without known ovarian masses;^{40,127,145,214,217} one was a voluntary screening program.²¹⁶ All addressed to some degree the use of interval ultrasound for detecting malignant masses. Although several used CA-125 as part of their followup, none reported any results based on the use of interval CA-125 in a population with adnexal lesions. None addressed the effects of changing the interval of testing on sensitivity and predictive value; the disparate nature of the studies prohibited any inferences on the effect of test interval on sensitivity.

Study	Population	N	Followup interval	Length of followup	Loss to followup	True/false positives detected during followup	Cancers missed
Populatio	on-based studio	es (follov	vup of "benign" ma	sses identifi	ed in screening) I)	•
Menon et al., 200 ¹⁴⁵	Followup of scans considered "equivocal"	17	"Equivocal" scans followed every 6 weeks until clearly normal or abnormal; normal scans followed with CA-125 every 3 months	Median 6.8 years	Not reported	1 cancer/5 benign lesions	0 (1 within 6 weeks of initial test, before first followup scan)
Modesitt et al., 2003 ⁴⁰	Followup of simple cysts < 10 cm	2,763	TVUS every 3-6 months for simple cysts	Mean 6.3 years	Not reported	7 cancers/0 benign lesions	3 cancers, none developed in the original cyst
Schin- caglia et al., 1994 ²¹⁷	Followup of post- menopausal ovaries > 9 cc, or with simple cyst	347	If cyst: followed with ultrasound every 6 months; if change, referred; others: referral if unchanged at 3 and 6 months	"At least" 1 year	Not reported, but all had "at least 1 year"	2 cancers/96 benign lesions	None in 249 not referred
Kurjak et al., 1994 ¹²⁷	Followup of post- menopausal women with simple cyst > 2.5 cm but < 5 cm, resistive	88 (of 404 with sim- ple cysts)	Repeat ultrasound every 6 months	6 months	Not reported	1/17 with benign lesions	0

Table 23. Studies of followup regimens for benign-appearing lesions

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

Study	Population	N	Followup interval	Length of followup	Loss to followup	True/false positives detected during followup	Cancers missed
Castillo et al., 2004 ²¹⁴	index ≥ 4.1) Followup of post- menopausal women with simple cyst < 10 cm	215	Repeat ultrasound and CA-125 in 3 months, then every 6 months	Median 27 months	30.6%	0/44 benign masses	1
Case ser	ries (clinical his	tory pric	r to identification o	of mass not re	outinely descri	bed)	•
Valentin and Akrawi, 2002 ²¹⁸	Followup of post- menopausal women with low score on ultrasound malignancy risk scale	162	Repeat ultrasound 3, 6, 9, and 12 months, then every 12 months; test positive if increase in size or cyst more complex	Median 3 years	0 (cancer and mortality tracked through registry)	0 cancers/7 patients underwent surgery for change	0
Mag- gino et al., 1994 ¹³⁵	Followup of post- menopausal women with cysts < 5 cm, thin wall, no septae, no free fluid	45	Details on followup strategy not reported	Not reported	4.4%	0/0	0
Levine et al., 1992 ²¹⁶	Followup of voluntary screening of post- menopausal women with unilocular simple cyst	32	Repeat ultrasound every 3 months x 1 year, then every 6 months	"Over half at least one year"	22.2%	0/0	0
Gold- stein et al., 1989 ²¹⁵	Followup of post- menopausal women with simple cysts ≤ 5 cm	16	Repeat ultrasound (abdominal)	Mean 29 months	6 (12% of original 48)	0/2 with benign lesions	0

Abbreviations: CA-125 = cancer antigen 125; TVUS = transvaginal ultrasound

Menon et al.¹⁴⁵ performed a large prospective screening study of 22,000 postmenopausal women older than 45 years. Initial screening consisted of CA-125; patients with CA-125 \geq 30 underwent endovaginal ultrasound evaluation. Results were interpreted as normal (ovarian volume < 8.8 ml/normal morphology), equivocal (volume < 8.8 ml, abnormal morphology), or abnormal (volume \geq 8.8 ml). Normal morphology was defined as uniform hypoechogenicity and smooth outline. Abnormal morphology was defined as simple cysts or complex lesions. Patients with normal scans were triaged to repeat CA-125 every 3 months for a year and subsequently returned to yearly screening; median followup was 6.8 years, with loss to followup not reported. Patients with abnormal scans were referred to a gynecologist for consideration of surgical intervention. Patients with equivocal scans were triaged to repeat ultrasound at 6-week intervals until a scan could be classified as normal or abnormal. Of 741 patients who were triaged to

ultrasound, 20 (2.7 percent) index cancers were identified. We focused on the group of patients with "equivocal" scans who were triaged to interval testing in an attempt to answer the study question. There were 17 equivocal scans. Of these, nine had simple cysts which were followed and did not result in a cancer diagnosis (true negatives). One patient died of pneumonia prior to her first repeat ultrasound, and one died of advanced ovarian cancer prior to her first repeat ultrasound; this cancer death could possibly be considered a false negative for the followup strategy, although it could also be considered a false negative from the original study since the death occurred within 6 weeks of the initial scan. Six patients were scheduled for surgery following an equivocal scan, presumably due to abnormal followup ultrasound. One of these had ovarian cancer (true positive), and the other five had benign disease (false positive). Because the number of equivocal scans was so small, and because the classification "equivocal" does not necessarily imply that the lesions were felt to be "suspected benign" as designated in Question 5, it is not possible to calculate the sensitivity and specificity of prolonged monitoring strategies using this study. The authors do not draw any conclusions regarding the appropriateness of interval testing.

Modesitt et al.⁴⁰ performed a large screening study of 15,106 asymptomatic women at least 50 years old without a history of ovarian cancer. Patients were screened with TVUS. Criteria for abnormality were ovarian volume > 10 ml and any morphologic abnormality, including simple or complex cysts. Patients with abnormal TVUS were triaged to repeat TVUS in 4 to 6 weeks, with Doppler flow ultrasound, CA-125 level, and tumor morphology indexing performed at the second visit. Patients with simple unilocular cysts which were considered likely benign were triaged to repeat TVUS every 3 to 6 months. Mean followup was 6.3 years. Two thousand and seven hundred and sixty-three (2,763) women were diagnosed with 3,259 unilocular cysts. Spontaneous resolution of unilocular cysts occurred in 2,261 (69.4 percent) of lesions. Ten patients subsequently developed ovarian cancer. Seven of these had additional abnormal areas which subsequently developed on TVUS (considered true positives because they were subsequently identified by interval testing). Two developed ovarian cancer after the cyst in question had resolved on sonographic followup (these might be considered false negatives). One patient developed cancer in the ovary opposite the cyst being followed (this might also be considered a false negative). Calculated on a per-patient basis, the sensitivity and specificity of followup testing in the population with a simple unilocular ovarian cyst are 70 percent (95% CI, 41.6 to 98.4 percent) and 100 percent (99.9 to 100 percent), respectively. Because none of the unilocular cysts subsequently developed into a cancer, the sensitivity and specificity improve to 100 percent (57.1 to 100 percent) and 100 percent (99.9 to 100 percent), respectively, when calculated on a per-lesion basis. Followup time is a major strength of this study. The authors conclude that unilocular ovarian cysts are associated with a very low risk of malignancy and can be safely followed with serial ultrasound.

Schincaglia et al.²¹⁷ performed a screening study of 3,541 asymptomatic postmenopausal patients. All patients underwent transabdominal ultrasonography with assessment of ovarian volume and morphology. Patients were divided into four groups based on the results of the initial ultrasound. All patients with ovarian volume > 15 ml (Group 4) were referred for repeat "level II" ultrasonography for morphologic assessment and fine needle aspiration (FNA) when feasible. Patients with ovarian volume between 9 and 15 ml (Group 3) were triaged to followup ultrasound at 3 and 6 months. Patients with ovarian volume < 9 cm but a cystic appearance (Group 2) were triaged to followup ultrasound in 6 months. Patients with ovarian volume < 9 ml and homogeneous appearance (Group 1) were considered negative and had no further

intervention. Clinical followup at 1 year and pathology results if surgery was performed were considered the reference standard. Two hundred and eighty-three (283) patients (Groups 2 and 3) were deemed appropriate for followup using repeat ultrasound at 3- to 6-month intervals without the need for immediate referral for FNA/surgery. Of these 283 patients, 34 subsequently developed concerning ultrasound findings and were referred for a level II scan and/or possible FNA. The clinical results of this group of 34 are not given separately. Of the 249 who had non-concerning followup scans, none developed cancer with followup of at least 1 year ("true negatives"). Therefore, the specificity of ultrasound followup is 100 percent (95% CI, 98.8 to 100 percent) for patients with an initial abnormal but "probably benign" ultrasound. Sensitivity within this group cannot be calculated with the information given in the publication. The ability to answer Question 5 would be enhanced if specific outcomes of each of the four groups defined by the authors had been given. The study was also limited by the fairly short followup interval and the lack of prior or concurrent validation of the ultrasonographic groups defined in the study.

Kurjak et al.¹²⁷ screened 5,013 women 40 years old or older (30.6% postmenopausal), of whom 404 had simple cysts with a diameter between 2.5 and 5 cm and a resistive index greater or equal to 0.41. These women received a followup scan in 6 months. Investigators reported the results of 88 women for whom the 6-month scan results were available. The definition of change prompting further diagnosis was not explicitly described. Of the 88 women, 18 ultimately underwent surgery based on the findings at 6 months, with one cancer detected and 17 benign lesions. Results stratified by menopausal status were not provided. This study was limited by lack of details on clinical decision rules, and short followup.

Castillo et al.²¹⁴ screened 8,794 postmenopausal women; 215 had simple unilocular cysts less than 10 cm in diameter. Twelve percent of these masses were asymptomatic. These women underwent repeat ultrasound and CA-125 in 3 months, with subsequent followup studies every 6 months. Progression was defined as an increase in diameter of 1 cm or more, regression as a decrease of 1 cm, and resolution as absence of the cyst at 2 consecutive visits 6 months apart. Median followup was 27 months. There was one interval ovarian cancer between studies, and 44 women had benign masses removed. Although this study was among the highest quality studies in terms of reporting of relevant data, it is limited by the relatively small size and the high loss to followup (30.6%).

The remaining four studies^{135,215,216,218} were all small (less than 200 patients), and of variable quality (Table 23). None reported any interval cancers in patients receiving followup, or cancers detected during followup. The study of Valentin et al.²¹⁸ was notable for length of followup (median 3 years) and complete ascertainment of followup status using Swedish cancer and death registry data.

Discussion

There are limited data available to support a global definition of "probably benign" ovarian lesions or to support a specific method of interval testing to identify ovarian malignancy among patients in whom such lesions have been identified. For the most part, studies are limited by small size, variable length of followup, variable definitions of significant change and thresholds for intervention, and methods for followup.

The question of how best to define and evaluate "sensitivity" of followup regimens is a difficult one. Several factors need to be considered. First, interval cancers presenting between the initial study and the first followup visit may well be considered false negatives of the initial

study; alternatively, they may reflect a too-long followup interval. Second, given the lack of data on the natural history of ovarian cancer, it is unclear whether cancers developing in benignappearing lesions represent subclinical cancers present at the time of the initial diagnosis, or new cancers representing malignant transformation of a benign cyst. If the latter, then the ultimate success of any followup regimen may depend as much on the natural history of a given malignancy as on the sensitivity and specificity of the tests used for followup. Finally, cancers identified during followup should ideally have high survival rates (although whether such high survival rates would reflect the efficacy of the followup or the biology of cancers which are associated with benign-appearing cysts is unclear). The number of cancers identified in the reviewed studies was too small to draw any inferences about relative survival.

Overall, only two interval cancers occurred during followup in the studies identified (one prior to the first followup scan), and 10 cancers were identified during followup. As noted, an additional three cancers developed after resolution of a cyst or in the contralateral ovary. The highest quality study⁴⁰ provides good evidence for the safety of prolonged followup with interval TVUS at 3- to 6-month intervals for patients with unilocular ovarian cysts of up to 10 cm in diameter, and the findings of the other studies are consistent with this conclusion.

Question 6: Surgical Morbidity and Mortality

Question 6 is: Among women with adnexal masses, what are the morbidity and mortality from diagnostic surgery (laparoscopy or laparotomy)? At what point does the risk of surgery outweigh the risk of detecting malignancy?

Approach

We searched the literature for studies that reported the morbidity and mortality of surgical management of adnexal masses. We also used the Nationwide Inpatient Sample (NIS) discharge database, maintained by the Agency for Healthcare Research and Quality (AHRQ), to obtain estimates of morbidity and mortality associated with diagnostic laparoscopy or exploratory laparotomy for a range of diagnoses associated with adnexal masses. The NIS is limited to inpatient procedures and does not cover ambulatory surgical centers, where some adnexal masses are likely to be managed, especially those masses thought to have a low likelihood of cancer. In addition to surgical complications, we also examined articles that provided data on the test characteristics of frozen section pathologic diagnosis; especially in the setting of minimally invasive procedures, false negative results on frozen section might lead to suboptimal surgical management and delayed therapy, while false positive results might lead to more extensive surgery than necessary, with possible implications for increased surgical morbidity and affects on ovarian function.

Results of Literature Search and Screening

We identified 24 articles that met our inclusion criteria;^{32,37,41,219-239} these are summarized in Evidence Table 6 (Appendix D^{*}). Twenty-two articles reported on the morbidity and mortality of surgical management of adnexal masses.^{32,37,41,219-234,237-239} In addition, two of the included articles reported on the sensitivity and specificity of frozen section;^{220,236} false negative frozen section results could lead to inadequate surgical management and delayed treatment, while false positive results could lead to more extensive surgery than necessary. Finally, one of the included articles addressed the potential effect of conservative surgery for removal of an ovarian cyst resulting from endometriosis (endometrioma) on subsequent fertility.²³⁵

Methodological Quality of Included Studies

Size of population. None of the papers provided a description of the referral base; two^{32,37} were limited to gynecologic oncology practices. Lack of information on the referral base prevents assessment of generalizability. Since all of these studies were performed in centers experienced in laparoscopic surgery, the generalizability may well be limited.

Number of cases. Five studies had fewer than 200 cases, with correspondingly wide confidence intervals for reported event rates. Two studies had larger numbers of cases, 683^{230} and 757^{219} . However, the study by Marana et al.²³⁰ was limited to women under 40.

Patient selection. None of the studies reported how patients were referred to the surgical practices. All provided criteria for laparoscopic management of masses, based on various criteria to suggest high or low risk of malignancy. We found two trials where patients were randomized to laparoscopy or laparotomy,^{224,225} but randomization methods were not well described.

Application of reference standard. In this sense, "reference standard" refers to the method by which a complication was diagnosed. Only two studies described followup beyond 8 weeks, but they did not detail whether all patients underwent similar followup protocols.

Results

There were three deaths in one study of 146 patients (all undergoing laparoscopy), and none in any of the other studies (a total of 5,599 patients). Pooling all patients, the mortality was 0.05 percent, with a 95% CI of 0.01 to 0.17 percent.

Table 24 shows the results from individual studies. The two randomized studies^{224,225} both showed lower morbidity with laparoscopy compared to laparotomy, although only one of them²²⁴ had sufficient power to show a statistically significant difference. Although the study of Deckardt and colleagues²²⁴ was randomized, there were substantial differences in the procedures performed in each arm. Laparoscopy patients tended to undergo more conservative procedures: they were significantly more likely to have cystectomy (60.0 vs. 20.2 percent), less likely to have oophorectomy (0.8 vs. 20.2 percent), and less likely to have bilateral salphingo-oophorectomy (4.0 vs. 21.4 percent). Both studies where laparoscopy was directly compared to laparotomy showed increased complication rates (primarily postoperative complications) among the

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

laparotomy patients. The four non-randomized studies all showed higher morbidity rates with laparoscopy, but there were substantial differences in patient selection criteria.

In series of laparoscopy cases, morbidity rates ranged from 0.9 percent to 22.1 percent (Table 24); series differed widely in their selection criteria for laparoscopic management of the mass. Few stratified results based on menopausal status; in some cases, postmenopausal patients were explicitly excluded. In one study where multivariate analysis was performed to assess for risks of morbidity, performance of additional procedures (hysterectomy) significantly increased the risk of morbidity, while a history of hysterectomy increased the likelihood of conversion to laparotomy (presumably because of increased technical difficulty secondary to postoperative adhesions).²²⁶

Study	N	Patient population	Complication rate (95% CI)	Notes			
Randomized trials of laparoscopy versus laparotomy							
Deckardt et al., 1994 ²²⁴	192	22.4% laparoscopy, 26.4% laparotomy postmenopausal	Laparotomy: 30.3% (21.8 to 42.3%) Laparoscopy: 11.2% (6.8 to 18.7%)	"Randomized," but some differences between two arms 3.5% conversion			
Fanfani et al., 2004 ²²⁵	100	Laparoscopy: 10% postmenopausal Laparotomy: 20% postmenopausal	Laparotomy 6% (1.8 to 17.5%) Laparoscopy 0% (0 to 10.6%)	No malignancies Small sample size			
Non-randomized	compari	sons		-			
Hidlebaugh et al., 1997 ²²⁷	405	199 laparoscopy 206 laparotomy 20.2% postmenopausal	Laparotomy 27.2% (21.8 to 34.0%) Laparoscopy 2.5% (1.0 to 6.0%)	Selection criteria for laparoscopy not defined Potential other risk factors for complications not described			
Yuen et al., 1997 ²³⁹	110	Laparotomy: 6% postmenopausal Laparoscopy: 3.8% postmenopausal	Laparotomy 28% (18.5 to 43.1%) Laparoscopy: 9.6% (4.2 to 21.8%)	Difference between complication rates attributable to higher number of postoperative complications in laparotomy group			
Carley et al., 2002 ²²¹	106	44 laparotomy 62 laparoscopy Menopausal status not reported	Laparotomy 4.6% (0.7 to 16.7%) Laparoscopy 0% (0 to 8.6%)				
Chapron et al., 1997 ²²²	186	121 laparoscopy, 65 laparotomy 43% postmenopausal	Laparotomy: 15.4% (8.9 to 27.0%) Laparoscopy: 8.3% (4.6 to 15.0%)	Patients with high suspicion of malignancy went directly to laparotomy Results not analyzed by "intention to treat"—19 of laparotomy patients started as laparoscopy 13.6% of laparoscopies converted to laparotomy			
Laparoscopy on	'v	L	1				
Childers et al., 1996 ³²	138	Not described in detail; age range 9-91	10.1% (6.2 to 16.7%)	Length of followup not given for benign cases			

Table 24.	Morbidity in series of	of patients undergoine	g surgical management o	of adnexal masses
		•. pane	g ea. g.eaa	

Study	N	Patient population	Complication rate (95% CI)	Notes
				Gynecologic oncology service
				Results not stratified by age or menopausal status
				8.0% conversion to laparotomy
Canis et al., 1994 ²¹⁹	757	11.4% postmenopausal	1.1% (0.53 to 2.1%)	Mean followup 42 months (range 3-153 months)
Dottino et al., 1999 ³⁷	160	53% postmenopausal	7.5% (4.3 to 12.9%)	Gynecologic oncology service
Marana et al., 2004 ²³⁰	620	All less than 40 years old	0.9% (0.4 to 2.0%)	Mean followup 30 months
Parker et al., 1994 ⁴¹	61	100% postmenopausal	3.3% (0.4 to 12.3%)	Single surgeon Masses "presumptively benign" based on imaging, exam, clinical history
Sadik et al., 1999 ²³²	220	3.2% postmenopausal	0.9% (0.06 to 3.5%)	4.9% conversion Malignant masses "excluded from study"
Chi et al., 2004 ²²³	146	Menopausal status not reported; median age 54	Mortality 2.5% (0.5 to 6.3%) Morbidity 22.1% (15.1 to 32.7%)	Clinical history not described—not clear if other conditions besides adnexal mass included
Havrilesky et al., 2003 ²²⁶	396	37.2% postmenopausal	Laparoscopy 8.3% (6.0 to 11.6%)	Risk of complication increased with concurrent hysterectomy
Lok et al., 2000 ²²⁸	513	5.5% postmenopausal	Laparoscopy 13.3% (10.6 to 16.6%)	No malignancies 75.% symptomatic
Mann and Reich, 1992 ²²⁹	44	100% postmenopausal	Laparoscopy 4.6% (0.7 to 16.7%)	1/44 had cancer
Parker and Proietto, 1997 ²³¹	86	Menopausal status not reported	Laparoscopy 22.1% (15.1 to 32.7%)	1/86 had cancer
Serur et al., 2001 ²³³	100	49% postmenopausal	Laparoscopy 10% (5.6 to 19.0%)	-
Shalev et al., 1994 ²³⁴	55	100% postmenopausal	Laparoscopy 10.9% (5.2 to 22.9%)	-
Tarik and Fehmi, 2004 ²³⁷	1478	Menopausal status not reported (but mean age 30)	Laparoscopy: Diagnostic procedures 1.8% (0.8 to 3.8%) Minor procedures: 1.4% (0.8 to 2.3%)	Proportion with preoperative diagnosis of adnexal mass not reported
Van Herendael et al., 1995 ²³⁸	121	Menopausal status not reported	Laparoscopy: 1.7% (0.1 to 6.4%)	-

Abbreviation: CI = confidence interval

Nationwide Inpatient Sample

Table 25 shows the estimated numbers of discharges in the United States in 2000-2001 under each diagnostic class and procedure (standard errors not shown for simplicity). The results illustrate the difficulty in using discharge data to attempt to estimate morbidity and mortality rates for surgical procedures. Both morbidity and mortality are highest for cancer diagnoses, but

there is no way to determine the extent to which the underlying disease process contributed to either complications or death; for example, "exploratory laparotomy" or "diagnostic laparoscopy" in many ovarian cancer patients likely represents a "second-look" procedure done to determine response to chemotherapy. Outcomes of these procedures are not relevant to estimating the risks of a primary diagnostic procedure. The laparoscopies that are included in the NIS are likely not representative of all laparoscopies for adnexal masses; since the NIS does not capture surgeries performed at ambulatory surgery centers, the cases within the NIS may represent those for which surgeons had a higher index of suspicion of malignancy, or anticipated higher technical difficulty. Another major limitation is the inability to distinguish between the initial indication for surgery and the final diagnosis. Finally, in order to try to eliminate confounding by additional procedures, we excluded cases in which hysterectomy was performed – however, because hysterectomy is part of the standard initial surgical treatment of ovarian cancer, many cases of initial management are excluded.

Table 25. Estimated U.S. discharges for exploratory laparotomy and diagnostic laparoscopy with discharge diagnoses consistent with adnexal mass, with mortality and complication rates

	Number of	Died	Mortality	Complica-	Complica-
	discharges		rate	tions	tion rate
OVARIAN CANCER	118,042	7099	6.0%	515	0.4%
Laparoscopy (no ovarian procedures)	222	5	2.3%	0	0.0%
Laparoscopy plus conservative ovarian					
procedure	27	0	0.0%	0	0.0%
Laparoscopy plus oophorectomy	16	0	0.0%	0	0.0%
Laparotomy (no ovarian procedure)	566	11	1.9%	5	0.9%
Laparotomy plus conservative ovarian					
procedure	68	0	0.0%	0	0.0%
Laparotomy plus oophorectomy	36	0	0.0%	0	0.0%
OTHER ADNEXAL CANCER	780	15	1.9%	5	0.6%
Laparoscopy (no ovarian procedures)	0	0	0.0%	0	0.0%
Laparoscopy plus conservative ovarian					
procedure	0	0	0.0%	0	0.0%
Laparoscopy plus oophorectomy	0	0	0.0%	0	
Laparotomy (no ovarian procedure)	15	15	100.0%	0	0.0%
Laparotomy plus conservative ovarian					
procedure	0	0	0%	0	
Laparotomy plus oophorectomy	0	0	0%	0	
BENIGN OVARIAN NEOPLASM	145,024	255	0.2%	964	0.7%
Laparoscopy (no ovarian procedures)	1,560	5	0.3%	35	2.2%
Laparoscopy plus conservative ovarian					
procedure	75	0	0.0%	0	0.0%
Laparoscopy plus oophorectomy	24	0	0.0%	0	0.0%
Laparotomy (no ovarian procedure)	700	4	0.6%	16	2.3%
Laparotomy plus conservative ovarian					
procedure	72	0	0.0%	0	0.0%
Laparotomy plus oophorectomy	31	0	0.0%	0	0.0%
PELVIC MASS	13,625	30	0.2%	60	0.4%
Laparoscopy (no ovarian procedures)					
Laparoscopy plus conservative ovarian					
procedure	41				
Laparoscopy plus oophorectomy					
Laparotomy (no ovarian procedure)	35	5	14.3%		ļ
Laparotomy plus conservative ovarian					
procedure					
Laparotomy plus oophorectomy					
OVARIAN CYSTS	474,485	376	0.08%	3045	0.6%

	Number of	Died	Mortality	Complica-	Complica-
	discharges		rate	tions	tion rate
Laparoscopy (no ovarian procedures)	5,508		0.00%	65	1.2%
Laparoscopy plus conservative ovarian					
procedure	274		0.00%		0.0%
Laparoscopy plus oophorectomy	173		0.00%		0.0%
Laparotomy (no ovarian procedure)	1,429	79	5.53%	19	1.3%
Laparotomy plus conservative ovarian					
procedure	99		0.00%		0.0%
Laparotomy plus oophorectomy	86		0.00%		0.0%
PARA-OVARIAN CYST	21,807	5	0.0%	92	0.4%
Laparoscopy (no ovarian procedures)	271		0.0%		0.0%
Laparoscopy plus conservative ovarian					
procedure	24	0	0.0%	0	0.0%
Laparoscopy plus oophorectomy	9	0	0.0%	0	0.0%
Laparotomy (no ovarian procedure)	61	10	16.4%	0	0.0%
Laparotomy plus conservative ovarian					
procedure	5	0	0.0%	0	0.0%
Laparotomy plus oophorectomy	5		0.0%		0.0%
PELVIC INFLAMMATORY DISEASE	430,027	439	0.1%	4793	1.1%
Laparoscopy (no ovarian procedures)	7,184	4	0.1%	150	2.1%
Laparoscopy plus conservative ovarian					
procedure	445	0	0.0%	9	2.0%
Laparoscopy plus oophorectomy	159	0	0.0%	5	3.1%
Laparotomy (no ovarian procedure)	2,129	10	0.5%	53	2.5%
Laparotomy plus conservative ovarian					
procedure	160	0	0.0%	0	0.0%
Laparotomy plus oophorectomy	45	0	0.0%	0	0.0%
NORMAL PELVIS	108.8	0	0	0	0

Other Outcomes

We identified two studies that reported on the sensitivity and specificity of intraoperative frozen section done to determine pathologic diagnosis.^{220,236} They reported similar findings. Both studies defined low malignant potential tumors as cancer. Canis et al.²²⁰ reported a sensitivity of 92.2 percent and a specificity of 92.2 percent in 141 women (29.8 percent postmenopausal, 35 percent with cancer or low malignant potential tumors). Tangjitgomol et al.²³⁶ estimated similar values, with a reported sensitivity of 91.3 percent and specificity of 93.3 percent in 212 women (menopausal status not reported, cancer prevalence 77 percent). Defining low malignant potential cancers as benign decreased sensitivity in both cases.

We identified only one article that addressed the potential impact of surgical management of benign cysts on fertility. Somigliana et al.²³⁵ followed 32 women who received ovarian stimulation after removal of an endometriotic cyst. The mean number of follicles observed in the ovary where the cyst had been removed (2.0 ± 1.5) was significantly lower than in the contralateral ovary (4.2 ± 2.5) , suggesting that the surgical procedure may have led to decreased ovarian reserve. An alternative explanation is that the cyst itself had an adverse effect on ovarian reserve.

Discussion

Ideally, reports of adverse outcomes of diagnostic surgery for adnexal masses would be divided into four separate categories, based on preoperative symptoms and postoperative findings: (1) women with symptomatic masses which ultimately proved malignant; (2) women with symptomatic masses which ultimately proved benign; (3) women with asymptomatic masses which ultimately proved malignant; and (4) women with asymptomatic masses which ultimately proved benign. For the first three groups, the operative procedure could be considered appropriate even in the event of morbidity, since there is some benefit (primary surgical therapy for malignancy, or management of symptomatic nonmalignant adnexal pathology) to be gained from surgical diagnosis and treatment. For women with asymptomatic benign masses, there are theoretical benefits for detecting some benign masses, including (1) prevention of subsequent malignant transformation, (2) avoidance of rupture which, for certain benign masses (endometrioma and mature teratoma) could cause acute symptoms, (3) easier surgical management, with fewer complications, compared to management of a larger symptomatic mass, (4) avoidance of torsion (twisting of the adnexa) and emergent surgical management and (5) avoidance of effects on fertility, either from the underlying condition itself or from more extensive surgery for a larger mass. However, we did not identify any evidence for these benefits; the probabilities of these potential benefits also would differ widely depending on the underlying pathology and natural history of a particular mass, the patient's age and reproductive status, and other comorbidities.

Unfortunately, neither the literature nor available discharge data allow estimates of the probabilities of outcomes based on initial presentation. In the case of the literature, this is because of a lack of reporting of the clinical path by which patients come to undergo surgery. In the case of discharge data, it is because of the inherent limitations of the *International Classification of Diseases, Ninth Revision* (ICD-9) coding. Even if more recent data on ambulatory surgery were available, it would still be limited by coding.

Summary

Mortality for laparoscopic management of adnexal masses at experienced centers appears to be quite low, although the upper bound of this low rate is unclear.

Patient characteristics that determine risk of morbidity are unclear, although the need for more extensive procedures appears to increase the risk. Laparoscopy may have a lower morbidity rate than laparotomy, but this appears to be due, at least in part, to different patient selection criteria and surgical procedures performed.

Two small studies suggest that the false negative rate of intraoperative frozen section diagnosis is approximately eight percent, and the false positive rate is approximately five to seven percent. Whether either type of false result has a significant impact on outcome is unclear.

There is suggestive evidence that removal of a cyst in premenopausal women may affect ovarian reserve, potentially affecting fertility and/or age of menopause, but the underlying pathologic process may also play a role. More data are needed.

There are no data to allow estimation of the risks of a diagnostic procedure in the patient with an asymptomatic mass, or to assess the benefits of surgery in that patient compared to the risk of malignancy.

Question 7: Modeling Diagnostic Strategies

Question 7 is: What are the estimated trade-offs resulting from various strategies for evaluation of the adnexal mass?

Approach

A formal decision analytic approach is often quite helpful for synthesizing evidence coming from a range of sources, of varying quality, and of varying degrees of precision in estimates. Such models are also helpful in identifying which parameters are most important, in order to prioritize future research. Ideally, the underlying natural history of the disease in question can be modeled, with the impact of subsequent clinical interventions estimated based on test characteristics, effectiveness and morbidity from treatment, patient preferences, etc. In addition, the effect of varying both the incidence and natural history of ovarian cancer based on risk factors such as genetic predisposition can also be taken into account if adequate data are available. For example, such models have been quite helpful in exploring the impact of various interventions for cervical cancer prevention.²⁴⁰ In addition, data from currently ongoing trials of ovarian cancer screening will also provide valuable data on natural history.²⁴¹

Because of the methodological limitations of the literature on management of adnexal masses cited in the previous sections, a formal decision analysis does not seem appropriate at this time. In order to illustrate some of the key areas for future research, we did a simple estimate of the expected outcomes of several strategies for evaluation of the adnexal mass based on the findings of this review. Because models will ultimately need to incorporate the natural history of ovarian cancer, either to evaluate screening or to estimate the consequences of false negative diagnoses, we also performed a literature review of existing models of the natural history of ovarian cancer and the impact of screening or testing and developed an alternative model.

Predicting Outcomes of Management Strategies

As an example, we can consider one clinical scenario: an asymptomatic postmenopausal woman undergoing a routine bimanual pelvic examination. If the bimanual examination is abnormal, she can undergo a variety of additional tests. We compared several strategies: (1) performing CA-125 only, then operating on women with values greater or equal to 35;(2) performing an ultrasound with Doppler velocimetry (the strategy with highest sensitivity and specificity in our review) and operating on women with positive results both morphologically and with Doppler; (3) performing CA-125, then performing ultrasound with Doppler on women with elevated CA-125 and operating on women with positive ultrasounds; (4) performing ultrasound with Doppler first, then performing CA-125 on women with positive ultrasound results, and operating on women with elevated CA-125, and (5) performing both ultrasound and CA-125 and combining these results with menopausal status to use the RMI (discussed in detail under Question 4); women with RMI scores above the threshold undergo surgery. Strategies 3 and 4 are examples of serial testing, Strategy 5 an example of parallel testing. Table 26 provides estimates for key parameters based on the previous chapters; estimates for test characteristics are taken from the point estimates of the pooled random-effects models.

Table 26. Estimates for key model parameters

Parameter	Value
Prevalence of adnexal masses in postmenopausal women (Question 1)	Malignant: 0.1% Benign: 1.0%
Sensitivity of the pelvic examination to detect adnexal masses (Question 2)	0.45
Specificity of the pelvic examination to detect adnexal masses (Question 2)	0.90
Sensitivity of combined morphology and Doppler (Question 3)	0.86
Specificity of combined morphology and Doppler (Question 3) Note: We assumed that the specificity of ultrasound for determining the absence of pelvic mass was 100%.	0.91
Sensitivity of CA-125 in postmenopausal women (Question 3)	0.80
Specificity of CA-125 in postmenopausal women (Question 3)	0.87
Sensitivity of RMI (Question 4)	0.74
Specificity of RMI (Question 4)	0.91

Abbreviation: RMI = Risk of Malignancy Index

At the initial pelvic examination, the probability of detecting a mass equals:

Probability of true positive test + Probability of true negative test, or (Prevalence of mass * Test sensitivity) + (1-Prevalence of mass)*(1-Test Specificity)

Similarly, the probability of a negative test equals:

Probability of true negative + Probability of false negative, or (1-Prevalence)*Test Specificity + Prevalence*(1-Sensitivity)

At the time of ultrasound, the "prevalence" of disease is equal to the positive predictive value of the preceding test, the ultrasound, or:

Probability of true positive pelvic/(Probability of true positive pelvic + Probability of false negative pelvic)

Similar calculations were made for each test or combination of tests.

Table 27 shows the predicted outcomes (in terms of detected and missed cancers) of testing with either ultrasound morphology with Doppler velocimetry or CA-125 alone in a hypothetical cohort of 100,000 postmenopausal women.

Table 27. Predicted outcomes of ultrasound plus Doppler or CA-125 testing to determine surgical
management in a hypothetical cohort of 100,000 postmenopausal women*

	Underlying pathology				Prevalence of		
	Cancer	Benign mass	Normal	Total	malignancy among test positives	Proportion of all tests positive	Missed cancers
Baseline cases	100	1,000	98,900	100,000	0.1%	-	
Pelvic exam							
Positive	45	450	9,890	10,385			
Negative	55	550	89,010	89615	0.4%	10.4%	55
STRATEGY: CA-125 only							
CA-125							
Positive	36	59	1,286	1,380			
Negative	9	392	8,604	9,005	2.6%	15.3%	9
Surgery							
Positive	36			36			
Negative		59	1286	1,345		2.6%	
STRATEGY: Morphology/ Doppler only							
Morphology/ Doppler							
Positive	39	41	0	80			
Negative	6	410	9,890	10,306	49.8%	0.8%	6
Surgery							
Positive	39	0	0	39			
Negative	0	41	0	41		49.8%	

* Some numbers may not add up correctly because of rounding. Abbreviation: CA-125 = cancer antigen 125

Table 28 shows the predicted outcomes of the serial and parallel testing strategies.

Table 28. Predicted outcomes of serial testing or parallel testing with ultrasound plus Doppler or CA-125 testing to determine surgical management in a hypothetical cohort of 100,000 postmenopausal women*

	Underlying pathology			Prevalence of			
	Cancer	Benign mass	Normal	Total	malignancy among positive tests	Proportion of all tests positive	Missed cancers
Baseline cases	100	1,000	98,900	100,000	0.1%	P • • • • • •	
Pelvic exam		450	0.000	40.005			
Positive	45	450	9,890	10,385	0.40/	10, 10/	
Negative	55	550	89,010	89,615	0.4%	10.4%	55
STRATEGY: CA-125, followed by morphology/ Doppler							
CA-125							
Positive	36	59	1,286	1,380			
Negative	9	392	8,604	9,005	2.6%	13.2%	9
Morphology/ Doppler							
Positive	32	5	0	37			
Negative	4	53	1,286	1,343	86.5%	2.7%	4
Surgery							
Positive	32	0	0	32			
Negative	0	5	0	5			
STRATEGY:							
Morphology/ Doppler followed by CA- 125 Morphology/							
Doppler							
Positive	40	41	0	81			
Negative CA-125	5	410	9,890	10,305	49.4%	0.8%	5
Positive	32	5	0	37			
Negative	8	35	0	43	86.5%	45.7%	8
Surgery	-						-
Positive	32			32			
Negative	0	5	0	5		86.5%	
STRATEGY: RMI (morphology + CA-125 + menopausal status)							
RMI Desitive				74			
Positive	33	41	0	74	11 60/	10 00/	
Negative	12	410	9,890	10,312	44.6%	13.2%	9
Surgery Positive	33	0	0	33			
Negative	0	41	0	41		44.6%	
negative	U	41	U	41		44.0%	

* Some numbers may not add up correctly because of rounding. Abbreviations: CA-125 = cancer antigen 125; RMI = Risk of Malignancy Index

Table 29 summarizes the outcomes of the five strategies in terms of total number of tests, total number of missed cancers, and total number of surgeries.

	Strategies							
	Singl	e tests	Seria	Parallel tests				
		Ultra-	CA-125 followed Ultrasound		Risk of			
	CA-125	sound*	by ultrasound	followed by CA-125	Malignancy Index			
Total tests	10,385	10,385	11,765	10,466	20,770			
Total missed	9	9	13	13	9			
cancers								
Total surgeries	1,380	80	37	37	74			

Table 29. Estimated numbers of tests, missed cancers, and surgeries for each strategy

Abbreviation: CA-125 = cancer antigen 125

Table 30 illustrates the effect of increasing the prevalence of cancer (for example, in symptomatic women with a known mass) from 0.1 percent to 10 percent. The size of the cohort here is 1,100 women with masses (the same as in the screening cohort).

Table 30. Estimated numbers of tests, missed cancers, and surgeries for each strategy in 1,100 women with known adnexal mass and underlying prevalence of ovarian cancer 10%

	Strategies							
	Sing	e tests	Seria	Parallel tests				
		Ultra-	CA-125 followed	Risk of				
	CA-125	sound*	by ultrasound	followed by CA-125	Malignancy Index			
Total tests	1,100	1,100	1,317	1,287	2,200			
Total missed	20	15	32	32	26			
cancers								
Total surgeries	197	184	90	90	155			

Abbreviation: CA-125 = cancer antigen 125

This simple "model" illustrates several key points:

- The prevalence of malignancy increases as additional diagnostic tests are performed. This is certainly clinically appropriate and reflects the effects of sequential testing strategies. However, specificity and, to some extent, sensitivity for many of the tests reviewed appear to vary with underlying disease prevalence. Thus, estimates for test characteristics calculated at one point in the clinical pathway may not be appropriate for other points.
- Despite a poor sensitivity of 45 percent, the negative predictive value of a negative pelvic examination for malignancy is quite high (99.94 percent). The reassurance provided by a "normal" exam reflects the epidemiology of the underlying disease, rather than the intrinsic value of the test in discriminating benign from malignant. This reflects the low prevalence of ovarian cancer in the population. Conversely, the positive predictive value is only 0.4 percent, despite a specificity of 92 percent.
- In order to judge the trade-offs between detection of masses that ultimately prove malignant compared with the risks of diagnostic surgery, we would need better estimates of morbidity and mortality within different diagnostic categories as noted previously, these do not exist.
- The most "efficient" strategy in terms of number of tests and surgeries is serial testing with ultrasound followed by CA-125; however, this results in four missed cancers compared with parallel testing using the RMI. However, parallel testing doubles the number of tests to be

performed. A formal cost-effectiveness analysis requires significantly more data on test characteristics and ovarian cancer natural history, as well as the morbidity of surgical management.

- Modeling parallel testing beyond the data in scoring systems is difficult. Besides requiring specific assumptions about how results that were positive for one test but negative for another would be managed, one would also need to know if the sensitivity and specificity of each test were independent or correlated in some way. For example, it seems likely that the sensitivity of both ultrasound and CA-125 would be greater for larger masses than for smaller masses.
- In scenarios where the likelihood of ovarian cancer is higher, the negative predictive value of any diagnostic strategy will decrease (more missed cancers), and the positive predictive value will increase (the proportion of surgical cases where cancer is found will be higher). This is seen clearly by comparing Tables 29 and 30. The number of women with adnexal masses is the same, but the number of missed cancers is substantially higher with each strategy.
- In addition, for any screening modality, there needs to be evidence that early detection reduces disease-specific morbidity and mortality. In addition, in order to judge the impact of false negative results, data on the natural history of ovarian cancer are also needed. Since data from large trials are still pending, one way to examine the potential impact of different testing strategies for both initial screening and subsequent testing is through the development of simulation models.

We next review published models of the natural history of ovarian cancer.

Models of Ovarian Cancer: Literature Review

Four articles were identified from the literature review that used modeling to determine the effectiveness and cost-effectiveness of different screening strategies for the detection and treatment of ovarian cancer. These are described in Evidence Table 7 (Appendix D^{*}). Studies were included if they were directly relevant to Question 7,²⁴²⁻²⁴⁴ or provided natural history information that could be used in the construction of a model.²⁴⁵

Schapira et al.²⁴² conducted a decision analysis comparing a one-time screen using transvaginal sonography and CA-125 either alone or in combination to determine life-expectancy gains in a cohort of 40-year-old women in the United States. In the model women could either be screened or unscreened. Probabilities were derived from the literature for the following: prevalence of disease in 40-year-old women, percentage of early stage disease, clinical detection of disease, sensitivity of the screening test for detection of early stage disease, specificity of the screening test, and the mortality rate associated with diagnostic laparotomy. Life expectancy was calculated for women who had no disease, early stage disease, and late stage disease. Table 31 summarizes key input parameters and ranges.

Assumptions in the model were that survival time for clinically and screen-detected early stage disease is the same; morbidity and mortality rates associated with diagnostic laparotomy are the same for people with and without the disease; and there is no benefit gained from identifying benign disease.

^{*} Appendixes cited in this report are provided electronically at http://www.ahrq.gov/downloads/pub/evidence/pdf/ adnexal/adnexal.pdf.

The results of the analysis suggested that use of the combined strategy would result in a gain in life expectancy (compared to no screening) of one third of a day of life. No screening was preferred if the postoperative mortality rate exceeded 7.32 percent or the specificity of the test was less than 98.53 percent. An additional analysis, examining the use of testing for women aged 65+ suggested that the combined strategy would result in an average gain in life expectancy of approximately 3/4 of a day of life.

Parameter	Value	Range	Source
Prevalence of ovarian cancer	28.6/100,000	20 to 200/100,000	NCI monograph No. 41; 1975
Percentage of prevalent cases in early stage	50%	20 to 80%	Assumed
Percentage of early stage disease diagnosed clinically	25%	20 to 80%	ACS Cancer Statistics 1990
Sensitivity of CA-125 and TVUS (combined) for early stage disease	45%	20 to 80%	Literature review
Sensitivity of CA-125 and TVUS (combined) for late stage disease	81%	50 to 100%	Literature review
Specificity of CA-125 and TVUS	99.95%	96 to 100%	Literature review
Probability of post-laparotomy death	0.23%	0 to 10%	National Halothane Study JAMA 1966

Abbreviations: ACS = American Cancer Society; NCI = National Cancer Institute; TVUS = transvaginal ultrasound

Skates and Singer²⁴⁴ developed a stochastic model to evaluate screening with CA-125. Key assumptions in this model included:

- Stepwise progression from Stage I through Stage II through Stage IV;
- Log-normal distributions of progression rates;
- Stage at clinical detection independent of duration of disease;
- The coefficient of variation in stage length is constant across all stages;
- Estimates for the duration of each stage were provided by two gynecologic oncologists.

In the base case, the model predicted that screening would save 3.4 years of life per detected case; of note, estimates for the gains in life expectancy for the entire population undergoing screening were not provided.

Urban et al.²⁴³ examined the cost-effectiveness of screening using CA-125 and TVUS alone or in combination in a cohort of 1 million 50-year-old women using a stochastic simulation model, building on the model of Skates and Singer (Table 32). Screening and case ascertainment was assumed to occur over a 3-year period; women were assumed to be followed until age 80 or death.

Table 32. Key assumptions and data sources used to derive values for parameters in the Urban model²⁴³

Parameter	Estimate	Source
Stage of ovarian cancer	FIGO	
Relative stage lengths (relative to Stage 1)	0.5, 1.333, 0.333	Skates et al. ²⁴⁴ FIGO stages III and IV assumed to comprise SEER stage 3
Geometric mean stage length in months	9; 4.5, 12 and 3 months	
Probability of disease during testing period	0.0121	Not stated
Probability of age at clinical detection	Age 50-54 - 0.153 Age 55-59 - 0. 184 Age 60-64 - 0.202 Age 65-69 - 0.179 Age 70-74 - 0.150 Age 75-80 - 0.132	SEER
Probability of stage at clinical detection	Stage 1 - 0.223 Stage 2 - 0.153 Stage 3/ 4 - 0.624	SEER
Point in stage at clinical detection	0.5 of stage length	Assumed
Stage length distribution	Log normal (9, 4.5)	Assumed
TVUS sensitivity	100%	van Nagell, CA 1990 van Nagell, CA 1991
TVUS – false positive	1 st screen 0.019; 2 nd screen 0.010; 3 rd screen 0.006	Campbell, Br J Obstet and Gynecol 1990
CA-125 level in cases	Refer to page 254 of article for formula	Skates et al. ²⁴⁴ Einhorn, Proc Am Soc Clin Oncol 1990
% of false negatives for CA-125	5%	Assumption
CA-125 specificity in women with false positive TVUS	0.85	Bast, Gyn Onc 1985 Woolas, JNCI, 1993
Return to normal life-expectancy post-diagnosis	15 years	Assumption
Probability of death in surgery among false-positive	0.001	Assumption

Abbreviations: FIGO = International Federation of Gynecology and Obstetrics; SEER = Surveillance, Epidemiology, and End Results; TVUS = transvaginal ultrasound

Six screening strategies using TVUS and CA-125 either alone or in combination: annual TVUS; annual CA-125, elevated (35U/ml used for referral to laparoscopy); annual CA-125, rising or elevated (rising defined as CA-125 level that has doubled since last screen); annual TVUS conditional on rising or elevated CA-125; 6-month TVUS condition on rising or elevated CA-125; 2-year TVUS conditional on rising or elevated CA-125. Of these, the strategy of

annual TVUS conditional on rising or elevated CA-125 was identified as efficient, meaning it saved an equivalent if not higher amount of life at lower costs compared to other strategies. The model was especially sensitive to assumptions about the duration of Stage I disease.


Discussion

Secondary prevention of cancer mortality through screening has been remarkably effective in the case of cervical cancer. Mammography has also reduced mortality from breast cancer, although there remains some controversy. To date, although survival in early stage ovarian cancer is considerably higher than survival in later stage cancers, trials of screening have not yet demonstrated reduction in disease-specific mortality. Although the relative lack of effectiveness of ovarian cancer screening to date may reflect the lack of an appropriate test, differences in the biology and natural history of the different cancers may also result in some of the differences.

As outlined in a recent review,²⁴⁶ the most critical criteria for an effective screening strategy for ovarian cancer is that there is a time of sufficient duration during the development of ovarian cancer when cancer is detectable but in a stage when treatment effectiveness is high. As shown in the two most sophisticated models reviewed, estimates of the effectiveness of screening are highly dependent on assumptions about the duration of Stage I cancer. The basis for the estimates used in both models was the opinion of two clinicians; the methods used to derive these estimates were not described.


Cervical cancer is, in the majority of cases, a squamous carcinoma, which spreads primarily through direct extension and secondarily through lymphatic invasion. The most common type of ovarian cancer, on the other hand, is typically an adenocarcinoma, which spreads by dissemination of tumor cells throughout the peritoneal cavity.

One assumption commonly made in the models of ovarian cancer we identified is that ovarian cancer staging represents the natural history. Figure 24 illustrates a simplified schematic model used in all three of the reviewed papers. Patients can develop ovarian cancer, die of other causes, or remain healthy. Those who develop ovarian cancer can present with symptoms or through testing to become an incident case, or remain undetected, and can either remain within the same stage or progress to the next. Figure 24. Schematic of Markov or stochastic model of ovarian cancer natural history



Although this stepwise progression through stages is the case for cervical cancer, there is no evidence to suggest that tumors limited to the ovary (Stage I) must necessarily spread first to adjacent pelvic organs (Stage II) prior to spread throughout the peritoneal cavity (Stage III). Although staging systems represent the extent of disease, they are developed to help with prognosis, and to allow comparison of treatment effectiveness – there is no explicit assumption that each stage necessarily must be preceded by the next lowest one. Figure 25 depicts an alternative model, which allows some Stage I cancers to progress directly to Stage III:

Figure 25. Alternative model of ovarian cancer history



Using the Markov model described in Chapter 2, we performed sensitivity analyses on progression rates and type of progression to determine if this second "model" of progression could result in similar stage distributions to observed data.

Figure 26 compares the predicted incidence of ovarian cancer derived from the model with incidence rates reported in the Surveillance, Epidemiology, and End Results (SEER) data set, under the assumption that there was a stepwise progression from Stage I through Stage IV:




Figure 26. Model predictions of ovarian cancer incidence (black triangles) compared to SEER incidence rates (closed circles)

We then allowed a proportion of Stage I cancers to proceed directly to Stage III and calibrated underlying progression rates. Table 33 compares the model input parameters and resulting stage distribution of the two models.

Table 33. Inputs and outputs of ovarian cancer models

	Model 1 (Stage 1 must progress through Stage II)	Model 2 (some Stage I can progress directly through Stage III)	Stage distribution: FIGO (local data from Skates et al. ²⁴⁴)	Stage distribution: SEER (1995- 2001)
Parameter estimate				
Annual probability of presenting with symptoms: Stage I	0.095	0.1		
Annual probability of presenting with symptoms: Stage II	0.095	0.15		
Annual probability of presenting with symptoms: Stage III	0.7	0.9		
Annual probability of presenting with symptoms: Stage IV	1	1		
Proportion of Stage I progressing directly to Stage III	0	0.25		
Model output: stage distribution				
FIGO:	10.40/	40.00/	05%	
Stage I	<u>19.1%</u> 8.2%	<u>19.6%</u> 9.3%	25% 8%	
Stage II Stage III	<u>8.2%</u> 54.2%	<u>9.3%</u> 65.2%	8% 52%	
Stage IV	18.6%	5.9%	15%	
SEER/WHO:	10.070	5.970	1070	
Local	19.1%	19.6%	25%	19%
Regional	8.2%	9.3%	8%	7%
Distant and unstaged	72.8%	71.1%	67%	75%

Abbreviations: FIGO = International Federation of Gynecology and Obstetrics; SEER = Surveillance, Epidemiology, and End Results; WHO = World Health Organization

With relatively small changes in the probability of presenting with symptoms, a model that allows 25 percent of Stage I tumors to progress directly to Stage III results in stage distributions similar to observed data, and results in similar lifetime risk of ovarian cancer as the Urban model,²⁴³ In a model with multiple input parameters, a huge number of combinations of parameters can result in similar outputs. Given that estimations of the duration of the different stages of ovarian cancer are based on little empirical data, and that there is no empirical data on the natural history of ovarian cancer, further exploration of the implications for screening, and the evaluation of masses detected through screening, is warranted.

Summary

The evidence is insufficient to develop a comprehensive model to estimate the relative benefits and risks of different management strategies for evaluating the adnexal mass.

Based on summary estimates of pooled sensitivity and specificity, management strategies that use imaging as the first step for evaluating an adnexal mass detected on examination (as opposed to CA-125) are more efficient, since they exclude false positive results from further examination. Serial testing with imaging followed by CA-125 results in the fewest number of

surgeries, but misses more cancers than parallel testing. Parallel testing greatly increases the number of tests required, but results in fewer missed cancers. Additional data are needed to evaluate cost-effectiveness.

Alternative assumptions about the natural history of ovarian cancer can result in modeled outcomes similar to those of published models; the implications of these assumptions should be explored further.

Chapter 4. Discussion

Limitations of the Report

There are several limitations to this evidence report:

- We did not review articles published in languages other than English because of a lack of resources for translation. It is possible that this led to the failure to include some relevant articles.
- For our review of prevalence studies (Question 1), we excluded studies performed outside the United States. Because the report was requested by the Centers for Disease Control and Prevention (CDC) to help with development of their policies and research agenda into ovarian cancer prevention strategies, we focused on U.S. populations and reasoned that the underlying prevalence of different conditions in women with adnexal masses could well differ in potentially important ways due to differences in racial/ethnic distribution and/or environmental exposures. As discussed in Chapter 2, this is supported by wide international variation in the incidence of cancer. Variations in screening, diagnosis, and surgical management could also lead to differences in the prevalence of various conditions among women with adnexal masses. It is possible that this reasoning was incorrect, and that some relevant articles were excluded. However, some non-U.S.-based articles were reviewed for other questions, and the majority shared the same biases as U.S.-based studies (i.e., most were done immediately preoperatively).
- There was considerable heterogeneity in design and patient populations among studies, and our use of a random-effects model to perform meta-analyses for some questions may have led to inaccurate estimates of pooled sensitivity and specificity. We also did not weight the results by anything other than sample size; it is possible that different results might have been obtained by weighting for study quality, for example.
- In our review of data from the Nationwide Inpatient Sample, we used only specific *International Classification of Diseases, Ninth Revision* (ICD-9) "E" class codes to identify complications. A more exhaustive strategy (e.g., identifying procedures not typically performed at the time of diagnostic surgery, identifying blood transfusions through procedure or charge codes, including patients with cancer who underwent hysterectomy) might have revealed more complications,²⁶ but would have required additional assumptions about the original indication for the surgery and the likely potential contribution of different aspects of the procedure to the complication (e.g., hysterectomy vs. oophorectomy).
- Our exploration of alternative models for the natural history of ovarian cancer did not directly compare estimated outcomes of screening strategies to other models. However, a comprehensive evaluation of screening for ovarian cancer was beyond the scope of this report. We are currently developing the model further to conduct these analyses.

Methodological Issues in the Literature

Description of the Patient Population

The main shortcoming of many of the papers reviewed was a failure to adequately describe the patient population, including the manner in which the adnexal mass was originally detected and subsequent evaluation. In Chapter 1, we described the importance of understanding the clinical presentation of the subjects in studies of management of adnexal masses. Because prevalence directly affects predictive values and may indirectly affect estimates of sensitivity and specificity, the probability that a patient is a true or false positive, or true or false negative, is dependent on the prevalence. In addition, the presence or absence of symptoms can affect the probability that a patient will undergo surgery if test findings indicate a benign mass, since surgery may still be the treatment of choice for the underlying condition. We were disappointed that the overwhelming majority of the studies we reviewed, relevant to all of the questions, did not adequately describe their population, so that the proportions of patients who presented with asymptomatic masses versus those with symptoms could be compared.

To be fair, there is an inherent feasibility issue in studies of diagnostic test accuracy for ovarian cancer – the ideal reference standard is histological confirmation, yet this confirmation requires surgery. Although this is a limitation of all cancer screening tests, the surgery required for a definitive diagnosis of ovarian cancer is more extensive than that for many cancers (for example, cervical, breast, and colon cancer can all be diagnosed without a requirement for general anesthesia). Especially with screening, or early in the diagnostic evaluation, the risks of surgery may be difficult to justify (especially since the low prevalence of malignancy makes the positive predictive value of tests early in the diagnostic test studies to patients already scheduled for surgery. However, readers of these studies should recognize that the prevalence of malignancy will be substantially higher in preoperative patients than in patients at the time of the initial diagnosis of adnexal mass. Because test performance may be affected by prevalence, the outcomes (in terms of true and false test results) may be quite different in these two patient populations.

The same caveats hold for studies of the outcomes of surgery. Morbidity and mortality related to surgical diagnosis are influenced by the underlying diagnosis, as well as the extent of the disease (such as size of the mass, presence of adhesions from the disease process or prior unrelated surgery, or cancer stage). Interpreting surgical outcomes from studies that do not provide relevant clinical information is difficult; at the least, generalizablity is a major concern. Lack of relevant clinical information is a particular problem with administrative databases, which otherwise have the attraction of large sample size and better generalizability.²⁶

An even more basic shortcoming was the failure to describe potential differences in study results stratified by age or menopausal status. Given the clear and widely recognized relationship between age and ovarian cancer risk, all studies in this area should present results in a way that allows separate estimation of outcome by age/menopausal status.

Sample Size

Few of the studies we reviewed included a priori sample size calculations. Use of confidence intervals for parameter estimates was uncommon. In studies of scoring systems, there were often too few cases of cancer for the number of variables included in the original models.

Blinding

Relatively few of the diagnostic studies reported whether those interpreting test results were blinded to either clinical presentation or ultimate diagnosis. This could clearly have an impact, particularly in studies of the bimanual pelvic examination; the finding that specificity decreased as prevalence increased suggests that the threshold for identifying a mass as cancer is lower if the clinical suspicion – based on other factors such as patient age, menopausal status, or history – is higher. Although this may be appropriate clinically, it results in biased estimates of test performance.

Observer Variability

Few studies addressed the potential impact of observer variability on the precision of test characteristics.

Natural History of Ovarian Cancer

As discussed in more detail in the section on Question 7, ovarian cancer has been implicitly assumed to progress through a series of stages in a way analogous to cervical cancer. Alternative models are biologically plausible, and mathematical models can be "fitted" to match reported data under a variety of scenarios. Since existing models already show that the effectiveness of screening is dependent on assumptions about the length of Stage I, further exploration of the impact of varying assumptions about natural history is warranted.

The most important parameter in these models, stage duration, is inherently unknowable; however, the source for the parameter estimate in the two most sophisticated models were "personal communications" with two gynecologic oncologists. At the least, more formal methods of eliciting expert opinion are probably warranted for future modeling studies.

Implications of Findings

Question 1

The prevalence of malignancy, even in postmenopausal women, is low – approximately 0.1 percent (1 in 10,000) in large screening studies in the United States. The potential for screening to reduce morbidity and mortality is currently being tested in at least three large trials; these trials should also provide valuable data on disease prevalence and the effectiveness of various followup strategies.

Question 2

Until the results of the large screening trials are available, many, if not most, women with asymptomatic adnexal masses will have had the mass detected as part of a routine health maintenance examination.

The bimanual pelvic examination appears to have a sensitivity of less than 60 percent, whether for detecting adnexal masses in general or for distinguishing benign from malignant masses. Based on the best pooled estimate of sensitivity (45 percent) and a prevalence of 0.1 percent, a normal risk, asymptomatic, postmenopausal woman with a normal pelvic examination has a 99.94 percent chance of not having cancer, even though over half of the cancers would be missed. This is due to the low prevalence of ovarian cancer, since, even without the test, her probability of not having cancer is 99.99 percent. Given these test characteristics, the value of the pelvic examination in reducing ovarian cancer morbidity and mortality appears to be extremely limited, at best. Although there may be some rationales for an annual bimanual examination (discussed in Chapter 5), ovarian cancer screening is not one of them.

Question 3

Of the various diagnostic imaging modalities, either a combination of ultrasound morphology and Doppler velocimetry, or magnetic resonance imaging (MRI), had the best combination of sensitivity and specificity for distinguishing benign from malignant disease. If confirmed by direct comparison, cost-effectiveness might be the most important determinant of which would be the optimal diagnostic procedure. Because the specificity of cancer antigen 125 (CA-125) is high in postmenopausal women, it is helpful in ruling in disease.

Question 4

Additional validation of scoring systems in new populations is required before widespread adaptation can be recommended.

Question 5

The most effective and efficient method for following patients who have been classified as having a benign mass is unclear, although unilocular cysts less than 10 cm appear to have a very low risk of malignancy.

Question 6

The risks of diagnostic laparoscopy or laparotomy, particularly in asymptomatic women who ultimately prove to have a benign lesion, are unclear. Overall morbidity appears to be low in reported series, but these are subject to numerous biases, particularly regarding selection for laparoscopy. Two small randomized trials suggest higher short-term morbidity with laparotomy compared to laparoscopy, but differences between the two groups raise the possibility of confounding.

Question 7

Based on our pooled estimates of sensitivity and specificity, serial testing of postmenopausal women with an adnexal mass detected by pelvic examination with either ultrasound morphology plus Doppler imaging, or MRI (which had similar sensitivities and specificities), followed by CA-125, resulted in the most efficient combination of number of tests, missed cancers, and surgeries. Parallel testing and using a scoring system such as the Risk of Malignancy Index resulted in fewer missed cancers than serial testing, but more overall tests and more surgeries. Additional data are needed to refine these estimates, to include the morbidities of the tests and surgeries, and to perform cost-effectiveness analyses. Either combined strategy is preferable to using imaging alone or CA-125 alone.

We cannot directly compare these results to the joint guidelines of the Society of Gynecologic Oncologists (SGO) and American College of Obstetricians and Gynecologists (ACOG) on which patient to refer to a gynecologic oncologist²⁴⁷ because the data were not available to replicate their findings. However, our results are consistent with the guidelines, which recommend a CA-125 level above 35 for postmenopausal women, the presence of ascites, or evidence of adnexal or distant metastasis.

Alternative assumptions and parameter estimates can be used to generate predicted cancer incidences similar to those seen in published models of the natural history of ovarian cancer. In order to better estimate the potential impact of different strategies for ovarian cancer screening, and for managing masses detected through screening or presenting with symptoms, additional models that explore the implications for alternative natural history assumptions are needed. Data from ongoing screening trials may provide estimates of many of the currently unknown parameters.

Chapter 5. Future Research

This section outlines research priorities identified through the review, both in terms of fundamental gaps in knowledge and in addressing methodological issues of existing studies.

Minimal Data Reporting

Our ability to stratify results by relevant patient characteristics, or to compare the potential effect of patient characteristics on different results from different studies, was limited by the lack of information in most studies. We would suggest that future studies relevant to the diagnosis and management of adnexal masses provide data on, and present results stratified by, the following minimum characteristics:

- Patient age and/or menopausal status
- Patient body mass index
- Patient race and ethnicity
- Presence or absence of risk factors for ovarian cancer, particularly family history
- Means by which the adnexal mass was initially diagnosed—pelvic examination or imaging
- Reason for the initial examination which led to diagnosis of mass: symptoms referable to pelvic mass or ovarian cancer, examination for other symptoms, asymptomatic screening for ovarian cancer, or asymptomatic screening for other conditions

Prevalence of Different Types of Adnexal Masses

- Large scale screening trials will provide some data on the prevalence of different types of masses.
- Administrative data from surgical procedures may provide crude estimates, but some important information (like stage and grade of cancer, or histologic subtype) will likely be missing. In addition, relevant clinical data on presence or absence of symptoms and the diagnostic pathway leading to diagnosis will likely be missing. The best resource for obtaining the necessary data would likely be a large health maintenance organization (HMO) or third-party payer, which would allow comparison of inpatient and outpatient records, and followup of patients after diagnosis. Medicare data would provide similar information for women 65 and older.
- Separate reporting of the prevalence of different types of masses among women with and without symptoms would be helpful for clinical decisionmaking.

Diagnostic Testing

• Ideally, tests would be evaluated at the stage in the clinical pathway in which they are to be used.

- Since this means that many women who have a negative test will not undergo the reference standard, careful attention should be paid to development of alternative reference standards, including definitions of appropriate length of followup.
- More direct comparisons of alternative tests should be performed; existing studies are frequently underpowered to detect clinically meaningful differences, or to establish equivalence. Based on pooled analyses, either magnetic resonance imaging (MRI) or combined ultrasound evaluation of morphology and Doppler velocimetry have attractive sensitivity and specificity. Only two studies, with a total of 200 subjects, have directly compared these modalities in the same patient population.^{91,100} In both of these studies, MRI was less sensitive but more specific than combined morphology/Doppler. More precise comparative estimates should be obtained.
- There is a paucity of studies on positron emission tomography (PET) compared to other imaging modalities. Given that the Centers for Medicaid and Medicare Services (CMS) is now reimbursing for PET scans done within the setting of a clinical trial, there is an excellent opportunity for high-quality studies which avoid the deficiencies outlined in this report.
- Although discriminating between benign and malignant lesions is the highest priority in most clinical situations, estimates of the sensitivity and specificity of various imaging modalities for specific nonmalignant lesions (endometriomas, mature teratomas, etc.) would be helpful for developing comprehensive management strategies, particularly in conjunction with good data on prevalence in premenopausal women. We identified multiple articles relevant to this question during our search, which were excluded because they were not relevant to the main study questions. Although many of the methodological issues identified here would be issues with these studies, a systematic review of this literature would have value.
- New tumor markers should continue to undergo evaluation as diagnostic tests as they are identified, using appropriate methodological standards.

Scoring Systems

- Validation studies in new populations are needed.
- Attention should be paid to adequate sample size.

Followup Studies

• Additional studies, with clear definitions for "benign" lesions and clear protocols for followup, with documentation of loss to followup, are needed. Because by definition these types of studies will not have histological confirmation of all test results, estimates of test performance from such studies may have some bias.

Adverse Outcomes of Surgery

• As with studies of prevalence, both currently published studies (mostly case series) and administrative data have significant deficiencies. Case series would be improved by clearer description of the clinical pathway by which patients ended up undergoing surgery, as well as

by providing relevant clinical data (such as body mass index, history of prior surgeries, and extent of disease).

- Data on outcomes from a variety of settings, including community settings, are needed.
- Again, as with studies of prevalence, data from sources able to provide both inpatient and outpatient data over time, such as HMOs, third-party payers, and Medicare, are likely to provide the best combination of sample size, generalizability, and clinical detail.

Sensitivity and Specificity of the Pelvic Examination

- The annual bimanual pelvic examination appears to have little, if any, benefit for reducing ovarian cancer morbidity and mortality in asymptomatic women. Given that many organizations now recommend less frequent cervical cancer screening in many women, that no screening test has ever been shown to reduce morbidity and mortality from endometrial cancer, and that other gynecological cancers are too rare to justify population-based screening, it would appear that annual bimanual pelvic exams do not have a substantial benefit in reducing mortality. Therefore, evidence on the benefits of the exam would be helpful for patients, clinicians, and policymakers. Possible research areas include:
 - Many clinicians argue that the annual exam provides a "cue" for women to interact with a clinician and receive other preventive services.
 - Would women be less likely to see a health professional on a regular basis if they would not get a pelvic examination?
 - If the exam does provide a "cue" for some women, what is its effectiveness and cost-effectiveness compared to alternative methods of improving adherence to periodic health maintenance schedules?
 - Are there some women who do not regularly see a health professional because of embarrassment/fear/discomfort regarding a pelvic exam who would be more likely to see one if they could be assured they would not get an exam?
 - Others have argued that, after long experience, women expect to receive a pelvic examination (and Pap test) on an annual basis and will continue to demand the examination, despite evidence that the test has little benefit, or does not need to be performed on an annual basis.
 - How have patients reacted to other changes or paradigm shifts in medicine? Can patient expectations be changed in the face of new evidence? Do patient responses differ between changes in which one intervention is replaced by another, versus changes in which an intervention is no longer performed at all?
 - Although the pelvic examination does not appear to have significant benefit as a screening test, does it have more value as a diagnostic test?
 - Assuming the pelvic examination does have value as a diagnostic test, is there a relationship between volume/experience and test accuracy, as suggested by two of the studies we reviewed? If so, can routine examinations in asymptomatic women be justified as a method for maintaining exam skills?
 - If there is a relationship between volume and accuracy, what are the implications for the performance of diagnostic bimanual examinations by generalists (e.g., internists, pediatricians, family practitioners, generalist nurse practitioners) versus specialists (e.g., obstetrician/gynecologists, nurse-midwives, etc)

Modeling the Outcomes of Different Screening Strategies

- Our modeling of the likely outcomes of different screening strategies was limited by the quantity and quality of data available for key parameters. Because this limited direct comparison of different testing strategies, we were not able to do a comprehensive comparison. The lack of data on patient characteristics, particularly symptom status, also prevented extensive analysis of the effects of different strategies in different clinical scenarios. Improving the evidence base for the other questions considered in the evidence report will make a substantial improvement in the ability to meaningfully model outcomes.
- Data on relevant patient preferences for different outcomes are needed.
- Data on relevant cost parameters are needed for cost-effectiveness analysis.
- Data on relative test reproducibility can help determine the effect of observer variability on effectiveness and cost-effectiveness.

Modeling the Natural History of Ovarian Cancer

- We identified only three models, one of which was an updated version of another. Having several groups working on simulation modeling, using different assumptions, software, model structure, etc., has proven quite helpful in the case of cervical cancer. Additional work should be strongly encouraged.
- In particular, models should explore alternative disease natural history parameters, and the implications for various strategies, including screening and primary prevention.

Chapter 6. Conclusions

Developing an effective and efficient algorithm for the evaluation of any condition requires good evidence on the prevalence of the condition at the first diagnostic encounter, and the sensitivity and specificity of the potential diagnostic tests to be used. With this information, one can estimate the outcomes, in terms of true and false positive and negative results, of each test. Various combinations of tests can be compared, and, ideally, the consequences of each test's results in terms of benefits, harms, and costs can be estimated.

In the setting of an adnexal mass, the primary issue is discriminating benign from malignant masses; ideally, all women with an underlying ovarian malignancy would receive appropriate surgical management (perfect sensitivity), and no woman with an asymptomatic benign mass would undergo unnecessary surgery (perfect specificity). The optimal strategy may well differ based on whether or not the patient presents with symptoms, both because the prevalence of disease is likely to be higher in the patient with symptoms (making the positive predictive value higher and the negative predictive value lower), and because surgical management may ultimately be appropriate for a symptomatic patient, and some asymptomatic patients, even if the mass is benign. Age and/or menopausal status are also important considerations, primarily because ovarian cancer is rare prior to age 50, but also because some of the risks of surgery may increase with age.

Unfortunately, the overwhelming majority of the literature we reviewed did not provide sufficient detail on these important patient characteristics to allow confident estimation of the outcomes of different diagnostic strategies, so that we are unable to conclude that any of the strategies achieve the aims of maximizing appropriate treatment and minimizing unnecessary surgery. Outside of studies that were explicitly designed to evaluate screening, few articles described whether patients were symptomatic or asymptomatic, or testing done prior to the diagnostic test being evaluated. Surprisingly few studies reported results separately for premenopausal and postmenopausal women. Future studies need to provide this information.

All of the diagnostic tests and scoring systems we evaluated exhibited a trade-off between sensitivity and specificity – studies of a given test that reported higher sensitivity had lower specificity, and vice versa. In pooled analysis, either the combination of ultrasound morphology and Doppler blood flow, or magnetic resonance imaging (MRI), had the best combination of sensitivity and specificity. Simple modeling of series and parallel tests suggests that, in postmenopausal women, imaging using ultrasound morphology and Doppler blood flow, or MRI, followed by CA-125, is both more sensitive (misses fewer cancers) and more specific (avoids more surgery) than either test alone. A strategy in which both tests were performed and used in a scoring system, the Risk Malignancy Index, prevented additional cancers but with twice as many tests and more surgeries. More data on key parameters are needed to determine if, in certain settings, alternative combinations of tests, performed in parallel or series, might have better outcomes or be more efficient.

Studies of surgical management suffered from the same limitations in terms of description of patient characteristics, making estimation of the risks of false positive diagnostic testing impossible. Similarly, administrative data that only includes discharge information do not provide important clinical information.

The bimanual pelvic examination has low sensitivity for both detection of adnexal masses and discriminating benign from malignant masses, raising doubts about its utility as a screening test in asymptomatic women.

Ultimately, evaluation of potential strategies for reducing morbidity and mortality from ovarian cancer may require use of simulation models, a technique that has proven helpful in evaluating prevention strategies for other cancers. Because the natural history of ovarian cancer is relatively unknown, testing of alternative models is critical. Although a few sophisticated models exist, development of additional models would be helpful, especially in the context of evaluating results from ongoing trials of screening. If any of these trials show a benefit from screening, then the need for better evidence on the diagnostic evaluation of adnexal masses will become even more critical.

References Cited in the Evidence Report

- Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. Ca: Cancer J Clin 2003;53(1):5-26.
- Anonymous. SEER Stat Databases: Incidence -SEER Regs Public - Use, Nov 2004 Sub for Expanded Races (1992-2002) and Incidence - SEER 13 Regs excluding AK Public - Use Nov 2004 Sub for Hispanics (1992-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on November 2004 submission. Available at: www.seer.cancer.gov. Accessed: May 25, 2005.
- Russell P, Robboy S, Anderson M. Ovarian tumors: classification and clinical perspective. In: Robboy SJ, Anderson MC, and Russell P, editors. Pathology of the female reproductive tract. London: Churchill Livingstone; 2002. p. 527-38.
- Eheman C, Bobo J, Lawson H, et al. Identifying public health opportunities to reduce the burden of ovarian cancer: workshop summary. Atlanta, Ga. Centers for Disease Control and Prevention, 2001. Available at: www.cdc.gov/cancer/ovarian/workshop.htm#conclu sion. Accessed: May 25, 2005.
- Eheman C, Brustrom J, Lawson H. The use of ultrasound in diagnosing ovarian cancer: can we improve on current practice? workshop summary. Atlanta, GA: Centers for Disease Control and Prevention, 2002. Accessed: http://www.cdc.gov/cancer/ovarian/workshop.htm. Accessed: May 25, 2005.
- Russell P, Robboy S, Anderson M. The ovary: normal appearances and non-neoplastic conditions. In: Robboy SJ, Anderson MC, and Russell P, editors. Pathology of the female reproductive tract. London: Churchill Livingstone; 2002. p. 475-526.
- 7. Barber H, Graber E. The PMPO syndrome (postmenopausal palpable ovary syndrome). Obstet and Gynecol. 1971;38(6):921-3.
- Munstedt K, von Georgi R, Misselwitz B, et al. Centralizing surgery for gynecologic oncology--a strategy assuring better quality treatment? [see comment]. Gynecol Oncol 2003;89(1):4-8.
- Junor E, Hole D, McNulty L, et al. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999;106(11):1130-6.

- Tingulstad S, Skeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 2003;102(3):499-505.
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002;100(6):1413-6.
- 12. American Academy of Family Physicians. Summary of recommendations for periodic health examinations. Leawood (KS):American Academy of Family Physicians. 2004.
- Geomini P, Bremer G, Kruitwagen R, et al. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol 2005;96(1):1-9.
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin 45. Cervical cytology screening. August 2003. 2003.
- Whiting P, Rutjes A, Reitsma JB, et al. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern. Med 2004;140(3):189-202.
- Gohagan J, Prorok P, Hayes R, et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization and status. Control Clin Trials 2000;21 (6Suppl):251S-72S.
- Prorok P, Andriole G, Bresalier R, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21 (6 Suppl):273S-309S.
- Jacobs I. European randomized trial of ovarian cancer screening (protocol). London: Wolfson Institute of Preventive Medicine, Department of Environmental and Preventive Medicine. 1995.
- Goff B, Mandel L, Melancon C, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. [see comment]. JAMA 2004;291(22):2705-12.
- 20. Thompson ISI ReseachSoft. ProCite [computer program]. Berkeley, CA: Thompson ISI ResearchSoft.

- 21. Nanda K, McCrory D, Myers E, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132(10):810-9.
- Lau J. Meta-Stat 0.6. Shareware program for performing meta-analyses of diagnostic tests. Available at: www.medepi.net/meta/software/MetaTest/Mtreadm e.txt. Accessed August 26, 2005.
- 23. DerSimonian R , Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88.
- Moses LE, Shapiro D. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-316.
- 25. Agency for Healthcare Research and Quality. Overview of the HCUP Nationwide Inpatient Sample. Rockville, MD. 2003.
- Myers E, Steege J. Risk adjustment for complications of hysterectomy:utility of routinely collected administrative data. Am J Obstet Gynecol 1999;181:567-75.
- Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1973-1999. National Cancer Institute: Bethesda, MD. 2002.
- Anderson R, DeTurk P. National vital statistics reports: United States life tables, 1999. National Center for Health Statistics: Hyattsville, MD. 2002.
- Jones H. Ovarian Cancer: The Clinical Problem in Early Detection of Ovarian Carcinoma with Transvaginal Sonography: Potentials and Limitations, H.W. Jones, editor. Raven Press, Ltd.: New York. 1993;3-9.
- 30. TreeAge Software. DATA 4.0 [computer program]. Williamstown, MA: TreeAge Software, Inc.
- Chalas E, Welshinger M, Engellener W, et al. The clinical significance of thrombocytosis in women presenting with a pelvic mass. Am J Obstet Gynecol 1992;166(3):974-7.
- Childers JM, Nasseri A, Surwit EA. Laparoscopic management of suspicious adnexal masses. Am J Obstet Gynecol 1996;175(6):1451-7; discussion 1457-9.
- Cohen LS, Escobar PF, Scharm C, et al. Threedimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001;82(1):40-8.

- DePriest PD, Gallion HH, Pavlik EJ, et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997;65(3):408-14.
- DePriest PD, Shenson D, Fried A, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51(1):7-11.
- DePriest PD, van Nagell JR Jr, Gallion HH, et al. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol 1993;51(2):205-9.
- Dottino PR, Levine DA, Ripley DL, et al. Laparoscopic management of adnexal masses in premenopausal and postmenopausal women. Obstet Gynecol 1999;93(2):223-8.
- Fleischer AC, Cullinan JA, Jones HW 3rd, et al. Correlation of histomorphology of ovarian masses with color Doppler sonography. Ultrasound Med Biol 1996;22(5):555-9.
- Lin JY, Angel C, DuBeshter B, et al. Diagnoses after laparotomy for a mass in the pelvic area in women. Surg Gynecol Obstet 1993;176(4):333-8.
- Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003;102(3):594-9.
- 41. Parker WH, Levine RL, Howard FM, et al. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg 1994;179(6):733-7.
- 42. Roman LD, Muderspach LI, Stein SM, et al. Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet Gynecol 1997;89(4):493-500.
- Schneider VL, Schneider A, Reed KL, et al. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses. Obstet Gynecol 1993;81(6):983-8.
- Scoutt LM, McCarthy SM, Lange R, et al. MR evaluation of clinically suspected adnexal masses. J Comput Assist Tomogr 1994;18(4):609-18.
- Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol 2002;87(1):77-83.
- Smikle CB, Lunt CC, Hankins GD. Clinical predictors in the evaluation of a pelvic mass. Mil Med 1995;160(5):233-5.

- Troiano RN, Quedens-Case C, Taylor KJ. Correlation of findings on transvaginal sonography with serum CA 125 levels. AJR Am J Roentgenol 1997;168(6):1587-90.
- Twickler DM, Forte TB, Santos-Ramos R, et al. The Ovarian Tumor Index predicts risk for malignancy. Cancer 1999;86(11):2280-90.
- 49. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77(3):350-6.
- Vasilev SA, Schlaerth JB, Campeau J, et al. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988;71(5):751-6.
- Adonakis GL, Paraskevaidis E, Tsiga S, et al. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 1996;65(2):221-5.
- Andolf E, Jorgensen C, Astedt B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol 1990;75(1):106-9.
- Balbi GC, Musone R, Menditto A, et al. Women with a pelvic mass: indicators of malignancy. Eur J Gynaecol Oncol 2001;22(6):459-62.
- Buckshee K, Temsu I, Bhatla N, et al. Pelvic examination, transvaginal ultrasound and transvaginal color Doppler sonography as predictors of ovarian cancer. Int J Gynaecol Obstet 1998;61(1):51-7.
- Dowd JR, Quinn MA, Rome R, et al. Women with a pelvic mass--when to perform an ultrasound. Aust N Z J Obstet Gynaecol 1993;33(4):404-7.
- Finkler NJ, Benacerraf B, Lavin PT, et al. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72(4):659-64.
- Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test. Med J Aust 1995;162(8):408-10.
- Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988;1(8580):268-71.
- Ong S, Duffy T, Murphy J. Transabdominal ultrasound and its correlation with clinical findings in gynaecology. Ir J Med Sci 1996;165(4):268-70.

- 60. Padilla LA, Radosevich DM, Milad MP. Accuracy of the pelvic examination in detecting adnexal masses. Obstet Gynecol 2000;96(4):593-8.
- 61. Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet 2005;88(1):84-8.
- 62. Schutter EM, Kenemans P, Sohn C, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994;74(4):1398-406.
- Schutter EM, Sohn C, Kristen P, et al. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol 1998;69(1):56-63.
- 64. Ueland F, DePriest P, DeSimone C, et al. The accuracy and examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol Oncol 2005 (in Press).
- 65. Alcazar JL, Castillo G. Comparison of 2dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Am J Obstet Gynecol 2005;192(3):807-12.
- 66. Alcazar JL, Errasti T, Zornoza A, et al. Transvaginal color Doppler ultrasonography and CA-125 in suspicious adnexal masses. Int J Gynaecol Obstet 1999;66(3):255-61.
- 67. Alcazar JL, Galan MJ, Garcia-Manero M, et al. Three-dimensional sonographic morphologic assessment in complex adnexal masses: preliminary experience. J Ultrasound Med 2003;22(3):249-54.
- Alcazar JL, Lopez-Garcia G. Transvaginal color Doppler assessment of venous flow in adnexal masses. Ultrasound Obstet Gynecol 2001;17(5):434-8.
- 69. Alcazar JL, Merce LT, Laparte C, et al. A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstet Gynecol 2003;188(3):685-92.
- Anandakumar C, Chew S, Wong YC, et al. Role of transvaginal ultrasound color flow imaging and Doppler waveform analysis in differentiating between benign and malignant ovarian tumors. Ultrasound Obstet Gynecol 1996;7:280-4.

- 71. Antonic J, Rakar S. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Anticancer Res 1995;15:1527-32.
- Asif N, Sattar A, Dawood MM, et al. Pre-operative evaluation of ovarian mass: risk of malignancy index. J Coll Physicians Surg Pak 2004;14(3):128-31.
- Benjapibal M, Sunsaneevitayakul P, Boriboonhirunsarn D, et al. Color Doppler ultrasonography for prediction of malignant ovarian tumors. J Med Assoc Thai 2002;85(6):709-15.
- 74. Benjapibal M, Sunsaneevitayakul P, Phatihattakorn C, et al. Sonographic morphological pattern in the pre-operative prediction of ovarian masses. J Med Assoc Thai 2003;86(4):332-7.
- 75. Berlanda N, Ferrari MM, Mezzopane R, et al. Impact of a multiparameter, ultrasound-based triage on surgical management of adnexal masses. Ultrasound Obstet Gynecol 2002;20(2):181-5.
- 76. Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol 1994;83(3):434-7.
- Brown DL, Doubilet PM, Miller FH, et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 1998;208(1):103-10.
- Buist MR, Golding RP, Burger CW, et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 1994;52(2):191-8.
- 79. Buy JN, Ghossain MA, Hugol D, et al. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. AJR Am J Roentgenol 1996;166(2):385-93.
- Canis M, Pouly JL, Wattiez A, et al. Laparoscopic management of adnexal masses suspicious at ultrasound. Obstet Gynecol 1997;89(5 Pt 1):679-83.
- Carter JR, Lau M, Fowler JM, et al. Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. Am J Obstet Gynecol 1995;172(3):901-7.

- 82. Carter PG, Iles RK, Neven P, et al. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses. Gynecol Oncol 1993;51(3):368-71.
- Caruso A, Caforio L, Testa AC, et al. Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol 1996;63(2):184-91.
- Chen DX, Schwartz PE, Li FQ. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990;75(4):701-4.
- Chen DX, Schwartz PE, Li XG, et al. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72(1):23-7.
- Chou CY, Chang CH, Yao BL, et al. Color Doppler ultrasonography and serum CA 125 in the differentiation of benign and malignant ovarian tumors. J Clin Ultrasound 1994;22:491-6.
- Davies AP, Jacobs I, Woolas R, et al. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993;100(10):927-31.
- DePriest PD, Varner E, Powell J. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol Oncol 1994;55:174-8.
- Einhorn N, Bast RC Jr, Knapp RC, et al. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986;67(3):414-6.
- 90. Ekerhovd E, Wienerroith H, Staudach A, et al. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol. 2001;184(2):48-54.
- 91. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002;223(3):780-8.
- 92. Ferdeghini M, Gadducci A, Prontera C, et al. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. Tumour Biol 1993;14(5):303-9.

- 93. Ferrazzi E, Zanetta G, Dordoni D, et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study.[erratum appears in Ultrasound Obstet Gynecol 1998 Jan;11(1):v Note: Lissoni G[corrected to Lissoni AA]]. Ultrasound Obstet Gynecol 1997;10(3):192-7.
- Fleischer AC, Rodgers WH, Kepple DM, et al. Color Doppler sonography of benign and malignant ovarian masses. Radiographics 1992;12(5):879-85.
- 95. Franchi M, Beretta P, Ghezzi F, et al. Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography. Acta Obstet Gynecol Scand 1995;74(9):734-9.
- 96. Gadducci A, Baicchi U, Marrai R, et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996;60(2):197-202.
- 97. Gadducci A, Capriello P, Bartolini T, et al. The association of ultrasonography and CA-125 test in the preoperative evaluation of ovarian carcinoma. Eur J Gynaecol Oncol 1988;9(5):373-6.
- Gadducci A, Ferdeghini M, Prontera C, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992;44(2):147-54.
- 99. Gadducci A, Ferdeghini M, Rispoli G, et al. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest Suppl 1991;207(19-24).
- Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77(3):454-9.
- Granberg S, Norstrom A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990;37(2):224-9.
- Granberg S, Norstrom A, Wikland M. Comparison ofendovaginal ultrasound and cytological evaluation of cystic ovarian tumors. J Ultrasound Med 1991;10:9-14.
- 103. Guerriero S, Ajossa S, Risalvato A, et al. Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses. Ultrasound Obstet Gynecol 1998;11(4):277-82.

- 104. Guerriero S, Ajossa S, Garau N, et al. Ultrasonography and color Doppler-based triage for adnexal masses to provide the most appropriate surgical approach. Am J Obstet Gynecol 2005;192(2):401-6.
- 105. Guerriero S, Alcazar JL, Coccia ME, et al. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a multicenter European study. J Ultrasound Med 2002;21(10):1105-11.
- 106. Hata K, Hata T, Manabe A, et al. A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol 1992;80(6):922-6.
- Hata K, Hata T, Kitao M. Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy. Am J Obstet Gynecol 1995;172:1496-500.
- Herrmann UJ Jr, Locher GW, Goldhirsch A. Sonographic patterns of ovarian tumors: prediction of malignancy. Obstet Gynecol 1987;69(5):777-81.
- Hillaby K, Aslam N, Salim R, et al. The value of detection of normal ovarian tissue (the 'ovarian crescent sign') in the differential diagnosis of adnexal masses. Ultrasound Obstet Gynecol 2004;23(1):63-7.
- 110. Hogdall EV, Hogdall CK, Tingulstad S, et al. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 2000;89(6):519-23.
- 111. Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging--multivariate analysis. Radiology 2000;214(1):39-46.
- 112. Huber S, Medl M, Baumann L, et al. Value of ultrasound and magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res 2002;22(4):2501-7.
- 113. Hurteau JA, Woolas RP, Jacobs IJ, et al. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 1995;76(9):1615-20.
- 114. Inoue M, Fujita M, Nakazawa A, et al. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol 1992;79(3):434-40.

- 115. Itakura T, Kikkawa F, Kajiyama H, et al. Doppler flow and arterial location in ovarian tumors. Int J Gynaecol Obstet 2003;83(3):277-83.
- 116. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97(10):922-9.
- 117. Jain KA. Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings. Radiology 1994;191(1):63-7.
- 118. Jain KA, Friedman DL, Pettinger TW, et al. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. Radiology 1993;186(3):697-704.
- 119. Juhasz B, Kurjak A, Lampe L, et al. Tissue characterization by transvaginal colour doppler for the evaluation of gynaecological tumours. Acta Med Hung 1990;47:149-56.
- Kawai M, Kikkawa F, Ishikawa H. Differential diagnosis of ovarian tumors by transvaginal color pulse Doppler sonography. Gynecol Oncol 1994;54:209-14.
- 121. Kawahara K, Yoshida Y, Kurokawa T, et al. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr 2004;28(4):505-16.
- 122. Komatsu T, Konishi I, Mandai M, et al. Adnexal masses: transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure. Radiology 1996;198(1):109-15.
- 123. Kurjak A, Kupesic S. Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. Croat Med J 1999;40(3):413-20.
- 124. Kurjak A, Kupesic S, Sparac V, et al. Threedimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet Gynecol 2000;16(4):365-71.
- 125. Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med 1992;11(12):631-8.

- 126. Kurjak A, Schulman H, Sosic A, et al. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol 1992;80(6):917-21.
- 127. Kurjak A, Shalan H, Kupesic S, et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994;13(4):295-301.
- Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991;10(6):295-7.
- 129. Kurtz AB, Tsimikas JV, Tempany CM, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group. Radiology 1999;212(1):19-27.
- 130. Leeners B, Schild RL, Funk A, et al. Colour Doppler sonography improves the pre-operative diagnosis of ovarian tumours made using conventional transvaginal sonography. Eur J Obstet Gynecol Reprod Biol 1996;64(1):79-85.
- Lerner JP, Timor-Tritsch IE, Federman A, et al. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170(1 Pt 1):81-5.
- Lin P, Wu C, Lee C, et al. Color Doppler Ultrasound in the Assessment of Ovarian Neoplasms. J Med Ultrasound 1993;1(4):172-6.
- Luxman D, Bergman A, Sagi J, et al. The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet Gynecol 1991;77(5):726-8.
- Ma S, Shen K, Lang J. A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chin Med J 2003;116(3):396-9.
- Maggino T, Gadducci A, D'Addario V, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54(2):117-23.
- 136. Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159(2):341-6.

- Maly Z, Riss P, Deutinger J. Localization of blood vessels and qualitative assessment of blood flow in ovarian tumors. Obstet Gynecol 1995;85(1):33-6.
- 138. Mancuso A, De Vivo A, Triolo O, et al. The role of transvaginal ultrasonography and serum CA 125 assay combined with age and hormonal state in the differential diagnosis of pelvic masses. Eur J Gynaecol Oncol 2004:25(2):207-10.
- Manjunath AP, Pratapkumar, Sujatha K, et al. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001;81(2):225-9.
- 140. Marchetti M, Zambon A, Lamaina V, et al. Ultrasound as a possible screening method in ovarian cancer.[erratum appears in Eur J Gynaecol Oncol. 2002;23(3):172 Note: Marchioro S [corrected to Marchiori S]]. Eur J Gynaecol Oncol 2002;23(2):123-6.
- Marret H, Sauget S, Giraudeau B, et al. Contrastenhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med. 2004;23(12):1629-39; quiz 1641-42.
- 142. Matthes AC, Moreira de Andrade JM, Bighetti S. Selection of criteria for the treatment of ovarian cysts on the bases of ultrasound and cytology. Gynecol Obstet Invest 1996;42:244-8.
- 143. McIntosh MW, Drescher C, Karlan B, et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian cancer. Gynecol Oncol 2004;95:9-15.
- 144. Medl M, Kulenkampff KJ, Stiskal M, et al. Magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res 1995;15(3):1123-5.
- 145. Menon U, Talaat A, Rosenthal AN, et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 2000;107(2):165-9.
- 146. Merce LT, Caballero RA, Barco MJ, et al. B-mode, utero-ovarian and intratumoural transvaginal colour Doppler ultrasonography for differential diagnosis of ovarian tumours. Eur J Obstet Gynecol Reprod Biol 1998;76(1):97-107.
- 147. Morgante G, la Marca A, Ditto A, et al. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999;106(6):524-7.

- 148. O'Connell GJ, Ryan E, Murphy KJ, et al. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 1987;70(6):930-2.
- 149. Onsrud M, Shabana A, Austgulen R. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumour Biol 1996;17(2):90-6.
- 150. Padungsutt P, Thirapagawong C, Senapad S, et al. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy. Anticancer Res 2000;20(2B):1291-5.
- Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988;159(4):873-6.
- 152. Prompeler HJ, Madjar H, Sauerbrei W. Classification of adnexal tumors by transvaginal color Doppler. Gynecol Oncol 1996;61(3):354-63.
- 153. Pyrgiotis E, Salamalekis E, Loghis C, et al. CA 125 in preoperative evaluation of pelvic masses. Eur J Gynaecol Oncol 1993;14(4):279-82.
- 154. Rehn M, Lohmann K, Rempen A. Transvaginal ultrasonography of pelvic masses: evaluation of Bmode technique and Doppler ultrasonography. Am J Obstet Gynecol 1996;175(1):97-104.
- 155. Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 1997;25(5):217-25.
- 156. Reuter M, Steffens J., Schuppler U. Critical evaluation of the specificity of MRI and TVUs for differentiation of malignant from benign adnexal lesions. Eur Radiol 1998;8(39-44).
- 157. Roman LD, Muderspach LI, Burnett AF, et al. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med 1998;43(5):403-7.
- 158. Salem S, White LM, Lai J. Doppler sonography of adnexal masses: the predictive value of the pulsatility index in benign and malignant disease. AJR Am J Roentgenol 1994;163(5):1147-50.
- 159. Sassone AM, Timor-Tritsch IE, Artner A, et al. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78(1):70-6.

- 160. Sawicki W, Spiewankiewicz B, Cendrowski K, et al. Preoperative discrimination between malignant and benign adnexal masses with transvaginal ultrasonography and colour blood flow imaging. Eur J Gynaecol Oncol 2001;22(2):137-42.
- 161. Schelling M, Braun M, Kuhn W, et al. Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 2000;77(1):78-86.
- 162. Schutter EM, Davelaar EM, van Kamp GJ, et al. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002;187(2):385-92.
- 163. Sengoku K, Satoh T, Saitoh S, et al. Evaluation of transvaginal color Doppler sonography, transvaginal sonography and CA 125 for prediction of ovarian malignancy. Int J Gynaecol Obstet 1994;46(1):39-43.
- 164. Shabana A, Onsrud M. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma. Tumour Biol 1994;15(6):361-7.
- 165. Siegel BA, Dehdashti F, Mutch DG, et al. Evaluation of 1111n-DTPA-folate as a receptortargeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44(5):700-7.
- 166. Sohaib SA, Mills TD, Sahdev A, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol 2005;60(3):340-8.
- Soper JT, Hunter VJ, Daly L, et al. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990;75(2):249-54.
- 168. Stein SM, Laifer-Narin S, Johnson MB, et al. Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 1995;164(2):381-6.
- 169. Strigini FA, Gadducci A, Del Bravo B, et al. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Gynecol Oncol 1996;61(1):68-72.
- Szpurek D, Moszyniki R, Sajdak S. Clinical value of the ultrasound Doppler index in determination of ovarian tumor malignancy. Eur J Gynaecol Oncol 2004;25(4):442-4.

- 171. Tailor A, Bourne TH, Campbell S, et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003;21(4):378-85.
- 172. Takac I. Analysis of blood flow in adnexal tumors by using color Doppler imaging and pulsed spectral analysis. Ultrasound Med Biol 1998;24(8):1137-42.
- 173. Tanir HM, Ozalp S, Yalcin OT, et al. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. Eur J Gynaecol Oncol 2003;24(3-4):271-4.
- 174. Tay SK, Chua EK. Correlation of serum, urinary and salivary CA 125 levels in patients with adnexal masses. Ann Acad Med Singapore 1994;23(3):311-4.
- 175. Tekay A, Jouppila P. Validity of pulsatility and resistance indices in classification of adnexal tumors with transvaginal color doppler ultrasound. Ultrasound Obstet Gynecol 1992;2:338-44.
- Tepper R, Lerner-Geva L, Altaras MM, et al. Transvaginal color flow imaging in the diagnosis of ovarian tumors. J Ultrasound Med 1995;14(10):731-4.
- 177. Tian J, Zhang J, Jiao L, et al. A prospective study of Tc-99m MIBI in the differential diagnosis of pelvic masses in female patients. Clin Nucl Med 2000;25(8):614-8.
- 178. Timmerman D, Verrelst H, Bourne TH, et al. Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. Ultrasound Obstet Gynecol 1999;13(1):17-25.
- 179. Timor-Tritsch LE, Lerner J, Monteagudo A, et al. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. Am J Obstet Gynecol 1993;168:909-13.
- 180. Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103(8):826-31.
- Torres JC, Derchain SF, Faundes A, et al. Risk-ofmalignancy index in preoperative evaluation of clinically restricted ovarian cancer. Rev Paul Med 2002;120(3):72-6.

- 182. Valentin L. Gray scale sonography, subjective evaluation of the color Doppler image and measurement of blood flow velocity for distinguishing benign and malignant tumors of suspected adnexal origin. Eur J Obstet Gynecol Reprod Biol 1997;72(1):63-72.
- Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 1999;14(5):338-47.
- 184. Valentin L. Comparison of Lerner score, Doppler ultrasound examination, and their combination for discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 2000;15(2):143-7.
- 185. Valentin L, Hagen B, Tingulstad S, et al. Comparison of 'pattern recognition' and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol 2001;18(4):357-65.
- 186. Vuento MH, Pirhonen JP, Makinen JI, et al. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995;76(7):1214-8.
- 187. Wakahara F, Kikkawa F, Nawa A, et al. Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors. Gynecol Obstet Invest 2001;52(3):147-52.
- 188. Weiner Z, Thaler I, Beck D, et al. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 1992;79(2):159-62.
- 189. Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59(1):111-6.
- 190. Wu CC, Lee CN, Chen T, et al. Factors contributing to the accuracy in diagnosing ovarian malignancy by color Doppler ultrasound. Obstet Gynecol 1994;84:605-8.
- 191. Yamashita Y, Hatanaka Y, Torashima M, et al. Characterization of sonographically indeterminate ovarian tumors with MR imaging. A logistic regression analysis. Acta Radiol 1997;38(4 Pt 1):572-7.
- 192. Yamashita Y, Torashima M, Hatanaka Y, et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology 1995;194(2):557-65.

- 193. Zanetta G, Vergani P, Lissoni A. Color Doppler ultrasound in the preoperative assessment of adnexal masses. Acta Obstet Gynecol Scand 1994;73:637-41.
- 194. Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999;73(1):56-61.
- 195. Zimmer Y, Tepper R, Akselrod S. An automatic approach for morphological analysis and malignancy evaluation of ovarian masses using Bscans. Ultrasound Med Biol 2003;29(11):1561-70.
- 196. Timmerman D, Schwarzler P, Collins WP, et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999;13(1):11-6.
- 197. Kinkel K, Hricak H, Lu Y, et al. US characterization of ovarian masses: a meta-analysis. Radiology 2000;217(3):803-11.
- 198. Larsen T, Torp-Pedersen ST, Ottesen M, et al. Abdominal ultrasound combined with histological and cytological fine needle biopsy of suspected ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1993;50(3):203-9.
- 199. Alcazar JL, Ruiz-Perez ML, Errasti T. Transvaginal color Doppler sonography in adnexal masses: which parameter performs best? Ultrasound Obstet Gynecol 1996;8(2):114-9.
- Kurjak A, Shalan H, Kupesic S, et al. Transvaginal color Doppler sonography in the assessment of pelvic tumor vascularity. Ultrasound Obstet Gynecol 1993;3(2):137-54.
- Valentin L. Prospective cross-validation of Doppler ultrasound examination and gray-scale ultrasound imaging for discrimination of benign and malignant pelvic masses. Ultrasound Obstet Gynecol 1999;14(4):273-83.
- 202. Andersen ES, Knudsen A, Rix P, et al. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol 2003;90(1):109-12.
- Aslam N, Banerjee S, Carr JV, et al. Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer. Obstet Gynecol 2000;96(1):75-80.

- 204. Aslam N, Tailor A, Lawton F, et al. Prospective evaluation of three different models for the preoperative diagnosis of ovarian cancer. BJOG 2000;107(11):1347-53.
- 205. Biagiotti R, Desii C, Vanzi E, et al. Predicting ovarian malignancy: application of artificial neural networks to transvaginal and color Doppler flow US. Radiology 1999;210(2):399-403.
- 206. Lu C, Van Gestel T, Suykens JA, et al. Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines. Artif Intell Med 2003;28(3):281-306.
- 207. Mol BW, Boll D, De Kanter M, et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80(2):162-7.
- Obeidat BR, Amarin ZO, Latimer JA, et al. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet 2004;85(3):255-8.
- 209. Tailor A, Jurkovic D, Bourne TH, et al. Sonographic prediction of malignancy in adnexal masses using an artificial neural network. Br J Obstet Gynaecol 1999;106(1):21-30.
- 210. Timmerman D, Bourne TH, Tailor A, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol 1999;181(1):57-65.
- 211. Tingulstad S, Hagen B, Skjeldestad FE, et al. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93(3):448-52.
- 212. Jacobs IJ, Rivera H, Oram DH, et al. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol 1993;100(12):1120-4.
- 213. Alcazar JL, Jurado M. Using a logistic model to predict malignancy of adnexal masses based on menopausal status, ultrasound morphology, and color Doppler findings. Gynecol Oncol 1998;69(2):146-50.
- Castillo G, Alcazar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004;92(3):965-9.

- 215. Goldstein SR, Subramanyam B, Snyder JR, et al. The postmenopausal cystic adnexal mass: the potential role of ultrasound in conservative management. Obstet Gynecol 1989;73(1):8-10.
- Levine D, Gosink BB, Wolf SI, et al. Simple adnexal cysts: the natural history in postmenopausal women.[see comment]. Radiology 1992;184(3):653-9.
- 217. Schincaglia P, Brondelli L, Cicognani A, et al. A feasibility study of ovarian cancer screening: does fine-needle aspiration improve ultrasound specificity? Tumori 1994;80(3):181-7.
- Valentin L, Akrawi D. The natural history of adnexal cysts incidentally detected at transvaginal ultrasound examination in postmenopausal women. Ultrasound Obstet Gynecol 2002;20(2):174-80.
- 219. Canis M, Mage G, Pouly JL, et al. Laparoscopic diagnosis of adnexal cystic masses: a 12-year experience with long-term follow-up. Obstet Gynecol 1994;83(5 Pt 1):707-12.
- 220. Canis M, Mashiach R, Wattiez A, et al. Frozen section in laparoscopic management of macroscopically suspicious ovarian masses. J Am Assoc Gynecol Laparosc 2004;11(3):365-9.
- 221. Carley ME, Klingele CJ, Gebhart JB, et al. Laparoscopy versus laparotomy in the management of benign unilateral adnexal masses. J Am Assoc Gynecol Laparosc 2002;9(3):321-6.
- 222. Chapron C, Dubuisson JB, Capella-Allouc S. Salpingo-oophorectomy for adnexal masses. Place and results for operative laparoscopy. Eur J Obstet Gynecol Reprod Biol 1997;73(1):43-8.
- 223. Chi DS, Abu-Rustum NR, Sonoda Y, et al. Tenyear experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol 2004;191(4):1138-45.
- 224. Deckardt R, Saks M, Graeff H. Comparison of minimally invasive surgery and laparotomy in the treatment of adnexal masses. J Am Assoc Gynecol Laparosc 1994;1(4 Pt 1):333-8.
- 225. Fanfani F, Fagotti A, Ercoli A, et al. A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum Reprod 2004;19(10):2367-71.
- 226. Havrilesky LJ, Peterson BL, Dryden DK, et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol 2003;102(2):243-51.

- 227. Hidlebaugh DA, Vulgaropulos S, Orr RK. Treating adnexal masses. Operative laparoscopy vs. laparotomy. J Reprod Med 1997;42(9):551-8.
- 228. Lok IH, Sahota DS, Rogers MS, et al. Complications of laparoscopic surgery for benign ovarian cysts. J Am Assoc Gynecol Laparosc 2000;7(4):529-34.
- Mann WJ, Reich H. Laparoscopic adnexectomy in postmenopausal women. J Reprod Med 1992;37(3):254-6.
- Marana R, Muzii L, Catalano GF, et al. Laparoscopic excision of adnexal masses. J Am Assoc Gynecol Laparosc 2004;11(2):162-6.
- Parker J, Proietto AM. Surgical treatment of adnexal cysts by laparotomy. Int J Gynaecol Obstet 1997;59(3):257-8.
- 232. Sadik S, Onoglu AS, Gokdeniz R, et al. Laparoscopic management of selected adnexal masses. J Am Assoc Gynecol Laparosc 1999;6(3):313-6.
- 233. Serur E, Emeney PL, Byrne DW. Laparoscopic management of adnexal masses. J Soc Laparoendosc Surg 2001;5(2):143-51.
- Shalev E, Eliyahu S, Peleg D, et al. Laparoscopic management of adnexal cystic masses in postmenopausal women. Obstet Gynecol 1994;83(4):594-6.
- 235. Somigliana E, Ragni G, Benedetti F, et al. Does laparoscopic excision of endometriotic ovarian cysts significantly affect ovarian reserve? Insights from IVF cycles. Hum Reprod 2003;18(11):2450-3.
- 236. Tangjitgamol S, Jesadapatrakul S, Manusirivithaya S, et al. Accuracy of frozen section in diagnosis of ovarian mass. Int J Gynecol Cancer 2004;14(2):212-9.
- Tarik A, Fehmi C. Complications of gynaecological laparoscopy--a retrospective analysis of 3572 cases from a single institute. J Obstet Gynaecol 2004;24(7):813-6.
- 238. van Herendael B, Beretta P, Slangen T, et al. Management of adnexal masses by operative laparoscopy. J Am Assoc Gynecol Laparosc 1995;2(3):273-7.
- 239. Yuen PM, Yu KM, Yip SK, et al. A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 1997;177(1):109-14.

- 240. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151(12):1158-71.
- Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103(4):619-31.
- 242. Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening. A decision analysis model. Ann Intern Med 1993;118(11):838-43.
- 243. Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997;18(3):251-70.
- 244. Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991;44(4-5):365-80.
- 245. Tengs TO, Winer EP, Paddock S, et al. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making 1998;18(4):365-75.
- 246. Bast RC Jr, Urban N, Shridhar V, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002;107:61-97.
- 247. Im S, Gordon A, Buttin B, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gyencol 2005;205(1):35-41.

Listing of Included Studies (alphabetical)

Adonakis GL, Paraskevaidis E, Tsiga S, et al. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 1996;65(2):221-5.

Alcazar JL, Castillo G. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Am J Obstet Gynecol 2005;192(3):807-12.

Alcazar JL, Errasti T, Zornoza A, et al. Transvaginal color Doppler ultrasonography and CA-125 in suspicious adnexal masses. Int J Gynaecol Obstet 1999;66(3):255-61.

Alcazar JL, Galan MJ, Garcia-Manero M, et al. Threedimensional sonographic morphologic assessment in complex adnexal masses: preliminary experience. J Ultrasound Med 2003;22(3):249-54.

Alcazar JL, Lopez-Garcia G. Transvaginal color Doppler assessment of venous flow in adnexal masses. Ultrasound Obstet Gynecol 2001;17(5):434-8.

Alcazar JL, Merce LT, Laparte C, et al. A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstet Gynecol 2003;188(3):685-92.

Anandakumar C, Chew S, Wong YC, et al. Role of transvaginal ultrasound color flow imaging and Doppler waveform analysis in differentiating between benign and malignant ovarian tumors. Ultrasound Obstet Gynecol 1996;7:280-4.

Andersen ES, Knudsen A, Rix P, et al. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol 2003;90(1):109-12.

Andolf E, Jorgensen C, Astedt B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol 1990;75(1):106-9.

Antonic J, Rakar S. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Anticancer Res 1995;15:1527-32.

Asif N, Sattar A, Dawood MM, et al. Pre-operative evaluation of ovarian mass: risk of malignancy index. J Coll Physicians Surg Pak 2004;14(3):128-31.

Aslam N, Banerjee S, Carr JV, et al. Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer. Obstet Gynecol 2000;96(1):75-80.

Aslam N, Tailor A, Lawton F, et al. Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG 2000;107(11):1347-53.

Balbi GC, Musone R, Menditto A, et al. Women with a pelvic mass: indicators of malignancy. Eur J Gynaecol Oncol 2001;22(6):459-62.

Benjapibal M, Sunsaneevitayakul P, Boriboonhirunsarn D, et al. Color Doppler ultrasonography for prediction of malignant ovarian tumors. J Med Assoc Thai 2002;85(6):709-15.

Benjapibal M, Sunsaneevitayakul P, Phatihattakorn C, et al. Sonographic morphological pattern in the pre-operative prediction of ovarian masses. J Med Assoc Thai 2003;86(4):332-7.

Berlanda N, Ferrari MM, Mezzopane R, et al. Impact of a multiparameter, ultrasound-based triage on surgical management of adnexal masses. Ultrasound Obstet Gynecol 2002;20(2):181-5.

Biagiotti R, Desii C, Vanzi E, et al. Predicting ovarian malignancy: application of artificial neural networks to transvaginal and color Doppler flow US. Radiology 1999;210(2):399-403.

Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol 1994;83(3):434-7.

Brown DL, Doubilet PM, Miller FH, et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 1998;208(1):103-10.

Buckshee K, Temsu I, Bhatla N, et al. Pelvic examination, transvaginal ultrasound and transvaginal color Doppler sonography as predictors of ovarian cancer. Int J Gynaecol Obstet 1998;61(1):51-7.

Buist MR, Golding RP, Burger CW, et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 1994;52(2):191-8.

Buy JN, Ghossain MA, Hugol D, et al. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. AJR Am J Roentgenol 1996;166(2):385-93. Canis M, Mage G, Pouly JL, et al. Laparoscopic diagnosis of adnexal cystic masses: a 12-year experience with long-term follow-up. Obstet Gynecol 1994;83(5 Pt 1):707-12.

Canis M, Mashiach R, Wattiez A, et al. Frozen section in laparoscopic management of macroscopically suspicious ovarian masses. J Am Assoc Gynecol Laparosc 2004;11(3):365-9.

Canis M, Pouly JL, Wattiez A, et al. Laparoscopic management of adnexal masses suspicious at ultrasound. Obstet Gynecol 1997;89(5 Pt 1):679-83.

Carley ME, Klingele CJ, Gebhart JB, et al. Laparoscopy versus laparotomy in the management of benign unilateral adnexal masses. J Am Assoc Gynecol Laparosc 2002;9(3):321-6.

Carter JR, Lau M, Fowler JM, et al. Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. Am J Obstet Gynecol 1995;172(3):901-7.

Carter PG, Iles RK, Neven P, et al. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses. Gynecol Oncol 1993;51(3):368-71.

Caruso A, Caforio L, Testa AC, et al. Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol 1996;63(2):184-91.

Castillo G, Alcazar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004;92(3):965-9.

Chalas E, Welshinger M, Engellener W, et al. The clinical significance of thrombocytosis in women presenting with a pelvic mass. Am J Obstet Gynecol 1992;166(3):974-7.

Chapron C, Dubuisson JB, Capella-Allouc S. Salpingooophorectomy for adnexal masses. Place and results for operative laparoscopy. Eur J Obstet Gynecol Reprod Biol 1997;73(1):43-8.

Chen DX, Schwartz PE, Li FQ. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990;75(4):701-4.

Chen DX, Schwartz PE, Li XG, et al. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72(1):23-7.

Chi DS, Abu-Rustum NR, Sonoda Y, et al. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol 2004;191(4):1138-45. Childers JM, Nasseri A, Surwit EA. Laparoscopic management of suspicious adnexal masses. Am J Obstet Gynecol 1996;175(6):1451-7; discussion 1457-9.

Chou CY, Chang CH, Yao BL, et al. Color Doppler ultrasonography and serum CA 125 in the differentiation of benign and malignant ovarian tumors. J Clin Ultrasound 1994;22:491-6.

Cohen LS, Escobar PF, Scharm C, et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001;82(1):40-8.

Davies AP, Jacobs I, Woolas R, et al. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993;100(10):927-31.

Deckardt R, Saks M, Graeff H. Comparison of minimally invasive surgery and laparotomy in the treatment of adnexal masses. J Am Assoc Gynecol Laparosc 1994;1(4 Pt 1):333-8.

DePriest PD, Gallion HH, Pavlik EJ, et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997;65(3):408-14.

DePriest PD, Shenson D, Fried A, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51(1):7-11.

DePriest PD, van Nagell JR Jr, Gallion HH, et al. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol 1993;51(2):205-9.

DePriest PD, Varner E, Powell J. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol Oncol 1994;55:174-8.

Dottino PR, Levine DA, Ripley DL, et al. Laparoscopic management of adnexal masses in premenopausal and postmenopausal women. Obstet Gynecol 1999;93(2):223-8.

Dowd JR, Quinn MA, Rome R, et al. Women with a pelvic mass--when to perform an ultrasound. Aust N Z J Obstet Gynaecol 1993;33(4):404-7.

Einhorn N, Bast RC Jr, Knapp RC, et al. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986;67(3):414-6.

Ekerhovd E, Wienerroith H, Staudach A, et al. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol. 2001;184(2):48-54. Fanfani F, Fagotti A, Ercoli A, et al. A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum Reprod 2004;19(10):2367-71.

Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002;223(3):780-8.

Ferdeghini M, Gadducci A, Prontera C, et al. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. Tumour Biol 1993;14(5):303-9.

Ferrazzi E, Zanetta G, Dordoni D, et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study.[erratum appears in Ultrasound Obstet Gynecol 1998 Jan;11(1):v Note: Lissoni G[corrected to Lissoni AA]]. Ultrasound Obstet Gynecol 1997;10(3):192-7.

Finkler NJ, Benacerraf B, Lavin PT, et al. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72(4):659-64.

Fleischer AC, Cullinan JA, Jones HW 3rd, et al. Correlation of histomorphology of ovarian masses with color Doppler sonography. Ultrasound Med Biol 1996;22(5):555-9.

Fleischer AC, Rodgers WH, Kepple DM, et al. Color Doppler sonography of benign and malignant ovarian masses. Radiographics 1992;12(5):879-85.

Franchi M, Beretta P, Ghezzi F, et al. Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography. Acta Obstet Gynecol Scand 1995;74(9):734-9.

Gadducci A, Baicchi U, Marrai R, et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996;60(2):197-202.

Gadducci A, Capriello P, Bartolini T, et al. The association of ultrasonography and CA-125 test in the preoperative evaluation of ovarian carcinoma. Eur J Gynaecol Oncol 1988;9(5):373-6.

Gadducci A, Ferdeghini M, Prontera C, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992;44(2):147-54.

Gadducci A, Ferdeghini M, Rispoli G, et al. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest Suppl 1991;207(19-24). Goldstein SR, Subramanyam B, Snyder JR, et al. The postmenopausal cystic adnexal mass: the potential role of ultrasound in conservative management. Obstet Gynecol 1989;73(1):8-10.

Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77(3):454-9.

Granberg S, Norstrom A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990;37(2):224-9.

Granberg S, Norstrom A, Wikland M. Comparison ofendovaginal ultrasound and cytological evaluation of cystic ovarian tumors. J Ultrasound Med 1991;10:9-14.

Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test. Med J Aust 1995;162(8):408-10.

Guerriero S, Ajossa S, Garau N, et al. Ultrasonography and color Doppler-based triage for adnexal masses to provide the most appropriate surgical approach. Am J Obstet Gynecol 2005;192(2):401-6.

Guerriero S, Ajossa S, Risalvato A, et al. Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses. Ultrasound Obstet Gynecol 1998;11(4):277-82.

Guerriero S, Alcazar JL, Coccia ME, et al. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a multicenter European study. J Ultrasound Med 2002;21(10):1105-11.

Hata K, Hata T, Kitao M. Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy. Am J Obstet Gynecol 1995;172:1496-500.

Hata K, Hata T, Manabe A, et al. A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol 1992;80(6):922-6.

Havrilesky LJ, Peterson BL, Dryden DK, et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol 2003;102(2):243-51.

Herrmann UJ Jr, Locher GW, Goldhirsch A. Sonographic patterns of ovarian tumors: prediction of malignancy. Obstet Gynecol 1987;69(5):777-81.

Hidlebaugh DA, Vulgaropulos S, Orr RK. Treating adnexal masses. Operative laparoscopy vs. laparotomy. J Reprod Med 1997;42(9):551-8.

Hillaby K, Aslam N, Salim R, et al. The value of detection of normal ovarian tissue (the 'ovarian crescent sign') in the differential diagnosis of adnexal masses. Ultrasound Obstet Gynecol 2004;23(1):63-7.

Hogdall EV, Hogdall CK, Tingulstad S, et al. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 2000;89(6):519-23.

Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging-multivariate analysis. Radiology 2000;214(1):39-46.

Huber S, Medl M, Baumann L, et al. Value of ultrasound and magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res 2002;22(4):2501-7.

Hurteau JA, Woolas RP, Jacobs IJ, et al. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 1995;76(9):1615-20.

Inoue M, Fujita M, Nakazawa A, et al. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol 1992;79(3):434-40.

Itakura T, Kikkawa F, Kajiyama H, et al. Doppler flow and arterial location in ovarian tumors. Int J Gynaecol Obstet 2003;83(3):277-83.

Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97(10):922-9.

Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988;1(8580):268-71.

Jain KA. Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings. Radiology 1994;191(1):63-7.

Jain KA, Friedman DL, Pettinger TW, et al. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. Radiology 1993;186(3):697-704.

Juhasz B, Kurjak A, Lampe L, et al. Tissue characterization by transvaginal colour doppler for the evaluation of gynaecological tumours. Acta Med Hung 1990;47:149-56. Kawahara K, Yoshida Y, Kurokawa T, et al. Evaluation of positron emission tomography with tracer 18fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr 2004;28(4):505-16.

Kawai M, Kikkawa F, Ishikawa H. Differential diagnosis of ovarian tumors by transvaginal color -pulse Doppler sonography. Gynecol Oncol 1994;54:209-14.

Komatsu T, Konishi I, Mandai M, et al. Adnexal masses: transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure. Radiology 1996;198(1):109-15.

Kurjak A, Kupesic S. Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. Croat Med J 1999;40(3):413-20.

Kurjak A, Kupesic S, Sparac V, et al. Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet Gynecol 2000;16(4):365-71.

Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med 1992;11(12):631-8.

Kurjak A, Schulman H, Sosic A, et al. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol 1992;80(6):917-21.

Kurjak A, Shalan H, Kupesic S, et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994;13(4):295-301.

Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991;10(6):295-7.

Kurtz AB, Tsimikas JV, Tempany CM, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group. Radiology 1999;212(1):19-27.

Leeners B, Schild RL, Funk A, et al. Colour Doppler sonography improves the pre-operative diagnosis of ovarian tumours made using conventional transvaginal sonography. Eur J Obstet Gynecol Reprod Biol 1996;64(1):79-85. Lerner JP, Timor-Tritsch IE, Federman A, et al. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170(1 Pt 1):81-5.

Levine D, Gosink BB, Wolf SI, et al. Simple adnexal cysts: the natural history in postmenopausal women.[see comment]. Radiology 1992;184(3):653-9.

Lin JY, Angel C, DuBeshter B, et al. Diagnoses after laparotomy for a mass in the pelvic area in women. Surg Gynecol Obstet 1993;176(4):333-8.

Lin P, Wu C, Lee C, et al. Color Doppler Ultrasound in the Assessment of Ovarian Neoplasms. J Med Ultrasound 1993;1(4):172-6.

Lok IH, Sahota DS, Rogers MS, et al. Complications of laparoscopic surgery for benign ovarian cysts. J Am Assoc Gynecol Laparosc 2000;7(4):529-34.

Lu C, Van Gestel T, Suykens JA, et al. Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines. Artif Intell Med 2003;28(3):281-306.

Luxman D, Bergman A, Sagi J, et al. The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet Gynecol 1991;77(5):726-8.

Ma S, Shen K, Lang J. A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chin Med J 2003;116(3):396-9.

Maggino T, Gadducci A, D'Addario V, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54(2):117-23.

Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159(2):341-6.

Maly Z, Riss P, Deutinger J. Localization of blood vessels and qualitative assessment of blood flow in ovarian tumors. Obstet Gynecol 1995;85(1):33-6.

Mancuso A, De Vivo A, Triolo O, et al. The role of transvaginal ultrasonography and serum CA 125 assay combined with age and hormonal state in the differential diagnosis of pelvic masses. Eur J Gynaecol Oncol 2004;25(2):207-10.

Manjunath AP, Pratapkumar, Sujatha K, et al. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001;81(2):225-9.

Mann WJ, Reich H. Laparoscopic adnexectomy in postmenopausal women. J Reprod Med 1992;37(3):254-6.

Marana R, Muzii L, Catalano GF, et al. Laparoscopic excision of adnexal masses. J Am Assoc Gynecol Laparosc 2004;11(2):162-6.

Marchetti M, Zambon A, Lamaina V, et al. Ultrasound as a possible screening method in ovarian cancer.[erratum appears in Eur J Gynaecol Oncol. 2002;23(3):172 Note: Marchioro S [corrected to Marchiori S]]. Eur J Gynaecol Oncol 2002;23(2):123-6.

Marret H, Sauget S, Giraudeau B, et al. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med. 2004;23(12):1629-39; quiz 1641-42.

Matthes AC, Moreira de Andrade JM, Bighetti S. Selection of criteria for the treatment of ovarian cysts on the bases of ultrasound and cytology. Gynecol Obstet Invest 1996;42:244-8.

McIntosh MW, Drescher C, Karlan B, et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian cancer. Gynecol Oncol 2004;95:9-15.

Medl M, Kulenkampff KJ, Stiskal M, et al. Magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res 1995;15(3):1123-5.

Menon U, Talaat A, Rosenthal AN, et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 2000;107(2):165-9.

Merce LT, Caballero RA, Barco MJ, et al. B-mode, uteroovarian and intratumoural transvaginal colour Doppler ultrasonography for differential diagnosis of ovarian tumours. Eur J Obstet Gynecol Reprod Biol 1998;76(1):97-107.

Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003;102(3):594-9.

Mol BW, Boll D, De Kanter M, et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80(2):162-7.

Morgante G, la Marca A, Ditto A, et al. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999;106(6):524-7.

O'Connell GJ, Ryan E, Murphy KJ, et al. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 1987;70(6):930-2.

Obeidat BR, Amarin ZO, Latimer JA, et al. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet 2004;85(3):255-8.

Ong S, Duffy T, Murphy J. Transabdominal ultrasound and its correlation with clinical findings in gynaecology. Ir J Med Sci 1996;165(4):268-70.

Onsrud M, Shabana A, Austgulen R. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumour Biol 1996;17(2):90-6.

Padilla LA, Radosevich DM, Milad MP. Accuracy of the pelvic examination in detecting adnexal masses. Obstet Gynecol 2000;96(4):593-8.

Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet 2005;88(1):84-8.

Padungsutt P, Thirapagawong C, Senapad S, et al. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy. Anticancer Res 2000;20(2B):1291-5.

Parker J, Proietto AM. Surgical treatment of adnexal cysts by laparotomy. Int J Gynaecol Obstet 1997;59(3):257-8.

Parker WH, Levine RL, Howard FM, et al. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg 1994;179(6):733-7.

Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988;159(4):873-6.

Prompeler HJ, Madjar H, Sauerbrei W. Classification of adnexal tumors by transvaginal color Doppler. Gynecol Oncol 1996;61(3):354-63.

Pyrgiotis E, Salamalekis E, Loghis C, et al. CA 125 in preoperative evaluation of pelvic masses. Eur J Gynaecol Oncol 1993;14(4):279-82.

Rehn M, Lohmann K, Rempen A. Transvaginal ultrasonography of pelvic masses: evaluation of B-mode technique and Doppler ultrasonography. Am J Obstet Gynecol 1996;175(1):97-104.

Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 1997;25(5):217-25.

Reuter M, Steffens J., Schuppler U. Critical evaluation of the specificity of MRI and TVUs for differentiation of malignant from benign adnexal lesions. Eur Radiol 1998;8(39-44).

Roman LD, Muderspach LI, Burnett AF, et al. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med 1998;43(5):403-7. Roman LD, Muderspach LI, Stein SM, et al. Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet Gynecol 1997;89(4):493-500.

Sadik S, Onoglu AS, Gokdeniz R, et al. Laparoscopic management of selected adnexal masses. J Am Assoc Gynecol Laparosc 1999;6(3):313-6.

Salem S, White LM, Lai J. Doppler sonography of adnexal masses: the predictive value of the pulsatility index in benign and malignant disease. AJR Am J Roentgenol 1994;163(5):1147-50.

Sassone AM, Timor-Tritsch IE, Artner A, et al. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78(1):70-6.

Sawicki W, Spiewankiewicz B, Cendrowski K, et al. Preoperative discrimination between malignant and benign adnexal masses with transvaginal ultrasonography and colour blood flow imaging. Eur J Gynaecol Oncol 2001;22(2):137-42.

Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening. A decision analysis model. Ann Intern Med 1993;118(11):838-43.

Schelling M, Braun M, Kuhn W, et al. Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 2000;77(1):78-86.

Schincaglia P, Brondelli L, Cicognani A, et al. A feasibility study of ovarian cancer screening: does fine-needle aspiration improve ultrasound specificity? Tumori 1994;80(3):181-7.

Schneider VL, Schneider A, Reed KL, et al. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses. Obstet Gynecol 1993;81(6):983-8.

Schutter EM, Davelaar EM, van Kamp GJ, et al. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002;187(2):385-92.

Schutter EM, Kenemans P, Sohn C, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994;74(4):1398-406.

Schutter EM, Sohn C, Kristen P, et al. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol 1998;69(1):56-63.

Scoutt LM, McCarthy SM, Lange R, et al. MR evaluation of clinically suspected adnexal masses. J Comput Assist Tomogr 1994;18(4):609-18.

Sengoku K, Satoh T, Saitoh S, et al. Evaluation of transvaginal color Doppler sonography, transvaginal sonography and CA 125 for prediction of ovarian malignancy. Int J Gynaecol Obstet 1994;46(1):39-43.

Serur E, Emeney PL, Byrne DW. Laparoscopic management of adnexal masses. J Soc Laparoendosc Surg 2001;5(2):143-51.

Shabana A, Onsrud M. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma. Tumour Biol 1994;15(6):361-7.

Shalev E, Eliyahu S, Peleg D, et al. Laparoscopic management of adnexal cystic masses in postmenopausal women. Obstet Gynecol 1994;83(4):594-6.

Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol 2002;87(1):77-83.

Siegel BA, Dehdashti F, Mutch DG, et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44(5):700-7.

Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991;44(4-5):365-80.

Smikle CB, Lunt CC, Hankins GD. Clinical predictors in the evaluation of a pelvic mass. Mil Med 1995;160(5):233-5.

Sohaib SA, Mills TD, Sahdev A, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol 2005;60(3):340-8.

Somigliana E, Ragni G, Benedetti F, et al. Does laparoscopic excision of endometriotic ovarian cysts significantly affect ovarian reserve? Insights from IVF cycles. Hum Reprod 2003;18(11):2450-3.

Soper JT, Hunter VJ, Daly L, et al. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990;75(2):249-54.

Stein SM, Laifer-Narin S, Johnson MB, et al. Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 1995;164(2):381-6.

Strigini FA, Gadducci A, Del Bravo B, et al. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Gynecol Oncol 1996;61(1):68-72.

Szpurek D, Moszyniki R, Sajdak S. Clinical value of the ultrasound Doppler index in determination of ovarian tumor malignancy. Eur J Gynaecol Oncol 2004;25(4):442-4.

Tailor A, Bourne TH, Campbell S, et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003;21(4):378-85.

Tailor A, Jurkovic D, Bourne TH, et al. Sonographic prediction of malignancy in adnexal masses using an artificial neural network. Br J Obstet Gynaecol 1999;106(1):21-30.

Takac I. Analysis of blood flow in adnexal tumors by using color Doppler imaging and pulsed spectral analysis. Ultrasound Med Biol 1998;24(8):1137-42.

Tangjitgamol S, Jesadapatrakul S, Manusirivithaya S, et al. Accuracy of frozen section in diagnosis of ovarian mass. Int J Gynecol Cancer 2004;14(2):212-9.

Tanir HM, Ozalp S, Yalcin OT, et al. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. Eur J Gynaecol Oncol 2003;24(3-4):271-4.

Tarik A, Fehmi C. Complications of gynaecological laparoscopy--a retrospective analysis of 3572 cases from a single institute. J Obstet Gynaecol 2004;24(7):813-6.

Tay SK, Chua EK. Correlation of serum, urinary and salivary CA 125 levels in patients with adnexal masses. Ann Acad Med Singapore 1994;23(3):311-4.

Tekay A, Jouppila P. Validity of pulsatility and resistance indices in classification of adnexal tumors with transvaginal color doppler ultrasound. Ultrasound Obstet Gynecol 1992;2:338-44.

Tengs TO, Winer EP, Paddock S, et al. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making 1998;18(4):365-75.

Tepper R, Lerner-Geva L, Altaras MM, et al. Transvaginal color flow imaging in the diagnosis of ovarian tumors. J Ultrasound Med 1995;14(10):731-4.

Tian J, Zhang J, Jiao L, et al. A prospective study of Tc-99m MIBI in the differential diagnosis of pelvic masses in female patients. Clin Nucl Med 2000;25(8):614-8.

Timmerman D, Bourne TH, Tailor A, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol 1999;181(1):57-65.

Timmerman D, Verrelst H, Bourne TH, et al. Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. Ultrasound Obstet Gynecol 1999;13(1):17-25.

Timor-Tritsch LE, Lerner J, Monteagudo A, et al. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. Am J Obstet Gynecol 1993;168:909-13.

Tingulstad S, Hagen B, Skjeldestad FE, et al. The risk-ofmalignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93(3):448-52.

Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103(8):826-31.

Torres JC, Derchain SF, Faundes A, et al. Risk-ofmalignancy index in preoperative evaluation of clinically restricted ovarian cancer. Rev Paul Med 2002;120(3):72-6.

Troiano RN, Quedens-Case C, Taylor KJ. Correlation of findings on transvaginal sonography with serum CA 125 levels. AJR Am J Roentgenol 1997;168(6):1587-90.

Twickler DM, Forte TB, Santos-Ramos R, et al. The Ovarian Tumor Index predicts risk for malignancy. Cancer 1999;86(11):2280-90.

Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997;18(3):251-70.

Valentin L. Gray scale sonography, subjective evaluation of the color Doppler image and measurement of blood flow velocity for distinguishing benign and malignant tumors of suspected adnexal origin. Eur J Obstet Gynecol Reprod Biol 1997;72(1):63-72.

Valentin L. Pattern recognition of pelvic masses by grayscale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 1999;14(5):338-47. Valentin L. Comparison of Lerner score, Doppler ultrasound examination, and their combination for discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 2000;15(2):143-7.

Valentin L, Akrawi D. The natural history of adnexal cysts incidentally detected at transvaginal ultrasound examination in postmenopausal women. Ultrasound Obstet Gynecol 2002;20(2):174-80.

Valentin L, Hagen B, Tingulstad S, et al. Comparison of 'pattern recognition' and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol 2001;18(4):357-65.

van Herendael B, Beretta P, Slangen T, et al. Management of adnexal masses by operative laparoscopy. J Am Assoc Gynecol Laparosc 1995;2(3):273-7.

van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77(3):350-6.

Vasilev SA, Schlaerth JB, Campeau J, et al. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988;71(5):751-6.

Vuento MH, Pirhonen JP, Makinen JI, et al. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995;76(7):1214-8.

Wakahara F, Kikkawa F, Nawa A, et al. Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors. Gynecol Obstet Invest 2001;52(3):147-52.

Weiner Z, Thaler I, Beck D, et al. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 1992;79(2):159-62.

Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59(1):111-6.

Wu CC, Lee CN, Chen T, et al. Factors contributing to the accuracy in diagnosing ovarian malignancy by color Doppler ultrasound. Obstet Gynecol 1994;84:605-8.

Yamashita Y, Hatanaka Y, Torashima M, et al. Characterization of sonographically indeterminate ovarian tumors with MR imaging. A logistic regression analysis. Acta Radiol 1997;38(4 Pt 1):572-7.

Yamashita Y, Torashima M, Hatanaka Y, et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology 1995;194(2):557-65.

Yuen PM, Yu KM, Yip SK, et al. A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 1997;177(1):109-14.

Zanetta G, Vergani P, Lissoni A. Color Doppler ultrasound in the preoperative assessment of adnexal masses. Acta Obstet Gynecol Scand 1994;73:637-41.

Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999;73(1):56-61.

Zimmer Y, Tepper R, Akselrod S. An automatic approach for morphological analysis and malignancy evaluation of ovarian masses using B-scans. Ultrasound Med Biol 2003;29(11):1561-70.

List of Acronyms/Abbreviations

2D 3D	Two-dimensional Three-dimensional
ACOG	
ACOU	American College of Obstetricians and Gynecologists American College of Radiology
AFP	Alpha-fetoprotein
AHRQ	Agency for Healthcare Research and Quality
AUC	Area under the curve
CA-125	Cancer antigen 125
CDC	Centers for Disease Control and Prevention
CEA	Carcinoembryonic antigen
CI	Confidence interval
CMS	Centers for Medicaid and Medicare Services
CT	Computed tomography
FDG	18-Fluorodeoxyglucose
FIGO	International Federation of Gynecology and Obstetrics
FNA	Fine needle aspiration
hCG	Human chorionic gonadotropin
ICD-9	International Classification of Diseases, Ninth Revision
LDH	Lactate dehydrogenase
LMP	Low malignant potential
MeSH	Medical Subject Heading
MRI	Magnetic resonance imaging
NIS	Nationwide Inpatient Sample
NPV	Negative predictive value
PET	Positron emission tomography
PI	Pulsatility index
PPV	Positive predictive value
RI	Resistance index
RMI	Risk of Malignancy Index
ROC	Receiver operating characteristic
SEER	Surveillance, Epidemiology, and End Results
SGO	Society of Gynecologic Oncologists
TAG-72	Tumor-associated glycoprotein 72
TVUS	Transvaginal ultrasound

APPENDIXES

to

"Management of Adnexal Mass"

Prepared by the Duke Evidence-based Practice Center (Contract #290-02-0025)

Appendix A: Exact Search Strings

Search Strategy 1: pelvic exam performance (developed and run by McCrory and Myers on September 10, 2004)

Database: Ovid MEDLINE(R) <1966 to September Week 1 2004> Search Strategy:

- 1 pelvic exam.mp.(53)
- 2 (bimanual adj pelvic).mp. [mp=title, original title, abstract, name of substance, mesh subject heading] (25)
- 3 (physical exam and pelvis).mp.(7)
- 4 "diagnostic techniques, obstetrical and gynecological"/ or culdoscopy/ or laparoscopy/ or physical examination/ (45383)
- 5 physical examination/ (18265)
- 6 Ovarian Cysts/ or Ovarian Neoplasms/ or Genital Neoplasms, Female/ or Adnexal Diseases/ or adnexal mass.mp. (48599)
- 7 exp Ovarian Cysts/ or exp Ovarian Neoplasms/ or Genital Neoplasms, Female/ or Adnexal Diseases/ or adnexal mass.mp. (53879)
- 8 exp fallopian tube diseases/ (4449)
- 9 5 and (7 or 8) (124)
- 10 (or/1-3) and (or/7-8) (18)
- 11 9 and 10 (5)
- 12 "diagnostic techniques, obstetrical and gynecological"/ and (or/7-8) (8)
- 13 culdoscopy/ and (or/7-8) (52)
- 14 or/1-3,9-10 (204)
- 15 limit 14 to (human and english language and yr=1980 2004) (147)
- 16 from 15 keep 1-147 (147)

Search Strategy 2: test performance Developed and run by McCrory on September 28, 2004

Database: Ovid MEDLINE(R) <1966 to September Week 3 2004> Search Strategy:

- 1 (vagin\$ adj ultraso\$).mp. [mp=title, original title, abstract, name of substance, mesh subject heading] (1391)
- 2 (adnex\$ adj2 mas\$).mp. (873)
- 3 (pelvi\$ adj mas\$).mp. (1537)
- 4 (ovar\$ adj mas\$).mp. (1479)
- 5 or/2-4 (3696)
- 6 "sensitivity and specificity"/ (121128)
- 7 6 and 1 (132)

8	6 and 5 (316)
9	7 or 8 (431)
10	limit 9 to (human and english language) (387)
11	from 10 keep 1-387 (387)
12	(ovar\$ adj tumo\$).mp. (11435)
13	12 and 6 (405)
14	ROC Curve/ (7282)
15	13 and 14 (27)
16	from 15 keep 4,7,9,15,19-20,22-23,27 (9)
17	from 15 keep 22-23,27 (3)
18	16 not 11 (4)
19	11 or 18 (391)
20	limit 19 to yr=1980 - 2004 (391)
21	from 20 keep 1-391 (391)

Search Strategy 3: predictive models (strategy developed and run by McCrory on September 29, 2004)

Database: Ovid MEDLINE(R) <1966 to September Week 3 2004> Search Strategy:

- (vagin\$ adj ultraso\$).mp. [mp=title, original title, abstract, name of substance, mesh 1 subject heading] (1391)
- 2 (adnex\$ adj2 mas\$).mp. (873)

- (pelvi\$ adj mas\$).mp. (1537) 3
- 4 (ovar\$ adj mas\$).mp. (1479)
- 5 or/2-4 (3696)
- 6 "sensitivity and specificity"/ (121128)
- 7 6 and 1 (132)
- 6 and 5 (316) 8
- 9 7 or 8 (431)
- limit 9 to (human and english language) (387) 10
- 11 predictive value of tests/ (56850)
- Risk Assessment/ (47548) 12
- 13 roc curve/ (7282)
- 14 "Multivariate Analysis"/ (31714)
- or/11-14 (136223) 15
- 16 15 and 5 (260)
- 17 16 not 9 (142)
- limit 17 to (human and english language) (131) 18
- from 18 keep 1-131 (131) 19

Appendix B: List of Excluded Studies

All excluded studies listed below were reviewed in their full text version. Following each reference, in italics, is the reason(s) for exclusion and the Question (Q) for which the article was considered. If no Q is indicated, then the article was excluded a priori from the study for the reason given. An article can be considered (and therefore excluded) for more than one question, and all questions for which the article was excluded are identified. Reasons for exclusion signify only the usefulness of the articles for this study and are not intended as criticisms of the articles.

For reference, the questions are:

Question 1: What is the prevalence of various tumor types among women with an adnexal mass, stratified by cancer status (malignant vs. benign), age, menopausal status, and size of tumor?

Question 2: What are the sensitivity, specificity, and reliability of the bimanual examination?

Question 3: Among women with a palpable adnexal mass on exam or a mass identified by ultrasound/imaging, what is the sensitivity/specificity of various evaluation modalities including ultrasound (transvaginal ultrasound, transabdominal ultrasound, color Doppler, 2D vs. 3D ultrasound, CT scan, MRI scan, and CA-125 levels) for diagnosing malignant masses?

Question 4: What is the accuracy of explicit scoring systems which incorporate various combinations of imaging findings, patient risk factors, and/or CA-125 levels for detecting malignancy? Have these scoring systems been applied to a population of women before laparoscopy?

Question 5: Among women with suspected benign lesions on initial investigation, what are the sensitivity and specificity of monitoring with periodic CA-125 and/or interval ultrasound examinations for detecting malignant masses? How does the interval of testing/definition of change affect sensitivity and predictive value?

Question 6: Among women with adnexal masses, what are the morbidity and mortality from diagnostic surgery (laparoscopy or laparotomy)? At what point does the risk of laparoscopy outweigh the risk of detecting malignancy?

Question 7: What are the estimated trade-offs resulting from various strategies for evaluation of the adnexal mass?

Abu-Rustum NR, Rhee EH, Chi DS, et al. Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease.[see comment]. Obstet Gynecol 2004;103(3):480-7. *Exclude no mass.*

Adonakis GL, Paraskevaidis E, Tsiga S, et al. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 1996;65(2):221-5. *Exclude Q5-wrong pt population.* Alcazar JL, Jurado M. Using a logistic model to predict malignancy of adnexal masses based on menopausal status, ultrasound morphology, and color Doppler findings. Gynecol Oncol 1998;69(2):146-50. *Exclude Q3-unable to construct 2x2.*

Alcazar JL, Jurado M. Prospective evaluation of a logistic model based on sonographic morphologic and color Doppler findings developed to predict adnexal malignancy. J Ultrasound Med 1999;18(12):837-42. *Exclude Q3-unable* to construct 2x2.

Alcazar JL, Laparte C, Jurado M, et al. The role of transvaginal ultrasonography combined with color velocity imaging and pulsed Doppler in the diagnosis of endometrioma. Fertil Steril 1997;67(3):487-91. *Exclude Q1-sample size*.

Alcazar JL, Ruiz-Perez ML, Errasti T. Transvaginal color Doppler sonography in adnexal masses: which parameter performs best? Ultrasound Obstet Gynecol 1996;8(2):114-9. *Exclude Q3-unable to construct 2x2*.

Alexander-Sefre F, Menon U, Jacobs IJ. Ovarian cancer screening. Hosp Med 2002;63(4):210-3. *Exclude review*.

Ali N, Jan H, Van Trappen P, et al. Radioimmunoscintigraphy with Tc-99m-labelled SM3 in differentiating malignant from benign adnexal masses. BJOG 2003;110(5):508-14. *Exclude Q3-experimental or non-standard test.*

Alvarez RD, Kilgore LC, Partridge EE, et al. Staging ovarian cancer diagnosed during laparoscopy: accuracy rather than immediacy. South Med J 1993;86(11):1256-8. *Exclude review*.

Alvarez-Sanchez F, Brache V, de Oca VM, et al. Prevalence of enlarged ovarian follicles among users of levonorgestrel subdermal contraceptive implants (Norplant). Am J Obstet Gynecol 2000;182(3):535-9. *Exclude Q3-no histol. dx.*

American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002;100(6):1413-6. *Exclude review*.

Anderiesz C, Quinn MA. Screening for ovarian cancer. Med J Aust 2003;178(12):655-6. *Exclude review*.

Andersen WA, Nichols GE, Avery SR, et al. Cytologic diagnosis of ovarian tumors: factors influencing accuracy in previously undiagnosed cases. Am J Obstet Gynecol 1995;173(2):457-63; discussion 463-4. *Exclude Q3-wrong test.*

Anderson MM, Irwin CE Jr, Snyder DL. Abnormal vaginal bleeding in adolescents. Pediatr Ann 1986;15(10):697-701. *Exclude Q1-no histol. dx.*

Andolf E, Jorgensen C, Astedt B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol 1990;75(1):106-9. *Exclude Q7-not descrip of sim model.* Angeid-Backman E, Coleman BG, Arger PH, et al. Comparison of resistive index versus pulsatility index in assessing the benign etiology of adnexal masses. Clin Imaging 1998;22(4):284-91. *Exclude no mass*.

Aslam N, Tailor A, Lawton F, et al. Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG 2000;107(11):1347-53. *Exclude Q3-inconsistent data.*

Aubel S, Wozney P, Edwards RP. MRI of female uterine and juxta-uterine masses: clinical application in 25 patients. Magn Reson Imaging 1991;9(4):485-91.*Exclude Q3sample size.*

Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 2003;15(1):51-5. Exclude review.

Baron AT, Cora EM, Lafky JM, et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003;12(2):103-13. *Exclude no mass.*

Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68(5):1331-7. *Exclude no mass*.

Bast RC Jr, Knauf S, Epenetos A, et al. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 1991;68(8):1758-63. *Exclude no mass.*

Bast RC Jr, Urban N, Shridhar V, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002;107:61-97. *Exclude review*.

Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. Br J Obstet Gynaecol 1998;105(11):1136-47. *Exclude no mass.*

Benacerraf BR, Finkler NJ, Wojciechowski C, et al. Sonographic accuracy in the diagnosis of ovarian masses. J Reprod Med 1990;35(5):491-5.*Exclude Q3-distguish malignant versus nonmalignant*.

Berlanda N, Ferrari MM, Mezzopane R, et al. Impact of a multiparameter, ultrasound-based triage on surgical management of adnexal masses. Ultrasound Obstet Gynecol 2002;20(2):181-5. *Exclude Q6-no M&M data*.

Biran G, Golan A, Sagiv R, et al. Conversion of laparoscopy to laparotomy due to adnexal malignancy. Eur J Gynaecol Oncol 2002;23(2):157-60.*Exclude Q6-no M&M data/Exclude Q4-unable to construct 2x2/ Exclude Q3unable to construct 2x2.* Blend MJ, Ostrowski GJ. Recent advances in the detection of ovarian cancer: a review.... J Am Osteopath Assoc 1994;94(4):305-18. *Exclude review*.

Bohm-Velez M, Mendelson E, Bree R, et al. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000;215(Suppl):861-71. *Exclude review*.

Bohm-Velez M, Mendelson E, Bree R, et al. Suspected adnexal masses. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000;215(Suppl):931-8. *Exclude review*.

Boll D, Geomini PM, Brolmann HA, et al. The preoperative assessment of the adnexal mass: the accuracy of clinical estimates versus clinical prediction rules. BJOG 2003;110(5):519-23. *Exclude Q4-partial dupl new data not relevant*.

Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Radiol 2003;58(8):575-80. *Exclude review*.

Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 1993;306(6884):1025-9. *Exclude no mass*.

Bourne TH, Hampson J, Reynolds K, et al. Screening for early ovarian cancer. Br J Hosp Med 1992;48(8):454-9. *Exclude review*.

Brown DL, Frates MC, Laing FC, et al. Ovarian masses: can benign and malignant lesions be differentiated with color and pulsed Doppler US? Radiology 1994;190(1):333-6. *Exclude Q3-sample size*.

Brown DL, Zou KH, Tempany CM, et al. Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study. Radiology 2001;219(1):213-8. *Exclude no mass*.

Buist MR, Golding RP, Burger CW, et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 1994;52(2):191-8.*Exclude Q6-no M&M data*.

Buquet RA, Amato AR, Huang GB, et al. Is preoperative selection of patients with cystic adnexal masses essential for laparoscopic treatment?. J Am Assoc Gynecol Laparosc 1999;6(4):477-81.*Exclude Q6-no M&M data*.

Buy JN, Ghossain MA, Mark AS, et al. Focal hyperdense areas in endometriomas: a characteristic finding on CT. AJR Am J Roentgenol 1992;159(4):769-71. *Exclude Q3distguish malignant versus nonmalignant.* Buy JN, Ghossain MA, Sciot C, et al. Epithelial tumors of the ovary: CT findings and corrrelation with US. Radiology 1991;178:811-18. *Exclude Q3-unable to construct 2x2*.

Campbell S, Bhan V, Royston P, et al. Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989;299(6712):1363-7. *Exclude no mass.*

Canis M, Bassil S, Wattiez A, et al. Fertility following laparoscopic management of benign adnexal cysts. Hum Reprod 1992;7(4):529-31. *Exclude Q6-review*.

Canis M, Pouly JL, Wattiez A, et al. Laparoscopic management of adnexal masses suspicious at ultrasound. Obstet Gynecol 1997;89(5 Pt 1):679-83. *Exclude Q6-no M&M data.*

Caoili EM, Hertzberg BS, Kliewer MA, et al. Refractory shadowing from pelvic masses on sonography: a useful diagnostic sign for uterine leiomyomas. AJR Am J Roentgenol 2000;174(1):97-101. *Exclude no mass*.

Cappelleri JC, Ioannidis JP, Schmid C. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA 1996;276:1332-8. *Exclude review*.

Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994;121(2):124-32. *Exclude review*.

Carter J. An update on ovarian cancer screening. Aust N Z J Obstet Gynaecol 1994;34(2):169-74. *Exclude no mass.*

Carter J, Fowler J, Carson L, et al. How accurate is the pelvic examination as compared to transvaginal sonography? A prospective, comparative study. J Reprod Med 1994;39(1):32-4. *Exclude Q3-distguish malignant versus nonmalignant/Exclude Q2-unable to construct 2x2*.

Carter J, Saltzman A, Hartenbach E, et al. Flow characteristics in benign and malignant gynecologic tumors using transvaginal color flow Doppler. Obstet Gynecol 1994;83(1):125-30. *Exclude Q3-distguish malignant versus nonmalignant*.

Chadha P, Puri M, Gupta R. A comparative evaluation of clinical examination, pelvic ultrasound and laparoscopy in the diagnosis of pelvic masses. Indian J Med Sci 1994;48(7):158-60. *Exclude Q2-unable to construct 2x2*.

Chalas E, Constantino J, Wickerham L, et al. Benign gynecologic conditions among participants in the breast cancer prevention trial. Am J Obstet and Gynecol 2005;192:1230-9. *Exclude Q1-wrong pt population*.

Cherry C, Vacchiano SA. Ovarian cancer screening and prevention. Semin Oncol Nurs 2002;18(3):167-73. *Exclude no mass*.

Childers JM, Aqua KA, Surwit EA, et al. Abdominal-wall tumor implantation after laparoscopy for malignant conditions. Obstet Gynecol 1994;84(5):765-9. *Exclude no mass*.

Close RJ, Sachs CJ, Dyne PL. Reliability of bimanual pelvic examinations performed in emergency departments. West J Med 2001;175(4):240-4. *Exclude Q2-unable to construct 2x2*.

Cohen L, Fishman DA. Ultrasound and ovarian cancer. Cancer Treat Res 2002;107:119-32. *Exclude review*.

Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002;8(10):3193-7. *Exclude Q3-experimental or nonstandard test.*

Crade M, Yiu-Chiu V, Kincaid K. Color Doppler and ovarian masses: familiarity breeds confidence. Ultrasound Obstet Gynecol 1995;6(5):373-4. *Exclude Q3-no histol. dx*

Crawford RA, Gore ME, Shepherd JH. Ovarian cancers related to minimal access surgery.[see comment]. Br J Obstet Gynaecol 1995;102(9):726-30. *Exclude no mass*.

Crayford TJ, Campbell S, Bourne TH, et al. Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 2000;355(9209):1060-3. *Exclude Q5-wrong pt population*.

Creasman WT, Soper JT. The undiagnosed adnexal mass after the menopause. Clin Obstet Gynecol 1986;29(2):446-52. Exclude Q1-study design not case series or cohort.

Crump C, McIntosh MW, Urban N, et al. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev 2000;9(10):1107-11. *Exclude review*.

Crvenkovic G, Karlan BY, Platt LD. Current role of ultrasound in ovarian cancer screening. Clin Obstet Gynecol 1996;39(1):259-67. *Exclude review*.

de Bruijn HW, van der Zee AG, Aalders JG. The value of cancer antigen 125 (CA 125) during treatment and followup of patients with ovarian cancer. Curr Opin Obstet Gynecol 1997;9(1):8-13. *Exclude Q3-distguish malignant versus nonmalignant.*

De Vries SO, Hunink MG, Polak JF. Summary receiver operating characteristic curves as a technique for meta analysis of the diganoistic performance of duplex ultrasonography in peripheral arterial disease. Acad Radiol 1996;3:361-9. *Exclude review*. Decloedt J, Berteloot P, Vergote I. The feasibility of open laparoscopy in gynecologic-oncologic patients. Gynecol Oncol 1997;66(1):138-40. *Exclude no mass*.

Demirkiran F, Kumbak B, Bese T, et al. Vascular endothelial growth factor in adnexal masses. Int J Gynaecol Obstet 2003;83(1):53-8. *Exclude Q3-experimental or nonstandard test.*

Dgani R, Shani A, Elchalal U, et al. The leukocyte adherence inhibition test (LAI) in preoperative diagnosis of epithelial ovarian cancer. Gynecol Oncol 1993;49(3):349-53. *Exclude Q3-wrong test.*

Dietrich M, Osmers RG, Grobe G, et al. Limitations of the evaluation of adnexal masses by its macroscopic aspects, cytology and biopsy. Eur J Obstet Gynecol Reprod Biol 1999;82(1):57-62. *Exclude Q3-wrong test.*

Dixon JG, Bognar BA, Keyserling TC, et al. Teaching women's health skills: confidence, attitudes and practice patterns of academic generalist physician. J Gen Intern Med 2003;18(6):411-8. *Exclude review*.

Dogan MM, Ugur M, Soysal SK, et al. Transvaginal sonographic diagnosis of ovarian endometrioma. Int J Gynaecol Obstet 1966;52(2):145-9. *Exclude no mass*.

Domar AD. Psychological aspects of the pelvic exam: individual needs and physician involvement. Women Health 1985-1986;10(4):75-90. *Exclude no mass*.

Dordoni D, Zaglio S, Zucca S, et al. The role of sonographically guided aspiration in the clinical management of ovarian cysts. J Ultrasound Med 1993;12(1):27-31. *Exclude Q3-wrong test.*

Dorum A, Blom G, Ekerhovd E, et al. Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. Am J Obstet Gynecol 2005;192:48-54. *Exclude non U.S.*

Dueholm M, Lundorf E, Hansen ES, et al. Magnetic resonance imaging and transvaginal ultrasonography for the diagnosis of adenomyosis. Fertil Steril 2001;76(3):588-94. *Exclude no mass.*

Ehlen T. Management of low malignant potential tumour of the ovary: a policy statement. SOGC/GOC/SCC Policy and Practice Guideline Committee 2000;(85). *Exclude review*.

Einhorn N. Ovarian cancer. Early diagnosis and screening. Hematol Oncol Clin North Am 1992;6(4):843-50. *Exclude no mass*.

Eisen A, Rebbeck TR, Wood WC, et al. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000;18(9):1980-95. *Exclude review.*

Elg S, Lee RB, Stones C, et al. Evaluation of serum haptoglobin levels in patients with adnexal masses. Mil Med 1989;154(5):234-6. *Exclude Q3-experimental or non-standard test.*

Elit L. Surgical management of an adnexal mass suspicious for malignancy. SOGC Clinical Practice Guidelines 2000;(97). *Exclude review*.

Elwood M. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360(9327):170-1. *Exclude no mass*.

Emery J, Yaphe J, Priest P, et al. Screening for ovarian cancer. Lancet 1999;354(9177):509-10. *Exclude no mass*.

Fadare O, Mariappan MR, Wang S, et al. The histologic subtype of ovarian tumors affects the detection rate by pelvic washings. Cancer 2004;102(3):150-6. *Exclude no mass*.

Fayed ST, Ahmad SM, Kassim SK, et al. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer. Dis Markers 1998;14(3):155-60. *Exclude Q3-no verification test negative.*

Fedele L, Bianchi S, Dorta M, et al. Transvaginal ultrasonography versus hysteroscopy in the diagnosis of uterine submucous myomas. Obstet Gynecol 1991;77(5):745-8. *Exclude no mass*.

Fedele L, Bianchi S, Dorta M, et al. Transvaginal ultrasonography in the differential diagnosis of adenomyoma versus leiomyoma. Am J Obstet Gynecol 1992;167(3):603-6. *Exclude no mass*.

Finkler NJ. Clinical utility of CA 125 in preoperative diagnosis of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 1993;49(1-2):105-7. *Exclude Review*.

Finkler NJ, Benacerraf B, Lavin PT, et al. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72(4):659-64. *Exclude Q1-no histol. dx.*

Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005;192(4):1214-21; discussion 1221-2. *Exclude Q3-unable to construct 2x2*.

Fleischer AC, Cullinan JA, Jones HW 3rd, et al. Correlation of histomorphology of ovarian masses with color Doppler sonography. Ultrasound Med Biol 1996;22(5):555-9. *Exclude Q3-unable to construct 2x2*. Fleischer AC, Cullinan JA, Kepple DM, et al. Conventional and color Doppler transvaginal sonography of pelvic masses: a comparison of relative histologic specificities. J Ultrasound Med 1993;12(12):705-12. *Exclude Q3-unable to construct 2x2.*

Fleischer AC, Jones HW 3rd. Color Doppler sonography of ovarian masses: the importance of a multiparameter approach. Gynecol Oncol 1993;50(1):1-2. *Exclude review*.

Fleischer AC, McKee MS, Gordon AN, et al. Transvaginal sonography of postmenopausal ovaries with pathologic correlation. J Ultrasound Med 1990;9(11):637-44. *Exclude no mass*.

Fleischer AC, Rodgers WH, Rao BK, et al. Assessment of ovarian tumor vascularity with transvaginal color Doppler sonography. J Ultrasound Med 1991;10(10):563-8. *Exclude Q3-publ duplicate*.

Flynn MK, Niloff JM. Outpatient minilaparotomy for ovarian cysts. J Reprod Med 1999;44(5):399-404. *Exclude Q6-no M&M data*.

Foxall MJ, Barron CR, Houfek JF. Ethnic influences on body awareness, trait anxiety, perceived risk, and breast and gynecologic cancer screening practices. Oncol Nurs Forum 2001;28(4):727-38. *Exclude review*.

Franchi M, Beretta P, Ghezzi F, et al. Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography. Acta Obstet Gynecol Scand 1995;74(9):734-9. *Exclude Q4-unable to construct 2x2*.

Frederick JL, Paulson RJ, Sauer MV. Routine use of vaginal ultrasonography in the preoperative evaluation of gynecologic patients. An adjunct to resident education. J Reprod Med 1991;36(11):779-82. *Exclude no mass*.

Frenkel Y, Oelsner G, Ben-Baruch G, et al. Major surgical complications of laparoscopy. Eur J Obstet Gynecol Reprod Biol 1981;12(2):107-11. *Exclude Other All Premenopausal.*

Gadducci A, Baicchi U, Marrai R, et al. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol 1994;53(3):352-6. *Exclude Q3wrong test.*

Gadducci A, Marrai R, Baicchi U, et al. Preoperative Ddimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol 1997;66(1):85-8. *Exclude no mass*.

Geomini P, Bremer G, Kruitwagen R, et al. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metanalysis. [Review] [43 refs] [Journal Article. Meta-Analysis. Review] Gynecol Oncol 2005; 96(1):1-9. *Exclude review*.

Goff BA, Mandel L, Muntz HG, et al. Ovarian carcinoma diagnosis. Cancer 2000;89(10):2068-75. *Exclude review*.

Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77(3):454-9.*Exclude Q4-not scoring system.*

Granberg S, Wikland M. A comparison between ultrasound and gynecologic examination for detection of enlarged ovaries in a group of women at risk for ovarian carcinoma. J Ultrasound Med 1988;7(2):59-64. *Exclude no mass*.

Gryspeerdt S, Clabout L, Van Hoe L, et al. Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer. Eur J Gynaecol Oncol 1998;19(5):434-7. *Exclude no mass*.

Guerriero S, Ajossa S, Lai MP, et al. The diagnosis of functional ovarian cysts using transvaginal ultrasound combined with clinical parameters, CA125 determinations, and color Doppler. Eur J Obstet Gynecol Reprod Biol 2003;110(1):83-8. *Exclude other all premenopausal.*

Guerriero S, Ajossa S, Lai MP, et al. Transvaginal ultrasonography associated with colour Doppler energy in the diagnosis of hydrosalpinx. Hum Reprod 2000;15(7):1568-72. *Exclude Q3-no cancer outcome*.

Guerriero S, Mais V, Ajossa S, et al. The role of endovaginal ultrasound in differentiating endometriomas from other ovarian cysts. Clin Exp Obstet Gynecol 1995;22(1):20-2. *Exclude Other All Premenopausal*.

Guerriero S, Mais V, Ajossa S, et al. Transvaginal ultrasonography combined with CA-125 plasma levels in the diagnosis of endometrioma. Fertil Steril 1996;65(2):293-8. *Exclude other all premenopausal*.

Guerriero S, Mallarini G, Ajossa S, et al. Transvaginal ultrasound and computed tomography combined with clinical parameters and CA-125 determinations in the differential diagnosis of persistent ovarian cysts in premenopausal women. Ultrasound Obstet Gynecol 1997;9(5):339-43. *Exclude Q4-all premenopausal/ Exclude Q3-all premenopausal.*

Guidozzi F. Screening for ovarian cancer. Obstet Gynecol Surv 1996;51(11):696-701. *Exclude no mass*.

Hakama M, Stenman UH, Knekt P, et al. CA 125 as a screening test for ovarian cancer. J Med Screen 1996;3(1):40-2. *Exclude no mass*.

Hall DJ, Hurt WG. The adnexal mass. J Fam Pract 1982;14(1):135-40. *Exclude no mass*.

Hamm B, Kubik-Huch RA, Fleige B. MR imaging and CT of the female pelvis: radiologic-pathologic correlation. Eur Radiol 1999;9(1):3-15. *Exclude Q3-sample size*.

Hamper UM, Sheth S, Abbas FM, et al. Transvaginal color Doppler sonography of adnexal masses: differences in blood flow impedance in benign and malignant lesions. AJR Am J Roentgenol 1993;160(6):1225-8. *Exclude Q3unable to construct 2x2.*

Hartge P, Hayes R, Reding D, et al. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors. Am J Obstet and Gynecol 2000;183(5):1232-7. *Exclude Q1-no histol. dx.*

Hata K, Hata T, Collins WP. Association of thymidine phosphorylase concentration with ultrasound-derived indices of blood flow in ovarian masses. Cancer 1997;80(6):1079-84. *Exclude Q3-sample size*.

Hata K, Miyazaki K, Collins WP. Value of end-points from multiple or worst case Doppler spectra for the assessment of ovarian masses. Ultrasound Obstet Gynecol 1999;13(4):284. *Exclude no mass*.

Hata K, Nagami H, Iida K, et al. Expression of thymidine phosphorylase in malignant ovarian tumors: correlation with microvessel density and an ultrasound-derived index of angiogenesis. Ultrasound Obstet Gynecol 1998;12(3):201-6. *Exclude Q3-no histol. dx*.

Hefler L, Mayerhofer K, Nardi A, et al. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol 2000;96(1):65-9. *Exclude no mass*.

Helzlsouer KJ, Bush TL, Alberg AJ, et al. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 1993;269(9):1123-6. *Exclude no mass*.

Hensley ML, Castiel M, Robson ME. Screening for ovarian cancer: what we know, what we need to know. Oncology (Huntingt) 2000;14(11):1601-8, 1613-6. *Exclude no mass*.

Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging-multivariate analysis. Radiology 2000;214(1):39-46. *Exclude Q1-denom is masses*.

Hulka JF, Hulka CA. Preoperative sonographic evaluation and laparoscopic management of persistent adnexal masses: a 1994 review.... J Am Assoc Gynecol Laparosc 1994;1(3):197-205. *Exclude review*.

Im S, Gordon A, Buttin B, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gyencol 2005;205(1):35-41. *Exclude Q4-not scoring system/Exclude Q3-unable to construct 2x2.*

Irwig L, Tosteson A, Gatsonis C. Guidelines for metaanalyses evaluating diagnositc tests. Ann Intern Med 1994;120:667-76. *Exclude review*.

Jacobs I. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer. Gynecol Oncol 1994;55(3 Pt 2):S22-7. *Exclude no mass*.

Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993;306(6884):1030-4. *Exclude no mass*.

Jacobs I, Oram D. Screening for ovarian cancer. Biomed Pharmacother 1988;42(9):589-96. *Exclude review*.

Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988;1(8580):268-71. *Exclude Q4-unable to construct 2x2*.

Jacobs IJ, Oram DH, Bast RC Jr. Strategies for improving the specificity of screening for ovarian cancer with tumorassociated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 1992;80(3 Pt 1):396-9. *Exclude no mass*.

Jacobs IJ, Rivera H, Oram DH, et al. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol 1993;100(12):1120-4. *Exclude Q4-partial dupl new data not relevant.*

Jain KA. Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings. Radiology 1994;191(1):63-7. *Exclude Q1-denom is masses*.

Kadar N. Port-site recurrences following laparoscopic operations for gynaecological malignancies. Br J Obstet Gynaecol 1997;104(11):1308-13. *Exclude no mass.*

Karlan BY. Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? J Cell Biochem 1995;23(227-32). *Exclude review*.

Karlan BY, Platt LD. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol 1994;55(3 Pt 2):S28-33. *Exclude review*.

Kerpsack JT, Finan MA. Thrombocytosis as a predictor of malignancy in women with a pelvic mass. J Reprod Med 2000;45(11):929-32. *Exclude Q3-wrong test.*

Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287(13):1671-9. *Exclude Q3-unable to construct 2x2*.

Kinkel K, Hricak H, Lu Y, et al. US characterization of ovarian masses: a meta-analysis. Radiology 2000;217(3):803-11. *Exclude Q3-review*. Klaren HM, van't Veer LJ, van Leeuwen FE, et al. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst 2003;95(13):941-7. *Exclude review*.

Kramer BS, Gohagan J, Prorok PC, et al. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993;71(2 Suppl):589-93. *Exclude review*.

Kruitwagen RF, Swinkels BM, Keyser KG, et al. Incidence and effect on survival of abdominal wall metastases at trocar or puncture sites following laparoscopy or paracentesis in women with ovarian cancer.[see comment]. Gynecol Oncol 1996;60(2):233-7. *Exclude Q6-sample size*.

Kupesic S, Kurjak A. Contrast-enhanced, threedimensional power Doppler sonography for differentiation of adnexal masses. Obstet Gynecol 2000;96(3):452-8. *Exclude Q3-sample size*.

Kurjak A, Kupesic S, Anic T, et al. Three-dimensional ultrasound and power doppler improve the diagnosis of ovarian lesions. Gynecol Oncol 2000;76(1):28-32. *Exclude Q3-publ duplicate*.

Kurjak A, Kupesic S, Babic MM, et al. Preoperative evaluation of cystic teratoma: what does color Doppler add? J Clin Ultrasound 1997;25(6):309-16. *Exclude no mass.*

Kurjak A, Predanic M. Ovarian cancer screening. Curr Opin Obstet Gynecol 1994;6(1):67-74. *Exclude review*.

Lang F. Resident behaviors during observed pelvic examinations. Fam Med 1990;22(2):153-5. *Exclude no mass*.

Larsen T, Torp-Pedersen ST, Ottesen M, et al. Abdominal ultrasound combined with histological and cytological fine needle biopsy of suspected ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1993;50(3):203-9. *Exclude Q3-experimental or non-standard test.*

Layfield LJ, Heaps JM, Berek JS. Fine-needle aspiration cytology accuracy with palpable gynecologic neoplasms. Gynecol Oncol 1991;40(1):70-3.*Exclude Q3-sample size*.

Lee JH, Jeong YK, Park JK, et al. "Ovarian vascular pedicle" sign revealing organ of origin of a pelvic mass lesion on helical CT. AJR Am J Roentgenol 2003;181(1):131-7. *Exclude Q3-distguish malignant versus nonmalignant*.

Lehner R, Wenzl R, Heinzl H, et al. Influence of delayed staging laparotomy after laparoscopic removal of ovarian masses later found malignant. Obstet Gynecol 1998;92(6):967-71. *Exclude no mass*.

Lerner JP, Timor-Tritsch IE, Federman A, et al. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170(1 Pt 1):81-5. *Exclude Q1-denom is masses*.

Levine D, Feldstein VA, Babcook CJ, et al. Sonography of ovarian masses: poor sensitivity of resistive index for identifying malignant lesions. AJR Am J Roentgenol 1994;162(6):1355-9. *Exclude Q3-sample size*.

Levine D, Gosink BB, Wolf SI, et al. Simple adnexal cysts: the natural history in postmenopausal women.[see comment]. Radiology 1992;184(3):653-9. *Exclude Q6-sample size.*

Levy G, Levine P, Brennan J, et al. Color flow-directed Doppler studies of ovarian masses. Computer analysis. J Reprod Med 1998;43(10):865-8. *Exclude Other*.

Lieberman G, Buscombe JR, Hilson AJ, et al. Preoperative diagnosis of ovarian carcinoma with a novel monoclonal antibody. Am J Obstet Gynecol 2000;183(3):534-40. *Exclude Q3-experimental or non-standard test.*

Lieberman G, MacLean AB, Buscombe JR, et al. The clinical application of a dual head gamma camera with coincidence detection in 20 women with suspected ovarian cancer. BJOG 2001;108(12):1229-36. *Exclude no mass*.

Liede A, Karlan B, Baldwin RL, et al. Cancer Incidence in a population of jewish women at risk of ovarian cancer. J Clin Oncol 2002;20(6):1570-77. *Exclude review*.

Lin P, Falcone T, Tulandi T. Excision of ovarian dermoid cyst by laparoscopy and by laparotomy. Am J Obstet Gynecol 1995;173(3 Pt 1):769-71. *Exclude Q6-sample size*.

Lynch HT, Albano WA, Lynch JF, et al. Surveillance and management of patients at high genetic risk for ovarian carcinoma. Obstet Gynecol 1982;59(5):589-96. *Exclude no mass*.

MacDonald ND, Rosenthal AN, Jacobs IJ. Screening for ovarian cancer. Ann Acad Med Singapore 1998;27(5):676-82. *Exclude review*.

Mackey SE, Creasman WT. Ovarian cancer screening. J Clin Oncol 1995;13(3):783-93. *Exclude review*.

Maggino T, Gadducci A. Serum markers as prognostic factors in epithelial ovarian cancer: an overview. Eur J Gynaecol Oncol 2000;21(1):64-9. *Exclude review*.

Mais V, Ajossa S, Piras B, et al. Treatment of nonendometriotic benign adnexal cysts: a randomized comparison of laparoscopy and laparotomy. Obstet Gynecol 1995;86(5):770-4. *Exclude Q6-sample size*. Mais V, Guerriero S, Ajossa S, et al. Transvaginal ultrasonography in the diagnosis of cystic teratoma. Obstet Gynecol 1995;85(1):48-52. *Exclude Q3-all premenopausal.*

Markman M. Limitations to the use of the CA-125 antigen level in ovarian cancer. Curr Oncol Rep 2003;5(4):263-4. *Exclude review*.

Masson V. Bodies of knowledge. Nurs Health Care Perspect 1997;18(6):291. *Exclude no mass*.

McIntosh MW, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 2003;4(1):27-40. *Exclude Q7-not descrip of sim model*.

Mendilcioglu I, Zorlu CG, Trak B, et al. Laparoscopic management of adnexal masses. Safety and effectiveness. J Reprod Med 2002;47(1):36-40. *Exclude Q6-sample size*.

Menon U, Jacobs IJ. Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol 2001;13(1):61-4. *Exclude review*.

Menon U, Talaat A, Rosenthal AN, et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 2000;107(2):165-9. *Exclude Q4-wrong pt population.*

Mensah LG. Gynecology in the generalist's office. Ethn Dis 2003;13(3 Suppl 3):S3-50-1. *Exclude Q1-no histol. dx.*

Merz E, Miric-Tesanic D, Bahlmann F, et al. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet Gynecol 1996;7(1):38-42. *Exclude no mass*.

Mettler L, Semm K, Shive K. Endoscopic management of adnexal masses. J Soc Laparoendosc Surg 1997;1(2):103-12. *Exclude Q6-no M&M data*.

Midgette AS, Stukel TA, Littenberg B. A meta-analytic method for summarizing diagnostic test performances: receiver-operating-characteristic-summary point estimates. Med Decis Making 1993;13:253-7. *Exclude review.*

Milad MP, Cohen L. Preoperative ultrasound assessment of adnexal masses in premenopausal women. Int J Gynaecol Obstet 1999;66(2):137-41. *Exclude other all premenopausal*.

Mills GB, Bast RC Jr, Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 2001;93(19):1437-9. *Exclude review*. Misawa T, Asai M, Higashide K. How to decrease falsepositive cases of ovarian cancer screening by transvaginal sonography. J Exp Clin Cancer Res 1997;16(2):217-20. *Exclude no mass*.

Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003;102(3):594-9. *Exclude Q3-no cancer outcome*.

Morgan A. Adnexal mass evaluation in the emergency department. Emerg Med Clin North Am 2001;19(3):799-816. *Exclude review*.

Moses LE, Shapiro D. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-316.*Exclude review*.

Muto MG, Cramer DW, Brown DL, et al. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 1993;51(1):12-20. *Exclude Q3-sample size*.

Nagarsheth NP, Rahaman J, Cohen CJ, et al. The incidence of port-site metastases in gynecologic cancers. J Soc Laparoendosc Surg 2004;8(2):133-9.*Exclude no mass*.

Nevin J, Denny L, Soeters R, et al. Ultrasonography of pelvic masses. Br J Obstet Gynaecol 1998;105(2):137-9. *Exclude review*.

Nezhat C, Santolaya J, Nezhat FR. Comparison of transvaginal sonography and bimanual pelvic examination in patients with laparoscopically confirmed endometriosis. J Am Assoc Gynecol Laparosc 1994;1(2):127-30. *Exclude Q3-distguish malignant versus nonmalignant.*

Nezhat F, Nezhat C, Welander CE, et al. Four ovarian cancers diagnosed during laparoscopic management of 1011 women with adnexal masses. Am J Obstet Gynecol 1992;167(3):790-6. *Exclude other*.

Nichols M, Morgan E, Jensen JT. Comparing bimanual pelvic examination to ultrasound measurement for assessment of gestational age in the first trimester of pregnancy. J Reprod Med 2002;47(10):825-8. *Exclude Q1-no histol. dx.*

O'Rourke J, Mahon SM. A comprehensive look at the early detection of ovarian cancer. Clin J Oncol Nurs 2003;7(1):41-7. *Exclude no mass*.

Ong S, Duffy T, Murphy J. Transabdominal ultrasound and its correlation with clinical findings in gynaecology. Ir J Med Sci 1996;165(4):268-70. *Exclude Q3-unable to construct 2x2.* Onsrud M, Shabana A, Austgulen R, et al. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer. Gynecol Oncol 1995;57(2):183-7. *Exclude Q3wrong test.*

Opala T, Drews K, Rzymski P, et al. Evaluation of soluble intracellular adhesion molecule-1 (sICAM-1) in benign and malignant ovarian masses. Eur J Gynaecol Oncol 2003;24(3-4):255-7. *Exclude Q3-experimental or nonstandard test.*

Opala T, Rzymski P, Wilczak M, et al. Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients. Eur J Gynaecol Oncol 2005;26(1):43-6.*Exclude Q3-wrong test.*

Oram DH, Jacobs IJ, Brady JL, et al. Early diagnosis of ovarian cancer. Br J Hosp Med 1990;44(5):320, 322, 324. *Exclude Q3-review*.

Paley PJ. Screening for the major malignancies affecting women: current guidelines. Am J Obstet Gynecol 2001;184(5):1021-30.*Exclude review*.

Papasakelariou C, Saunders D, De La Rosa A. Comparative study of laparoscopic oophorectomy. J Am Assoc Gynecol Laparosc 1995;2(4):407-10.*Exclude Q6-no M&M data*.

Pardo J, Kaplan B, Yitzhak M, et al. Ultrasonographic evaluation of hysterectomized patients with and without concomitant adnexectomy? Clin Exp Obstet Gynecol 1998;25(4):133-4. *Exclude no mass*.

Parker WH. Management of adnexal masses by operative laparoscopy. Selection criteria. J Reprod Med 1992;37(7):603-6. Exclude *no mass*.

Parker WH, Berek JS. Management of selected cystic adnexal masses in postmenopausal women by operative laparoscopy: a pilot study. Am J Obstet Gynecol 1990;163(5 Pt 1):1574-7. *Exclude Q2-no physical exam.*

Patel MD, Feldstein VA, Chen DC, et al. Endometriomas: diagnostic performance of US. [erratum appears in Radiology 1999 Dec;213(3):930]. Radiology 1999;210(3):739-45. Exclude Q3-distguish malignant versus nonmalignant.

Patel MD, Feldstein VA, Lipson SD, et al. Cystic teratomas of the ovary: diagnostic value of sonography. AJR Am J Roentgenol 1998;171(4):1061-5. *Exclude Q3-distguish malignant versus nonmalignant*.

Patsner B, Mann WJ, Chalas E. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 1988;71(6 Pt 1):949-50. *Exclude review*.

Pauler DK, Menon U, McIntosh M, et al. Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10(5):489-93. *Exclude Q1-no histol. dx.*

Pearson VA. Screening for ovarian cancer: a review.... Public Health 1994;108(5):367-82. *Exclude review*.

Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572-7.*Exclude no mass.*

Predanic M, Vlahos N, Pennisi JA, et al. Color and pulsed Doppler sonography, gray-scale imaging, and serum CA 125 in the assessment of adnexal disease. Obstet Gynecol 1996;88(2):283-8. *Exclude Q1-sample size*.

Prefontaine M, Kroft T, Monck M, et al. Evaluation of a simple line width test involving magnetic resonance spectroscopy of plasma in carcinoma of the ovary. Cancer 1991;67(2):406-11.*Exclude Q3-wrong test*.

Pugh CM, Youngblood P. Development and validation of assessment measures for a newly developed physical examination simulator. J Am Med Inform Assoc 2002;9(5):448-60. *Exclude review*.

Qureshi IA, Ullah H, Akram MH, et al. Transvaginal versus transabdominal sonography in the evaluation of pelvic pathology. J Coll Physicians Surg Pak 2004;14(7):390-3. *Exclude Q3-no histol. dx*.

Ramirez PT, Frumovitz M, Wolf JK, et al. Laparoscopic port-site metastases in patients with gynecological malignancies. [Review...] [58 refs]. Int J Gynecol Cancer 2004;14(6):1070-7.*Exclude review*.

Rifkin JI, Shapiro H, Regensteiner JG, et al. Why do some women refuse to allow male residents to perform pelvic exams? Acad Med 2002;77(10):1034-8. *Exclude no mass*.

Rollins G. Developments in cervical and ovarian cancer screening: implications for current practice. Ann Intern Med 2000;133(12):1021-4. *Exclude review*.

Roman LD, Muderspach LI, Stein SM, et al. Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet Gynecol 1997;89(4):493-500. Exclude Q7-not descrip of sim model/Exclude Q5-wrong pt population.

Rosenthal AN, Jacobs IJ. The role of CA 125 in screening for ovarian cancer. Int J Biol Markers 1998;13(4):216-20. *Exclude review*.

Sari R, Buyukberber S, Sevinc A, et al. The effects of abdominal and bimanual pelvic examination and transvaginal ultrasonography on serum CA-125 levels. Clin Exp Obstet Gynecol 2000;27(1):69-71. *Exclude review*.

Sassone AM, Timor-Tritsch IE, Artner A, et al. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78(1):70-6. *Exclude Q1-denom is masses.*

Schwartz LB, Seifer DB. Diagnostic imaging of adnexal masses. A review. J Reprod Med 1992;37(1):63-71. *Exclude review*.

Seewaldt VL, Cain JM, Greer BE, et al. Reviving the pelvic examination for evaluating the status of ovarian carcinoma. J Clin Oncol 1995;13(3):799. *Exclude Q1-no histol. dx.*

Sengoku K, Satoh T, Saitoh S, et al. Evaluation of transvaginal color Doppler sonography, transvaginal sonography and CA 125 for prediction of ovarian malignancy. Int J Gynaecol Obstet 1994;46(1):39-43. *Exclude Q4-sample size.*

Shaharabany Y, Akselrod S, Tepper R. A sensitive new indicator for diagnostics of ovarian malignancy, based on the Doppler velocity spectrum. Ultrasound Med Biol 2004;30(3):295-302 *Exclude Q3-unable to construct 2x2*.

Shalev E, Eliyahu S, Peleg D, et al. Laparoscopic management of adnexal cystic masses in postmenopausal women. Obstet Gynecol 1994;83(4):594-6. *Exclude Q3-not complete series*.

Shapiro I, Friedman Z, Lysyansky P, et al. The instantaneous measurement of multiple Doppler spectra in the investigation of ovarian masses. Ultrasound Obstet Gynecol 1998;11(5):353-6. *Exclude Q3-no histol. dx*

Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol 2002;87(1):77-83. *Exclude Q3-unable to construct 2x2/ Exclude Q2-only 1 patient had ascites.*

Sheppard R, Fry A, Rush R, et al. Women at risk of ovarian cancer: attitudes towards and expectations of the familial ovarian cancer clinic. Fam Cancer 2001;1(1):31-7. *Exclude no mass.*

SOGC/GOC/SCC Policy and Practice Guideline Committee. Guidelines for the Laparoscopic Management of the adnexal mass: a policy statement. SOGC Clinical Practice Guidelines 1998;(76). *Exclude review*.

Soriano D, Yefet Y, Seidman DS, et al. Laparoscopy versus laparotomy in the management of adnexal masses during pregnancy. Fertil Steril 1999;71(5):955-60. *Exclude Other All Premenopausal.*

Sparks JM, Varner RE. Ovarian cancer screening. Obstet Gynecol 1991;77(5):787-92. *Exclude review*.

Stein SM, Laifer-Narin S, Johnson MB, et al. Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 1995;164(2):381-6. *Exclude Q1-denom is masses*.

Tailor A, Jurkovic D, Bourne TH, et al. Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound Obstet Gynecol 1997;10(1):41-7. *Exclude Q4-sample size.*

Tailor A, Jurkovic D, Bourne TH, et al. Sonographic prediction of malignancy in adnexal masses using an artificial neural network. Br J Obstet Gynaecol 1999;106(1):21-30. *Exclude Q3-unable to construct 2x2*.

Tailor A, Jurkovic D, Bourne TH, et al. A comparison of intratumoural indices of blood flow velocity and impedance for the diagnosis of ovarian cancer. Ultrasound Med Biol 1996;22(7):837-43. *Exclude Q3-sample size*.

Tangjitgamol S, Jesadapatrakul S, Manusirivithaya S, et al. Accuracy of frozen section in diagnosis of ovarian mass. Int J Gynecol Cancer 2004;14(2):212-9. *Exclude Q3-wrong test.*

Tekay A, Jouppila P. Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand 1996;75(4):316-29. *Exclude Q3-review*.

Tempfer C, Hefler L, Heinzl H, et al. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases. Br J Cancer 1998;78(8):1108-12. *Exclude Q3-experimental or non-standard test.*

Teneriello MG, Park RC. Early detection of ovarian cancer. CA Cancer J Clin 1995;45(2):71-87. *Exclude review*.

Tepper R, Keselbrener L, Manor M, et al. Decay constant of Doppler flow waveform as a possible indicator of ovarian malignancy. Ultrasound Med Biol 1997;23(8):1171-7. *Exclude Q3-unable to construct 2x2*.

Thorvinger B. Diagnostic and interventional radiology in gynecologic neoplasms. Acta Radiol Suppl 1992;378(Pt 3):93-108. *Exclude Q1-no histol. dx*.

Timmerman D, Bourne TH, Tailor A, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol 1999;181(1):57-65. *Exclude Q3-unable to construct 2x2*.

Timmerman D, Schwarzler P, Collins WP, et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999;13(1):11-6. *Exclude Q3-unable to construct 2x2*.

Timor-Tritsch IE. Is office use of vaginal ultrasonography feasible? Am J Obstet Gynecol 1990;162(4):983-5. *Exclude Q1-no histol. dx.*

Togashi K, Nishimura K, Kimura I, et al. Endometrial cysts: diagnosis with MR imaging. Radiology 1991;180(1):73-8. Exclude Q3-no cancer outcome.

Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21(3):215-45. *Exclude Q3-review*.

U.S. Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. Ann Fam Med 2004;2(3):260-2. *Exclude Q1-no histol. dx.*

Ueland F, DePriest P, DeSimone C, et al. The accuracy and examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol Oncol 2005 (in Press) *Exclude no mass.*

Urban N. Screening for ovarian cancer. We now need a definitive randomised trial. BMJ 1999;319(7221):1317-8. *Exclude Q1-no histol. dx.*

Urban N, McIntosh MW, Andersen M, et al. Ovarian cancer screening. Hematol Oncol Clin North Am 2003;17(4):985-1005. *Exclude review*.

Usubutun A, Altinok G, Kucukali T. The value of intraoperative consultation (frozen section) in the diagnosis of ovarian neoplasms. Acta Obstet Gynecol Scand 1998;77(10):1013-6. *Exclude Q3-wrong test.*

Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol 2003;30(3):401-12. *Exclude Q1-no histol. dx.*

Valentin L. Prospective cross-validation of Doppler ultrasound examination and gray-scale ultrasound imaging for discrimination of benign and malignant pelvic masses. Ultrasound Obstet Gynecol 1999;14(4):273-83. Exclude Q3-publ duplicate.

Valentin L, Sladkevicius P, Marsal K. Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstet Gynecol 1994;83(3):425-33. *Exclude Q3-unable to construct 2x2*.

van Dam PA, DeCloedt J, Tjalma WA, et al. Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced?. Am J Obstet Gynecol 1999;181(3):536-41. *Exclude no mass*

van der Burg ME, Lammes FB, Verweij J. The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary. Surg Gynecol Obstet 1993;176(4):310-4. *Exclude Q3-wrong test.* van Nagell JR Jr, DePriest PD, Gallion HH, et al. Ovarian cancer screening. Cancer 1993;71(4 Suppl):1523-8. *Exclude review*.

van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77(3):350-6. *Exclude Q5-wrong pt population.*

van Nagell JR Jr, Higgins RV, Donaldson ES, et al. Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened. Cancer 1990;65(3):573-7.*Exclude Q1-pop is subset of larger study* (#2730).

van Nagell JR Jr, Ueland FR. Ultrasound evaluation of pelvic masses: predictors of malignancy for the general gynecologist. Curr Opin Obstet Gynecol 1999;11(1):45-9.*Exclude review*.

Varpula M. Magnetic resonance imaging of female pelvic masses and local recurrent tumors at an ultra low (0.02 T) magnetic field: correlation with computed tomography. Magn Reson Imaging 1993;11(1):35-46.*Exclude Q3-sample size*

Varras M. Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer. Clin Exp Obstet Gynecol 2004;31(2):85-98. *Exclude review*.

Vogl FD, Frey M, Kreienberg R, et al. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000;83(10):1338-43. *Exclude Q3-sample size*.

von Schlippe M, Rustin GJ. Circulating tumour markers in ovarian tumours. Forum 2000;10(4):383-92. *Exclude review.*

Voss SC, Lacey CG, Pupkin M, et al. Ultrasound and the pelvic mass. J Reprod Med 1983;28(12):833-7. Exclude Q3-no verification test negative/ *Exclude Q2-unable to construct 2x2*.

Wakahara F, Kikkawa F, Nawa A, et al. Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors. Gynecol Obstet Invest 2001;52(3):147-52. *Exclude Q4-unable to construct 2x2*.

Wardle FJ, Collins W, Pernet AL, et al. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst 1993;85(8):653-7. *Exclude review*.

Weerakiet S, Wongkularb A, Rochanawutanon M, et al. Transvaginal ultrasonography combined with pelvic examination in the diagnosis of ovarian endometrioma. J Med Assoc Thai 2000;83(5):523-8. *Exclude Q3-no cancer outcome*.

Weiner Z, Beck D, Brandes JM. Transvaginal sonography, color flow imaging, computed tomographic scanning, and CA 125 as a routine follow-up examination in women with pelvic tumor: detection of recurrent disease. J Ultrasound Med 1994;13(1):37-41. *Exclude no mass*.

Westhoff C, Levin B, Ladd G, et al. Sources of variability in normal CA 125 levels. Cancer Epidemiol Biomarkers Prev 1992;1(5):357-9. *Exclude review*.

Yawn BP, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clinic Proceedings 2004;79(10):1277-82. *Exclude review*.

Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.[see comment]. Cancer Res 2004;64(16):5882-90. *Exclude Q3-experimental or non-standard test.*

Zurawski VR Jr, Knapp RC, Einhorn N, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 1988;30(1):7-14. *Exclude Q3-distguish malignant versus nonmalignant.*

Zygmunt A, Markowska J, Fischer N. Significance of tissue polypeptide specific antigen (TPS) in diagnosis and monitoring of treatment in ovarian cancer. Eur J Gynaecol Oncol 1998;19(5):484-6. *Exclude review*.

Appendix C: Sample Data Abstraction Forms

Question 1: What is the prevalence of various tumor types among peri- and postmenopausal women with an adnexal mass, stratified by cancer status (malignant vs. benign), age, and size of tumor?

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
StudyID	Geographical location:	Age: Mean (SD): Median: Range:	Symptomatic (n [%]):	[Proportion of each type of finding, stratified by cancer status, age/menopausal status (<45, 45-55, >55 or pre-peri-post- menopausal), and size of tumor. Include	[IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
	Dates:	Kunge.	Detected by exam (n [%]):	individual tumor types where possible.]	
	Size of population: [num/denom for screening studies]	Menopausal status (n [%]): Pre (< 45): Peri (45-55): Post (> 55):	Detected by imaging (n [%]):	Use Excel spreadsheet to calculate confidence intervals for prevalence data from screening studies 1)	[COMMENT ON BIASES, ETC. AFFECTING CLINICAL INTERPRETATION]
	Screening study	Race/ethnicity (n [%]):	Combination (n [%]):		Quality assessment:
	Registry Other			2)	[assign + or - to each item, and provide a brief rationale]
	[delete all but one; please specify "Other"]	Risk factors (n [%]): Family history: Genotype: Other [specify]:	Additional data used for diagnosis:	3)	Size of population from which sample drawn: Number of cases: Patient selection: Application of reference standard:
				4)	
					This article is also relevant to: [delete as appropriate]
				5)	Question 2 Question 3 Question 4 Question 5 Question 6 Question 7

Question 2: What are the sensitivity, specificity, and reliability of the bimanual examination?

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
StudyID	Geographical location:	Age: Mean (SD): Median: Range:	Symptomatic (n [%]):	[Please provide brief description of clinical setting in which bimanual exam was performed]	[For bimanual exam, provide reported sensitivity/specificity and provide 2x2 tables (if possible). If possible and appropriate, stratify by age or	[IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
	Dates:		Detected by exam		menopausal status. If data are available on reliability/ reproducibility,	
	Size of population: [num/denom for screening studies]	Menopausal status (n [%]): Pre (< 45): Peri (45-55):	(n [%]):		report these as well. Include kappa scores if these are reported or can be calculated.]	[COMMENT ON BIASES, ETC. AFFECTING CLINICA INTERPRETATION]
	Screening study Registry	Post (> 55): Race/ethnicity	Detected by imaging (n [%]):		 [Use this space to provide information needed for reader to interpret Test +, Test -, Disease +, and Disease - headings in following table.] 	
	Other [delete all but one; please specify "Other"]	(n [%]):	Combination (n [%]):			Quality assessment: [assign + or - to each item, and provide a brief rationale]
	Reference standard:	Risk factors (n [%]): Family history: Genotype:	Additional data			Reference standard: Verification bias: Test reliability/variability:
	Reference standard applied to all test negatives?:	Other [specify]: Inclusion criteria:	used for diagnosis:			Sample size: Statistical tests: Blinding: Definition of +/- on screening test:
	Test reliability established?:	Exclusion criteria:			2)	This article is also relevant to: [delete as appropriate]
	Statistical tests used:					Question 1 Question 2 Question 3
	Blinding:					Question 4 Question 5 Question 7
	Definition of positive and negative on screening test:					

Question 3: Among peri- and postmenopausal women with a palpable adnexal mass on exam or a mass identified by ultrasound/imaging, what is the sensitivity/specificity of various evaluation modalities including ultrasound (transvaginal ultrasound, transabdominal ultrasound, color Doppler, 2-D vs 3D ultrasound, CT scan, MRI scan, and CA-125 levels) for diagnosing malignant masses?

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
StudyID	Geographical location: Dates:	Age: Mean (SD): Median: Range:	Symptomatic (n [%]):	[For each test reported, please provide a 2x2 table and report or calculate sensitivity, specificity, NPV, and PPV (all with confidence intervals). If possible and	[IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
			Detected by exam (n [%]):	appropriate, stratify by age or menopausal status.]	
	Size of population: [num/denom for screening studies]	Menopausal status (n [%]): Pre (< 45): Peri (45-55):	Detected by imaging (n [%]):	 [Use this space to provide information needed for reader to interpret Test +, Test -, Disease +, and Disease - headings in 	[COMMENT ON BIASES, ETC. AFFECTING CLINICAL INTERPRETATION]
	Screening study	Post (> 55):		following table.]	
	Registry Other [delete all but one; please specify "Other"]	Race/ethnicity (n [%]):	Combination (n [%]):		Quality assessment: [assign + or - to each item, and
	Reference standard:	Risk factors (n [%]): Family history: Genotype: Other [specify]:	Additional data used for diagnosis:		provide a brief rationale] Reference standard: Verification bias: Test reliability/variability:
	Reference standard applied to all test negatives?:	Inclusion criteria:			Sample size: Statistical tests: Blinding: Definition of +/- on screening test
	Test reliability established?:	Exclusion criteria:		2)	
	Statistical tests used:				This article is also relevant to: [delete as appropriate]
	Blinding:				Question 1 Question 3 Question 4
	Definition of positive and negative on screening test:				Question 5 Question 6 Question 7

Question 4: What is the accuracy of explicit scoring systems which incorporate various combinations of imaging findings, patient risk factors, and/or CA-125 levels for detecting malignancy? Have these scoring systems been applied to a population of peri-/postmenopausal women before laparoscopy?

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
StudyID	Geographical location:	Age: Mean (SD):	Symptomatic (n [%]):	1)	[For each reported scoring system (and individual components, if reported),	[IF ARTICLE SHOULD BE EXCLUDED, PLEASE
		Median: Range:		2)	provide reported sensitivity/specificity and provide 2x2 table; if multivariate	EXPLAIN WHY HERE]
	Dates:		Detected by exam (n [%]):	3)	analysis, provide area under ROC curve or c-statistic, if reported. If	
	Size of population:	Menopausal status (n [%]):	([//]).	4)	possible and appropriate, stratify by age or menopausal status.]	[COMMENT ON BIASES,
	[num/denom for screening studies]	Pre (< 45): Peri (45-55):	Detected by imaging	5)	 IUse this space to provide 	ETC. AFFECTING CLINICA
	screening studies	Post (> 55):	(n [%]):	6)	information needed for reader to interpret Test +, Test -, Disease +, and	INTERPRETATION]
	Screening study	Dece/othricity/		7)	Disease - headings in following table.]	
	Registry Other	Race/ethnicity (n [%]):	Combination (n [%]):	8)	· · · · · · · · · · · · · · · · · · ·	Quality assessment:
[delete all but one; please specify "Other"			9)		[assign + or - to each item, and provide a brief rationale]	
	Reference standard:	Risk factors (n [%]): Family history: Genotype: Other [specify]:	Additional data used for diagnosis:	10)		Reference standard: Verification bias: Test reliability/variability: Sample size:
	Reference standard applied to all test negatives?:	Other [specify].				Statistical tests: Blinding: Definition of +/- on screening
		Inclusion criteria:				test: Explicit validation method?:
	Statistical tests used:				2)	
	40041	Exclusion criteria:				
Defi and	Blinding:					This article is also relevan to: [delete as appropriate]
	Definition of positive and negative on screening test:					Question 1 Question 2 Question 4 Question 5 Question 6 Question 7

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
					Results were reported, but have not been abstracted, for the following combinations: [list]	

Question 5: Among women with suspected benign lesions on initial investigation, what is the sensitivity and specificity of monitoring with periodic CA-125 and/or interval ultrasound examinations for detecting malignant masses? How does the interval of testing/definition of change affect sensitivity and predictive value?

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Results	Comments/Quality Scoring
StudyID	Geographical location:	Age: Mean (SD): Median:	Symptomatic (n [%]):	Monitoring test:	[For each reported monitoring strategy, provide reported sensitivity/specificity and provide 2x2 table; if multivariate analysis, provide area under ROC	[IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
	Dates:	Range:	Detected by exam	Interval of testing:	curve or c-statistic, if reported. If possible and appropriate, stratify by	
	Size of population: [num/denom for screening studies]	Menopausal status (n [%]): Pre (< 45): Peri (45-55): Post (> 55):	(n [%]): Detected by imaging (n [%]):	Definition of change:	 age or menopausal status.] 1) [Use this space to provide information needed for reader to interpret Test +, Test -, Disease +, and Disease - headings in following table.] 	[COMMENT ON BIASES, ETC. AFFECTING CLINICAL INTERPRETATION]
	Screening study Registry Other [delete all but one; please specify "Other"]	Race/ethnicity (n [%]):	Combination (n [%]):			Quality assessment: [assign + or - to each item, and provide a brief rationale]
	Reference standard: Reference standard	Risk factors (n [%]): Family history: Genotype: Other [specify]:	Additional data used for diagnosis:			Reference standard: Verification bias: Test reliability/variability: Sample size: Statistical tests:
	applied to all test negatives?:	Inclusion criteria:			2)	Blinding: Definition of +/- on screening test: Explicit validation method?:
	Test reliability established?:	Exclusion criteria:				
	Statistical tests used:	Loss to follow up:				This article is also relevant to: [delete as appropriate]

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Result	S	Comments/Quality Scoring
	Blinding: Definition of positive				-		Question 1 Question 2 Question 3 Question 5 Question 6
	and negative on screening test:						Question 7
	Length of follow up:				3)		
	Type of follow up:				F		
	Follow-up interval:						

Question 6: Among women with adnexal masses, what is the morbidity and mortality from diagnostic laparoscopy? At what point does the risk of laparoscopy outweigh the risk of detecting malignancy?

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
StudyID	Geographical location:	Age: Mean (SD): Median: Range:	Symptomatic (n [%]):	[For each, provide reported rate and 95% CI, if appropriate. If possible and appropriate, stratify results by age or menopausal status.]	[IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
	Dates:	Kungo.	Detected by exam (n [%]):	Use Excel spreadsheet to calculate	
		Menopausal status		confidence intervals for morbidity/mortality	
	Size of population: [num/denom for screening studies]	(n [%]): Pre (< 45): Peri (45-55): Post (> 55):	Detected by imaging (n [%]):	1) Mortality:	[COMMENT ON BIASES, ETC. AFFECTING CLINICAL INTERPRETATION]
	Single center Registry	Race/ethnicity (n [%]):	Combination (n [%]):	2) Morbidity (total all complications):	Quality assessment: [assign + or - to each item, and
	[delete one]	Risk factors (n [%]):	Additional data used for		provide a brief rationale]
	Morbidity definitions:	Family history: Genotype: Other [specify]:	diagnosis:	3) Specific complications:	Size of population from which sample drawn: Number of cases: Patient selection: Application of reference standard:
	Length of follow up after surgery:	Loss to follow up:		4) Rate of conversion to laparotomy:	
				5)	This article is also relevant to: [delete as appropriate]
				5 7	Question 1 Question 2
				6)	Question 3 Question 4 Question 6 Question 7

Question 7: What are the estimated trade-offs resulting from various strategies for evaluation of the adnexal mas	ss?
---	-----

Study	Study Design	Study Outcomes	Sources for Model Probabilities	Sources for Model Outcomes	Results	Comments
StudyID	Type of model:	[Life expectancy, quality of life, cancer incidence, cancer death, etc. Include costs, but we will not	[In particular, sources for transition probabilities between different stages of pre- cancer/cancer]		[For each strategy compared, compare results for different outcomes; also, report results of significant sensitivity analyses.]	[IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
	Population modeled (age, range):	be using them here]	cancer, cancer]		1)	[COMMENT ON BIASES, ETC. AFFECTING CLINICAL INTERPRETATION]
	Strategies compared:				2)	
			Simplifying assumptions:		3)	This article is also relevant to: [delete as appropriate] Question 1 Question 2
					4)	Question 3 Question 4 Question 5 Question 6
					5)	
					6)	

Appendix D: Evidence Tables

Evidence Table 1: Question 1: What is the prevalence of various tumor types among women with an adnexal mass, stratified by cancer status (malignant vs. benign), age, menopausal status, and size of tumor?

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Chalas, Welshinger, Engellener,	Geographical location: Stony Brook, NY	Age: NR	Symptomatic (n [%]): NR	Of the 241: 121/241 were malignant = 50.2%; 95% CI, 44.4 to 56.9	Comments: Clinical presentation not described Patients scheduled for surgery;
et al., 1992	Dates: May 1980-Apr 1990	Menopausal status (n [%]):	Detected by exam (n [%]): NR	18/241 borderline = 7.5%; 4.8 to 11.7 102/241 benign = 42.3%; 36.6 to 49	malignancy likely overrepresented
#5100	Size of population: 241	NR; authors present some findings by age > 50, but do not report the numbers of women	Detected by imaging (n [%]): NR	Malignant: Serous epithelial 66 = 27.4%; 95% CI, 22.4 to 33.6	Quality assessment: Size of population from which sample drawn: - (unclear) Number of cases: - (241)
	Other: Retrospective chart review of patients with	Race/ethnicity (n [%]): NR	Combination (n [%]): NR	Mucinous epithelial $12 = 5.0\%$; 2.8 to 8.7 Clear cell epithelial $13 = 5.4\%$; 3.2 to 9.2 Endometrioid epithelial $11 = 4.6\%$; 2.5 to 8.2 Papillary mixed epithelial $5 = 2.1\%$; 0.8 to	
	pelvic mass who underwent laparotomy to look at thrombocytosis as NR a predictor of cancer		Additional data used for diagnosis: CA-125 and thrombocytosis	Papillary mixed epithelial $5 = 2.1\%$; 0.8 to 5.0 Dysgerminoma $2 = 0.8\%$; 0.05 to 3.2 Immature teratoma $1 = 0.4\%$; 0 to 2.6 Endodermal tumor $1 = 0.4\%$; 0 to 2.6 Granulose cell tumor $1 = 0.4\%$; 0 to 2.6 Sertoli-Leydig cell tumor $2 = 0.8\%$; 0.05 to 3.2 Peritoneal primary $1 = 0.4\%$; 0 to 2.6 Malignant mesothelioma $1 = 0.4\%$; 0 to 2.6 Other cancer $5 = 2.1\%$; 0.8 to 5.0 Borderline tumors (LMP): Serous epithelial $9 = 3.7\%$; 95% CI, 1.9 to 7.1 Mucinous epithelial $7 = 2.9\%$; 1.3 to 6.1 Endometrioid epithelial $1 = 0.4\%$; 0 to 2.6	(all had biopsy)
				Papillary mixed epithelial $1 = 0.4\%$; 0 to 2.6 Benign: Functional ovarian cyst 22 = 9.1%; 95% CI, 6.1 to 13.6 Serous cystadenoma 14 = 5.8%; 3.5 to 9.7 Mucinous cystadenoma 9 = 3.7%; 1.9 to 7.1 Brenner tumor 1 = 0.4%; 0 to 2.6 Endometrioma 10 = 4.1%; 2.2 to 7.6 Mature teratoma 6 = 2.5%; 1.1 to 5.5 Thecoma of fibroma 4 = 1.7%; 0.5 to 4.4	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Hydrosalpinx 4 = 1.7% ; 0.5 to 4.4 Paratubal cyst 1 = 0.4%; 0 to 2.6 Leiomyoma 22 = 9.1% ; 6.1 to 13.6Pseudomyxoma 2 = 0.8% ; 0.05 to 3.2 Endometriosis 1 = 0.4%; 0 to 2.6 Mesothelial cyst 1 = 0.4%; 0 to 2.6 Diverticular abscess 1 = 0.4%; 0 to 2.6	
Childers, Nasseri, and Surwit, 1996 #6940	Geographical location: Tucson, AZ Dates: 1991-1995 Size of population: 138 Other 138 with adnexal mass	Age: Mean: 52 Range: 9-91 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: All subjects had some concerning finding: CA-125 elevated: 39 (28%) Abnormal US: 127 (92%) Mass > 10 cm: 43 (32%)	Benign: 119/138 (86.2%; 95% Cl, 80.8 to 92.1) 23 (16.7%; 11.6 to 24.2) cystadenoma 9 (6.5%) 3.4 to 12.3) mucinous cystadenoma 9 (6.5%; 3.4 to 12.3) cystadenofriboma 11 (8.0%; 4.5 to 14.1) benign teratoma 21 (15.2%; 10.3 to 22.5) endometrioma 2 (1.4%; 0.1 to 5.6) Brenner cell 1 (0.7%; 0 to 4.5) struma ovarii 9 (6.5%; 3.4 to 12.3) hydrosalpinx 3 (2.2%; 0.5 to 6.6) corpus luteum 6 (4.3%; 1.9 to 9.5) paraovarian cyst 15 (10.9%; 6.8 to 17.5) leiomyoma 6 (4.3%; 1.9 to 9.5) ovarian fibroma 3 (2.2%; 0.5 to 6.6) chronic tuboovarian abscess Malignant: 19/138 (13.8%; 95% Cl, 9.1 to 20.9) (16 of 19 adnexal primaries) 5 (3.6%; 1.4 to 8.6) serous cystadenocarcinoma 6 (4.3%; 1.9 to 9.5) endometroid carcinoma 3 (2.2%; 0.5 to 6.6) mixed endometroid and serous carcinoma Stage 1= 6 Stage 2 = 2 Stage 3 = 5 Unstaged = 3 (assumed to be Stage I), but 2 had recurrence	Comments: Patients pre-selected for higher prevalence of malignancy -Clinical presentation not described Quality assessment: Size of population from which sample drawn: - (all women at one hospital) Number of cases: - (wide Cls) Patient selection: + (consecutive) Application of reference standard: (all had biopsy)

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Cohen, Escobar, Scharm, et al., 2001 #2460	Geographical location: Chicago, IL Dates: Apr 1999-Jun 2000 Size of population: 71 Other Women with a complex pelvic mass undergoing laparotomy	Age: Range: 22-80 Menopausal status (n [%]): Pre (< 45): 40 (56%) Post (> 55): 31 (44%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Malignant: $13/71 = 18.3\%$; 95% Cl, 11.4 to 29.7 Serous cystadenocarcinoma $5 = 7\%$; 2.9 to 16.2 Mucinous cystadenocarcinoma $1 = 1.4\%$; 0 to 8.6 Clear cell adenocarcinoma $1 = 1.4\%$; 0 to 8.6 Clear cell adenocarcinoma $1 = 1.4\%$; 0 to 8.6 Mixed mullerian $1 = 1.4\%$; 0 to 8.6 Malignant germ cell tumor $2 = 2.8\%$; 0.3 to 10.6 Metastatic sarcoma $1 = 1.4\%$; 0 to 8.6 Metastatic colon $2 = 2.8\%$; 0.3 to 10.6 Borderline tumors (LMP): $1/71 = 1.4\%$; 0 to 8.6 Serous cystadenocarcinoma $1 = 1.4\%$; 0 to 8.6 Benign: $57/71 = 80.3\%$; 71.9 to 89.7 Serous cystadenocarcinoma $1 = 1.4\%$; 0 to 8.6 Benign: $57/71 = 80.3\%$; 71.9 to 89.7 Serous cystadenoma $9 = 12.7\%$; 7.0 to 23.2 Mucinous cystadenoma $9 = 12.7\%$; 7.0 to 23.2 Mucinous cystadenoma $6 = 8.4\%$; 3.9 to 18.0 Adenofibroma $10 = 14.1\%$; 8 to 24.8 Endometrioma $11 = 15.5\%$; 9.1 to 26.5 Cystic teratoma $13 = 18.3\%$; 11.4 to 29.7 Thecoma $1 = 1.4\%$; 0 to 8.6 Hydrosalpinx $4 = 5.6\%$; 2 to 14.4 Tamoxifen stimulation $2 = 2.8\%$; 0.3 to 10.6 Leiomyoma $1 = 1.4\%$; 0 to 8.6 <td>Comments: 8/13 and the 1 borderline malignancy were in postmenopausal women Clinical presentation not described Patients scheduled for surgery; malignancy likely to be overrepresented Quality assessment: Size of population from which sample drawn: - (unclear) Number of cases: + Patient selection: - (only complex adnexal masses) Application of reference standard: + (all had biopsy)</td>	Comments: 8/13 and the 1 borderline malignancy were in postmenopausal women Clinical presentation not described Patients scheduled for surgery; malignancy likely to be overrepresented Quality assessment: Size of population from which sample drawn: - (unclear) Number of cases: + Patient selection: - (only complex adnexal masses) Application of reference standard: + (all had biopsy)

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Gallion, Pavlik, et	Lexington, KY	Mean: 58 Range: 30-92	NR	7/6,470 malignant (ovarian) = 0.11%; 95% CI, 0.05 to 0.2	Overlap in data from previous study published by this group
al., 1997	Dates: Dec 1987-Dec 1993	Menopausal status	Detected by exam (n [%]): NR	1/6,470 malignant (non-ovarian) = 0.02%; 0 to 0.1	(DePriest, van Nagell Jr., Gallion, et al., 1993 [#6880])
#3650	Size of population:	(n [%]): NR	Detected by imaging	83/6,470 benign = 1.2%; 1.0 to 0.12	Most patients had either ovarian, breast or colon cancer family history
	6470; 8 found to have		(n [%]):	Malignant:	
	cancer (7 of these cancers were ovarian)	Race/ethnicity (n [%]) : NR	99% (all but one was detected by imaging)	Granulosa cell tumor 3 = 0.05%; 95% Cl, 0.01 to 0.14	Quality assessment: Size of population from which
	Screening study Used TVUS in asymptomatic women >	Risk factors (n [%]): Family history of: Ovarian cancer: 24%	Combination (n [%]): NR	Adenocarcinoma $2 = 0.03\%$; 0 to 0.12 Serous cystadenocarcinoma $1 = 0.02\%$; 0 to 0.1 Endometrioid carcinoma $1 = 0.02\%$; 0 to 0.1	sample drawn: + (6,470/small city) Number of cases: - (8 with cancer) Patient selection: + (well-specified mix of postmenopausal women and
	50 or postmenopausal and women > 30 with	Breast cancer: 30% Colon cancer: 15%	Additional data used for diagnosis:	Metastatic colon cancer 1 = 0.02%; 0 to 0.1	high-risk younger women) Application of reference standard: +
	positive family history of ovarian carcinoma		NR	Benign: Serous cystadenoma 37 = 0.6%; 95% CI, 0.4 to 0.8 Endometriosis 18 = 0.3%; 0.2 to 0.4	(all had biopsy)
				Mucinous cystadenoma $3 = 0.05\%$; 0.01 to 0.14	
				Cystic teratoma $3 = 0.05\%$; 0.01 to 0.14 Hemorrhagic cyst $2 = 0.03\%$; 0 to 0.12 Fibroma/thecoma/Brenner tumor $4 = 0.06\%$;	
				0.02 to 0.2 Leiomyomata 4 = 0.06%; 0.02 to 0.2 Hydrosalpinx/paratubal 8 = 0.12%; 0.06 to 0.25 Other 4 = 0.06%; 0.02 to 0.2	

DePriest,	Geographical location:	Age:	Symptomatic (n [%]):	Malignant: 13/121 = 10.7%; 95% CI, 6.5 to	Comments:
Shenson,	Lexington , KY	Range: 3-74	NR	17.9	Clinical presentation not described

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Study Fried, et al., 1993 #6390		Patients Menopausal status (n [%]): Pre (< 45): 62 (51%)	Clinical Presentation Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Results Serous cystadenocarcinoma 6 = 5%; 2.2 to 10.8 Mucinous cystadenocarcinoma 2 = 1.6%; 0.1 to 6.4 Granulosa cell tumor 1 = 0.8%; 0 to 5.1 Metastatic adenocarcinoma 2 = 1.6%; 0.1 to 6.4 Neurogenic sarcoma 1 = 0.8%; 0 to 5.1 Lymphoma 1 = 0.8%; 0 to 5.1 Benign: 108/121 = 89.3%; 95% Cl, 84 to 94.8 Serous cystadenoma 21 = 17.4%; 11.9 to 25.5 Mucinous cystadenoma 2 = 1.6%; 0.1 to 6.4 PID 18 = 14.9%; 9.8 to 22.7 Benign cysts = 17 = 14%; 9.1 to 21.8	Patients scheduled for surgery; malignancy likely overrepresented Quality assessment: Size of population from which
				Endometriosis 14 = 11.6%; 7.1 to 18.9 Hemorrhagic corpus luteum cyst 12 = 9.9%; 5.8 to 16.9 Teratoma 11 = 9.1%; 5.2 to 16 Fibroma = 5 = 4.1%; 1.6 to 9.7 Leiomyoma 4 = 3.3%; 1.1 to 8.6 Normal ovary 4 = 3.3%; 1.1 to 8.6	

DePriest,	Geographical location:	Age:	Symptomatic (n [%]):	Benign: 41/3220 (1.3%; 95% CI, 0.9 to	Comments:
van Nagell	Lexington, KY	Mean: 60	0	1.7)	 Majority, if not all, patients had
Jr., Gallion,		Range: 33-90		21 (0.7%; 0.4 to 1.0) serous cystadenoma	either breast, ovarian, or colorectal

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
et al., 1993	Dates:		Detected by exam (n [%]):	4 (0.1%; 0.04 to 0.30) endometrioma	cancer family history
	Nov 1987-Jun 1992	Menopausal status	0	1 (0.03%; 0.0.2) cystadenofibroma	True negative defined as negative
#6880		(n [%]):	Detected by imperime	1(0.03%; 0.0.2) thecoma	biopsy or no diagnosed cancer
	Size of population: 3220	Post (> 55): 100%	Detected by imaging (n [%]):	1 (0.03%; 0.0.2) teratoma 2 (0.06%; 0 to 0.2) fibroma	within 1 year of ultrasound
	3 had cancer	Race/ethnicity (n [%]):	44 had abnormal TVUS	3 (0.09%; 0.02 to 0.3) hydrodsalpinx	Quality assessment:
		NR	(1.4%)	5 (0.16%; 0.06 to 0.4) paratubal cyst	Size of population from which
	Screening study (and		(1.470)	3 (0.09%; 0.02 to 0.3) myoma	sample drawn: - (unclear how
	most had a positive	Risk factors (n [%]):	Combination (n [%]):	0 (0.00 %, 0.02 to 0.0) myoma	representative – small city)
	family history)	Family history of: Ovarian cancer: 502	0	Malignant: 3/3220 (0.09%; 95% Cl, 0.02, 0.29%)	Number of cases: + (although only 3 with cancer)
		(15.6%)	Additional data used for	3 primary ovarian adenocarcinoma	Patient selection: - (some had family
		Breast cancer: 1034	diagnosis:	2 Stage IA	history)
		(32.1%)	NR	1 Stage IIIB	Application of reference standard: +
		Colorectal cancer: 678 (21.1%)			(exploratory lab with biopsy)
Dottino, Levine,	Geographical location: New York, NY	Age: Mean (SD): 52.2 (13.1)	Symptomatic (n [%]) : NR	Benign: 139/160 (86.9%; 95% Cl, 81.9 to 92.2)	Comments: Clinical presentation not described
Ripley, et	,				· · · ·
al., 1999	Dates:	Menopausal status	Detected by exam (n [%]):	Borderline: 8 (5%; 95% Cl, 2.5 to 9.9)	Quality assessment:
	Apr 1992-Apr 1996	(n [%]):	NR		Size of population from which
#6920		Pre (< 45): 75 (47%)		Malignant: 13 (8.1%; 95% CI, 4.8 to 13.7)	sample drawn: + (large city)
	Size of population: 160	Post (> 55): 85 (53%)	Detected by imaging (n [%]):	6 epithelial cancers (3.7%; 1.6 to 8.2) 2 Stage 1A (1.2%; 0.09 to 4.8)	Number of cases: - (wide CIs) Patient selection: - (not described)
		Race/ethnicity (n [%]):	NR	1 Stage 2C (0.6%; 0 to 3.9)	Application of reference standard: +
	Other	White 146 (91%)		1 Stage 3A (0.6%; 0 to 3.9)	(all had biopsy)
	Adnexal mass		Combination (n [%]):	1 Stage 3C (0.6%; 0 to 3.9)	
	undergoing laparoscopic	Risk factors (n [%]):	NR	1 Stage 4 (0.6%; 0 to 3.9)	
	surgery	NR		3 sex cord stromal tumors (1.9%; 0.4 to 5.7)	
	0,			2 Contali Loudin call $(1.20/:0.00$ to (1.0)	
	0,		Additional data used for	2 Sertoli-Leydig cell (1.2%; 0.09 to 4.8)	
	0, 1		Additional data used for diagnosis: NR	2 Serton-Leydig cell (1.2%, 0.09 to 4.8) 1 granulosa cell (0.6%; 0 to 3.9) 4 non-gynecologic cancers (4%; 0.8 to 6.6)	

Fleischer,	Geographical location:	Age:	Symptomatic (n [%]) :	Benign: 31/62 (50%; 95% Cl, 39.5 to 63.5)	
Cullinan,	Nashville, TN	Mean: 50	NR	10 (16.1%; 9.3 to 28.2) hemorrhagic corpus	
Jones 3 rd , et	1	Range: 17-88		luteum	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
al., 1996	Dates:	••	Detected by exam (n [%]):	1 (1.6%; 0 to 9.8) serous cyst	Quality assessment:
#2040	1990-1995	Menopausal status	NR	4 (6.4%; 2.3 to 16.4) cystadenomas	Size of population from which
#3840	Size of population:	(n [%]): Pre (< 45): NR	Detected by imaging	4 (6.4%; 2.3 to 16.4) endometriomas 8 (12.9%; 6.9 to 24.4) dermoid cysts	sample drawn: - (1 hospital) Number of cases: - (small and wide
	62	Peri (45-55): NR	(n [%]):	2 (3.2%; 0.4 to 12.1) ovarian fibroma	Cls)
	52	Post (> 55): (over 50%)	100%	2 (3.2%; 0.4 to 12.1 leiomyoma	Patient selection: - (not described)
	Other			_ (Application of reference standard:
	Patients who underwent	Race/ethnicity (n [%]):	Combination (n [%]):		(all had biopsy)
	Doppler for adnexal	NR	NR	Malignant: 31/62 (50%; 95% CI, 39.5 to	
	mass			63.5)	
		Risk factors (n [%]):	Additional data used for	16 (25.8%; 17.3 to 39.0) cystadeno-	
		NR	diagnosis:	carcinomas	
			NR	1 (1.6%; 0 to 9.8) papillary serous	
				adenocarcinomas 1 (1.6%; 0 to 9.8) endometroid carcinoma	
				1 (1.6%; 0 to 9.8) dysgerminoma	
				4 (6.4%; 2.3 to 16.4) metastases	
				4 (6.4%; 2.3 to 16.4) germ cell tumors	
				4 (6.4%; 2.3 to 16.4) stromal tumors	
Lin, Angel,	Geographical location:	Age:	Symptomatic (n [%]):	Benign: 32/80 (40%; 95% CI, 30.9 to 52)	Comments:
DuBeshter, et al., 1993	Rochester NY	Median: 56 Range: 19-88	70 (87%)	23 (28.7%; 20.6 to 40.3) benign cyst 8 (10%; 5.2 to 19.2) other benign	Clinical presentation not described
	Dates:		Detected by exam (n [%]):	gynecologic condition	Quality assessment:
#4890	Jun 1989-Jun 1990	Menopausal status	80 (100%)	1 (1.2%; 0 to 7.7) diverticular disease	Size of population from which
		(n [%]):	59 (74%) with discrete		sample drawn: - (1 hospital)
	Size of population:	Pre (< 45): NR	mass	Borderline: 2/80 (2.5%; 95% Cl, 0.3 to 9.5)	
	80	Peri/Post: 62 (76%)	21 (26%) ill-defined fullness	Mellowents 40/00 (F7 5%) + 40 to (0.4)	Patient selection: - (not described)
	Other	Base/othnisity (n [%])	Detected by imaging	Malignant: 46/80 (57.5%; 48 to 69.1) 6 (7.5%; 3.4 to 16.1) colorectal carcinoma	Application of reference standard: + (all had biopsy)
	Pelvic masses	Race/ethnicity (n [%]): White 72 (90%)	(n [%]):	1 (1.2%; 0 to 7.7) endometrial carcinoma	(all had blopsy)
	undergoing laparoscopic	Black 8 (10%)	NR	1 (1.2%; 0 to 7.7) vaginal carcinoma	
	surgery			2 (2.5%; 0.3 to 9.5) breast carcinoma	
		Risk factors (n [%]):	Combination (n [%]):	2 (2.5%; 0.3 to 9.5) lymphoma	
		Family history of:	NR	4 (5%; 1.7 to 12.9) multiple sites	
		Ovarian/breast/colon		30 (37.5%; 28.6 to 49.5) ovarian carcinoma	
		cancer: 11 (14%)	Additional data used for	6 (7.5%; 3.4 to 16.1) Stage 1	
			diagnosis:	26 (32.5%; 24 to 44.3) Stage 3	
			NR	4 (5%; 1.7 to 12.9) Stage 4	
Modesitt,	Geographical location:	Age:	Symptomatic (n [%]):	Benign: 117/15106 (0.8%; 95% CI, 0.6 to	Comments:
Pavlik,	Lexington, KY	Range: 50-70+	0	0.9)	Although cumulative incidence data
	Lonington, it i	1.ango. 00 / 01	•	61 (0.4%; 0.3 to 0.5) serous cystadenomas	are helpful, unable to calculate

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
al., 2003	Dates:	Menopausal status	Detected by exam (n [%]):	14 (0.09%; 0.05 to 0.16) serous	annual incidence rates given data
	1987-2002	(n [%]):	0	cystadenofibromas	provided
#5560		Post (> 55): 100%		9 (0.06%; 0.03 to 0.12) mucinous	
	Size of population:		Detected by imaging	cystadenoma	Quality assessment:
	27 cancers/15,106	Race/ethnicity (n [%]):	(n [%]):	9 (0.06%; 0.03 to 0.12) paraovarian	Size of population from which
		NR	100%	7 (0.05%; 0.02 to 0.1) fibrothecoma	sample drawn: + (population-based)
	Screening study with			5 (0.03%; 0.01 to 0.08) endometrioma	Number of cases: + (narrow Cls)
	TVUS and followed up	Risk factors (n [%]):	Combination (n [%]):	3 (0.02%; 0 to 0.06) cystic teratoma	Patient selection: Screening study,
	with Doppler and CA-	Family history: some but	NR (, , , , , , , , , , , , , , , , , ,	1 (0.01%; 0 to 0.04) mucinous	all over 50
	125 if abnormal	NR		cystadenofibroma	Application of reference standard: +
			Additional data used for	8 (0.05%; 0.03 to 0.11) other	(subset of patient underwent biopsy)
			diagnosis:		
			NR	Malignant: 27/15106 (0.18%; 95% CI, 0.12	2
				to 0.26)	
				17 (0.11%; 0.07 to 0.18) Stage 1	
				4 (0.03%; 0.01 to 0.07) Stage 2	
				6 (0.04%; 0.02 to 0.09) Stage 3	
				Note: this is a separate group; of these 27,	
				10 had had simple ovarian cyst at one point	
				in screening; 7 had additional morphologic	
				abnormality, 2 had resolution of cyst before	
				developing cancer, 1 had cancer in	
				contralateral ovary	
				Unilocular cyst – cumulative incidence by	
				age:	
				50-54 1315/5229 (25.1%)	
				55-59 481/3278 (14.7%)	
				60-64 373/2694 (13.8%)	
				65-69 271/2008 (13.5%)	
				70+ 323/1897 (17.0%)	

	Parker, Levine,	Geographical location: Santa Monica, Irvine, and	Mean: 65	Symptomatic (n [%]): NR	All tumors were benign and were in postmenopausal women:	Comments: Clinical presentation not reported
	Howard, et	Los Angeles, CA;	Range: 47-81		27 (44.3%; 95% CI, 33.9 to 58.1) serous	
al., 1994 Louisville, KY; Detected by exam (n [%]): cystomas Quality assessment:	al., 1994	Louisville, KY;		Detected by exam (n [%]):	cystomas	Quality assessment:

Evidence	Table	1 (c	continued)
----------	-------	------	------------

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
#910	Rochester, NY Dates: NR; published 1994 Size of population: 61 Other Laparoscopic management of benign- appearing cystic masses	Menopausal status (n [%]): Post (> 55): 61 (100%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	NR Detected by imaging (n [%]): 100% Combination (n [%]): NR Additional data used for diagnosis: NR	15 (24.6%; 16.2 to 37.8) serous cystadenomas 1 (1.6%; 0 to 9.9) mucinous cystadenomas 5 (8.2%; 3.5 to 18.7) cystadenofibromas 4 (6.6%; 2.4 to 16.7) hydrosalpinges 6 (9.8%; 4.6 to 20.8) paratubal cysts 3 (4.9%; 1.4 to 14.5) paraovarian cysts	Size of population from which sample drawn: + (multiple sites) Number of cases: - (no cancers; wide Cls) Patient selection: - (limited to benign-appearing cystic masses) Application of reference standard: + (all had biopsy)
Roman, Muder- spach, Stein, et al., 1997 #6160	Geographical location: Los Angeles, CA Dates: Jul 1992-Mar 1994 Size of population: 226 Other: Prospective study of women scheduled for removal of pelvic mass; included women with pregnancy	Age: NR Menopausal status (n [%]): Pre (< 45): 181 (80%) Post (> 55): 45 (20%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Of the 226 enrolled: 26/226 were malignant = 11.5%; 95% Cl, 8.0 to 16.5 17/226 borderline tumors = 7.5%; 4.8 to 11.9 183/226 were benign = 81%; 76.1 to 86.2 Malignant: Epithelial cancer 15 = 6.6%; 95% Cl, 4.1 to 10.9 Germ cell cancer 4 = 1.8%; 0.6 to 4.7 Stromal cancer 6 = 2.7%; 1.1 to 5.9 Sarcoma 1 = 0.4%; 0 to 2.8 Borderline tumors: LMP 17 = 7.5%; 95% Cl, 4.8 to 11.9 Benign: Simple or functional cyst 46 = 20.4%; 95% Cl, 15.8 to 26.3 Inflammatory process 18 = 8.0%; 5.1 to 12.4 Endometrioma 32 = 14.2%; 10.3 to 19.5 Leiomyoma 11 = 4.9%; 2.7 to 8.7 Fibroma-thecoma 6 = 2.7%; 1.1 to 5.9 Cystadenoma 35 = 15.5%; 11.5 to 21 Cystadenofibroma 3 = 1.3%; 0.3 to 4.1	Comments: Clinical presentation not described Patients underwent surgery; malignancy likely overrepresented Included women with pregnancy Age range NR, but 80% reported to be premenopausal Quality assessment: Size of population from which sample drawn: - (unknown) Number of cases: - (226) Patient selection: + (prospectively collected information among women already scheduled for surgery) Application of reference standard: + (all had biopsy)
Schneider, Schneider, Reed, et al., 1993	Geographical location: Tucson, AZ Dates:	Age: Mean: 53 Median: 53 Range: 10-79	Symptomatic (n [%]): NR Detected by exam (n [%]):	Of the 55 enrolled: 14/55 were malignant = 25.5%; 95% CI, 16.6 to 39.5 2/55 were borderline tumors = 3.6%; 0.5	Comments: Clinical presentation not described Patients underwent surgery and therefore malignancy likely to be

Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
NR; published 1993	Monopousal status	NR	to13.5	over-represented
Size of population:	•	Detected by imaging	39/33 were benigh 70.9%, 00.3 to 83.4	Quality assessment:
			Malignant:	Size of population from which
	Post (> 55): 33 (60%)	NR	Endometriod cancer 6 = 10.9%; 95% CI, 5.2	
Other:			to 22.9	Number of cases: - (55)
Patients undergoing	Race/ethnicity (n [%]):	Combination (n [%]):	Adenocarcinoma, undifferentiated 3 = 5.5%;	
surgery for adnexal mass	NR	NR		Application of reference standard: +
				(all had biopsy)
	· · · ·			
	NK			
			Leiomyosarcoma 1 = 1.8%; 0 to 11	
			Borderline tumors (LMP):	
			Serous cystadenocarcinoma 2 = 3.6%; 95%	
			Cl, 0.5 to13.5	
			Benign:	
			Brenner tumor 1 = 1.8%; 0 to 11	
			Corpus luteum cyst 1 = 1.8%; 0 to 11	
			,	
			,	
			Peritoneal inclusion cyst $1 = 1.8\%$; 0 to 11	
	Size of population: 55 Other: Patients undergoing	Size of population: Menopausal status (n [%]): 55 Pre (< 45): 22 (40%) Post (> 55): 33 (60%) Other: Post (> 55): 33 (60%)	Size of population: 55Menopausal status (n [%]): Pre (< 45): 22 (40%) Post (> 55): 33 (60%)Detected by imaging (n [%]): NROther: Patients undergoing surgery for adnexal massRace/ethnicity (n [%]): NRCombination (n [%]): NRRisk factors (n [%]):Additional data used for	Menopausal status (n [%]): Post (> 55): 33 (60%)Detected by imaging (n [%]): NR39/55 were benign 70.9%; 60.5 to 83.4Other: Patients undergoing surgery for adnexal massRace/ethnicity (n [%]): NRNRMalignant: Endometriod cancer 6 = 10.9%; 95% Cl, 5.2 to 22.9Additional data used for diagnosis: NRAdditional data used for diagnosis: NRCombination (n [%]): NRAdditional data used for diagnosis: NRNRMalignant Brenner tumor 1 = 1.8%; 0 to 11 Uear-cell adenocarcinoma 2 = 3.6%; 95% Cl, 0.5 to 13.5Borderline tumors (LMP): Serous cystadenoma 12 = 21.8%; 95% Cl, 1.5 to 16 Adenotion at 3 = 5.5%; 1.5 to 16 Adenotion at 1 = 1.8%; 0 to 11 Brenner tumor 1 = 1.8%; 0 to 11 Brenos Cystadenoffbrom at = 1.8%; 0 to 11 Brenos Cystadenoffbrom at = 1.8%; 0 to 11 Brenos Cystadenoffbrom at = 1.8%; 0 to 11 Brenos C

Scoutt, McCarthy, Lange, et	Geographical location: Connecticut	Age: Median: 40 Range: 2-87	Symptomatic (n [%]): NR	Benign: 87/109 (79.8%; 95% Cl, 72.8 to 87.5) 17 (15.6%; 10.2 to 24.1) leiomyoma	Comments: Clinical presentation not described
al., 1994	Dates: 1988-1990	Menopausal status	Detected by exam (n [%]): NR	19 (17.4%; 11.7 to 26.1) dermoid 13 (11.9%; 7.2 to 19.8) endometrioma	Quality assessment: Size of population from which

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
#4530		(n [%]):		9 (8.3%; 4.4 to 15.4) hemorrhagic cysts	sample drawn: - (1 hospital)
	Size of population:	NR	Detected by imaging	9 (8.3%; 4.4 to 15.4) simple cysts	Number of cases: - (wide Cls)
	109 masses with MRI		(n [%]):	5 (4.6%; 1.8 to 10.8) serous cystadenoma	Patient selection: - (suspected mass
		Race/ethnicity (n [%]):	ŇR	3 (2.7%; 0.7 to 8.3) mucinous cystadenoma	who had MRI)
	Other	NR		3 (2.7%; 0.7 to 8.3) friboma	Application of reference standard: +
	Clinical masses that		Combination (n [%]):	3 (2.7%; 0.7 to 8.3) tuboovarian abscess	(all had biopsy)
	underwent MRI and then	Risk factors (n [%]):	109 (100%)	3 (2.7%; 0.7 to 8.3) paratubal cyst	
	biopsy	NR		1 (0.9%; 0 to 5.7) fibrothecoma	
			Additional data used for	1 (0.9%; 0 to 5.7) leutinized thecoma	
			diagnosis:	1 (0.9%; 0 to 5.7) hematosalpinx	
			NR		
				Malignant: 22/109 (20.2%; 95% CI, 14 to	
				29.2)	
				5 (4.6%; 1.8 to 10.8) papillary serous	
				cystadenocarcinoma	
				4 (3.7; 1.2 to 9.6%) metastatic	
				adenocarcinoma	
				3 (2.7%; 0.7 to 8.3) mucinous	
				cystadenocarcinoma	
				3 (2.7%; 0.7 to 8.3) endometroid carcinoma	
				2 (1.8%; 0.2 to 7.0) adenocarcinoma	
				1 (0.9%; 0 to 5.7) immature teratoma	
				1 (0.9%; 0 to 5.7) embryonal cell carcinoma	
				1 (0.9%; 0 to 5.7) dysgerminoma	
				1 (0.9%; 0 to 5.7) granulosa cell tumor	
				1 (0.9%; 0 to 5.7) endometrial carcinoma	

Shen- Gunther and	Geographical location: Las Vegas, NV;	Age: Median: 58	Symptomatic (n [%]) : NR	Benign: 57/125 (45.6%; 95% Cl, 37.8 to 55.1)	Comments: Large proportion of subjects had
Mannel,	Oklahoma City, OK	Range: 18-86		22 (17.6%; 12.1 to 25.6) serous	ascites on exam or imaging – very
2002	-	-	Detected by exam (n [%]):	cystadenoma	high prevalence of malignancy
	Dates:	Menopausal status	6%	3 (2.4%; 0.6 to 7.3) mucinous cystadenoma	
#2090	Jan 1994-Dec 1994 and	(n [%]):		4 (3.2%; 1.1 to 8.4) friboma	Quality assessment:

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Jan 1999-Dec 2001 Size of population: 125 Other Patients treated for pelvic mass	NR Race/ethnicity (n [%]): White 82% Black 9% Hispanic 2% Asian 4% American Indian 3% Risk factors (n [%]): NR	Detected by imaging (n [%]): Ultrasound 46% CT 18% Both 31% Combination (n [%]): NR Additional data used for diagnosis: NR	2 (1.6%; 0.1 to 6.2) thecoma 5 (4%; 1.6 to 9.4) teratoma 5 (4%; 1.6 to 9.4 follicular cyst 1 (0.8%; 0 to 5) paratubal cyst 5 (4%; 1.6 to 9.4 hemorrhagic cysts 2 (1.6%; 0.1 to 6.2) tuboovarian adhesions 8 (6.4%; 3.2 to 12.5) endometrioma Borderline (LMP): 12/125 (9.6%; 95% CI, 5.6 to 16.4) 8 (6.4%; 3.2 to 12.5) serous low malignant potential 4 (3.2%; 1.1 to 8.4) mucinous low malignant	Size of population from which sample drawn: + (2 cities) Number of cases: - (wide Cls) Patient selection: - (2 separate time frames introduces bias; also high prevalence of ascites) Application of reference standard: + (all had biopsy)
				 A (0.2.%, 1.1 to 0.4) indentous four manipitant potential Malignant: 56/125 (44.8%; 37.1 to 54.3) 39 (31.2%; 24.2 to 40.3) serous cystadenocarcinoma 2 (1.6%; 0.1 to 6.2) mucinous cystadenocarcinoma 4 (3.2%; 1.1 to 8.4) endometroid carcinoma 4 (3.2%; 1.1 to 8.4) primary peritoneal carcinoma 2 (1.6%; 0.1 to 6.2) clear cell carcinoma 1 (0.8%; 0 to 5) undifferentiated adenocarcinoma 2 (1.6%; 0 to 5) immature teratoma 	
				Stage 1 = 11 Stage 2 = 1 Stage 3 = 33 Stage 4 = 5 Unstaged = 6	

Smikle, Lunt, and Hankins,	Geographical location: San Antonio, TX	Age: Range: < 20 and > 61	Symptomatic (n [%]) : NR	Benign: 169/195 (86.7%; 95% Cl, 82.1 to 95.0) 37 (19.0%; 14.3 to 25.3) serous	Comments: Clinical presentation not described
1995	Dates:	Menopausal status	Detected by exam (n [%]):	cystadenoma	Quality assessment:
	Jun 1990-Aug 1992	(n [%]):	NR	11 (5.6%; 3.2 to 10.1) mucinous	Size of population from which
#6290		Pre (< 45): NR		cystadenoma	sample drawn: - (military hospital)
	Size of population:	Peri (45-55): NR	Detected by imaging	26 (13.3%; 9.4 to 19.1) hemorrhagic cysts	Number of cases: - (26 cancers and

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	195 Other Surgical cases with preoperative diagnosis of pelvic mass	Post (> 55): 78 (40%) 51 and older Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	(n [%]): NR Combination (n [%]): 195 (100%) Additional data used for diagnosis: NR	20 (10.3%; 6.8 to 15.6) endometriosis 17 (8.7%; 5.5 to 13.8) teratoma (mature) 7 (3.6%; 1.7 to 7.6) cyst of Morgagni Data not provided for 27 cases Malignant: 26/195 (13.3%; 95% Cl, 9.4 to 19.1) 14 (7.2%; 4.3 to 11.9) serous cystadenocarcinoma 5 (2.6%; 1.0 to 6.3) mucinous cystadenocarcinoma 1 (0.5%; 0 to 3.2) endometroid carcinoma 4 (2.1%; 0.7 to 5.4) undifferentiated adenocarcinoma 1 (0.6%; 0 to 3.2) granulosa cell carcinoma 4 (2.1%; 0.7 to 5.4) undifferentiated adenocarcinoma 1 (0.6%; 0 to 3.2) granulosa cell carcinoma Benign mass by age: Age \leq 50 (n = 117) Serous cystadenoma: 19 (16.2%; 95% Cl, 10.9 to 24.4) Functional cyst: 20 (17.1%; 11.6 to 25.4) Hydrosalpinx/tuboovarian abscess: 18 (15.4%; 10.1 to 23.5%) Endometriosis: 16 (13.7%; 8.7 to 21.5) Mature teratoma: 11 (9.4%; 5.4 to 16.5) Mucinous cystadenoma: 3 (2.6%; 0.6 to 7.8) Cyst of Morgagni: 4 (3.4%; 1.1 to 8.9) Age $>$ 50 (n = 78) Serous cystadenoma: 18 (23.1%;15.6 to 34.4) Functional cyst: 6 (7.7%; 3.5 to 16.5) Hydrosalpinx/ tuboovarian abscess: 5 (6.4%; 2.6 to 14.9) Endometriosis: 4 (5.1%; 1.8 to13.2) Mature teratoma: 6 (7.7%; 3.5 to 16.5) Mucinous cystadenoma: 8 (10.3%; 5.3 to 19.7) Cyst of Morgagni: 3 (3.9%; 1.0 to 11.5%)	wide CIs) Patient selection: - (all surgical cases) Application of reference standard: + (all had biopsy)
Troiano, Quedens- Case, and Taylor, 1997	Geographical location: New Haven, CT 7 Dates: 1991-1996	Age: Mean: Approx. 45 Range: 18-79 Menopausal status	Symptomatic (n [%]): NR Detected by exam (n [%]): 100% suspected mass on	Malignant: 17/144 = 11.8%; 95% Cl, 7.6 to 18.4 Serous cystadenocarcinoma 7 = 4.9%; 2.3 to 10 Mucinous cystadenocarcinoma 1 = 0.7%; 0	Comments: Not all subjects went to surgery; better generalizability, but possible error in diagnosis

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
#3680	Size of population: 144 patients Other Patients with suspected mass on exam and referred for US; not all went on to surgery, but all had followup	(n [%]): Pre (< 45): 101 (70%) Post (> 55): 42 (29%) Missing 1 case Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	exam Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	to 4.3 Endometrioid carcinoma 1 = 0.7%; 0 to 4.3 Embryonal cell carcinoma 1 = 0.7%; 0 to 4.3 Granulosa cell 1 = 0.7%; 0 to 4.3 Fallopian tube carcinoma 1 = 0.7%; 0 to 4.3 Endometrial 1 = 0.7%; 0 to 4.3 Metastatic 4 = 2.8%; 0.9 to 7.3 Borderline tumors 3/144 = 2.1%; 0.5 to 6.3 Borderline papillary serous 3 = 2.1%; 0.5 to 6.3 Benign: 97/144 = 67.4%; 95% Cl, 60.3 to 75.3 Serous cystadenoma 1 = 0.7%; 0 to 4.3 Mucinous cystadenoma 3 = 2.1%; 0.5 to 6.3 Functional ovarian cyst 3 = 2.1%; 0.5 to 6.3 Paratubal cyst 4 = 2.8%; 0.9 to 7.3 Ovarian dermoid cyst 4 = 2.8%; 0.9 to 7.3 Fibroma or thecoma 2 = 1.4%; 0.1 to 5.4 Cystadenofibroma 1 = 0.7%; 0 to 4.3 Endometriosis or hemorrhagic cyst 16 = 11.1%; 7 to 17.6 Leiomyomas or adenomyosis 43 29.9%; 23.4 to 38.3 Leiomyomas with endometriosis 6 = 4.2%; 1.8 to 9.1 Leiomyomas with paratubal cyst 1 = 0.7%; 0 to 4.3 Leiomyomas with paratubal cyst 1 = 0.7%; 0 to 4.3 Leiomyomas with paratubal cyst 1 = 0.7%; 0 to 4.3 Leiomyomas with ovarian fibroma 1 = 0.7%; 0 to 4.3 Leiomyomas with ovarian cystadenoma 2 = 1.4%; 0.1 to 5.4 Cirrhosis 1 = 0.7%; 0 to 4.3 Pregnancy 1 = 0.7%; 0 to 4.3 Pregnancy 1 = 0.7%; 0 to 4.3 No biopsy because ultrasound negative: 27 = 18.7%; 95% Cl, 13.4 to 26.3	Number of cases: - (wide CIs) Patient selection: + (better than the others – all with suspected mass on exam) Application of reference standard: + (not all had biopsy, but all had followup)
Twickler, Forte, Santos-	Geographical location: Dallas, TX	Age: Mean: 38.6 Range: 15-80	Symptomatic (n [%]) : NR	Malignant: 14/244 = 5.7%; 95% Cl, 3.4 to 9.6 Serous 4 = 1.6%; 0.5 to 4.4	Comments: Not all subjects went to surgery; better generalizability, but more

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Ramos, et	Dates:		Detected by exam (n [%]):	Metastasis 4 = 1.6%; 0.5 to 4.4	possibility of error
al., 1999	Feb 1993-Aug 1996	Menopausal status	NR	Adenocarcinoma 2 = 0.8%; 0.05 to 3.2	
		(n [%]):		Mucinous 1 = 0.4%; 0 to 2.6	Quality assessment:
#3080	Size of population:	NR	Detected by imaging	Small cell 1 = 0.4%; 0 to 2.6	Size of population from which
	244 women		(n [%]):	Sarcoma 1 = 0.4%; 0 to 2.6	sample drawn: - (not known)
		Race/ethnicity (n [%]):	NR	Mixed germ cell 1 = 0.4%; 0 to 2.6	Number of cases: +
	Other	NR			Patient selection: - (not clear)
	304 had ultrasound for		Combination (n [%]):	Borderline tumors: 16/244 = 6.6%; 95%	Application of reference standard: ·
	mass, and 217 had	Risk factors (n [%]):	NR	Cl, 4.1 to 10.6	(not all had biopsy and some were
	surgery and another 27	NR		Mucinous 8 = 3.3%; 1.6 to 6.5	lost to followup)
	had ultrasound followup,		Additional data used for	Serous 5 = 2%; 0.8 to 4.9	
	for a total of 244		diagnosis:	Granulosa cell 2 = 0.8%; 0.05 to 3.2	
			NR	Endometrioid 1 = 0.4%; 0 to 2.6	
				Benign: 214/244 = 87.7%; 83.7 to 91.9	
				Simple functional cyst 69 = 28.3%; 23.2 to	
				34.5	
				PID mass 25 = 10.2%; 7.1 to 14.9	
				Endometriomas 13 = 5.3%; 3.1 to 9.1	
				No ovarian mass 7 = 2.9%; 1.3 to 6	
				Non-defined ovarian cystic disease 8 =	
				3.3%; 1.6 to 6.5	
				Para-ovarian cyst 1 = 0.4%; 0 to 2.6	
				Paratubal cyst 1 = 0.4%; 0 to 2.6	
				Fibrovascular ampullary mass 1 = 0.4%; 0 to	
				2.6	
				Ectopic mass 1 = 0.4%; 0 to 2.6	
				Ovarian lymphocele 1 = 0.4%; 0 to 2.6	
				Peritoneal cyst 1 = 0.4%; 0 to 2.6	
				Mesonephric cyst 1 = 0.4%; 0 to 2.6	
				Dermoid/cystic teratoma 35 = 14.3%; 10.6 to	
				19.5	
				Serous cystadenoma 19 = 7.8%; 5.1 to 12	
				Cystadenofibroma 13 = 5.3%; 3.1 to 0.1	
				Mucinous cystadenoma $7 = 2.9\%$; 1.3 to 6	
				Cystadenoma (unspecified) $3 = 1.2\%$; 0.3 to	
				3.8	
				Fibroma 2 = 0.8%; 0.05 to 3.2	
				Fibrothecoma $1 = 0.4\%$; 0 to 2.6	
				Seromucinous $1 = 0.4\%$; 0 to 2.6	
				Other $4 = 1.6\%$; 0.5 to 4.4	
	O a survey bis a bis a fi	A	O		0
van Nagell	Geographical location:		Symptomatic (n [%]):	Benign: 155/14,469 (1.1%; 95% CI, 0.9 to	Quality assessment:
Jr.,	Kentucky	Mean (SD): 54.7 (10.7)	0		Size of population from which
DePriest,		Range: 25-92	_	78 (0.5%; 0.4 to 0.7) serous cystadenomas	sample drawn: + (screening study)
Reedy, et	Dates:		Detected by exam (n [%]):	25 (0.2%; 0.1 to 0.3) endometriomas	Number of cases: + (large screenin

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
al., 2000	1987-1999	Menopausal status (n [%]):	3/17 cancers were palpated on exam but not detected on	10 (0.07%; 0.04 to 0.1) mucinuos cystadenomas	study with narrow CIs) Patient selection: - (most with family
#2730	Size of population: 17 cancers/14,469 (actually 3 were borderline)	All ≥ 50 or ≥ 25 with family history Race/ethnicity (n [%]): NR	exam Detected by imaging (n [%]): 100% had TVUS	11 (0.08%; 0.04 to 0.1) cystic teratomas 13 (0.09%; 0.05 to 0.2) fibroma/thecoma 4 (0.03%; 0.01 to 0.07) leiomyoma 14 (0.1%; 0.06 to 0.2) hydrosaplinx/ paratubal cyst	history) Application of reference standard: + (all with abnormal TVUS had biopsy)
	Screening study (most had positive family history; 180 had a biopsy)	Risk factors (n [%]): Family history of: Ovarian cancer: 23% Breast cancer: 34% Colon cancer: 23%	Combination (n [%]): NR Additional data used for diagnosis: NR	Borderline (LMP): 3/14,469 (0.02%; 95% Cl, 0 to 0.06) All 3 serous low malignant potential Malignant: 14/14469 (0.1%; 95% Cl, 0.06 to 0.2) 1 (0.01%; 0 to 0.04) serous cystadenocarcinoma 1 (0.01%; 0 to 0.04) mucinous cystadenocarcinoma 3 (0.02%; 0 to 0.06) endometroid carcinoma 6 (0.04%; 0.02 to 0.09) undifferentiated adenocarcinoma 3 (0.02%; 0 to 0.06) granulosa cell carcinoma	

Vasilev, Schlaerth, Campeau, et	Geographical location: Los Angeles, CA	Age: NR	Symptomatic (n [%]) : NR	Malignant: 15/182 = 8.2%; 95% Cl, 5.1 to 13.4 Serous cystadenocarcinoma 4 = 2.2%; 0.7	Comments: 8 of 10 masses in women over 50 were malignant
al., 1988 #6770	Dates: Apr 1984-Feb 1986	Menopausal status (n [%]): NR	Detected by exam (n [%]): NR	to 5.8 Mucinous cystadenocarcinoma 2 = 1.1%; 0.1 to 4.3	Selection criteria for inclusion in series not included
	Size of population: 182 non-consecutive patients with pelvic mass	Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	Endometrioid carcinoma 1 = 0.5%; 0 to 3.4	Quality assessment: Size of population from which sample drawn: -
	Other	Risk factors (n [%]):	Combination (n [%]):	Gastric Krukenberg tumor 1 = 0.5%; 0 to 3.4 Hypernephroma 1 = 0.5%; 0 to 3.4	Number of cases: - Patient selection: - (all had mass)

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Non-consecutive series of patients scheduled for	NR	NR	Lymphoma 1 = 0.5%; 0 to 3.4 Melanoma 1 = 0.5%; 0 to 3.4	Application of reference standard: - (not all had biopsy)
	surgery for adnexal mass	diag	Additional data used for diagnosis: NR	Uterine leiomyosarcoma 3 = 1.6%; 0.4 to 5	· · · ·
			INIX	Borderline tumors 3/182 = 1.6%; 95% Cl,	
				0.4 to 5	
				Serous low malignant potential $1 = 0.5\%$; 0	
				to 3.4 Mucinous low malignant potential 2 = 1.1%;	
				0.1 to 4.3	
				Benign: 164/182 = 90.1%; 95 % Cl, 85.9 to 94.5	
				Adhesions complex $2 = 1.1\%$; 0.1 to 4.3	
				Paratubal cysts 6 = 3.3%; 1.4 to 7.3	
				Ectopic pregnancy 2 = 1.1%; 0.1 to 4.3	
				Acute salpingitis $12 = 6.6\%$; 3.8 to 11.4	
				Chronic salpingitis 3 = 1.6%; 0.4 to 5	
				Serous cystadenoma 9 = 4.9%; 2.6 to 9.4	
				Mucinous cystadenoma $4 = 2.2\%$; 0.7 to 5.8	
				Benign cystic teratoma 13 = 7.1%; 4.2 to 12.1	
				Fibroma $2 = 1.1\%$; 0.1 to 4.3	
				Brenner tumor 1 = 0.5%; 0 to 3.4	
				Endometrioma 5 = 2.7%; 1.1 to 6.5	
				Simple ovarian cyst 2 = 1.1%; 0.1 to 4.3	
				Leiomyoma 71 = 39%; 32.6 to 46.7	
				adenomyosis $9 = 4.9\%$; 2.6 to 9.4	
				Leiomyomas with endometriosis 2 = 1.1%; 0.1 to 4.3	
				Leiomyomas with adenomyosis 8 = 4.4%;	
				2.2 to 8.7	
				Leiomyomas with chronic salpingitis 5 =	
				2.7%; 1.1 to 6.5	
				Leiomyomas with endometriosis and adenomyosis 1 = 0.5%; 0 to 3.4	
				Leiomyomas with Brenner tumor and	
				mucinous cystadenoma $1 = 0.5\%$; 0 to 3.4	
				Leiomyomas with serous cystadenoma 1 =	
				0.5%; 0 to 3.4	
				Leiomyomas with adenomyosis and chronic	
				salpingitis 2 = 1.1%; 0.1 to 4.3 Leiomyomas with endometriosis and chronic	
				salpingitis $1 = 0.5\%$; 0 to 3.4	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Leiomyomas and salpingitis and paratubal cyst $1 = 0.5\%$; 0 to 3.4 Cystadenofibroma and Leiomyoma and endometriosis $1 = 0.5\%$; 0 to 3.4	

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Adonakis, Para- skevaidis, Tsiga, et al., 1996 #810	Geographical location: Greece Dates: Mar 1991-Jun 1993 Size of population: 2000 Screening study Reference standard: US if BME abnormal or ambiguous; surgery if US positive; 12-month CA-125 if negative Reference standard applied to all test negatives?: Yes Test reliability established?: No; performed by 3 gynecological oncologists Statistical tests used: Se, Sp Blinding: Yes Definition of positive and negative on screening test: Positive exam: palpable adnexal mass	Menopausal status (n [%]): Pre: 405 (20%) Peri: 293 (15%) Post: 1302 (65%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Women > 45, no evidence of adnexal pathology, agreed to participate Exclusion criteria: History of ovarian cancer or any other malignancy, history of bilateral oophorectomy, ascites	Symptomatic (n [%]): 0 (0%) Detected by exam (n [%]): 50 (3%) positive exam 115 (6%) "ambiguous" exam Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: Women with elevated CA-125 or and abnormal or ambiguous BME were recalled for TVUS. Only women with +TVUS were referred for further management	Screening study	1) Benign vs. malignant: T+ Dis+ Dis- Tot 59 T- 1 1940 1941 Tot 3 1997 2000 <u>Lower Upper</u> <u>Value 95% CI 95% CI</u> Se 66.7% 13.3% 100.0% Sp 97.1% 96.4% 97.9% PPV 3.4% 0.0% 8.0% NPV 99.9% 99.8% 100.0%	Comments: 1 tumor LMP grouped in with 2 other malignancies "Ambiguous" BME was classed as Test -, although all patients with ambiguous BME had TVUS to further evaluate Borderline tumors considered Dis+ Quality assessment: Reference standard: + (followup with CA-125 at 12 months reasonable for screening study) Verification bias: + (all test negatives had 12-month CA 125) Test reliability/variability: - Sample size: + Statistical tests: + Blinding: + Definition of +/- on screening test: - ("palpable" not precise)

Evidence Table 2: Question 2: What are the sensitivity, specificity, and reliability of the bimanual pelvic examination?

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Andolf, Jorgensen, and Astedt, 1990 #1200	Geographical location: Sweden Dates: Oct 1984-Jul 1987 Size of population: 801 Screening study For women at high risk for ovarian cancer Reference standard: All had US and some had biopsies Reference standard applied to all test negatives?: No Test reliability established?: No Statistical tests used: None Blinding: NR Definition of positive and negative on screening test: NR	Risk factors (n [%]): Family history: 190 (23.7%) Inclusion criteria: Women older than 40	Symptomatic (n [%]): 419 (52.3%) Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	One gynecologist clinical examiner, and then a midwife did the US	1) Abnormal vs. normal US: T+ Dis+ Dis- Tot 106 55 51 106 695 Tot 163 638 801 Value 95% Cl 95% Cl 95% Cl 9	Comments: US by midwife and not a radiologist; only 30 abnorma scans went on to surgery 2 endometrial carcinomas and 1 borderline ovarian tumor Quality assessment: Reference standard: - (all had US and not all had biopsy) Verification bias: - Test reliability/variability: - Sample size: - (no ovarian cancer) Statistical tests: - Blinding: - (not stated) Definition of +/- on screening test: -

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Balbi, Musone, Menditto, et al., 2001 #2320	Geographical location: Naples, Italy Dates: Jan 1996-Mar 2000 Size of population:	Menopausal status (n [%]): NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR	Women with pelvic mass prior to surgery. Physical exam by standard protocol. Examiner was asked to predict benign or malignant.	1) Benign vs. malignant: T+ Dis- Tot T- 2 37 39 Tot 22 50 72	Comments: 20 patients excluded for reasons that seem to indicate there wasn't blinding Vague definition of PE Although RI measured, not included in definition of +US
	92 Case series Reference standard: Histopathological diagnosis Reference standard applied to all test negatives?: No – 18 women with "clearly benign" masses not verified; 2 patients with "clearly malignant" disease (metastases) also excluded Test reliability established?: Not for PE or CA-72-4 Uncertain for US and RI Yes for CA-125	Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: "Women with a pelvic mass originating in the ovary" Exclusion criteria: NR	Combination (n [%]):		Lower Upper 95% CI 95% CI 95 95% CI 95 74.0% 61.8% 86.2% PPV 60.6% 43.9% NPV 94.9% 87.9% 100.0%	Quality assessment: Reference standard: + Verification bias: - ("clearly benign" excluded) Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: - (definition of "clinical impression" not provided)
	Statistical tests used: Se, Sp, multivariate logistic analysis					
	Blinding: NR Definition of positive					
	and negative on screening test: PE: "malignant clinical impression"					

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Buckshee, Temsu, Bhatla, et al., 1998 #710	Geographical location: India Dates: May 1995-Apr 1997 Size of population: 34 non-consecutive women with 36 tumors Other: Women scheduled for surgery for adnexal mass Reference standard: Biopsy Reference standard applied to all test negatives?: Yes Test reliability established?: No Statistical tests used: McNemar test Blinding: Yes Definition of positive and negative on screening test: Yes Clinical diagnosis- benign vs. malignant	(n [%]): Pre (< 45): NR Peri (45-55): NR Post (> 55): 5 > 50	Symptomatic (n [%]): NR Detected by exam (n [%]): 10 (2.8%) Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	One gynecologist clinical examiner	1) Malignant vs. benign: T+ Dis+ Dis- Tot T- 2 24 26 Tot 9 27 36 Value 95% Cl 95% Cl Se 77.8% 50.6% 100.0% Sp 88.9% 77.0% 100.0% PPV 70.0% 41.6% 98.4% NPV 92.3% 82.1% 100.0%	Quality assessment: Reference standard: + (all had biopsy) Verification bias: + Test reliability/variability: - Sample size: - (small study) Statistical tests: + Blinding: + (yes) Definition of +/- on screening test: - (not very specific; essentially a clinical impression of benign vs. malignant)

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Dowd, Quinn, Rome, and Koh, 199 #4680	Geographical Iocation: Melbourne, Australia Dates: 1978-1989 Size of population: 264 (n = 225 with definite clinical impression) Case series Reference standard: Pathology Reference standard applied to all test negatives?: Yes Test reliability established?: Not referenced or measured Statistical tests used: Se, Sp, NPV, PPV Blinding: No Definition of positive and negative on screening test: "Mass described as 'hard, irregular, fixed, attached to other structures', or associated with ascites, or a specific statement from a consultant gynaecologist of the suspected malignant nature of the mass"	Age: Mean: 47 Range: 15-89 Menopausal status (n [%]): Pre (< 45): 78 (61%) Peri (45-55): Post (> 55): 50 (39%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Suspected pelvic mass, CA-125 level available Exclusion criteria: Screening, inadequate documentation of clinical findings of pathology	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Not described; presumably, in outpatient setting	 Benign vs. malignant - all patients: Dis+ Dis- Tot Tot	Comments: Examiners not blinded to history, possibly other findings High prevalence of malignancy History not provided; unclear how many subjects were symptomatic Quality assessment: Reference standard: + Verification bias: - Test reliability/variability: - Sample size: + (but confidence intervals not given) Statistical tests: + Blinding: - Definition of +/- on screening test: - (definitions not explicit)

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Finkler, Benacerraf, Lavin, et al., 1988 #1230	Geographical location: Boston, MA Dates: Nov 1986-Apr 1987 Size of population: 106 Other: Consecutive patients with adnexal mass scheduled for surgery Reference standard Biopsy Reference standard applied to all test negatives?: Yes Test reliability established?: No Statistical tests used: Fisher's exact test Blinding: NR Definition of positive and negative on screening test: Clinicians asked to judge the clinical appearance of the mass based on history and physical exam combined	Age: Mean: 45.2 Range: 17-84 Menopausal status (n [%]): Pre (< 45): 74 (69.8%) Post (> 55): 32 (30.2%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Adnexal mass scheduled for surgery Exclusion criteria: US unavailable or uninterpretable; pregnancy; known cancer	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	One gynecologist examiner who gave his/her verbal clinical impression before surgery	1) Total study - clinical impression is test, and malignant (yes/no) is disease state: $\frac{1}{1} + \frac{16}{21} + \frac{16}{59} + \frac{16}{59} + \frac{12}{22} + \frac{16}{59} + \frac{16}{102} + \frac{12}{21} + \frac{16}{59} + \frac{16}{50} + \frac{12}{22} + \frac{12}{59} + \frac{10}{59} + \frac{10}{50} + \frac$	Comments: Definition of a positive physical examination is the "impression of clinical exam" that includes history Quality assessment: Reference standard: + (all had biopsy) Verification bias: - Test reliability/variability: - Sample size: - (small study) Statistical tests: - Blinding: - (not stated) Definition of +/- on screening test: - ("impression of clinical exam" that includes history)

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Grover and Quinn, 1995 #830	Geographical location: Melbourne, AustraliaDates: NRDates: NRSize of population: 2623Screening study Healthy volunteersReference standard: US if mass or elevated CA-125 Surgery or 12-month followup questionnaireReference standard applied to all test negatives?: Yes – 12-month followup questionnaire for allTest reliability established?: No; single examinerStatistical tests used: 	Age: Mean: 51 Range: 25-92 Menopausal status (n [%]): Pre (< 45): 1121 (43%) Peri (45-55): 384 (15%) Post (> 55): 1118 (42%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Asymptomatic, recruited (not clear how) Exclusion criteria: NR	Symptomatic (n [%]): 0 (0%) Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Single examiner	1) All women: 1 Dis+ Dis- Tot 1 2582 2583 Tot 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2623 1 2622 2633 1 2622 2633 1 2620 253 1 2620 253 1 2620 253 1 2620 253 1 2620 253 1 260 39.9% 1 200 99.9% 1 200 99.9% 1 200 99.9% 1 200 <t< td=""><td>Comments: Single examiner; interobserver variability not an issue 83% followup at 1 year 1 malignancy in patient with normal exam, US, elevated CA-125; menopausal status not reported Prevalence of abnormal adnexae 1.8% in pre-, 1% in peri-, and 1.4% in postmenopausal women Normal US in 37.5% of post-, 50% pre- and perimenopausal women Benign ovarian disease in 20% pre-, 25% peri-, 25% postmenopausal women Benign ovarian disease in 20% pre-, 25% postmenopausal women</td></t<>	Comments: Single examiner; interobserver variability not an issue 83% followup at 1 year 1 malignancy in patient with normal exam, US, elevated CA-125; menopausal status not reported Prevalence of abnormal adnexae 1.8% in pre-, 1% in peri-, and 1.4% in postmenopausal women Normal US in 37.5% of post-, 50% pre- and perimenopausal women Benign ovarian disease in 20% pre-, 25% peri-, 25% postmenopausal women Benign ovarian disease in 20% pre-, 25% postmenopausal women

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Jacobs, Stabile, Bridges, et al., 1988 #6830	Geographical location: London, UK Dates: Patients recruited over a 6- month period; published 1988 Size of population: 1010 women Screening study Reference standard: Biopsy or 12-month followup Reference standard applied to all test negatives?: All had followup, and a few had biopsy Test reliability	Age: Mean: 54 Range: 45-83 Menopausal status (n [%]): Post (> 55): 1010 (100%) Race/ethnicity (n [%]): NR Risk factors (n [%]): 18 (1.8%) had history of breast cancer Inclusion criteria: Age over 45 and postmenopausal Exclusion criteria: History of ovarian cancer or undergoing	Presentation Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	One clinical examiner	1) Abnormal US as gold standard: T+ T- T- Tot Tot Tot Tot Tot Tot Tot Tot	Comments: "Palpable pelvic mass of any size that could be clinically distinguished as being separate from the uterus and Gl tract" Quality assessment: Reference standard: + (biopsy and/or 12-month followup) Verification bias: Test reliability/variability: Sample size: - (one cancer) Statistical tests: + Blinding: - (not stated) Definition of +/- on screening test: - (palpable pelvic mass of any size)
	established?: No Statistical tests used: Chi-square	treatment for other cancer; history of bilateral oophorectomy			Se 100.0% 0.0% 100.0% Sp 97.3% 96.3% 98.3% PPV 3.6% 0.0% 10.4% NPV 100.0% 99.7% 100.0%	
	Blinding: NR					
	Definition of positive and negative on screening test: "Palpable pelvic mass of any size that could be clinically distinguished as being separate from the uterus and GI tract"					

Study	Study Design	Patients	Clinical Clinical Setting of Presentation Exam		Results	Comments/Quality Scoring	
Ong, Duffy, and Murphy, 1996	Geographical location: Dublin, Ireland	Age: NR	Symptomatic (n [%]): NR	One gynecologist examiner	 Ovarian mass yes/no by Dis+ Dis- 	US: Tot	Comments: Separates the Se/Sp for detection of uterine mass
#780	Dates: Jan 1993-Feb 1995 Size of population: 86 undergoing laparotomy Other:	Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]):	enopausal status [%]): Detected by exam (n [%]): NR nce/ethnicity [%]): Detected by (maging (n [%]): NR		T+ 46 9 T- 18 13 Tot 64 22 Lower Value 95% Cl Se 71.9% 60.9% Sp 59.1% 38.5% PPV 83.6% 73.9%	55 31 86 Upper 95% CI 82.9% 79.6% 93.4%	and ovarian mass Quality assessment: Reference standard: + (biopsy) Verification bias: - Test reliability/variability: - Sample size: - Statistical tests: +
	Patients undergoing surgery	NR Inclusion criteria:	Combination (n [%]): NR		NPV 41.9% 24.6%2) Uterine mass:	59.3%	Blinding: - (not stated) Definition of +/- on screening test: - (not stated)
	Reference standard: Biopsy Reference standard applied to all test negatives?: Yes	NR Exclusion criteria: Pregnant; missing information or no US	Additional data used for diagnosis: NR		Dis+ Dis- T+ 14 5 T- 4 63 Tot 18 68	Tot 19 67 86	
	Test reliability established?: No Statistical tests used: Se, Sp				ValueLower 95% CISe77.8%58.6%Sp92.6%86.4%PPV73.7%53.9%NPV94.0%88.4%	Upper 95% CI 97.0% 98.9% 93.5% 99.7%	
	Blinding: NR						
	Definition of positive and negative on screening test: NR (retrospective chart review)						

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Padilla, Radosevich, and Milad, 2000 #460	Geographical location: Chicago, IL Dates: Mar 1997-Mar 1998 Size of population: 82 adnexal masses in 140 patients undergoing surgery Other: Women undergoing laparotomy Reference standard: Surgery Reference standard applied to all test negatives?: Yes Test reliability established?: No Statistical tests used: Youden j statistic, Se, Sp Blinding: NR Definition of positive and negative on screening test: Adnexal mass defined as approx. 5 cm or more in greatest diameter		Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Exam under anesthesia by attendings, residents, and medical students	1) Left adnexa by attending: T+ $Dis+ Dis- Tot$ T- $333 69$ Tot Tot 49 78 127 Value 95% Cl 95% Cl Se $32.7\% 19.5\% 45.8\%$ Sp $88.5\% 81.4\% 95.6\%$ PPV $64.0\% 45.2\% 82.8\%$ NPV $67.6\% 58.6\% 76.7\%$ 2) Right adnexa by attending: T+ $T 7 20 27$ T- $26 74 100$ Tot 33 94 127 Value 95% Cl 95% Cl Se $21.2\% 7.3\% 35.2\%$ Sp $78.7\% 70.4\% 87.0\%$ PPV $25.9\% 9.4\% 42.5\%$ NPV $74.0\% 65.4\% 82.6\%$ 3) Left adnexa by resident: T+ $18 8 8 2.6\%$ 3) Left adnexa by resident: T+ $18 8 112$ Value 95% Cl 95% Cl Se $36.7\% 23.2\% 50.2\%$ Sp $91.0\% 85.1\% 97.0\%$ PPV $69.2\% 51.5\% 87.0\%$	Comments: Left and right adnexa were considered separately – abstractor not sure 2x2 tables are correct – don't tell us number of Dis - Quality assessment: Reference standard: + (all had surgery) Verification bias: - Test reliability/variability: + Sample size: - (small study) Statistical tests: + Blinding: - (not stated) Definition of +/- on screening test: + (greater than 5 cm adnexa)

	Clinical Presentation	Clinical Setting of Exam	Results Comments/Quality Scoring
			Dis+ Dis- Tot T+ 9 14 23 T- 24 91 115 Tot 33 105 138
			Lower Upper Value 95% CI 95% CI Se 27.3% 12.1% 42.5% Sp 86.7% 80.2% 93.2% PPV 39.1% 19.2% 59.1% NPV 79.1% 71.7% 86.6%
			5) Left adnexa by student:
			Dis+ Dis- Tot T+ 11 6 17 T- 38 42 80 Tot 49 48 97
			ValueLowerUpper95% CI95% CISe22.4%10.8%34.1%Sp87.5%78.1%96.9%PPV64.7%42.0%87.4%NPV52.5%41.6%63.4%
			6) Right adnexa by student:
			Dis+ Dis- Tot T+ 5 5 10 T- 28 59 87 Tot 33 64 97
			Value Upper 95% CI 95% CI Se 15.2% 2.9% 27.4% Sp 92.2% 85.6% 98.8% PPV 50.0% 19.0% 81.0% NPV 67.8% 58.0% 77.6%

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Padilla, Radosevich, and Milad, 2005 #7280	Geographical location: Chicago, IL Dates: Mar 1997-Mar 1998 Size of population: 84 Screening study Registry Other Series of women undergoing gyn surgery Reference standard: Surgery Reference standard applied to all test negatives?: Yes Test reliability established?: Not discussed Statistical tests used: Se, Sp, NPV, PPV, Youden's J statistic, likelihood ratio, logistic regression Blinding: Examiners blinded to symptoms, indications Definition of positive and negative on screening test: Positive: Adnexal mass ≥ 5 cm	Age: Mean (SD): 37.7 (0.93) Menopausal status (n [%]): Pre (< 45): 95.2% Peri (45-55): NR Post (> 55): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Other: Mean BMI 26.5 18% BMI > 30 Inclusion criteria: Women presenting for laparoscopy or laparotomy; range of indications: diagnostic laparoscopy, sterilization, suspected malignancy, etc. Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]):	Examination under anesthesia in dorsal lithotomy position. Bladder drained. Examiners reported adnexal size, presence of mass, uterine position, size, contour, mobility. Examiners divided into board-certified OB/GYN (n = 52), OB/GYN residents (n = 30), 3 rd and 4 th year med students (n = 40).	1) Total all examiners – detection of adnexal mass: T+ Dis+ Dis- Tot T- 76 152 228 Tot 90 162 252 Value 95% Cl 95% Cl Se 15.6% 8.1% 23.0% Sp 93.8% 90.1% 97.5% PPV 58.3% 38.6% 78.1% NPV 66.7% 60.5% 72.8% (calculated by summing results for atttendings, residents, and students) 2) Attendings – detection of adnexal mass: T+ Dis+ Dis- Tot Tot 30 54 84 Value 95% Cl 95% Cl Se 28.0% 11.9% 44.1% Sp 93.0% 86.2% 99.8% PPV 66.7% 40.0% 93.3% NPV 69.4% 58.8% 80.1% 3) Residents – detection of adnexal mass: T+ Dis+ Dis- Tot Tot 30 54 84 Value 95% Cl 95% Cl Se 28.0% 11.9% 44.1% Sp 93.0% 86.2% 99.8% PPV 66.7% 40.0% 93.3% NPV 69.4% 58.8% 80.1% 3) Residents – detection of adnexal mass: T+ Dis+ Dis- Tot Tot 30 54 84 Value 95% Cl 95% Cl Se 16.0% 2.9% 29.1% Se 95.0% 89.2% 100.0%	Comments: Final diagnoses not presented Reasons for surgery not systematically presented Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - (reliability not referenced or discussed) Sample size: + (but no a priori sample size presented Statistical tests: + Blinding: + Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results Comments/Quality Scoring
				PPV 62.5% 29.0% 96.0% NPV 67.1% 56.5% 77.7%	
					 Students – detection of adnexal mass:
					$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
					Lower Upper Value 95% CI 95% CI Se 4.0% 0.0% 11.0% Sp 95.0% 89.2% 100.0% PPV 25.0% 0.0% 67.4% NPV 63.8% 53.2% 74.3%
					5) Other: Likelihood of not detecting an adnexal mass increased with less experience (OR for resident 1.13, student 1.36 compared to attending, although 95% Cls cross 1).
					Statistically significant increase in missed diagnosis if subject with BMI > 30 (OR 2.57; 95% CI 1.36 to 4.87), and significant decrease in presence of enlarged uterus (OR 0.48; 95% CI 0.25 to 0.93).

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Resul	ts			Comments/Quality Scoring
Study Roman, Muder- spach, Stein, et al., 1997 #6160	Study Design Geographical location: Los Angeles, CA Dates: Jul 1992-Mar 1994 Size of population: 226 Other Nonconsecutive case series Reference standard: Surgical/path findings Reference standard applied to all test negatives?: Yes Test reliability established?: No Statistical tests used:	Patients Age: NR Menopausal status (n [%]): Pre (< 45): 181 (80.1%) Post (> 55): 45 (19.9%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Suspicious mass needing surgical evaluation Exclusion criteria: Emergent laparotomy, clinical or radiologic evidence of	Presentation Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	-	Results whom r 1) All v T+ T- Tot Se Sp PPV NPV 2) Pret	s not given mass was i vomen: Dis+ 22 21 43 Value 51.2% 83.6% 45.8% 86.2% menopaus: ont data no	Dis- 26 131 157 Lower 95% Cl 36.3% 77.8% 31.7% 80.7% al women:	Tot 48 152 200 Upper 95% CI 66.1% 89.4% 59.9% 91.7%	Scoring Comments: Preselected group with "suspicious masses" Results don't include 26 with nonpalpable masses; data on final diagnosis in these patients not provided Not clear how low malignant potential tumors were classified in terms of calculation of Se/Sp Quality assessment: Reference standard: + Verification bias: - Test reliability/variability: - Sample size: - Statistical tests: +
	Pearson, logistic regression	metastatic disease, U/S by gynecologist				tmenopaus ent data no			
	Blinding: No Definition of positive and negative on screening test: Positive = fixed, irregular contour, or clinical ascites				Se Sp PPV NPV	53.3% 85.7% 66.7% 77.4%			

Study S	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Kenemans, I Sohn, et al., 1 1994 #940	Biopsy	Age: Mean: 63 Median: 62 Range: 45-88 Menopausal status (n [%]): Post (> 55): 100% Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: > 45 years, postmenopausal Exclusion criteria: Another cancer, indeterminate exam	Symptomatic (n [%]): NR Detected by exam (n [%]): 199 (87%) Detected by imaging (n [%]): 28 (12%) by US Combination (n [%]): NR Additional data used for diagnosis: NR	One gynecologist examiner	1) Malignant vs. benign: T+ Dis+ Dis- Tot T- 7 80 Tot 95 127 222 Value 95% Cl 95% Cl Se 92.6% 87.4% 97.9% Sp 63.0% 54.6% 71.4% PPV 65.2% 57.1% 73.2% NPV 92.0% 86.2% 97.7%	Quality assessment: Reference standard: + (all had biopsy) Verification bias: - Test reliability/variability: - Sample size: + (good size) Statistical tests: + Blinding: - (not stated) Definition of +/- on screening test: + (benign or malignant)

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
Schutter, Sohn, Kristen, et al., 1998 #730	Geographical Iocation: Amsterdam, Netherlands; Wurzburg and Mainz, Germany Dates: NR (referenced in another paper by this group) Size of population: 180 (155 met inclusion/exclusion criteria) Other Case series Reference standard: Surgery/pathology Reference standard applied to all test negatives?: Yes Test reliability established?: Lack of data on reliability discussed Statistical tests used: Se, Sp, NPV, PPV Blinding: NR Definition of positive and negative on screening test: Abnormal: mass of any size clinically distinguishable as being separate from uterus and GI tract; examiner asked to	Median: 61 Range: 45-88 Menopausal status (n [%]): Post (> 55): 180 (100%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Not described (referenced) Exclusion criteria: Not described (referenced)	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Not described; presumably, in outpatient setting	1) Benign vs. malignant (borderlin benign): T+ <u>54 24</u> T- <u>59 92</u> 151 <u>Value 95% Cl 95%</u> Se <u>91.5% 84.4% 98.6</u> Sp 73.9% 64.9% 82.9 PPV 69.2% 59.0% 79.5 NPV 93.2% 87.4% 98.9	Examiners not blinded High prevalence of disease Clinical history prior to examination not described Quality assessment: Reference standard: + Verification bias: - CI Test reliability/variability: + (discussed) Sample size: + Statistical tests: +

Study	Study Design	Patients	Clinical Presentation	Clinical Setting of Exam	Results	Comments/Quality Scoring
	state whether benign or malignant					

Evidence Table 3: Question 3: Among women with a palpable adnexal mass on exam or a mass identified by ultrasound/imaging, what is the sensitivity/specificity of various evaluation modalities including ultrasound (transvaginal ultrasound, transabdominal ultrasound, color Doppler, 2D vs. 3D ultrasound), CT scan, MRI scan, and CA-125 levels for distinguishing benign from malignant masses?

Study	Study Design	Patients	Clinical Presentation	Resul	ts	Comments/Quality Scoring
Adonakis, Para- skevaidis.	Geographical location: Greece	Age: Mean (SD): 58.1(6.9) Range: 45-80	Symptomatic (n [%]): 0 (0%)	1) CA-	-125 (T+ ≥ 35 U/mI) Dis+ Dis- Tot	Comments: 1 tumor LMP grouped in with 2 other malignancies
Tsiga, et al.,	Dates: Mar 1991- Jun	Range. 45-60	Detected by exam (n [%]):	T+	3 15 18	"Ambiguous" BME was classed as
1996	1993	Menopausal status (n [%]):	50 (3%) + exam 115 (6%) "ambiguous" exam	T- Tot	0 1982 1982 3 1997 2000	Test -, although all patients with ambiguous BME had TVUS to
#810	Size of population: 2000/2000	Pre: 405 (20%) Peri: 293 (15%)	Detected by imaging	101	Lower Upper	further evaluate Borderline tumors considered Dis+
	Screening study	Post: 1302 (65%)	(n [%]): NR	Se	Value 95% Cl 95% Cl 100.0% 0.0% 100.0%	Quality assessment:
	Reference standard: Histopathology for	Race/ethnicity (n [%]): NR	Combination (n [%]): NR	Sp PPV NPV	99.2% 98.9% 99.6% 16.7% 0.0% 33.9% 100.0% 99.8% 100.0%	Reference standard: +; all had at least 12 months of followup. Verification bias: +; reference
	selected positives; followup at 12 months for	Risk factors (n [%]): NR	Additional data used for	2) PE	100.0% 99.6% 100.0%	standard of followup applied to all Test reliability/variability: + CA-125,
	all others Reference standard	Inclusion criteria: Women > 45, no evidence	diagnosis: Women with elevated CA- 125 or and abnormal or	T+	Dis+ Dis- Tot	- BME Sample size: -; large sample size, but small number of cases makes
	applied to all test negatives?: 180 of the 2000 patients	of adnexal pathology, agreed to participate	ambiguous BME were recalled for TVUS. Only women with +TVUS were	T- Tot	1 1940 1941 3 1997 2000	CIs around test characteristic estimates wide, especialy for sensitivity
	went onto TVUS, and only 35 these had	Exclusion criteria: Women with history of	referred for further management.		Lower Upper Value 95% CI 95% CI	Statistical tests: + Blinding: +
		ovarian cancer or any other malignancy, history of bilateral oophorectomy,		Se Sp	66.7% 13.3% 100.0% 97.1% 96.4% 97.9%	Definition of +/- on screening test: + CA-125, - BME
	exam, TVUS and/or CA- 125. No reported loss to followup (although not explicitly stated).			PPV NPV	3.4% 0.0% 8.0% 99.9% 99.8% 100.0%	
	Test reliability established?: BME – No					
	CA-125 – Yes Statistical tests used: Se, Sp					
	Blinding: NR, but exams preceded surgery					

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Definition of positive and negative on screening test: CA-125 ≥ 35 U/mL BME – "palpable mass"				
Alcazar and Castillo, 2005	Geographical location: Pamplona, Spain Dates: Jan 2002 – Apr	Age: Mean (SD): 48.4 (16.4) Range: 17-82	Symptomatic (n [%]): NR Detected by exam (n [%]):	All results for masses not patients 1) 2D (combined Doppler and morphology)	Comments: 14 of the 60 patients included in this study were included in a previous study by the authors
#7460	2004	Menopausal status (n [%]):	NR	Dis+ Dis- Tot T+ 44 3 47	(Alcazar 2003, ref 17) One person performed all scans
	Size of population: 60 patients 69 masses	Pre (< 45): 32 (53%) Post (> 55): 28 (47%)	Detected by imaging (n [%]): NR	T- <u>1</u> <u>21</u> <u>22</u> Tot <u>45</u> <u>24</u> <u>69</u>	(both 2D and 3D); however, he only interpreted the 2D scans. 3D scans interpreted by other individual
	Case series	Race/ethnicity (n [%]): NR	Combination (n [%]): NR	Lower Upper Value 95% Cl 95% Cl Se 97.8% 93.5% 100.0%	blinded to 2D results. Kappa index calculated for interobserver agreement (k = 0.90)
	Reference standard: Histopathology	Risk factors (n [%]): NR	Additional data used for diagnosis:	Sp 87.5% 74.3% 100.0% PPV 93.6% 86.6% 100.0% NPV 95.5% 86.8% 100.0%	No discussion of clinical pathway to diagnosis. No discussion of why decision for
	Reference standard applied to all test negatives?:	Inclusion criteria: Women with diagnosis of adnexal mass who	NR	2) 3D (combined)	3D US – most likely suspicious 2D scan High incidence of cancer in this
	Yes	received treatment at institution in time frame for		Dis+ Dis- Tot T+ 44 5 49	study Descriptive morphologic
	Test reliability established?: Yes	who got 2D and 3D US Exclusion criteria:		T- <u>1 19</u> 20 Tot <mark>45 24</mark> 69	classification for 2D and doppler- no scoring system used 3D US - definition of
		"Masses in which the echo features were highly characteristic of a given pathologic condition (such		Lower Upper Value 95% Cl 95% Cl Se 97.8% 93.5% 100.0% Sp 79.2% 63.0% 95.4%	positive/negative test not mentioned Unclear how Doppler included in final table Unable to stratify by menopausal
	Blinding: Yes	as simple cyst, cystic teratoma, or endometrioma)"		PPV 89.8% 81.3% 98.3% NPV 95.0% 85.4% 100.0%	status Results reported by masses not patients
	Definition of positive and negative on screening test: 2D US – presence of at least one of the following:				LMP tumors grouped in with malignant Numbers in text and table II don't mesh exactly (2x2 tables here from Table II data) Authors note no difference in Se

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	thick wall (> 3 mm), thick papillary projections (> 3 mm), solid areas or purely solid echogenicity = complex mass. Doppler – blood flow detected within a papillary projection, solid area, or central area of solid tumor = malignant. 3D – not mentioned.				and Sp between 2D and 3D p = 0.250 Good discussion of literature on 3D TVUS only Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: -
Alcazar, Errasti, Zornoza, et al., 1999 #3110	Geographical location: Spain Dates: Jan 1995- Feb 1998 Size of population: 94 of 480 Other Retrospective case series Reference standard: Pathology Reference standard applied to all test negatives?: Yes Test reliability established?: Inter and intra assay coefficient for CA-125 reported Statistical tests used: Kolmogorov-Smirnov Student t-test	Age: Mean (SD): 47.4 (16.1) Range: 17-79 Menopausal status (n [%]): Pre (< 45): 55.3% Post (> 55): 44.7% Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Sonographically suspicious adnexal mass, "presence of at least one of the following: gross septa (> 3 mm), gross papillary projections (> 3 mm), solid wall nodules, multilocularity, irregular borders or ascitis" Transvaginal color Doppler evaluation and serum CA-125 levels determined prior to	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) Color Doppler – all $\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Comments: LMP tumors grouped in with malignant Inclusion criteria predispose to increased likelihood of cancer Pre-study history (symptomatic vs asymptomatic) not described Quality assessment: Reference standard: +; pathology Verification bias: +; all underwent surgery Test reliability/variability: +; one reader for Doppler; inter and intra assay coefficient of variation for CA- 125 Sample size: + Statistical tests: + Blinding: - Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Chi-square			Dis+ Dis- Tot	
	McNemars Test	Definitive histopathological		T+ 23 5 28	
	ROC	diagnosis		T- <u>3</u> 21 24	
				Tot 26 26 52	
	Blinding:	Exclusion criteria:			
	NR	NR		Lower Upper	
				Value 95% CI 95% CI	
	Definition of positive			Se 88.5% 76.2% 100.0%	
	and negative on			Sp <mark>80.8%</mark> 65.7% 95.9%	
	screening test:			PPV 82.1% 67.9% 96.3%	
	Doppler			NPV 87.5% 74.3% 100.0%	
	Resistance index [RI=S-				
	D] calculated for each			4) CA-125 – Premenopausal	
	case				
	Malignancy suspected if			Dis+ Dis- Tot	
	lowest RI ≤ 0.45			T+ 22 8 30	
	CA-125 level			T- 4 18 22	
	CA-125 = 35 U/ml			Tot 26 26 52	
	considered as suspicious				
	for malignancy			Lower Upper	
				Value 95% CI 95% CI	
				Se 84.6% 70.7% 98.5%	
				Sp <mark>69.2%</mark> 51.5% 86.9%	
				PPV 73.3% 57.5% 89.1%	
				NPV <mark>81.8%</mark> 65.7% 97.9%	
				5) Doppler – Postmenopausal	
				Dis+ Dis- Tot	
				T+ <u>26</u> <u>1</u> <u>27</u>	
				T- 4 11 15	
				Tot 30 12 42	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 86.7% 74.5% 98.9%	
				Sp 91.7% 76.1% 100.0%	
				PPV 96.3% 89.2% 100.0%	
				NPV 73.3% 50.9% 95.7%	
				6) CA-125 – Postmenopausal	
				Dis+ Dis- Tot	
				T+ 25 4 29	
				T- <u>5</u> 8 13	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
				Tot	30	12	42	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	83.3%	70.0%	96.6%	
				Sp	66.7%	40.0%	93.4%	
				PPV	86.2%	73.6%	98.8%	
				NPV	61.5%	35.0%	88.0%	
Alcazar,	Geographical location:	Age:	Symptomatic (n [%]):	1) 2D	US			Comments:
Galan,	Spain	Mean (SD): 49.5	NR	,				Descriptive not
Garcia-		Range: 23-75			Dis+	Dis-	Tot	numerical/reproducible scoring
Manero, et	Dates: Jun 2001 to Jun	-	Detected by exam (n [%]):	T+	19	9	28	system
al., 2003	2002	Menopausal status	NR	Т-	2	14	16	2x2 tables for masses not for
		(n [%]):		Tot	21	23	44	individuals
#1990	Size of population:	Pre (< 45): 20 (49%)	Detected by imaging					Pre-study history (symptomatic ve
	44 masses	Post (> 55): 21 (51%)	(n [%]):			Lower	Upper	asymptomatic) not described
	41 women		NR		Value	95% CI	95% CI	
		Race/ethnicity (n [%]):		Se	90.0%	77.2%	100.0%	Quality assessment:
	Other	NR	Combination (n [%]):	Sp	61.0%	41.1%	80.9%	Reference standard: +
	Prospective case series		NR	PPV	67.9%	50.6%	85.2%	Verification bias: +
		Risk factors (n [%]):		NPV	87.5%	71.3%	100.0%	Test reliability/variability: +
	Reference standard:	NR	Additional data used for					Sample size: +; "state small
	Histopathology	In closed on a side size	diagnosis:	2) 3D	US			numbers of patients"
	Defense of a dead	Inclusion criteria:	NR					Statistical tests: +
	Reference standard	Women with the diagnosis			Dis+	Dis-	Tot	Blinding: NR
	applied to all test	of complex adnexal		T+	21	5	26	Definition of +/- on screening test:
	negatives?:	masses on 2D TVUS		Т-	0	18	18	stated
	Yes	Exclusion criteria:		Tot	21	23	44	
	Test reliability	NR						
	established?:					Lower	Upper	
	Yes using kappa				Value	95% CI	95% CI	
	Tes using kappa			Se	100.0%	85.7%	100.0%	
	Statistical tests used:			Sp	78.0%	61.1%	94.9%	
	McNemars			PPV	80.8%	65.6%	95.9%	
	Mortoniaio			NPV	100.0%	83.3%	100.0%	
	Blinding:							
	Second 3D reviewer							
	blinded, 2D and first 2D							
	reviewer not							
	Definition of positive							
	and negative on							
	screening test:							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Presence of one of the following fulfilled criteria for adnexal mass: A thick wall (> 3 mm) A thick septum (> 3 mm) Thick papillary projections (> 3 mm), solid areas, purely solid echogenicity				
Alcazar and Lopez- Garcia, 2001	Geographical location: Spain University Hospital	Age: Mean (SD): 46.6 (14.1) Range: 16-81	Symptomatic (n [%]) : NR	1) Morphology criteria of Sassone et al <u>Dis+</u> Tot	Comments: LMP tumors considered malignant in analysis
#5740	Dates: Jun 1998 – May 1999	Menopausal status (n [%]): Pre (< 45): 58 (63.7%)	Detected by exam (n [%]): NR Detected by imaging	T+ 23 19 42 T- 2 47 49 Tot 25 66 91	There seems to be an inconsistency between the definition of Venous Doppler; the Se/Sp reported in text and; and the Se/Sp
	Size of population: 180 women	Post (> 55): 33 (36.3%) Race/ethnicity (n [%]):	(n [%]): NR	Lower Upper Value <u>95% Cl 95% Cl</u> Se <u>92.0% 81.4% 100.0%</u>	reported in Table 3 Pre-study history (symptomatic vs asymptomatic) not described
	Other Consecutive patients undergoing surgery with masses	NR Risk factors (n [%]): NR	Combination (n [%]): NR Additional data used for	Se 32.0% 81.4% 100.0% Sp 71.2% 60.3% 82.1% PPV 54.8% 39.7% 69.8% NPV 95.9% 90.4% 100.0%	Results for 89 subjects not undergoing surgery not provided Quality assessment:
	Reference standard: Surgery	Inclusion criteria: Adnexal mass undergoing surgery	diagnosis: NR	 2) Arterial Doppler (RI) T+≤ 0.45 (in patients in whom arterial flow was detected) (Table 3) 	Reference standard: + Verification bias: + Test reliability/variability: + for Sasonne and RI
	Reference standard applied to all test negatives?: No, 180 patients evaluated by TVUS for adnexal mass; only 91 underwent surgery	Exclusion criteria: NR		Dis+ Dis- Tot T+ 17 1 18 T- 6 26 32 Tot 23 27 50 Lower Upper Value 95% CI 95% CI	Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: + morphology criteria and RI ; - for arterial and venous Doppler
	Test reliability established?: Yes			Value 95% Ci 95% Ci Se 76.0% 58.5% 93.5% Sp 95.5% 87.7% 100.0% PPV 94.4% 83.9% 100.0% NPV 81.3% 67.7% 94.8%	
	Statistical tests used: ROC Se, Sp McNemar test			3) Venous Doppler; cutoff not described Dis+ Dis- Tot T+ 12 1 13	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Blinding:			T- 6 13 19	
	Surgeons blinded to US			Tot 18 14 32	
	result				
	Prospective study			Lower Upper	
	Definition of positive			Value 95% CI 95% CI	
	and negative on			Se 68.0% 46.4% 89.6% Sp 93.9% 81.4% 100.0%	
	screening test:			PPV 92.3% 77.8% 100.0%	
	Sasonne's scoring			NPV 68.4% 47.5% 89.3%	
	system (ref 20)				
	Wall thickness (1-3)			4) Venous flow velocity; cutoff 10 cm/s	
	Septa (1-3)			AUC = 0.859 ± 0.06 SEM	
	Inner wall structure (1-4)				
	Echogenicity (1-5)			Dis+ Dis- Tot	
	Total score is sum,			T+ 17 4 21	
	ranges from 4-15			T- 1 10 11	
	T+ if score ≥ 9			Tot 18 14 32	
	Arterial flow lowest RI ≤ 0.45				
	Venous Doppler			Lower Upper	
	calculated from ROC			Value 95% CI 95% CI	
	curve but no number			Se 94.0% 83.0% 100.0%	
	given in text			Sp 71.0% 47.2% 94.8% PPV 81.0% 64.2% 97.7%	
				NPV 90.9% 73.9% 100.0%	
Alcazar,	Geographical location:	Age: Part 2	Symptomatic (n [%]):	1) Sassone	Comments:
Merce,	Pamplona and Madrid,	Mean (SD): 53.5 (11.3)	NR		Stepwise regression (forward)
Laparte, et	Spain	Range: 20-80		Dis+ Dis- Tot	Their model not reproducible from
al., 2003			Detected by exam (n [%]):	T+ 20 7 27	description in article
	Dates:	Menopausal status	NR	T- 11 52 63	Borderline tumors grouped in with
#5390	Part 1	(n [%]):	Defended has imposing	Tot 31 59 90	malignant
	Jan 1995 – Jun 201	Pre (< 45): 26 (30.2%)	Detected by imaging		2x2 tables use cases not
	Part 2 Jul 2001 – Apr 2002	Post (> 55): 60 (69.8%)	(n [%]): NR	Lower Upper	individuals Pre-study history (symptomatic vs
		Race/ethnicity (n [%]):	NIX .	Value 95% CI 95% CI Se 64.5% 47.7% 81.3%	asymptomatic) not described
	Size of population:	NR	Combination (n [%]):	Se 64.5% 47.7% 81.3% Sp 88.1% 79.8% 96.4%	
	Part One 665 (705		NR	PPV 74.1% 57.5% 90.6%	Quality assessment:
	masses)	Risk factors (n [%]):		NPV 82.5% 73.2% 91.9%	Reference standard: +
	Part Two 86 (90 masses)		Additional data used for		Verification bias: +
			diagnosis:	2) DePriest	Test reliability/variability: + for
	Other	Inclusion criteria:	NR	,	Sassone and DePriest, ? for
	Part 1 retrospective	Part 1 retrospective		Dis+ Dis- Tot	Ferrazzi, - for current study
	analysis of ultrasound	analysis of 665 women		T+ <u>31</u> 11 42	Sample size: -
	data to construct scoring	with adnexal masses who		T- 0 48 48	Statistical tests: +/-
	system	had US in hospital during			Blinding: +/-

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
		time frame.		Tot 31 59 90	Definition of +/- on screening test:
	consecutive patients to	Part 2 – prospective			for current study
	test scoring system and	analysis of women		Lower Upper	
	compare with other	(consecutive? - NR) with		Value 95% CI 95% CI	
	ultrasound scoring	adnexal masses who had		Se 100.0% 90.3% 100.0%	
	systems	surgery in time frame at		Sp 81.4% 71.5% 91.3%	
		hospital		PPV 73.8% 60.5% 87.1%	
	Reference standard:	Evolution enitories		NPV 100.0% 93.8% 100.0%	
	Histopathology	Exclusion criteria:		0) 5	
	Reference standard	NK		3) Ferrazzi	
	applied to all test			Dia L Dia Tat	
	negatives?:			Dis+ Dis- Tot T+ 26 10 36	
	Yes				
	163			T- <u>5</u> 49 54	
	Test reliability			Tot 31 59 90	
	established?:			Lower Unper	
	Sassone – Yes			Lower Upper Value 95% CI 95% CI	
	DePriest – Yes				
	Ferrazzi - ?			Se <mark>83.9%</mark> 71.0% 96.8% Sp <mark>83.1%</mark> 73.5% 92.7%	
	This one - ?			PPV 72.2% 57.6% 86.9%	
				NPV 90.7% 83.0% 98.5%	
	Statistical tests used:			NIV 90.770 00.070 90.070	
	Multivariate logistic			4) Current study	
	regression			-, ourient study	
	ROC curves			Dis+ Dis- Tot	
				T+ 31 3 34	
	Blinding:			T- 0 56 56	
	NR – same individual did			Tot 31 59 90	
	all US – prospective part				
	2			Lower Upper	
				Value 95% CI 95% CI	
	Definition of positive			Se 100.0% 90.3% 100.0%	
	and negative on			Sp 94.9% 89.3% 100.0%	
	screening test:			PPV 91.2% 81.6% 100.0%	
	Not described for			NPV 100.0% 94.6% 100.0%	
	Sassone, DePries,t or Ferrazzi (but can assume				
	to be identical to reported			5) Menopause Sassone	
	in literature).				
	Their scoring system			Dis+ Dis- Tot	
	used variables only for:			T+ 17 4 21	
	Thick papillary			T- <u>11 30</u> 41	
	projections, high			Tot 28 34 62	
	velocity/low resistance,				
	solid area, and central			Lower Upper	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	flow (unclear how this	is		Value 95% CI 9	5% CI
	measured).			Se 61.0% 42.9%	79.1%
				Sp 88.0% 77.1% 9	98.9%
				PPV 81.0% 64.2% 9	97.7%
				NPV 73.2% 59.6% 8	36.7%
				6) Menopause DePriest	
				Dis+ Dis-	Tot
				T+ 28 6	34
				T- 0 28	28
				Tot 28 34	62
				Lower	Jpper
				Value 95% CI 9	5% CI
					00.0%
				Sp 82.4% 69.5%	95.2%
				PPV 82.4% 69.5%	95.2%
					00.0%
				7) Menopause Ferrazzi	
				Dis+ Dis-	Tot
				T+ 23 6	29
				T- 5 28	33
				Tot 28 34	62
				Lower	Jpper
				Value 95% CI 9	5% CI
					96.2%
				Sp <mark>82.0%</mark> 69.1% §	94.9%
				PPV 79.3% 64.6% 9	94.1%
					97.1%
				8) Menopause current study	
				Dis+ Dis-	Tot
				T+ 28 2	30
				T- 0 32	32
				Tot 28 34	62
				Lower	Jpper
				Value 95% CI 9	5% CI
					00.0%
				Sp 94.1% 86.2% 1	00.0%
				-p 01.170 00.270 1	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				PPV 93.3% 84.4% 100.0%	
				NPV 100.0% 90.6% 100.0%	
				9) Premenopause Sassone	
				Dis+ Dis- Tot	
				T+ <mark>3 3</mark> 6	
				T- 0 22 22 Tot 3 25 28	
				Lower Upper Value 95% CI 95% CI	
				Se 100.0% 0.0% 100.0%	
				Sp 88.0% 75.3% 100.0%	
				PPV 50.0% 10.0% 90.0%	
				NPV 100.0% 86.4% 100.0%	
				10) Premenopause DePriest	
				Dis+ Dis- Tot	
				T+ 3 5 8 T- 0 20 20	
				Tot 3 25 28	
				Lower Upper Value 95% CI 95% CI	
				Se 100.0% 0.0% 100.0%	
				Sp 80.0% 64.3% 95.7%	
				PPV 37.5% 4.0% 71.0%	
				NPV 100.0% 85.0% 100.0%	
				11) Premenopause Ferrazzi	
				Dis+ Dis- Tot	
				T+ <u>3 4</u> 7 T- <u>0 21</u> 21	
				T- 0 21 21 Tot 3 25 28	
				Lower Upper Value 95% CI 95% CI	
				Se 100.0% 0.0% 100.0%	
				Sp 84.0% 69.6% 98.4%	
				PPV 42.9% 6.2% 79.5% NPV 100.0% 85.7% 100.0%	
				TVL V 100.070 03.770 100.070	

				12) Pr	emenopau	se current	study	
					Dis+	Dis-	Tot	
				T+	3	1	4	
				T-	0	24	24	
				Tot	3	25	28	
						Lower	Upper	
				•	Value	95% CI	95% CI	
				Se	100.0% 96.0%	0.0% 88.3%	100.0% 100.0%	
				Sp PPV	96.0% 75.0%	88.3% 32.6%	100.0%	
				NPV	100.0%	32.0 <i>%</i> 87.5%	100.0%	
				INF V	100.078	07.5%	100.076	
Ananda-	Geographical location:	Age:	Symptomatic (n [%]):	1) Pre	sence of fl	ow – color	imaging alone	Comments:
umar,	Singapore	Mean:For benign 35; for	NR	,			00	LMP tumors grouped in with
hew,		malignant 42.9			Dis+	Dis-	Tot	malignant
	Dates: 1991-1993	Range: for whole study	Detected by exam (n [%]):	T+	26	39	65	2x2 tables and results calculated
996		pop 16-71	NR	T-	8	83	91	for masses not patients
	Size of population:	•• • • •		Tot	34	122	156	No description of why 0.66 used
10980	146 patients	Menopausal status	Detected by imaging					cut point for RI
	156 tumors	(n [%]):	(n [%]):			Lower	Upper	"Color flow imaging alone" criteria
	Case series	NR	NR	-	Value	95% CI	95% CI	for positive subjective and not reproducible
	Case series	Race/ethnicity (n [%]):	Combination (n [%]):	Se	76.5%	62.2%	90.8%	Overlap in RI range with benign
	Reference standard:	NR	NR	Sp PPV	68.0%	59.7%	76.3%	tumors (0.44-0.80) and malignant
	Histopathology			NPV	40.0% 91.2%	28.1% 85.4%	51.9% 97.0%	(0.3-0.60)
	There particlegy	Risk factors (n [%]):	Additional data used for	INF V	91.270	00.4%	97.0%	From their data, performance of
	Reference standard	NR	diagnosis:					Doppler improves if masses with
	applied to all test		NR	3) RI ≤	0.66			solid components, however, I was
	negatives?:	Inclusion criteria:		0) 14 -	0.00			unable to get 2x2 table from these
	Yes	Women with pelvic tumors			Dis+	Dis-	Tot	results (Tables 4, 5)
		detected clinically		T+	24	24	48	TVUS only
	Test reliability			T-	10	98	108	
	established?:	Exclusion criteria:		Tot	34	122	156	Quality assessment:
	Yes	NR						Reference standard: +/-
	Ctatiotical tests used					Lower	Upper	Verification bias: +
	Statistical tests used:				Value	95% CI	95% CI	Test reliability/variability: +/-
	Student's t-test Z test of proportions and			Se	71.0%	55.7%	86.3%	Sample size: - Statistical tests: +
	indices of normality			Sp	80.3%	73.2%	87.4%	Blinding: -
	Se, Sp			PPV	50.0%	35.9%	64.1%	Definition of +/- on screening test:
	· ·			NPV	90.7%	85.3%	96.2%	+/-
	Blinding: Not described							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Definition of positive and negative on screening test: RI <= 0.66 Color flow alone = abnormal vessels "continuously fluctuating rather than pulsatile, also with mosaic pattern with yellow-green color combinations indicating turbulent flow"				
Andolf, Jorgensen, and Astedt, 1990 #1200	Geographical location: Lund Sweden Dates: Oct 1984-Jul 1987 Size of population: 801 screened Screening study Reference standard: Surgery or repeat US or CT within 6 months Reference standard applied to all test negatives?: No – but follow up US for all test positives who did not go to surgery Test reliability established?: Yes Statistical tests used: Not described Blinding:	Age: Range: 40-70 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): Family history: 190 (23.7%) Inclusion criteria: Women 40-70 years old who attended outpatient clinic of OB/GYN university hospital Lund, Sweden Exclusion criteria: NR; 6 scans excluded from analysis secondary to poor image quality	Symptomatic (n [%]): 419 (52.3%) Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) Using US and BME combined (both positive for test to be positive) T+ Dis+ Dis- Tot T- 0 746 746 Tot 6 795 801 Value 95% Cl 95% Cl Se 100.0% 50.0% 100.0% Sp 93.8% 92.2% 95.5% PPV 10.9% 2.7% 19.1% NPV 100.0% 99.6% 100.0%	Comments: No description of what constituted an abnormal US No description of what constituted an abnormal manual exam Women with normal US and exam - half contacted via mail, cancer cases would have been detected in hospital system, only 2% of them had moved out of cachement area Six women excluded from results secondary to poor quality scans – nor- mention of follow up in them (cancer? etc.) Unable to get 2x2 tables for US and BME by itself Abdominal US only Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: - Blinding: - Definition of +/- on screening test: -

	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring	
	Definition of positive and negative on screening test: Not described					
	Geographical location: Ljubljana, Slovenia	Premenopausal women:	Symptomatic (n [%]) : NR	1) Presence or absence of color flow in mass for all patients	Comments: LMP tumors grouped in with	
#10830	Dates: Jan-Jul 1993	mean 41; range 35-54 Peri 53 (52-53)	Detected by exam (n [%]):	Dis+ Dis- Tot	malignantNo description of clinical path	
		Post 63 (51-82)	NR	T+ 16 28 44	Good data on overlap of PI and R	
	Size of population:	••		T- 2 25 27	range in malignant and non	
	71	Menopausal status (n [%]):	Detected by imaging (n [%]):	Tot 18 53 71	malignant outcomes. Did not clearly define visualization	
	Prospective case series	Pre (< 45): 32 (45.1%) Peri (45-55): 4 (5.6%)	NR	Lower Upper Value 95% CI 95% CI	of color flow or not No discussion of inter observer	
	Reference standard:	Post (> 55): 29(40.8%)	Combination (n [%]):	Se 88.9% 74.4% 100.0%	reliability	
	Histopathology	6 had undergone	NR	Sp 47.2% 33.7% 60.6%	Combination TVUS and abdomina	
	1 05	hysterectomy (8.5%)		PPV 36.4% 22.1% 50.6%	US used (N for each not specified,	
	Reference standard		Additional data used for	NPV 92.6% 82.7% 100.0%	unable to stratify)	
	applied to all test	Race/ethnicity (n [%]):	diagnosis:			
	negatives?:	NR	NR	2) Presence or absence of color flow in	Quality assessment:	
	Yes			mass for menopausal patients	Reference standard: +	
		Risk factors (n [%]):			Verification bias: +	
	Test reliability	NR		Dis+ Dis- Tot	Test reliability/variability: -	
	established?:	Inclusion eniteria.		T+ 13 3 16	Sample size: -	
	Yes	Inclusion criteria: NR		T- 2 11 13	Statistical tests: + Blinding: +	
	Statistical tests used:			Tot 15 14 29	Definition of +/- on screening test:	
	Fisher exact test	Exclusion criteria:			for CA-125, - for Doppler	
	Se, Sp	NR		Lower Upper		
	Mann-Whitney U test			Value 95% CI 95% CI		
				Se 86.7% 69.5% 100.0%		
	Blinding:			Sp 78.6% 57.1% 100.0% PPV 81.3% 62.1% 100.0%		
	Not described but			NPV 84.6% 65.0% 100.0%		
	prospective			Ni v 04.070 05.070 100.070		
	Definition of positive			3) CA-125 for all patients		
	and negative on			Dis+ Dis- Tot		
	screening test:			T+ 15 4 19		
	PI [=(S-D)/M] and RI			T- 3 49 52		
	[=(S-D)/S] were			Tot 18 53 71		
	calculated but test used					
	presence or absence of			Lower Upper		
	colored flow without			==		

Study	Study Design	Patients	Clinical Presentation	Results				Comments/Quality Scoring
	calculation CA-125 > 34 U/ml			Se 83 Sp 92 PPV 78	alue 3.3% 2.5% 8.9% 4.2%	95% Cl 66.1% 85.3% 60.6% 87.9%	95% Cl 100.0% 99.6% 97.3% 100.0%	
				4) CA-125	for pos	tmenopa	usal patients	
				T+ T Tot	Dis+ 13 2 15	Dis- 1 13 14	Tot 14 15 29	
				Se 86 Sp 92 PPV 92	/alue 6.7% 2.9% 2.9% 6.7%	Lower 95% Cl 69.5% 79.4% 79.4% 69.5%	Upper 95% CI 100.0% 100.0% 100.0% 100.0%	
Asif, Sattar, Dawood, et al., 2004	Geographical location: Rawalpindi, Pakistan	Age: Mean (SD): For malignant – 45(11)	Symptomatic (n [%]) : NR		i for who Dis+	ole study Dis-	pop (> 35 U/ml) Tot	Comments: No tests of significance done Unable to do 2x2 table for
#1580	Dates: Jan 2001 – Jan 2002	For B9 $- 37(14)$	Detected by exam (n [%]): NR	T+	45 10	7 38	52 48	postmenopause (even though have info: 33 cancer, 11 benign – can't
	Size of population: 100	Menopausal status (n [%]): Pre (< 45): 56(56%) Peri (45-55):	Detected by imaging (n [%]): NR	Tot	55	45 Lower	100 Upper 95% CI	assume same test characteristics) Pre-study history (symptomatic vs asymptomatic) not described
	Other Consecutive preoperative patients at hospital with mass	Post (> 55): 44(44%) Race/ethnicity (n [%]): NR	Combination (n [%]): NR	Se 82 Sp 84 PPV 86	′alue 2.0% 4.0% 6.5% 9.2%	95% CI 71.8% 73.3% 77.3% 67.7%	92.2% 94.7% 95.8% 90.7%	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + (for
	Reference standard: Histopathology	Risk factors (n [%]) : NR	Additional data used for diagnosis: NR	2) US score	e (Jaco	bs) ≥ 1		CA125) Sample size: - Statistical tests: +/-
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: 100 consecutive women admitted to hospital in time frame for surgery for adnexal mass		T+ T- Tot	Dis+ 53 2 55	Dis- 38 7 45	Tot 91 9 100	Blinding: - Definition of +/- on screening test:
	Test reliability established?: CA-125 yes	Exclusion criteria:			′alue 6.4%	Lower 95% CI 91.4%	Upper 95% CI 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results				Comments/Quality Scoring
	US - ?			Sp	15.6%	5.0%	26.1%	
				ΡΡV	58.2%	48.1%	68.4%	
	Statistical tests used:			NPV	77.8%	50.6%	100.0%	
	ROC Se, Sp			37110	scoro (la	icobs) ≥ 2		
	3e, 3p			3) 03	SCOLE (32	10005) = 2		
	Blinding:				Dis+	Dis-	Tot	
	NR – prospective study			T+	4			
				Т-	1			
	Definition of positive			Tot	5	5 45	100	
	and negative on							
	screening test:					Lower	Upper	
	CA-125 – 35U/mL				Value		95% CI	
	US – Jacobs scoring			Se	76.4%		87.6%	
	system: cutoff not			Sp	88.9%		98.1%	
	described in article			PPV			98.2%	
				NP∖	75.5%	63.9%	87.1%	
albi,	Geographical location:	Age:	Symptomatic (n [%]):	Note	nough in	fo to strati	fy by age or	Comments:
lusone,	Naples, Italy Range: 40-80 NR				pausal s		ly by age of	20 patients excluded for reasons
lenditto, et	Naples, Italy	Range. 40-00		ment	pausai s	latus		that seem to indicate there wasn't
al., 2001	Dates: Jan 1996-Mar	Jan 1996-Mar Menopausal status Detected by exam (n [%]					andard protocol.	blinding
, 2001	2000	(n [%]):	NR				edict benign or	Physical exam had high sensitivit
2320	2000	NR		malig			oulot bollight of	but examiners not blinded to patier
	Size of population:		Detected by imaging					history or prior diagnosis of pelvic
	92 women	Race/ethnicity	(n [%]):		Dis+	Dis-	Tot	mass
		(n [%]):	NR	T+	2			Although RI measured, not
	Other	NR		Т-		2 37		included in definition of +US
	Case series		Combination (n [%]):	Tot	2			Pre-study history (symptomatic ve
		Risk factors (n [%]):	NR				. –	asymptomatic) not described
	Reference standard:	NR				Lower	Upper	
	Histopathological		Additional data used for		Value		95% CI	Quality assessment:
	diagnosis	Inclusion criteria:	diagnosis:	Se	90.0%		100.0%	Reference standard: +
		"Women with a pelvic	NR	Sp	74.0%		86.2%	Verification bias: -
	Reference standard	mass originating in the		PPV			77.3%	Test reliability/variability: + for CA-
	applied to all test	ovary"		NP∖	94.9%	87.9%	100.0%	125; ? for PE, CA-72-4, and US
	negatives?:							Sample size: -
	No, 18 women with	Exclusion criteria:		2) U	6			Statistical tests: +
	"clearly benign" masses	NR		, -				Blinding: -
	not verified; 2 patients				Dis+	Dis-	Tot	Definition of +/- on screening test:
	with "clearly malignant"			T+	1			
	disease (metastases)			Т-		3 36	39	
	also excluded.			Tot	2			
	Test reliability							

Study	Study Design	Patients Clinical Presentation			ts		Comments/Quality Scoring	
	established?:				Lower	Upper		
	Not for PE or CA-72-4				Value	95% CI	95% CI	
	? US and RI			Se	86.0%	71.5%	100.0%	
	Yes for CA-125			Sp	72.0%	59.6%	84.4%	
				PPV	57.6%	40.7%	74.4%	
	Statistical tests used:			NPV	92.3%	83.9%	100.0%	
	Se, Sp							
	Multivariate logistic			3) CA-	125			
	analysis			,				
					Dis+	Dis-	Tot	
	Blinding:			T+	15	7	22	
	NR			Т-	7	43	50	
				Tot	22	50	72	
	Definition of positive							
	and negative on					Lower	Upper	
	screening test:				Value	95% CI	95% CI	
	PE – "palpable mass of			Se	68.0%	48.5%	87.5%	
	any sizeclinically			Sp	86.0%	76.4%	95.6%	
	distinguishable from the			PPV	68.2%	48.7%	87.6%	
	gastrointestinal tract";			NPV	86.0%	76.4%	95.6%	
	clinician asked to							
	designate as benign or			4) CA-	72-4 > 3 l	J/ml		
	malignant			,				
	CA-125 > 35 U/ml				Dis+	Dis-	Tot	
	CA-72-4 > 3 U/ml			T+	13	6	19	
	US "multilocular solid			Т-	9	44	53	
	tumor or solid tumor"			Tot	22	50	72	
	from Valentin et al							
	classification ref 19					Lower	Upper	
	RI < 0.4				Value	95% CI	95% CI	
				Se	59.0%	38.4%	79.6%	
				Sp	88.0%	79.0%	97.0%	
				PPV	68.4%	47.5%	89.3%	
				NPV	83.0%	72.9%	93.1%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Benjapibal, Sunsanee- vitayakul, Boriboon- hirunsarn, et al., 2002 #2150	Geographical location: Bangkok, ThailandDates:Jun 2000-Sep 2001Size of population: 120 7 excluded for no measurable flowOther: Consecutive patientsConsecutive patientsReference standard: HistopathologyReference standard applied to all test negatives?: YesTest reliability established?: YesStatistical tests used: Student t-test Chi-square analysisBlinding: Blinded to ultimate diagnosis, but not to other clinical factorsDefinition of positive and negative on 	Age: Mean (SD): 41 (14) Range: 12-81 Menopausal status (n [%]): Pre (< 45): NR Post (> 55): "one fourth" Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Patients with suspected ovarian tumors admitted for surgery PI measured Exclusion criteria: PI not measurable (7)	Symptomatic (n [%]): Abdominal pain 30.8% Detected by exam (n [%]): Palpable mass 30% Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) PI ≤ 1.0 is T+ T+ $Dis+ Dis- Tot 44$ T- $6 6 63$ 69 Tot 35 78 113 $M = \frac{Value 95\% CI}{Value 95\% CI} 95\% CI$ Se 82.9% 70.4% 95.4% Sp 80.8% 72.1% 89.5% PPV 65.9% 51.9% 79.9% NPV 91.3% 84.7% 98.0%	Comments: No discussion of 7 excluded (no intent to treat analysis) One of few studies to describe pre- study clinical history Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Benjapibal, Sunsanee- vitayakul, Boriboon- hirunsarn, et al., 2003 #5600	Geographical location: Bangkok, Thailand Dates: Jul 2001-Jun 2002 Size of population: 123 3 excluded Other Patients with suspected ovarian tumor admitted for elective surgery Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: No Statistical tests used: Chi-square Blinding: NR Prospective study (but not blinded to clinical history) Definition of positive and negative on screening test: Sonographic score modified from Vera (ref 11) and Kawai (ref 12) positive > 9 (10-14)	Age: Mean (SD): 41.5 (14.1) Range: 12-81 Menopausal status (n [%]): Pre (< 45): NR Peri (45-55): NR Post (> 55): "one fourth" Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Suspicion of ovarian mass, admitted for surgery Exclusion criteria: Non ovarian origin of tumor (n = 3; leiomyoma and parovarian cyst)	Symptomatic (n [%]): 92% had gynecological symptoms that made them contact their physicians Detected by exam (n [%]): 8% diagnosed at routine gynecological checkup Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) Sonographic pattern score ≥ 10 is T+ T+ <u>131 9</u> 40 T- <u>44 76</u> 80 Tot <u>35 85 120</u> <u>Value 95% CI 95% CI</u> Se <u>88.6% 78.1% 99.1%</u> Sp <u>89.4% 82.9% 95.9%</u> PPV 77.5% 64.6% 90.4% NPV 95.0% 90.2% 99.8% Complete data on varying cutoffs provided (ROC curve could be constructed)	Comments: Overlap in dates (3 months) from other study by same group (#2150) Reliability of scoring system not established Pre-study clinical history described Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: -

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Berlanda, Ferrari,	Geographical location: Milan, Italy	Median = 60; 47-69	Symptomatic (n [%]): NR	1) Test characteristics based on algorithm	Comments: Present number of malignancies
Mezzopane, et al., 2002	Dates: NR; 3-year	(interquartile) for women with malignant masses	Detected by exam (n [%]):	Dis+ Dis- Tot T+ 27 6 33	for pre and post menopausal but no other information provided to create
#2180	period	Median = 32 and 27-43 for interguartile range	NR	T- <u>3 198</u> 201 Tot <u>30 204</u> 234	2x2. NOTE: N for 2x2 is masses NOT
#2100	Size of population:	intorquarino rango	Detected by imaging	101 30 204 234	women.
	215 women	Menopausal status	(n [%]):	Lower Upper	RI ≤ 0.6 cutoff not explained
	234 masses	(n [%]): Pre (< 45): 177	NR	Value 95% CI 95% CI Se 90.0% 79.3% 100.0%	Masses with "appearance of cystic teratoma" considered benign
	Other:	Peri (45-55):	Combination (n [%]):	Sp 97.0% 94.7% 99.3%	regardless of morphology US score
	Prospective case series	Post (> 55): 57	NR	PPV 81.8% 68.7% 95.0%	Pre-study history (symptomatic vs
	Reference standard:	Race/ethnicity (n [%]):	Additional data used for	NPV 98.5% 96.8% 100.0%	asymptomatic) not described
	Histology	Italian	diagnosis:	2) Test characteristics based on	Quality assessment:
			None	morphological score (Ferrazzi)	Reference standard: +
	Reference standard applied to all test	Risk factors (n [%]): NR		Dis+ Dis- Tot	Verification bias: + Test reliability/variability: -
	negatives?:			T+ 28 24 52	Sample size: -
	Assumed yes	Inclusion criteria:		T- 2 180 182	Statistical tests: +
	Test reliability	Patients undergoing elective surgical treatment		Tot 30 204 234	Blinding: - Definition of +/- on screening test:
	established?:	for adnexal masses		Laura Hanan	+
	NR			Lower Upper Value 95% CI 95% CI	
		Exclusion criteria:		Se 93.0% 83.9% 100.0%	
	Statistical tests used:	NR		Sp 88.0% 83.5% 92.5%	
	Student t-tests			PPV 53.8% 40.3% 67.4%	
	Mann Witney U Fischers Exact			NPV 98.9% 97.4% 100.0%	
	McNemars				
	monternare			3) CA-125 > 35 U/ml	
	Blinding:			Dis+ Dis- Tot	
	NR			T+ 22 1 23	
	Definition of positive			T- 6 23 29	
	and negative on			Tot 28 24 52	
	screening test:				
	Ferrazzi's morphological			Lower Upper	
	score (table 1)			Value 95% CI 95% CI Se 78.6% 63.4% 93.8%	
	Ultrasound			Se 78.6% 63.4% 93.8% Sp 95.8% 87.8% 100.0%	
	1 = ≤ 3 mm; septa =			PPV 95.7% 87.3% 100.0%	
	none, vegetations =			NPV 79.3% 64.6% 94.1%	
	none; echogenicity = Sololucent				
	2 = > 3 mm, septa > 3			4) RI ≤ 0.6	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring	
Study	Study Design mm, low echogenicity 3 = septa > 3 mm, 4 = irregular, mostly solid; vegetations ≤ 3, with echogenic areas 5 = irregular, non- applicable, > 3mm, with heterogeneous echogenic areas, solid Score ≥ 9 considered suspicious for malignancy Additional factors considered Mean diameter ≥ 10 cm;	mm, low echogenicity 3 = septa > 3 mm, 4 = irregular, mostly solid; vegetations ≤ 3, with echogenic areas 5 = irregular, non- applicable, > 3mm, with heterogeneous echogenic areas, solid Score ≥ 9 considered suspicious for malignancy Additional factors considered			Dis+ Dis- Tot T+ 19 6 25 T- 9 18 27 Tot 28 24 52 Lower Upper Value 95% CI 95% CI Se 67.9% 50.6% 85.2% Sp 75.0% 57.7% 92.3% PPV 76.0% 59.3% 92.7% NPV 66.7% 48.9% 84.4%	
	immobility, bilaterality, presence of ascites, resistance index < 0.6 and serum CA-125 > 35 IUmI Note: additional factors used to develop an algorithm. Algorithm compared to					
	morphological score. Low risk – masses with score < 9 mm and typica cystic teratomas	I				
	Moderate risk ≥ 9 suspicious for malignancy, absence of any one of the additional criteria defined above					
	High risk ≥ 9 and any of the above factors.					

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Bromley, Goodman,	Geographical location: Boston, MA	Age: NR	Symptomatic (n [%]) : NR	1) Scoring system	Comments: Unclear where RI 0.6 came from
and		•• • • • •		Dis+ Dis- Tot	Borderline tumors in malignant
Benacerraf, 1994	Dates: Mar 1992-Apr 1993	Menopausal status (n [%]): Post (> 55): 100%	Detected by exam (n [%]): NR	T+ 11 10 21 T- 1 11 12 T- 0 01 02	group 33 sonographic masses in 1 year seems rather low for tertiary
#4630	Size of population:	FOST (> 55). 100 %	Detected by imaging	Tot 12 21 33	women's hospital
4050	33	Race/ethnicity (n [%]):	(n [%]):	Lower Upper	Pre-study history (symptomatic vs
	55	NR	NR	Lower Upper Value 95% CI 95% CI	asymptomatic) not described
	Other			Value 95% CI 95% CI Se 91.0% 74.8% 100.0%	asymptomatic) not described
	Prospective series	Risk factors (n [%]):	Combination (n [%]):	Sp 52.0% 30.6% 73.4%	Quality assessment:
		NR	NR	PPV 52.4% 31.0% 73.7%	Reference standard: +
	Reference standard:			NPV 91.7% 76.0% 100.0%	Verification bias: +
	Pathology	Inclusion criteria:	Additional data used for	NFV 91.7% 70.0% 100.0%	Test reliability/variability:-
	r allology	Pelvic masses diagnosed	diagnosis:	2) Resistance index using 0.6	Sample size: -
	Reference standard	by sonography and	Scanned transabdominally	2) Resistance index using 0.0	Statistical tests: -
	applied to all test	histopathologic verification		Dis+ Dis- Tot	Blinding: -
	negatives?:	of disease		T+ 8 4 12	Definition of +/- on screening test:
	Yes	Consecutive cases		$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	+
	Test reliability	Exclusion criteria:		Tot 12 21 33	
	established?:	NR		Lower Upper	
	NR			Lower Upper Value 95% CI 95% CI	
	Statistical tests used:				
	None stated			Sp 81.0% 64.2% 97.8% PPV 66.7% 40.0% 93.3%	
	Se, Sp, PPV, NPV			PPV 66.7% 40.0% 93.3% NPV 81.0% 64.2% 97.7%	
				NPV 81.0% 64.2% 97.7%	
	Blinding:				
	NR				
	Definition of positive				
	and negative on				
	screening test:				
	Sonography				
	Clear cyst < 3 cm -1				
	Clear cyst ≥ 3 cm – 2				
	Cyst with slight irregular				
	wall on one side 3				
	Cyst with uniform low-				
	level echoes or a single				
	thin septation - 4				
	Solid ovarian				
	enlargement; cyst with				
	irregular borders,				

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	nonspecific ovarian masses 5-6 Multiple septations and nodular cystic mass 7-9 7 = less nodularity; 9 = more nodules and septations Same as 7-9 with ascites 10	 ;						
	Doppler Resistance index = (systolic peak – diastolic trough)/ systolic peak							
	Lowest resistance index used RI < 0.6							
Brown, Doubilet, Miller, et al.,	Geographical location: Boston, MA			1) Malignancy score – cutoff 453 AUC 0.98 \pm 0.01			ff 453	Comments: No model validation Pre-study history (symptomatic vs
1998	Dates: Jul 1991-Jul	Ū	Detected by exam (n [%]):		Dis+	Dis-	Tot	asymptomatic) not described
#3350	1996	Menopausal status (n [%]):	NR	T+ T	26	13	39	Quality assessment:
#3330	Size of population: 194	Pre (< 45): 135 (69.6%) Post (> 55): 38 (19.6%) don't add to 100%	Detected by imaging (n [%]): NR	T- Tot	2 28	183	172 211	Reference standard: + Verification bias: + Test reliability/variability: -
	Other	because 21 (10.8%) had			Value	Lower 95% Cl	Upper 95% CI	Sample size: -
	Consecutive patients	hysterectomy	Combination (n [%]):	Se	93.0%	83.5%	100.0%	Statistical tests: +
	Reference standard:	Paga/othniaity (n [9/])	NR	Sp	93.0%	89.3%	96.7%	Blinding: - Definition of +/- on screening test: ·
	Histopathology	Race/ethnicity (n [%]): NR	Additional data used for diagnosis:	PPV NPV	66.7% 98.8%	51.9% 97.2%	81.5% 100.0%	variables in model not specified, no independent validation
	Reference standard applied to all test negatives?:	applied to all test NR			ignancy so .98 ± 0.01	core – cuto	ff 433	
	No (but negatives without	Inclusion criteria:	logistic regression model		Diat	Die	Tot	
	surgery had followup US		derived from gray-scale and	T+	Dis+ 28	Dis-	54	
	that demonstrated	scanned at the institution	Doppler sonography features	T-	0		157	
	resolution)	where both gray-scale and	Solid component	Tot	28	183	211	
	Test reliability	Doppler sonography had been done and	None (0)					
	established?:		Hyperechoic (13)		\/_b	Lower 95% CI	Upper	
			,,		Value		95% CI	

Study	Study Design	Patients Pregnant masses Premenopausal patients > 10 days after LMP Simple cysts < 2 cm in premenopausal women Extraovarian masses on US	Clinical Presentation	Resu	ts		Comments/Quality Scoring	
	Statistical tests used: Mann-Whitney U test Fisher exact test Chi-square Stepwise logistic regression ROC curves Blinding: Yes US done prospectively, scale done after by blinded individual Definition of positive and negative on screening test: See column 3		Fluid component (anechoic, echogenic, none) Septations Thin (0) Thick (22) None (38) Wall (thin, thick, none) Free fluid Present (38) Absent (0) Bilateral masses (yes, no) Size, average (cm) Size, maximum (cm) Flow location Central (37) Peripheral only (1) None detected (0)	Se Sp PPV NPV	100.0% 85.8% 51.9% 100.0%	89.3% 80.7% 38.5% 98.1%	100.0% 90.9% 65.2% 100.0%	
Buckshee, Temsu, Bhatla, et al., 1998	Geographical location: New Delhi, India Dates: May 1995-Apr 1997	Age: 20-30: n = 10 31-40: n = 13 41-50: n = 6 > 50: n = 5	Symptomatic (n [%]): 1) PE (diagnosed as NR Dis+ [Detected by exam (n [%]): T+ 7 NR T- 2				nant = T+) Tot 10 26	Comments: Unclear how patients were choser given non-consecutive enrollment Did blind PE to US This study validates previous
#710	Size of population: 34 individuals 36 tumors	Menopausal status (n [%]): Pre (< 40): 23 (67.6%)	Detected by imaging (n [%]): NR	Tot	9 Value	24 27 Lower 95% CI	36 Upper 95% CI	measures PI and Sassone Pre-study history (symptomatic vs asymptomatic) not described
	Other Reference standard:	Peri (41-50): 6 (17.6) Post (> 50): 5 (14.7%) Race/ethnicity (n [%]):	Combination (n [%]) : NR	Se Sp PPV NPV	77.8% 88.9% 70.0% 92.3%	50.6% 77.1% 41.6% 82.1%	100.0% 100.0% 98.4% 100.0%	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: -
	Histopathology Reference standard applied to all test	Risk factors (n [%]): Family history: 1 (2.9%)	Additional data used for diagnosis: NR		JS score (≥ 9 indicat	tes T+) Sassone	Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: ·
	negatives?: Yes Test reliability established?:	Inclusion criteria: Women with presumed adnexal mass going to surgery		T+ T- Tot	Dis+ 9 0 9	Dis- 4 23 27	Tot 13 23 36	
	No for PE Yes for US	Exclusion criteria: Women with proven			Value	Lower 95% CI	Upper 95% CI	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Statistical tests used:	diagnosis of		Se 100.0% 66.7% 100.0%	
	Fisher's exact test	malignancy/metastatic		Sp 85.2% 71.8% 98.6%	
	Se, Sp	disease on ultrasound or		PPV 69.2% 44.1% 94.3%	
		СТ		NPV 100.0% 87.0% 100.0%	
	Blinding:				
	No but prospective enrollment			3) Pulsatility Index (< 1 indicates T+)	
	PE was blinded to US			Dis+ Dis- Tot	
	result			T+ 6 1 7	
	result			T- 3 26 29	
	Definition of positive			Tot 9 27 36	
	and negative on			101 9 27 30	
	screening test:			Lower Upper	
	PE – clinical impression				
	of benign or malignant				
	Gray-scale sonography –				
	Sassone criteria ≥ 9			Sp 96.3% 89.2% 100.0% PPV 85.7% 59.8% 100.0%	
	malignant			NPV 89.7% 59.8% 100.0%	
	PI < 1 malignant			NFV 09.7 // 70.0 // 100.0 //	
Pulat	Coorrentical location	A	Sumatomotic (n F0/1).		Commente
Buist,	Geographical location: The Netherlands	Age: Median: 60	Symptomatic (n [%]): NR	Data are for primary cancer	Comments:
Golding,	The Nethenands	Range: 24-84	NR	Recurrent presented but not included here.	PE by gynecological oncologist Population "clinically suspected of
Burger, et al., 1994	Dates: Nov 1988-Sep	Range. 24-04	Detected by exam (n [%]):	1) CT – reviewer a	having primary or recurrent ovarian
al., 1994	1992	Menopausal status	NR	I) CI – leviewei a	CA"-likely to increase sensitivity of
#960	1992	•	INF	Dis+ Dis- Tot	unblinded physical exam
4900	Size of population:	(n [%]): NR	Detected by imaging	T+ 26 10 36	45 with r/o primary cancer, 19 with
	64	INIT	(n [%]):		r/o recurrence (2x2 tables for r/o
	04	Race/ethnicity (n [%]):	(II [/0]). NR	T- <u>1</u> 8 9 Tot 27 18 45	primary group)
	Other	NR	INF	10t 27 18 45	Imaging used descriptive yes/no fo
	Prospective series		Combination (n [%]):	Lewen Hener	cancer – no scoring system used for
	i lospective series	Risk factors (n [%]):	NR	Lower Upper	test
	Reference standard:	NR		Value 95% CI 95% CI	No CA-125 level stated
	Pathology		Additional data used for	Se 96.0% 88.6% 100.0%	No PE criteria stated
	i athology	Inclusion criteria:	diagnosis:	Sp 44.0% 21.1% 66.9%	Pre-study history (symptomatic vs
	Reference standard	Clinically suspected of	NR	PPV 72.2% 57.6% 86.9%	asymptomatic) not described
	applied to all test	having primary or		NPV 88.9% 68.4% 100.0%	
	negatives?:	recurrent cancer		2) CT reviewerk	Quality assessment:
	Yes			2) CT – reviewer b	Reference standard: +
	100	Exclusion criteria:			Verification bias: +
	Test reliability	Declined participation,		Dis+ Dis- Tot	Test reliability/variability: +
	established?:	contraindications for one		T+ 24 3 27	Sample size: -; wide confidence
	Yes	of the diagnostic methods		T- <u>3 15</u> 18	intervals
	169	or organizational reasons		Tot 27 18 45	Statistical tests: +
	Statistical tasts used				
	Statistical tests used:	prevented all methods			Blinding: + for final results, but

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	ROC curves Fisher's exact Chi-square Se, Sp Blinding: Yes	being performed before surgery		Value Lower 95% CI Upper 95% CI Se 89.0% 77.2% 100.0% Sp 83.0% 65.6% 100.0% PPV 88.9% 77.0% 100.0% NPV 83.3% 66.1% 100.0%	examiners all knew patient suspected of having disease Definition of +/- on screening test -
	Definition of positive and negative on			3) MRI – reviewer a Dis+ Dis- Tot	
	screening test: NR			$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
				LowerUpper 95% CISe96.0%88.6%100.0%Sp33.0%11.3%54.7%PPV68.4%53.6%83.2%NPV85.7%59.8%100.0%	
				4) MRI – reviewer b	
				Dis+ Dis- Tot T+ 26 1 27 T- 1 17 18 Tot 27 18 45	
				ValueLower 95% CIUpper 95% CISe96.0%88.6%100.0%Sp94.0%83.0%100.0%PPV96.3%89.2%100.0%NPV94.4%83.9%100.0%	
				5) US	
				Dis+ Dis- Tot T+ 24 10 34 T- 3 8 11 Tot 27 18 45	
				Lower Upper Value 95% CI 95% CI Se 89.0% 77.2% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Sp44.0%21.1%66.9%PPV70.6%55.3%85.9%NPV72.7%46.4%99.0%	
				6) Physical Exam	
				Dis+ Dis- Tot T+ 26 1 27 T- 1 17 18 Tot 27 18 45	
				Lower Upper 95% CI 95% CI 96.0% 88.6% 100.0% Sp 94.0% 83.0% 100.0% PPV 96.3% 89.2% 100.0% NPV 94.4% 83.9% 100.0%	
				7) CA-125	
				Dis+ Dis- Tot T+ 22 6 28 T- 5 12 17 Tot 27 18 45	
				ValueLower 95% CIUpper 95% CISe81.0%66.2%95.8%Sp67.0%45.3%88.7%PPV78.6%63.4%93.8%NPV70.6%48.9%92.2%	
				Kappa for inter-observer reliability: CT = 0.28 MRI = 0.41	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Buy, Ghossain, Hugol, et al.	Geographical location: Paris, France	Age: Benign Mean: 40	Symptomatic (n [%]) : NR	 Conventional sonography – indeterminate masses classified as malignant 	Comments: Unable to stratify Menopause not defined
1996	Dates: Jan 1993 – Dec 1994	Range: 22-73 Menopausal = 28	Detected by exam (n [%]): NR	Dis+ Dis- Tot	No scoring system for US – descriptive only
#4030		Borderline		T+ 22 16 38	Borderline on both US and on path
	Size of population: 160 patients 115 met inclusion criteria	47 and 50 years Both premenopausal	Detected by imaging (n [%]): NR	T- <u>3</u> 74 77 Tot <u>25 90</u> 115	grouped in with malignant in analysis Pre-study history (symptomatic vs asymptomatic) not described
	01	Malignant		Lower Upper	0
	Other Prospective series	57 mean; 22-84 Menopausal =15	Combination (n [%]): NR	Value 95% CI 95% CI	Quality assessment: Reference standard: +
		Menopausai – 15		Se <mark>88.0%</mark> 75.3% 100.0% Sp <mark>82.0%</mark> 74.1% 89.9%	Verification bias: +
	Reference standard:	Menopausal status	Additional data used for	PPV 57.9% 42.2% 73.6%	Test reliability/variability: -
	Pathology	(n [%]):	diagnosis:	NPV 96.1% 91.8% 100.0%	Sample size: -
	Reference standard applied to all test	Pre (< 45): 72 (63%) Post (> 55): 43 (37%)	NR	2) Color Doppler and sonography	Statistical tests: + Blinding: - Definition of +/- on screening test:
	negatives?:	Race/ethnicity (n [%]):		Dis+ Dis- Tot	+
	Yes	NR		T+ 22 3 25	
	Test reliability established?:	Risk factors (n [%]): NR		T- <u>3</u> 8790 Tot 2590 115	
	No	Inclusion criteria.		Lower Upper	
	Statistical tests used:	Inclusion criteria: Adnexal mass suspected		Value 95% CI 95% CI	
	Mann Witney	by physical exam or		Se 88.0% 75.3% 100.0% Sp 97.0% 93.5% 100.0%	
	McNemar	discovered during		PPV 88.0% 75.3% 100.0%	
	Dlinding	previous sonography		NPV 96.7% 93.0% 100.0%	
	Blinding: NR	Only patients who had laparoscopy			
		Laparotomy (not		3) Resistive Index	
	Definition of positive	laproscopy)		Dis+ Dis- Tot	
	and negative on	included.		T+ 5 3 8	
	screening test: Sonography	Exclusion criteria:		T- 21 87 108	
	Borderline or malignant	NR		Tot 25 90 116	
	Echogenic structure			Lower Linner	
	against the wall of the			Lower Upper Value 95% CI 95% CI	
	cyst present; large			Se 18.0% 2.9% 33.1%	
	irregular homogeneous or heterogeneous			Sp 97.0% 93.5% 100.0%	
	echogenic structure			PPV 62.5% 29.0% 96.0%	
	Irregular thickened (3			NPV 80.6% 73.1% 88.0%	
	mm) wall or septum				

tudy	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	present.			4) Pulsatility Index	
	Benign – mass did not			Dis+ Dis- Tot	
	present with any of the			T+ 18 3 21	
	findings of malignant			T- 7 87 94	
	tumors, or pattern typical			Tot 25 90 115	
	of a benign ovarian				
	mass.			Lower Upper	
				Value 95% CI 95% CI	
	Method 2. Morphology +			Se 71.0% 53.2% 88.8%	
	color Doppler			Sp 97.0% 93.5% 100.0%	
	Presence of color flow in			PPV 85.7% 70.7% 100.0%	
	echogenic portion			NPV 92.6% 87.2% 97.9%	
	charac. As malignant -				
	considered malignant			5) Peak systolic velocity	
	Absence of color flow –			Dis+ Dis- Tot	
	considered benign			T+ 12 3 15	
	-			T- 13 87 100	
	If mass classified as			Tot 25 90 115	
	benign using morphology	1		100 25 50 115	
	then malignant if color			Lower Upper	
	flow in a regular wall,			Value 95% CI 95% CI	
	regular septum or regular	r		Se 47.0% 27.4% 66.6%	
	solid mass – benign.			Sp 97.0% 93.5% 100.0%	
	No color flow – benign.			PPV 80.0% 59.8% 100.0%	
				NPV 87.0% 80.4% 93.6%	
	Method 3.			NIV 07.070 00.470 93.070	
	Spectral Doppler analysis	3			
	Absence of arterial flow -	-			
	considered benign.				
	Measured RI, PI and				
	PSV (no definition				
	provided). Lowest values				
	retained.				
	Mass malignant if				
	Resistive Index ≤ 0.4;				
	Pulsatility Index ≤ 1 and				
	Peak systolic velocity ≥				
	15 cm/sec.				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Canis, Pouly, Wattiez, et	Geographical location: Clermont-Ferrand, France	Age: NR	Symptomatic (n [%]) : NR	 Ultrasound results; low malignant potential = benign 	Comments: Clinical history not described Other test results (CA-125) not
al., 1997	Dates: Jan 1992-Dec	Menopausal status (n [%]):	Detected by exam (n [%]) : NR	Dis+ Dis- Tot T+ 29 218 247	given Not stated whether TVUS or
#3710	1994	NR		T- 1 310 311	abdominal US
	Size of population:	Race/ethnicity (n [%]):	Detected by imaging (n [%]):	Tot 30 528 558	Quality assessment:
	558	NR	NR	Lower Upper Value 95% CI 95% CI	Reference standard:+ Verification bias:+
	Other Case series	Risk factors (n [%]): NR	Combination (n [%]): NR	Se 96.7% 90.2% 100.0% Sp 58.7% 54.5% 62.9%	Test reliability/variability: - Sample size: +
	Reference standard:	Inclusion criteria:	Additional data used for	PPV 11.7% 7.7% 15.8% NPV 99.7% 99.0% 100.0%	Statistical tests: + Blinding: -
	Surgery	NR	diagnosis : NR	2) Low malignant potential = cancer	Definition of +/- on screening test: +
	Reference standard applied to all test	Exclusion criteria: Masses discovered at		Dis+ Dis- Tot	
	negatives?: Yes	surgery		T+ 43 204 247 T- 2 309 311	
	Test reliability			Tot 45 513 558	
	established?: No			Lower Upper Value 95% CI 95% CI	
	Statistical tests used:			Se 95.6% 89.5% 100.0% Sp 60.2% 56.0% 64.5%	
	Se, Sp			PPV 17.4% 12.7% 22.1% NPV 99.4% 98.5% 100.0%	
	Blinding: No				
	Definition of positive and negative on				
	screening test: Ultrasound "suspicious" if				
	solid, mixed, mixed with calcified area,				
	vegetations, cyst wall \geq 3 mm, thick septa \geq 3 mm,				
	 > 3 septae, multicystic, or ascites"; otherwise 				
	considered benign				

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
Carter, lles, Neven, et al., 1993	Geographical location: England	NR	Not specified Symptomatic (n [%]): NR				o stratify table by	Comments: Pre-study history (symptomatic vs. asymptomatic) not described
#6370	Dates: NR Size of population: 152 Study type NR Reference standard: Histology Reference standard applied to all test negatives?: Yes Test reliability established?: For CA-125 Statistical tests used: None Blinding: NR Definition of positive and negative on screening test: "95% of normal blood samples have a CA-125 level < 37.2 u/ml" but not necessarily used	Menopausal status (n [%]): Pre (< 45): 86 Post (> 55): 66 Race/ethnicity (n [%]): NR Risk factors (n [%]): None Inclusion criteria: Presentation with pelvic mass Exclusion criteria: NR	Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	T+ T- Tot Sp PPV NPV	Dis+ 77 10 87 Value 88.5% 98.5% 98.7% 86.5%	Dis- 1 64 65 Lower 95% CI 81.8% 95.5% 96.2% 78.7%	Tot 78 74 152 Upper <u>95% CI</u> 95.2% 100.0% 94.3%	Unclear how patients selected Recurrent disease included in sample CA-125 cutoff not clearly defined (35? 37.2?) Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + Sample size: + Statistical tests: + Blinding: - Definition of +/- on screening test: -

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Carter, Lau, Fowler, et al., 1995	Geographical location: Minneapolis, MN	Age: Mean: 48.3	Symptomatic (n [%]): NR	1) PI < 1.0 (AUC = 0.732 ± 0.069)	Comments: No results by menopausal status
	Dates: NR	Menopausal status	Detected by exam (n [%]):	<u>Dis+ Dis-</u> Tot T+ <u>13 21</u> 34	Pre-study history (symptomatic vs. asymptomatic) not described
#4240	Size of population:	(n [%]): Pre (< 45): 72 (58.5%)	NR	T- <u>10 79</u> 89 Tot 23 100 123	Quality assessment:
	123 women	Post (> 55): 51(41.5%)	Detected by imaging (n [%]):	Lower Upper	Reference standard: + Verification bias: +
	Other Consecutive	Race/ethnicity (n [%]):	NR	Value 95% CI 95% CI	Test reliability/variability: +/- Sample size: -
			Combination (n [%]):	Se 57.0% 36.8% 77.2% Sp 79.0% 71.0% 87.0%	Statistical tests: +
	Reference standard: Histopathology or 12	Risk factors (n [%]): NR	NR	PPV 38.2% 21.9% 54.6% NPV 88.8% 82.2% 95.3%	Blinding: + Definition of +/- on screening test: +
	month followup	Inclusion criteria:	Additional data used for diagnosis:		5
	Reference standard	Women with suspected	NR	2) RI < 0.4 (AUC = 0.684 ± 0.068)	
	applied to all test negatives?:	adnexal mass presenting to University of Minn		Dis+ Dis- Tot T+ 5 4 9	
	No, but those without operative intervention	women's hospital		T- 18 96 114	
	were followed by US for	Exclusion criteria:		Tot 23 100 123	
	12 months	NR (everyone else)		Lower Upper Value 95% CI 95% CI	
	Test reliability established?:			Se 22.0% 5.1% 38.9%	
	Yes			Sp 96.0% 92.2% 99.8% PPV 55.6% 23.1% 88.0%	
	Statistical tests used:			NPV 84.2% 77.5% 90.9%	
	Se, Sp Chi-squared ROC			2x2 table also calculable for PI at cutoffs of 0.6, 0.8 and 1.4	
	Blinding: NR but prospective study (but not blinded to clinical history)			RI at cutoffs of 0.6, 0.8 and 1.0	
	Definition of positive and negative on screening test: Calculated from ROC curves Best P I< 1.0 RI < 0.4				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Caruso, Caforio,	Geographical location: Rome, Italy	Age: Mean (SD): 38.4 (16.5)	Symptomatic (n [%]): NR	1) Sasonne's criteria	Comments: Aside from Valentin scoring system
Testa, et al.,		Mean (SD). 36.4 (10.5)		Dis+ Dis- Tot	(which the authors described as
1996	Dates: NR	Menopausal status	Detected by exam (n [%]):	T+ 21 27 48	"arbitrary"), no description of other
		(n [%]):	NR	T- 0 74 74	scoring systems
#3810	Size of population:	Pre: 88 (70.5%)		Tot 21 101 122	Their "vascular scoring system" -
	122	Post: 36 (29.5%)	Detected by imaging		mostly subjective measurements
			(n [%]):	Lower Upper	save RI of 0.43 as RI cutoff.
	Other	Race/ethnicity (n [%]):	NR	Value 95% CI 95% CI	Menopause not defined and unable
	Consecutive patients with	NR		Se 100.0% 85.7% 100.0%	to stratify. Statement in text must be
	diagnosis of adnexal		Combination (n [%]):	Sp 73.3% 64.6% 81.9%	error ("the % of postmenopausal
	mass scheduled for	Risk factors (n [%]):	NR	PPV 43.8% 29.7% 57.8%	women with benign and malignant
	surgery	NR		NPV 100.0% 95.9% 100.0%	lesions was 21 and 71%
	Reference standard:	Inclusion criteria:	Additional data used for		respectively")
	Histopathology	122 consecutive patients	diagnosis: NR	2) DePriest Score	Reported Se/Sp for Sassone criteria (Table 5) do not agree
	riistopatilology	with diagnosis of adnexal		Dia L Dia Tat	precisely with data reported in Fig 3
	Reference standard	mass scheduled to		Dis+ Dis- Tot T+ 21 31 52	precisely with data reported in Fig.5
	applied to all test	undergo surgery at the		T- 0 70 70	Quality assessment:
	negatives?:	study hospital		Tot 21 101 122	Reference standard: +
	Yes	· ·		101 21 101 122	Verification bias: +
		Exclusion criteria:		Lower Upper	Test reliability/variability: ? for
	Test reliability	NR		Value 95% CI 95% CI	Sassonne, De Preist and Valentin
	established?:			Se 100.0% 85.7% 100.0%	(references given but no discussion
	Sasonne's [3] – yes			Sp 69.3% 60.3% 78.3%	of reliability)
	DePriest {1} - ?			PPV 40.4% 27.0% 53.7%	+ for "vascular score" – intraobserver
	Valentine [2] - ?			NPV 100.0% 95.7% 100.0%	CV was calculated for RI portion of
	"Vascular score" - NO				the score on 10 patients and was 3.5 (+/-%)
	Statistical tests used:			3) Valentin score	Sample size: -
	Student's t test				Statistical tests: +
	Fisher's exact test			Dis+ Dis- Tot	Blinding: - to clinical history but
				T+ 21 39 60	prospective in that US preceded
	Blinding:			T- 0 62 62	surgery
	NR but US prior to			Tot 21 101 122	Definition of +/- on screening test: +
	surgery			Lower Lloper	for Valentin and vascular
				Lower Upper Value 95% CI 95% CI	Others assumed from literature
	Definition of positive			Se 100.0% 85.7% 100.0%	
	and negative on			Sp 61.4% 51.9% 70.9%	
	screening test:			PPV 35.0% 22.9% 47.1%	
	Sasonne and DePriest – not described			NPV 100.0% 95.2% 100.0%	
	Valentine positive ≥ 3				
	(where 1 = unilocular			4) Vascular score	
				-	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	cyst, 3 = unilocular solid cyst, 4 = multilocular solid tumor, 5 = solid tumor)			Dis+ Dis- Tot T+ 21 8 29 T- 0 93 93	
	"Vascular score" – [table1] ≥ 5 is positive (where 1 for vessels present, vascular location 1 for pericystic 2 for in solid part, 2 for randomly			Tot 21 101 122 Lower Upper Value 95% CI 95% CI Se 100.0% 85.7% 100.0% Sp 92.1% 86.8% 97.3%	
	dispersed vessels, 2 for "smooth waveform", 2 for lowest RI < 0.430	-		 PPV 72.4% 56.1% 88.7% NPV 100.0% 96.8% 100.0% 5) Vascular score excluding the 6 patients with a score .+5 studied in luteal phase 	5
				Dis+ Dis- Tot T+ 18 4 22 T- 0 93 93 Tot 18 97 115	
				Lower Upper Value 95% CI 95% CI Se 100.0% 83.3% 100.0% Sp 96.0% 92.1% 99.9% PPV 81.8% 65.7% 97.9% NPV 100.0% 96.8% 100.0%	

Platelets > 400,000/pico L

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Chalas, Welshinger, Engellener, et al., 1992 #5100	Geographical location: Stony Brook, NY Dates: May 1980-Apr 1990 Size of population: 288 (47 excluded) Other Series of patients at single center with pelvic mass who were operated	Age: NR Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR	Results 1) CA-125 > 35 Dis+ Dis- Tot T+ 60 8 68 62 Tot 74 56 130 Dis- Cl 95% Cl 9	Comments: LMP tumors grouped in with malignant Although Se, Sp reported for CA- 125 and platelets for age > 50, no other numbers reported (no n) ; cannot do 2x2 table; reported Se fo CA-125 74% < 50, 85% > 50, Sp 83% < 50, 88% > 50; for thrombocytosis, Se < 50 50%, > 50 60%; Sp < 50 83%, > 50 87% Se, Sp in abstract differ from those in table VI (which is consistent with
	on Reference standard: Histopathology	Inclusion criteria: Women with pelvic mass diagnosis who underwent surgery in hospital during	Additional data used for diagnosis: NR	2) Platelets > 400,000/microliter Dis+ Dis- Tot	calculations from table V) Clinical presentation not described Quality assessment:
	Reference standard applied to all test negatives?: Yes	time frame Exclusion criteria: 47 excluded because 1) lack of preop platelet		T+ 78 16 94 T- 61 86 147 Tot 139 102 241 Lower Upper	Reference standard: + Verification bias: + Test reliability/variability: +/- Sample size: - Statistical tests: +
	Test reliability established?: Yes for CA-125 No for platelet count	count 2) underlying condition associated with thrombocytosis		Value 95% Cl 95% Cl Se 56.1% 47.9% 64.4% Sp 84.3% 77.3% 91.4% PPV 83.0% 75.4% 90.6% NPV 58.5% 50.5% 66.5%	Blinding: + Definition of +/- on screening test: ·
	Statistical tests used: Chi-square Se, Sp				
	Blinding: NR But prospective				
	Definition of positive and negative on screening test: CA-125 > 35U/mL				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Chen, Schwartz, and Li, 1990 #5330	Geographical location: China Dates: NR Size of population: 188 Other Convenience sample Reference standard: Histology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: Regression analyses Chi-square Blinding: NR Definition of positive and negative on screening test: CA-125 (serum) > 65 U/ml considered positive	Age: 20-42 for healthy blood donors – age not provided for 92 patients with benign pelvic masses and 41 patients with malignant masses of whom 16 had ovarian cancer Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: 55 health female blood donors 92 patients with benign pelvic masses 41 patients with malignant masses Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) CA-125 – serum (among the 92 women with benign masses and 16 patients with ovarian cancer) T+ <u>Dis+ Dis-</u> Tot T- <u>15 37</u> 52 Tot <u>16 92</u> 108 <u>Value 95% Cl 95% Cl</u> Se <u>93.8% 82.0% 100.0%</u> Sp <u>59.8% 49.8% 69.8%</u> PPV 28.8% 16.5% 41.2% NPV 98.2% 94.7% 100.0%	Comments: Knew in advance what the diagnosis was, so don't know how this impacted outcomes. CA-125 ≥ 65 = + Borderline included in malignant Not prospective Clinical presentation not described Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Only 8 ovarian cancers Statistical tests: + Blinding: - Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Chen, Schwartz,	Geographical location: Changsha, China	Age: Mean (SD): Benign masses 38 (11)	Symptomatic (n [%]): NR	1) CA-125 for 211 operative patients (> 35 U/ml = T+)	Comments: No follow up on "normal" patient group (especially the 2 with CA-125
Li, et al., 1988	Dates: Sep 1985 – Aug 1986	Malignant 43 (5)	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 48 61 109	 > 35) therefore excluded from 2x2 table
#6870	Size of population: 211 preoperative 44 normal patients Other "Screening" for "normal"	Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR Combination (n [%]): NR	T- Tot To	Borderline masses included in malignant group (there were 4) No description of how subjects chosen (consecutive NR) Most analyses use CA-125 > 65 as abnormal This study illustrates the impact of
	patients (but no follow up described) For 211 – diagnosis of	Risk factors (n [%]): NR	Additional data used for diagnosis:	PPV 44.0% 34.7% 53.4% NPV 90.2% 84.4% 96.0%	excluding non-ovarian malignancies from the analysis
	mass undergoing surgery at the hospital	"Normal" – normal physical exam and LFTs	NR	 CA-125 (> 35 U/ml = T+) limited to patients with epithelial ovarian cancer (excludes non-ovarian malignancies) 	Quality assessment: Reference standard: + Verification bias: +
	Reference standard: Histopathology	211 – "pelvic mass" who had surgery		Dis+ Dis- Tot T+ 30 61 91	Test reliability/variability: + Sample size: - not described Statistical tests: +
	Reference standard applied to all test negatives?: Not to "normal"	Exclusion criteria:		T- 0 92 92 Tot 30 153 183	Blinding: - but testing before surger Definition of +/- on screening test: +
	comparison group but to all of 211 preop patients.			Lower Upper Value 95% CI 95% CI Se 100.0% 90.0% 100.0% CO 00 00 00 00 00 00 00	
	Test reliability established?: Yes			Sp 60.1% 52.3% 67.9% PPV 33.0% 23.3% 42.6% NPV 100.0% 96.7% 100.0%	
	Statistical tests used: Se, Sp			2x2 tables also provided for cutoffs of > 65 U/ml and > 194 U/ml	
	Blinding: NR but testing preceded surgery				
	Definition of positive and negative on screening test: CA-125 > 35 (see comments)				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Chou, Chang, Yao, et al., 1994	Geographical location: Taiwan, China	Age: Mean: 38 Range: 11-85	Symptomatic (n [%]): NR	1) RI < 0.5 Dis+ Dis- Tot	Comments: 5 patients were premenarchal Unclear why the 6 patients were
#10930	Dates: Jan 1991 – Feb 1993	Menopausal status	Detected by exam (n [%]) : NR	T+ 22 7 29 T- 3 76 79	excluded (did they have a diagnosis of ovarian cancer from previous
	Size of population: 108	(n [%]): Pre (< 45): 89 (82.4%) Post (> 55): 19 (17.6%)	Detected by imaging (n [%]): NR	Tot 25 83 108 Lower Upper	surgery, etc?) Clinical pathway not described Mostly TVUS, however, abdominal used for "those patients who had no
	Case Series	Race/ethnicity (n [%]) : NR	Combination (n [%]):	Value 95% Cl 95% Cl Se 88.0% 75.3% 100.0% Sp 92.0% 86.2% 97.8%	sexual experience" – not stated how many there were
	Reference standard: Histopathology	Risk factors (n [%]): NR	NR Additional data used for	PPV 75.9% 60.3% 91.4% NPV 96.2% 92.0% 100.0%	Quality assessment: Reference standard: +
	Reference standard applied to all test	Inclusion criteria:	diagnosis: NR	2) CA-125 > 35U/ml	Verification bias: + Test reliability/variability: -
	negatives?: Yes	Scheduled for surgery in time frame for mass		Dis+ Dis- Tot T+ 23 21 44 T- 2 62 64	Sample size: - Statistical tests: + Blinding: -
	Test reliability established?:	Exclusion criteria: 6 excluded : 3 with		Tot 25 83 108	Definition of +/- on screening test: +
	Yes Statistical tests used:	ovarian CA, 1 with borderline tumor, and 2 with chronic tubal		Lower Upper Value 95% CI 95% CI Se 92.0% 81.4% 100.0%	
	Se, Sp Blinding:	pregnancy		Sp 75.0% 65.7%84.3%PPV52.3%37.5%67.0%	
	NR			NPV 96.9% 92.6% 100.0% 3) Combined CA-125 and RI	
	Definition of positive and negative on screening test:			Dis+ Dis- Tot	
	RI > 0.5 CA-125 > 35U/ml			T+ 25 2 27 T- 0 81 81 Tot 25 83 108	
				Lower Upper Value 95% CI 95% CI Se 100.0% 88.0% 100.0%	
				Se 100.0% 88.0% 100.0% Sp 97.0% 93.3% 100.0% PPV 92.6% 82.7% 100.0% NPV 100.0% 96.3% 100.0%	

Scharm, et al., 2001Pre - 32' Detes: Apr 1999-Jun 2000Pre - 32' Pre - 32' Range: 22-80Detected by exam (n [%]): NR $T + \frac{14}{14} \frac{12}{26} 440$ TotConstitued a positive test - questionable reproductibility -Doppler measurements not totDetected by maging (n [%]): NR $T + \frac{14}{14} \frac{12}{25} 840$ TotDis- TotTotConstitued a positive test - questionable reproductibility -Doppler measurements not totDetected by maging (n [%]): NRTotDis- TotTotDis- TotTotConstitued a positive test - questionable reproductibility -Doppler measurements not totDetected by maging (n [%]): NRTotDis- TotTotDis- TotTotConstitued a positive test - questionable reproductibility -Doppler measurements not tot 14 57 71Dis- Statistical tests used: Se, Sp PFV, NPVDis- Race/ethnicity (n [%]): NRDis- NRDis- TotDis- TotDis- TotDis- TotTotConstrained statistical tests used: Se, Sp PFV, NPVBinding: No - see commentsInclusion criteria: NRInclusion criteria: NRTotDis- TotDis- TotTotDis- Tot <td< th=""><th>Study</th><th>Study Design</th><th>Patients</th><th>Clinical Presentation</th><th>Results</th><th>Comments/Quality Scoring</th></td<>	Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
al., 2001 Dates: Apr 1999-Jun Post - 59 Detected by exam (n [%]): T<	Escobar,		Mean (SD):			Very poor description of what
#2460 Tot Tot 14 57 71 2D modality only in 3D - so that study is operative on screening test: Yes Post: 31 Combination (n [%]): NR NR Lower Upper -No discussion of inter-, intra Women neferred for surgery at the same hospital Receletinicity (n [%]): NR NR Se 100.0% 76.6% 100.0% -No discussion of inter-, intra -No discussion of inter-, intra No discussion of inter-, intra N	,	•	Post - 59		T+ 14 26 40	questionable reproducibility
Size of population: (T1 women Menopausal status (T1 women Menopausal status (T1 women Detected by imaging (T1 women Lower (T4): (T4	#2460	2000	Range: 22-80	NR		
Other Women refered for surgery at the same hospital Post: 31 Combination (n [%]): NR See Tobility (n [%]): NR Combination (n [%]): NR See Tobility (n [%]): NR See Tobility (n [%]): NR Combination (n [%]): NR See Tobility (n [%]): NR See Tobility (n [%]): NR Combination (n [%]): NR See Tobility (n [%]): NR See Tobility (n [%]): NR Combination (n [%]): NR See Tobility (n [%]): NR See Tobility (n [%]): NR Combination (n [%]): NR See Tobility (n [%]):	12400		(n [%]):	(n [%]):	Lower Upper	study is comparing both 2D to 3D and no Doppler to Doppler.
Women referred for surgery at the same hospital Race/ethnicity (n [%]): NR NR Sp 54.0%, 24.1.1%, PPV 41.1%, 35.0%, 30.0%		Other				
hospital NR Additional data used for diagnosis: NR NPV 100.0% 90.3% 100.0% por description of positive and polied to all test negatives?: Yes por description of positive ass referred for preoperative US Additional data used for diagnosis: NR NPV 100.0% 90.3% 100.0% 90.3% 100.0% por description of positive and polied to all test mass referred for preoperative US Dis+ Dis- Tot Cluster (14 ± 57 71) Quality assessment: Reference standard Tot See Tot Tot Tot Tot Tot See			Race/ethnicity (n [%]):	·/	Sp 54.0% 41.1% 66.9%	No discussion of inter-, intra- observer reliability (especially given
Reference standard: Histopathology Risk factors (n [%]): NR diagnosis: NR 2) 2D plus 3D TVUS colon cancer included in 14 malignant cases Reference standard applied to all test negatives?: Yes Inclusion criteria: Known 'complex,' pelvic mass referred for preoperative US T+ Tot Dis+ 14 14 57 Dis- 14 14 57 Cuality assessment: Reference standard: + Verification bias: + Test reliability established?: NR Cuality assessment: Reference standard: T- Tot Sample size - 95% CI 95% CI 95		hospital				poor description of positive test)
Histopathology NR NR NR NR MR MR <td></td> <td>Reference standard:</td> <td>Pick factors (n [%]):</td> <td></td> <td>$(\mathbf{x}) = (\mathbf{x}) + ($</td> <td>1 borderline tumor and 2 metastatic</td>		Reference standard:	Pick factors (n [%]):		$(\mathbf{x}) = (\mathbf{x}) + ($	1 borderline tumor and 2 metastatic
Reference standard applied to all test negatives ?: Yes Inclusion criteria: Known "complex" pelvic mass referred for preoperative US T+ T- T4 14 14 28 43 Quality assessment: Reference standard: + Verification bias: + Test reliability established?: No – see comments Test reliability established?: No – see comments Statistical tests used: Se, Sp PPV, NPV Blinding: No but US preoperative Definition of positive and negative on screening test: "Any multiloculated, complex, or solid mass in which the echo architecture was not highly suggestive of benign histology was					, i	
Test reliability established?: Exclusion criteria: Value Lower 95% CI 95%		applied to all test negatives?:	Known "complex" pelvic mass referred for		T+ 14 14 28 T- 0 43 43	Reference standard: + Verification bias: +
Statistical tests used: PPV 50.0% 51.5% 60.5% 1 Se, Sp NPV 100.0% 93.0% 100.0% Blinding: No but US preoperative Definition of positive and negative on screening test: * * * "Any multiloculated, complex, or solid mass in which the echo architecture was not highly suggestive of benign histology was * * *		established?:	Exclusion criteria:		Value 95% CI 95% CI Se 100.0% 78.6% 100.0% Sp 75.0% 63.8% 86.2%	Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: -
No but US preoperative Definition of positive and negative on screening test: "Any multiloculated, complex, or solid mass in which the echo architecture was not highly suggestive of benign histology was		Se, Sp				
and negative on screening test: "Any multiloculated, complex, or solid mass in which the echo architecture was not highly suggestive of benign histology was						
complex, or solid mass in which the echo architecture was not highly suggestive of benign histology was		and negative on				
architecture was not highly suggestive of benign histology was		complex, or solid mass in	ı			
benign histology was						
0		highly suggestive of benign histology was categorized as				
malignant" For 3D Doppler "masses		0				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	with central vascular flow, vascular flow with in excrescences, or flow within septations were graded malignant" based on modified system by Guerriero (ref 9)				
Davies, Jacobs, Woolas, et al., 1993 #4720	Geographical location: London Dates: NR Size of population: 124 Other Case series - Retrospective review of consecutive analysis of women with diagnosis of mass admitted to hospital for surgery Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes		Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) CA-125 > 30 U/mL T+ T- T- Tot Tot Tot Tot Tot Tot Tot Tot	Comments: Standard CA-125 cutoff of 35 not examined US scoring system for RMI (Jacobs) not often used in other contexts Clinical presentation not described Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: +; discussed Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: +
	Se, Sp Chi-square Students t test Mann-Whitney U test Blinding:			Dis+ Dis- Tot T+ 37 62 99 T- 0 25 25 Tot 37 87 124	
	NR			Lower Upper	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Definition of positive and negative on screening test: NR – because test of RMI, various cutoff values analyzed			Value 95% Cl 95% Cl Se 100.0% 91.9% 100.0% Sp 29.0% 19.5% 38.5% PPV 37.4% 27.8% 46.9% NPV 100.0% 88.0% 100.0% 4) US 3 3	
				Dis+ Dis- Tot T+ 32 23 55 T- 5 64 69 Tot 37 87 124	
				LowerUpperValue95% CI95% CISe87.0%76.2%97.8%Sp74.0%64.8%83.2%PPV58.2%45.1%71.2%NPV92.8%86.6%98.9%	
				5) Menopausal status alone	
				Dis+ Dis- Tot T+ 32 36 68 T- 5 51 56 Tot 37 87 124	
				Lower Upper Value 95% CI 95% CI Se 87.0% 76.2% 97.8% Sp 59.0% 48.7% 69.3% PPV 47.1% 35.2% 58.9% NPV 91.1% 83.6% 98.5%	

Study	Study Design	Patients	Clinical Presentation	Resu	ts			Comments/Quality Scoring
DePriest,	Geographical location:	Age:	Symptomatic (n [%]):	1) TVI	JS			Comments:
Gallion,	Kentucky	Mean: 58	0 (0%)	,				Data not provided to stratify by
Pavlik, et		Range: 30-92			Dis+	Dis-	Tot	menopausal status
l., 1997	Dates: Dec 1987-Dec	-	Detected by exam (n [%]):	T+	6	84	90	None of the cases with primary
	1993	Menopausal status	NR	Т-	1	6379	6380	ovarian cancer who had CA-125
3650		(n [%]):		Tot	7	6463	6470	drawn had level > 35
	Size of population:	Numbers of women by	Detected by imaging					DePriest morphology index used
	6470	menopausal status not	(n [%]):			Lower	Upper	90 operative cases
		specified although used as	NR		Value	95% CI	95% CI	% followup of normals not
	Screening study	an entry criterion.		Se	85.7%	59.8%	100.0%	described
			Combination (n [%]):	Sp	98.7%	98.4%	99.0%	
	Reference standard:	Race/ethnicity (n [%]):	NR	PPV	6.7%	1.5%	11.8%	Quality assessment:
	Histology and follow up	NR		NPV	100.0%	100.0%	100.0%	Reference standard: +
			Additional data used for					Verification bias: -
	Reference standard	Risk factors (n [%]):	diagnosis:	2) For	operative of	cases with	morphology	Test reliability/variability: -
	applied to all test	Family history:	NR	index <	< 4			Sample size: +
	negatives?:	Ovarian cancer = 1597						Statistical tests: +
	Followup applied	(24%)			Dis+	Dis-	Tot	Blinding: +; prospective US
		Breast cancer = 1976		T+	7	34	41	Definition of +/- on screening test:
	Test reliability	(30%)		T-	0	49	49	+
	established?:	Colon cancer = 990 (15%)		Tot	7	83	90	
	NR							
		Inclusion criteria:				Lower	Upper	
	Statistical tests used:	Asymptomatic			Value	95% CI	95% CI	
	Fischers exact test	postmenopausal women >		Se	100.0%	57.1%	100.0%	
		50 years of age		Sp	59.0%	48.5%	69.6%	
	Blinding:	Asymptomatic women >		PPV	17.1%	5.6%	28.6%	
	NR	30 years of age with a		NPV	100.0%	93.9%	100.0%	
		documented history of						
	Definition of positive	ovarian cancer in at least						
	and negative on	one primary or secondary						
	screening test:	relative.						
	Ultrasound Ovarian volume >10 cm ³	Exclusion criteria:						
	for postmenopausal	Known ovarian tumor or						
	women and $> 20 \text{ cm}^3$ for							
	premenopausal	personal history of ovarian cancer.						
	Cystic tumor with internal							
	papillary or complex							
	projections into its lumen							
	was considered							
	abnormal.							
	Used an algorithm for							
	disease detection							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	If TVUS abnormal, repeat 4-6 weeks. If that's abnormal used additional tests and then surgery. If normal repeat TVUS in one year. If TVUS initially normal, repeat in one year.				
Shenson, Fried, et al., 1993 #6390	Geographical location: Lexington, Kentucky USA University Hospital Dates: Jan 1987 – Jan 1992 Size of population: 121 Other Case series Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: No Statistical tests used: T test for means Chi-square and Fisher's exact test for proportions Blinding: NR (but prospective)		Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) DePriest ≥ 5 T+ Dis- Tot T- 0 80 Tot 13 108 121 Lower Upper Value 95% Cl 95% C Se 100.0% 76.9% 100.0% Sp 74.1% 65.8% 82.3% PPV 31.7% 17.5% 46.0% NPV 100.0% 96.3% 100.0%	Clinical presentation not described Quality assessment: Reference standard: +
	Definition of positive				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	and negative on screening test: Morphology index score ≥ 5 (Table 1)				
DePriest, van Nagell Jr., Gallion, et al., 1993 #6880	Geographical location: Kentucky USA University Dates: Nov 1987 - June 1992 Size of population: 44/3220 Screening study Reference standard: For women with abnormal TVUS - pathology Reference standard applied to all test negatives?: No Test reliability established?: No Statistical tests used: Fischer's exact test Blinding: NR - prospective Definition of positive and negative on screening test: US – ovarian volume > 10 cm ³ or "cystic ovarian tumor with a papilary projection into its lumen" Also DePriest score also	Age: Mean: 60 Range: 33-90 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): Family history: 502 (15.6%) ovarian CA 1034 (32.1%) breast CA 678 (21.1%) colon CA Inclusion criteria: Volunteers for screening program at U of K Exclusion criteria: Individuals with prior history of ovarian cancer or pelvic radiation	Symptomatic (n [%]): 0 (0%) Detected by exam (n [%]): NA Detected by imaging (n [%]): NA Combination (n [%]): NR Additional data used for diagnosis: NR	1) US score ≥ 5 T+ $Dis+ Dis- 70 + 9 + 15 + 15 + 15 + 15 + 24$ T + 1 + 1 + 1 + 1 + 1 + 15 + 24 T + 1 + 1 + 1 + 15 + 15 + 15 + 15 + 24 T + 100.0% + 100.0% + 100.0% + 100.0% + 100.0% + 100.0% + 100.0% + 100.0% + 100.0% + 100.0%	Comments: Screening study Test negatives had repeat US in 1 year (don't report compliance with follow up US, or results of those US) No discussion of reliability of DePriest index Multipassessment: Reference standard: + Verification bias: +/- Test reliability/variability: - Sample size: - Statistical tests: +/- Blinding: + Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	used (but unclear how used at what cutoff)				
DePriest, Varner, Powell, et	Geographical location: USA	For benign tumors mean 44.9 with range (16-84)	Symptomatic (n [%]): NR	1) RI ≥ 0.5 Dis+DisTot	Comments: LMP grouped in with malignant Good data on reliability/variability
al., 1994	Dates: NR	For malignant mean 53.8 (25-78)	Detected by exam (n [%]): NR	T+ 39 46 85 T- 5 123 128	TVUS only
#10950	Size of population: 213	Menopausal status (n [%]):	Detected by imaging (n [%]):	Tot 44 169 213 Lower Uppe	Quality assessment: Reference standard: + r Verification bias: +
	Retrospective chart review with re-analysis	NR	NR	Value 95% CI 95% C Se 89.0% 79.8% 98.2%	CI Test reliability/variability:+ Sample size: -
	of US data	Race/ethnicity (n [%]): NR	Combination (n [%]): NR	Sp 73.0% 66.3% 79.7% PPV 45.9% 35.3% 56.5%	Blinding: +
	Reference standard: Histopathology	Risk factors (n [%]): NR	Additional data used for diagnosis:	NPV 96.1% 92.7% 99.5%	Definition of +/- on screening test: +
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: NR	NR		
	Test reliability established?: Yes	Exclusion criteria: 11 patients excluded due to lack of US or surgical information			
	Statistical tests used: Kappa statistic, Regression analysis				
	Blinding: Yes				
	Definition of positive and negative on screening test: DePriest morphology index score >=5				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Dowd, Quinn,	Geographical location: Melbourne, AU	Range: 15-35 for	Symptomatic (n [%]): NR	1) CA-125 premenopausal	Comments: Unable to construct 2x2 tables for
Rome, et al., 1993	Dates: 1978 to 1989	premenopausal Range: 40 –89 for post	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 32 21 53 T- 11 57 68	stratified US results; reported values for premenopausal women: Sensitivity 63%, specificity 89%;
#4680	Size of population: 264 patients total although not all had ultrasound, CA-125 and exam results	Menopausal status (n [%]): Pre (< 45): 121 Post (> 55): 143 Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR Combination (n [%]):	Tot 43 78 121 Lower Upper Value 95% CI 95% CI Se 74.0% 60.9% 87.1% Sp 73.0% 63.1% 82.9%	postmenopausal, sensitivity 87%, specificity 75% LMP tumors grouped in with malignant Clinical presentation not described
	Other Retrospective chart review	NR Risk factors (n [%]) : NR	NR Additional data used for diagnosis:	PPV 60.4% 47.2% 73.5% NPV 83.8% 75.1% 92.6% 2) CA-125 post menopausal	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability:
	Reference standard: Pathology	Inclusion criteria: Patients who had CA-125	NR	Dis+ Dis- Tot T+ 80 9 89	Sample size: + Statistical tests: + Blinding: - to clinical history
	Reference standard applied to all test negatives?:	performed in presence of pelvic mass		T- <u>13 41</u> 54 Tot <u>93 50</u> 143	Definition of +/- on screening test: +
	Yes Test reliability established?: NR	Exclusion criteria: Test performed for screening purposes only, in absence of pelvic mass excluded Inadequate documentation		Lower Upper Value 95% CI 95% CI Se 86.0% 78.9% 93.1% Sp 82.0% 71.4% 92.6% PPV 89.9% 83.6% 96.2%	
	Statistical tests used: Chi square or Fishers	for pathology.		NPV 75.9% 64.5% 87.3% 3) CA-125 all patients	
	Blinding: Tried to predict disease outcome based on clinical exam and ultrasound			Dis+ Dis- Tot T+ 112 30 142 T- 24 98 122 Tot 136 128 264	
	Definition of positive and negative on screening test: CA ≤ 35 u/ml considered normal US impression of reviewer drawn from US report (not film review): "simple, smooth, and/or			Value Lower 95% CI Upper 95% CI Se 82.4% 75.9% 88.8% Sp 76.6% 69.2% 83.9% PPV 78.9% 72.2% 85.6% NPV 80.3% 73.3% 87.4% 4) Ultrasound all patients 80.3% 94.1%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	unilateral likely to be benign; "solid or mixed consistency, bilateral, irregular or associated asciteslikely malignancy" Clinical exam: "mass hard, irregular, fixed, attached to other structures."			Dis+ Dis- Tot T+ 61 17 78 T- 14 90 104 Tot 75 108 183 Lower Upper Value 95% Cl 95% Cl Se 81.0% 72.1% 89.9% Sp 84.0% 77.1% 90.9% PPV 78.0% 68.8% 87.2%	
				NPV 86.0% 79.3% 92.7%	
Einhorn, Bast Jr., Knapp, et	Geographical location: Sweden	Age: NR	Symptomatic (n [%]): NR	1) CA-125 > 35 (excluding non-ovarian primary)	Comments: Borderline tumors included in malignant
al., 1986	Dates: Since 1983 – dates unclear	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 14 9 23	Slight difference in 2x2 table specificity calculated here (89%) and
#6860		NR		T- 4 73 77	from text (93%)
	Size of population: 100	Race/ethnicity (n [%]):	Detected by imaging (n [%]):	Tot 18 82 100	No statistical tests of significance
	Other Retrospective comparison of serum samples with operative outcomes	Swedish Risk factors (n [%]): NR Inclusion criteria: Patients with pelvic mass	NR Combination (n [%]): NR Additional data used for diagnosis:	LowerUpperValue95% CI95% CISe77.8%58.6%97.0%Sp89.0%82.3%95.8%PPV60.9%40.9%80.8%NPV94.8%89.8%99.8%	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + Sample size: - Statistical tests: - Blinding: -
	Reference standard: Histopathology	who had surgery For whom banked serum present	NR	 CA-125 > 35 (includes metastatic disease) 	Definition of +/- on screening test: +
	Reference standard applied to all test negatives?: Yes	Exclusion criteria: NR		Dis+ Dis- Tot T+ 18 5 23 T- 5 72 77 Tot 23 77 100	
	Test reliability established?: Yes			Lower Upper Value 95% Cl 95% Cl Se 78.3% 61.4% 95.1%	
	Statistical tests used: Se, Sp			Sp 93.5% 88.0% 99.0% PPV 78.3% 61.4% 95.1% NPV 93.5% 88.0% 99.0%	
	Blinding: NR			2) CA-125 > 35 (classifying borderline as "benign"	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Definition of positive and negative on screening test: CA-125 > 35 U/ml			Dis+ Dis- Tot T+ 16 7 23 T- 5 72 77 Tot 21 79 100	
				ValueLowerUpper95% CI95% CISe76.2%58.0%94.4%Sp91.1%84.9%97.4%PPV69.6%50.8%88.4%NPV93.5%88.0%99.0%	
	Geographical location: Salzburg, Austria, and Goteborg, Sweden	Age: Range: 14-90 NR for entire group	Symptomatic (n [%]): NR Detected by exam (n [%]):	 Low malignant potential = benign, presence of solid areas or papillations = positive test 	Comments: TVUS only Quality assessment:
#8780	Dates: Jan 1992-Dec 1997	Menopausal status (n [%]): Pre (< 45): 927 (71.1%)	Detected by exam (in [76]).	Dis+ Dis- Tot T+ <mark>13 631</mark> 644 T- 4 656 660	Reference standard: + Verification bias: + Test reliability/variability: -
	Size of population: 1304	Post (> 55):377 (28.9%) Race/ethnicity (n [%]):	(n [%]): NR	Tot 17 1287 1304	Sample size: + Statistical tests:+ Blinding: -
	Other Case series of all women with unilocular adnexal cyst on transvaginal US	Race/etimicity (if [%]). NR Risk factors (n [%]): NR	Combination (n [%]): NR Additional data used for diagnosis:	Lower Upper Value 95% CI 95% CI Se 76.5% 56.3% 96.6% Sp 51.0% 48.2% 53.7% PPV 2.0% 0.9% 3.1% NPV 99.4% 98.8% 100.0%	Definition of +/- on screening test: -
	Reference standard: Surgery	Inclusion criteria: Scheduled for surgery and unilocular cyst	NR	2) Low malignant potential = cancer	
	Reference standard applied to all test negatives?: Yes	Exclusion criteria: Presence of internal septae		Dis+ Dis- Tot T+ 24 620 644 T- 7 653 660 Tot 31 1273 1304	
	Test reliability established?: No			Lower Upper Value 95% CI 95% CI Se 77.4% 62.7% 92.1%	
	Statistical tests used: t-test, chi-square			Sp 51.3% 48.6% 54.0% PPV 3.7% 2.3% 5.2% NPV 98.9% 98.2% 99.7%	
	Blinding:				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Definition of positive and negative on screening test: Suspicious: unilocular with small solid areas or papillary formation Benign: Simple cysts				
Fenchel, Grab, Nuessle, et al., 2002	Geographical location: Ulm, Germany University hospital	Age: Mean (SD):46(15) Range: 18-83	Symptomatic (n [%]): 0 (0%) Detected by exam (n [%]):	1) Combined US and Doppler Dis+ Dis- Tot T+ 11 35 46	Comments: Three different US scores used (DePriest, Kawai,and RI) – although each is well described, how each
#2220	Dates: May 1997 – Feb 1999	Menopausal status (n [%]): NR	NR Detected by imaging	T- <u>1 52</u> 53 Tot 12 87 99	contributed to the overall diagnosis for this study is not discussed (used in series, or in parallel?)
	Size of population: 99 women	Race/ethnicity (n [%]): NR	(n [%]): NR	Lower Upper Value 95% Cl 95% Cl Se 92.0% 76.7% 100.0%	Hospital referrals – not population- based Borderline tumors (LMP = 2)
	Other Consecutive patients referred to hospital	Risk factors (n [%]): NR	Combination (n [%]): NR Additional data used for	Sp 60.0% 49.7% 70.3% PPV 23.9% 11.6% 36.2% NPV 98.1% 94.5% 100.0%	probably included in malignant category (unclear – but no example of borderline in benign tumor descriptions)
	Reference standard: Histopathology	Inclusion criteria: Consecutive, asymptomatic	diagnosis: NR	2) MRI Dis+ Dis- Tot	May be same patient population as Grab #2720
	Reference standard applied to all test negatives?: 97 had histopathology,	"sonographically suspect" (by referring physician adnexal mass referred to hospital		T+ 10 15 25 T- 2 72 74 Tot 12 87 99	Quality assessment: Reference standard: +/-; length of time for followup for one non-surgic case not described
	1 had cytology 1 US follow up	Exclusion criteria: Pregnant women, clinical		Lower Upper Value 95% Cl 95% Cl Se 83.0% 61.7% 100.0%	Verification bias: -; not discussed Test reliability/variability: + for component US tests, however it is
	Test reliability established?: No for PET Yes for US ? for MRI	symptoms of malignancy, under 18 years		Sp83.0%75.1%90.9%PPV40.0%20.8%59.2%NPV97.3%93.6%100.0%	unclear how these were grouped together for this study's single diagnostic assessment Other tests - Sample size: -
	Statistical tests used:			3) FDG PET Dis+ Dis- Tot	Statistical tests: + Blinding: +
	Se, Sp, PPV, NPV			T+ 7 21 28 T- 5 66 71	Definition of +/- on screening test: +/-
	Yes			Tot 12 87 99	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	Definition of positive and negative on screening test: For PET – "interpreted visually in consensus" by "2 or 3 experiences nuclear med physicians For FDG uptake – "subjective" scale US DePriest,(≥ 5), Kawai (9-12 = malignant) and Doppler RI < 0.45 = malignant	Value 95% Cl reening test: Se 58.0% 30.1% r PET – "interpreted Sp 76.0% 67.0% ually in consensus" by PPV 25.0% 9.0% or 3 experiences NPV 93.0% 87.0% clear med physicians r FDG uptake – bjective" scale 76.0% 90% DePriest.(≥ 5), Kawai 12 = malignant) and ppler RI < 0.45 = 76.0% 76.0%	Upper 95% CI 85.9% 85.0% 41.0% 98.9%					
Ferdeghini, Gadducci, Prontera, et	Geographical location: Italy	Age: Median (with range): Ovarian cancer = 60 (35-	Symptomatic (n [%]): NR	1) CA-	125 Dis+	Dis-	Tot	Comments: CA-125 ≥ 83 U/ml
al., 1993	Dates: NR	91) Benign = 35 (13 – 76)	Detected by exam (n [%]): NR	T+ T-	42 12	9	51 132	Quality assessment: Reference standard: +
#4710	Size of population: 183	Menopausal status (n [%]):	Detected by imaging (n [%]):	Tot	54	129 Lower	183 Upper	Verification bias: + Test reliability/variability: - Sample size: +
	Other 2 retrospective samples: one if cancer one if benign – both consecutive Reference standard: Histology	NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	NR Combination (n [%]): NR Additional data used for diagnosis: NR	Se Sp PPV NPV	Value 77.8% 93.0% 82.4% 90.9%	95% CI 66.7% 88.6% 71.9% 86.0%	95% CI 88.9% 97.4% 92.8% 95.8%	Statistical tests:+ Blinding: + Definition of +/- on screening test:
	Reference standard applied to all test negatives?: Yes Test reliability	Inclusion criteria: Had pre-operative levels of SIL-2R and CA-125 Exclusion criteria: Autoimmune or rheumatic disease						
	established?: No Statistical tests used: Student t test Chi square Fishers exact test							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Blinding: NR				
	Definition of positive and negative on screening test: CA-125 ≥ 83 U/ml.				
Ferrazzi, Zanetta, Dordoni, et	Geographical location: Milan, Italy University	Age: Mean (SD): 45 (16) Range: 19-89	Symptomatic (n [%]): NR	1) This study > 9 Dis+DisTot	Comments: No discussion of inter/intra observer reliability variability with this
al., 1997 #3570	Dates: 1995-96 (2 yrs)	Menopausal status (n [%]):	Detected by exam (n [%]): NR	T+ 60 86 146 T- 9 175 184 Tot 69 261 330	new scoring system No power calculation for study Good use of ROC curves and
	Size of population: 330 masses	NR Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	Lower Upper Value 95% CI 95% CI	testing between curves Quality assessment:
	Other Case series in multi- center	NR Risk factors (n [%]):	Combination (n [%]): NR	Se 87.0% 79.1% 94.9% Sp 67.0% 61.3% 72.7% PPV 41.1% 33.1% 49.1%	Reference standard: + Verification bias: + Test reliability/variability: -
	Reference standard: Pathology	NR Inclusion criteria:	Additional data used for diagnosis:	NPV 95.1% 92.0% 98.2% 2) Sassone > 9	Sample size: - Statistical tests: + Blinding: +
	Reference standard applied to all test negatives?: Yes	Surgery within 7 days of US, detailed pathology available, women with mass in time frame at three hospitals in Italy	NR	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Definition of +/- on screening test: +/-
	Test reliability established?: Sassone – yes DePriest – yes This study – no	Exclusion criteria: NR		Lower Upper Value 95% CI 95% CI Se 74.0% 63.7% 84.3% Sp 65.0% 59.2% 70.8% PPV 35.9% 28.0% 43.8%	-
	Statistical tests used: ROC curve			NPV 90.4% 86.2% 94.6% 3) DePriest	
	Blinding: NR - prospective			Dis+ Dis- Tot T+ 61 157 218	
	Definition of positive and negative on screening test:			T- 8 104 112 Tot 69 261 330	
	Sassone (per original			Lower Upper	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	article) > 9 DePriest (per original article) > 5 This study – Table 2 > 9			Se Sp PPV NPV	Value 88.0% 40.0% 28.0% 92.9%	95% CI 80.3% 34.1% 22.0% 88.1%	95% CI 95.7% 45.9% 33.9% 97.6%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Finkler, Benacerraf, Lavin, et al., 1988	Geographical location: Boston, MA Dates: Nov 1986 to Apr	Age: Mean: 45.2 Range: 17-84	Symptomatic (n [%]): NR Detected by exam (n [%]):	1) Original ultrasound – premenopausal Dis+ Dis- Tot T+ 2 2 4	Comments: Original US based on impression of cancer vs. benign only "Specialist" US used scoring
#1230	1987	Menopausal status (n [%]): 74	NR	T- <u>16 54</u> 70 Tot <u>18 56</u> 74	system Unclear if "specialist" US was
	Size of population: 131 consecutive patients 106 eventually retained	Pre (< 45): Peri (45-55): Post (> 55):	Detected by imaging (n [%]): NR	Lower Upper Value 95% CI 95% CI	blinded Abdominal US – no TVUS CA-125 significantly improved
	Other Prospective series	Race/ethnicity (n [%]): NR	Combination (n [%]): NR	Se 11.0% 0.0% 25.5% Sp 96.0% 90.9% 100.0% PPV 50.0% 1.0% 99.0% NPV 77.1% 67.3% 87.0%	positive and negative predictive values in postmenopausal women when added to clinical impression or prior ultrasound
	Reference standard: Pathology	Risk factors (n [%]): NR	Additional data used for diagnosis: NR	 2) Specialist ultrasound – premenopausal 	Quality assessment: Reference standard: +
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: Ovarian mass who were scheduled to under exploratory laparotomy Had a pre-operative		T+ 9 2 11 T- 9 54 63 Tot 18 56 74	Verification bias: + Test reliability/variability: - Sample size: - ; underpowered Statistical tests: + Blinding: -
	Test reliability established?: NR	ultrasound Consecutive patients Exclusion criteria:		Lower Upper Value 95% CI 95% CI Se 50.0% 26.9% 73.1% Sp 96.0% 90.9% 100.0% PPV 81.8% 59.0% 100.0%	Definition of +/- on screening test: +
	Statistical tests used: Fisher's exact	Original ultrasound unavailable or uninterpretable.		NPV 85.7% 77.1% 94.4%	
	Blinding: Yes	Pregnant or with histologic cancer diagnosis		 CA-125 – premenopausal Dis+ Dis- Tot 	
	Definition of positive and negative on screening test:			T+ 9 17 26 T- 9 39 48 Tot 18 56 74	
	CA-125 > 35 U/mL considered positive US had two evaluations first (Table 1) Finkler score \geq 7 = malignant second Primary US = impression only			Lower Upper Value 95% CI 95% CI Se 50.0% 26.9% 73.1% Sp 69.0% 56.9% 81.1% PPV 34.6% 16.3% 52.9% NPV 81.3% 70.2% 92.3%	
				4) Original US – postmenopausal	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot T+ 9 2 11 T- 10 11 21 Tot 19 13 32	
				LowerUpper 95% CISe47.0%24.6%69.4%Sp85.0%65.6%100.0%PPV81.8%59.0%100.0%NPV52.4%31.0%73.7%	
				5) Specialist US – postmenopausal	
				Dis+ Dis- Tot T+ 15 1 16 T- 4 12 16 Tot 19 13 32	
				LowerUpperValue95% CI95% CISe78.0%59.4%96.6%Sp92.0%77.3%100.0%PPV93.8%81.9%100.0%NPV75.0%53.8%96.2%	
				6) CA-125 – postmenopausal	
				Dis+ Dis- Tot T+ 16 1 17 T- 3 12 15 Tot 19 13 32	
				LowerUpperValue95% Cl95% ClSe84.0%67.5%100.0%Sp92.0%77.3%100.0%PPV94.1%82.9%100.0%NPV80.0%59.8%100.0%	
				7) CA-125 – all ages combined	
				Dis+ Dis- Tot T+ 25 18 43 T- 12 51 63	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
				Tot	37	69	106	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	67.6%	52.5%	82.7%	
				Sp	73.9%	63.6%	84.3%	
				PPV	58.1%	43.4%	72.9%	
				NPV	81.0%	71.3%	90.6%	
				8) US t	otal			
					Dis+	Dis-	Tot	
				T+	24	55	79	
				Т-	22	68	90	
				Tot	46	123	169	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	52.2%	37.7%	66.6%	
				Sp	55.3%	46.5%	64.1%	
				PPV	30.4%	20.2%	40.5%	
				NPV	75.6%	66.7%	84.4%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Fleischer, Rodgers, Kepple, et	Geographical location: Nashville, TN	Age: NR	Symptomatic (n [%]): NR	1) Doppler Dis+ Dis- T	Comments: 2x2 tables different if pull data from fot text or from Table 2
al., 1992	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR		 Table 2 and text confuse positive/negative predictive value
#6460	Size of population: 62	NR Race/ethnicity (n [%]):	Detected by imaging (n [%]):	Tot 20 42 6	and sensitivity/specificity
	Other Case series	Risk factors (n [%]):	NR Combination (n [%]):	Value 95% CI 95% Se 85.0% 69.4% 100	Koll Reference standard: + 0.0% Verification bias: +
	Reference standard: Pathology	NR	Additional data used for	PPV 94.4% 83.9% 100	00% Sample size: - 00% Statistical tests: -
	Reference standard applied to all test negatives?:	NR – mass – surgery - US Exclusion criteria:			Blinding: - Definition of +/- on screening test: +
	Yes Test reliability established?: No	NR			
	Statistical tests used: Se, Sp				
	Blinding: NR				
	Definition of positive and negative on screening test: PI < 1.0				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Franchi, Beretta,	Geographical location: Italy	Median: 44	Symptomatic (n [%]): NR	1) Premenopausal - CA-125	Comments: ROC curves used to generate RI
Ghezzi, et		Range: 12-91		Dis+ Dis- Tot	cutoff
al., 1995	Dates: Jan 1991 to Dec		Detected by exam (n [%]):	T+ 8 26 34	CA-125 > 40 U/ml
	1993	Menopausal status	NR	T- 3 46 49	No US scoring system –
#6270		(n [%]):		Tot 11 72 83	descriptive only
	Size of population:	Pre (< 45): 83 (64.3%)	Detected by imaging		
	129	Peri (45-55): NR	(n [%]):	Lower Upper	Quality assessment:
		Post (> 55): NR	NR	Value 95% CI 95% CI	Reference standard: +
	Screening study			Se 72.7% 46.4% 99.0%	Verification bias: +
	Case series	Race/ethnicity (n [%]):	Combination (n [%]):	Sp 63.8% 52.7% 74.9%	Test reliability/variability: -
		Italian	NR	PPV 23.5% 9.3% 37.8%	Sample size: +
	Reference standard:			NPV 93.9% 87.2% 100.0%	Statistical tests: +
	Pathology	Risk factors (n [%]):	Additional data used for		Blinding: -
		NR	diagnosis:	2) Premenopausal - Sonography	Definition of +/- on screening test: +
	Reference standard		NR	, , , , , , , , , , , , , , , , , , , ,	
	applied to all test	Inclusion criteria:		Dis+ Dis- Tot	
	negatives?:	Abnormal findings on		T+ 8 10 18	
	Yes	pelvic exam and 2D		T- <u>3</u> 62 65	
		sonographic features of		Tot 11 72 83	
	Test reliability	adnexal mass			
	established?:			Lower Upper	
	NR	Exclusion criteria:		Value 95% CI 95% CI	
		NR		Se 72.7% 46.4% 99.0%	
	Statistical tests used:				
	Mann-Witney U			Sp <mark>86.1%</mark> 78.1% 94.1% PPV 44.4% 21.5% 67.4%	
	ROC curves			NPV 95.4% 90.3% 100.0%	
				NPV 95.4% 90.3% 100.0%	
	Blinding:			2) Combined ages	
	US blinded to lab results			3) Combined ages	
				Dis+ Dis- Tot	
	Definition of positive				
	and negative on			T+ <u>31 15</u> 46	
	screening test:			T- <u>6</u> 77 83	
	2D Ultrasound:			Tot 37 92 129	
	Maximum diameter (5				
	cm), solid areas, high			Lower Upper	
	echogenicity, multilocular			Value 95% CI 95% CI	
	appearance, irregular			Se 83.8% 71.9% 95.7%	
	borders, papillary			Sp 83.7% 76.1% 91.2%	
	intracystic vegetations,			PPV 67.4% 53.8% 80.9%	
	presence of ascites			NPV 92.8% 87.2% 98.3%	
	•			4) Premenopausal - Color Doppler Im	aging
	Color Doppler Imaging				aging
	RI = systolic peak –				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	diastolic peak/systolic peak. Artery with lowest RI considered to indicate the malignant potential of			Dis+ Dis- Tot T+ 9 20 29 T- 2 52 54 Tot 11 72 83	
	the tumor. RI < 0.65 CA-125 ≥ 40UI/mI suspected of malignant pelvic tumor			LowerUpper 95% ClSe81.8%Sp72.2%61.9%82.5%PPV31.0%14.2%47.9%NPV96.3%91.3%100.0%	
				5) Color Doppler Imaging - combined ag Dis+ Dis- Tot T+ <u>30 26</u> 56 T- <u>7 66</u> 73 Tot 37 92 129	jes
				LowerUpper 95% ClSe81.1%68.5%93.7%Sp71.7%62.5%80.9%PPV53.6%40.5%66.6%NPV90.4%83.7%97.2%	
				6) Postmenopausal – CA-125	
				Dis+ Dis- Tot T+ 20 3 23 T- 6 17 23 Tot 26 20 46	
				ValueLower 95% CIUpper 95% CISe76.9%60.7%93.1%Sp85.0%69.4%100.0%PPV87.0%73.2%100.0%NPV73.9%56.0%91.9%	
				7) All ages CA-125	
				Dis+ Dis- Tot T+ 28 29 57 T- 9 63 72	

Study	Study Design	Patients	Clinical Presentation	Results Comments/Quality Scori
				Tot 37 92 129
				Lower Upper
				Value 95% CI 95% CI
				Se 75.7% 61.9% 89.5%
				Sp 68.5% 59.0% 78.0%
				PPV 49.1% 36.1% 62.1%
				NPV 87.5% 79.9% 95.1%
				8) Postmenopausal - Sonography
				Dis+ Dis- Tot
				T+ 23 5 28
				T- <u>3 15</u> 18
				Tot 26 20 46
				Lower Upper
				Value 95% CI 95% CI Se 88.5% 76.2% 100.0%
				Sp 75.0% 56.0% 94.0%
				Sp
				NPV 83.3% 66.1% 100.0%
				9) Postmenopausal - Color Doppler Imaging
				Dis+ Dis- Tot
				T+ 21 6 27
				T- 5 14 19
				Tot 26 20 46
				Lower Upper
				Value 95% CI 95% CI
				Se 81.8% 67.0% 96.6%
				Sp <mark>72.2%</mark> 52.6% 91.8% PPV 77.8% 62.1% 93.5%
				NPV 73.7% 53.9% 93.5%

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Gadducci, Baicchi,	Geographical location: Pisa, Italy	Age: NR	Symptomatic (n [%]): NR	1) CA-125 > 65 U/ml – premenopause	Comments: Most of the 124 patients in this
Marrai, et al., 1996	University Hospital	Menopausal status	Detected by exam (n [%]):	Dis+ Dis- Tot T+ 8 4 12	study were included in Gadducci et al., 1988 (#6650)
	Dates: NR	(n [%]):	NR	T- 4 41 45	Age breakdown or definition of
#6230	Cize of nonvelotion.	Pre: 57 (47.1%) Post: 64 (52.9%)	Detected by imaging	Tot 12 45 57	menopause not described – however. this article stratifies results
	Size of population: 124 women (3 excluded	POSI. 64 (52.9%)	Detected by imaging (n [%]):	Lower Upper	by menopausal status.
	= 121)	Race/ethnicity (n [%]):	NR	Value 95% CI 95% CI	Cutoff for CA-125 is > 65 U/ml
	0.0	NR		Se 66.7% 40.0% 93.4%	D-Dimer - cutoff had been
	Other Consecutive patients	Risk factors (n [%]):	Combination (n [%]): NR	Sp 91.1% 82.8% 99.4%	previously evaluated in other study (using most of the same patients) by
	referred for surgery with			PPV 66.7% 40.0% 93.3% NPV 91.1% 82.8% 99.4%	same authors [Reference 22]
	diagnosis of ovarian		Additional data used for		D-dimer performance characteristic
	mass	Inclusion criteria: Consecutive women with	diagnosis: NR	2) D-Dimer - premenopause	likely overestimated since these data are not independent of the data used
	Reference standard:	clinical diagnosis of		Dis+ Dis- Tot	to select cutoff value.
	Histopathology	ovarian mass to undergo		T+ 12 4 16	
	Defense of an doud	surgery		T- 0 41 41	Quality assessment:
	Reference standard applied to all test	Exclusion criteria:		Tot 12 45 57	Reference standard: + Verification bias: +
	negatives?:	Cardiovascular disease,		Lower Upper	Test reliability/variability: +
	Yes	diabetes, acute or chronic		Value 95% CI 95% CI	Sample size: - not discussed
	Test reliability	inflammatory disease,		Se 100.0% 75.0% 100.0%	Statistical tests: +
	established?:	previous malignancy, or previous episodes of		Sp 91.1% 82.8% 99.4%	Blinding: - Definition of +/- on screening test: +
	Yes	thrombophlebitis or		PPV 75.0% 53.8% 96.2% NPV 100.0% 92.7% 100.0%	Demittor of the off scienting test.
		thromboembolia.		NFV 100.0% 92.7% 100.0%	
	Statistical tests used: Mann-Whitney U test	2 patients excluded for uterine fibroid (after		3) D-Dimer – combined ages	
	Spearman rank	surgery)			
	correlation test	1 excluded for		Dis+ Dis- Tot T+ 51 11 62	
	Logistic regression	leiomyosarcoma, of small		T- 5 54 59	
	ROC curves	bowel		Tot 56 65 121	
	Blinding:				
	No – but consecutive			Lower Upper Value 95% CI 95% CI	
	enrollment			Se 91.1% 83.6% 98.5%	
	Definition of positive			Sp 83.1% 74.0% 92.2%	
	and negative on			PPV 82.3% 72.7% 91.8%	
	screening test:			NPV 91.5% 84.4% 98.6%	
	CA-125 > 65 U/ml			4) CA-125 > 65 U/ml - postmenopause	
	D-Dimer > 416 ng/ml				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot T+ 35 0 35 T- 9 20 29 Tot 44 20 64	
				LowerUpper 95% CISe79.5%67.6%91.4%Sp100.0%85.0%100.0%PPV100.0%91.4%100.0%NPV69.0%52.1%85.8%	
				5) CA-125 > 65 U/ml – all ages	
				Dis+ Dis- Tot T+ 43 4 47 T- 13 61 74 Tot 56 65 121	
				ValueLower 95% ClUpper 95% ClSe76.8%65.7%87.8%Sp93.8%88.0%99.7%PPV91.5%83.5%99.5%NPV82.4%73.8%91.1%	
				6) D-Dimer - postmenopause	
				Dis+ Dis- Tot T+ 39 7 46 T- 5 13 18 Tot 44 20 64	
				Lower Upper Value 95% CI 95% CI Se 88.6% 79.2% 98.0% Sp 65.0% 44.1% 85.9% PPV 84.8% 74.4% 95.2% NPV 72.2% 51.5% 92.9%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Gadducci, Capriello, Bartolini, et	Geographical location: Pisa Italy University Hospital	Age: NR	Symptomatic (n [%]): NR	1) CA-125 ≥ 35 U/ml	Comments: US scoring system described but not grounded – appears to be a
al., 1988 #6650	Dates: NR	Menopausal status (n [%]): NR	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 31 20 51 T 5 20 20	unique (hospital specific? operator specific?) scoring system – also unclear how cutoff of ≥ 10 was fixed
#0050	Size of population: 119 women	Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	T- <u>5 63</u> 68 Tot <u>36 83</u> 119 Lower Upper	CA-125 cutoff \ge 65 U/ml preferred by authors, but 2x2 table reported only for \ge 35 U/ml as that is what is
	Other Patients undergoing surgery for mass	Risk factors (n [%]):	Combination (n [%]):	Value 95% Cl 95% Cl Se 86.1% 74.8% 97.4%	in common clinical practice. Patient data overlaps with article Gadducci et al., 1996 (#6230)
	Reference standard:	Inclusion criteria:	Additional data used for	Sp 75.9% 66.7% 85.1% PPV 60.8% 47.4% 74.2% NPV 92.6% 86.4% 98.9%	Referral criteria etc. not described
	Histopathology Reference standard	Patients undergoing surgery for mass	diagnosis: NR	2) US	Quality assessment: Reference standard: + Verification bias: +
	applied to all test negatives?: Yes	Exclusion criteria: NR		Dis+ Dis- Tot T+ 26 2 28 T- 10 81 91	Test reliability/variability: - especially given the novel US scoring system Sample size: -
	Test reliability established?:			Tot 36 83 119 Lower Upper	Statistical tests: + Blinding: ? Definition of +/- on screening test: +
	For CA-125 – yes For US – no			Value 95% CI 95% CI Se 72.2% 57.6% 86.8% Sp 97.9% 94.8% 100.0%	-
	Statistical tests used: Sensitivity, specificity			PPV 92.9% 83.3% 100.0% NPV 89.0% 82.6% 95.4%	
	Blinding: No – probably prospective				
	Definition of positive and negative on screening test: US scoring system ≥ 10 (of 16 with 4 points for				
	shape, ascites, outline, and structure)				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Gadducci, Ferdeghini,	Geographical location: Italy	Age: NR	Symptomatic (n [%]): NR	1) CA-125 ≥ 65 U/ml (Age < 50 years)	Comments: Data stratified by age/menopausal
Prontera, et al., 1992	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 8 146 154 T- 8 51 59	status for CA-125 using lower cutpoint not presented. Appears that borderline tumors
#6850	Size of population: 344	NR	Detected by imaging	Tot 16 197 213	grouped with malignant Unclear how patients chosen; no
	Other	Race/ethnicity (n [%]): Italian	(n [%]) : NR	Lower Upper Value 95% CI 95% CI	definition of menopause
	Consecutive case series	Risk factors (n [%]):	Combination (n [%]):	Se 50.0% 25.5% 74.5% Sp 26.0% 19.9% 32.1%	Quality assessment: Reference standard: +
	Reference standard: Pathology	NR Inclusion criteria:	NR Additional data used for	PPV 5.2% 1.7% 8.7% NPV 86.4% 77.7% 95.2%	Verification bias: + Test reliability/variability: - Sample size: +
	Reference standard applied to all test	Patients undergoing laparotomy for ovarian	diagnosis: NR	2) CA-125 ≥ 65U/ml (Age ≥ 50)	Statistical tests: + Blinding: -
	negatives?: Yes	masses		Dis+ Dis- Tot T+ 60 8 68	Definition of +/- on screening test: +
	Test reliability established?:	Exclusion criteria: NR		T- <u>14 49</u> 63 Tot 74 57 131	
	Yes for CA-125			Lower Upper Value 95% CI 95% CI	
	Statistical tests used: Chi-square			Se 81.1% 72.2% 90.0% Sp 86.0% 77.0% 95.0%	
	Blinding: NR			PPV 88.2% 80.6% 95.9% NPV 77.8% 67.5% 88.0%	
	Definition of positive			3) CA-125 ≥ 35 (for all ages)	
	and negative on screening test: CA-125 35 and 65 U/ml			Dis+ Dis- Tot T+ 74 83 157 T- 16 171 187 Tot 90 254 344	
				Lower Upper Value 95% CI 95% CI Se 82.3% 74.4% 90.2%	
				Sp 67.3% 61.5% 73.1% PPV 47.1% 39.3% 54.9% NPV 91.4% 87.4% 95.5%	
				4) CA-125 ≥ 65 (for all ages)	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot T+ 68 154 222 T- 22 100 122 Tot 90 254 344 95% CI 95% CI Se 75.6% 66.7% 84.4% Sp 39.4% 33.4% 45.4% PPV 30.6% 24.6% 36.7% NPV 82.0% 75.1% 88.8%	
Gadducci, Ferdeghini, Rispoli, et	Geographical location: Pisa, Italy University Hospital	Age: NR	Symptomatic (n [%]): NR	1) CA-125 > 35 U/ml	Comments: No description on inclusion etc. Hospital based study
al., 1991 #6490	Dates: NR	Menopausal status (n [%]): NR	Detected by exam (n [%]) : NR	Dis+ Dis- Tot T+ 49 66 115 T- 8 97 105	Although info in article on TATI, this was excluded from 2x2 table because it's not common test
	Size of population: 220 women	Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	Tot 57 163 220 Lower Upper	Quality assessment: Reference standard: +
	Other Preop patients at university hospital	Risk factors (n [%]): NR	Combination (n [%]): NR	Value 95% Cl 95% Cl Se 86.0% 77.0% 95.0% Sp 59.5% 52.0% 67.0%	Verification bias: + Test reliability/variability:+ Sample size: - not discussed Statistical tests: +
	Reference standard: Histopathology	Inclusion criteria: NR aside from undergoing gynecological surgery	Additional data used for diagnosis: None	PPV 42.6% 33.6% 51.6% NPV 92.4% 87.3% 97.5%	Blinding: +/- not discussed but prospective? Definition of +/- on screening test:
	Reference standard applied to all test	(presumably for mass)	NOTE		
	negatives?: Yes	Exclusion criteria: NR			
	Test reliability established?: Yes				
	Statistical tests used: Se, Sp				
	Blinding: NR but serum drawn prior to surgery				

e e e	Comments/Quality Scoring	
er Er Dis+ Dis- Tot 11 36 47 1 53 54 12 89 101 Lower Upper /alue 95% Cl 95% Cl 2.0% 76.7% 100.0% 0.0% 49.8% 70.2% 3.4% 11.3% 35.5% 8.1% 94.6% 100.0% Dis+ Dis- Tot 12 89 101 Lower Upper /alue 95% Cl 95% Cl 3.0% 61.7% 100.0% Lower Upper /alue 95% Cl 95% Cl 3.0% 61.7% 100.0% 4.0% 76.4% 91.6% 1.7% 21.9% 61.4% 7.18 25	Comments: No description of who refused surgery Unclear how patients came to hav diagnosis of mass Descriptive analysis of MRI and CT; no scoring system used RI cut point (0.45) not described why chosen No discussion of inter/intra observer variability Unclear if combination morphology and Doppler used in series or parallel One of few studies to explicitly state presence or absence of symptoms Quality assessment: Reference standard: Verification bias: + Test reliability/variability: + Sample size: + Statistical tests: - Blinding: + Definition of +/- on screening test: +, but how all 3 modalities used not described	
4.0% 76.4% 91 1.7% 21.9% 61 7.4% 93.8% 100 Dis+ Dis- T 7 18 2 5 71 7 12 89 1 Lower Up	.6% .4% 0.0%	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
			Se	58.0%	30.1%	85.9%		
	MRI			Sp	80.0%	71.7%	88.3%	
	Lesions considered			PPV	28.0%	10.4%	45.6%	
	benign if one or more of			NPV	93.4%	87.8%	99.0%	
	the following were met:							
	cystic structures without			4) All 3	(definitior	n of positive	e/negative not	
	any solid areas, diameter			gíven)		·	0	
	4 cm or less wall			σ,				
	thickness < 3 mm and				Dis+	Dis-	Tot	
	presence of typical			T+	11	13	24	
	characteristics of			T-	1	76	77	
	dermoid cyst or			Tot	12	89	101	
	endometrioma. If one of							
	these not fulfilled then					Lower	Upper	
	considered malignant.				Value	95% CI	95% CI	
				Se	92.0%	76.7%	100.0%	
	PET			Sp	85.0%	77.6%	92.4%	
	If uptake of F-FDG			PPV	45.8%	25.9%	65.8%	
	equaled or exceeded that			NPV	98.7%	96.2%	100.0%	
	of the liver and they were							
	not localized within							
	structures with							
	physiologic uptake.							
	COMBINATION							
	All 3 used in conference,							
	but criteria not described							

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
Granberg, Norstrom, and	Geographical location: Sweden	Age: Range: < 20 to > 70	Symptomatic (n [%]): 71% had symptoms	1) Vaginal ultrasound (data not presented by menopausal status)				No US scoring system used –
Norstrom, and Wikland, 1990 #5320	Dates: 1987-1988 Size of population: 180 Other Prospective series Reference standard: Pathology Reference standard applied to all test negatives?: Yes Test reliability established?: Used the same MD for all exams	Menopausal status (n [%]): Pre (< 45): 86 (48%) Post (> 55): 94 (52%) Race/ethnicity (n [%]): Swedish Risk factors (n [%]): NR Inclusion criteria: Women scheduled for elective surgery due to adnexal masses Exclusion criteria: NR	71% had symptoms Detected by exam (n [%]): 100% found at a gyn exam performed 1 week to 1 month prior to surgery, but unclear whether symptoms present Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Т+	Dis+ 32 7 39 Value 82.1% 92.2% 74.4% 94.9%	Dis- 11 130 141 Lower 95% Cl 70.0% 87.8% 61.4% 91.2%	Tot 43 137 180 Upper <u>95% CI</u> 94.1% 96.6% 87.5% 98.6%	No US scoring system used – descriptive only Unclear how patients selected (if consecutive) Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: + Statistical tests: - Blinding: - Definition of +/- on screening test: -
	Statistical tests used: None Blinding: NR Definition of positive and negative on screening test: "Classified as malignant the more complex it looked on ultrasound"							

Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Geographical location: Sweden	Mean: 53.8	Symptomatic (n [%]): NR	1) US – all patients	Comments: No scoring system used for US morphology – descriptive and not
Dates: May 1988 – Dec 1988	Menopausal status	Detected by exam (n [%]): NR	T+ <u>16 6</u> 22 T- <u>0 28 28</u>	reproducible Clinical pathway not described in
Size of population: 50	(n [‰]): NR	Detected by imaging (n [%]):		patients TVUS only
Case series	Race/ethnicity (n [%]) : NR	NR	Value 95% CI 95% CI Se 100.0% 81.3% 100.0%	Quality assessment: Reference standard: + Verification bias: +
Reference standard: Histopathology	Risk factors (n [%]): NR	NR	Sp 82.0% 69.1% 94.9% PPV 72.7% 54.1% 91.3% NPV 100.0% 89.3% 100.0%	Test reliability/variability: - Sample size: - Statistical tests: +
Reference standard applied to all test	Inclusion criteria: Surgical series	diagnosis: NR		Blinding: - Definition of +/- on screening test: +
Yes	Exclusion criteria: NR			
Test reliability established?: Not really				
Statistical tests used: Student's T test Linear regression Se, Sp				
Blinding: NR				
Definition of positive and negative on screening test: US – at least one of the				
following criteria fulfilled: 1) tumor > 10 cm in diameter (excluding				
unilocular cysts), 2) unilocular with echogenic				
areas inside the cyst, 3) multilocular with more than one thick (> 1 mm)				
	Sweden Dates: May 1988 – Dec 1988 Size of population: 50 Case series Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Not really Statistical tests used: Student's T test Linear regression Se, Sp Blinding: NR Definition of positive and negative on screening test: US – at least one of the following criteria fulfilled: 1) tumor > 10 cm in diameter (excluding simple completely unilocular with echogenic areas inside the cyst, 3) multilocular with more	SwedenMean: 53.8 Range: 21-92Dates: May 1988 – Dec 1988Menopausal status (n [%]): Size of population: 50Menopausal status (n [%]): NRSize of population: 50NRCase seriesRace/ethnicity (n [%]): NRReference standard: HistopathologyRisk factors (n [%]): NRReference standard applied to all test negatives?: YesInclusion criteria: Surgical seriesTest reliability established?: Not reallyStatistical tests used: Student's T test Linear regression Se, SpBlinding: NRNRDefinition of positive and negative on screening test: US – at least one of the following criteria fulfilled: 1) tumor > 10 cm in diameter (excluding simple completely unilocular with echogenic areas inside the cyst, 3) multilocular with more than one thick (> 1 mm)	Sweden Mean: 53.8 Range: 21-92 NR Dates: May 1988 – Dec 1988 Menopausal status (n [%]): NR Detected by exam (n [%]): NR Size of population: NR Detected by imaging (n [%]): Race/ethnicity (n [%]): NR Case series NR Combination (n [%]): NR Reference standard: Histopathology Risk factors (n [%]): NR NR Reference standard applied to all test negatives?: Yes Inclusion criteria: Surgical series MR Test reliability established?: Not really Exclusion criteria: NR NR Statistical tests used: Student's T test Linear regression Se, Sp Satistical test used: Student's T test Linear regression Se, Sp Blinding: NR NR Definition of positive and negative on screening test: US – at least one of the following criteria fulfilled: 1) turno > 10 cm in diameter (excluding simple completely unilocular with echogenic areas inside the cyst, 3) mutilocular with more than one thick (> 1 mm)	Sweden Mean: 53.8 Range: 21-92 NR Dates: May 1988 – Dec 1998 Menopausal status (n [%]): Size of population: 50 NR Detected by exam (n [%]): NR T+ T- to 16 16 0 22 28 Z2 28 Size of population: 50 NR Detected by imaging (n [%]): NR Tot 16 0 34 50 Case series NR Detected by imaging (n [%]): NR Detected by imaging (n [%]): NR NR Upper Reference standard applied to all test negatives?: Yes Risk factors (n [%]): NR NR Combination (n [%]): NR NR Sp 82.0% 69.1% 94.9% Statistical test negatives?: Yes Exclusion criteria: Surgical series Combination (n [%]): NR NR NR Additional data used for NR NPV 100.0% 89.3% 100.0% Statistical tests used: Student's T test Linear regression Se, Sp Exclusion criteria: NR NR S<

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	echoes, 4) multilocular- solid.				
Guerriero, Ajossa, Garau, et	Geographical location: Cagliari, Italy	Age: Mean (SD): 39 (15) Range: 14-79	Symptomatic (n [%]): NR	1) US morphology Dis+ Dis- Tot	Comments: Definition of positive morphology scan or Doppler very unclear (used
al., 2005	Dates: NR	Menopausal status	Detected by exam (n [%]) : NR	T+ <u>95 64</u> 159 T- <u>0 294</u> 294	some subjective description) – no score or calculation used
#7470	Size of population: 424 women 453 masses	(n [%]): Pre (< 45): 323 (76%) Post (> 55): 101 (24%)	Detected by imaging (n [%]):	Tot 95 358 453 Lower Upper	Kappa statistic calculated TVUS only
	Case series	Race/ethnicity (n [%]):	NR Combination (n [%]):	Value 95% Cl 95% Cl Se 100.0% 96.8% 100.0% Sp 82.0% 78.0% 86.0%	Quality assessment: Reference standard: + Verification bias: +
	Reference standard: Histopathology	Risk factors (n [%]) : NR	NR Additional data used for	PPV 59.7% 52.1% 67.4% NPV 100.0% 99.0% 100.0%	Test reliability/variability: + Sample size: - Statistical tests: +
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: NR	diagnosis: NR	2) Doppler Dis+DisTot	Blinding: - Definition of +/- on screening test: -
	Test reliability established?:	Exclusion criteria: NR		T+ 95 32 127 T- 0 326 326 Tot 95 358 453	
	Not really Statistical tests used: Se, Sp			Lower Upper Value 95% CI 95% CI Se 100.0% 96.8% 100.0% Sp 91.0% 88.0% 94.0%	
	Kappa statistic, Blinding: NR			PPV 74.8% 67.3% 82.4% NPV 100.0% 99.1% 100.0%	
	Definition of positive and negative on screening test:				
	US morphology : benign was anything that resembled an endometrioma, or a				
	cystic teratoma, or with appearance of non- malignant(not defined) Doppler – not clearly stated but appears to be				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	simple presence or absence of flow visualized in "echogenic structure"				
Guerriero, Ajossa, Risalvato, et al., 1998 #3400	Geographical location: Italy Dates: Jan 1996-May 1997 Size of population: 240 178 women with 192 masses Other Prospective series Reference standard: Pathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: Kappa for reliability Blinding: NR Definition of positive and negative on screening test: B-mode: Malignant when echogenic structure situated adjacent to wall of cyst is present, when a large > 3 mm irregular		Symptomatic (n [%]): NR Detected by exam (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Estimates are for masses not women 1) Post menopause $PI \le 1$ T $\frac{Dis+}{12}$ $\frac{Dis-}{35}$ $\frac{Tot}{35}$ Tot 26 25 51 $\frac{Value}{95\%} \frac{95\%}{Cl} \frac{95\%}{95\%} \frac{Cl}{95\%} \frac{95\%}{Cl}$ Se $\frac{88.0\%}{75.5\%}$ $\frac{100.0\%}{100.0\%}$ Sp 52.0% 32.4% 71.6% PPV 65.7% 50.0% 81.4% NPV 81.3% 62.1% 100.0% 2) Total for PI ≤ 1 T $\frac{Dis+}{14} \frac{Dis-}{75} \frac{Tot}{79}$ Tot 33 159 192 $\frac{Value}{95\%} \frac{95\%}{Cl} \frac{95\%}{95\%} \frac{Cl}{95\%} \frac{95\%}{51} \frac{25.7\%}{17.6\%} \frac{33.7\%}{33.7\%} \frac{100.0\%}{99.1\%} \frac{94.9\%}{90.1\%} \frac{90.1\%}{99.8\%}$	Comments: 2x2 analysis of masses not women US – descriptive no scoring system used Unclear why different PI cut points used No explanation for why RI cut point chosen Good use of kappa Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: +/- Sample size: - Statistical tests: + Blinding: +/ Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	homogeneous or				
	heterogeneous				
	echogenic structure				
	present or when an				
	irregular thickened > 3				
	mm wall or septum				
	present.				
	Color Doppler imaging				
	RI < 0.4, PI ≤ 1 or a PI ≤				
	0.8				
	CA-125: 35 and 65U/ml				
	CA-125. 55 and 050/mi				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Guerriero, Alcazar, Coccia, et	Geographical location: Italy	Age: Mean (SD): 40 (14) Range: 14-81	Symptomatic (n [%]): NR	1) Transvaginal sonography: Premenopausal	Comments: CA-125 used but data not presented separately
al., 2002	Dates: Apr 1997 to Jul 2000	-	Detected by exam (n [%]): NR	Dis+ Dis- Tot	Estimates are for masses, not individuals – difficult to determine
#2130		Menopausal status (n [%]):		T+ <u>48 62</u> 110 T- <u>1 506</u> 507	denominator being used
	Size of population: 789 women with 826 masses	Pre (< 45): 617 (78%) Post (> 55): 172 (22%)	Detected by imaging (n [%]): NR	Tot 49 568 617	Quality assessment: Reference standard: +
		Race/ethnicity (n [%]):		Lower Upper Value 95% CI 95% CI	Verification bias: +
	Other Case series	NR	Combination (n [%]): NR	Se 98.0% 94.1% 100.0% Sp 89.0% 86.4% 91.6%	Test reliability/variability: + Sample size: +
	Reference standard: Pathology	Risk factors (n [%]): NR	Additional data used for diagnosis:	PPV 43.6% 34.4% 52.9% NPV 99.8% 99.4% 100.0%	Statistical tests: + Blinding: - Definition of +/- on screening test:
	Reference standard applied to all test	Inclusion criteria: All women scheduled for surgery in the presence of	NR	 Transvaginal sonography: Postmenopausal 	-; not detailed enough to reproduce
	negatives?: Yes	a persistent adnexal mass		Dis+ Dis- Tot T+ 91 84 175	
	Test reliability established?:	Exclusion criteria: Women with an anechoic unilocular or bilocular		T- 0 88 88 Tot 91 172 263	
	Yes	cystic mass with a thin regular wall without		Lower Upper Value 95% CI 95% CI	
	Statistical tests used: Z statistic	endocystic vegetation		Se 100.0% 96.7% 100.0% Sp 51.0% 43.5% 58.5%	
	K statistic for agreement			PPV 52.0% 44.6% 59.4% NPV 100.0% 96.6% 100.0%	
	Blinding: NR			3) Color Doppler – Premenopausal	
	Definition of positive and negative on			Dis+ Dis- Tot	
	screening test: TV sonography:			T+ 46 23 69 T- 3 545 548 Tot 49 568 617	
	multiloculated, complex or solid mass in which			Lower Upper	
	the echo architecture was not highly indicative			Value 95% CI 95% CI Se 94.0% 87.4% 100.0%	
	of a benign histologic type was categorized as malignant.			Sp 96.0% 94.4% 97.6% PPV 66.7% 55.5% 77.8% NPV 99.5% 98.8% 100.0%	
	Color Doppler:				

tudy	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	malignancy was			4) Color Doppler: Postmenopausal	
	assumed if arterial flow	V			
	was visualized in an			Dis+ Dis- Tot	
	echogenic structure or			T+ <u>87</u> 40 127	
	an irregular solid portio	on		T- 4 132 136	
	defined as malignant o	n		Tot 91 172 263	
	B-mode imaging.				
				Lower Upper Value 95% CI 95% CI	
				Se 96.0% 92.0% 100.0% Sp 77.0% 70.7% 83.3%	
				PPV 68.5% 60.4% 76.6%	
				NPV 97.1% 94.2% 99.9%	
				5) Color Doppler: combined ages	
				Dis+ Dis- Tot	
				T+ 133 63 196	
				T- 7 677 684	
				Tot 140 740 880	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 95.0% 91.4% 98.6%	
				Sp 91.5% 89.5% 93.5%	
				PPV 67.9% 61.3% 74.4%	
				NPV 99.0% 98.2% 99.7%	
				6) US morphology – combined ages	
				Dis+ Dis- Tot	
				T+ 139 146 285	
				T- 1 594 595	
				Tot 140 740 880	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 99.3% 97.9% 100.0%	
				Sp 80.3% 77.4% 83.1%	
				PPV 48.8% 43.0% 54.6%	
				NPV 99.8% 99.5% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Hata, Hata, and Kitao, 1995	Geographical location: Japan	Age: Mean: 46.1 Range: 20-78	Symptomatic (n [%]) : NR	1) Peak systolic velocity > 16 cm/sec Dis+ Dis- Tot	Comments: US morphology descriptive – no scoring system used,
1995	Dates: NR	Range. 20-76	Detected by exam (n [%]):	T+ 25 6 31	Unclear why RI of 0.72 was used
#10960		Menopausal status	NR	T- <u>5</u> 66 71	or PSV of 16cm/sec
	Size of population:	(n [%]):		Tot 30 72 102	LMP tumors grouped in with
	102	NR	Detected by imaging		malignant
	- ·		(n [%]):	Lower Upper	TVUS only
	Case series	Race/ethnicity (n [%]):	NR	Value 95% CI 95% CI	0
	Reference standard:	Japanese	Combination (n [%]):	Se 83.3% 70.0% 96.6%	Quality assessment: Reference standard: +
	Histopathology	Risk factors (n [%]):	NR	Sp 91.7% 85.3% 98.1%	Verification bias: +
	ristopatiology	NR		PPV 80.6% 66.7% 94.6% NPV 93.0% 87.0% 98.9%	Test reliability/variability: -
	Reference standard		Additional data used for	NPV 93.0% 87.0% 98.9%	Sample size: -
	applied to all test	Inclusion criteria:	diagnosis:	2) RI <0.72	Statistical tests: +
	negatives?:	Referred to hospital with	NR	2) 10 0012	Blinding: -
	Yes	mass who had US prior to		Dis+ Dis- Tot	Definition of +/- on screening test:
		surgical evaluation		T+ 28 23 51	
	Test reliability			T- 2 49 51	
	established?: Not really	Exclusion criteria:		Tot 30 72 102	
	Notreally	INIX		Laura Haras	
	Statistical tests used:			Lower Upper Value 95% CI 95% CI	
	Se, Sp,			Se 93.3% 84.4% 100.0%	
	Kappa statistic			Sp 68.1% 57.3% 78.9%	
	Chi square			PPV 54.9% 41.2% 68.6%	
	5			NPV 96.1% 90.8% 100.0%	
	Blinding: NR				
	NK			US morphology	
	Definition of positive			Dis+ Dis- Tot	
	and negative on			T+ 26 22 48	
	screening test:			T- 4 50 54	
	US morphology :			Tot 30 72 102	
	"features that suggested			101 50 72 102	
	the possibility of			Lower Upper	
	malignancy" such as dense irregular septa,			Value 95% CI 95% CI	
	multilocular cysts,			Se 86.7% 74.5% 98.9%	
	papillary formation,			Sp <mark>69.4%</mark> 58.8% 80.0%	
	poorly defined borders,			PPV 54.2% 40.1% 68.3%	
	solid focus, echogenic			NPV 92.6% 85.6% 99.6%	
	core				
	R< 0.72				
	PSV > 16 cm/sec				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Hata, Hata,	Geographical location:		Symptomatic (n [%]):	1) RI < 0.72	Comments:
Manabe, et	Japan	Mean: 47.4 Range: 20-78	NR	Dis+ Dis- Tot	Unclear how patients selected
al., 1992	Dates: NR	Range. 20-76	Detected by exam (n [%]):	T+ 25 17 42	Borderline tumors grouped in with malignant
#5010	Dates. INIX	Menopausal status	NR	T- 2 19 21	No US scoring system used (and
	Size of population:	(n [%]):		Tot 27 36 63	means of diagnosis not well
	63	Pre (< 45): 35 (56%)	Detected by imaging		described)
		Post (> 55): 28 (44%)	(n [%]):	Lower Upper	MRI almost scoring system
	Other		NR	Value 95% CI 95% CI	RI cut point determined from
	Prospective series	Race/ethnicity (n [%]):		Se 92.6% 82.7% 100.0%	analysis of this data
		Japanese	Combination (n [%]):	Sp 52.8% 36.5% 69.1%	Unable to stratify by age
	Reference standard:		NR	PPV 59.5% 44.7% 74.4%	O
	Histopathology	Risk factors (n [%]):	Additional data used for	NPV 90.5% 77.9% 100.0%	Quality assessment: Reference standard: +
	Reference standard	NR	diagnosis:	0) 110	Verification bias: +
	applied to all test	Inclusion criteria:	NR	2) US	Test reliability/variability: -
	negatives?:	Suspected pelvic tumors		Dis+ Dis- Tot	Sample size: -
	Yes			T+ 23 11 34	Statistical tests: +
		Exclusion criteria:		T_{-} 4 25 29	Blinding: -
	Test reliability	NR		Tot 27 36 63	Definition of +/- on screening test:
	established?:				+/-
	CA-125 – yes			Lower Upper	
	RI - no			Value 95% CI 95% CI	
	Statistical tests used:			Se 85.2% 71.8% 98.6%	_
	ROC curves			Sp 69.4% 54.3% 84.5%	
	T tests, Chi-square			PPV 67.6% 51.9% 83.4%	
				NPV 86.2% 73.7% 98.8%	
	Blinding:				
	NR			3) MRI	
				Dis+ Dis- Tot	
	Definition of positive			T+ 18 1 19	
	and negative on screening test:			T- 9 35 44	
	CA-125 > 35 U/ml			Tot 27 36 63	
	RI – calculated from own				
	analysis of data < 0.72			Lower Upper	
	US – not described			Value 95% CI 95% CI	_
	MRI – malignant = size >			Se 66.7% 48.9% 84.5%	
	4 cm and (any of the			Sp 97.1% 91.6% 100.0% PPV 94.7% 84.7% 100.0%	
	following): 1) cystic, wall			NPV 94.7% 84.7% 100.0% NPV 79.5% 67.6% 91.5%	
	> 3 mm +/- nodularity			NEV 19.0% 01.0% 91.5%	
	2) predom solid lesion			4) CA-125 > 35	
	3) involvement of other			-, 0/(120, 00	
	organs or sidewalls or				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	omental dz or ascites or			Dis+ Dis- Tot	
	adenopathy			T+ 16 3 19	
				T- 11 33 44	
				Tot 27 36 63	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 59.3% 40.8% 77.8%	
				Sp 91.7% 82.7% 100.0%	
				PPV 84.2% 67.8% 100.0%	
				NPV 75.0% 62.2% 87.8%	
Herrmann Jr., Locher,	Geographical location: Germany	Age: NR	Symptomatic (n [%]): NR	1) US (borderline tumors excluded)	Comments: Excluded 92 patients who did not
and	Cermany			Dis+ Dis- Tot	get operated on within 3 weeks of
Goldhirsch,	Dates: 1981-1985	Menopausal status	Detected by exam (n [%]):	T+ 38 8 46	sonography – delay may be related
1987	Dates. 1901-1903	(n [%]):	NR	T- 14 177 191	to test result
1307	Size of population:	NR			Borderline tumors were excluded
#6840	312/404	INIX	Detected by imaging	Tot 52 185 237	from authors calculations, but
#0040	312/404	Decelethnicity (n [9/]).			
	Concerning a study	Race/ethnicity (n [%]):	(n [%]): NR	Lower Upper	reported separately
	Screening study	NR	NR	Value 95% CI 95% CI	Data reported separately for pelvic
	Retrospective series			Se 73.1% 61.0% 85.1%	versus adnexal masses, except for
		Risk factors (n [%]):	Combination (n [%]):	Sp 95.7% 92.7% 98.6%	benign tumors, which were reported
	Reference standard:	NR	NR	PPV 82.6% 71.7% 93.6%	together (Table 1). This may raise
	Pathology			NPV 92.7% 89.0% 96.4%	numbers in Dis- column of 2x2 table
		Inclusion criteria:	Additional data used for		with corresponding error for PPV
	Reference standard	NR	diagnosis:	US (borderline tumors considered	and NPV.
	applied to all test		NR	benign)	Data presented on page 779 re:
	negatives?:	Exclusion criteria:			prevalence of disease by age, but
	Yes	Very young age		Dis+ Dis- Tot	need additional information to fill in
		Pregnancy		T+ 38 11 49	2x2.
	Test reliability	Endocrinologic disorder		T- 14 178 192	Very unclear how patients selected
	established?:	Recurrent tumors		Tot 52 189 241	US scoring system from Fleischer e
	No	No pathology diagnosis		101 32 103 241	al (not well used criteria) – and not
	Statistical tests used:			Lower Upper	described in text
				Value 95% CI 95% CI	Quality accomments
	Chi-square			Se 73.1% 61.0% 85.1%	Quality assessment:
	Dlinding			Sp 94.2% 90.8% 97.5%	Reference standard: -
	Blinding:			PPV 77.6% 65.9% 89.2%	Verification bias: -
	NR			NPV 92.7% 89.0% 96.4%	Test reliability/variability:-
	Definition of month				Sample size: +
	Definition of positive				Statistical tests:+
	and negative on				Blinding: -

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	screening test: Ultrasound: Thick septae, irregular solid parts within a mass, indefinite margins, and the presence of ascites and matted bowel loops regarded as malignant.				Definition of +/- on screening test: +
Hillaby, Aslam, Salim, et al., 2004 #1620	Geographical location: London, UK Dates: Apr 2000 – Jun 2003 Size of population: 119 women Case series Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Interobserver reliability for 2 examiners on 15 cases showed agreement for crescent sign Statistical tests used: Se, Sp Blinding: Yes (prospective study) Definition of positive and negative on	Age: Mean: 43 Range: 15-81 Menopausal status (n [%]): Pre: 70 (70%) Post: 30 (30%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Scheduled to undergo surgery for adnexal pathology, referred to tertiary referral gyn scanning unit Exclusion criteria: None	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) US – ovarian crescent sign (T+ = negative) T+ $Dis+ Dis- Tot 41$ T- $1 58 59$ Tot 24 76 100 Value 95% CI 95% CI Se $96.0\% 88.2\% 100.0\%$ Sp $76.0\% 66.4\% 85.6\%$ PPV $56.1\% 40.9\% 71.3\%$ NPV $98.3\% 95.0\% 100.0\%$ 2) PI < 1.0 T+ $14 8 22$ Tot 24 76 100 Value 95% CI 95% CI Se $58.0\% 38.3\% 77.7\%$ Sp $89.0\% 82.0\% 96.0\%$ PPV $63.6\% 43.5\% 83.7\%$ NPV $87.2\% 79.8\% 94.6\%$ 3) CA-125 ≥ 35 U/ml T+ $21 26 47$ T- $3 50 53$ Tot 24 76 100	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: ±, crescent sign evaluated for reliability, but only in 15 cases and 2 observers. Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Yes				
	Ovarian crescent sign -	-		Lower Upper	
	presence of normal			Value 95% CI 95% CI	
	ovarian tissue on TVUS	6:		Se 88.0% 75.0% 100.0%	
	Criteria to identify norm			Sp 66.0% 55.3% 76.7%	
	ovarian tissues were:			PPV 44.7% 30.5% 58.9%	
	Hypoechogenic tissue			NPV 94.3% 88.1% 100.0%	
	with or without ovarian				
	follicles located adjacer	at		4) Tumor volume ≥ 180 mL	
	to the cyst wall, which	it i		4) Turnor volume \geq 100 mL	
	could not be separated			Dis+ Dis- Tot	
	from the cyst by applyir	ng		T+ <u>19 35</u> 54	
	a moderate amount of			T- <u>5</u> 41 46	
	pressure and which wa	S		Tot 24 76 100	
	enclosed within the				
	ovarian capsule			Lower Upper	
	encircling the tumor.			Value 95% CI 95% CI	
	Also			Se 79.0% 62.7% 95.3%	
	CA-125 ≥ 35 U/ml			Sp 54.0% 42.8% 65.2%	
	PI < 1.0			PPV 35.2% 22.4% 47.9%	
				NPV 89.1% 80.1% 98.1%	
				5) Papillary proliferations	
				Dis+ Dis- Tot	
				T+ 10 10 20	
				T- 14 66 80	
				Tot 24 76 100	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 41.0% 21.3% 60.7%	
				Sp <mark>87.0%</mark> 79.4% 94.6%	
				PPV 50.0% 28.1% 71.9%	
				NPV 82.5% 74.2% 90.8%	
				6) Time-averaged maximum velocity	
				$(TAMXV \ge 12 \text{ cm/s})$	
				Dis+ Dis- Tot	
				T+ 15 7 22	
				T- 9 69 78	
				Tot 24 76 100	
				Lower Upper	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
			Value 95% CI 95% CI Se 63.0% 43.7% 82.3% Sp 91.0% 84.6% 97.4% PPV 68.2% 48.7% 87.6% NPV 88.5% 81.4% 95.6%		
Hogdall, Hogdall, Tingulstad, et al., 2000 #2610	Geographical location: Denmark Dates: Sep 1994 to Apr 1996 Size of population: 168 Screening study Prospective series Reference standard: Pathology Reference standard applied to all test negatives?: Yes Test reliability established?: ? Interassay coefficient? Statistical tests used: ROC curves Mann-Witney Spearman-Rank Blinding: NR Definition of positive and negative on screening test: Not pre-specified	Age: Benign Median: 48 Range: 19-86 Non-ovarian cancer Median: 69 Range:42-79 Ovarian cancer Median:61.5 Range:31-82 Menopausal status (n [%]): NR Race/ethnicity (n [%]): Danish? Risk factors (n [%]): NR Inclusion criteria: Presence of a pelvic mass and a decision taken to proceed with surgical exploration Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) Overall sensitivity for CA-125 using a cutpoint of 35U/ml T+ Dis+ Dis- Tot T- 10 96 106 Tot 44 124 168 <u>Lower Upper</u> <u>Value 95% CI 95% CI</u> Se 77.3% 64.9% 89.7% Sp 77.4% 70.0% 84.8% PPV 54.8% 42.5% 67.2% NPV 90.6% 85.0% 96.1%	Comments: Data are presented in Table 4 by age 50, but total N seems to indicate that this is based on only the women with ovarian cancer; determination of specificity doesn't seem valid. Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: + Statistical tests: + Blinding: - Definition of +/- on screening test: -

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	"generally accepted cutpoints"				
Hricak, Chen, Coakley, et al., 2000 #2800	Geographical location: San Francisco, CA University Hospital Dates: Apr 1993 – May 1996 Size of population: 128 women (187 masses) Other Consecutive patients referred for MRI from gynecologist who had surgery Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes; inter- and intraobserver variability explicitly measured Statistical tests used: Logistic regression ROC curves Se, Sp Kappa Blinding: Yes	Age: Mean: 53 Range: 18-83 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Women with diagnosis of adnexal mass referred for MR from Gynoncol clinic who subsequently underwent surgery Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: Compared gadolinium enhanced MRI versus not enhanced	1) Non-enhanced MRI T+ $Dis+ Dis- Tot$ T- $13 - 68$ 81 Tot 96 91 187 Value 95% CI 95% CI Se $86.5\% 79.6\% 93.3\%$ Sp $74.7\% 65.8\% 83.7\%$ PPV $78.3\% 70.5\% 86.1\%$ NPV 84.0% $76.0\% 91.9\%$ 2) Gadolinium-enhanced MRI T+ $91 - 19$ 110 T- $5 - 72$ 77 Tot 96 91 187 Value 95% CI 95% CI Se $94.8\% 90.3\% 99.2\%$ Sp $79.1\% 70.8\% 87.5\%$ PPV $82.7\% 75.7\% 89.8\%$ NPV $93.5\% 88.0\% 99.0\%$	Comments: LMP tumors grouped into malignant Referral population from gynecological clinic - (probability of malignancy before imaging 51%); sicker population, not representative Data collected and analyzed per mass, not per patient Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + Sample size: - not discussed Statistical tests: + Blinding: + Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	screening test: [From ref 19] Malignant = at least one of the following primary criteria present: > 4 cm, bilateral, predominantly solid, cystic with wall or septum > 3 mm or papillary projections. OR at least 2 of the following secondary criteria present: ascites, peritoneal metastasis, adenopathy.				
Huber,	Geographical location:	Age:	Symptomatic (n [%]):	1) US morphology	Comments:
Medl, Baumann,	Austria	NR	NR	Dis+ Dis- Tot	Patients all referred with suspicion of ovarian cancer (hence high
et al., 2002	Dates: May 1995 – Jan	Menopausal status	Detected by exam (n [%]): NR	T+ 54 8 62	incidence of cancer in this group)
#5700	2001	(n [%]): NR	NR	T- 9 22 31 Tot 63 30 93	Unclear and not reproducible criteria for + or - US and MRI – no
	Size of population:		Detected by imaging		scoring system used
	93	Race/ethnicity (n [%]):	(n [%]): NR	Lower Upper Value 95% CI 95% CI	Combination TVUS and abdomin US (unable to stratify, no N stated
	Reference standard:			Se 85.0% 76.2% 93.8%	for each)
	Histopathology	Risk factors (n [%]): NR	Combination (n [%]):	Sp 73.0% 57.1% 88.9%	Quality assessment:
	Reference standard	INIX	INIX	PPV 87.1% 78.8% 95.4% NPV 71.0% 55.0% 86.9%	Reference standard: +
	applied to all test	Inclusion criteria:	Additional data used for		Verification bias: +
	negatives?: Yes	Patients suspected of having ovarian cancer in	diagnosis: NR	2) MRI	Test reliability/variability: - Sample size: -
	Tast as list life.	time frame referred for		Dis+ Dis- Tot	Statistical tests: +
	Test reliability established?:	surgery and had imaging done		T+ <u>56</u> <u>4</u> 60 T- <u>7</u> <u>26</u> <u>33</u>	Blinding: + Definition of +/- on screening test:
	No			Tot 63 30 93	
	Statistical tests used:	Exclusion criteria:			
	Chi square			Lower Upper Value 95% CI 95% CI	
	Fisher exact test			Se 89.0% 81.3% 96.7%	
	Blinding:			Sp 86.0% 73.6% 98.4%	
	Yes			PPV 93.3% 87.0% 99.6% NPV 78.8% 64.8% 92.7%	
	Definition of positive and negative on				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	screening test: US – "detection of complex (noncystic) and/or solid mass, which was ≥ 5 cm in premenopausal woman or any size in postmenopausal woman. MRI – descriptive				
Hurteau, Woolas, Jacobs, et al., 1995 #4060	postmenopausal woman. MRI – descriptive Geographical location: Patients from London, UK Dates: NR Size of population: Unclear – article mentions 100 patients preop evaluation as well as 88 "healthy subjects", but analysis done on 92 Other Series in single center Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes	Age: NR Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Unclear – preop with diagnosis of adnexal mass Exclusion criteria: NR	NR Combination (n [%]): NR Additional data used for diagnosis:	1) CA-125 > 35 T+ 32 31 63 T- 7 30 37 Tot 39 61 100 Lower Upper Value 95% Cl 95% Cl Se 82.1% 70.0% 94.1% Sp 49.2% 36.6% 61.7% PPV 50.8% 38.4% 63.1% NPV 81.1% 68.5% 93.7%	Comments: Very unclear patient selection, inclusion and exclusion criteria (numbers don't match up – no explanation of how went from 100 to 92) Data on IL 2 alpha not included in 2x2 table as this is not a common test Inclusion of healthy subjects not necessarily appropriate for diagnostic (as opposed to screening test Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + - not discussed in article but well established test Sample size: - Statistical tests: +/- Blinding: + Definition of +/- on screening test: +
	Statistical tests used: Sen, Sp Student's t test Blinding: NR – prospective sampling				

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	Definition of positive and negative on screening test: CA-125 > 35 U/mL							
Inoue, Fujita, Nakazawa, et al., 1992	Geographical location: Osaka, Japan University Hospital Dates: Sep 1989 – May	NR Menopausal status	Symptomatic (n [%]): NR Detected by exam (n [%]): NR	1) CA-125 (> 65 U/mL) Dis+ Dis- Tot T+ <u>25 44</u> 69			Comments: CA-125 limit 65U/mL No description of patient populatior at all 5 surface epithelial tumors of LMP	
#5120	1991	(n [%]): NR	Detected by imaging	T- Tot	40 65	273 317	313 382	were grouped into malignant category
	Size of population: 382 women	Race/ethnicity (n [%]): NR	(n [%]) : NR	Se	Value 38.0%	Lower 95% CI 26.2%	Upper 95% CI 49.8%	Quality assessment: Reference standard: +
	Other Patents who underwent surgery for adnexal mass	Risk factors (n [%]): NR Inclusion criteria:	Combination (n [%]): NR Additional data used for	Sp PPV NPV	86.0% 36.2% 87.2%	82.2% 24.9% 83.5%	89.8% 47.6% 90.9%	Verification bias: + Test reliability/variability: + (COV discussed in serum samples between labs)
	Reference standard: Histopathology	Women undergoing surgery for (presumed) adnexal mass at one of	diagnosis: None	2) CEA	A Dis+	Dis-	Tot	Sample size: - (not discussed) Statistical tests: + Blinding: +
	Reference standard applied to all test negatives?:	the University hospitals in time frame		T+ T- Tot	14 51 65	10 307 317	24 358 382	Definition of +/- on screening test: +
	Yes Test reliability	Exclusion criteria: LMP tumors other than those of surface epithelial-) (=	Lower	Upper	
	established?: Yes	stromal type and non- gynecological tumors.		Se Sp PPV	Value 22.0% 97.0% 58.3%	<u>95% CI</u> 11.9% 95.1% 38.6%	95% CI 32.1% 98.9% 78.1%	
	Statistical tests used: ROC curves Se, Sp			NPV	85.8%	82.1%	89.4% other markers,	
	Blinding : No			Sialyl-1	n (STN), :		s Xi (SLX), CA	
	Definition of positive and negative on screening test: CA-125 > 65 U/mL CEA > 2.4 ng/mL							

Study	Study Design	y Design Patients	Clinical Presentation	Comments/Quality Scoring	
ltakura, Kikkawa, Kaiivama, et	Geographical location: Japan University Hospital	Age: Mean (SD): 49.1	Symptomatic (n [%]): NR	1) Morphological index of DePriest (> 7)	Comments: Se and Sp reported unclear if for patient or for tumor (most likely for
al., 2003		Menopausal status	Detected by exam (n [%]):	Dis+ Dis- Tot	tumor)
#1690	Dates: Jun 1998 – Jul 2000	(n [%]): Pre: 41 (48.8%)	NR	T+ 24 15 39 T- 3 42 45	CA-125 cutoff 65 U/mL Borderline tumors lumped into
	Size of population:	Post: 43 (51.2%)	Detected by imaging (n [%]):	Tot 27 57 84	malignant
	84 women (95 tumors)	Race/ethnicity (n [%]): NR	NR	Lower Upper	Quality assessment: Reference standard: +
	Other		Combination (n [%]):	Value 95% CI 95% CI Se 90.3% 79.1% 100.0%	Verification bias: +
	Hospital referral for	Risk factors (n [%]):	NR	Sp 73.4% 61.9% 84.9%	Test reliability/variability: +
	surgery secondary to	NR		PPV 61.5% 46.3% 76.8%	Sample size: - not discussed
	mass		Additional data used for	NPV 93.3% 86.0% 100.0%	Statistical tests: +/-
		Inclusion criteria:	diagnosis:		Blinding: -
	Reference standard: Histopathology	Patients who underwent surgery at university	NR	2) PI (min < 1.0)	Definition of +/- on screening test: +
		hospital for mass		Dis+ Dis- Tot	
	Reference standard	(not clearly described)		T+ 22 8 30	
	applied to all test	Evolution enitories		T- <u>5</u> 49 54	
	negatives?: Yes	Exclusion criteria: NR		Tot 27 57 84	
	Test reliability			Lower Upper Value 95% CI 95% CI	
	established?:			Se 80.6% 65.7% 95.5%	
	CA-125 – yes			Sp 85.9% 76.9% 94.9%	
	DePriest – yes			PPV 73.3% 57.5% 89.2%	
	PI - yes			NPV 90.7% 83.0% 98.5%	
	Statistical tests used:			3) CA-125 (> 65 U/ml)	
	Se, Sp			, , , ,	
	Blinding:			Dis+ Dis- Tot	
	Prospective study –			T+ 19 7 26	
	blinding not discussed			T- <u>8 50</u> 58 Tot 27 57 84	
	Definition of positive			Lower Upper	
	and negative on			Value 95% CI 95% CI	
	screening test: CA-125 > 65 U/mL			Se 70.4% 53.2% 87.6%	
				Sp 87.7% 79.2% 96.2%	
	Morphological index of DePriest score > 7			PPV 73.1% 56.0% 90.1%	
	PI < 1.0			NPV 86.2% 77.3% 95.1%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Jacobs, Oram, Fairbanks,	Geographical location: London	Mean (SD):	Symptomatic (n [%]) : NR	1) CA-125 > 30 Dis+ Dis- Tot	Comments: CA-125 cutoff of 30U/mL used
et al., 1990	Dates: NR	Benign 48.8 (14.3) Malignant 59.0 (11.8)	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 34 25 59 T- 8 76 84	Quality assessment: Reference standard: +
#6820	Size of population: 143 Other Consecutive series	Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR Combination (n [%]):	Value 95% Cl 95% Cl Se 81.0% 69.1% 92.9% Sp 75.0% 66.6% 83.4%	Verification bias: + Test reliability/variability: + Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: +
	Reference standard: Histopathology	Risk factors (n [%]): NR	NR Additional data used for	PPV 57.6% 45.0% 70.2% NPV 90.5% 84.2% 96.8%	(but didn't explain why 30 U/mL used as cutoff for CA-125)
	Reference standard applied to all test negatives?:	Inclusion criteria: Consecutive admissions	diagnosis: NR	2) US score <u>></u> 1	
	Yes	for elective surgical investigation of pelvic		Dis+ Dis- Tot T+ 41 52 93 T- 0 46 46	
	Test reliability established?: CA-125 - yes	mass in hospital in time frame		Tot 41 98 139	
	Statistical tests used: Stepwise logistic regression Se, Sp RMI	Exclusion criteria: NR		Lower Upper Value 95% Cl 95% Cl Se 100.0% 92.7% 100.0% Sp 46.9% 37.0% 56.8% PPV 44.1% 34.0% 54.2% NPV 100.0% 93.5% 100.0%	
	Blinding: NR – but prospective			3) US score ≥ 2 Dis+ Dis- Tot	
	Definition of positive and negative on screening test:			T+ 29 17 46 T- 12 81 93 Tot 41 98 139	
	CA-125 > 30U/mL US: 1 point assigned for each of the following: multilocular cyst solid areas metastases ascites bilateral lesion			ValueLower 95% ClUpper 95% ClSe70.7% 82.7%56.8% 75.2%84.6% 90.2%PPV63.0% 87.1%49.1% 80.3%77.0% 93.9%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Jacobs, Stabile,	Geographical location: London, UK	Mean: 54	Symptomatic (n [%]): 0 (0%)	 CA-125 > 30 U/ml (assuming all test negatives truly negative) 	Comments: Unclear where definition of ovarian
Bridges, et al., 1988	Dates: NR	Range: 45-83	Detected by exam (n [%]):	Dis+ Dis- Tot	volume as abnormal (> 8.8ml) came from
uii, 1000	Batoon nat	Menopausal status	NR	T+ 1 30 31	Vague criteria for BME
#6830	Size of population:	(n [%]):		T- 0 979 979	Low incidence of cancer in this
	and CA-125	Post (> 55): 1010 (100%)	Detected by imaging (n [%]):	Tot 1 1009 1010	screening study Abdominal US only
	58 US done secondary to		NR	Lower Upper	
	abnormal BME or CA-	NR	Combination (n 19/1)	Value 95% CI 95% CI	Quality assessment:
	125 9 went to surgery	Risk factors (n [%]):	Combination (n [%]): NR	5 100.0% 200.0% 100.0%	Reference standard: - Verification bias: -
	5 went to surgery	NR		Se 100.0% 200.0% 100.0% Sp 97.0% 96.0% 98.1%	Test reliability/variability: -
	Screening study		Additional data used for	PPV 3.2% 0.0% 9.4%	Sample size: -
		Inclusion criteria:	diagnosis:	NPV 100.0% 99.7% 100.0%	Statistical tests: +
	Reference standard:	NR	NR		Blinding: -
	Surgery for 9 repeat US and BME at 3 month	Exclusion criteria:		2) CA-125 > 30U/ml not assuming test	Definition of +/- on screening test: +
	intervals for one year for			negatives true negative (including only the	se
	initial abnormals (by CA-			which had US)	
	125 or BME)			Dis+ Dis- Tot	
	•			T+ 1 30 31	
	Reference standard			T- 0 27 27	
	applied to all test negatives?:			Tot 1 57 58	
	No			Lower Upper	
	Test reliability			Value 95% CI 95% CI	
	established?:			Se 100.0% 200.0% ^{100.0%}	
	Yes			Se 100.0% 200.0% Sp 47.4% 34.4% 60.3%	
				PPV 3.2% 0.0% 9.4%	
	Statistical tests used: Se, Sp			NPV 100.0% 88.9% 100.0%	
	Blinding: NR			 BME (assuming all negatives true negative) 	
	Definition of positive				
	and negative on			Dis+ Dis- Tot T+ 1 27 28	
	screening test:			T- 0 982 982	
	BME – "palpable mass of			Tot 1 1009 1010	
	any size separate from uterus or GI tract"				
	CA-125 \geq 30 U/ml			Lower Upper	
	US ovarian volume >			Value 95% CI 95% CI	
	8.8ml			- 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				200.0% Sp 97.3% 96.3% 98.3% PPV 3.6% 0.0% 10.4% NPV 100.0% 99.7% 100.0%	
				 BME not assuming test negatives true negative 	
				Dis+ Dis- Tot T+ 1 27 28 T- 0 30 30 Tot 1 57 58	
				Lower Upper Value 95% Cl 95% Cl	
				Se 100.0% 200.0% ^{100.0%} Sp 52.6% 39.7% 65.6% PPV 3.6% 0.0% 10.4% NPV 100.0% 90.0% 100.0%	
				4) US alone (ovarian volume > 8.8ml)	
				Dis+ Dis- Tot T+ 1 12 13 T- 0 45 45 Tot 1 57 58	
				Lower Upper Value 95% CI 95% CI	
				Se 100.0% 200.0% 100.0% Sp 78.9% 68.4% 89.5% PPV 7.7% 0.0% 22.2% NPV 100.0% 93.3% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Jain, 1994	Geographical location:		Symptomatic (n [%]):	1) RI < 0.4 of MASSES	Comments:
	Stanford, CA	Mean: 43	NR		Data presented such that LMP
#4620		Range: 33-55		Dis+ Dis- Tot	could be easily excluded from
	Dates: NR		Detected by exam (n [%]):	T+ 7 7 14	analysis
		Menopausal status	NR	T- 2 33 35	Unclear if anyone other than author
	Size of population:	(n [%]):	Defended by investigation	Tot 9 40 49	did US examinations
	42 women (50 masses)	NR	Detected by imaging		No discussion of inter/intra
	Other		(n [%]):	Lower Upper	operator variability
	Other Prospective series of	Race/ethnicity (n [%]):	NR	Value 95% CI 95% CI	Data presented with N = masses
		NR	Combination (n [9/1);	Se 77.8% 50.6% 100.0%	not patients
	surgical cases with US	Dick factors (n [9/1);	Combination (n [%]): NR	Sp 82.5% 70.7% 94.3%	Quality assessment:
	Deference standard	Risk factors (n [%]): NR		PPV 50.0% 23.8% 76.2%	Reference standard: +
	Reference standard: Histopathology	NR	Additional data used for	NPV 94.3% 86.6% 100.0%	Verification bias: +
	Histopathology	Inclusion criteria:	diagnosis:		Test reliability/variability: -
	Reference standard	42 women with clinically	NR	2) US (MASSES)	Sample size: -
	applied to all test	suspected adnexal			Statistical tests: -
	negatives?:	masses undergoing		Dis+ Dis- Tot	Blinding: +/-
	Yes	surgery – US performed 1-		T+ 9 2 11	Definition of +/- on screening test: -
	165	5 days prior		T- 0 38 38	Deminition of the off screening test.
	Test reliability	5 days prior		Tot 9 40 49	
	established?:	Exclusion criteria:			
	RI – yes	Obstetrical cases		Lower Upper	
	US – not really	Obstetrical cases		Value 95% CI 95% CI	
	(references his own			Se 100.0% 66.7% 100.0%	
	article the next in this			Sp 95.0% 88.2% 100.0%	
	batch #4950)			PPV 81.8% 59.0% 100.0%	
	batch #4930)			NPV 100.0% 92.1% 100.0%	
	Statistical tests used:				
	NR				
	Blinding:				
	NR – but prospective				
	Definition of positive				
	and negative on				
	screening test:				
	RI < 0.4				
	Grey scale US –				
	Presence of any of the				
	following:				
	Irregular solid portion,				
	irregular wall, thick				
	irregular septa, mural				
	notdule; Doppler done,				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	but neovascularization not required for diagnosis of malignancy				
Jain, Friedman, Pettinger, et al., 1993 #4950	Geographical location: Davis and Palo Alto, CA	Mean: 41.5 Range: 29-54 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]):	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) US: Cancer vs. benign $\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Comments: Kappa calculated Unclear how individuals chosen for study (if not consecutive) US score consisted of diagnosis as did MRI – ?reproducible Pathology not available for all, laproscopy patients had FNA with examination of ovaries Se/Sp based on masses, not patients Cuality assessment: Reference standard: + Verification bias: +/- Test reliability/variability: + Sample size: - Statistical tests: +/- Blinding: + Definition of +/- on screening test: -

							Comments/Quality Scoring
Geographical location: Yugoslavia and Hungary	Age: NR	Symptomatic (n [%]): NR	1) Col		esent or ab		Comments: Unclear exactly what was meant by
Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Т+ т-	21	17	38	present flow on Doppler No description of patient characteristics
Size of population: 147	NR	Detected by imaging	Tot	22	125	147	TVUS only
Case series	Race/ethnicity (n [%]): NR	(n [%]): NR	50	Value	Lower 95% Cl	95% CI	Quality assessment: Reference standard: + Verification bias: +
Reference standard: Histopathology	Risk factors (n [%]) : NR	Combination (n [%]): NR	Sp PPV	86.4% 55.3%	80.4% 39.5%	92.4% 71.1%	Test reliability/variability: - Sample size: - Statistical tests: -
Reference standard applied to all test negatives?:	Inclusion criteria: NR	Additional data used for diagnosis: NR	NPV	99.1%	97.3%	100.0%	Blinding: - Definition of +/- on screening test: -
Test reliability	NR						
established?: Yes							
Statistical tests used: Se, Sp							
Blinding: NR							
Definition of positive and negative on screening test:							
Presence or absence of color flow within adnexal mass on Doppler							
	Dates: NR Size of population: 147 Case series Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: Se, Sp Blinding: NR Definition of positive and negative on screening test: Presence or absence of color flow within adnexal	Dates:NRMenopausal status (n [%]):Size of population:NR147Race/ethnicity (n [%]):Case seriesNRReference standard:Risk factors (n [%]):HistopathologyNRReference standard applied to all test negatives?: YesInclusion criteria: NRTest reliability established?: YesNRStatistical tests used: Se, SpStatistical tests used: Se, SpBlinding: NRDefinition of positive and negative on screening test: Presence or absence of color flow within adnexal	Dates: NRMenopausal status (n [%]): NRDetected by exam (n [%]): NRSize of population: 147NRDetected by imaging (n [%]): NR147Race/ethnicity (n [%]): NRDetected by imaging (n [%]): NRCase seriesNRCombination (n [%]): NRReference standard: HistopathologyRisk factors (n [%]): NRCombination (n [%]): NRReference standard applied to all test negatives?: YesInclusion criteria: NRAdditional data used for diagnosis: NRTest reliability established?: YesNRStatistical tests used: NRNRStatistical tests used: Se, SpStatistical tests used: NRStatistical tests used: Se, SpBlinding: NRDefinition of positive and negative on screening test: Presence or absence of color flow within adnexalStatistical tests used: Se, Sp	Dates: NR Size of population: 147Menopausal status (n [%]): NRDetected by exam (n [%]): NRT+ T- Tot147NRDetected by imaging (n [%]): NRDetected by imaging (n [%]): NRT- TotCase seriesNRRace/ethnicity (n [%]): NRNRSe Sp PPV NPVReference standard: HistopathologyRisk factors (n [%]): NRCombination (n [%]): NRSe Sp PPV NPVReference standard applied to all test negatives?: YesInclusion criteria: NRAdditional data used for diagnosis: NRSe Sp PPV NPVTest reliability established?: YesExclusion criteria: NRNRSe Sp Statistical tests used: 	Dates: NR Menopausal status (n [%]): Detected by exam (n [%]): T+ 21 Size of population: NR Tot 22 147 Race/ethnicity (n [%]): NR Tot 22 Case series NR NR Value Reference standard: Risk factors (n [%]): NR Value Value Histopathology NR NR Se 95.5% Reference standard applied to all test negatives?: Inclusion criteria: Additional data used for diagnosis: NPV 99.1% Yes Exclusion criteria: NR Se Se 99.1% Blinding: NR NR Se Se Se NR Presence or absence of color flow within adnexal Se Se Se	Dates: NR Menopausal status (n [%]): NR Detected by exam (n [%]): NR T+ T- Tot Dis- 21 147 NR Case series NR Reference standard: Histopathology Risk factors (n [%]): NR NR Reference standard: applied to all test negatives?: Yes Risk factors (n [%]): NR Combination (n [%]): NR Se 99.1% Se 99.1% Test reliability established?: Yes Exclusion criteria: NR Additional data used for diagnosis: NR NR Definition of positive and negative on screening test: Presence or absence of color flow within adnexal NR Se	Dates: NR Menopausal status (n [%]): Detected by exam (n [%]): T+ NR Dis- 22 Tot Size of population: NR Detected by imaging (n [%]): NR Tot 38 147 Race/ethnicity (n [%]): NR Detected by imaging (n [%]): Tot 22 125 147 Case series NR Race/ethnicity (n [%]): NR Detected by imaging (n [%]): Tot 22 125 147 Reference standard: Risk factors (n [%]): NR Combination (n [%]): Se 95.5% 86.8% 100.0% Reference standard applied to all test negatives?: Inclusion criteria: Additional data used for diagnosis: NPV 99.1% 97.3% 100.0% Yes Exclusion criteria: NR Additional data used for diagnosis: NPV 99.1% 97.3% 100.0% NR Provide Se Se

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Kawahara, Yoshida,	Geographical location: Fukui, Japan	Age: NR	Symptomatic (n [%]): NR	1) MRI	Comments: LMP tumors grouped in with
Kurokawa, et al., 2004	Dates: Sept 2001 – Aug	Menopausal status	Detected by exam (n [%]):	Dis+ Dis- Tot T+ 21 2 23	malignant Patient referral from onc clinic, not
·	2003	(n [%]):	NR	T- 2 13 15	representative, sicker
#10	Size of population.	NR	Detected by imaging	Tot 23 15 38	MRI scoring system vague and not reproducible
	Size of population: 38	Race/ethnicity (n [%]) : NR	Detected by imaging (n [%]): NR	Lower Upper	No discussion of inter/intra observer variability
	Other			Value 95% CI 95% CI Se 91.3% 79.8% 100.0%	In reporting PET results authors
	Series of suspected	Risk factors (n [%]):	Combination (n [%]):	Sp 86.7% 69.5% 100.0%	state "the benign tumors were
	ovarian cancer cases	NR	NR	PPV 91.3% 79.8% 100.0%	correctly identified as negative for
	who went to surgery	Inclusion criteria:	Additional data used for	NPV 86.7% 69.5% 100.0%	malignancy in all 13 patients with benign lesion" however there were
	Reference standard: Histopathology	Patients who had been screened in gynecological	diagnosis:	2) FDG-PET	15 patients with benign lesions
		oncology clinic with BME		Dis+ Dis- Tot	Quality assessment:
	Reference standard	and US and considered to		T+ 18 0 18	Reference standard: +
	applied to all test negatives?:	have masses suspicious for malignancy		T- 5 15 20	Verification bias: + Test reliability/variability: -
	Yes	for manynancy		Tot 23 15 38	Sample size: -
	Test reliability	Exclusion criteria: NR		Lower Upper	Statistical tests: - Blinding: +/-
	established?:			Value 95% CI 95% CI	Definition of +/- on screening test: -
	MRI – yes			Se 78.3% 61.4% 95.1% Sp 100.0% 80.0% 100.0%	
	PET scan - ?			Sp 100.0% 80.0% 100.0% PPV 100.0% 83.3% 100.0% NPV 75.0% 56.0% 94.0%	
	Statistical tests used: Se, Sp			NFV 75.070 50.070 54.070	
	Blinding: NR – prospective study				
	Definition of positive and negative on				
	screening test:				
	MRI – if any of these features was met, mass				
	considered suspicious for				
	malignancy: "cystic				
	without solid areas,				
	diameter of 4cm or less,				
	wall thickness < 0.3 cm, the presence of typical				
	characteristics of				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	dermoid cyst or endometrioma" For PET scan with 18- Flourodeoxyglucose – "hypermetabolic lesions that were more intense than the liver and not attributable to bladder etc. were considered positive for malignancy"				
Kawai, Kikkawa, Ishikawa, et al., 1994		Age: NR Menopausal status	Symptomatic (n [%]): NR	1) Doppler <u>Dis+ Dis-</u> Tot T+ <u>30 14</u> 44	Comments: Means of evaluating Doppler (1/PI) is unusual and not justified in text Cut point for PI of 1.25 is also
al., 1994 #10940	Dates: Apr 1990 – Aug 1993	(n [%]): NR	Detected by exam (n [%]) : NR	T+ 30 14 44 T- 10 55 65 Tot 40 69 109	unusual LMP tumors grouped in with
	Size of population: 109	Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR	Lower Upper Value 95% CI 95% CI	malignant Calculated PPV and NPV differ slightly from text
	Case series	Risk factors (n [%]):	Combination (n [%]):	Se 75.0% 61.6% 88.4% Sp 79.2% 69.6% 88.8%	TVUS only
	Reference standard: Histopathology	NR Inclusion criteria:	NR Additional data used for	PPV 68.2% 54.4% 81.9% NPV 84.6% 75.8% 93.4%	Quality assessment: Reference standard: + Verification bias: +
	Reference standard applied to all test	NR	diagnosis: NR	2) CA-125 > 35U/ml	Test reliability/variability: - Sample size: -
	negatives?: Yes	Exclusion criteria: NR		Dis+ Dis- Tot T+ 29 37 66	Statistical tests: - Blinding: - Definition of +/- on screening test: -
	Test reliability established?: Yes			T- <u>11 32</u> 43 Tot 40 69 109 Lower Upper	
	Statistical tests used: Student's t test Chi square analysis			Value 95% CI 95% CI Se 72.2% 58.3% 86.1% Sp 45.8% 34.0% 57.6% PPV 43.9% 32.0% 55.9%	
	Blinding: NR			NPV 74.4% 61.4% 87.5% 3) CA-72-4	
	Definition of positive and negative on screening test:			Dis+ Dis- Tot T+ <u>17 12</u> 29 T- <u>23 57</u> 80	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	Doppler: 1/PI with cut			Tot	40	69	109	
	0.8 (which equals a cu	utoff						
	for PI of 1.25)					Lower	Upper	
					Value	95% CI	95% CI	
	CA-125 > 35 U/ml			Se	41.7%	26.4%	57.0%	
	CA-72-4 > 4U/ml			Sp	83.3%	74.5%	92.1%	
	CA-19-9 > 37U/ml			PPV	58.6%	40.7%	76.5%	
				NPV	71.3%	61.3%	81.2%	
				4) CA-				
				4) OA-	13-3			
					Dis+	Dis-	Tot	
				T+	14	12	26	
				Т-	26	57	83	
				Tot	40		109	
							100	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	36.1%	21.2%	51.0%	
				Sp	83.3%	74.5%	92.1%	
				PPV	53.8%	34.7%	73.0%	
				NPV	68.7%	58.7%	78.7%	
					50.770	50.770	10.170	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Komatsu, Konishi, Mandai, et	Geographical location: Kyoto, Japan	Age: Mean: 45.9 Range: 17-89	Symptomatic (n [%]) : NR	 US: benign vs. malignant (US class 0 or 1a benign, all other malignant); borderline counted as malignancy 	Comments: Unclear how patients chosen for study (consecutive?)
al., 1996	Dates: May 1989 – May 1993	5	Detected by exam (n [%]): NR	Dis+ Dis- Tot	Clinical presentation not described Outcome of 73 patients who did not
#4050	Size of population: 82	(n [%]): Pre (< 45): 54 (65.9%) Post (> 55): 28 (34.1%)	Detected by imaging (n [%]):	T+ 34 26 60 T- 0 22 22 Tot 34 48 82	undergo surgery not described Over half of masses were malignant
	Other Retrospective case	Race/ethnicity (n [%]) : NR	NR Combination (n [%]) : NR	Lower Upper Value 95% CI 95% CI	Results not stratified by age/menopausal status
	series comparing US and MR Reference standard:	Risk factors (n [%]): NR	Additional data used for diagnosis:	Se 100.0% 91.2% 100.0% Sp 45.8% 31.7% 59.9% PPV 56.7% 44.1% 69.2%	Quality assessment: Reference standard: +; pathology Verification bias: -; large portion did not undergo surgery
	Histopathology	Inclusion criteria: NR	NR	NPV 100.0% 86.4% 100.0%2) MRI: benign vs. malignant (MRI class 1b)	Test reliability/variability:-; not
	Reference standard applied to all test negatives?:	Exclusion criteria: NR		malignant, all others benign); borderline counted as malignancy	Sample size:-; wide Cls Statistical tests: -; 2x2 tables not presented
	Yes Test reliability established?:			Dis+ Dis- Tot T+ 31 3 34 T- 3 22 25 Tot 34 25 59	Blinding: + Definition of +/- on screening test:
	Statistical tests used:			Lower Upper	
	Blinding: Yes			Value 95% CI 95% CI Se 91.2% 81.6% 100.0% Sp 88.0% 75.3% 100.0%	
	Definition of positive and negative on screening test: US classification:			PPV 91.2% 81.6% 100.0% NPV 88.0% 75.3% 100.0%	
	0 = cyst with well- defined, thin wall 1a = septation				
	1b = solid tissue 2a = complex mass with internal structure with				
	diffuse low-level echoes, no distinct findings of cyst				
	2b = complex mass with internal structure with				

tudy	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	excrescences with low-				
	level echoes and blurred				
	margin 1b, 2a, 2b considered				
	possibly malignant				
	MRI:				
	0 = cyst with well-defined				
	wall, no internal				
	enhancement,				
	homogenous low intensity on T-1 weighted				
	images, high intensity on				
	T2				
	1a = neoplasm with				
	septation				
	1b = solid 2a = cystic mass with				
	complex fluid such as				
	blood, proteinaceous				
	fluid, or fat				
	2b = cystic mass with				
	unenhanced				
	excrescences				
	1b considered possibly malignant				
	mangnant				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Kurjak and Kupesic,	Geographical location: Zagreb, Croatia	Mean (SD):	Symptomatic (n [%]) : NR	1) 2D US combined	Comments: TVUS and 3D/Doppler scoring
1999	University Hospital	Pre 34		Dis+ Dis- Tot	systems invented by authors (?) and
		Peri 49	Detected by exam (n [%]):	T+ 10 3 13	no reference of use given (no
#2920	Dates: Jan 1997 – Jun	Post 61	NR	T- 1 106 107	reliability calculation etc.) –
	1998	Range: 18-77		Tot 11 109 120	reproducibility?
		•• • • • •	Detected by imaging		Same group of patients as #2820
	Size of population:	Menopausal status	(n [%]):	Lower Upper	
	120 women	(n [%]):	NR	Value 95% CI 95% CI	Quality assessment:
		Pre: 76 (63.3%)		Se 90.9% 73.9% 100.0%	Reference standard: +
	Other	Peri: 7 (5.8%)	Combination (n [%]):	Sp 97.3% 94.2% 100.0%	Verification bias: +
	Patients scheduled for	Post: 37 (30.8%)	NR	PPV 76.9% 54.0% 99.8%	Test reliability/variability:-
	surgery at university			NPV 99.1% 97.2% 100.0%	Sample size: -
	hospital	Race/ethnicity (n [%]):	Additional data used for		Statistical tests: +
		NR	diagnosis:	2) 3D US combined	Blinding: +
	Reference standard:		NR	_,	Definition of +/- on screening test: +
	Histopathology	Risk factors (n [%]):		Dis+ Dis- Tot	
		NR		T+ 11 1 12	
	Reference standard			T- 0 108 108	
	applied to all test	Inclusion criteria:		Tot 11 109 120	
	negatives?:	Not clearly stated –		101 11 109 120	
	Yes	women with masses to		Lewen Lienen	
		undergo surgery in		Lower Upper	
	Test reliability	hospital		Value 95% CI 95% CI	
	established?:	Premenopausal women		Se 100.0% 72.7% 100.0%	
	No	had US during early		Sp 99.1% 97.3% 100.0%	
	110	proliferative phase only		PPV 91.7% 76.0% 100.0%	
	Statistical tests used:	promotative phase only		NPV 100.0% 97.2% 100.0%	
	Se, Sp	Exclusion criteria:			
	86, 8р	NR			
	Blinding:				
	No – but prospective				
	No – but prospective				
	Definition of positive				
	and negative on				
	screening test:				
	TVUS score \geq 5 (where				
	+2 for papillarities > 3				
	mm, +1 for shadowing				
	present, +1 for septa > 3				
	mm, +2 for solid parts				
	present, +2 for mixed or				
	high echogenicity, +1 for				
	peritoneal fluid, +2 for RI				
	≤ 0.42				

Sparac, et al., 2000University HospitalPre – 34Dis+Dis+Dis-TotinventedDates:Jan 1998 – JunPost – NRNRT+6511independ#25601999Median: Range:18-77Detected by imagingTot98190Differen assessme	
Kupesic, Sparac, et al., 2000Zagreb, Croatia University HospitalMean (SD): Pre - 34 Peri - 49NRThe sca Dis+The sca inventedDates: #2560Jan 1998 – Jun 1999Post – NR Median: Range: 18-77NRT+6511independ inventedTot98190Different assessment	
Sparac, et al., 2000University HospitalPre – 34Dis+Dis+Dis-TotinventedDates:Jan 1998 – JunPost – NRNRT+6511independ#25601999Median: Range:18-77Detected by imagingTot98190Differen assessme	Its: le used for scoring
al., 2000 Peri – 49 Detected by exam (n [%]): T+ 6 5 11 independ Dates: Jan 1998 – Jun Post – NR NR T- 3 76 79 the literat #2560 1999 Median: Range: 18-77 Detected by imaging Tot 9 81 90 Differen	by authors – not
Dates:Jan 1998 – JunPost – NRNRT-37679the literat#25601999Median: Range:18-77Detected by imagingTot98190Differen assessme	ently verified, not part of
#2560 1999 Median: Range: 18-77 Tot 9 81 90 Differen assessme	ure (used also in #2920)
	tiation of US from Dopple
Size of nonulation: (n [%]):	ent in terms of scale not
90 women Menopausal status NR Value 95% CI 95% CI	
	issessment:
	e standard: + on bias: +
	bility/variability: -
masses for surgery in Post: 28 (31.1%) NPV 96.2% 92.0% 100.0% Test relia university hospital Additional data used for Sample s	
	l tests: +/-
Reference standard: NR NR Blinding:	
	of +/- on screening test:
Risk factors (n [%]): T+ 8 4 12 +/-	-
Reference standard NR T- 1 77 78	
applied to all test Tot 9 81 90	
negatives?: Inclusion criteria:	
Yes Prospective patients with Lower Upper	
ovarian mass scheduled to Value 95% CL 95% CL	
Test reliability Have surgery in hospital Se 88.9% 68.4% 100.0%	
established?: Sp. 05.1% of 3% of 8%	
No (although same scale Exclusion criteria:	
used in articles #2820 or NR NPV 98.7% 96.2% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Statistical tests used:			3) Combined 2D US and Doppler	
	Se, Sp				
				Dis+ Dis- Tot	
	Blinding:			T+ 8 2 10	
	Yes			T- 1 79 80	
				Tot 9 81 90	
	Definition of positive				
	and negative on			Lower Upper	
	screening test:			Value 95% CI 95% CI	
	2D US			Se 88.9% 68.4% 100.0%	
	for 2D alone score ≥ 3 is			Sp 97.5% 94.1% 100.0%	
	positive			PPV 80.0% 55.2% 100.0%	
	for Doppler alone score	<u>></u>		NPV 98.8% 96.3% 100.0%	
	2 is positive				
	for combined 2D score ≥			4) 3D TVUS	
	5 score is positive where			,	
	+2 for papillarities, +1 for				
	shadowing present, +1			Dis+ Dis- Tot	
	for septa > 3 mm thick,			T+ 7 2 9	
	+2 for solid parts present			T- <u>2</u> 79 81	
	+2 for mixed of high leve	I		Tot 9 81 90	
	echogenicity, +1 for				
	peritoneal fluid present,			Lower Upper	
	+2 for RI ≤ 0.42			Value 95% CI 95% CI	
				Se 77.8% 50.6% 100.0%	
	3D US score ≥ 5 is+			Sp 97.5% 94.1% 100.0%	
	for Doppler alone score	2		PPV 77.8% 50.6% 100.0%	
	2+ for combined score ≥			NPV 97.5% 94.2% 100.0%	
	7 where +2 for				
	papillarities, +1 for			5) 3D Doppler	
	shadowing present, +1				
	for septa > 3 mm thick,			Dis+ Dis- Tot	
	+2 for solid parts present			T+ <u>8</u> <u>2</u> 10	
	+2 for mixed of high leve	1		T- 1 79 80	
	echogenicity, +1 for			Tot 9 81 90	
	peritoneal fluid present,				
	+2 for irregular surface,			Lower Upper	
	+2 for disturbed relation			Value 95% CI 95% CI	
	with surrounding			Se 88.9% 68.4% 100.0%	
	structures, +2 for chaotic	;		Sp 97.5% 94.1% 100.0%	
	vessel arrangement, +2			PPV 80.0% 55.2% 100.0%	
	for complex branching			NPV 98.8% 96.3% 100.0%	
	pattern				
				6) Combined 3D	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot T+ 9 1 10 T- 0 80 80 Tot 9 81 90	
				LowerUpper 95% CISe100.0%98.8%96.4%9PV90.0%71.4%100.0%NPV100.0%96.3%100.0%	
Kurjak and Predanic,	Geographical location: Zagreb Croatia	Age: Mean (SD): 48	Symptomatic (n [%]): NR	1) Morphologic scoring system	Comments: Article attempts to verify scoring
1992	University Hospital	Range: 19-76		Dis+ Dis- Tot	system these authors developed and
#4990	Datage Con 1000 Con	Menopausal status	Detected by exam (n [%]):	T+ <u>35</u> 7 42	used previously (in #2820 and
#4990	Dates: Sep 1990 – Sep 1991	(n [%]):	Presumably 100%	T- <u>3 129</u> 132 Tot <u>38 136</u> 174	#2560) (modification of Sassone criteria)
	1991	Pre: 111 (72%)	Detected by imaging	10t <u>38</u> 136 174	Data analyzed in terms of masses
	Size of population: 812 women screened	Post: 43 (28%)	(n [%]): Not applicable	Lower Upper Value 95% CI 95% CI	not individuals
	with US in whom 174	Race/ethnicity (n [%]):		Se 92.1% 83.5% 100.0%	Quality assessment:
	masses detected in 154	NR	Combination (n [%]):	Sp <mark>94.8%</mark> 91.1% 98.5%	Reference standard: +
	women		NR	PPV 83.3% 72.1% 94.6%	Verification bias: +
	Other	Risk factors (n [%]): NR	Additional data used for	NPV 97.7% 95.2% 100.0%	Test reliability/variability: - Sample size: -
	Combination – initially		diagnosis:	2) Color Doppler scoring system	Statistical tests: - (no discussion in
	screening of women with	Inclusion criteria:	NR	2) Color Doppler scoring system	any of their papers of kappa etc.)
	"clinical suspicion of	Initially, all women referred		Dis+ Dis- Tot	Blinding: +/-
	mass" then analysis of	to hospital in time frame		T+ 37 0 37	Definition of +/- on screening test: +
	subset who went to	with clinical suspicion of		T- 1 136 137	
	surgery (n = 154)	adnexal mass. Then		Tot 38 136 174	
	Reference standard:	those who had mass on US and went to surgery			
	For subset -	US and went to surgery		Lower Upper	
	Histopathology	Exclusion criteria:		Value 95% CI 95% CI	
	,	NR		Se 97.3% 92.1% 100.0% Sp 100.0% 97.8% 100.0%	
	Reference standard			PPV 100.0% 91.9% 100.0%	
	applied to all test			NPV 99.3% 97.8% 100.0%	
	negatives?:				
	Yes for subset			3) Combined Doppler and morphology	
	Test reliability				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	established?: No Statistical tests used:			Dis+ Dis- Tot T+ 37 0 37 T- 1 136 137 Tot 38 136 174	
	Se, Sp Blinding: NR but prospective Definition of positive and negative on screening test: TVUS for 2D alone score ≥ 3 is positive for Doppler alone score ≥ 2 is positive for combined 2D score ≥ 5 score is positive where +2 for papillarities, +1 for shadowing present, +1			ValueLowerUpper 95% CISe97.3%92.1%100.0%Sp100.0%97.8%100.0%PPV100.0%91.9%100.0%NPV99.3%97.8%100.0%	
	for septa > 3 mm thick, +2 for solid parts present, +2 for mixed of high level echogenicity, +1 for peritoneal fluid present, +2 for RI ≤ 0.42				
Kurjak, Schulman, Sosic, et al., 1992 #5020	Geographical location: Zagreb, Croatia Dates: 1989-1990 Size of population: 1000 screened	Age: NR Menopausal status (n [%]): Post (> 55): 83 (100%)	Symptomatic (n [%]): For N = 1000, 257 (25.7%) were symptomatic For N = 83 of the 29 with malignant tumors, 25 were symptomatics	1) For RI < 0.41 T+ <u>28 3</u> 31 T- <u>1 51</u> 52 Tot 29 54 83	Comments: US scoring system although illustrated in figure 1, was not described in text – unclear where and how scoring system derived, if tested/verified RI cutoff of < 0.41 used based
	Screening study For N = 83, operative series Reference standard: Histopathology (for N = 83)	Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Age > 40 At least 12 months since	Detected by exam (n [%]): NR Detected by imaging (n [%]): For N = 1000, 83 had US that lead to surgery (8.3%) Combination (n [%]):	Lower Upper 95% CI 95% CI 96.0% 88.9% 100.0% Sp 95.0% 89.2% 100.0% PPV 90.3% 79.9% 100.0% NPV 98.1% 94.3% 101.0% 2) US morphology 4 4 4	 RI cutoff of < 0.41 used based upon distribution of RI data points in from this study itself – also similar to prior retrospective cutpoint by study authors Doppler Index – although descriptive in nature, appears in data to be identical to the RI results, with the exception that the RI "unable to measure" are included in results as 0

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
		LMP	NR	Dis+ Dis- Tot	leading to a drop in sensitivity of
	Reference standard	Criteria for surgery		T+ 14 1 15	results
	applied to all test	included:	Additional data used for	T- 15 53 68	No discussion of inter/intra
	negatives?:	Mass 5 cm or greater on	diagnosis:	Tot 29 54 83	observer variability
	Yes for N = 83	at least 2 exams	NR		Numbers in Table 4 inconsistent
		Cyst associated with		Lower Upper	Followup of initial test negatives
	Test reliability	persistent or acute pain		Value 95% CI 95% CI	not reported
	established?:	Enlarged ovary or cyst		Se 48.0% 29.8% 66.2%	·
	Yes	with RI "near" 0.4 on 2		Sp 98.0% 94.3% 100.0%	Quality assessment:
		separate		PPV 93.3% 80.7% 100.0%	Reference standard: +
	Statistical tests used:	•		NPV 77.9% 68.1% 87.8%	Verification bias: + for surgical
	Chi-square	Exclusion criteria:			series, - for screening series
	Fisher exact	NR		3) For Doppler score (> 2)	Test reliability/variability: -
	Student t test			(2) 1 of Dopplet score (2)	Sample size: -
	Se, Sp			Dis+ Dis- Tot	Statistical tests: +
	00, op			T+ 26 1 27	Blinding: but prospective
	Blinding:				Definition of +/- on screening test:
	NR – but prospective			T- 3 53 56	for RI, +/- for US
	NIX – but prospective			Tot 29 54 83	
	Definition of positive			Lower Upper	
	and negative on			Value 95% CI 95% CI	
	screening test:			Se 89.7% 78.6% 100.0%	
	RI < 0.41			Sp 98.1% 94.6% 100.0%	
	US morphology score > 4			PPV 96.3% 89.2% 100.0%	
	(figure 1):			NPV 94.6% 88.7% 100.0%	
	Color Doppler score – 0				
	for vessels not seen, 1 for regular separate			4) For combined US and Doppler (< 6)	
	vessels, 2 for randomly			Dis+ Dis- Tot	
	dispersed vessels			T+ 26 3 29	
				T- <u>3 51</u> 54	
				Tot 29 54 83	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 89.7% 78.6% 100.0%	
				Sp 94.4% 88.3% 100.0%	
				PPV 89.7% 78.6% 100.0%	
				NPV 94.4% 88.3% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Kurjak, Shalan, Kupesic, et	Geographical location: Zagreb, Croatia	Age: Mean (SD): Pre 45.1 (3.5)	Symptomatic (n [%]): 0 (0%)	1) US – persistent mass; only those with surgical confirmation	Comments: Decision to operate not described Screening series not complete –
al., 1994	Dates: Jan 1988 to Dec 1992	· · ·	Detected by exam (n [%]): 0 (0%)	Dis+ Dis- Tot T+ 4 1 5	316 women undergoing followup US still (from total of 404 needing it!) –
#4470	 1992 Size of population: 5013 screened 38 operated on Screening study Reference standard: Histopathology for few who went to surgery Otherwise repeat US Reference standard applied to all test negatives?: No But US repeated in initial abnormals (cycstic structures less than 5cm) followed up after 6 months Test reliability established?: Yes Statistical tests used: NR - proportions Blinding: NR - prospective Definition of positive and negative on 	Menopausal status (n [%]): Pre (< 45): 2214 (44%) Post (> 55): 2799 (56%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Age \ge 40 No "pelvic symptoms" Exclusion criteria: Women on hormonal	0 (0%) Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: Premenopausal women scanned during day 3-8 of cycle STUDY FLOW – 5013 screened 424 abnormal ovaries, of whom 20 went to surgery, leaving 404 repeat US (316 still pending), of whom 70 resolved spontaneously 18 persistent went to surgery	T- Tot 0 27 27 Se $Value$ 95% Cl 95% Cl 95% Cl Sp 96.4% 89.6% 100.0% 95% Cl PPV 80.0% 44.9% 100.0% NPV 100.0% 88.9% 100.0% 2) US, assuming all test negative true negatives, excluding 316 with results not reported Tot 5 T+ $Dis+$ $Dis-$ Tot 5 Tot 4 98 102 102 Value 95% Cl 95% Cl 95% Cl So $Value$ 25% Cl 95% Cl	still (from total of 404 needing it!) – this is confusing Unclear what was used in US diagnosis (assume from title combination of doppler and US morphology, but nothing in article) US followup after 6 months, but span of time not mentioned Assume 100% followup? – no discussion of drop out etc. No discussion of inter/intra observer variability Results not stratified by age/menopausal status Quality assessment: Reference standard: +/- Verification bias: Test reliability/variability: - Sample size: - Statistical tests: - (no significance testing done) Blinding: + Definition of +/- on screening test: -
	NR - prospective Definition of positive				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	US morphology score > 4	,			
Kurjak, Zalud, and Alfirevic, 1991 #5190	Geographical location: Zagreb, CroatiaDates: NRSize of population: 14317 total 8,620 asymptomatic for screening 5697 with "suspected adnexal mass" 680 operated onScreening studyReference standard: Histopathology in 680 operated onReference standard applied to all test negatives?: Only to surgical casesTest reliability 	Age: Mean: Pre 42 Post 56 Range: 18-72 Menopausal status (n [%]): Pre (< 45): 7495 Post (> 55): 1125 This is of the 8620 women referred from clinic Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: NR Exclusion criteria: NR	Symptomatic (n [%]): Unclear Detected by exam (n [%]): ?5697/14,317: Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) $RI < 0.4$ T+ $Dis+ Dis- Tot 55$ Tot $56 624$ 625 625 625 626 800 Value 95% CI 95% CI Se 96.4% 91.6% 100.0% PPV 98.2% 94.7% 100.0% PPV 99.7% 99.2% 100.0% NPV 99.7% 99.2%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Kurtz, Tsimikas,	Geographical location: Ann Arbor, MI	Mean: 52	Symptomatic (n [%]) : NR	1) Doppler and Conventional US	Comments: Data in 2x2 tables derived from
Tempany, et al., 1999	Baltimore, MD Boston, MA Philadelphia, PA	Median: 51.5 Range 19-82	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 82 6 88	ROC curves, estimated based on total N's for each test; numbers agree with Table 6 in manuscript.
#2940	University Hospitals	Menopausal status (n [%]):	Detected by imaging	T- <u>27 149</u> 176 Tot 109 155 264	Referral base for study from oncology clinic – sicker pop
	Dates: May 1993 – Apr 1996	NR	(n [%]): NR	Lower Upper	Quality assessment:
	Size of population:	Race/ethnicity (n [%]): NR	Combination (n [%]):	Value 95% Cl 95% Cl Se 75.2% 67.1% 83.3%	Reference standard: + Verification bias: +, few women
	280 women	Risk factors (n [%]):	NR	Sp 96.1% 93.1% 99.2% PPV 93.2% 87.9% 98.4%	were excluded Test reliability/variability: -
	Other All eligible patients	NR	Additional data used for diagnosis:	NPV 84.7% 79.3% 90.0%	Sample size: - Statistical tests: +
	referred by Gyn Onc to University hospital for surgery	Inclusion criteria: Over 18, suspected of having ovarian cancer	NR	2) CT	Blinding: + Definition of +/- on screening test:
	Reference standard:	based on physical exam or pelvic US		Dis+ Dis- Tot T+ 58 16 74 T- 5 134 139	
	Histopathology	Exclusion criteria:		Tot 63 150 213	
	Reference standard applied to all test	Unable to provide consent, not a surgical candidate,		Lower Upper Value 95% CI 95% CI	
	negatives?: Yes	pregnancy, prior surgery within 6 months of entry		Se 92.1% 85.4% 98.7% Sp 89.3% 84.4% 94.3%	
	Test reliability established?:	into study		PPV 78.4% 69.0% 87.8% NPV 96.4% 93.3% 99.5%	
	No			3) MRI	
	Statistical tests used: Se, Sp, ROC			Dis+ Dis- Tot T+ 47 16 63	
	Blinding: Yes to outcome			T- <u>1 115</u> 116 Tot 48 131 179	
	(prospective) radiologists not blinded to diagnosis			Lower Upper Value 95% CI 95% CI	
	Definition of positive and negative on			Se 97.9% 93.9% 100.0% Sp 87.8% 82.2% 93.4%	
	screening test:			PPV 74.6% 63.9% 85.4% NPV 99.1% 97.5% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Leeners, Schild, Funk, et al.,	Geographical location: Aachen, Germany Academic	Age: Mean: 48.4 Range: 16-84	Symptomatic (n [%]): 52 (51.5%)	1) Sassone score <u>Dis+ Dis-</u> Tot T+ 16 13 29	Comments: Borderline tumors grouped in with malignant 2x2 tables calculated in terms of
1996 #3940	Dates: Jan 1993 – Sep 1994	Menopausal status (n [%]):	Detected by exam (n [%]): NR	T+ 16 13 29 T- 7 73 80 Tot 23 86 109	2X2 tables calculated in terms of masses not patients Patients had been referred from
	Size of population: 101 patients (109	Pre (< 45): 67 (66.3%) Post (> 55): 34(33.7%)	Detected by imaging (n [%]): NR	Lower Upper Value 95% CI 95% CI	gynecologic clinic where had often times already had US No discussion of followup of 6
	tumors) 95 women got surgery	Race/ethnicity (n [%]): NR	Combination (n [%]): NR	Se 69.8% 51.0% 88.5% Sp 85.0% 77.5% 92.5% PPV 55.2% 37.1% 73.3%	initial who didn't get surgery RI and PI cutoff calculated from data itself – not using prior cutoffs
	Other Consecutive series in single center	Risk factors (n [%]): Family history: 16 (15.8%)		NPV 91.3% 85.1% 97.4%	Clinical presentation not described Quality assessment:
	Reference standard: Histopathology for 95 Unclear what for the other 6	Inclusion criteria: Consecutive patients referred to US for "clinical suspicion of an adnexal mass"	NR	2) Doppler (RI – lowest from a series of measurements) <u>Dis+ Dis-</u> Tot T+ <u>16 34</u> 50 T- <u>7 52</u> 59	Reference standard: +/- Verification bias: +/- Test reliability/variability: - Sample size: - Statistical tests: +
	Reference standard applied to all test	Exclusion criteria: NR		Tot 23 86 109 Lower Upper	Blinding: - Definition of +/- on screening test: -
	negatives?: No – see above			Value 95% Cl 95% Cl Se 70.9% 52.3% 89.5% Sp 60.9% 50.6% 71.2%	
	Test reliability established?: Yes			PPV 32.0% 19.1% 44.9% NPV 88.1% 79.9% 96.4%	
	Statistical tests used: Fisher exact			3) Combined Doppler and Sassone score	
	Wilcoxon 2 sample test			Dis+ Dis- Tot T+ 17 23 40 T- 6 63 69	
	NR but prospective			Tot 23 86 109 Lower Upper	
	Definition of positive and negative on screening test: Sassone's score > 9 PI < 0.65 RI < 0.45			Value 95% Cl 95% Cl Se 74.0% 56.1% 91.9% Sp 73.7% 64.4% 83.0% PPV 42.5% 27.2% 57.8% NPV 91.3% 84.7% 98.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Lerner, Timor- Tritsch,	Geographical location: New York, NY University Hospital	Age: Mean: 44.5 Range: 12-85	Symptomatic (n [%]): NR	1) US scoring system of Sassone (cuto for T+)	The article uses data from its institution to fit a linear model from
Federman, et al., 1994 #6360	Dates: May 1990 – Mar 1993 Size of population: 312 patients with 350 ovarian masses Other Retrospective analysis of US of women who had gone to surgery for adnexal mass Reference standard: Histopathology Reference standard	Menopausal status (n [%]): Pre (< 45): 228 (73%) Post (> 55): 84 (27%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Women who had surgery in time frame for whom images were available Exclusion criteria:	Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Dis+ Dis- Tot T- 1 247 248 Tot 31 319 350 Value 95% Cl 95% Cl 95% Cl Se 96.8% 90.6% 100.0% Sp 77.4% 72.8% 82.0% PPV 29.4% 20.6% 38.3% NPV 99.6% 98.8% 100.0%	 which they modify Sassonne's criteria their criteria actually performs worse that the original from Sassone (Se 100, Sp 83) which isn't discussed fully Denominator in 2x2 tables is masses not individuals LMP tumors included as benign Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: -, cutoff may have been selected a posteriori Sample size: - Statistical tests: -, analysis based on tumors not patients. Blinding: +
	applied to all test negatives?: Yes Test reliability established?: Yes for Sasonne, no for modified criteria used here	Attempts made to not perform US in luteal phase			Definition of +/- on screening test: +
	Statistical tests used: Se, Sp Blinding: Yes				
	Definition of positive and negative on screening test: Modified Sasonne where + was \geq 3 and +1 for shadowing present, +1 for \geq 3 mm walls, +2 for solid wall structure, +3				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	for papillarities ≥ 3 mm, +3 for mixed or high echogenicity				
Lin, Angel, DuBeshter, et al., 1993 #4890	Geographical location: Rochester, NY, USA Dates: Jul 1989 – Jun 1990 Size of population: 80 women Other Case series Retrospective Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: No for US and CT (no scoring system used) Statistical tests used: P value calculated by NR Blinding: No; retrospective Definition of positive and negative on screening test: US and CT – "presence of a complex or heterogenous mass, ascites, omental tumor or other evidence of metastatic tumor in the	Median: 56 Range: 19-88 Menopausal status (n [%]): Pre (< 45): 18 (22.5%) Post (> 55): 62 (77.5) Race/ethnicity (n [%]): Caucasian 72 (90%) Black 8 (10%) Risk factors (n [%]): Family history: 11 (13.8%) Inclusion criteria: "Mass in the pelvic area" who underwent surgery in time frame Exclusion criteria: NR	Symptomatic (n [%]): Pain - 37(46.3%) Asymptomatic – 70(87.5%) Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) US $\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Comments: Patients referred from gynecological onconlogy clinic No scoring system for US or CT used Retrospective with subjective means of judging "suspicious for malignancy" and no mention of blinding or how this assessment of prior radiology studies was made Borderline tumors grouped in with malignant Not all tests available for all patients – hence difference in N for each 2x2 table The PPV and NPV of CT 2x2 table differ significantly in my calculation than that reported in the article (PPV-75%, NPV-71%) Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: -

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	pelvic area or abdomen"				
Lin, Wu, Lee, et al., 1993	Geographical location: Taiwan University Hospital	Age: Mean: 40.5 Range: 11-81	Symptomatic (n [%]): NR Detected by exam (n [%]):	1) RI ≤ 0.4 <u>Dis+ Dis-</u> Tot T+ 62 8 70	Comments: Borderline tumors grouped in malignant category "Satisfactory arterial waveforms"
#6990	Dates: Jul 1990 – Oct 1993	Menopausal status (n [%]): NR	Detected by exam (in [/oj).	T+ 62 8 70 T- 28 272 300 Tot 90 280 370	only in 111(40.7%) of benign masses (and in 87(96.7%) of malignant) – however, all were
	Size of population: 370 women	Race/ethnicity (n [%]): NR	(n [%]): 370 (100%)	Lower Upper Value 95% CI 95% CI Se 68.9% 59.3% 78.5%	included in the 2x2 table (assume 60% non-satisfactory wave forms used in benign lesions?)
	Other Hospital referrals for adnexal masses	Risk factors (n [%]): NR	Combination (n [%]): NR	Sp 97.1% 95.1% 99.1% PPV 88.6% 81.1% 96.0% NPV 90.7% 87.4% 94.0%	Report treats no satisfactory wave form as "test negative."
	Reference standard: Histopathology	Inclusion criteria: Suspected ovarian mass on US referred to hospital	Additional data used for diagnosis: NR	2) RI ≤ 0.5	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - (not
	Reference standard applied to all test negatives?:	for surgery		Dis+ Dis- Tot T+ 71 22 93 T- 19 258 277 Tot 90 280 370	discussed or calculated for operators in study) Sample size: -
	Yes Test reliability	Study US in luteal phase		Lower Upper	Statistical tests: + Blinding: +/- Definition of +/- on screening test: +
	established?: RI – yes (usually with 0.4 cutoff)			Value 95% Cl 95% Cl Se 78.9% 70.5% 87.3% Sp 92.1% 88.9% 95.3% PPV 76.3% 67.7% 85.0%	
	Statistical tests used: Se, Sp			NPV 93.1% 90.2% 96.1% 3) RI ≤ 0.6	
	Blinding: NR but study prospective			Dis+ Dis- Tot T+ 82 38 120	
	Definition of positive and negative on screening test:			T- 8 242 250 Tot 90 280 370	
	RI \leq 0.4 or 0.5 or 0.6			Lower Upper Value 95% Cl 95% Cl Se 91.1% 85.2% 97.0% Sp 86.4% 82.4% 90.4% PPV 68.3% 60.0% 76.7%	
				NPV 96.8% 94.6% 99.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Luxman, Bergman, Sagi, et al.,	Geographical location: Tel Aviv, Israel	Age: Mean: 62 Range: 42-90	Symptomatic (n [%]): NR	 US—Size > 5 cm and/or complex/solid = malignant 	Comments: All postmenopausal but age range 42-90
1991	Dates: NR	Menopausal status	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 27 42 69	Very unclear how tests were graded + or - (more than "simple" vs
#6530	Size of population: 102	(n [%]): Post (> 55): 102 (100%)	Detected by imaging	T- <u>2</u> <u>31</u> <u>33</u> Tot <u>29</u> <u>73</u> 102	"complex"?)
	Other Case series	Race/ethnicity (n [%]) : NR	(n [%]) : NR	Lower Upper Value 95% CI 95% CI	Quality assessment: Reference standard: + Verification bias: +
	Reference standard: Histopathology	Risk factors (n [%]): NR	Combination (n [%]): NR	Se 93.0% 83.7% 100.0% Sp 42.0% 30.7% 53.3% PPV 39.1% 27.6% 50.6%	Test reliability/variability:- Sample size: - Statistical tests: +/-
	Reference standard applied to all test negatives?:	Inclusion criteria: NR – presumable, presence of mass	Additional data used for diagnosis: NR	NPV 93.9% 85.8% 100.0% 2) US—size > 5 cm alone = malignant	Blinding: + Definition of +/- on screening test: -
	Yes	scheduled for surgery during time frame		Dis+ Dis- Tot T+ 24 12 36	
	Test reliability established?: No	Exclusion criteria:		T- 5 61 66 Tot 29 73 102	
	Statistical tests used: Se, Sp			Lower Upper Value 95% CI 95% CI Se 82.8% 69.0% 96.5%	
	Blinding: No			Sp 83.6% 75.1% 92.1% PPV 66.7% 51.3% 82.1% NPV 92.4% 86.0% 98.8%	
	Definition of positive and negative on			3) US—complex or solid = malignant	
	screening test: US – unclear "simple" if lesion unilocular and lacking septa			Dis+ Dis- Tot T+ 27 33 60 T- 2 40 42 Tot 29 73 102	
	"complex" if solid area, papillae, septa, enhanced echogenicity			Lower Upper <u>Value 95% Cl 95% Cl</u> Se 93.1% 83.9% 100.0% Sp 54.8% 43.4% 66.2%	
				PPV 45.0% 32.4% 57.6% NPV 95.2% 88.8% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Ma, Shen, and Lang,	Geographical location: Peking, China		1) CA-125 ≥ 30 U/ml	Comments: Menopause defined	
2003	University			Dis+ Dis- Tot	Unclear where US scoring system
#1900		Menopausal status (n [%]):	Detected by exam (n [%]): NR	T+ <u>56</u> <u>27</u> 83 T- <u>7</u> <u>50</u> <u>57</u>	comes from and how calculated. Unclear if US score done at time of
	1999	Pre: 89 (64%)		Tot 63 77 140	imaging study or when looking back.
		Post: 51 (36%)	Detected by imaging		CA-125 cutoff (30, 50) not what
	Size of population: 140 women	> 1 year of amenorrhea or if s/p hysterectomy, age >	(n [%]): NR	Lower Upper	used in States now
	140 women	50 years	NR .	Value 95% CI 95% CI Se 88.9% 81.1% 96.7%	Quality assessment:
	Other		Combination (n [%]):	Se 88.9% 81.1% 96.7% Sp 64.9% 54.2% 75.6%	Reference standard: +
	Retrospective analysis of	Race/ethnicity (n [%]):	NR	PPV 67.5% 57.4% 75.6%	Verification bias: +
	surgical patients with CA-			NPV 87.7% 79.2% 96.2%	Test reliability/variability:
	125 and US in single		Additional data used for	11 0111/0 10.270 00.270	+ for CA-125
	academic center	Risk factors (n [%]):	diagnosis:	2) CA-125 ≥ 50	- for US
		NR	NR	,	Sample size: -
	Reference standard:			Dis+ Dis- Tot	Statistical tests: +
	Histopathology	Inclusion criteria:		T+ 53 21 74	Blinding: -
	Defense of a lord	"Ovarian neoplasm"		T- 10 56 66	Definition of +/- on screening test: +
	Reference standard	patients over 30 years		Tot 63 77 140	
	applied to all test	admitted to a single institution			
	negatives?: Yes	Institution		Lower Upper	
	163	Exclusion criteria:		Value 95% CI 95% CI	
	Test reliability	NR		Se 84.1% 75.1% 93.1%	
	established?:			Sp <mark>72.7%</mark> 62.7% 82.7% PPV 71.6% 61.3% 81.9%	
	CA-125 – yes			PPV 71.6% 61.3% 81.9% NPV 84.8% 76.2% 93.5%	
	US – unclear what			NFV 04.0% 70.2% 93.5%	
	scoring system used –			3) US score ≥ 2	
	reliability probably not			5) 00 3001C = 2	
	established			Dis+ Dis- Tot	
				T+ 59 13 72	
	Statistical tests used:			T- 4 64 68	
	Se, Sp, PPV			Tot 63 77 140	
	Blinding:				
	NR (retrospective			Lower Upper	
	analysis of already			Value 95% CI 95% CI	
	collected data)			Se <mark>93.7%</mark> 87.7% 99.7%	
				Sp 83.1% 74.7% 91.5%	
	Definition of positive			PPV 81.9% 73.1% 90.8%	
	and negative on			NPV 94.1% 88.5% 99.7%	
	screening test:				
	CA-125 > (various cutoffs				
	analyzed 30, 50, 100)				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring	
	US score 0 or 1 point given for: multi-focal lesion, nature of focal lesion, unilateral or bilateral lesion, ascites, metastasis Max = 5	given for: multi-focal lesion, nature of focal lesion, unilateral or bilateral lesion, ascites,		Symptomatic (n [%]): 1		
Maggino, Gadducci,	Geographical location: Padua, Pisa, Bari,	Age: Range: 40-91	Symptomatic (n [%]): 209 (72.1%)	 CA-125, threshold >35, EXCLUDING 45 patients not operated on because of US and 	Comments:	
D'Addario,	Brescia, and Milan, Italy	Overall mean not reported		CA-125	all test negatives	
et al., 1994			Detected by exam (n [%]):		-2x2 tables are limited to patients	
	Dates: Mar 1991-Mar	Menopausal status	NR	<u>Dis+ Dis-</u> Tot	with adnexal masses (excluding	
#4500	1992	(n [%]):		T+ 83 24 107	other non-ovarian pelvic masses)	
		100% post menopausal	Detected by imaging	T- 23 110 133		
	Size of population:		(n [%]):	Tot 106 134 240	Quality assessment:	
	383; 48 excluded based	Race/ethnicity (n [%]):	NR		Reference standard: +	
	on criteria, 45 not	NR		Lower Upper	Verification bias: -	
	reported because	Dials factors (n. 19/1).	Combination (n [%]):	Value 95% CI 95% CI	Test reliability/variability: -	
	ultrasound and CA-125	Risk factors (n [%]): NR	NR	Se 78.3% 70.5% 86.1%	Sample size: - Statistical tests: +	
	did not lead to surgery	NR	Additional data used for	Sp 82.1% 75.6% 88.6%	Blinding: -	
	Other	Inclusion criteria:	diagnosis:	PPV 77.6% 69.7% 85.5%	Definition of +/- on screening test:	
	Multicenter series	Clinical diagnosis of pelvic		NPV 82.7% 76.3% 89.1%	+	
	Multicenter series	mass		2) CA 125 threeholds CE EVOLUDING 15	•	
	Reference standard:	Postmenopausal at least 1		2) CA-125, threshold > 65, EXCLUDING 45		
	Surgery	year		patients not operated on because of US and CA-125		
	Reference standard applied to all test negatives?: No	Exclusion criteria: Premenopausal, Previous malignancy, except breast ca		Dis+ Dis- Tot T+ 76 10 86 T- 30 124 154 Tot 106 134 240		
	Test velichility	Previous bilateral				
	Test reliability established?:	adnexectomy Previous hysterectomy if <		Lower Upper		
	Not referenced or	55 years		Value 95% CI 95% CI		
	discussed (ultrasound)	oo yaalo		Se 71.7% 63.1% 80.3%		
				Sp 92.5% 88.1% 97.0%		
	Statistical tests used: Se, Sp			PPV 88.4% 81.6% 95.1% NPV 80.5% 74.3% 86.8%		
	Blinding: No			 Ultrasound, equivocal or higher as positive, EXCLUDING patients not operated on because of findings 		
	Definition of positive and negative on					

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	screening test: Probably benign:			Dis+ Dis- Tot T+ 105 72 177	
	• < 5 cm			T- 1 62 63	
	 thin, clear wall 			Tot 106 134 240	
	hypoechogenic				
	 no septae, or no 			Lower Upper	
	more than 3 thin			Value 95% CI 95% CI	
	septae			Se 99.1% 97.2% 100.0%	=
	 No fluid in cul de 			Sp 46.3% 37.8% 54.7%	
	sac			PPV 59.3% 52.1% 66.6%	
				NPV 98.4% 95.3% 100.0%	
	Equivocal:				
	Between 5 and 10			4) Ultrasound, malignant as positive	3
	cm			EXCLUDING patients not operated of	n
	Thick, clear, smooth			because of findings	
	wall				
	Hypoechogenic			Dis+ Dis- Tot	
	liquid or solid			T+ 90 30 120	
	homogeneous			T- 16 104 120	
	content			Tot 106 134 240	
	 > 3 thin septae 				
	Thick, regular			Lower Upper	
	septae			Value 95% CI 95% CI	_
	No vegetations			Se 84.9% 78.1% 91.7%	
	No free peritoneal			Sp 77.6% 70.6% 84.7%	
	fluid			PPV 75.0% 67.3% 82.7%	
				NPV 86.7% 80.6% 92.7%	
	Malignant: none of the				
	above				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Malkasian Jr., Knapp, Lavin, et al., 1988	Geographical location: Rochester, MN; Boston, MA; Hershey, PA; Los Angeles, CA	Age: Benign Mean: 43.5 Range: 15-88	Symptomatic (n [%]): Clinical presentation not described	1) All patients, CA-125 > 35 as positive Dis+ Dis- Tot T+ 53 18 71	Comments: Unclear how subjects selected Spectrum of disease described Tests all drawn within 1 week of
#6810	Dates: NR	Malignant	Detected by exam (n [%]): NR	T- 15 72 87 Tot 68 90 158	surgery; unclear if results would have been different if drawn prior to
	Size of population: 172; 14 excluded for total of 158	Mean: 63.5 Range: 16-96 Menopausal status	Detected by imaging (n [%]): NR	Lower Upper Value 95% Cl 95% Cl Se 77.9% 68.1% 87.8%	decision for surgery Borderline tumors included with malignant
	Other Multicenter, case series	(n [%]): Benign Pre (< 45): 56 (62.2%) Post (> 55): 34 (37.8%)	Combination (n [%]) : NR	Sp 80.0% 71.7% 88.3% PPV 74.6% 64.5% 84.8% NPV 82.8% 74.8% 90.7%	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability:+
	Reference standard: Surgery/pathology	Malignant:	Additional data used for diagnosis:	2) All patients, CA-125 > 100 as threshold	Sample size: + (confidence intervals given)
	Reference standard applied to all test negatives?:	Pre 10 (14.7%) Post: 58 (85.3%) Race/ethnicity (n [%]):	Stage 23.3% 10.0% 61.5%	Dis+ Dis- Tot T+ 50 4 54 T- 18 86 104 Tot 68 90 158	Statistical tests: + Blinding: + Definition of +/- on screening test: +
	Yes Test reliability established?: Yes Statistical tests used:	NR Risk factors (n [%]): NR Inclusion criteria: Palpable mass	IV 5.0%	Lower Upper Value 95% CI 95% CI Se 73.5% 63.0% 84.0% Sp 95.6% 91.3% 99.8% PPV 92.6% 85.6% 99.6% NPV 82.7% 75.4% 90.0%	
	Se/Sp Blinding: Yes	Scheduled for surgery Blood drawn within 1 week of surgery		 3) Premenopausal patients, CA-125 > 35 a threshold 	s
	Definition of positive and negative on screening test: CA-15 at various	Exclusion criteria: Preop definitive diagnosis of ovarian cancer (n = 11) Blood > 1 week (n = 3)		Dis+ Dis- Tot T+ 6 15 21 T- 4 41 45 Tot 10 56 66	
	thresholds			Lower Upper 95% CI 95% CI Se 60.0% 29.6% 90.4% Sp 73.2% 61.6% 84.8% PPV 28.6% 9.2% 47.9% NPV 91.1% 82.8% 99.4% 4) Premenopausal patients, CA-125 > 100	

Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
			as threshold	
			Dis+ Dis- Tot T+ 6 3 9 T- 4 53 57 Tot 10 56 66	
			LowerUpper 95% CI95% CISe60.0%29.6%90.4%Sp94.6%88.7%100.0%PPV66.7%35.9%97.5%NPV93.0%86.4%99.6%	
			 Postmenopausal patients, CA-125 > 3 as threshold 	5
			Dis+ Dis- Tot T+ 47 3 50 T- 11 31 42 Tot 58 34 92	
			Lower Upper Value 95% CI 95% CI Se 81.0% 70.9% 91.1% Sp 91.2% 81.6% 100.0% PPV 94.0% 87.4% 100.0% NPV 73.8% 60.5% 87.1%	
			6) Postmenopausal patients, CA-125 > 1 as threshold	00
			Dis+ Dis- Tot T+ 44 1 45 T- 13 33 46 Tot 57 34 91	
			LowerUpper95% CI95% CI95% CI95% CI97.2%66.3%88.1%97.1%91.4%100.0%PPV97.8%93.5%100.0%NPV71.7%58.7%84.8%	
	Study Design	Study Design Patients	Study Design Patients Clinical Presentation	as threshold $ \begin{array}{c} T + & Dis+ & Dis- & Tot \\ T + & \hline 4 & 53 & 57 \\ Tot & 10 & 56 & 66 \\ \hline & & & & & & & & & & & & & & & & & & &$

Study	Study Design Geographical location: Vienna, Austria	Study Design Patients	Clinical Presentation	Results				Comments/Quality Scoring
Maly, Riss, and		Age: Range: 28-75	Symptomatic (n [%]): Clinical presentation not	1) Diastolic notch absent			- .	Comments: Unclear how patient pop chosen, if
Deutinger, 1995	Dates: NR	Menopausal status (n [%]):	described Detected by exam (n [%]):	T+ T-	Dis+ 37 0	Dis- 5 39	Tot 42 39	consecutive, if any excluded Quality assessment:
#6800	Size of population: 102 women	Pre (< 45): 55 (53.9%) Post (> 55): 47 (46.1%)	NR	Tot	37	44	81	Reference standard: + Verification bias: -
	Other Case series	Race/ethnicity (n [%]) : NR	Detected by imaging (n [%]): NR	Se	Value 100.0%	Lower 95% CI 91.9%	Upper 95% CI 100.0%	Test reliability/variability: - Sample size: - Statistical tests: +
	Reference standard: Pathology	Risk factors (n [%]) : NR	Combination (n [%]): NR	Sp PPV NPV	88.6% 88.1% 100.0%	79.3% 78.3% 92.3%	98.0% 97.9% 100.0%	Blinding: - Definition of +/- on screening test: - (not clearly defined)
	Reference standard applied to all test	Inclusion criteria: NR	Additional data used for diagnosis:	2) Dem	nonstrable	blood ves	sels	
	negatives?: Yes	Exclusion criteria:	Premenopausal US in secretory phase	T+ T-	Dis+	Dis- 44 19	Tot 81 21	
	Test reliability established?: Not referenced or			Tot	39	63	102	
	discussed			Se	Value 94.9%	Lower 95% CI 87.9%	Upper 95% CI 100.0%	
	Statistical tests used: Chi-square, t-test			Sp PPV	30.2% 45.7%	18.8% 34.8%	41.5% 56.5%	
	Blinding: NR			NPV	90.5%	77.9%	100.0%	
	Definition of positive and negative on screening test: Diastolic notch: "short drop of flow curve at							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Mancuso, De Vivo, Triolo, et al., 2004 #1610	Geographical location: Italy University Hospital Dates: NR Size of population: 125 women Other Patients referred to hospital with mass who had surgery	Age: Mean (SD): 42.2 Range: 18 - 82 Menopausal status (n [%]): Pre 76 (61%) Post 49 (39%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR): 42.2 68 (54.4%) symptomatic 8 - 82 5 (4%) had urinary or intestinal symptoms sal status only 30 (24%) described as asymptomatic (61%) (39%) Detected by exam (n [%]): NR hicity (n [%]): Detected by imaging (n [%]):	1) US T+ $Dis+ Dis- Tot$ T+ $14 24$ 38 87 Tot 14 111 125 Value 95% Cl 95% Cl Se 100.0% 78.6% 100.0% Sp 78.6% 71.0% 86.2% PPV 36.8% 21.5% 52.2% NPV 100.0% 96.6% 100.0%	Comments: Menopause versus fertile not defined Even though data on menopausal status collected, analysis used age > or < 50 as US scoring system not described (?Sasonne or modified) – positive or negative US not defined Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: -
	Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: CA-125 - yes US – unclear what was used	Inclusion criteria: Patients referred to hospital with mass who had surgery Exclusion criteria: NR	Combination (n [%]): NR Additional data used for diagnosis: 22 (17.6%) reported a menstrual disorder as main symptom	2) CA-125 ≥ 35 U/ml T+ Dis+ Dis- Tot T- 0 87 87 Tot 14 111 125 Value 95% Cl 95% Cl Se 100.0% 78.6% 100.0% Sp 78.6% 71.0% 86.2% PPV 36.8% 21.5% 52.2% NPV 100.0% 96.6% 100.0%	Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: + for CA-125 - for US
	Statistical tests used: Se, Sp, LR Blinding: NR (US and serum prior to surgery) Definition of positive and negative on screening test: CA-125 \geq 35 U/ml US – NR what was + or negative or what scoring system used				

Study	Study Design Geographical location: Manipal, India	n Patients Clinical Presentation R		Results	Comments/Quality Scoring
Manjunath, Pratap- kumar,		Age: NR	Symptomatic (n [%]) : NR	1) CA-125 ≥ 35 U/ml Dis+ Dis- Tot	Comments: LMP tumors grouped into malignant
Sujatha, et al., 2001	Dates: Jan 1997 – Aug 1999	Menopausal status (n [%]): Pre (< 45): 84(55.2%)	Detected by exam (n [%]) : NR	T+ 77 10 87 T- 16 45 61 Tot 93 55 148	Although menopausal status was reported, results were not stratified by menopausal status (or age)
#2510	Size of population: 152 women	Post (> 55): 64(42.1%)	Detected by imaging (n [%]):	Lower Upper	Unclear US scoring system
		Race/ethnicity (n [%]):	NR	Value 95% CI 95% CI	
	Other	NR		Se 83.0% 75.4% 90.6%	Reference standard: +
	Retrospective analysis of women admitted to		Combination (n [%]):	Sp 82.0% 71.8% 92.2%	Verification bias: +
		Risk factors (n [%]): NR	NR	PPV 88.5% 81.8% 95.2%	Test reliability/variability: + for CA- 125
	academic hospital with pelvic mass who had	INIK	Additional data used for	NPV 73.8% 62.7% 84.8%	?/- for US
	surgery	Inclusion criteria: Patients who had surgery	diagnosis: NR	2) US score ≥ 2	Sample size: - Statistical tests: +
	Reference standard:	for pelvic masses		Dis+ Dis- Tot	Blinding: -
	Histopathology			T+ 40 6 46	Definition of +/- on screening test:
		Exclusion criteria:		T- 53 49 102	+/-
	Reference standard	NR		Tot 93 55 148	
	applied to all test				
	negatives?:			Lower Upper	
	Yes			Value 95% CI 95% CI	
				Se 43.0% 32.9% 53.1%	
	Test reliability			Sp 89.0% 80.7% 97.3%	
	established?:			PPV 87.0% 77.2% 96.7%	
	CA-125 – yes			NPV 48.0% 38.3% 57.7%	
	US - ?				
	Statistical tests used: Se, Sp, ROC curves				
	Se, Sp, NOC curves				
	Blinding: NR				
	Definition of positive and negative on screening test: CA-125 (multiple cutoffs)				
	US score 1 point given for presence of multi- locular systic lesion, solid				
	area, bilateral, ascites, intraabdominal mets.				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Marchetti, Zambon, Lamaina, et al., 2002 #2230	Geographical location: Padua, Italy Dates: Sep 1996-Oct 2001 Size of population: 176 positives/4,350 exams Screening study Reference standard: Surgery, followup Reference standard applied to all test negatives?: No Test reliability established?: Not referenced or discussed Statistical tests used: Chi-square, Se/Sp Blinding: Yes Definition of positive and negative on screening test: Criteria for referral or positive test not described	Age: Mean: 49 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Borderline classified as malignant Exclusion criteria: NR	Symptomatic (n [%]): 518 (11.9%) Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: Screening frequency not described	1) All patients with positive ultrasound, borderline classified as malignant, assuming negative ultrasound truly negative $\begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	Comments: Variable reference standard Length of followup, loss to followup not clearly described Results not stratified by age, menopausal status Quality assessment: Reference standard:- Verification bias: - Test reliability/variability: - Sample size: + Statistical tests:- Blinding: + Definition of +/- on screening test: -

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
Marret, Sauget,	Geographical location: France	Mean: 46.2	Symptomatic (n [%]) : NR	1) RI <				Comments: Analysis done for masses not
Giraudeau, et al., 2004	Dates: Feb 2002 – Mar 2003	Range: 19-72	Detected by exam (n [%]):	T+ T	Dis+ 18		Tot 31	women Study looks specifically at the use of IV contrast at the time of US (as
#7680		Menopausal status (n [%]):	NR	T- Tot	5 23	65 78	70 101	this is a novel method, data from that
	Size of population: 99 women 101 masses	Pre (< 45): 58 (58.6%) Post (> 55): 41 (41.4%)	Detected by imaging (n [%]): NR		Value	Lower 95% CI	Upper 95% Cl	outcome is not included in this evidence table) Unable to stratify by menopausal
	Prospective series	Race/ethnicity (n [%]) : NR	Combination (n [%]):	Se Sp	78.0% 83.0%	61.1% 74.7%	94.9% 91.3%	status Interobserver correlation coefficient
	("pilot" per authors)	Risk factors (n [%]):	NR	SP PPV NPV	58.1% 92.9%	40.7% 86.8%	91.3% 75.4% 98.9%	0.92 US modality (TVUS vs. abdominal)
	Reference standard: Histopathology	NR Inclusion criteria:	Additional data used for diagnosis: NR		125 ≥ 25	00.070	30.370	not specified – assume TV?
	Reference standard applied to all test negatives?:	Woman with diagnosis of adnexal mass admitted to hospital in time frame	NK	T+ T-	Dis+ 19 4		Tot 31 70	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability:+
	Yes	Exclusion criteria:		Tot	23	78	101	Sample size: - Statistical tests: +
	Test reliability established?: Yes	NR			Value	Lower 95% Cl	Upper 95% CI	Blinding: + Definition of +/- on screening test: +
	Statistical tests used:			Se Sp	83.0% 85.0%	67.6% 77.1%	98.4% 92.9%	
	Kappa statistics AUC Se, Sp			PPV NPV	61.3% 94.3%	44.1% 88.8%	78.4% 99.7%	
	Chi square – Fisher exact							
	Blinding: NR							
	Definition of positive and negative on screening test: RI < 0.53							

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring		
Matthes, Moreira de Andrade,	Geographical location: Brazil			1) US	(Kurjak mo Dis+	orphology) Dis-	Tot	Comments: 8 patients dropped from analysis – not mentioned why		
and Bighetti, 1996	Dates: Feb 1992 – Feb 1994	Range: 15-83 Menopausal status	Detected by exam (n [%]): NR	T+ T- Tot	8 2 10	7 26 33	15 28 43	Kurjak criteria for morphologic classification (without Doppler), and cutpoint not described for this study		
#11020	Size of population: 51, however results only available for 43	(n [%]): NR	Detected by imaging (n [%]): NR	TOU	Value	Lower 95% CI	Upper 95% Cl	LMP included with malignant Unclear if TVUS or abdominal US or combination used		
	Reference standard:	Race/ethnicity (n [%]): NR	Combination (n [%]): NR	Se Sp PPV	80.0% 78.8% 53.3%	55.2% 64.8% 28.1%	100.0% 92.7% 78.6%	Quality assessment: Reference standard: +		
	Reference standard applied to all test negatives?:	Risk factors (n [%]): NR	Additional data used for diagnosis:	NPV	92.9%	83.3%	100.0%	Verification bias: + Test reliability/variability: - Sample size: -		
	Test reliability established?:	Inclusion criteria: Unclear	NR					Statistical tests: + Blinding: - Definition of +/- on screening test:		
	Statistical tests used:	Exclusion criteria: NR						+/-		
	Blinding:									
	Definition of positive and negative on screening test:									

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
McIntosh, Drescher, Karlan, et	Geographical location: Seattle, WA	Age: NR	Symptomatic (n [%]): NR	 CA-125 (cutoff not specified; sensitivity calculated corresponding to 98% specificity on ROC curve based on LR model) 	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + Sample size: +
al., 2004	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot	
#6700	Size of population: 95/315 total including healthy controls (no mass)	Pre: 90 (29%) Post: 225 (71%) Race/ethnicity (n [%]): White: 268 (85%)	Detected by imaging (n [%]): NR	T+ 19 1 20 T- 33 42 75 Tot 52 43 95 Lower Upper	Statistical tests: + Blinding: - Definition of +/- on screening test: -
	52 ovarian cancer 43 benign ovarian tumors = 95 used for calculations here	Hispanic: 4 (1%%)	Combination (n [%]): NR Additional data used for diagnosis:	Value 95% CI 95% CI Se 37.2% 24.1% 50.3% Sp 98.0% 93.8% 100.0% PPV 95.0% 85.4% 100.0% NPV 56.0% 44.8% 67.2%	
	Other	,	NR	NIV 30.070 44.070 07.270	
	Case-control	Risk factors (n [%]) : NR		Also reported for soluble mesothelin related (SMR) marker; not reported here.	
	Reference standard: Histopathology	Inclusion criteria: Cases and controls –			
	Reference standard applied to all test negatives?:	randomly selected from repository			
	Yes	Exclusion criteria: NR			
	Test reliability established?: Yes				
	Statistical tests used: ROC, LR models				
	Blinding: NR				
	Definition of positive and negative on screening test: SA 125 – cutoffs not selected a priori				

Study	Study Design	Patients	Clinical Presentation	Result	S			Comments/Quality Scoring
kampff,	Geographical location: Vienna, Austria	Age: NR	Symptomatic (n [%]) : NR	1) Ultra			_	Comments:: Unclear how cases selected
Stiskal, et				_ r	Dis+	Dis-	Tot	Clinical presentation not described
al., 1995	Dates: NR	Menopausal status	Detected by exam (n [%]):	T+ -	30	8	38	No scoring system for US – unclea
#6300		(n [%]):	NR	T-	7	22	29	if descriptive analysis required all or
#0300	Size of population: 73 women	NR	Detected by imaging	Tot	37	30	67	any of the findings to be considered malignant – MRI more clearly
	75 women	Race/ethnicity (n [%]):	(n [%]):			Lower	Linner	described
	Other	NR	NR		Value	Lower 95% CI	Upper 95% CI	described
	Case series			Se		68.4%	93.6%	Quality assessment:
		Risk factors (n [%]):	Combination (n [%]):	Sp		57.1%	93.0% 88.9%	Reference standard: +
	Reference standard:	NR	NR	PPV	78.9%	66.0%	91.9%	Verification bias: +
	Surgery			NPV		60.3%	91.9 <i>%</i> 91.4%	Test reliability/variability: -
	3- 3- 5	Inclusion criteria:	Additional data used for		10.070	00.070	51.470	Sample size: -
	Reference standard	NR	diagnosis:	2) MRI				Statistical tests: +
	applied to all test		Stage	_,				Blinding: -
	negatives?:	Exclusion criteria:	I: n=11 (29.7%)		Dis+	Dis-	Tot	Definition of +/- on screening test: +
	Yes	NR	II: n=1 (2.7%)	T+	36	5	41	
			III: n=24 (64.9%)	Т-	1	25	26	
	Test reliability		IV: n=1 (2.7%)	Tot	37	30	67	
	established?:				-			
	Not described or					Lower	Upper	
	discussed				Value	95% CI	95% CI	
				Se	97.3%	92.1%	100.0%	
	Statistical tests used:			Sp	83.3%	70.0%	96.7%	
	Se/Sp			PPV		77.8%	97.8%	
	Dlinding			NPV	96.2%	88.8%	100.0%	
	Blinding: Not described							
	Not described							
	Definition of positive							
	and negative on							
	screening test:							
	Ultrasound:							
	Cyst with irregular							
	wall							
	• Wall thickness > 3 cm							
	Papillary wall							
	structures							
	 Solid components 							
	 Presence of ascites 							
	MRI:							
	• > 4cm							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	 Wall thickness > 3 mm or nodular or other solid components Entirely solid Involvement of adjacent organs Ascites Lymph node > 1 cm Peritoneal, mesenteric, or omental disease 				
Menon, Talaat, Rosenthal,	Geographical location: London, UK	Age: NR	Symptomatic (n [%]): NR	All results given using number of scans as denominator (n = 1219), disease defined as incident cancer within 1 year of scan	Comments: Authors state no significant differences in sensitivity, but
et al., 2000	Dates: 1986-1989	Menopausal status (n [%]):	Detected by exam (n [%]):	1) Abnormal volume as threshold	underpowered to detect differences
#2780	Size of population: 22,000 in prevalence	100% postmenopausal, > 45	Detected by imaging	Dis+ Dis- Tot	Quality assessment: Reference standard: +
	screen, 10,958	10	(n [%]):	T+ 17 63 80	Verification bias: +
	randomized to 3 annual	Race/ethnicity (n [%]):	NR	T- 2 945 947	Test reliability/variability: -
	incidence screens. Results based on	NR	Combination (n [%]):	Tot 19 1008 1027	Sample size: - (large study, but small number of cancers)
	741women	Risk factors (n [%]):	NR	Lower Upper	Statistical tests: -
		All with elevated CA-125		Value 95% CI 95% CI	Blinding: +
	Screening study		Additional data used for	Se 89.5% 75.7% 100.0%	Definition of +/- on screening test:
	Defense etcaded	Inclusion criteria:	diagnosis:	Sp 93.8% 92.3% 95.2%	+
	Reference standard: Surgery, registry	NR	All with CA-125 > 30 75.3% of scans	PPV 21.3% 12.3% 30.2%	
	diagnosis of cancer,	Exclusion criteria:	transabdominal, 8.4%	NPV 99.8% 99.5% 100.0%	
	followup questionnaire	NR	transvaginal, 16.2% both	2) Abnormal morphology as threshold	
	Reference standard			Dis+ Dis- Tot	
	applied to all test			T+ 19 61 80	
	negatives?: Yes			T- 0 947 947 Tot 19 1008 1027	
	Test reliability			Lower Upper	
	established?:			Value 95% CI 95% CI	
	Not referenced or			Se 100.0% 84.2% 100.0%	
	discussed			Sp 93.9% 92.5% 95.4%	
	Statistical tests used:			PPV 23.8% 14.4% 33.1%	
	Statistical lesis used:			NPV 100.0% 99.7% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Resul	s			Comments/Quality Scoring
	Se/Sp							
				3) Con	plex mor	phology as	threshold	
	Blinding:				D ¹	D .	- 4	
	Yes			_ 1	Dis+	Dis-	Tot	
				T+	16	27	43	
	Definition of positive			T-	3	981	984	
	and negative on			Tot	19	1008	1027	
	screening test:							
	If CA-125 > 30 U/ml,					Lower	Upper	
	ultrasound				Value	95% CI	95% CI	
	If alter a sum day sum als			Se	84.2%	67.8%	100.0%	
	If ultrasound normal:			Sp	97.3%	96.3%	98.3%	
	< 8.8 ml volume, uniform			PPV	37.2%	22.8%	51.7%	
	hypoechogenicity,			NPV	99.7%	99.4%	100.0%	
	smooth outlines, or not visualized but no							
	abnormality repeated CA-125 q 3							
	months x 1 year, then							
	annual screening:							
	Equivocal:							
	Ovarian volume < 8.8 ml							
	with abnormal							
	morphology: repeat scar	n						
	g 6 weeks until either	•						
	normal or abnormal scan							
	normal of abriormal scan							
	Abnormal: Ovarian							
	volume > 8.8 ml, referred	1						
	to gynecologist, with	-						
	management at their							
	discretion							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Merce, Caballero,	Geographical location: Spain	Mean: 41	Symptomatic (n [%]): NR	1) US score ≥ 6	Comments: Time interval from original
Barco, et al.,		Range: 15 - 87		Dis+ Dis- Tot	diagnosis of mass to followup US
1998	Dates: 1990 - 1995		Detected by exam (n [%]):	T+ 21 34 55	was 2 weeks to 3 months
		Menopausal status	NR	T- 1 73 74	US score developed by authors in
#3510	Size of population:	(n [%]):		Tot 22 107 129	different paper [ref 15] and unclear
	213	NR	Detected by imaging		how reliable. Test features of score
	129 had surgery		(n [%]):	Lower Upper	not described.
		Race/ethnicity (n [%]):	NR	Value 95% CI 95% CI	2x2 tables based on the 129 who
	Other	NR		Se 95.5% 86.8% 100.0%	had surgery only
	Patients with masses		Combination (n [%]):	Sp 68.2% 59.4% 77.0%	
	?referred to hospital	Risk factors (n [%]):	NR	PPV 38.2% 25.3% 51.0%	Quality assessment:
		NR		NPV 98.6% 96.0% 100.0%	Reference standard: +, 2x2 table
	Reference standard:		Additional data used for		based only on those who had
	Histopathology for those	Inclusion criteria:	diagnosis:	2) RI ≤ 0.5	surgery
	in surgery, repeat US for	Premenopausal women	NR		Verification bias: -, only US followup
	the others	with ovarian mass >28mm		Dis+ Dis- Tot	in 213-129 patients
		in diameter, or >10mm for		T+ 18 36 54	Test reliability/variability: -
	Reference standard	menopausal women.		T- 4 71 75	Sample size: -
	applied to all test			Tot 22 107 129	Statistical tests: +
	negatives?:	Exclusion criteria:			Blinding: -
	No	NR		Lower Upper	Definition of +/- on screening test: +
				Value 95% CI 95% CI	
	Test reliability			Se 80.0% 63.3% 96.7%	
	established?:			Sp 66.7% 57.8% 75.6%	
	Unclear for US score			PPV 33.3% 20.8% 45.9%	
	Yes for RI			NPV 94.7% 89.6% 99.8%	
	Statistical tests used: ROC curves				
	Blinding: NR but US prior to surgery				
	Definition of positive and negative on screening test: $RI \le 0.5$ For US sonographic index score ≥ 6 which was volume + morphology score				

Morgante, la Marca, Ditto, et al., 1999Geographical location: Narca, Ditto, et al., 1997Age: NR: NR: NR:Symptomatic (n [%]): NR1) US score of 21999Dates: Jan 1995 – Dec 1997Menopausal status (n [%]): Pre (< 45): 69 (55.6%) Post (> 55): 55 (44.3%) 124Detected by exam (n [%]): NRT+Dis+Dis- 122To 31319312Other Case series Consecutive admissions for surgeryNRNRDetected by imaging (n [%]): NRTo NR31939312Reference standard applied to all test negatives?: YesInclusion criteria: NRNRCombination (n [%]): NRNRSeTot 25.0%87.0%80.2%93.8Test reliability established?: YesTest reliability established?: YesExclusion criteria: NRNRNR2)CA-125 ≥ 5 U/mlTo 313912Test reliability established?: YesTest reliability established?: YesNRDis+Dis- TotTo 319312ValueMarca, PV61.5%63.0%76.5%95.6%Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testNR3)CA-125 ≥ 50 U/mlStatistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe3)CA-125 ≥ 50 U/mlStatistical tests used: Mann-Whitney U testSe903)CA-125 ≥ 50 U/ml	
1999Dates: Jan 1995 – Dec 1997Menopausal status (n [%]): Pre (< 45): 69 (55.6%) Post (> 55): 55 (44.3%) Post (> 55)	Comments: What constitutes + CA-125 or US
#29001997(n [%j]: Pre (< 45): 69 (55.6%) Post (> 55): 55 (44.3%) Post (> 55): 55 (44.3%) 	score not discussed
#2900Pre $(< 45): 69 (55.6\%)$ Post (> 55): 55 (44.3%) Post (> 55): 55 (44.3%) Post (> 55): 55 (44.3%) Post (> 55): 55 (44.3%) NRDetected by imaging (n [%]): NRTot3193124Other Case series Consecutive admissions for surgeryRace/ethnicity (n [%]): NRNRNRSe71.0%55.0%87.0%Other Case series Consecutive admissions for surgeryRisk factors (n [%]): NRNRSe71.0%55.0%87.0%Additional data used for diagnosis: NgInclusion criteria: Age >30 Mass scheduled for surgery in time frameAdditional data used for diagnosis: NR2)CA-125 ≥ 25 U/mlTest reliability established?: YesExclusion criteria: NRNRDis+Dis- Tot3193Test reliability established?: YesStatistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testNRSeSo U/mlStatistical tests used: Mann-Whitney U testSo U/ml3)CA-125 ≥ 50 U/ml	Borderline tumors grouped in with
Size of population: 124Post (> 55): 55 (44.3%) (n [%]): NRDetected by imaging (n [%]): NRLower ValueUpp 95% C1Other Case series Consecutive admissions for surgeryRisk factors (n [%]): NRNRSe $Value$ 95% C195% 95.0%80.2%93.8Reference standard: HistopathologyInclusion criteria: Age >30Additional data used for diagnosis: NRAdditional data used for diagnosis: NR2) CA-125 \geq 25 U/ml12Test reliability established?: YesExclusion criteria: NRNRTo319312YesStatistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testNRSeSe16.5%46.3%97.6Size of population: (hi square Mann-Whitney U testUestSe3) CA-125 \geq 50 U/mlSeSeSeSe	malignant in analysis
124(n [%]): NRNRLower ValueUpp 95% ClOther Case series Consecutive admissions for surgeryNRSe71.0%55.0%87.0%Reference standard: HistopathologyRisk factors (n [%]): NRNRNRSe71.0%55.0%80.2%Reference standard: HistopathologyInclusion criteria: Age >30 Mass scheduled for surgery in time frame yesAdditional data used for diagnosis: NR2) CA-125 ≥ 25 U/ml2) CA-125 ≥ 25 U/mlTest reliability established?: YesExclusion criteria: NRNR2) Test reliability established?: YesExclusion criteria: NRNR2) Se71.0% Se30.4%Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe76.5% Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe71.0% Se50.0% Se70.0% Se3) CA-125 ≥ 50 U/ml	
Other Case series Consecutive admissions for surgeryRace/ethnicity (n [%]): NRNRValue95% Cl95% 95%Risk factors (n [%]): NRRisk factors (n [%]): NRNRSe71.0%55.0%87.0Reference standard: HistopathologyInclusion criteria: Age >30 Mass scheduled for surgery in time frame applied to all test negatives?: YesInclusion criteria: Surgery in time frame NRAdditional data used for diagnosis: NR2) CA-125 \geq 5 U/mlTest reliability established?: YesExclusion criteria: NRNR2) CA-125 \geq 50 U/mlToTest reliability established?: YesStatistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe78.0%63.4%92.6Statistical tests used: Mann-Whitney U testSe50.0%76.5%91.5Statistical tests used: Mann-Whitney U testSe71.0%55.0%85.9%97.6Statistical tests used: Mann-Whitney U testSe50.0095%91.5Statistical tests used: Mann-Whitney U testSe78.0%63.4%92.6Statistical tests used: Mann-Whitney U testSe78.0%63.4%92.6Statistical tests used: Mann-Whitney U testSe78.0%91.591.5Statistical tests used: Mann-Whitney U testSe3)CA-125 \geq 50 U/ml	Quality assessment:
OtherNRCase seriesRisk factors (n [%]):Combination (n [%]):Se71.0%55.0%87.0Consecutive admissions for surgeryRisk factors (n [%]):NRNRSp87.0%80.2%93.8NRNRNRAdditional data used for diagnosis:NPV90.0%83.8%96.2Reference standard: HistopathologyInclusion criteria: Age >30 Mass scheduled for surgery in time frame applied to all test negatives?: YesInclusion criteria: Exclusion criteria: NRNR2)CA-125 \geq 25 U/mlTest reliability established?: YesExclusion criteria: NRNR1241539Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe78.0%63.4%92.63)CA-125 \geq 50 U/ml31CA-125 \geq 50 U/ml32	
Case series Consecutive admissions for surgeryRisk factors (n [%]): NRCombination (n [%]): NRSp Sp Sp Additional data used for diagnosis: NRSp Sp Sp Additional data used for diagnosis: NRSp Sp Sp Sp Sp Additional data used for diagnosis: NRSp Sp Sp Sp Sp Additional data used for diagnosis: NRSp Sp Sp Sp Sp Additional data used for diagnosis: NRSp S	
Consecutive admissions for surgeryRisk factors (n [%]): NRNRNRPPV64.7% 48.6%48.6% 80.8 80.8 NPV80.8 96.2Reference standard: HistopathologyInclusion criteria: Age >30 Mass scheduled for surgery in time frameAdditional data used for diagnosis: NRQ) CA-125 \geq 25 U/mlReference standard applied to all test negatives?: YesExclusion criteria: NRNRDis+Dis- ToToTest reliability established?: YesStatistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testStatistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testStatistical tests statistical test used: Se, Sp, ROC Chi-square Mann-Whitney U testSite of the state statistical test used: Se, Sp, ROC Chi-square Mann-Whitney U testRStatistical tests statistical testStatistical test used: Sp, Statistical testStatistical test statistical testNRStatistical test statistical testStatistical test <br< td=""><td>· · · ·</td></br<>	· · · ·
for surgeryNRAdditional data used for diagnosis: NRNPV 90.0% 83.8% 96.2 Reference standard: HistopathologyInclusion criteria: Age >30 Mass scheduled for surgery in time frame regatives?: YesInclusion criteria: NRNR $125 \ge 25 \text{ U/ml}$ Test reliability established?: YesExclusion criteria: NRNR 124 15 124 31 93 93 124 Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testNR 126 155 126 150 126 124 Statistical tests used: Mann-Whitney U test 126 125 126 126 126 126 126 126 Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U test 126 126 126 126 126 126 Statistical tests used: Mann-Whitney U test 126 126 126 126 126 126 Statistical tests used: Mann-Whitney U test 126 126 126 126 126 126 Statistical tests used: Mann-Whitney U test 126 126 126 126 126 126	
Additional data used for HistopathologyInclusion criteria: Age >30 Mass scheduled for surgery in time frameAdditional data used for diagnosis: NR2) CA-125 \geq 25 U/mlReference standard applied to all test negatives?: YesExclusion criteria: NRNR2) CA-125 \geq 25 U/mlTest reliability established?: YesExclusion criteria: NRTot3193124Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe 78.0% 63.4%63.4% 92.692.6Solor a boldSe Sp, ROC Chi-square Mann-Whitney U testSe Sp U/mlSe Sp U/ml	DP P
Reference standard: HistopathologyInclusion criteria: Age >30 Mass scheduled for surgery in time framediagnosis: NR2) CA-125 \geq 25 U/mIReference standard applied to all test negatives?: YesExclusion criteria: NRNR2) CA-125 \geq 25 U/mITest reliability established?: YesExclusion criteria: NRTot10 s- 1 93124Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe78.0% 46.3%63.4% 92.6Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe78.0% 76.5%63.4% 97.68Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe78.0% 76.5%63.4% 97.68Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe3) CA-125 \geq 50 U/mI	6 Blinding: + Definition of +/- on screening test:
HistopathologyAge >30NRDist into a contract of the	
Mass scheduled for surgery in time frameDis+Dis-Toapplied to all test negatives?: YesExclusion criteria: 	
Reference standard applied to all test negatives?: Yessurgery in time frameT + 24 15 105 T- 7 78 85 Tot 31 93 124 Test reliability established?: YesNR $Value$ 95% CI 95% Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe 78.0% 63.4% 92.6 Statistical tests 85.9% 76.5% 91.5 Statistical tests 85.9% 76.8% 76.5% 91.5 Se, Sp, ROC Chi-square Mann-Whitney U test 3) CA-125 \geq 50 U/ml 3) CA-125 \geq 50 U/ml	
applied to all test negatives?:TTTest reliability established?: YesTest reliability 95% TotTestUpp 95% Upp 95% Upp <b< td=""><td></td></b<>	
negatives?: YesExclusion criteria: NRTotTotTotTotTest reliability established?: YesSeTot 31 93 124 Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe 78.0% A 63.4% 63.4% 92.6 92.6 Statistical tests used: Mann-Whitney U testSe 78.0% A 63.4% 63.4% 92.6 95% 97.6Statistical tests used: NPVSp 84.0% 91.8\% 76.5% 97.6Statistical tests used: NPVSp 84.0% 91.8% 76.5% 97.6	
YesNRTot3193124Test reliability established?: YesSe 78.0% 63.4%92.6Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe 78.0% 63.4%92.6Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe 78.0% 63.4%92.6Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe 78.0% 61.5%91.5%Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U testSe 3 CA-125 \geq 50 U/ml	
Test reliability established?: Yes Lower 95% Cl Upp 95% Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U test Se 78.0% 76.5% 63.4% 92.6 92.6 Statistical tests used: NPV Sp 84.0% 46.3% 76.5% 76.8 91.5 Statistical tests used: Se, Sp, ROC Chi-square Mann-Whitney U test NPV 91.8% 91.8% 85.9% 97.6	
Test reliability Value 95% Cl 95% established?: Se 78.0% 63.4% 92.6 Yes Sp 84.0% 76.5% 91.5 Statistical tests used: PPV 61.5% 46.3% 76.8 Se, Sp, ROC NPV 91.8% 85.9% 97.6 Chi-square 3) CA-125 \geq 50 U/ml	
established?: Value 95% Cl 95% Cl Yes Se 78.0% 63.4% 92.6 Sp 84.0% 76.5% 91.5 Statistical tests used: PPV 61.5% 46.3% 76.8 Se, Sp, ROC NPV 91.8% 85.9% 97.6 Chi-square 3) CA-125 \geq 50 U/ml 3) CA-125 \geq 50 U/ml	
Yes Sp 84.0% 76.5% 91.5 Statistical tests used: PPV 61.5% 46.3% 76.8 Se, Sp, ROC NPV 91.8% 85.9% 97.6 Chi-square 3) CA-125 ≥ 50 U/mI	
Statistical tests used: PPV 61.5% 46.3% 76.8 Se, Sp, ROC NPV 91.8% 85.9% 97.6 Chi-square 3) CA-125 ≥ 50 U/mI	
Statistical tests used: NPV 91.8% 85.9% 97.6 Se, Sp, ROC Chi-square 3) CA-125 ≥ 50 U/ml Mann-Whitney U test 3) CA-125 ≥ 50 U/ml	
Se, Sp, ROC Chi-square 3) CA-125 ≥ 50 U/ml Mann-Whitney U test	
Chi-square3) CA-125 ≥ 50 U/mlMann-Whitney U test3)	0
Mann-whitney U test	
Blinding: T+ 23 5 28	
NR - prospective T- 8 88 96	
Tot 21 02 12	
Definition of positive	
and negative on Lower Upp	r
Screening test.	
CA = 123 = 100 mge $CA = 123 = 100 mge$ $CA = 123 = 100 mge$ $CA = 123 = 100 mge$ $CA = 123 mge$ $CA = 1$	
(1), solid dieds (1) ,	
bilateral resions (1),	-
ascites (1), intraabdominal mets (1)	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
O'Connell, Ryan, Murphy, et al., 1987	Geographical location: Hamilton, Ontario Dates: Nov 1984-May 1986	Age: Mean (SD): 55 Range: 13-81 Menopausal status	Symptomatic (n [%]): NR Detected by exam (n [%]): NR	1) CA-125 threshold >35 U/ml, ovarian cancer vs. any other diagnosis (including other malignancy) Dis+ Dis- Tot	Comments: Clinical presentation not reported Very high prevalence of cancer Borderline masses included in malignant
#6690	Size of population: 56 women	(n [%]): NR Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	T+ 26 17 43 T- 0 13 13 Tot 26 30 56	Quality assessment: Reference standard: + Verification bias: +
	Other Case series Reference standard: Surgery/pathology	NR Risk factors (n [%]): NR	Combination (n [%]): NR Additional data used for	Lower Upper Value 95% CI 95% CI Se 100.0% 88.5% 100.0% Sp 43.3% 25.6% 61.1% PPV 60.5% 45.9% 75.1%	Test reliability/variability: + Sample size: - Statistical tests: - Blinding: + Definition of +/- on screening test:
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: NR Exclusion criteria: NR	diagnosis: "High clinical suspicion of ovarian cancer" CA-125 drawn within 3 days of surgery	 NPV 100.0% 76.9% 100.0% 2) CA-125 threshold > 60 U/ml, ovarian cancer vs. any other diagnosis (including other malignancy) 	+
	Test reliability established?: Yes Statistical tests used:			Dis+ Dis- Tot T+ 24 12 36 T- 2 18 20 Tot 26 30 56	
	Se/Sp/ROC Blinding: Yes			Lower Upper 95% CI 95% CI Se 92.0% 81.6% 100.0% Sp 60.0% 42.5% 77.5% PPV 66.7% 51.3% 82.1%	
	Definition of positive and negative on screening test: Varied			NPV 90.0% 76.9% 100.0% 3) CA-125 threshold > 35 U/ml, any malignancy vs. benign	
				Dis+ Dis- Tot T+ 36 7 43 T- 2 11 13 Tot 38 18 56	
				Lower Upper Value 95% CI 95% CI Se 95.0% 88.1% 100.0% Sp 61.0% 38.5% 83.5%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				PPV 83.7% 72.7% 94.8	
				NPV 84.6% 65.0% 100.	0%
				 CA-125 threshold > 60 U/ml, a malignancy vs. benign 	ny
				Dis+ Dis- To T+ <u>33 3</u> 36	6
				T- <u>5 15</u> 20 Tot <u>38 18</u> 56	
				Lower Upp Value 95% CI 95%	
				Se 87.0% 76.3% 97.7 Sp 83.0% 65.6% 100.1	%
				PPV 91.7% 82.6% 100. NPV 75.0% 56.0% 94.0	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Onsrud, Shabana,	Geographical location: Trondheim, Norway	Age: Range: 19-80 years	Symptomatic (n [%]): NR	1) CA-125 > 20 U/ml	Comments: Clinical presentation not reported
and	frontancini, rtorway	Runge. To be years		Dis+ Dis- Tot	Spectrum of disease reported
Austgulen, 1996	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	T+ 37 4 41 T- 8 23 31	Patient selection criteria not described
	Size of population:	NR		Tot 45 27 72	CA-125 cutpoint derived from
#3950	72 women		Detected by imaging	101 43 21 12	mean +2 SD of the 26 control
-5550	72 Women	Race/ethnicity (n [%]):	(n [%]):	Lewen Linner	women
	Other	NR	NR	Lower Upper	women
		INIX	INK	Value 95% CI 95% CI	Quality appagaments
	Case series			Se 82.0% 70.8% 93.2%	Quality assessment:
		Risk factors (n [%]):	Combination (n [%]):	Sp <mark>85.0%</mark> 71.5% 98.5%	Reference standard: +
	Reference standard:	NR	NR	PPV 90.2% 81.2% 99.3%	Verification bias: +
	Surgery/pathology			NPV 74.2% 58.8% 89.6%	Test reliability/variability: +
		Inclusion criteria:	Additional data used for		Sample size: -
	Reference standard	NR	diagnosis:	 TNF p 55 > 2.0 ng/ml 	Statistical tests: +
	applied to all test		Stage I: 20/45 (44.4%)	_) p co	Blinding: +
	negatives?:	Exclusion criteria:	Stage II: 1/45 (2.2%)	Dis+ Dis- Tot	Definition of +/- on screening test:
	Yes	NR	Stage III: 21/45 (46.7%)	T+ 26 3 29	+
			Stage IV: 1/45 (2.2%)		
	Test reliability		Stage 111 1/10 (2:270)		
	established?:			Tot 45 27 72	
	Yes			Lower Upper	
				Value 95% CI 95% CI	
	Statistical tests used:			Se 58.0% 43.6% 72.4%	
	Wilcoxon rank sum,			Sp 89.0% 77.2% 100.0%	
	Se/Sp			PPV 89.7% 78.6% 100.0%	
	·				
	Blinding:			NPV 55.8% 41.0% 70.7%	
	Yes				
	100			3) TNF p 75 > 4.3 ng/ml	
	Definition of positive				
	and negative on			Dis+ Dis- Tot	
				T+ 7 1 8	
	screening test:			T- 38 26 64	
	Varied			Tot 45 27 72	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 16.0% 5.3% 26.7%	
				Sp 96.0% 88.6% 100.0%	
				PPV 87.5% 64.6% 100.0%	
				NPV 40.6% 28.6% 52.7%	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
Padungsutt, Thira- pagawong, Senapad, et al., 2000 #520	Bangkok, Thailand	Age: Mean (SD): 38.8 (2.8) Range: 10-69 Menopausal status (n [%]): Pre (< 45): 64 (69.6%) Post (> 55): 28 (30.4%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: NR Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: Stage I: 17/40 (42.5%) Stage II: 3/40 (7.5%) Stage III: 20/40 (50%)	1) Tiss U/L T+ T- Tot Se Sp PPV NPV	Dis+ 36 4 40 Value 90.0% 71.2% 70.6% 90.2%	ptide spec	ific antigen > 80 Tot 51 41 92 Upper 95% CI 99.3% 83.5% 83.1% 99.3%	Comments: Clinical presentation not described Not stratified by age, menopausal status Patient selection criteria not described Borderline tumors grouped with malignant Not a common test modality Quality assessment: Reference standard: + Verification bias: + Test reliability/variability:+ Sample size: - Statistical tests:+ Blinding: + Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Patsner and Mann, 1988	Geographical location: Stony Brook, NY	Age: NR	Symptomatic (n [%]): NR	1) CA-125 > 35 U/ml, All patients Dis+ Dis- Tot	Comments: Clinical presentation not described Borderline tumors grouped with
#5360	Dates: Jul 1985-Jul 1987	Menopausal status (n [%]):	Detected by exam (n [%]) : NR	Dis+ Dis- Tot T+ 92 25 117 T- 36 97 133	malignant
	Size of population: 250 women	Pre (< 45): 125 (50%) Post (> 55): 125 (50%)	Detected by imaging (n [%]):	Tot 128 122 250 Lower Upper	Quality assessment: Reference standard: + Verification bias: +
	Other	Race/ethnicity (n [%]) : NR	NR	<u>Value 95% CI 95% CI</u> Se 71.9% 64.1% 79.7%	Test reliability/variability: + Sample size: -
	Consecutive case series	Risk factors (n [%]):	Combination (n [%]): NR	Sp 79.5% 72.3% 86.7% PPV 78.6% 71.2% 86.1%	Statistical tests: + Blinding: +
	Reference standard: Surgery/pathology	NR Inclusion criteria:	Additional data used for diagnosis:	NPV 72.9% 65.4% 80.5%	Definition of +/- on screening test: +
	Reference standard applied to all test	NR	Invasive ovarian cancer Stage I: 14/80 (17.5%)	2) CA-125 > 35 U/ml, Premenopausal Dis+ Dis- Tot	
	negatives?: Yes	Exclusion criteria: NR	Stage II: 3/80 (3.8%) Stage III: 50/80 (62.5%)	DIS+ DIS- Tot T+ 33 16 49 T- 18 58 76	
	Test reliability		Stage IV: 13/80 (16.3%)	Tot 51 74 125	
	established?: Yes			Lower Upper Value 95% CI 95% CI	
	Statistical tests used: Se/Sp			Se 65.0% 51.9% 78.1% Sp 78.0% 68.6% 87.4% PPV 67.3% 54.2% 80.5%	
	Blinding: Yes			NPV 76.3% 66.8% 85.9%	
	Definition of positive			3) CA-125 > 35 U/ml, Postmenopausal	
	and negative on screening test: CA-125 > 35			Dis+ Dis- Tot T+ 59 9 68 T- 18 39 57 Tot 77 48 125	
				Lower Upper Value 95% CI 95% CI	
				Se 77.0% 67.6% 86.4% Sp 81.0% 69.9% 92.1% PPV 86.8% 78.7% 94.8%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Prompeler, Madjar, and Sauerbrei, 1996	Geographical location: Freiburg, Germany Dates: Jul 1992-Jul	Age: NR Menopausal status	Symptomatic (n [%]): NR Detected by exam (n [%]):	Malignant disease includes borderline (n = 9) 1) Total number of arteries > 4, all patients	Comments: Clinical presentation not described LMP tumors grouped with malignant
	1994	(n [%]):	NR		0
#3960	Size of population: 212 consecutive cases	Pre (< 45): 81 (38.2%) Post (> 55): 131 (61.8%) Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	Dis+ Dis- Tot T+ 56 34 90 T- 12 110 122 Tot 68 144 212	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: +
	Other Case series Reference standard:	NR Risk factors (n [%]): NR	Combination (n [%]): NR	Lower Upper Value 95% CI 95% CI	Sample size: + (discussion of power) Statistical tests: + Blinding:
	Surgery	Inclusion criteria:	Additional data used for diagnosis:	Se 82.4% 73.3% 91.5% Sp 76.4% 69.5% 83.3% PPV 62.2% 52.2% 72.2%	Definition of +/- on screening test: +
	Reference standard applied to all test	NR	US timed to surgery date – therefore not all	NPV 90.2% 84.9% 95.4%	
	negatives?: Yes	Exclusion criteria: NR	premenopausal US done in proliferative phase	 Total number of arteries > 4, postmenopausal 	
	Test reliability established?: Discussed			Dis+ Dis- Tot T+ 45 14 59 T- 10 62 72 Tot 55 76 131	
	Statistical tests used: Spearman's, Mann- Whitney, See/Sp			Lower Upper Value 95% CI 95% CI	
	Blinding: No			Se 81.8% 71.6% 92.0% Sp 81.6% 72.9% 90.3% PPV 76.3% 65.4% 87.1% NPV 86.1% 78.1% 94.1%	
	Definition of positive and negative on screening test: 20 different measures of			3) Total number of arteries > 4, premenopausal	
	ovarian vascularity, flow studied. 4 best criteria were • Minimum resistive			Dis+ Dis- Tot T+ 11 20 31 T- 2 48 50	
	index (difference of peak systolic and maximum end diastolic, divided by			Tot 13 68 81 Lower Upper <u>Value 95% Cl 95% Cl</u> Se 84.6% 65.0% 100.0%	
	peak systolic flow velocity; cutpoint 0.5	5		Sp 70.6% 59.8% 81.4%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Total number of			PPV 35.5% 18.6% 52.3%	
	tumor arteries in			NPV 96.0% 90.6% 100.0%	
	color mode; cutpoi 4	nt		4) Min resistive index > 0.5, all patients	
	Maximum systolic				
	flow velocity;			Dis+ Dis- Tot	
	cutpoint 30 cm/sec	;		T+ <u>56 59</u> 115	
	Sum of all systolic			T- <u>12</u> 85 97	
	flow velocities; cutpoint 75 cm/sec			Tot 68 144 212	
		, ,		Lower Upper	
				Value 95% CI 95% CI	
				Se 82.1% 73.0% 91.2%	
				Sp 59.2% 51.2% 67.2% PPV 48.7% 39.6% 57.8%	
				NPV 87.6% 81.1% 94.2%	
				5) Min resistive index, postmenopausal	
				Dia L Dia Tat	
				Dis+ Dis- Tot T+ 45 23 68	
				T- <u>10</u> <u>53</u> <u>63</u>	
				Tot 55 76 131	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 81.5% 71.2% 91.8%	
				Sp 69.2% 58.8% 79.6%	
				PPV 66.2% 54.9% 77.4% NPV 84.1% 75.1% 93.2%	
				6) Min resistive index, premenopausal	
				Dis+ Dis- Tot	
				T+ 11 36 47	
				T- 2 32 34	
				Tot 13 68 81	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 84.6% 65.0% 100.0% Sp 47.1% 35.2% 58.9%	
				PPV 23.4% 11.3% 35.5%	
				NPV 94.1% 86.2% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				7) Maximum systolic velocity, all patients	i
				Dis+DisTot	
				T+ 54 33 87	
				T- 14 111 125	
				Tot 68 144 212	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 79.1% 69.4% 88.8%	
				Sp 76.8% 69.9% 83.7%	
				PPV 62.1% 51.9% 72.3%	
				NPV 88.8% 83.3% 94.3%	
				8) Max systolic velocity, postmenopausa	I
				Dis+DisTot	
				T+ 42 9 51	
				T- 13 67 80	
				Tot 55 76 131	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 75.9% 64.6% 87.2%	
				Sp 87.7% 80.3% 95.1%	
				PPV 82.4% 71.9% 92.8%	
				NPV 83.8% 75.7% 91.8%	
				9) Max systolic velocity, premenopausal	
				Dis+ Dis- Tot	
				T+ 21 24 45	
				T- 1 44 45	
				Tot 22 68 90	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 95.5% 86.8% 100.0%	
				Sp 64.7% 53.3% 76.1% PPV 46.7% 32.1% 61.2%	
				PPV 46.7% 32.1% 61.2%	
				NPV 97.8% 93.5% 100.0%	
				10) Sum of systolic velocities, all patients	3
				,,,,,,,,	

Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
		Dis+ Dis- Tot		
			Tot 68 144 212	
			Lower Upper	
			Value 95% CI 95% CI	
			Se 89.6% 82.3% 96.9%	
			Sp 73.6% 66.4% 80.8%	
			PPV 61.6% 52.0% 71.2%	
			NPV 93.8% 89.4% 98.2%	
			11) Sum of systolic velocities,	
			postmenopausal	
			Dis+ Dis- Tot	
			T+ <u>50</u> 12 62	
			Tot 55 76 131	
			Lower Upper	
			Value 95% CI 95% CI	
			Se 90.7% 83.0% 98.4%	
			Sp <mark>84.6%</mark> 76.5% 92.7%	
			PPV 80.6% 70.8% 90.5%	
			NPV 92.8% 86.6% 98.9%	
	Study Design	Study Design Patients	Study Design Patients Clinical Presentation	$\begin{array}{c ccccc} T+ & Dis- & Tot\\ \hline T+ & 61 & 38 & 99\\ T- & 7 & 106 & 113\\ Tot & 68 & 144 & 212\\ & & & & & & & & & & & & & & & & & & &$

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring	
Pyrgiotis, Sala- malekis,	Geographical location: Athens, Greece			 All pelvic masses Borderline included as malignant (n = 4) 	Comments: Clinical presentation not describe Drawn within 2 days of surgery	
Loghis, et al., 1993	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	CA-125 > 35 U/ml Dis+ Dis- Tot	Quality assessment:	
	Size of population:	NR		T+ 48 7 55	Reference standard: +	
#4790	126 women	Race/ethnicity (n [%]):	Detected by imaging (n [%]):	T- 14 57 71 Tot 62 64 126	Verification bias: + Test reliability/variability: +	
	Other Case series	NR	NR	Lower Upper	Sample size: - Statistical tests: +	
	Reference standard:	Risk factors (n [%]): NR	Combination (n [%]): NR	Value 95% CI 95% CI	Blinding: + Definition of +/- on screening test: +	
	Surgery/pathology	Inclusion criteria:	Additional data used for	Sp 89.1% 81.4% 96.7%	Demnitor of 77 of boleening test.	
	Reference standard applied to all test	NR	diagnosis: NR	PPV 87.3% 78.5% 96.1% NPV 80.3% 71.0% 89.5%		
	negatives?: Yes	Exclusion criteria: NR		 Ovarian masses only (excluding fibroids etc) 		
	Test reliability			Dis+ Dis- Tot		
	established?: Yes			T+ 46 3 49 T- 8 26 34		
	Statistical tests used:			Tot 54 29 83		
	Se/Sp			Lower Upper Value 95% CI 95% CI		
	Blinding:			Se 85.2% 75.7% 94.7%		
	Yes			Sp 89.7% 78.6% 100.0% PPV 93.9% 87.2% 100.0%		
	Definition of positive and negative on screening test: CA-125 > 35 U/ml			NPV 76.5% 62.2% 90.7%		

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Rehn, Lohmann,	Geographical location: Wurzburg, Germany	Age: Mean: 43.5	Symptomatic (n [%]):	1) Sassone's score ≥ 9	Comments: Document overlap in RI between
and	Wuizburg, Germany	Range: 17-88	NIX .	Dis+ Dis- Tot	benign and malignant masses
Rempen,	Dates: Mar 1992 – Dec	Range. 17-66	Detected by exam (n [%]):	T+ 43 70 113	Unclear if prospective or
1996	1994	Menopausal status	NR	T- 8 189 197	retrospective case series
1330	1994	(n [%]):			LMP tumors grouped with
#3910	Size of population:	Pre (< 45): 227 (73%)	Detected by imaging	Tot 51 259 310	malignant
	310	Post (> 55): 83(27%)	(n [%]):	Lower Upper	Overlap noted for PI between
	310	1 031 (* 00). 00(2170)	310(100%)		malignant and benign masses
	Case series	Race/ethnicity (n [%]):	310(10070)		Regression analysis showed
	Case series	NR	Combination (n [%]):		negative correlation of PI and tumo
	Reference standard:		NR	Sp 73.0% 67.6% 78.4%	size for malignant masses and in
	Histopathology	Risk factors (n [%]):		PPV 38.1% 29.1% 47.0%	total, but independence when only
	riistopatriology	NR	Additional data used for	NPV 95.9% 93.2% 98.7%	benign lesions analysed
	Reference standard		diagnosis:	2) LIC meansheld and descriptions (means 4)	TVUS only
	applied to all test	Inclusion criteria:	NR	2) US morphology descriptive (group 4)	
	negatives?:	Unclear – presumably		Dia L Dia Tat	Quality assessment:
	Yes for 300 women	women with masses in		Dis+ Dis- Tot	Reference standard: +
	10 premenopausal	hospital during time frame		T+ 46 91 137	Verification bias: +
	women were "followed up			T- <u>5 168</u> 173	Test reliability/variability: -
	to resolution"			Tot 51 259 310	Sample size: -
	10 1030101011	Exclusion criteria:			Statistical tests: +
	Test reliability	Uterine malignancy		Lower Upper	Blinding: -
	established?:	Sterine maighaney		Value 95% CI 95% CI	Definition of +/- on screening test:
	Yes			Se 90.0% 81.8% 98.2%	Bennition of W on corconing tool.
	100			Sp 65.0% 59.2% 70.8%	
	Statistical tests used:			PPV 33.6% 25.7% 41.5%	
	Chi square			NPV 97.1% 94.6% 99.6%	
	U test				
	Wilcoxon test			3) PI ≤ 1.0	
	Regression analysis				
	i logi occion analycio			Dis+ Dis- Tot	
	Blinding:			T+ <u>34</u> 122 156	
	NR			T- <u>17</u> 137 154	
				Tot 51 259 310	
	Definition of positive				
	and negative on			Lower Upper	
	screening test:			Value 95% CI 95% CI	
	US morphology –			Se 67.0% 54.1% 79.9%	
	Sassone's criteria score			Sp 53.0% 46.9% 59.1%	
	≥ 9 as well as presence			PPV 21.8% 15.3% 28.3%	
	of "inhomogeneous			NPV 89.0% 84.0% 93.9%	
	echogenicity, irregular				
	wall, or solid portion"				
	considered suggestive of				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	malignancy PI ≤ 1.0				
	Geographical location: Berlin, Germany	Age: NR	Symptomatic (n [%]): NR	Cancers of non-ovarian origin (n = 7) not included	Comments: Clinical presentation not described 2x2 tables for pre and post
#6090	Dates: Mar 1992-Aug 1994	Menopausal status (n [%]): Pre (< 45):33 (36.3%)	Detected by exam (n [%]): NR	1) TVUS, all patients Dis+ Dis- Tot	menopausal subgroups are approximate, with N, Se, Sp consistent with Table 3, but allowing
	Size of population: 98 women	Post (> 55): 52 (57.1%) Unknown: 5 (5.55%)	Detected by imaging (n [%]):	T+ 20 11 31 T- 2 58 60	for some discrepancies with PPV or NPV
	Other Case series	Race/ethnicity (n [%]) : NR	NR Combination (n [%]): NR	Tot 22 69 91 Lower Upper	Quality assessment: Reference standard: + Verification bias: +
	Reference standard: Surgery/pathology	Risk factors (n [%]): NR	Additional data used for diagnosis:	Value 95% Cl 95% Cl Se 90.9% 78.9% 100.0% Sp 84.1% 75.4% 92.7% PPV 64.5% 47.7% 81.4%	Test reliability/variability: - Sample size: - Statistical tests:+
	Reference standard applied to all test negatives?:	Inclusion criteria: NR	NR	NPV 96.7% 92.1% 100.0%	Blinding: - Definition of +/- on screening test:
	Yes	Exclusion criteria: NR		2) TVUS, premenopausal (n = 33)	
	Test reliability established?: Not referenced or discussed			Dis+ Dis- Tot T+ 5 6 11 T- 0 22 22 Tot 5 28 33	
	Statistical tests used: Chi-square, Mann- Whitney, Se/Sp			Lower Upper Value 95% CI 95% CI Se 100.0% 40.0% 100.0%	
	Blinding: NR			Sp 78.6% 63.4% 93.8% PPV 45.5% 16.0% 74.9% NPV 100.0% 86.4% 100.0%	
	Definition of positive and negative on screening test:			3) TVUS, postmenopausal (n = 52)	
	 Morphology: Malignant if Complex cystic pattern with irregularly thick septae Cystic or polycystic 			Dis+ Dis- Tot T+ 13 4 17 T- 2 33 35 Tot 15 37 52	

tudy	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	pattern with papilla	ry		Lower Upper	
	or indented mural p			Value 95% CI 95% CI	
	 Polycystic pattern v 			Se 86.7% 69.5% 100.0%	
	irregularly thick			Sp 89.2% 79.2% 99.2%	
	septae and solid pa	art		PPV 76.5% 56.3% 96.6%	
	< 50%			NPV 94.3% 86.6% 100.0%	
	 Solid pattern 				
	(>50%) with			 Color Doppler pulsatility index < 1.1 	
	irregular cystic pa	art		,, <u> </u>	
	Completely solid			Dis+ Dis- Tot	
	homogeneous or			T+ 18 12 30	
	inhomogeneous			T- 2 34 36	
	patter			Tot 20 46 66	
	(modified morphology				
	classification from Ver			Lower Upper	
	1986 and Kawai 1992)		Value 95% CI 95% CI	
		, ,		Se 90.0% 76.9% 100.0%	
	Color Doppler			Sp 74.0% 61.3% 86.7%	
	Pulsatility index ≤ 1.1			PPV 60.1% 42.5% 77.6%	
	Resistive index 0.7			NPV 94.5% 87.0% 100.0%	
	Lowest measured PI a	ind			
	RI used			5) Color Doppler pulsatility index \leq 1.1,	
				premenopausal (n = 24)	
				Dis+ Dis- Tot	
				T+ 4 6 10	
				T- 1 13 14	
				Tot 5 19 24	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 80.0% 44.9% 100.0%	
				Sp 68.4% 47.5% 89.3%	
				PPV 40.0% 9.6% 70.4%	
				NPV 92.9% 79.4% 100.0%	
				6) Color Doppler pulsatility index \leq 1.1,	
				postmenopausal (n = 37)	
				Dis+ Dis- Tot	
				T+ 13 4 17	
				T- 1 19 20	
				Tot 14 23 37	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
			ValueLower 95% ClUpper 95% ClSe92.9%79.4%100.0%Sp82.6%67.1%98.1%PPV76.5%56.3%96.6%NPV95.0%85.4%100.0%		
Reuter, Steffens, Schuppler, et al., 1998 #10990	Geographical location: Germany Dates: Jan 1994 – Aug 1995 Size of population: 65 Case series (retrospective) Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: Chi square Blinding: NR Definition of positive and negative on screening test: Used criteria from reference [16] Malignancy assumed if	Age: Mean: 48.8 Range: 18-84 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Patients with suspected adnexal tumors in time frame Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) MRI $\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Comments: For MRI used different machines, different contrast materials, different imaging techniques with study group Diagnosis done by consensus in conference (2 gynecologists for US, 2 radiologists for MRI) – not blinded to each other No mention of whether blinded to pathologic results Used criteria for malignancy (citation 16) which are not common Borderline grouped with malignant -TVUS only Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: +/- Blinding: - Definition of +/- on screening test: +/-

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	one or more of the following was present: solid growth or solid component wall with or without necrosis; cystic lesion with thickness of walls or septa more than 3 mm; nodular or papillary projections; excessive multilocularity; infiltration in neighboring organs or pelvic wall; tumor manifestation in the peritoneum, mesentery, omentum; lymphadenopathy. Benign was none of the above present				
Roman, Muder- spach,	Geographical location: Los Angeles, CA	Age: Mean: 39 Range: 13-80	Symptomatic (n [%]) : NR	 CEA > 3 ng/ml, borderline classified as malignant 	Comments: Clinical presentation not described Not stratified by age or
Burnett, et al., 1998	Dates: Jul 1992-Mar 1994	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 7 13 20 T- 25 181 206	Borderline tumors included with malignant
#3410	Size of population: 226 women	NR	Detected by imaging (n [%]):	Tot 32 194 226	Quality assessment:
	Other Case series	Race/ethnicity (n [%]): NR	NR 2 2 Combination (n [%]):	Lower Upper Value 95% CI 95% CI	Reference standard: + Verification bias: + Test reliability/variability: +
	Reference standard:	Risk factors (n [%]): NR	NR	Se 21.9% 7.6% 36.2% Sp 93.3% 89.8% 96.8%	Sample size: - Statistical tests: +
	Surgery/pathology	Inclusion criteria:	Additional data used for diagnosis:	PPV 35.0% 14.1% 55.9% NPV 87.9% 83.4% 92.3%	Blinding: + Definition of +/- on screening test: +
	Reference standard applied to all test negatives?:	Isolated pelvic mass with surgery planned	NR	 CEA > 3 ng/ml, borderline classified as benign 	
	Yes	Exclusion criteria: Emergency surgery		Dis+ Dis- Tot T+ 5 15 20	
	Test reliability established?: Yes	Evidence of metastases Past history of cancer		T- 17 189 206 Tot 22 204 226	
	Statistical tests used: Fisher's exact test, Se/Sp)		Lower Upper Value 95% CI 95% CI	

Study	Study Design	dy Design Patients Clinical Presentation		Results	Comments/Quality Scoring	
		Blinding: Yes Definition of positive and negative on screening test: CEA: > 3.0 ng/ml in nonsmokers, > 5.0 ng/ml in smokers			Se 22.7% 5.2% 40.2% Sp 92.6% 89.1% 96.2% PPV 25.0% 6.0% 44.0% NPV 91.7% 88.0% 95.5%	
Roman, Muder-	Geographical location: Los Angeles, CA	Age: NR	Symptomatic (n [%]) : NR	1) Borderline classified as malignant CA-125 > 35 U/ml	Comments: Clinical presentation not described	
spach, Stein, et al., 1997	Dates: Jul 1992-Mar 1994	Menopausal status (n [%]): Pre (< 45): 181 (80.1%)	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ <mark>29 54</mark> 83 T- 14 129 143	US authors stated scoring system used, however, description in text makes it seem more of a descriptive not numeric score	
#6160	Size of population: 226	Post (> 55): 45 (19.9%)	Detected by imaging (n [%]):	Tot 43 183 226	Quality assessment:	
	Other Non-consecutive case	Race/ethnicity (n [%]): NR	NR Combination (n [%]):	Lower Upper Value 95% CI 95% CI	Reference standard:+ Verification bias: + Test reliability/variability: -	
	series	Risk factors (n [%]): NR	NR	Se 67.4% 53.4% 81.4% Sp 70.5% 63.9% 77.1% PPV 34.9% 24.7% 45.2%	Sample size: - Statistical tests: +	
	Reference standard: Surgery/pathology	Inclusion criteria:	Additional data used for diagnosis:	NPV 90.2% 85.3% 95.1%	Blinding: - Definition of +/- on screening test: +	
	Reference standard applied to all test	Isolated pelvic mass with surgery planned	NR	 Any positive tumor marker Dis+ Dis- Tot 		
	negatives?: Yes	Exclusion criteria: Emergency surgery Evidence of metastases		T+ <u>31 55</u> 86 T- <u>12 128</u> 140		
	Test reliability established?:	Past history of cancer		Tot 43 183 226 Lower Upper		
	Statistical tests used: Chi-square, logistic			Value 95% Cl 95% Cl Se 72.1% 58.7% 85.5% Sp 70.0% 63.4% 76.6%		
	regression, Se/Sp Blinding:			PPV 36.1% 25.9% 46.2% NPV 91.4% 86.8% 96.1%		
	NR			 Any positive tumor marker, post- menopausal 		
	Definition of positive and negative on					

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	screening test: CA-125: >35 U/mL HCG: > 15 AFP: > 10 ng/ml			Dis+ Dis- Tot T+ 11 6 17 T- 5 23 28 Tot 16 29 45	
	LDH: > 350 U/L Gray scale ultrasound: Cystic with one large (> 1 cm) or multiple nodules or cystic/solid; completel solid masses not appearing to arise from the uterus in postmenopausal women Simplified scoring syster used (not described in scoring fashion) Doppler (only if gray	У		$\begin{array}{c cccccc} & & & & & & & & & & & & & & & & $	
	scale suspicious) PI < 1.0 or RI < 0.4			Lower Upper 95% CI 95% CI Se 88.4% 78.8% 98.0% Sp 86.9% 82.0% 91.8% PPV 61.3% 49.2% 73.4% NPV 97.0% 94.3% 99.6% 5) Ultrasound: Premenopausal	
				Dis+ Dis- Tot T+ 25 13 38 T- 2 141 143 Tot 27 154 181	
				ValueLower 95% CIUpper 95% CISe92.6% 91.6%82.7% 87.2%100.0%Sp91.6% 65.9%87.2% 50.8%96.0%PPV65.9% 98.6%50.8% 96.7%81.0%	
				6) Ultrasound: Postmenopausal	
				Dis+ Dis- Tot T+ 13 11 24 T- 3 18 21	

Study	Study Design	sign Patients Clinical Presentation		Results				Comments/Quality Scoring
				Tot	16	29	45	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	81.3%	62.2%	100.0%	
				Sp	62.1%	44.4%	79.8%	
				PPV	54.2%	34.3%	74.1%	
				NPV	85.8%	70.8%	100.0%	
Salem,	Geographical location:		Symptomatic (n [%]):	1) PI <	: 1			Comments:
White, and	Toronto, Canada	Range: 15-58	NR					Analysis done on masses not
Lai, 1994					Dis+	Dis-	Tot	individuals
	Dates: Sep 1992 – Jan	Menopausal status	Detected by exam (n [%]):	T+	10	17	27	No flow detected in 7 of 89 benig
#4430	1994	(n [%]):	NR	T-	3	65	68	lesions; these cases excluded.
		Pre (< 45): 57 (57.6%)		Tot	13	82	95	Scoring system most likely
	Size of population:	Peri (45-54): 23 (23.2%)	Detected by imaging					Sasonne or modified but not
	99 patients	Post (> 55): 19 (19.2%)	(n [%]):			Lower	Upper	described at all.
	102 masses from among		100% had adnexal mass		Value	95% CI	95% CI	But unable to use US morpholog
	377 women with adnexal	Race/ethnicity (n [%]):	detected at sonography	Se	76.9%	54.0%	99.8%	to construct 2x2 tables
	mass at sonography	NR		Sp	79.3%	70.5%	88.0%	
			Combination (n [%]):	PPV	37.0%	18.8%	55.3%	Quality assessment:
	Other	Risk factors (n [%]):	NR	NPV	95.6%	90.7%	100.0%	Reference standard: +
	Referral series	NR						Verification bias: -, only 99 womer
	Defense of a dead	In close to a contract.	Additional data used for			nd postme	nopausal	had histopathol of 377 women with
	Reference standard:	Inclusion criteria:	diagnosis:	patient	S			adnexal masses at US
	Histopathology	Women with diagnosis of	NR					Test reliability/variability: +
	Reference standard	mass referred for surgery			Dis+	Dis-	Tot	Sample size: -
		Evolucion esiteria.		T+	8		17	Statistical tests: +
	applied to all test	Exclusion criteria:		T-	3	22	25	Blinding: +
	negatives?:	Studies done not in first 10		Tot	11	31	42	Definition of +/- on screening test: for PI
	No	days after menstruation in						101 P1
	Test reliability	premenopausal women (to				Lower	Upper	
	Test reliability established?:	avoid luteal phase) PI that couldn't be			Value	95% CI	95% CI	
				Se	72.7%	46.4%	99.0%	
	US – probably Sassone PI yes	measured due to no flow (present in 7 masses)		Sp	71.0%	55.0%	86.9%	
	FT yes	(present in / masses)		PPV	47.1%	23.3%	70.8%	
	Statistical tests used:			NPV	88.0%	75.3%	100.0%	
	Se, Spec			3) PI <	: 1, preme	nopausal j	patients	
	Blinding:							
	Yes				Dis+	Dis-	Tot	
	1 62			T+	2	8	10	
				Т-	0	43	43	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	Definition of positive	Definition of positive and negative on	Tot	2	51	53		
	screening test:					Lower	Upper	
	Pulsatility index (PI) =				Value	95% CI	95% CI	
	(PSV-EDV)/mean			Se	100.0%	0.0%	100.0%	
	velocity. Considered			Sp	84.3%	74.3%	94.3%	
	positive if < 1.			PPV	20.0%	0.0%	44.8%	
				NPV	100.0%	93.0%	100.0%	
				4) PI <	< 1, age >	45 years		
					Dis+	Dis-	Tot	
				T+	8	3	11	
				T-	9	22	31	
				Tot	17	25	42	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	47.1%	23.3%	70.8%	
				Sp	88.0%	75.3%	100.0%	
				PPV	72.7%	46.4%	99.0%	
				NPV	71.0%	55.0%	86.9%	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
Sassone, Timor- Tritsch,	Geographical location: New York, NY	Age: Mean: 41.6 Median: 41	Symptomatic (n [%]) : NR	1) Sassone ≥ 9 Dis+ Dis- Tot				Comments: This is the original article describing the Sassone scoring
Artner, et al., 1991	Dates: Jun 1987 – Dec 1989	Range: 20-85	Detected by exam (n [%]): NR	T+ T-	13 0	22 108	35 108	system – good description of criteria with photos
#6780	Size of population: 143 women	Menopausal status (n [%]): Pre (< 45): 116(80.4%) Post (> 55): 24(16.8%)	Detected by imaging (n [%]): NR	Tot	13 Value	130 Lower 95% Cl	143 Upper 95% CI	Borderline tumors grouped in with benign No mention of clinical pathway of patients
	Retrospective case series	3 unknown secondary to hysterectomy (2.1%)	Combination (n [%]):	Se Sp	100.0% 83.0%	76.9% 76.5%	100.0% 89.5%	TVUS only Quality assessment:
	Reference standard: Histopathology	Race/ethnicity (n [%]) : NR	Additional data used for diagnosis:	PPV NPV	37.1% 100.0%	21.1% 97.2%	53.2% 100.0%	Reference standard: + Verification bias: + Test reliability/variability: +/-
	Reference standard applied to all test negatives?:	Risk factors (n [%]): NR	NR					Sample size: - Statistical tests: + Blinding: +
	Yes	Inclusion criteria: All laparotomy performed						Definition of +/- on screening test: +
	Test reliability established?: No	for gynecologic indications in hospital in time frame						
	Statistical tests used: Se, Sp Correlation coefficient for US and pathology	Exclusion criteria: Pregnancy Previous BSO Previous treated carcinoma						
	Blinding: Yes							
	Definition of positive and negative on screening test: Sassone ≥ 9							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Sawicki, Spiewan-	Geographical location: Warsaw, Poland	arsaw, Poland Range: 15-88 NR	1) TVUS, morphology only	Comments: Clinical presentation not described	
kiewicz,		Mean for patients with		Dis+ Dis- Tot	Unclear how Doppler is being
Cendrowski,	Dates: NR	benign lesions: 42.6	Detected by exam (n [%]):	T+ 64 83 147	compared to morphology—
et al., 2001		(12.3)	NR	T- 10 172 182	independently or as adjunct
	Size of population:	Mean for patients with		Tot 74 255 329	Unclear what was included in
#2450	329 women	malignant lesions: 53.1	Detected by imaging		"Doppler" measurement – RI,
		(12.6)	(n [%]):	Lower Upper	vascularization, and "a subjective
	Other		NR	Value 95% CI 95% CI	semiquantitative assessment of the
	Case series	Menopausal status		Se 86.5% 78.7% 94.3%	amount of blood flow (area and color
		(n [%]):	Combination (n [%]):	Sp 67.5% 61.8% 73.2%	scale)" within lesion
	Reference standard:	NR	NR	PPV 43.6% 35.6% 51.6%	
	Surgery/pathology			NPV 94.5% 91.2% 97.8%	Quality assessment:
		Race/ethnicity (n [%]):	Additional data used for		Reference standard: +
	Reference standard	NR	diagnosis:	Color Doppler (unclear if test	Verification bias:+
	applied to all test		Premenopausal US on day	characteristics calculated based on Doppler	Test reliability/variability: -
	negatives?:	Risk factors (n [%]):	7-8	alone, or Doppler plus morphology)	Sample size: - (formal statistical
	Yes	NR			testing of differences in test
			Stage I: 20/74 (27%)	Dis+ Dis- Tot	characteristics, but no discussion of
	Test reliability	Inclusion criteria:	Stage II: 9/74 (12.2%)	T+ 69 14 83	Statistical tests: - (basis of
	established?:	NR	Stage III: 42/74 (56.7%)	T- <u>5 241</u> 246	comparison not described)
	Not referenced or		Stage IV: 3/74 (4.1%)	Tot 74 255 329	Blinding:
	discussed	Exclusion criteria:			Definition of +/- on screening test:
		NR		Lower Upper	- (resistive index threshold given,
	Statistical tests used:			Value 95% CI 95% CI	but not clear how other parameters
	Chi-square, Fishers's			Se 93.2% 87.5% 98.9%	used)
	exact test, Mann-			Sp 94.5% 91.7% 97.3%	
	Whitney, t-test, Se/Sp			PPV 83.1% 75.0% 91.2%	
				NPV 98.0% 96.2% 99.7%	
	Blinding:				
	Not described				
	Definition of positive				
	and negative on				
	screening test:				
	Gray-scale ultra				
	sound:				
	(Sassone's criteria)				
	Solid or mixed				
	solid/cystic				
	Faded borders				
	 Septae > 3 mm 				
	 Solid papillary 				
	projections into cyst				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	cavity > 3 mm • > 50 mm free fluid in cul de sac	n free fluid in			
	Color Doppler: RI < 0.5 Other criteria included presence of "intense" angiogenesis within septae or solid parts of tumor, but unclear how this was used in determining benign vs malignant				
Schelling, Braun, Kuhn, et al.,	Geographical location: Munich, Germany	Age: NR	Symptomatic (n [%]): NR	 Ultrasound (any solid component = positive), all patients 	Comments: Clinical presentation not described Criteria for selecting cases not
2000	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 38 42 80	described For model development – with N =
#2770	Size of population: 63 in development set; 257 in validation set	Pre (< 45): 166 (64.6%) Post (> 55): 91 (35.4%)	Detected by imaging (n [%]):	T- 1 176 177 Tot 39 218 257	65 can you have 12 variables in predictive model and still be stable/valid? Too many variables fo
	Other	Race/ethnicity (n [%]): NR	NR	Lower Upper Value 95% CI 95% CI	a predictive model (including also the Doppler variables(9 additional
	Development and validation	Risk factors (n [%]): NR	Combination (n [%]): NR	Se 97.4% 92.5% 100.0% Sp 80.7% 75.5% 86.0%	variables)?
	Reference standard: Surgery/pathology	Inclusion criteria:	Additional data used for diagnosis: NR	PPV 47.5% 36.6% 58.4% NPV 99.4% 98.3% 100.0%	Quality assessment: Reference standard: + Verification bias:+ Test reliability/variability: -
	Reference standard applied to all test	Exclusion criteria:		2) Ultrasound, any solid component, premenopausal	Sample size: - Statistical tests: +
	negatives?: Yes	History of malignancy		Dis+ Dis- Tot T+ 10 25 35 T- 1 130 131	Blinding: + Definition of +/- on screening test: +
	Test reliability established?: Discussed			Tot 11 155 166 Lower Upper	
	Statistical tests used: Logistic regression for development; Se/Sp for validation			Value 95% Cl 95% Cl Se 90.9% 73.9% 100.0% Sp 83.9% 78.1% 89.7% PPV 28.6% 13.6% 43.5% NPV 99.2% 97.7% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Blinding: Yes		 Utrasound, any solid component, postmenopausal 		
	Definition of positive and negative on screening test: Solid component on morphology, presence o central vascularization o Doppler	f n		Dis+ Dis- Tot T+ 28 17 45 T- 0 46 46 Tot 28 63 91 Lower Upper Value 95% CI 95% CI Se 100.0% 89.3% 100.0%	
				Sp 73.0% 62.1% 84.0% PPV 62.2% 48.1% 76.4% NPV 100.0% 93.5% 100.0% 4) Central vascularity on Doppler in solid	
				Dis+ Dis- Tot T+ 36 14 50 T- 3 204 207 Tot 39 218 257	
				ValueLower 95% CIUpper 95% CISe92.3%83.9%100.0%Sp93.6%90.3%96.8%PPV72.0%59.6%84.4%NPV98.6%96.9%100.0%	
				5) Central vascularity on Doppler in solid component, premenopausal	
				Dis+ Dis- Tot T+ 10 9 19 T- 1 146 147 Tot 11 155 166	
				LowerUpper 95% CISe90.9%73.9%100.0%Sp94.2%90.5%97.9%PPV52.6%30.2%75.1%NPV99.3%98.0%100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				6) Central vascularity on Doppler in solid component, postmenopausal	
				Dis+ Dis- Tot	
				T+ 26 5 31	
				T- 2 58 60	
				Tot 28 63 91	
				Lower Upper Value 95% CI 95% CI	
				Se 92.9% 83.3% 100.0%	
				Sp 92.1% 85.4% 98.7%	
				PPV 83.9% 70.9% 96.8%	
				NPV 96.7% 92.1% 100.0%	
Schneider.	Geographical location:	Age:	Symptomatic (n [%]):	1) RI ≤ 0.8	Comments:
Schneider,	Arizona, USA	Mean: 53	NR	.,	RI cutoff calculated from this data
Reed, et al.,	Academic Center	Median: 53		Dis+ Dis- Tot	(not prospective)
1993		Range: 10-79	Detected by exam (n [%]):	T+ 15 17 32	RI ≤ 0.8 not uniform in literature
	Dates: NR		NR	T- 1 22 23	(1.0)
#4830		Menopausal status		Tot 16 39 55	
	Size of population:	(n [%]):	Detected by imaging		Quality assessment:
	55 women	Pre: 22 (40%)	(n [%]):	Lower Upper	Reference standard: +
		Post: 33 (60%)	All patients had ultrasound	Value 95% CI 95% CI	Verification bias: +
	Other		finding of adnexal mass	Se 93.8% 81.9% 100.0%	Test reliability/variability:
	"Cross-sectional" referral	Race/ethnicity (n [%]):		Sp 56.4% 40.8% 72.0%	+ for CA-125 and Sasonne
		NR	Combination (n [%]):	PPV 46.9% 29.6% 64.2%	? for other US
	Reference standard:		NR	NPV 95.7% 87.3% 100.0%	Sample size: -
	Histopathology	Risk factors (n [%]):			Statistical tests: +
	Defense of a dead	NR	Additional data used for	Granberg et al method US	Blinding: +
	Reference standard	In alwais a suitaria.	diagnosis:		Definition of +/- on screening test:
	applied to all test	Inclusion criteria: Women referred to	NR	Dis+ Dis- Tot	+/-
	negatives?: Yes	OB/Gyn department with		T+ 14 6 20	
	100	diagnosis of mass and		T- 2 33 35	
	Test reliability	scheduled for surgery		Tot 16 39 55	
	established?:	already			
	Yes Sasonne	ancady		Lower Upper	
	? Granberg	Exclusion criteria:		Value 95% CI 95% CI	
	RI - yes	NR		Se 87.5% 71.3% 100.0%	
				Sp 84.6% 73.3% 95.9%	
	Statistical tests used:			PPV 70.0% 49.9% 90.1%	
				NPV 94.3% 86.6% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Se, Sp	e, Sp			
				3) Sasonne (cut off 9)	
	Blinding:				
	Yes			Dis+ Dis- Tot	
				T+ 14 10 24	
	Definition of positive			T- 2 29 31	
	and negative on			Tot 16 39 55	
	screening test:				
	Sasonne's score			Lower Upper	
	Granberg [5] method of 2D US			Value 95% CI 95% CI	
	20 03 RI ≤ 0.8			Se 87.5% 71.3% 100.0%	
	CA-125 > 35 U/ml			Sp 74.4% 60.7% 88.1%	
	CA-123 > 55 0/11			PPV 58.3% 38.6% 78.1%	
				NPV 93.5% 84.9% 100.0%	
				4) CA-125 > 35 U/ml	
				Dis+ Dis- Tot	
				T+ 12 6 18	
				T- 4 33 37	
				Tot 16 39 55	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 75.0% 53.8% 96.2%	
				Sp 84.6% 73.3% 95.9%	
				PPV 66.7% 44.9% 88.4%	
				NPV 89.2% 79.2% 99.2%	

Study	Study Design	Patients	Clinical Presentation	Results	5			Comments/Quality Scoring
Schutter, Davelaar, van Kamp,	Geographical location: Amsterdam and Enschede, The	Age: NR	Symptomatic (n [%]) : NR	 CA-125, ovarian cancer vs benign ovarian mass, threshold = 35 u/mL 				Comments: Clinical presentation not described
et al., 2002	Netherlands	Menopausal status	Detected by exam (n [%]) : NR	т. Г	Dis+	Dis-	Tot 143	Quality assessment: Reference standard: +
#2160	Dates: Nov 1990-Dec 1992	(n [%]): NR		T+ T-	108 25	35 94	119	Verification bias: +
		Race/ethnicity (n [%]):	Detected by imaging (n [%]):	Tot	133	129	262	Test reliability/variability:+ Sample size: -
	Size of population: 511; serum available for	NR	NR	_	Value	Lower 95% Cl	Upper 95% CI	Statistical tests: Blinding: +
	412	Risk factors (n [%]): NR	Combination (n [%]): NR	Se Sp	81.0% 73.0%	74.3% 65.3%	87.7% 80.7%	Definition of +/- on screening test: +
	Other Serum bank	Inclusion criteria: NR	Additional data used for diagnosis:		75.6% 78.8%	68.5% 71.5%	82.6% 86.2%	
	Reference standard: Surgery/pathology	Exclusion criteria:	NR			an cancer eshold = 5		
	Reference standard applied to all test			T+ [Dis+ 102	Dis- 23	Tot 126	
	negatives?: Yes			T- Tot	31 133	106 129	136 262	
	Test reliability established?: Yes				Value	Lower 95% CI	Upper 95% CI	
	Statistical tests used: Se/Sp; logistic regression				77.0% 82.0% 81.5%	69.8% 75.4% 74.7%	84.2% 88.6% 88.3%	
	Blinding: Yes						84.6% vs benign ma	ass,
	Definition of positive and negative on			т+ Г	Dis+ 82	Dis-	Tot 91	
	screening test: Varied; "optimal" cutpoints			T- Tot	51 133	120 129	171 262	
	CA-125: 57 u/mL CA-15-3: 26 u/mL CA-724: 3.5 u/mL			_	Value	Lower 95% Cl	Upper 95% CI	
				Se Sp PPV	62.0% 93.0% 90.1%	53.8% 88.6% 84.0%	70.2% 97.4% 96.2%	
					70.4%	63.5%	77.2%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				4) CA-724, Ovarian cancer vs benign ovarian mass, threshold = 3.5 u/mL	
				Dis+ Dis- Tot T+ 84 18 102 T- 49 111 160 Tot 133 129 262	
				ValueLower 95% ClUpper 95% ClSe63.0%54.8%71.2%Sp86.0%80.0%92.0%PPV82.3%74.9%89.7%NPV69.3%62.1%76.4%	
				5) CA-125, all malignancy vs all benign, threshold = 35 u/mL	
				Dis+ Dis- Tot T+ 136 41 177 T- 90 130 220 Tot 226 171 397	
				ValueUpper 95% CIUpper 95% CISe60.0%53.6%66.4%Sp76.0%69.6%82.4%PPV76.8%70.5%83.0%NPV59.0%52.5%65.5%	
				 CA-125, all malignancy vs all benign, threshold = 57 u/mL 	
				Dis+ Dis- Tot T+ 118 27 145 T- 108 144 252 Tot 226 171 397	
				Lower Upper 95% CI 95% CI Se 52.0% 45.5% Sp 84.0% 78.5% PPV 81.1% 74.7% 87.5% NPV 57.0% 50.9% 63.1%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				 CA 15-3, all malignancy vs all benign, threshold = 26 u/mL 	
				Dis+ Dis- Tot T+ 106 15 122 T- 120 156 275 Tot 226 171 397	
				LowerUpper 95% CISe47.0%40.5%53.5%Sp91.0%86.7%95.3%PPV87.3%81.4%93.3%NPV56.5%50.7%62.4%	
				8) CA-724, all malignancy vs all benign, threshold = 3.5 U/mL	
				Dis+ Dis- Tot T+ 118 27 145 T- 108 144 252 Tot 226 171 397	
				Lower Upper 95% CI 95% CI Se 52.0% 45.5% Sp 84.0% 78.5% PPV 81.1% 74.7% 87.5% NPV 57.0% 50.9% 63.1%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Schutter, Kenemans, Sohn, et al., 1994	Geographical location: Amsterdam, The Netherlands; and Heidelberg, Koln,	Age: Mean: 63 Range: 45-88	Symptomatic (n [%]): NR Detected by exam (n [%]):	Borderline tumors (n = 6) not included 1) CA-125 > 35 U/ml	Comments: Clinical presentation not described (symptoms vs. no symptoms)
#940	Wurzburg, and Ulm, Germany Dates: Nov 1990-Dec 1992	Menopausal status (n [%]): 100% postmenopausal Race/ethnicity (n [%]):	199 (87.3%) Detected by imaging (n [%]): 28 (12.7%)	Dis+ Dis- Tot T+ 68 25 93 T- 27 102 129 Tot 95 127 222	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: + (95% Cl's given)
	Size of population: 276; 48 excluded (13 45 years old or less, 16 not amenorrheic for 12 months, 4 no path dx, 14 additional malignancy, 10 indeterminate pelvic exam, 3 no preop CA- 125), for total of 228 Other Multicenter, prospective.		Combination (n [%]): NR Additional data used for diagnosis: Stage distribution: I: 16/72 (22.2%) II: 7/72 (9.7%) III: 34/72 (47.2%) IV: 15/72 (20.8%)	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Statistical tests: + Blinding: - Definition of +/- on screening test: -
	patients referred for pelvic mass Reference standard: Surgery/pathology	Exclusion criteria: NR		Tot 95 127 222 Lower Upper Value 95% Cl 95% Cl Se 88.4% 82.0% 94.9%	
	Reference standard applied to all test negatives?: Yes			Sp 63.8% 55.4% 72.1% PPV 64.6% 56.4% 72.8% NPV 88.0% 81.4% 94.7%	
	Test reliability established?: Not referenced or discussed				
	Statistical tests used: Se/Sp; logistic regression				
	Blinding: No				
	Definition of positive				

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	and negative on screening test: Ultrasound: Positive if multiseptated or irregular cystic mass "consistent in appearance with ovarian tumor; or presence of ascites CA-125: > 35 U/mL							
Schutter, Sohn,	Geographical location: Germany	Age: Mean: 63	Symptomatic (n [%]) : NR	1) PE				Comments: Borderline tumors (n = 4) omitted
Kristen, et	-	Median: 61			Dis+	Dis-	Tot	from 2x2 tables by authors
al., 1998	Dates: NR	Range: 45-88	Detected by exam (n [%]):	T+	54	24	78	Note "semi-quantitative
			NR	Т-	5	68	73	parameters" of Finkler scoring
#730	Size of population:	Menopausal status		Tot	59	92	151	system
	155 women	(n [%]): Post (> 55): 155 (100%)	Detected by imaging (n [%]):			Lauran	Linner	Finkler scoring system? variable
	Other	1 USt (2 33). 133 (100 %)	NR		Value	Lower	Upper	Quality assessment:
	Unclear	Race/ethnicity (n [%]):		0.	Value	95% CI	95% CI	Reference standard: +
	Officieal	NR (assume 100% white)	Combination (n [%]):	Se	91.5%	84.4%	98.6%	Verification bias: - unclear how
	Reference standard:		NR	Sp PPV	73.9% 69.2%	64.9%	82.9% 79.5%	many negatives didn't have surgery
	Histology	Risk factors (n [%]):		NPV	69.2% 93.2%	59.0% 87.4%	79.5% 98.9%	Test reliability/variability: + for PE,
	Thotology	NR	Additional data used for	NPV	93.2%	87.4%	98.9%	U/S, CA-125
	Reference standard		diagnosis:	2) US				Sample size: -
	applied to all test	Inclusion criteria:	NR	2) 03				Statistical tests: +
	negatives?:	NR (see citation 25)			Dis+	Dis-	Tot	Blinding: -
	Yes	(T+	51	28	79	Definition of +/- on screening test:
		Exclusion criteria:		T-	8	64	72	Ũ
	Test reliability	NR		Tot	59	92	151	
	established?:			101	55	52	151	
	For pelvic exam – No					Lower	Upper	
	CA-125 – Yes				Value	95% CI	95% CI	
	CA-72-4 - ? (mostly in			Se	86.4%	77.7%	95.2%	
	gastric CA) they set own			Sp	69.6%	60.2%	79.0%	
	cutoff point here			PPV	64.6%	54.0%	75.1%	
	US - Yes			NPV	88.9%	81.6%	96.1%	
	Statistical tests used: Chi-square			3) CA-	125 ≥ 35 (J/ml		
	ROC				Dis+	Dis-	Tot	
	Logistic regression			T+	41	15	56	
	Blinding:			T-	18	77	95	
	No			Tot	59	92	151	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Definition of positive and negative on screening test: Table 1 Exam – clinical impression of malignancy US – Finkler Score 7-10 CA-125 - ≥ 35 U/ml			ValueLowerUpper95% CI95% CISe69.5%57.7%81.2%Sp83.7%76.1%91.2%PPV73.2%61.6%84.8%NPV81.1%73.2%88.9%	
Scoutt, McCarthy, Lange, et al., 1994	Geographical location: New Haven, CT Dates: 1988-1990	Age: Median: 40 Range: 2-87	Symptomatic (n [%]): NR Detected by exam (n [%]):	 Data provided for mass, not patient MRI, malignant vs. benign; threshold for positive MR = indeterminate or malignan 	Comments: Clinical presentation not described Length of followup not described
#4530	Size of population: 103 patients with 121 masses; data provided on 120 Other Case series Reference standard: Surgery Reference standard applied to all test negatives?: No; 11 with "classic" leiomyomas, 2 with "no mass' Test reliability established?: Not referenced or discussed Statistical tests used: Se/Sp Blinding: Yes	Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: NR Exclusion criteria: NR	Detected by exam (ii [%]). NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Dis+ Dis- Tot 1 11 32 88 81 10 Value 95% Cl 95% Cl 95 86.8% 100.0% Sp 88.8% 82.5% 95.0% PPV 65.6% 49.2% 82.1% NPV 98.9% 96.6% 100.0%	Quality assessment: Reference standard: - Verification bias: - Test reliability/variability: - Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: +
	Definition of positive				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	and negative on screening test: Malignancy: solid or highly complex, mural nodules, septations > 3 mm, ascites.	screening test: Malignancy: solid or highly complex, mural nodules, septations > 3			
	Indeterminate if not definitely benign or malignant				
Sengoku, Satoh, Saitoh, et al., 1994	Geographical location: Asahikawa, Japan Dates: Apr 1991-May	Age: Mean (SD): 49 (15) Range: 19-80	Symptomatic (n [%]): NR Detected by exam (n [%]):	1) CA-125 > 35 U/ml, benign vs malignant <u>Dis+ Dis-</u> Tot T+ 13 3 16	Comments: Clinical presentation not described Small numbers No description of where PI < 1.5
al., 1994 #4390	1992	Menopausal status (n [%]):	NR	T+ 13 3 16 T- 3 9 12 Tot 16 12 28	comes from
	Size of population: 28 women	Pre (< 45): 17 (60.7%) Post (> 55): 11 (39.3%)	Detected by imaging (n [%]): NR	Lower Upper	Quality assessment: Reference standard: + Verification bias: +
	Other Case series	Race/ethnicity (n [%]): NR	Combination (n [%]):	Value 95% Cl 95% Cl Se 81.3% 62.1% 100.0% Sp 75.0% 50.5% 99.5% PPV 81.3% 62.1% 100.0%	Test reliability/variability: + Sample size: - Statistical tests: +
	Reference standard: Surgery/pathology	Risk factors (n [%]): NR	Additional data used for diagnosis:	NPV 75.0% 50.5% 99.5% 2) Ultrasound morphology	Blinding:- Definition of +/- on screening test: +
	Reference standard applied to all test negatives?:	Inclusion criteria: NR	NR	Dis+ Dis- Tot T+ 13 4 17	
	Yes	Exclusion criteria: NR		T- <u>3</u> 8 11 Tot 16 12 28	
	Test reliability established?: Discussed			Lower Upper Value 95% CI 95% CI	
	Statistical tests used: Se/Sp, t-test			Se 81.3% 62.1% 100.0% Sp 66.7% 40.0% 93.3% PPV 76.5% 56.3% 96.6%	
	Blinding: No			NPV 72.7% 46.4% 99.0% 3) Pulsatility index < 1.5	
	Definition of positive and negative on			Dis+ Dis- Tot T+ 13 1 14	
	screening test: Ultrsound morphology			T- <u>3 11</u> 14	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	Sassone system (referenced, not described) Pulsatility index: < 1.5 CA-125> > 35	(referenced, not described) Pulsatility index: <1.5	Tot Se Sp PPV NPV	16 Value 81.3% 91.7% 92.9% 78.6%	12 Lower 95% CI 62.1% 76.0% 79.4% 57.1%	28 Upper 95% CI 100.0% 100.0% 100.0%		
Shabana and Onsrud, 1994 #4400	Geographical location: Trondheim, Norway Dates: NR Size of population: 85 women Other – Case control Three groups compared in terms of serum markers:33 with ovarian Ca, 26 with benign pelvic masses, and 26 with normal pelvis Reference standard: Histopathology for all but those with "normal pelvis" which was assessed at laparoscopy Reference standard applied to all test negatives?: Yes Test reliability established?: Yes for CA-125 Statistical tests used: Se, Sp, ROC	Inclusion criteria: NR Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) CA- T+ T- Tot Se Sp PPV NPV	125 > 25 Dis+ 26 4 30 Value 86.7% 92.3% 92.9% 85.7%	U/ml Dis- 24 26 Lower 95% CI 74.5% 82.1% 83.3% 72.8%	Tot 28 28 56 Upper 95% CI 98.8% 100.0% 100.0% 98.7%	Comments: Not prospective data Only 26 with benign pelvic masses included in analysis – no discussion of this in text. CA-125 cutoff – 25 – not discussed in text Unclear how the three groups chosen Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: -

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	Blinding: NR				
	Definition of positive and negative on screening test: CA-125 > 25 U/ml				
Siegel, Dehdashti, Mutch, et al., 2003 #1960	Geographical location: St Louis, MO; Houston, TX; Indianapolis, IN; Dates: NR Size of population: 35; 2 did not undergo surgery Other Validation Reference standard: Surgery Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: Se/Sp Blinding: Yes Definition of positive and negative on screening test: "Focal increased uptake of radiotracer at sites not	Age: Mean: 55 Range: 31-78 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: NR Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) Results provided only for newly diagnosed pelvic masses (n = 26) Borderline excluded (faint uptake by 1 reader, none by other) T+ <u>T</u> <u>10</u> <u>14</u> <u>11</u> Tot <u>7</u> <u>18</u> <u>25</u> <u>Value 95% Cl 95% Cl</u> Se <u>100.0% 57.1% 100.0%</u> Sp <u>77.8% 58.6% 97.0%</u> PPV 63.6% <u>35.2% 92.1%</u> NPV 100.0% 78.6% 100.0% Specificity increased to 82% when re-read with clinical information available	Comments: Clinical presentation not described Not a commonly used test modality Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	corresponding to obvious normal anatomic structures"				
Smikle, Lunt, and Hankins, 1995 #6290	Geographical location: USA Dates: Jun 1990 – Aug 1992 Size of population: 195 Retrosceptive case series Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: Fisher exact test Blinding: NR Definition of positive and negative on screening test: CA-125 >= 35 U/ml	Age: Those with benign lesions: mean age – 45 (14.7) Those with malignant lesions: mean – 56.9 (13.9) Menopausal status (n [%]): Not clear for those for whom CA-125 was available (n = 100) 50 were > 50 years old and 50 were <=50 Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Chart review of all cases with operative reports of "rule-out malignancy" "pelvic mass" "adnexal mass" in time frame Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) CA-125 >= 35 U/ml in postmenopausal women (age >50) T+ $11 26 37$ T- 2 32 34 Tot 13 58 71 Lower Upper Value 95% Cl 95% Cl Se 84.6% 65.0% 100.0% Sp 55.2% 42.4% 68.0% PPV 29.7% 15.0% 44.5% NPV 94.1% 86.2% 100.0% 2) CA-125 in women <= 50 T+ $2 12$ 14 T- $0 36$ 36 Tot 2 48 50 Lower Upper Value 95% Cl 95% Cl Se 100.0% -50.0% 100.0% Sp 75.0% 62.8% 87.3% PPV 14.3% 0.0% 32.6% NPV 100.0% 91.7% 100.0% 3) CA-125 for all women combined T+ $13 17$ 30 T- $2 68$ 70 Tot 15 85 100 Lower Upper Value 95% Cl 95% Cl Se 86.7% 69.5% 100.0% Sp 80.0% 71.5% 88.5%	Comments: Borderline tumors grouped in with malignant Of 195 charts identified, only 100 had CA-125 levels for analysis State that platelet count failed to distinguish benign from malignant, however, data not reported such that could be included in meta-analysis Not recorded whether TVUS or abdominal US done Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: +/- Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Sohaib, Mills, Sahdev, et	Geographical location : UK	Age: Mean: 53 Range: 19-86	Symptomatic (n [%]): NR	PPV 43.3% 25.6% 61.1% NPV 97.1% 93.2% 100.0% 1) US Dis+ Dis- Tot	Comments: Borderline tumors grouped in with malignant
al., 2005 #7430	Dates: NR Size of population:	Menopausal status (n [%]):	Detected by exam (n [%]): NR	T+ <u>29 26</u> 55 T- 0 17 17	Se, Sp reported for CA-125 , however, no mention of what cutpoint used was in article, and no
	Size of population. 89, however only data for 72 Prospective case series Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: ROC curves Student's t-test Mann-Whitney U test Chi square	NR Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	eutpoint used was in anole, and no enough raw data for extraction – authors do state, however, that that MRI performed better than US in cases with normal levels of CA-125 - TVUS done in 65/72 cases – unable to stratify results Quality assessment: Reference standard:+ Verification bias:+ Test reliability/variability: + Sample size: - Statistical tests: + Blinding: + Definition of +/- on screening test:
	Blinding: Yes Definition of positive and negative on screening test: US – morphology and RI and PI were noted and a "subjective assessment was made as to whether each mass was benign or				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	assigned to groups: 1) benign, 2) probably benign, 3) possibly malignant, 4) probably malignant, 5) malignant For Se and Sp calcs, groups 1 and 2 were evaluated together as were 3, 4, 5. MRI – classified into malignant or benign by radiologist "impression" and into same 5 categories.				
Soper, Hunter,	Geographical location: Durham, NC	Age: NR	Symptomatic (n [%]) : NR	1) CA-125—All malignancies, > 35 U/mL as threshold	Comments: Unclear if this represents all patients with adnexal mass
Daly, et al., 1990	Dates: Jan 1985-Jan 1986	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 38 14 52	Clinical presentation not describe Borderline tumors included with
#6590	Size of population: 100 women	NR Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR	T- <u>16 32</u> 48 Tot 54 46 100	malignant Quality assessment: Reference standard: +
	Other Single center Prospective series	Risk factors (n [%]): NR	Combination (n [%]):	Lower Upper Value 95% CI 95% CI Se 70.4% 58.2% 82.5% Sp 69.6% 56.3% 82.9%	Verification bias: + Test reliability/variability: + Sample size: -
	Reference standard: Pathology	Inclusion criteria: "Diagnostic laparotomy for	Additional data used for	Sp 69.0% 50.3% 62.9% PPV 73.1% 61.0% 85.1% NPV 66.7% 53.3% 80.0%	Statistical tests: - Blinding: - Definition of +/- on screening test:
	Reference standard applied to all test	pelvic mass" Exclusion criteria:	NR	2) CA-125—ovarian cancer, > 35 U/mL as threshold	N/AS
	negatives?: Yes	NR		Dis+ Dis- Tot T+ 38 22 60	
	Test reliability established?:			T- 4 36 40 Tot 42 58 100	
	Yes (reference) Statistical tests used: NR			Lower Upper <u>Value 95% Cl 95% Cl</u> Se 90.5% 81.6% 99.4%	
	Blinding: Assays done after			Sp 62.1% 49.6% 74.6% PPV 63.3% 51.1% 75.5% NPV 90.0% 80.7% 99.3%	

Study	Study Design	udy Design Patients Clinical Presentation		Results	Comments/Quality Scoring
	surgery Definition of positive		 CA-125—All malignancies, > 65 U/ml as threshold 		
	and negative on screening test:			Dis+ Dis- Tot T+ 42 8 50 T- 12 38 50 Tot 54 46 100	
				ValueLower 95% CIUpper 95% CISe77.8%66.7%88.9%Sp82.6%71.7%93.6%PPV84.0%73.8%94.2%NPV76.0%64.2%87.8%	
				4) CA-125Ovarian cancer, > 65 U/ml as threshold	
				Dis+ Dis- Tot T+ 35 15 50 T- 7 43 50 Tot 42 58 100	
				LowerUpper 95% CISe83.3%72.1%94.6%Sp74.1%62.9%85.4%PPV70.0%57.3%82.7%NPV86.0%76.4%95.6%	
				5) TAG-72Ovarian cancer	
				Dis+ Dis- Tot T+ 21 4 25 T- 21 54 75 Tot 42 58 100	
				LowerUpper 95% CISe50.0%34.9%65.1%Sp93.1%86.6%99.4%69.6%PPV84.0%69.6%98.4%NPV72.0%61.8%82.2%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				6) CA-15-3—Ovarian cancer	
				Dis+ Dis- Tot T+ 23 11 34 T- 19 47 66 Tot 42 58 100	
				Lower Upper 95% CI 95% CI Se 54.8% 39.7% 69.8% Sp 81.0% 70.9% 91.1% PPV 67.6% 51.9% 83.4% NPV 71.2% 60.3% 82.1% Results not reported separately, but CA-125 > 65 sensitivity of 79%, specificity of 86% in patients > 50.	
Stein, Laifer-Narin,	Geographical location: Los Angeles, CA	Age: NR	Symptomatic (n [%]): NR	1) Ultrasound morphology (transvaginal in all but 23)	Comments: Denominator should include those
Johnson, et al., 1995 #4280	Dates: Jul 1992-Feb 1993	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 46 47 93	excluded because of findings Results not presented by menopausal status
+4200	Size of population: 161 patients, 170	Pre (< 45):114 (70.8%) Post (> 55): 39 (24.2%) 8 (4.9%) post	Detected by imaging (n [%]):	T- 1 76 77 Tot 47 123 170	Analysis, 2x2 tables done for masses not patients
	masses Other	hysterectomy Race/ethnicity (n [%]):	NR Combination (n [%]):	Lower Upper Value 95% CI 95% CI Se 97.9% 93.7% 100.0%	Quality assessment: Reference standard: Verification bias: -
	Single center series Reference standard:	NR Risk factors (n [%]):	NR Additional data used for	Sp 61.8% 53.2% 70.4% PPV 49.5% 39.3% 59.6%	Test reliability/variability: + Sample size: + Statistical tests:+
	Surgery/pathology	NR	diagnosis: NR	2) Color Doppler-internal flow within solid	Blinding: - Definition of +/- on screening test:
	Reference standard applied to all test negatives?:	Inclusion criteria: NR		component or septation Dis+ Dis- Tot	
	Yes	Exclusion criteria: Premenopausal with		T+ 36 38 74 T- 11 85 96	
	Test reliability established?: References provided	simple or hemorrhagic cysts that resolved on followup, or if examined on		Tot 47 123 170	
	Statistical tests used:	any day other than days 3- 10 of menstrual cycle;		Lower Upper <u>Value 95% Cl 95% Cl</u> Se 76.6% 64.5% 88.7%	

Sp 69.1% 60.9% 77.3% PPV 48.6% 37.3% 60.0% NPV 88.5% 82.2% 94.9%
3) Spectral Doppler—pulsatility index < 1.0
Dis+ Dis- Tot T+ 31 42 73
T- <u>16 81</u> 97 Tot 47 123 170
Lower Upper Value 95% CI 95% CI
Se 67.0% 53.6% 80.4% Sp 66.0% 57.6% 74.4%
PPV 42.5% 31.1% 53.8% NPV 83.5% 76.1% 90.9%
4) Spectral Doppler—resistive index < 0.4
Dis+ Dis- Tot T+ 11 12 23
T- <u>36 111</u> 147 Tot 47 123 170
Lower Upper Value 95% CI 95% CI
Value 55 // 61 55 // 61 Se 23.4% 11.3% 35.5% Sp 90.2% 85.0% 95.5%
PPV 47.8% 27.4% 68.2% NPV 75.5% 68.6% 82.5%

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Strigini, Gadducci, Del Bravo,	Geographical location: Pisa, Italy	Age: Median: 43 Range: 18-80	Symptomatic (n [%]): NR	1) Ultrasound: Premenopausal Dis+ Dis- Tot	Comments: Clinical presentation not described Unclear how many excluded by
et al., 1996	Dates: Jan 1993-June 1994	Menopausal status	Detected by exam (n [%]): NR	T+ 6 2 8 T- 0 67 67	resolution on serial scans US criteria descriptive – not
#4000	Size of population: 109 women	(n [%]): Pre (< 45): 75 (69%) Post (> 55): 34 (31%)	Detected by imaging (n [%]):	Tot 6 69 75 Lower Upper	reproducible? – no discussion of variability of interpretation
	Other Case series	Race/ethnicity (n [%]): NR	NR Combination (n [%]):	Value 95% Cl 95% Cl Se 100.0% 40.0% 100.0% Sp 97.1% 93.1% 100.0%	Quality assessment: Reference standard: + Verification bias: -
	Reference standard: Surgery	Risk factors (n [%]): NR	NR Additional data used for	PPV 75.0% 45.0% 100.0% NPV 100.0% 92.0% 100.0%	Test reliability/variability: - Sample size: - Statistical tests:+
	Reference standard applied to all test	Inclusion criteria: Not clearly described	diagnosis: "Most" premenopausal women followed over several	2) Ultrasound: Postmenopausal Dis+ Dis- Tot	Blinding: + Definition of +/- on screening test: +
	negatives?: Yes	Consecutive patients scheduled for laparotomy for adnexal mass in time	menstrual cycles to rule out functional cyst	T+ 10 2 12 T- 3 19 22 Tot 13 21 34	
	Test reliability established?: No	frame Exclusion criteria:		Lower Upper	
	Statistical tests used: Mann-Whitney U test,	NR		Value 95% Cl 95% Cl Se 76.9% 54.0% 99.8% Sp 90.5% 77.9% 100.0% PPV 83.3% 62.2% 100.0%	
	chi-square Blinding: Unclear			NPV 86.4% 72.0% 100.0% 3) Ultrasound: Combined pre and post	
	Definition of positive and negative on screening test: Ultrasound: solid,			Dis+ Dis- Tot T+ 16 4 20 T- 3 86 89 Tot 19 90 109	
	irregular structure, thick septae, irregular margins Doppler: PI < 1 CA-125: > 65 U/mL			Lower Upper Value 95% CI 95% CI Se 84.2% 67.8% 100.0% Sp 95.6% 91.3% 99.8% PPV 80.0% 62.5% 97.5% NPV 96.6% 92.9% 100.0%	
				4) Doppler: Premenopausal	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot T+ 5 19 24 T- 1 50 51 Tot 6 69 75	
				LowerUpper 95% ClSe83.3%53.5%100%Sp72.5%61.9%83.0%PPV20.8%4.6%37.1%NPV98.0%94.2%100%	
				5) Doppler: Postmenopausal	
				Dis+ Dis- Tot T+ 11 4 15 T- 2 17 19 Tot 13 21 34	
				Lower Upper Value 95% Cl 95% Cl Se 84.6% 65.0% 100% Sp 81.0% 64.2% 97.7% PPV 73.3% 51.0% 95.7% NPV 89.5% 75.7% 100%	
				6) Doppler: pre and post combined	
				Dis+ Dis- Tot T+ 16 23 39 T- 3 67 70 Tot 19 90 109	
				Lower Upper 95% Cl 95% Cl Se 84.2% 67.8% 100.0% Sp 74.4% 65.4% 83.5% PPV 41.0% 25.6% 56.5% NPV 95.7% 91.0% 100.0%	
				7) CA-125: Premenopausal	
				Dis+ Dis- Tot T+ 3 7 10 T- 3 62 65	

Study	Study Design		Resu	ts		Comments/Quality Scoring		
			Tot	6	69	75		
					Malua	Lower	Upper	
				0.	Value	95% CI	95% CI	
				Se	50.0%	10.0%	90.0%	
				Sp PPV	89.9% 30.0%	82.7% 1.6%	97.0% 58.4%	
				NPV	95.4%	90.3%	100.0%	
					95.4 /0	90.370	100.076	
				8) CA	-125: Post	menopaus	sal	
					Dis+	Dis-	Tot	
				T+	8	2		
				T-	5	19	24	
				Tot	13	21	34	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	61.5%	35.1%	88.0%	
				Sp	90.5%	77.9%	100%	
				PPV	80.0%	55.2%	100%	
				NPV	79.2%	62.9%	95.4%	
				9) CA	-125: com	bined		
					Dis+	Dis-	Tot	
				T+	77	9		
				T-	8	81	89	
				Tot	85	90	175	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	90.6%	84.4%	96.8%	
				Sp	90.0%	83.8%	96.2%	
				Sp PPV	89.5%	83.1%	96.0%	
				NPV	91.0%	85.1%	97.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Szpurek, Moszyniki, and Sajdak,	Geographical location: Poland	Age: Pre-menopause: Mean (SD): 37.4 (9.7)	Symptomatic (n [%]) : NR	1) Doppler index (cutoff $DS \ge 4$) postmenopausal women only (n = 101)	Comments: Cut off point for DS calculated for
2004	Dates: NR	Post-menopause:	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 68 0 68	this study Quality assessment:
#1530	Size of population: 464 women	Mean (SD): 63.4 (8.7)	Detected by imaging	T+ 68 0 68 T- 6 27 33 Tot 74 27 101	Reference standard: + Verification bias: -
	Case series	Menopausal status (n [%]): Pre: 363 (78%)	(n [%]): NR	Lower Upper Value 95% CI 95% CI	Test reliability/variability: - Sample size: + Statistical tests: +
	Reference standard: Pathology	Post: 101 (22%) Race/ethnicity (n [%]):	Combination (n [%]): NR	Se 91.9% 85.7% 98.1% Sp 100.0% 88.9% 100.0%	Blinding: - Definition of +/- on screening test: -
	Reference standard applied to all test	NR	Additional data used for diagnosis:	PPV 100.0% 95.6% 100.0% NPV 81.8% 68.7% 95.0% AUC = 0.9775	
	negatives?: Yes	Risk factors (n [%]): NR	DS index 1 point given for each of the	2) Doppler index (cutoff DS \geq 4) all women (n = 464)	
	Test reliability established?: No	Inclusion criteria: Women undergoing	following: Number of vessels (≥ 5) Location of vessels (in	Dis+ Dis- Tot	
	Statistical tests used:	surgery for ovarian mass who had had Doppler u/s done at the hospital	septae, in papillae or solid parts)	T+ 143 20 163 T- 22 279 301 Tot 165 299 464	
	Se, Sp, ROC Blinding:	Exclusion criteria: NR	Arrangement of vessels (Irregular, random) Shape of velocity waves	Lower Upper Value 95% CI 95% CI	
	No Definition of positive		(smooth; low waveform amplitude) Presence of protodiastolic	Se 86.7% 81.5% 91.9% Sp 93.3% 90.5% 96.1%	
	and negative on screening test: DS index ≥ 4		notch (absent)	PPV 87.7% 82.7% 92.8% NPV 92.7% 89.8% 95.6% AUC = 0.9315	
	Doppler Subjective Index			 Doppler index (cutoff DS ≥ 4) premenopause 	
				Dis+ Dis- Tot T+ 75 20 95 T- 16 252 268 Tot 91 272 363	
				Lower Upper <u>Value 95% Cl 95% Cl</u> Se 82.4% 74.6% 90.2% Sp 92.6% 89.5% 95.7%	

Study	Study Design	Patients	Clinical Presentation	Results		Comments/Quality Scoring
				PPV 78.9% 70.7% NPV 94.0% 91.2%	87.1% 96.9%	
Tailor, Bourne,	Geographical location:	Age: Mean: 48	Symptomatic (n [%]): 0 (0%)	1) US for the first screenin	g episode	Comments: Borderline grouped in with
Campbell, et		Range: 17-78	0 (070)	Dis+ 5	Tot	malignant
al., 2003	Dates: NR	Range. II Ie	Detected by exam (n [%]):	T+ 6 76		Good data on family history
,		Menopausal status	0 (0%)	T- 1 2417	2418	specific risk (however, data
#1970	Size of population:	(n [%]):		Tot 7 2493	2500	organized by screen events, not by
	2500 screened	Pre (< 45): 1629 (65%)	Detected by imaging			patient)
		Post (> 55): 644 (26%)	(n [%]):	Lower	Upper	Menopause not defined
	Screening study	And 227(9%) were post	0	Value 95% CI	95% CI	Unable to calculate 2x2 table for
		hysterectomy		Se 85.7% 59.8%	100.0%	CA-125 as don't know either the true
	Reference standard:		Combination (n [%]):	Sp 97.0% 96.3%	97.6%	negative rate or the N
	Histopathology or repeat		NR	PPV 7.3% 1.7%	13.0%	Subjective morphologic criteria
	US at between 12 weeks	NR		NPV 100.0% 99.9%	100.0%	used
	and six months depending on	Risk factors (n [%]):	Additional data used for diagnosis:			Inclusion criteria shifted through study period
	characteristic of first US	See below	NR	2) US for the second scree	ening episode (n	TVUS only
	and individual family	See below	NK	= 998)		1003 0119
	history	Inclusion criteria:		Dis+ 5	Tot	Quality assessment:
	history	Self-referred women in		Dis+ 5 T+ 3 11		Reference standard: -
	Reference standard	time frame for screening		T- 0 984	984	Verification bias: +/-
	applied to all test	Women with at least 1		Tot 3 995	998	Test reliability/variability: -
	negatives?:	relative with ovarian		101 5 995	990	Sample size: +
	No	cancer and another with		Lower	Upper	Statistical tests: +
		another cancer		Value 95% Cl	95% CI	Blinding: +
	Test reliability			Se 100.0% 0.0%	100.0%	Definition of +/- on screening test: -
	established?:	Exclusion criteria:		Sp 98.9% 98.2%	99.5%	
	No for US	NR		PPV 21.4% 0.0%	42.9%	
	Yes for CA-125			NPV 100.0% 99.7%	100.0%	
	Statistical tests used: Se Sp.			3) for >= 3 rd screen episod	e (n = 733)	
	Posterior, prior oddss					
	r osterior, prior oddas			Dis+ 5	Tot	
	Blindina:			T+ 2 6		
	Not described – but			T- 0 725	725	
	prospective study			Tot 2 731	733	
				1	Linner	
	Definition of positive			Lower Value 95% Cl	Upper 95% Cl	
	and negative on			Se 100.0% -50.0%	100.0%	
	screening test:			Se 100.0% -50.0% Sp 99.2% 98.5%	99.8%	
	US – considered			op 99.270 90.070	33.0 /0	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	abnormal is: "ovary enlarged (>95 th centile), a cyst was detected, and areas of hypo- or hyperechogenicity were seen which were inconsistent with normalphysiology" CA-125 – range used	ged (>95 th centile), a vas detected, and s of hypo- or rechogenicity were which were sistent with alphysiology"		PPV 25.0% 0.0% 55.0% NPV 100.0% 99.6% 100.0%	
Takac, 1998 #3240	Geographical location: Maribor, Slovenia Dates: Jan 1994-Dec 1995 Size of population: 120 women Other Case series Reference standard: Surgery Reference standard applied to all test negatives?: Yes Test reliability established?: Yes; referenced and discussed Statistical tests used: Mann-Whitney Blinding: Not mentioned Definition of positive and negative on screening test: ROC done on varying	Age: Overall not reported; mean age of patients with benign masses 42 (13.5), malignant 53.3 (17.1) Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Adnexal mass that had surgery Exclusion criteria: Not undergoing surgery		Dis+ Dis- Tot T+ 32 2 34 T- 7 76 83 Tot 39 78 117	Quality assessment: Reference standard: + Verification bias: - Test reliability/variability: + Sample size: - Statistical tests: - Blinding: + Definition of +/- on screening test:

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	definitions for resistive index Both highest and lowest measured RI used in calculating final RI				
Tanir, Ozalp, Yalcin, et al., 2003	Geographical location: Eskisehir, Turkey Dates: Aug 1991-Sept	Reported separately by diagnosis: Non-neoplastic 39.0 (2.0)	Symptomatic (n [%]): NR Detected by exam (n [%]):	1) VEGF—threshold 68.7 <u>Dis+ Dis-</u> Tot T+ <u>11 6</u> 17	Comments: Clinical presentation not described Borderline tumors grouped in with malignant
#1850	2002	Benign 42.2 (5.2) Malignant 56.9 (4.2)	NR	T- <u>1 44</u> 45 Tot 12 50 62	 Unable to calculate 2x2 tables by menopausal status, but AUC's giver
	Size of population: 63 women	Menopausal status (n [%]):	Detected by imaging (n [%]): NR	Lower Upper Value 95% CI 95% CI	Premenopausal VEGF: AUC 0.938 CA-125: AUC 0.769
	Other Case series	Pre (< 45): 40 (63%) Post (> 55): 23 (37%)	Combination (n [%]):	Se 92.0% 76.7% 100.0% Sp 88.0% 79.0% 97.0%	Postmenopausal VEGF: AUC 0.902 CA-125: 0.873
	Reference standard: Surgery/pathology	Race/ethnicity (n [%]) : NR	Additional data used for diagnosis:	PPV 64.7% 42.0% 87.4% NPV 97.8% 93.5% 100.0%	Reported Se Sp inconsistent with reported LR+ and LR-, 2x2 tables uncertain.
	Reference standard applied to all test	Risk factors (n [%]): NR	Ultrasound (including Doppler)	2) CA-125 ≥ 37 U/mL Dis+ Dis- Tot	
	negatives?: Yes	Inclusion criteria: NR		T+ 11 23 34 T- 1 27 28 Tot 12 50 62	Quality assessment: Reference standard: + Verification bias: +
	Test reliability established?: Yes	Exclusion criteria: NR		Lower Upper	Test reliability/variability: + Sample size: - Statistical tests: +
	Statistical tests used:	INFA		Value 95% Cl 95% Cl Se 92.0% 76.7% 100.0% Sp 54.0% 40.2% 67.8%	Blinding: _ Definition of +/- on screening test:
	ROC			PPV 32.4% 16.6% 48.1% NPV 96.4% 89.6% 100.0%	+
	Blinding: Yes			INI V 20.770 03.070 IUU.U70	
	Definition of positive and negative on screening test: Varied cutoff for VEGF, CA-125				

Study	Study Design	Patients	Clinical Presentation	Resul	lts	Comments/Quality Scoring
Tay and Chua, 1994	Geographical location: Singapore	Age: Mean (SD): 38.6 (12.9)	Symptomatic (n [%]) : NR	1) Ser	rum CA-125 > 35 U/ml Dis+ Dis- Tot	Comments: Unclear how patients chosen ("cysts")
#4450	Dates: Oct 1991 – Apr 1992	Menopausal status (n [%]): NR	Detected by exam (n [%]): NR	T+ T- Tot	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Study compares salivary CA-125 with urine and serum There appears to be an error in
	Size of population: 105 women	Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	TOL	Lower Upper Value 95% CI 95% CI	reported statistics – not all of Se, Sp, PPV, and NPV can be correct. "In this study the false positive rate was
	Other Prospective study of patients admitted to single center with mass for surgery	Risk factors (n [%]): NR Inclusion criteria: Patients admitted to	Combination (n [%]): 105 (100%) Additional data used for diagnosis:	Se Sp PPV NPV	88.9% 68.4% 100.0% 77.9% 69.6% 86.2% 27.6% 11.3% 43.9% 98.7% 96.1% 100.0%	22%" suggests that the Sp reported as 79.2 % was in error and should be 78% (or 77.9% as shown in our 2x2 table abstraction). Quality assessment:
	Reference standard: Histopathology	hospital with diagnosis of "ovarian cysts" for elective surgery.	NR			Reference standard: + Verification bias: + Test reliability/variability: +
	Reference standard applied to all test negatives?: Yes	Exclusion criteria: NR				Sample size: - not discussed Statistical tests: + Blinding: - Definition of +/- on screening test: +
	Test reliability established?: Yes					
	Statistical tests used: Se, Sp					
	Blinding:					
	Definition of positive and negative on screening test: CA-125 > 35 U/mL					

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Tekay and Jouppila, 1992	Geographical location: Finland	Age: Premenopausal – mean 37 range 17-50	Symptomatic (n [%]): NR	1) RI <=0.6 Dis+ Dis- Tot	Comments: Borderline tumors grouped with malignant
#10970	Dates: NR Size of population: 72 Case series	Post menopausal – mean age 60 range 42-74 Menopausal status (n [%]): Pre (< 45): 46 (63.9%)	Detected by exam (n [%]): NR Detected by imaging (n [%]): NR	T+ 9 17 26 T- 2 44 46 Tot 11 61 72 Lower Upper Value 95% CI 95% CI	Although data collected on US morphology and PI, only data for RI able to be extracted into 2x2 table Overlap in PI and RI noted for all malignant and benign tumors 68 examined with TVUS, 4 with
	Reference standard: Histopathology Reference standard	Post (> 55): 26(36.1%) Race/ethnicity (n [%]): NR	Combination (n [%]): NR Additional data used for	Se 82.0% 59.3% 100.0% Sp 72.0% 60.7% 83.3% PPV 34.6% 16.3% 52.9% NPV 95.7% 89.8% 100.0%	abdominal US – unable to stratify results Quality assessment: Reference standard: +
	applied to all test negatives?: Yes Test reliability	Risk factors (n [%]): NR Inclusion criteria: Referral to hospital for	diagnosis: NR	2) RI <+ 0.5 Dis+ Dis- Tot T+ 5 7 12 T- 6 54 60	Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: +
	established?: Yes Statistical tests used: Se, Sp	adnexal mass who underwent surgery Exclusion criteria: NR		Tot 11 61 72 Lower Upper Value 95% CI 95% CI	Definition of +/- on screening test: +
	Mann-Whitney U test Blinding: Not mentioned but			Se 46.0% 16.5% 75.5% Sp 89.0% 81.1% 96.9% PPV 41.7% 13.8% 69.6% NPV 90.0% 82.4% 97.6%	
	prospective Definition of positive and negative on screening test: RI <= 0.6 or 0.5				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Tepper, Lerner- Geva, Altaras, et al., 1995	Geographical location: Kfar Saba, Israel Dates: 1990-1993	Age: Mean (SD): 44.3 Range: 8-79 Menopausal status	Symptomatic (n [%]): NR Detected by exam (n [%]): NR	1) RI (cutoff < 0.4), only considering patients in whom blood flow velocity waveforms could be detected, borderline tumors excluded	Comments: To translate data into 2x2 table, abstractor had to round figures, so could be introducing error Unclear inclusion criteria
#4090	Size of population: 217 women	(n [%]): NR	Detected by imaging	Dis+ Dis- Tot	Interobserver variability not
#4090			(n [%]):	T+ 17 3 20 T- 8 79 87	discussed Tumors of low malignant potential
	Other All patients admitted to	Race/ethnicity (n [%]) : NR	NR	Tot 25 82 107	are not included in 2x2 tables
	hospital with mass for surgery	Risk factors (n [%]):	Combination (n [%]): NR	Lower Upper Value 95% CI 95% CI	Authors calculated Se/Sp only on patients in whom blood flow velocity
	Reference standard: Histopathology	NR Inclusion criteria: Admitted to hospital for	Additional data used for diagnosis: NR	Se 68.0% 49.7% 86.3% Sp 96.3% 92.3% 100.0% PPV 85.0% 69.4% 100.0% NPV 90.8% 84.7% 96.9%	waveforms could be detected: 25/38 (65.8%) malignant tumors 12/14 (85.7%) borderline tumors 82/165 (49.7%) benign tumors
	Reference standard applied to all test negatives?:	surgery for diagnosis of adnexal mass		 2) RI (cutoff < 0.4), borderline tumors counted as malignant 	Quality assessment: Reference standard: +
	Yes	Exclusion criteria: NR		Dis+ Dis- Tot	Verification bias: \pm Test reliability/variability: -
	Test reliability established?: Yes, by reference			T+ 19 3 22 T- 33 162 195 Tot 52 165 217	Sample size: - Statistical tests: +/- Blinding: -
	Statistical tests used: Se, Sp			Lower Upper Value 95% CI 95% CI	Definition of +/- on screening test: +
	Blinding: NR			Se 36.5% 23.5% 49.6% Sp 98.2% 96.1% 100.0% PPV 86.4% 72.0% 100.0% NPV 83.1% 77.8% 88.3%	
	Definition of positive and negative on screening test: RI cutoff of < 0.4			3) RI (cutoff < 0.4) borderline tumors counted as benign	
	(literature standard) compared with 0.47 (study mean) and 0.53 (mean + 2SD)			Dis+ Dis- Tot T+ 17 5 22 T- 21 174 195 Tot 38 179 217	
				LowerUpperValue95% CI95% CISe44.7%28.9%60.5%Sp97.2%94.8%99.6%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				PPV 77.3% 59.8% 94.8% NPV 89.2% 84.9% 93.6%	
				4) RI (cutoff < 0.47)	
				Dis+ Dis- Tot	
				T+ 33 23 56	
				T- 5 142 147	
				Tot 38 165 203	
				Lower Upper	
				Value 95% CI 95% CI Se 86.8% 76.1% 97.6%	
				Sp 86.1% 80.8% 91.3%	
				Sp 86.1% 80.8% 91.3% PPV 58.9% 46.0% 71.8%	
				NPV 96.6% 93.7% 99.5%	
				5) RI (cutoff < 0.53)	
				Dis+ Dis- Tot	
				T+ 38 43 81	
				T- 0 122 122	
				Tot 38 165 203	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 100.0% 92.1% 100.0%	
				Sp 73.9% 67.2% 80.6%	
				PPV 46.9% 36.0% 57.8%	
				NPV 100.0% 97.5% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Tian, Zhang, Jiao, et al., 2000	Geographical location: Beijing, China	Age: Benign Range: 15-72	Symptomatic (n [%]): "Most" had "no symptoms other than slight abdominal	1) Tc-99m Dis+ Dis- Tot	Comments: Small study Different numbers of patients had
#2670	Dates: April 1996-Nov 1998	Malignant Range: 25-70	pain"	T+ 22 7 29 T- 1 41 42	different tests Clinical presentation not reported
	Size of population: 71 women	Menopausal status (n [%]): NR	Detected by exam (n [%]): 65 (91.5%; unclear if screening exam)	Tot 23 48 71 Lower Upper Value 95% CI 95% CI	Explicitly states that readers blinded to clinical history No description of CT-MRI diagnostic criteria (unclear if analysis
	Other Case series	Race/ethnicity (n [%]):	Detected by imaging (n [%]):	Se 92.0% 80.9% 100.0% Sp 54.0% 39.9% 68.1%	based on outcome of either CT or MRI or both)
	Reference standard:	NR	28 (39.4%); MRI or CT	Op 04.0% 00.0% 00.1% PPV 75.9% 60.3% 91.4% NPV 97.6% 93.0% 100.0%	Quality assessment:
	Surgery/pathology Reference standard	Risk factors (n [%]): NR	Combination (n [%]): NR	2) CA-125 (>35 U/ml)	Reference standard:+ Verification bias: + Test reliability/variability:-
	applied to all test negatives?: Yes	Inclusion criteria: Mass, scheduled for laparoscopy	Additional data used for diagnosis: NR	Dis+ Dis- Tot T+ 20 12 32 T- 3 18 21	Sample size: - Statistical tests: - Blinding: + Definition of +/- on screening test:
	Test reliability established?:	Exclusion criteria: NR		Tot 23 30 53 Lower Upper	+
	Not referenced or discussed			Value 95% CI 95% CI Se 87.0% 73.2% 100.0% Se 60.0% 43.5% 100.0%	
	Statistical tests used: Chi-square, t-test			Sp 60.0% 42.5% 77.5% PPV 62.5% 45.7% 79.3% NPV 85.7% 70.7% 100.0%	
	Blinding: Yes; explicitly stated			3) CT-MRI	
	Definition of positive and negative on screening test: Grade 1 or 2 uptake of c-			Dis+ Dis- Tot T+ 10 8 18 T- 3 7 10 Tot 13 15 28	
	99m, no move with peristalsis or volume change of bladder, or signs of intestinal, peritoneal, or lymphatic involvement			Value Lower 95% CI Upper 95% CI Se 76.9% 54.0% 99.8% Sp 46.7% 21.4% 71.9% PPV 55.6% 32.6% 78.5% NPV 70.0% 41.6% 98.4%	

Verrelst, Bourne, et al., 1999 #5940	Geographical location: UK Dates: Aug 1994 – Aug 1996	Age: Mean: Pre 40 Post 64	Symptomatic (n [%]): NR Detected by exam (n [%]):	1) CA- maligna	borderline	included as	Comments: Clinical presentation not described
al., 1999 #5940			Detected by exam (n [%]).				
	Size of population: 173 women Other Consecutive case series Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: Logistic regression ROC Se Sp Blinding:	Range: 22-93 Menopausal status (n [%]): Pre (< 45): 83 (48.0%) Post (> 55): 90 (52.0%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Prospective patients to get surgery for mass Exclusion criteria: No CA-125 preoperatively available	NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	T+ T- Tot Se Sp PPV NPV 2) CA- benign T+ T- Tot Se Sp PPV	Dis- 23 101 124 Lower 95% CI 68.3% 74.7% 50.9% 85.7% borderline Dis- 27 102 129 Lower 95% CI 64.9% 72.0% 43.3%	Tot 62 111 173 Upper 95% CI 90.9% 88.3% 74.9% 96.3% included as Tot 61 112 173 Upper 95% CI 89.7% 86.1% 68.2%	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + Sample size: - Statistical tests: + Blinding: +/- Definition of +/- on screening test: +/-

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Timor- Tritsch, Lerner, Montea- gudo, et al., 1993 #10840	Geographical location: USA Dates: Apr 1991 – May 1992 Size of population: 93 patients 115 masses Case series Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: Se, Sp Blinding: Not described but prospective	Age: Mean: 43.2 Range: 13-74 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Presenting to hospital with diagnosis of mass in time frame Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) Sassone morphologic criteria $\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Comments: Excluded from analysis those masses in which no flow could be measured (although none were CA) Borderline tumors grouped in with malignant RI and PI cutpoints calculated from results of patient series (predefined cutpoints not used) Don't mention cutpoint for Sassone's criteria (assume 9 from original article) Clinical pathway not illuminated Although much of the article data was reported for masses not individuals, these 2x2 tables are for individuals TVUS only Cuality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: +/- Blinding: + Definition of +/- on screening test: +
	Definition of positive and negative on screening test: Sassone scoring system Used (cutoff not mentioned but assume >= 9) RI < 0.46 PI < 0.62			Dis+ Dis- Tot T+ 11 1 12 Tot 12 70 82 Value 95% CI 95% CI Se 93.8% 80.2% 100.0% Sp 98.7% 96.0% 100.0% PPV 91.7% 76.0% 100.0% NPV 98.6% 95.8% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Tingulstad, Hagen,	Geographical location: Norway	Age: NR	Symptomatic (n [%]): NR	1) CA-125 > 25 U/ml	Comments: RMI study – no cutoffs in analysis
Skjeldestad, et al., 1996	Dates: Feb 1992 - Feb	Menopausal status	Detected by exam (n [%]):	Dis+ Dis- Tot T+ <u>45 22</u> 67	No description of inter
#3890	1994	(n [%]): Pre (< 45): 82 (47.4%)	NR	T- <u>11 95</u> 106 Tot 56 117 173	Quality assessment: Reference standard: +
	Size of population: 173 women	Post (> 55): 91 (52.6%) (defined as > 12 months amenorrhea or age > 50 if	Detected by imaging (n [%]): NR	Lower Upper	Verification bias: + Test reliability/variability: - /intraobserver variability with US
	Other	hysterectomy)		Value 95% CI 95% CI Se 80.0% 69.5% 90.5%	Sample size: -
	Consecutive patient series	Race/ethnicity (n [%]):	Combination (n [%]): NR	Sp <mark>81.0%</mark> 73.9% 88.1% PPV 67.2% 55.9% 78.4%	Statistical tests: + Blinding: -
	Reference standard:	NR	Additional data used for	NPV 89.6% 83.8% 95.4%	Definition of +/- on screening test: +
	Histopathology	Risk factors (n [%]): NR	diagnosis: NR	2) CA-125 > 50 U/ml	
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: Age >30 with pelvic mass scheduled for surgery		Dis+ Dis- Tot T+ 41 7 48 T- 15 110 125 T+ 50 447 170	
		concation for cargory		Tot 56 117 173	
	Test reliability established?: Yes Statistical tests used:	Exclusion criteria: NR		Lower Upper Value 95% Cl 95% Cl Se 73.0% 61.4% 84.6% Sp 94.0% 89.7% 98.3% PPV 85.4% 75.4% 95.4%	
	Chi square, Se Sp, ROC Mann-Whitney U test			NPV 88.0% 82.3% 93.7%	
	Mann-Whitney O test			2) US appro > 2	
	Blinding:			3) US score > 2	
	NR - prospective			Dis+ Dis- Tot	
	Definition of positive and negative on screening test:			T+ 38 21 59 T- 18 96 114 Tot 56 117 173	
	CA-125 - range US ≥ 2 , where			Lower Upper Value 95% CI 95% CI	
	1 point assigned for each of the following:			Se 68.0% 55.8% 80.2%	
	multilocular cystic lesion			Sp <mark>82.0%</mark> 75.0% 89.0% PPV 64.4% 52.2% 76.6%	
	solid areas bilateral lesion			NPV 84.2% 77.5% 90.9%	
	ascites intra-abdominal ascites			 Menopausal status (postmenopausal = malignant) 	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot T+ 45 46 91 T- 11 71 82 Tot 56 117 173	
				LowerUpperValue95% CI95% CISe80.4%70.0%90.8%Sp60.7%51.8%69.5%PPV49.5%39.2%59.7%NPV86.6%79.2%94.0%	
Torres, Derchain,	Geographical location: Sao Paulo, Brazil	Age: NR	Symptomatic (n [%]): NR	1) CA-125 > 35 U/ml	Comments: RMI study so no exact cutoffs
Faundes, et al., 2002	Dates: Jan 1996 – Mar	Menopausal status	Detected by exam (n [%]):	Dis+ Dis- Tot T+ 52 23 75	given, rather 2x2 tables done at various levels
#2170	1998	(n [%]): NR	NR	T- 15 68 83	Unclear where patients referred from or how decision to do surgery
#2170	Size of population: 158 women	Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	Lower Upper	done -No discussion of variability in US
	Other	NR	NR	Value 95% CI 95% CI Se 78.0% 68.1% 87.9%	Quality assessment:
	Series	Risk factors (n [%]): NR	Combination (n [%]): NR	Sp 75.0% 66.1% 83.9% PPV 69.3% 58.9% 79.8%	Reference standard: + Verification bias: +
	Reference standard: Histopathology	Inclusion criteria:	Additional data used for	NPV 81.9% 73.6% 90.2%	Test reliability/variability: CA-125 + US -
	Reference standard	Pelvic mass who had surgery in time frame	diagnosis: NR	2) US score ≥ 2	Sample size: - Statistical tests: +
	applied to all test negatives?: Yes Test reliability	Exclusion criteria: Lung masses, Signs of hepatic or intraperitoneal mets		Dis+ Dis- Tot T+ 55 30 85 T- 12 61 73 Tot 67 91 158	Blinding: +/- (not discussed but prospective) Definition of +/- on screening test: +/-
	established?: Yes	initapentoneal mets		Lower Upper Value 95% CI 95% CI	
	Statistical tests used: Se, Sp Regression			Se 82.0% 72.8% 91.2% Sp 67.0% 57.3% 76.7% PPV 64.7% 54.5% 74.9% NPV 83.6% 75.1% 92.1%	
	Blinding: NR – but prospective			3) US score ≥ 3	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot	
	Definition of positive			T+ <u>50</u> <u>26</u> 76	
	and negative on			T- 17 65 82	
	screening test:			Tot 67 91 158	
	US score – range from				
	other RMI literature (0-8)			Lower Upper	
	CA-125 - range			Value 95% CI 95% CI	
				Se 75.0% 64.6% 85.4%	
				Sp 71.0% 61.7% 80.3%	
				PPV 65.8% 55.1% 76.5%	
				NPV 79.3% 70.5% 88.0%	
				4) Menopausal status (menopausal =	
				malignant)	
				Dis+ Dis- Tot	
				T+ 49 28 77	
				T- 18 63 81	
				Tot 67 91 158	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 73.0% 62.4% 83.6%	
				Sp <mark>69.0%</mark> 59.5% 78.5%	
				PPV 63.6% 52.9% 74.4%	
				NPV 77.8% 68.7% 86.8%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Troiano, Quedens- Case, and	Geographical location: New Haven, CT	Age: NR	Symptomatic (n [%]): NR	1) CA-125 ≥ 36 U/ml Dis+ Dis- Tot	Comments: Reported sensitivity/specificity not consistent with data provided in
Taylor, 1997	Dates: 1991-1996	Menopausal status (n [%]):	Detected by exam (n [%]): NR	T+ <u>17 88</u> 105 T- <u>3 36</u> 39	Table 1 of paper Diagnostic criteria not explicit
#3680	Size of population: 144 women	Pre (< 45): 102 (70.8%) Post (> 55): 42 (29.2%)	Detected by imaging (n [%]):	Tot 20 124 144 Lower Upper	Unable to calculate 2x2 table for ultrasound results Borderline tumors grouped with
	Other Case series	Race/ethnicity (n [%]) : NR	NR	Value 95% CI 95% CI Se <mark>85.0%</mark> 69.4% 100.0%	malignant
	Reference standard: Surgery (45); serial ultrasound (followup 1-6 years)	Risk factors (n [%]): NR Inclusion criteria:	Combination (n [%]): NR Additional data used for diagnosis:	Sp 29.0% 21.0% 37.0% PPV 16.2% 9.1% 23.2% NPV 92.3% 83.9% 100.0%	Quality assessment: Reference standard: + Verification bias: - Test reliability/variability: - Sample size: -
	Reference standard applied to all test	NR Exclusion criteria:	NR	 2) CA-125 ≥ 36 U/ml, postmenopausal Dis+ Dis- Tot T+ 10 25 35 	Statistical tests: - Blinding: - Definition of +/- on screening test:
	negatives?: See above	NR		T- 0 7 7 Tot 10 32 42	-
	Test reliability established?: Not referenced or discussed			Value Lower Upper 95% CI 95% CI Se 100.0% 70.0% 100.0% Sp 21.9% 7.6% 36.2%	
	Statistical tests used: Descriptive			PPV 28.6% 13.6% 43.5% NPV 100.0% 57.1% 100.0%	
	Blinding: No				
	Definition of positive and negative on screening test: Solid components, thickened septation, nodules; Dopplers; no explicit scoring or cutpoint used. CA-125 \geq 36 U/m;				

Study	Study Design	Patients	Clinical Presentation	Result	S			Comments/Quality Scoring
Valentin,	Geographical location:	Age:	Symptomatic (n [%]):	1) PI (c	utoff < 1))		Comments:
1997	Malmo, Sweden	Mean: 47.8	NR	, (,			Negative surgeries but with
		Range: 20-90			Dis+	Dis-	Tot	diagnosis of myoma were excluded
#6170	Dates: NR	-	Detected by exam (n [%]):	T+	19	74	93	(7)
		Menopausal status	NR	T-	4		42	Unclear why the 5 who had only
	Size of population:	(n [%]):		Tot	23		135	diagnostic laparoscopy were
	151 women	Pre (< 45): 92 (62.9%)	Detected by imaging					excluded
		Post (> 55): 53 (37.1%)	(n [%]):			Lower	Upper	LMP tumors lumped in with
	Other	6 women who had	NR		Value	95% CI	95% CI	malignant
	Prospective study at	undergoing hysterectomy		Se	82.6%	67.1%	98.1%	 Visibility of color lakes is subjective
	university hospital of	were classified a pre or	Combination (n [%]):	Sp	33.9%	25.2%	42.7%	evaluation of Doppler, uncertain
	consecutive patients with		NR	PPV	20.4%	12.2%	28.6%	reliability
	adnexal mass scheduled	basis of age.		NPV	90.5%	81.6%	99.4%	
	for surgery		Additional data used for					Quality assessment:
		Race/ethnicity (n [%]):	diagnosis:	2) Colo	r lakes vi	sible on D	oppler	Reference standard: +
	Reference standard:	NR	NR					Verification bias: +
	Histopathology			_	Dis+	Dis-	Tot	Test reliability/variability: -
		Risk factors (n [%]):		T+	21	42	63	Sample size: -
	Reference standard	NR		T-	3	85	88	Statistical tests: +
	applied to all test			Tot	24	127	151	Blinding: -
	negatives?:	Inclusion criteria:						Definition of +/- on screening test: ·
	Yes, but 49 were	NR				Lower	Upper	
	excluded for technical	Evolucion esiteria.		_	Value	95% CI	95% CI	
	reasons	Exclusion criteria: 49 excluded for:		Se	87.5%	74.3%	100.0%	
	Toot reliability			Sp	66.9%	58.7%	75.1%	
	Test reliability established?:	uninterpretable US examinations (12), surgery		PPV	33.3%	21.7%	45.0%	
	established ?.	canceled (replaced by		NPV	96.6%	92.8%	100.0%	
		laparoscopy) (5), biopsy						
	Statistical tests used:	with cytologic diagnosis		3) Men	opausal s	status (pos	t =T+)	
	Se, Sp, regression	(3), or clinical followup						
	00, 0p, regression	(22), myoma at time of		F	Dis+	Dis-	Tot	
	Blinding:	surgery (7)		T+	19		24	
	NR	surgery (7)		T-	37	90	127	
				Tot	56	95	151	
	Definition of positive							
	and negative on					Lower	Upper	
	screening test:			_	Value	95% CI	95% CI	
				Se	33.9%	21.5%	46.3%	
				Sp	94.7%	90.2%	99.2%	
				PPV	79.2%	62.9%	95.4%	
				NPV	70.9%	63.0%	78.8%	
				Multiple	logiotic r	egression	model	
							solid tumors	
				CONSULU		unnocuial	solid turnors.	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				results not reported here.	
Valentin, 1999b	Geographical location: Malmo, Sweden	Age: NR	Symptomatic (n [%]): NR	1) "Subjective" Morphology alone	Quality assessment: Reference standard: -
#3100	Dates: NR Size of population: 173 women Other Series	Menopausal status (n [%]): Pre (< 45): 98 (59.5%) Peri (45-55): Post (> 55): 70 (40.5%) Race/ethnicity (n [%]):	Detected by exam (n [%]): NR Detected by imaging (n [%]): NR	Dis+ Dis- Tot T+ 21 6 27 T- 3 143 146 Tot 24 149 173 Lower Upper Value 95% CI 95% CI Se 87.5% 74.3% 100.0%	Verification bias: - Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test +
	Reference standard: Pathology	NR Risk factors (n [%]): NR	Combination (n [%]): NR Additional data used for	Sp 96.0% 92.8% 99.1% PPV 77.8% 62.1% 93.5% NPV 97.9% 95.6% 100.0%	
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: NR Exclusion criteria:	diagnosis: NR	2) Morphology plus Doppler Dis+ Dis- Tot T+ 20 5 25	
	Test reliability established?: No	NR		T- <u>4 144</u> 148 Tot 24 149 173 Lower Upper	
	Statistical tests used: Chi-square			Value 95% Cl 95% Cl Se 83.3% 68.4% 98.2% Sp 96.6% 93.8% 99.5% PPV 80.0% 64.3% 95.7%	
	Blinding: No			NPV 97.3% 94.7% 99.9% 3) Lerner score	
	Definition of positive and negative on screening test: Morphology: solid components Lerner score: ≥ 3			Dis+ Dis- Tot T+ 22 96 118 T- 2 53 55 Tot 24 149 173	
	Color score: ≥ 40 or 65 Pulsatility < 1.0 Resistive index < 0.4 Time-averaged max velocity: ≥ 7.2 cm/s Peak systolic velocity: ≥ 14.4 cm/s			Lower Upper Value 95% CI 95% CI Se 91.7% 80.6% 100.0% Sp 35.6% 27.9% 43.3% PPV 18.6% 11.6% 25.7% NPV 96.4% 91.4% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scorin
				4) Time-averaged max velocity	
				Dis+ Dis- Tot	
				T+ 24 61 85	
				T- 0 59 59	
				Tot 24 120 144	
				Lower Upper	
				Value 95% Cl 95% Cl Se 100.0% 87.5% 100.0%	
				Sp 49.2% 40.2% 58.1%	
				PPV 28.2% 18.7% 37.8%	
				NPV 100.0% 94.9% 100.0%	
				5) Morphology plus peak systolic velo	city
				Dis+ Dis- Tot	
				T+ 19 44 63	
				T- <u>5 99</u> 104 Tot 24 143 167	
				Lower Upper	
				Value 95% Cl 95% Cl Se 79.2% 62.9% 95.4%	
				Sp 69.2% 61.7% 76.8%	
				PPV 30.2% 18.8% 41.5%	
				NPV 95.2% 91.1% 99.3%	
				6) Morphology plus color score	
				Dis+ Dis- Tot	
				T+ 17 39 56	
				T- 7 106 113 Tot 24 145 169	
				Lower Upper Value 95% CI 95% CI	
				Se 70.8% 52.6% 89.0%	
				Sp 73.1% 65.9% 80.3%	
				PPV 30.4% 18.3% 42.4%	
				NPV 93.8% 89.4% 98.2%	
				7) Morphology	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot T+ 23 94 117	
				T- <u>1</u> <u>55</u> 56	
				Tot 24 149 173	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 95.8% 87.8% 100.0%	
				Sp 36.9% 29.2% 44.7% PPV 19.7% 12.5% 26.9%	
				NPV 98.2% 94.7% 100.0%	
				111 0 30.270 34.770 100.070	
				8) Resistance index	
				Dis+ Dis- Tot	
				T+ 6 7 13	
				T- 18 113 131	
				Tot 24 120 144	
				Lower Upper	
				Value 95% CI 95% CI	
				Se 25.0% 7.7% 42.3% Sp 94.2% 90.0% 98.4%	
				Sp 94.2% 90.0% 98.4% PPV 46.2% 19.1% 73.3%	
				NPV 86.3% 80.4% 92.2%	
				9) Pulsatility index	
				Dis+ Dis- Tot	
				T+ 21 81 102	
				T- 3 39 42	
				Tot 24 120 144	
				Lower Upper Value 95% CI 95% CI	
				Value 95% CI 95% CI Se 87.5% 74.3% 100.0%	
				Se 87.3% 74.3% 100.0% Sp 32.5% 24.1% 40.9%	
				Sp 32.5% 24.1% 40.9% PPV 20.6% 12.7% 28.4%	
				NPV 92.9% 85.1% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Valentin,	Geographical location:	Age:	Symptomatic (n [%]):	1) Lerner score ≥ 3	Comments:
2000	Malmo, Sweden	Median: pre 37.5 for post 66	NR	Dis+ Dis- Tot	Undetectable velocity measures classified as "benign"
#2760	Dates: NR	Range: 18-88	Detected by exam (n [%]):	T+ 22 53 75	LMP tumors grouped into
		range. To be	NR	T- 2 96 98	malignant
	Size of population:	Menopausal status		Tot 24 149 173	Lerner score not described
	173 women	(n [%]):	Detected by imaging		
		Pre: 98 (56.6%)	(n [%]):	Lower Upper	Quality assessment:
	Other	Post: 70 (40.5%)	NR	Value 95% CI 95% CI	Reference standard: +
	Consecutive patients scheduled for surgery in	4 hysterectomy 1 unknown	Combination (n [%]):	Se 91.7% 80.6% 100.0%	Verification bias: + Test reliability/variability:-
	university hospital	T UTKHOWN	NR	Sp 64.4% 56.7% 72.1%	Sample size: -
		Race/ethnicity (n [%]):		PPV 29.3% 19.0% 39.6% NPV 98.0% 95.2% 100.0%	Statistical tests: +
	Reference standard:	NR	Additional data used for	NIV 90.078 93.278 100.078	Blinding: -
	Histopathology		diagnosis:	2) PI < 1.0	Definition of +/- on screening test:
		Risk factors (n [%]):	NR	, -	+/-
	Reference standard	NR		Dis+ Dis- Tot	
	applied to all test	Inclusion esiteria.		T+ 21 81 102	
	negatives?: Yes	Inclusion criteria: Women admitted to		T- 3 68 71	
	163	hospital for surgery due to		Tot 24 149 173	
	Test reliability	pelvic mass during time		Lower Linner	
	established?:	frame		Lower Upper Value 95% CI 95% CI	
	Lerner's ?			Se 87.5% 74.3% 100.0%	
	PI and RI yes	Exclusion criteria:		Sp 45.6% 37.6% 53.6%	
	Valentin's Doppler	26 excluded because 10		PPV 20.6% 12.7% 28.4%	
	variable - no	surgery canceled or replaced with cytology, 13		NPV 95.8% 91.1% 100.0%	
	Statistical tests used:	had normal US preop of			
	Se, Sp	whom 9 had normal		3) RI < 0.4	
	,	laparoscopy and 4 had		Dis+ Dis- Tot	
	Blinding:	normal US followup		T+ 6 7 13	
	NR – prospective though			T- 18 142 160	
				Tot 24 149 173	
	Definition of positive and negative on				
	screening test:			Lower Upper	
	Lerner's score [4] >3			Value 95% CI 95% CI	
	RI < 0.4			Se 25.0% 7.7% 42.3%	
	PI < 1.0			Sp 95.3% 91.9% 98.7%	
				PPV 46.2% 19.1% 73.3% NPV 88.8% 83.9% 93.6%	
				INF V 00.070 03.970 93.0%	
				Additional analyses for combination of	
				Lerner score ≥3 and Doppler variable	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				positive, combined as "both" or "eithe	r" = T+
Valentin, Hagen, Tingulstad, et al., 2001 #2340	Geographical location: Trondheim, Norway, and Malmo, Sweden Dates: NR Size of population: 136 Other Prospective validation Reference standard: Surgery Reference standard applied to all test negatives?: Yes Test reliability established?: Referenced Statistical tests used: ROC, logistic regression Blinding: No Definition of positive and negative on screening test: "Pattern recognition" referenced, but not described in this paper		Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) "Pattern recognition" (threshold no defined, but referenced) T+ <u>30 9</u> Tot <u>36 91</u> 97 Tot <u>36 100 136</u> <u>Value 95% CI 95% CI</u> Se <u>83.3%</u> 71.2% 95.5% Sp 91.0% 85.4% 96.6% PPV 76.9% 63.7% 90.1% NPV 93.8% 89.0% 98.6%	 Comments: For CA-125 – unable to get data for 2x2 table as it is reported in Means only For US – scoring system broken into parts in tables – unable to reassemble to get 2x2 table for US alone Threshold given in references 1 and 2 (Valentin et al, Ultrasound Obstet Gynecol 1999;14:273-83, and 1999:14:338-47) Clinical presentation not described Quality assessment: Reference standard: + Verification bias: - Test reliability/variability: + Sample size: - (wide CI's) Statistical tests: + Blinding: - Definition of +/- on screening test: + (not given here, but referenced)

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Van Nagell Jr., DePriest, Reedy, et al., 2000 #2730	Study Design Geographical location: USA Dates: 1987 - 1999 Size of population: 14469 180with persistently abnormal screens leading to surgery Screening study	Age: Mean (SD): 54.7 (10.7) Range: 25-92 Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	Clinical Presentation Symptomatic (n [%]): 0 (0%) Detected by exam (n [%]): 0 (0%) Detected by imaging (n [%]): 180 (1.2%) Combination (n [%]): NR	Results 1) For the screened population as a whole $Dis+$ 5 Tot T+ 17 163 180 T- 4 14285 14289 Tot 21 14448 14469 Lower Upper Value 95% Cl 95% Cl Se 81.0% 64.2% 97.7% Sp 98.9% 98.7% 99.0% PPV 9.4% 5.2% 13.7% NPV 100.0% 99.9% 100.0%	Comments/Quality Scoring 4 patients developed ovarian CA 12+ months after screen – these were included in the true negative analysis (because they had failed in 12 month followup)Borderline tumors grouped in with benignTVUS only Quality assessment: Reference standard: - Verification bias: +
	Reference standard: Histopathology Reference standard applied to all test negatives?: No Normal screens were repeated in one year Abnormal screens were repeated in 4-6 weeks with morphology, CA-125 and Doppler Test reliability established?: yes	Inclusion criteria: Age >=50 or age >=25 with documented family history of ovarian CA Exclusion criteria: NR	Additional data used for diagnosis: NR	NPV 100.0% 99.9% 100.0% 2) Adding the 4 (Table 6) who got CA > 12 months out T+ 17 163 T- 8 14281 Tot 25 14444 14469 $\frac{Value 95\% CI 95\% CI}{95\% CI}$ Se $68.0\% 49.7\% 86.3\%$ Sp $98.9\% 98.7\% 99.0\%$ PPV $9.4\% 5.2\% 13.7\%$ NPV $99.9\% 99.9\% 100.0\%$	Test reliability/variability: - Sample size: + Statistical tests: + Blinding: + Definition of +/- on screening test: +/-
	Statistical tests used: Chi square Fisher's exact test Kaplan Meier survival curve plotted Blinding: Prospective Definition of positive and negative on screening test: US – ovarian volume > 20cm3 for				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	premenopausal women, and > 10cm3 for postmenopausal women Or any cystic ovarian tumor with a solid or papillary projection into its lumen. For subsequent screening DePriest scoring system used with CA-125 and doppler				
Vasilev, Schlaerth, Campeau, et al., 1988 #6770	Geographical location: Los Angeles, CA Dates: Mar 1984-Feb 1986 Size of population: 182 women Other Nonconsecutive case series Reference standard: Surgery/pathology Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests used: NR Blinding: Yes	Age: NR Menopausal status (n [%]): ≤ 50: 152 (83.1%) >50: 31 (17.0%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Preoperative diagnosis of pelvic mass Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) All patients CA-125 \ge 35 U/ml T+ T- T- Tot Tot Tot Tot Tot Tot Tot Tot	Comments: Unclear what implications of "nonconsecutive" are—how many patients not included Text description does not match data provided in Table 3 Borderline grouped with malignant Quality assessment: Reference standard: - Verification bias: - Test reliability/variability:+ Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: +
	Definition of positive			· · ·	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	and negative on screening test: > 35 u/ML	screening test:	Dis+ Dis- Tot T+ 8 2 10 T- 4 17 21 Tot 12 19 31		
				ValueLower 95% ClUpper 95% ClSe66.7%40.0%93.3%Sp89.5%75.7%100.0%PPV80.0%55.2%100.0%NPV81.0%64.2%97.7%	
Vuento, Pirhonen, Makinen, et		Age: Mean (SD): 59 Range: 56-61	Symptomatic (n [%]): 100% asymptomatic	1) Combined US morphology and Doppler	Comments: Population based study Some potential for verification bias,
al., 1995	Dates: NR	Menopausal status	Detected by exam (n [%]): NR	T+ 1 159 160 T- 0 1204 1204	but registry capture reasonable alternative
#4070	Size of population: 1846 in initial pool; 1364 (74%) consented	(n [%]): Post (> 55): 1364 (100%)	Detected by imaging (n [%]):	Tot 1 1363 1364 Lower Upper	Quality assessment: Reference standard: +
	Screening study	Race/ethnicity (n [%]): NR	NR Combination (n [%]):	Value 95% Cl 95% Cl Se 100.0% 0.0% 100.0% Sp 88.3% 86.6% 90.0%	Verification bias: + Test reliability/variability:- Sample size: +
	Reference standard: Cases reported to Finnish Cancer Registry	Risk factors (n [%]): Family history: 376 (27.6%)	NR Additional data used for	PPV 0.6% 0.0% 1.8% NPV 100.0% 99.8% 100.0%	Statistical tests: + Blinding: + Definition of +/- on screening test:
	over 2 ½ year followup; true negative considered no cancer within 1 year		diagnosis: NR	Positive case was borderline 2 cancers, 1 Stage 1A and 1 Stage III, within 2 years	+
	Reference standard applied to all test negatives?: Yes	Exclusion criteria: NR		 Combined US morphology and Doppler, results of followup US in 160 women with abnormal screening ultrasound on first screen 	
	Test reliability established?: Not referenced or described			Dis+ Dis- Tot T+ 1 27 28 T- 0 132 132 Tot 1 159 160	
	Statistical tests used: Chi-square			Lower Upper Value <u>95% Cl 95% Cl</u> Se 100.0% 0.0% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
	Blinding: Yes Definition of positive and negative on screening test: Negative: not visualized, volume less than 8 cc.	s finition of positive d negative on reening test: gative: not visualized,		Sp PPV NPV	83.0% 3.6% 100.0%	77.2% 0.0% 97.7%	88.9% 10.4% 100.0%	
	uniformly hypoechogenic; PI < 1.0 – lowest measured value used US – Fleischer criteria							
Wakahara, Kikkawa, Nawa, et al.,	Geographical location: Nagoya, Japan	Age: Mean (SD): 40.3 Range: 11-79	Symptomatic (n [%]): NR	1) Ultra cancer		ncluding b	orderline as	Comments: Clinical presentation not described Not stratified by menopausal status
2001	Dates: 1994-1999		Detected by exam (n [%]):	_	Dis+	Dis-	Tot	
#2370	Size of population:	Menopausal status (n [%]):	NR	T+ T-	69 15	37 171	106	Quality assessment: Reference standard: +
+2370	292 women	(i [//]). NR	Detected by imaging (n [%]):	Tot	84	208	186 292	Verification bias: + Test reliability/variability: -
	Other Case series	Race/ethnicity (n [%]): NR	NR		Value	Lower 95% CI	Upper 95% Cl	Sample size: - Statistical tests: +
	Reference standard: Surgery/pathology	Risk factors (n [%]): NR	Combination (n [%]): NR Additional data used for	Se Sp PPV	82.1% 82.2% 65.1%	74.0% 77.0% 56.0%	90.3% 87.4% 74.2%	Blinding: - Definition of +/- on screening test: +
	Reference standard applied to all test	Inclusion criteria: Presence of adnexal	diagnosis: NR	NPV	91.9% asound—r	88.0%	95.8% borderline as	
	negatives?: Yes	mass, scheduled for surgery		benign		, ,		
	Test reliability established?:	Exclusion criteria:		T+ T-	Dis+ 57 9	Dis- 49 177	Tot 106 186	
	Not referenced or discussed	NR		Tot	66	226	292	
	Statistical tests used: Se/Sp			Se	Value 86.4%	Lower 95% CI 78.1%	Upper 95% CI 94.6%	
	Blinding: Yes			Sp PPV NPV	78.3% 53.8% 95.2%	72.9% 44.3% 92.1%	83.7% 63.3% 98.2%	
	Definition of positive and negative on			3) CA-	125 > 35	J/ml; bord	erline classified	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	screening test: Positive ultrasound: cyst with irregular solid component or thickened septum, or solid mass. Ultrasound interpretation	т+ т-	T- 77 131 208		
	by gyn oncologist, not radiologist CA-125: 35 U/mL CA-19-9: 37 IU/mL CA-72-4: 4 U/mL			LowerUpperValue95% CI95% CISe44.6%36.3%52.9%Sp85.6%80.1%91.2%PPV73.8%64.4%83.2%NPV63.0%56.4%69.5%	
				 CA-125 > 35 U/ml; borderline classified as benign 	
				Dis+ Dis- Tot T+ 51 88 139 T- 15 138 153 Tot 66 226 292	
				LowerUpper 95% CISe77.3%67.2%87.4%Sp61.1%54.7%67.4%PPV36.7%28.7%44.7%NPV90.2%85.5%94.9%	
				5) CA 19-9 > 37 IU/ml, borderline classifie as malignant	d
				Dis+Dis-TotT+2978107T-55127182Tot84205289	
				LowerUpper 95% CISe34.5%24.4%44.7%Sp62.0%55.3%68.6%PPV27.1%18.7%35.5%NPV69.8%63.1%76.5%	
				6) CA 19-9 >37 IU/ml, Borderline classifie	b

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				as benign	
				Dis+ Dis- Tot T+ 24 83 107 T- 42 140 182 Tot 66 223 289	
				ValueLower 95% ClUpper 95% ClSe36.4%24.8%48.0%Sp62.8%56.4%69.1%PPV22.4%14.5%30.3%NPV76.9%70.8%83.0%	
				 CA-72-4 > 4 U/ml, borderline classified as malignant 	
				Dis+ Dis- Tot T+ 23 18 41 T- 28 104 132 Tot 51 122 173	
				LowerUpperValue95% CI95% CISe45.1%31.4%58.8%Sp85.2%79.0%91.5%PPV56.1%40.9%71.3%NPV78.8%71.8%85.8%	
				8) CA-72-4 > 4 U/ml, borderline classified as benign	
				Dis+ Dis- Tot T+ 20 21 41 T- 20 116 136 Tot 40 137 177	
				LowerUpper 95% CISe50.0%34.5%65.5%Sp84.7%78.6%90.7%PPV48.8%33.5%64.1%NPV85.3%79.3%91.2%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Weiner, Thaler, Beck, et al.,	Geographical location: Haifa, Israel	Age: Range: 20-69	Symptomatic (n [%]): NR	1) CA-125 > 35 U/ml	Comments: LMP grouped with malignant for analysis
1992	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 14 14 28	Classification of sonographic findings unclear [7] reference doesn'
#6480	Size of population: 62 women	NR	Detected by imaging (n [%]):	T- <u>3 22</u> 25 Tot 17 36 53	illuminate scoring system PPV for CA-125 reported in article as 45% (this may be typographical
	Other Prospective surgical candidates in single	NR Risk factors (n [%]):	NR Combination (n [%]):	Lower Upper Value 95% Cl 95% Cl Se 82.4% 64.2% 100.0%	error) Borderline cystadenocarcinomas are classified as malignant in 2x2
	center	NR ()	NR	Sp 61.1% 45.2% 77.0% PPV 50.0% 31.5% 68.5%	tables
	Reference standard: Histopathology	Inclusion criteria: Women referred to US department for suspicion	Additional data used for diagnosis: NR	NPV 88.0% 75.3% 100.0% 2) PI < 1.0	Quality assessment: Reference standard: + Verification bias: +
	Reference standard applied to all test negatives?: No – 9 had "functional	of pelvic tumor 62 referred – 9 with cysts that disappeared after 6 weeks		Dis+ Dis- Tot T+ 16 1 17 T- 1 35 36	Test reliability/variability: + for CA-125 and PI - for US Sample size: -
	cysts" which had regressed on followup US	Exclusion criteria: NR		Tot 17 36 53	Statistical tests: + Blinding: - Definition of +/- on screening test:
	Test reliability established?: CA-125 – yes			Value 95% Cl 95% Cl Se 94.1% 82.9% 100.0% Sp 97.2% 91.9% 100.0% PPV 94.1% 82.9% 100.0%	+ for CA-125 and PI - for US
	PI +/- Statistical tests used: Se, Sp			NPV 97.2% 91.9% 100.0% 3) US	
	Blinding: NR – prospective study			Dis+ Dis- Tot T+ 16 11 27 T- 1 25 26 Tot 17 36 53	
	Definition of positive and negative on screening test: CA-125 > 35 U/ml			Lower Upper Value 95% CI 95% CI	
	PI < 1.0 US - {7} - not described			Se 94.1% 82.9% 100.0% Sp 69.4% 54.4% 84.5% PPV 59.3% 40.7% 77.8% NPV 96.2% 88.8% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
Woolas, Conaway, Xu, et al.,	Geographical location: Durham, NC, and London, UK	Age: NR	Symptomatic (n [%]): NR	1) CA-	125 > 35 Dis+	U/ml Dis-	Tot	Comments: Clinical presentation not described- Spectrum of disease (cancer stage
1995	Dates: NR	Menopausal status	Detected by exam (n [%]):	T+	150	55	205	distribution) adequately described
#4140		(n [%]) : NR	All patients with "clinically detected masses"	T- Tot	42 192		224 429	Unclear how subjects selected (random, consecutive, or to
	Size of population: 429	Race/ethnicity (n [%]): NR	Detected by imaging (n [%]):		Value	Lower	Upper 95% CI	approximated distribution of disease Not stratified by age or menopausal status
	Other		NR	Se	Value 78.1%	95% CI 72.3%	83.9%	Prevalence of cancer higher than
	Series from two hospitals	Risk factors (n [%]) : NR	Combination (n [%]):	Sp	76.8%	71.4%	82.2%	would be expected in general population
	Reference standard:	INK	NR	PPV	73.2%	67.1%	79.2%	population
	Surgery, pathology	Inclusion criteria: NR	Additional data used for	NPV	81.3%	76.1%	86.4%	Quality assessment: Reference standard: +
	Reference standard	NR	diagnosis:	2) M-C	SF			Verification bias: +
	applied to all test	Exclusion criteria: NR	148 primary ovarian cancers 26% Stage I		Dis+	Dis-	Tot	Test reliability/variability: +
	negatives?: Yes	INIT	3% Stage II	T+	127		184	Sample size: + Statistical tests: +
	103		55% Stage III	T-	65		245	Blinding: +
	Test reliability		16% Stage IV	Tot	192	237	429	Definition of +/- on screening test:
	established?: Yes					Lower	Upper	+
	163				Value	95% CI	95% CI	
	Statistical tests used:			Se	66.2%	59.5%	72.9%	
	ROC, logistic modeling			Sp PPV	76.0% 69.0%	70.6% 62.3%	81.4% 75.7%	
				NPV	73.5%	67.9%	79.0%	
	Blinding:				10.070	07.070	10.070	
	Not described			3) OV)	K 1			
	Definition of positive				Dis+	Dis-	Tot	
	and negative on screening test:			T+	77		118	
	CA-125: 35 u/ML			T-	115		311	
	M-CSF: 3.1 ng/ml			Tot	192	237	429	
	OVX 1: 12.1 U/mL							
	LASA: 200.0 mg/ml				Value	Lower	Upper	
	CA 15-3: 32.0 u/ml			80	Value 40.1%	95% CI 33.2%	95% CI 47.0%	
	CA-72-4: 3.8 u/ml			Se Sp	40.1% 82.7%	33.2% 77.9%	47.0% 87.5%	
	CA 19-9: 39.0 u/ml			PPV	65.3%	56.7%	73.8%	
	CA 54/61: 20.0 u/ml			NPV	63.0%	57.7%	68.4%	
				4) LAS	SA			

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot	
				T+ <u>100</u> <u>29</u> 129 T- <u>92</u> 208 300	
				Tot 192 237 429	
				Lower Linner	
				Lower Upper Value 95% CI 95% CI	
				Se 52.1% 45.0% 59.2%	
				Sp 87.8% 83.6% 92.0%	
				PPV 77.5% 70.3% 84.7%	
				NPV 69.3% 64.1% 74.6%	
				5) CA 15-3	
				Dis+ Dis- Tot	
				T+ 120 32 152	
				T- 72 205 277	
				Tot 192 237 429	
				Lower Upper	
				Value 95% CI 95% CI Se 62.5% 55.7% 69.3%	
				Sp 86.5% 82.1% 90.9%	
				PPV 78.9% 72.5% 85.4%	
				NPV 74.0% 68.8% 79.2%	
				6) CA-72-4	
				Dis+ Dis- Tot	
				T+ 104 20 124	
				T- 88 217 305	
				Tot 192 237 429	
				Lower Upper	
				Value 95% CI 95% CI Se 54.2% 47.2% 61.2%	
				Se 54.2% 47.2% 61.2% Sp 91.6% 88.1% 95.1%	
				PPV 83.9% 77.4% 90.3%	
				NPV 71.1% 66.1% 76.2%	
				7) CA 19-9	
				Dis+ Dis- Tot	
				T+ 46 28 74	
				T- 146 209 355	

Study	Study Design	Patients	Clinical Presentation	Resul	ts			Comments/Quality Scoring
			Tot	192	237	429		
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	24.0%	18.0%	30.0%	
				Sp	88.2%	84.1%	92.3%	
				PPV	62.2%	51.1%	73.2%	
				NPV	58.9%	53.8%	64.0%	
				8) CA 5	54/61			
					Dis+	Dis-	Tot	
				T+	100	28	128	
				Т-	92	209	301	
				Tot	192	237	429	
						Lower	Upper	
					Value	95% CI	95% CI	
				Se	52.1%	45.0%	59.2%	
				Sp	88.2%	84.1%	92.3%	
				PPV	78.1%	71.0%	85.3%	
				NPV	69.4%	64.2%	74.6%	
					00.170	0		

Study	Study Design	Patients	Clinical Presentation	Result	ts			Comments/Quality Scoring
Study Wu, Lee, Chen, et al., 1994 #10900	Geographical location:		Clinical Presentation Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Result 1) RI < T+ T- Tot Se Sp PPV NPV		Dis- 8 299 307 Lower 95% CI 59.0% 95.6% 83.0% 86.8%	Tot 78 332 410 Upper <u>95% Cl</u> 77.0% 99.2% 96.5% 93.3%	Comments/Quality Scoring Comments:Clinical pathway not describedCombined TVUS and abdominal US (no N for each reported) unable to stratify Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: Sample size: Statistical tests: Blinding: Definition of +/- on screening test:
	Statistical tests used: Chi square Fisher exact Student t test Linear regression Blinding: Not mentioned (prospective) Definition of positive and negative on screening test: Positive: RI > 0.4							

Study	Study Design	Patients	Clinical Presentation	Resu	ts			Comments/Quality Scoring
Yamashita, Hatanaka,	Geographical location: Japan	Age: NR	Symptomatic (n [%]) : NR	1) LR	· ·		t) cutoff = 0.49	Comments: Low malignant potential treated as
Torashima, et al., 1997	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	T+ T-	Dis+ 21 7	Dis- 4 43	Tot 25 50	malignant in this analysis. LR model fit 5 variables to 50 positive cases (at limit of 1:10 rule of
#6120	Size of population: 104 women	NR	Detected by imaging	Tot	28	47	75	thumb) 2x2 table reported to validation
	Other MRI series	Race/ethnicity (n [%]) : NR	(n [%]): 100% ultrasound	50	Value 75.0%	Lower 95% CI 59.0%	Upper 95% CI 91.0%	doesn't match articles reported Se, Sp. Our abstraction based on 2x2 table.
	Reference standard:	Risk factors (n [%]): NR	Combination (n [%]): NR	Se Sp PPV	91.5% 84.0%	59.0% 83.5% 69.6%	99.5% 98.4%	Validation in separate data set.
	Histopathology	Inclusion criteria:	Additional data used for	NPV	86.0%	76.4%	95.6%	Quality assessment: Reference standard: +
	Reference standard applied to all test negatives?:	Ovarian masses and MRI to further investigate indeterminate ultrasound	diagnosis: LR model					Verification bias: Test reliability/variability: - Sample size: -
	Yes	Exclusion criteria:	Logit(y)= -2.7 + 0.4 (tumor size)					Statistical tests: + Blinding: +
	Test reliability established?: No	NR	+ 1.8 (ascites) + 1.4 (bilateral) + 0.5 (complex internal architecture)					Definition of +/- on screening test: -, cutoff was data driven.
	Statistical tests used: LR		+ 1.6 (solid or irregular wall structure)					
	Blinding: Yes for MRI, independent interpretation by 3		Where tumor size (cm), other variables scored 1if present; 0 if absent.					
	radiologists - surgical and pathological reports were not available		Best discrimination obtained in test set with cutoff our 0.49.					
	Definition of positive and negative on screening test:							
	MRI evaluated for 1) size; 2) bilaterality; 3) wall structure; 4) internal architectures; 5)							
	presence of thick (< 3 mm) septa; 6) signal intensity; 7) ascites							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Yamashita, Torashima, Hatanaka, et	Geographical location: Kumamoto, Japan	Age: Mean (SD): 43 Range: 13-74	Symptomatic (n [%]): NR	 Transvaginal ultrasound, benign vs malignant, all readings by 5 radiologists (results presented by lesion, not patient; 19 	Comments: Observer variability measured Kappa 0.71 for pre-contrast MRI,
al., 1995	Dates: NR	Menopausal status	Detected by exam (n [%]): NR	patients had malignancy, 61 benign lesions)	
#4290	Size of population: 72 women 80 masses	(n [%]): NR	Detected by imaging (n [%]):	Dis+ Dis- Tot T+ 17 10 27 T- 2 51 53	Se/Sp calculated by lesion, not patient—CI's subsequently smaller Not stratified by age, menopausal
	Other Consecutive case series	Race/ethnicity (n [%]): NR; presumably 100% Asian	NR Combination (n [%]):	Tot 19 61 80 Lower Upper	status Clinical presentation not described LMP tumors grouped in with malianant
	Reference standard: Surgery/pathology	Risk factors (n [%]): NR	NR Additional data used for diagnosis:	Value 95% Cl 95% Cl Se 89.0% 74.9% 100.0% Sp 84.0% 74.8% 93.2% PPV 63.0% 44.7% 81.2%	malignant Quality assessment: Reference standard: +
	Reference standard applied to all test negatives?:	Inclusion criteria: Pelvic mass, scheduled for surgery	NR	NPV 96.2% 91.1% 100.0% 2) Preconstrast MRI, benign vs malignant	Verification bias: + Test reliability/variability: + Sample size: -
	Yes Test reliability established?: Inter-rater reliability	Exclusion criteria: NR		Dis+ Dis- Tot T+ 15 4 19 T- 4 57 61 Tot 19 61 80	Statistical tests: + Blinding: + Definition of +/- on screening test: +
	measured Statistical tests used: ROC, kappa			Lower Upper Value 95% CI 95% CI Se 78.0% 59.4% 96.6%	
	Blinding: Yes			Sp93.0%86.6%99.4%PPV78.9%60.6%97.3%NPV93.4%87.2%99.7%	
	Definition of positive and negative on screening test:			3) Contrast-enhanced MRI, benign vs malignant	
	 Benign if 3 of 4 criteria: Diameter ≤ 4 cm Entirely cystic Lesion wall < 3mm No internal structure 			Dis+ Dis- Tot T+ 17 4 21 T- 2 57 59 Tot 19 61 80	
	Malignancy if 2 of 5 criteria: Diameter > 4 cm Wall or septum >			Lower Upper Value 95% CI 95% CI Se 91.0% 78.1% 100.0% Sp 93.0% 86.6% 99.4% PPV 81.0% 64.2% 97.7%	

Study	Study Design	Patients	Clinical Presentation	Result	ts			Comments/Quality Scoring
	3mm Nodularity, vegetations, or large solid component Necrosis or hemorrhage in lesion 	•		NPV	96.6%	92.0%	100.0%	
	 And/or if any 1 of the following criteria: Involvement of adjacent organs or pelvic sidewall Peritoneal, mesenteric, or omental lesions Ascites Adenopathy 							
	Borderline tumors classified as malignant							

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Zanetta, Vergani,	Geographical location: Milan, Italy	Age: NR	Symptomatic (n [%]): 71(88.8%)	1) US Sassone	Comments: N = 80 however, n = 78 for all the
and Lissoni, 1994	Dates: May 1992 – May 1993	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Dis+ Dis- Tot T+ 32 11 43 T- 1 36 37	cases that they report Borderline grouped with malignant Overlap in both RI and PI noted in
#10850	Size of population:	NR	Detected by imaging	Tot 33 47 80	malignant and benign lesionsTVUS only
	80	Race/ethnicity (n [%]) : NR	(n [%]): 5(6.3%) (infertility work up	Lower Upper Value 95% CI 95% CI	
	Case series	Risk factors (n [%]):	imaging)	Se 97.0% 91.2% 100.0% Sp 76.0% 63.8% 88.2%	Quality assessment: Reference standard: +
	Reference standard: Histopathology	NR	Combination (n [%]): NR	PPV 74.4% 61.4% 87.5% NPV 97.3% 92.1% 100.0%	Verification bias: + Test reliability/variability: -
	Reference standard applied to all test	Inclusion criteria: Surgical referral to hospital secondary to mass	Additional data used for diagnosis:	2) CA 126 > 30	Sample size: - Statistical tests: + Blinding: +/-
	negatives?: Yes	Exclusion criteria:	4 (5%) referred for abdominal enlargement but	Dis+ Dis- Tot T+ <u>30 19</u> 49	Definition of +/- on screening test: +
	Test reliability established?:	NR	were asymptomatic	T- <u>3</u> 28 31 Tot <u>33</u> 47 80	
	Yes Statistical tests used:			Lower Upper Value 95% CI 95% CI Se 91,0% 81,2% 100,0%	
	Se, Sp			Se 60.0% 81.2% 100.0% Sp 60.0% 46.0% 74.0% PPV 61.2% 47.6% 74.9%	
	Blinding: Not mentioned (prospective)			NPV 90.3% 79.9% 100.0%	
	Definition of positive			3) PI 1.0	
	and negative on screening test: US morphology – Sassone's criteria			Dis+ Dis- Tot T+ 32 6 38 T- 1 41 42 Tot 33 47 80	
	Doppler: PI>=1.0 RI range investigated			Lower Upper Value 95% CI 95% CI	
	(0.50, 0.56, 0.60) CA-125 >30U/ml			Se97.0%91.2%100.0%Sp87.0%77.4%96.6%PPV84.2%72.6%95.8%NPV97.6%93.0%100.0%	
				4) RI 0.60	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
				Dis+ Dis- Tot T+ 30 7 37	
				T- 3 40 43	
				Tot 33 47 80	
				Lower Upper	
				Value 95% Cl 95% Cl Se 91.0% 81.2% 100.0%	
				Sp <mark>85.0%</mark> 74.8% 95.2%	
				PPV 81.1% 68.5% 93.7%	
				NPV 93.0% 85.4% 100.0%	
				5) RI 0.56	
				Dis+ Dis- Tot	
				T+ 28 4 32	
				T- <u>5 43</u> 48 Tot <u>33 47</u> 80	
				Lower Upper Value 95% CI 95% CI	
				Se 85.0% 72.8% 97.2%	
				Sp <mark>91.0%</mark> 82.8% 99.2%	
				PPV 87.5% 76.0% 99.0% NPV 89.6% 80.9% 98.2%	
				6) RI 0.50	
				Dis+ Dis- Tot	
				T+ <u>22</u> <u>2</u> <u>24</u>	
				T- <u>11 45</u> 56 Tot 33 47 80	
				Lower Upper Value 95% CI 95% CI	
				Se 67.0% 51.0% 83.0%	
				Sp 96.0% 90.4% 100.0%	
				PPV 91.7% 80.6% 100.0% NPV 80.4% 70.0% 90.8%	
				NPV 80.4% 70.0% 90.8%	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Zhang, Barnhill, Zhang, et	Geographical location: London, England	Age: NR	Symptomatic (n [%]): NR	2) CA-125 > 35 U/ml	
al., 1999	Dates: NR	Menopausal status (n [%]):	Detected by exam (n [%]): NR	T+ 75 29 10 T- 6 57 6	
#3020	Size of population: 429 women	NR Race/ethnicity (n [%]):	Detected by imaging (n [%]):	Tot 81 86 16	
	Registry Reference standard:	NR	NR	Value 95% Cl 95% Se <mark>92.6%</mark> 86.9% 98.	6 CIconditions. This may be less3%applicable to real life than leaving all
	Pathology	Risk factors (n [%]) : NR	Combination (n [%]): NR	Sp 66.3% 56.3% 76. PPV 72.1% 63.5% 80. NPV 90.5% 83.2% 97.	7% 7% Quality assessment:
	Reference standard applied to all test negatives?:	Inclusion criteria: Pelvic mass/had pathology	Additional data used for diagnosis: NR		Reference standard: + Verification bias: - Test reliability/variability: -
	Yes	Exclusion criteria: NR			Sample size: + Statistical tests: +
	Test reliability established?:				Blinding: - Definition of +/- on screening test: -
	Statistical tests used: Se, Sp, ROC				
	Blinding: NR				
	Definition of positive and negative on screening test: Artificial Neural Network (ANN), cutoff 0.5 Ca 125 > 35U/ml				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Zimmer, Tepper, and Akselrod,	Geographical location: Dates:	NŘ	Symptomatic (n [%]): NR	1) Benign vs malignant, from 28 preoperative images	Comments: Clinical presentation not described Spectrum of disease not described
2003 #1740	NR Size of population: 28 images; number of patients not described Other Development of quantitative analytic method for ultrasound images; initial validation Reference standard:	Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: NR	Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis:	Dis+ Dis- Tot T+ 20 0 20 T- 5 3 8 Tot 25 3 28 Lower Upper Value 95% CI 95% CI Se 80.0% 64.3% 95.7% Sp 100.0% 0.0% 100.0% PPV 100.0% 85.0% 100.0% NPV 37.5% 4.0% 71.0%	Quality assessment: Reference standard: + Verification bias: - Test reliability/variability: - Sample size: - Statistical tests: - Blinding: + (computerized) Definition of +/- on screening test: +
	Reference standard: Presumably surgery/pathology Reference standard applied to all test negatives?: Yes Test reliability	Exclusion criteria: NR	NR		
	established?: Not described Statistical tests used: Not described Blinding: Yes				
	Definition of positive and negative on screening test: Algorithm based on lesion size, structure, turbidity, amount of solid material				

Evidence Table 4: Question 4: What is the accuracy of explicit scoring systems which incorporate various combinations of imaging findings, patient risk factors, and/or CA-125 levels for detecting malignancy? Have these scoring systems been applied to a population of women before laparoscopy or laparotomy?

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Adonakis, Para- skevaidis, Tsiga, et al., 1996 #810	Geographical location: loannina, Greece Dates: Mar 1991-Jun 1993 Size of population: 2000 screened Screening study Reference standard: Histology or followup (at least 1 visit with CA-125 1 year later) Reference standard applied to all test negatives?: Yes Statistical tests used: Se, Sp, PPV Blinding: No Definition of positive and negative on screening test: See Scoring column	Age: Mean: 58.1 Range: 45-80 Menopausal status (n [%]): Pre: 1302 Peri: 293 Post: 405 Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Age ≥ 45 years "without any evidence of adnexal pathology" Exclusion criteria: Prior history of ovarian cancer, any other malignancy, bilateral salpingo- oophorectomy or ascites	Presentation Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): 59 115 with "ambiguous" exam Combination (n [%]): NR Additional data used for diagnosis: NR		1) PE + CA-125 ("ambiguous" PE	Scoring -2x2 tables constructed from Table 2 and data reported in text; not able to reproduce the Se, Sp and PPV reported in Table 3 of manuscript Only one followup visit was required for patients with negative screening – some patients who subsequently developed cancer could have been missed Quality assessment: Reference standard: + Verification bias: - (only one followup visit was required for test negatives who did not have surgery) Test reliability/variability: - Sample size: + Statistical tests: - (not enough data given to reproduce results reported) Blinding: - Definition of +/- on screening test: + Explicit validation method?: -
					negatives) (see next page)	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
					Dis+ Dis- T+ 3 6 T- 0 10 Tot 3 17	
					Lowe Value 95% (Se 100.0% 0.0% Sp 61.6% 54.49 PPV 4.2% 0.0% NPV 100.0% 97.29	CI 95% CI 100.0% 68.7% 8.9% 8.9%

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Alcazar, Errasti, Zornoza, et al., 1999 #3110	Geographical location: Pamplona, Spain Dates: Jan 1995-Feb 1998 Size of population: 94 women of 480 women screened	Detaction:Mean: 47.4 NRLamplona, SpainRange: 17.79 2) $RI \le 0.4$ Dates:Menopausal status (n [%]):Detected by exam (n [%]):an 1995-Feb 1998(n [%]): Pre: $52 (55.3\%)$ NRize of population:Post: $42 (44.7\%)$ Detected by imaging (n [%]):4 women of 480 romen screenedRace/ethnicityAll 100%	1) CA-125 ≥ 35 U/ml	1) Combination of RI ≤ 0.4 and CA- 125 ≥ 35 U/mI T+ $22 = 1$ 43 T- $14 = 37$ 51 Tot 56 38 94 25 = 25% CI 95% CI	Scoring Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: + Explicit validation method?: -	
	Registry Retrospective single- institution series	(n [%]): NR Risk factors (n [%]): NR	Combination (n [%]): NR Additional data used		Se 75.0% 63.7% 86.3% Sp 97.4% 92.3% 100.0% PPV 97.7% 93.2% 100.0% NPV 72.5% 60.3% 84.8%	
	Reference standard: Histopathology	Inclusion criteria: Diagnosed as having	for diagnosis: Morphological evaluation including			
	Reference standard applied to all test negatives?: Yes	sonographically suspicious findings; transvaginal color	of: Multilocularity, gross septations (> 3 mm), gross papillary			
	Statistical tests used: Se, Sp, ROC curves/AUC	Doppler and CA-125 level before surgery; and definitive histopathological diagnosis	projections (> 3 mm), solid wall nodules, irregular borders, solid mass or ascites			
	Blinding: No	Exclusion criteria: NR				
	Definition of positive and negative on screening test: Yes					

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Andolf, Jorgensen, and Astedt, 1990	Geographical location: Lund, Sweden Dates:	Age: Range: 40-70 Menopausal status (n [%]):	Symptomatic (n [%]): NR Detected by exam (n [%]):	 Bimanual PE Abdominal US 	1) Either US or PE abnormal Dis+ Dis- Tot T+ <u>8 206</u> 214 T- <u>0 587</u> 587	Comments: Results are not stratified by risk group or by menopausal status The portions of diagnostic
#1200	Oct 1984-Jul 1987 Size of population: 801 women Screening study Registry Reference standard:	(17,5). Pre (< 45):	106 total 51 (7.9%) of women with normal US 55 women with abnormal US Detected by imaging (n [%]): 163 women total		T- Tot 0 587 8 587 801 Lower Upper 95% CI 95% CI Se 100.0% 62.5% 100.0% Sp 74.0% 71.0% 77.1% PPV 3.7% 1.2% 6.3% NPV 100.0% 99.5% 100.0%	evaluation that would normally lead to referral (e.g., symptomatic presentation or positive findings on bimanual pelvic exam) are incorporated into the diagnostic assessment in this study.
	Histopathology	NR	108 women with normal manual exam		2) Both US and PE abnormal	Quality assessment: Reference standard: +
	Reference standard applied to all test negatives?: No, women without abnormality or cysts < 20 mm diameter considered normal and not verified. Ascertainment of ovarian cancer in test negative relies on Sweden's public health cancer registry system, which is well validated. Statistical tests used: Se, Sp	 abdominal pain, frequent micturition or irregular bleeding; nulliparity; 3) 	55 women with abnormal manual exam Combination (n [%]): 55 women with abnormal exam and US Additional data used		Dis+ Dis- Tot 5 50 55 Tot 3 743 Tot 8 793 801 Value 95% CI 95% CI Se 62.5% 29.0% 96.0% Sp 93.7% 92.0% 95.4% PPV 9.1% 1.5% 16.7% NPV 99.6% 99.1% 100.0%	Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: - Explicit validation method?: -
	Blinding: None					
	Definition of positive and negative on screening test: NR					

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results				Comments/Quality Scoring
Asif, Sattar, Dawood, et al., 2004 #1580	location: Rawalpindi, Pakistan	et location: Mean (SD): 41.4 NR Rawalpindi, Pakistan Menopausal status Detected by exam	Symptomatic (n [%]): NR Detected by exam (n [%]):	1) CA-125 Absolute value of serum CA-125 by solid phase two-site chemiluminescent		with cuto Dis+ 47 8	ff value of Dis- 3 42	f 200 Tot 50 50	Comments: No stratification by menopausal status Incomplete data reporting makes exact numbers in 2x2
	Jan 2001 to Jan 2002 Size of population:	(n [%]): Pre (< 45): 56 (56%) Post (> 55): 44 (44%)		enzyme immunometric assay using Immulite CA-125 kit (DPC, USA)	Tot	55	45 Lower	100 Upper	tables uncertain: There is some discrepancy with PPV and NPV reported in paper;
	100 women Surgical case series	≥ 1 year amenorrhea Race/ethnicity	(n [%]): NR	2) Ultrasound score (U; transvaginal) based on	Se 8	Value 85.0% 93.0%	<u>95% CI</u> 75.6% 85.5%	<u>95% CI</u> 94.4% 100.0%	couldn't find 2x2 cell values to match Se, Sp, PPV and NPV assuming 55 Disease+
	Reference standard: Histopathological	(n [%]): NR	Combination (n [%]): NR	following factors: solid areas (1)	PPV 9	94.0% 84.0%	87.4% 73.8%	100.0% 100.0% 94.2%	and 45 Disease- patients.
	diagnosis	Risk factors (n [%]): NR	Additional data used for diagnosis: NR	multilocularity (1) bilaterality (1)	2) RMI1 v				Reference standard: + Verification bias: +
	applied to all test negatives?: Yes	Inclusion criteria: Consecutive women admitted to one of 2 military hospitals for	NK	ascites (1) extraovarian tumors (1) If total is 0, then U = 0 If total is 1, then U = 1		Dis+ 48 7 55	Dis- 5 40 45	Tot 53 47 100	Test reliability/variability: - Sample size: - Statistical tests: + Blinding: _ Definition of +/- on screening
	Statistical tests used: Se, Sp, PPV, NPV Blinding:	elective surgical exploration and resection of proven ovarian mass		If total ≥ 2, then U = 3 3) Menopausal score (M): Postmenopausal (> 1	Se 8 Sp 8 PPV 9	Value 87.0% 88.0% 90.6%	Lower 95% Cl 78.1% 78.5% 82.7%	Upper 95% CI 95.9% 97.5% 98.4%	test: -, did not choose a priori cutoff values Explicit validation method?: + (this was a validation of RMI1)
	None Definition of positive and negative on	Exclusion criteria: None		year of amenorrhea) = 3 Premenopausal = 1 RMI1 = U x M x CA-125	Results v			95.3% t have not	
	screening test: Implicitly defined by use of Jacobs instrument (Jacobs, Oram, Fairbanks, et al., 1990 [#6820]), but analysis considered multiple cutoff values			(Jacobs, Oram, Fairbanks, et al., 1990 [#6820])	been abs combinat RMI1 with 100, 150,	tions:	vels of 25	5, 50, 75,	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Aslam, Banerjee, Carr, et al., 2000 #2690	Geographical location: South London, UK Dates: NR Size of population: 100 women Registry Reference standard: Histopathological diagnosis from laparotomy Reference standard applied to all test negatives?: Yes Statistical tests used: Se, Sp, ROC curves/AUC Blinding: No Definition of positive and negative on screening test: NA	Age: Mean: 45.6 Range: 20-78 Menopausal status (n [%]): Pre: 63 (63%) Post: 37 (37%) ≥ 1 year amenorrhea or age > 50 if status post hysterectomy Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Women with known adnexal masses and due to undergo surgery at one of 3 UK hospitals Exclusion criteria: None	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis:	Scoring System1) Tailor model LR1 uses age, TAMXV (Doppler), papillary projection score (US): $P = 1/(1 + e - z)$, where $z = 0.1273 \times age +$ $0.2794 \times TAMXV +$ $4.4136 \times PPS - 14.2046$ Cutoff = 50%2) Timmerman model LR3 uses CA-125, morphologic and demographic data. $Z = 0.5948 \times$ menopausal status + $0.0205 \times CA-125 +$ $0.5446 \times ascites - 0.762 \times$ unilocularity 1.1606 x smooth + 1.5409 x PPS + $0.7633 \times$ bilateral - 1.0889 P > 50% assumed to be diagnostic of malignancy3) LR1 + LR2 4) LR1 + LR35) LR1 + LR2 + LR3Where LR2 = Alcazar (1998) model using morphologic features with Doppler blood flow variablesAscites = 1 or 0	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Scoring Comments:Although study applied reference standard to all test negative women, study included only women already referred for surgery; thus, there is a referral bias in the populationBorderlines counted as malignant Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: + Explicit validation method?: + (study validates 2 previously reported models)

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
					4) LR1 + LR3	
					Dis+ Dis- Tot T+ 26 4 30 T- 7 63 70 Tot 33 67 100	
					Lower Upper Value 95% CI 95% CI Se 79.0% 65.1% 92.9% Sp 94.0% 88.3% 99.7% PPV 86.7% 74.5% 98.8% NPV 90.0% 83.0% 97.0% AUC 0.95 5 5 5	
					5) LR2 + LR3	
					Dis+ Dis- Tot T+ 24 11 35 T- 9 56 65 Tot 33 67 100	
					Lower Upper 95% CI 95% CI Se 73.0% 57.9% 88.1% Sp 84.0% 75.2% 92.8% PPV 68.6% 53.2% 84.0% NPV 86.2% 77.8% 94.6% AUC 0.88 50.2% 50.2% 50.2%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Study Aslam, Tailor, Lawton, et al., 2000 #2580	Study Design Geographical location: South London, UK Dates: Jul 1997-Sep 1998 Size of population: 61 women Diagnostic test study Reference standard: Histopathological diagnosis Reference standard applied to all test negatives?: Yes Statistical tests used: Se, Sp Blinding: None Definition of positive and negative on screening test: As defined by models used	Age: Mean: 46.8 Range: 20-77 Menopausal status (n [%]): Pre (< 45): 36 Post (> 55): 25 ≥ 1 year amenorrhea or age > 50 if status	Presentation Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis:	Scoring System 1) RMI1 – Jacobs, Oram, Fairbanks, et al., 1990 (#6820) RMI1 = ultrasound score (U; 0, 1, 3) x menopausal status (M; 1, 3) x serum CA-125 RMI1 > 200 indicates malignancy 1 point each for: Bilateral lesions Multilocular Ascites Solid areas Intraabdominal metastases U = 0 if total is 0 1 if total is 1 and 3 if total is 2 M: Premenopausal = 1 Postmenopausal = 3 CA-125 in kU/L 2) RMI2 – Tingulstad, Hagen, Skjeldestad, et al., 1996 (#3890) As RMI1 except U = 1 if total is 0 or 1 4 if total ≥ 2 ; M = 1 or 4 in this model 3) Tailor model [Ref # 17] LR1 uses	1) RMI1 with cutoff value of 200 T+ $\frac{\text{Dis}+}{6}$ $\frac{\text{Dis}-}{35}$ Tot T- $\frac{6}{35}$ $\frac{35}{41}$ Tot 23 38 61 $\frac{\text{Lower}}{95\% \text{ Cl}}$ $\frac{\text{Upper}}{95\% \text{ Cl}}$ Se 73.9% 56.0% 91.9% Sp 92.1% 83.5% 100.0% PPV 85.0% 69.4% 100.0% PPV 85.0% 69.4% 100.0% NPV 85.4% 74.5% 96.2% 2) RMI2 with cutoff value of 200 T+ $\frac{\text{Dis}+}{17}$ $\frac{17}{4}$ 21 T- $\frac{6}{34}$ 40 Tot 23 38 61 $\frac{\text{Lower}}{95\% \text{ Cl}}$ $\frac{\text{Upper}}{95\% \text{ Cl}}$ Se 73.9% 56.0% 91.9% Sp 89.5% 79.7% 99.2% PPV 81.0% 64.2% 97.7% NPV 85.0% 73.9% 96.1% 3) Tailor's model with cutoff value of 50% T+ $\frac{10}{3}$ $\frac{13}{13}$ $\frac{13}{35}$ 48 Tot 23 38 61	•
				age, TAMXV (Doppler), PPS (US): P = 1/(1 + e - z), where z = 0.1273 x age + 0.2794 x TAMXV + 4.4136 x PPS - 14.2046	Se 43.5% 23.2% 63.7% Sp 92.1% 83.5% 100.0% PPV 76.9% 54.0% 99.8% NPV 72.9% 60.3% 85.5%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Balbi, Musone,	Geographical location: Naples, Italy Dates: Jan 1996-Mar 2000 Size of population: 92 women Case series Reference standard: Histopathological	Geographical Age: Symptomatic (n [%]): 1) Logistic regression 1) location: Range: 40-80 NR fitted model: Z = -5.39224 + Naples, Italy Menopausal status Detected by exam 2.35132 x US + T Dates: (n [%]): (n [%]): 2.81806 x PE + T Jan 1996-Mar 2000 NR NR 1.58268 x CA-125 + T Size of population: Race/ethnicity Detected by imaging 1.11594 x RI 1.11594 x RI 92 women (n [%]): NR NR Each variable is Suspicious" (1) or "not Suspicious" (1) or "not Suspicious" (0) F Reference standard: NR NR NR Suspicious" (0) F	1) Logistic regression model prediction T+ 17 5 22 T- 5 45 50 Tot 22 50 72 Lower Upper Value 95% Cl 95% Cl Se 77.3% 59.8% 94.8% Sp 90.0% 81.7% 98.3% PPV 77.3% 59.8% 94.8% NPV 90.0% 81.7% 98.3%	Scoring		
	diagnosis Reference standard applied to all test negatives?: No, 18 women with "clearly benign" masses not verified; 2 patients with "clearly malignant" disease (metastases) also excluded Statistical tests used:	Inclusion criteria: Women evaluated for pelvic mass at one institution Exclusion criteria: None	Additional data used r for diagnosis: None	transabdominal imaging if large tumor) Interpreted according to Valentin et al.: unilocular (1); multilocular (2); unilocular solid cyst (3); multilocular solid cyst (4); solid tumor (5) 3) PE physical exam by standard protocol. Examiner was asked to guess benign or malignant. This clinical	Results were reported, but have not been abstracted, for the following combinations: Se and Sp were given for individual components (PE, US, CA-125, CA-72- 4) as well as various combinations (not clearly defined how these were operationalized – but apparently not with fitted LR models)	test: + Explicit validation method?: -
	Se, Sp Blinding: None Definition of positive and negative on			 impression was used in model. No mention of blinding to other data. 4) CA-125 levels > 35 U/ml considered abnormal 		
	screening test: Defined			 5) CA-72-4 levels > 3 U/ml considered abnormal 6) Intratumoral resistance index (RI) was evaluated by color Doppler. RI < 0.4 		

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
				considered abnormal.		
Biagiotti, Desii, Vanzi, et al., 1999	Geographical location: Florence, Italy	Age: Range: 21-74	Symptomatic (n [%]): NR	models built from five training subsets of the	 Logistic regression models T+ indicates > 50% probability of malignancy. Analysis based on 	Comments: Analysis based on numbe of tumors rather than numb
#2990	Dates: NR	Menopausal status (n [%]): Pre (< 45): 146 (70.5%)	Detected by exam (n [%]): NR	data; candidate variables included: age, and 6 US variables: mean diameter of mass	number of tumors rather than number	of patients This study used almost exclusively US predictors; age was the only non-US
	Size of population: 207 women (226 adnexal masses)	Post (> 55): 61 (29.5%) Race/ethnicity	Detected by imaging (n [%]): NR	(mm), multilocularity, papillary projections, random echogenicity, peak systolic velocity	T+ 43 6 49 T- 8 169 177 Tot 51 175 226	predictor. Formula not given for multiple logistic regression model
	Case series; diagnostic test study	(n [%]): NR	Combination (n [%]): NR	(cm/sec), RI 2) Artificial neural	Lower Upper Value 95% CI 95% CI Se 84.3% 74.3% 94.3%	Quality assessment: Reference standard: +
	Reference standard: Histopathological diagnosis	Risk factors (n [%]): 19 patients had bilateral adnexal masses	Additional data used for diagnosis: NR	network using the 5 predictor variables identified from forward stepwise selection in LR	Sp96.6%93.9%99.3%PPV87.8%78.6%96.9%NPV95.5%92.4%98.5%	Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: +
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: Women undergoing TVUS before surgery for adnexal masses		training set models: age, and 6 US variables: papillary projections, random echogenicity, peak	 Artificial neural networks Analysis based on number of tumors rather than number of patients. Cutoff > 50%. 	Blinding: - Definition of +/- on screening
	Statistical tests used: Se, Sp Blinding:	Exclusion criteria: None		systolic velocity (cm/sec), RI 3) TVUS with transabdominal US for	Dis+ Dis- Tot T+ 49 4 53 T- 2 171 173 Tot 51 175 226	validation
	None Definition of positive and negative on screening test: Determined by model fit			large masses. Color Doppler imaging used to calculate RI.	ValueLower 95% CIUpper 95% CISe96.1%90.8%100.0%Sp97.7%95.5%99.9%PPV92.5%85.3%99.6%NPV98.8%97.3%100.0%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Chou, Chang, Yao, et al., 1994	Tainan, Taiwan	Age: Mean: 38 Range: 11-85	Symptomatic (n [%]): NR Detected by exam	2) Color Doppler US to visualize intratumoral	1) RI < 0.5 or CA-125 > 35 U/ml Dis+ Dis- Tot T+ 25 2 27 T+ 25 2 10 10	Comments: Poor description of morphologic criteria for positive ultrasound
#10930	Dates: Jan 1991-Feb 1993 Size of population:	Menopausal status (n [%]): Pre (< 45): 84 (78%) Post (> 55): 19	(n [%]): NR Detected by imaging	vessel and flow velocity3) RI with cutpoint of 0.5	T- 0 81 81 Tot 25 83 108 Lower Upper	2x2 tables do not agree with Se, Sp, PPV, and NPV statistics reported; not consistent with rounding
	108 women Registry	(18%) Premenarchal: 5 (4%)	(n [%]): 108 (100%) by CT or US	4) Serum CA-125 level with cutpoint of 35 U/ml or 65 U/ml	Value 95% Cl 95% Cl Se 100.0% 88.0% 100.0% Sp 97.0% 93.3% 100.0% PPV 92.6% 82.7% 100.0%	error alone Quality assessment: Reference standard: +
	Reference standard: Histopathology	Race/ethnicity (n [%]): NR	Combination (n [%]): NR		NPV 100.0% 96.3% 100.0% 2) RI < 0.5 or CA-125 > 65 U/ml	Verification bias: + Test reliability/variability: - Sample size: -
	Reference standard applied to all test negatives?: Yes	Risk factors (n [%]): NR	Additional data used for diagnosis: NR		Dis+ Dis- Tot T+ 25 0 25 T- 0 83 83	Statistical tests: + Blinding: - Definition of +/- on screening test: -
	Statistical tests used: Se, Sp, PPV, NPV	Inclusion criteria: Women undergoing surgery for adnexal tumors			Tot 25 83 108 Lower Upper Value 95% CI 95% CI	Explicit validation method?: -
	Blinding: None	Exclusion criteria: NR			Se100.0%88.0%100.0%Sp100.0%96.4%100.0%PPV100.0%88.0%100.0%	
	Definition of positive and negative on screening test: See under "Scoring System." Neither TVUS morphology criteria nor color Doppler US intratumoral vessel criteria were explicitly defined/described.				NPV 100.0% 96.4% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Davies, Jacobs, Woolas, et al., 1993	Geographical location: London, UK	Age: NR Menopausal status	Symptomatic (n [%]): NR Detected by exam	Óram, Fairbanks, et al., a	200 for T+	Comments: Borderlines counted as malignant
#4720	Dates: NR	(n [%]): Pre: 86 (69%) Post: 38 (31%)	(n [%]): NR	 Menopausal status (M) scored as follows: 	Dis+ Dis- Tot T+ 33 11 44 T- 4 76 80	Quality assessment: Reference standard: - (operative diagnosis
	Size of population: 124 women	≥ 1 year amenorrhea or age > 50 if status post hysterectomy	Detected by imaging (n [%]): NR	Postmenopausal (> 1 year of amenorrhea) = 3 Premenopausal =1	Tot 37 87 124	accepted in absence of histopathological diagnosis) Verification bias: +
	Retrospective series	Race/ethnicity	Combination (n [%]):	3) Serum CA-125 level	Value 95% CI 95% CI Se 89.0% 78.9% 99.1%	Test reliability/variability: +/- (intra- and inter-assay
	Reference standard: Histopathological or operative report diagnosis	(n [%]): NR Risk factors (n [%]):	NR Additional data used for diagnosis:	by RIA kit (CIS Bioindustries, France). Scored as absolute value.	Sp 87.0% 79.9% 94.1% PPV 75.0% 62.2% 87.8% NPV 95.0% 90.2% 99.8%	coefficients of variation > 10% for CA-125) Sample size: - Statistical tests: +
	Reference standard applied to all test negatives?: Yes	NR Inclusion criteria: Consecutive admissions for surgical exploration	NR	4) Pelvic US score (U; transabdominal) based on presence of the following factors:	Results were reported, but have not been abstracted, for the following combinations: CA-125 with cutoff values of 30, 50, 70, 90, 120 Ultrasound score with cutoff values of 1	Blinding: - Definition of +/- on screening test: - Explicit validation method?: + (this is a validation study of RMI1)
	Statistical tests used: Se, Sp, ROC curves	of adnexal mass Exclusion criteria: None		solid areas (1) bilaterality (1) ascites (1) extraovarian tumors (1)	and 3 Menopausal status (post vs pre) RMI with cutoffs of 25, 50, 75, 100,	
	Blinding: None			If total is 0, then $U = 0$ If total is 1, then $U = 1$	150, 250	
	Definition of positive and negative on screening test: Multiple cutoffs tested; measures defined as per Jacobs, Oram, Fairbanks, et al., 1990 (#6820)			If total ≥ 2, then U = 3		

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Dowd, Quinn, Rome, et al., 1993 #4680	Geographical location: Melbourne, Australia Dates: NR Size of population: 264 women Registry Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Statistical tests used: Se, Sp Blinding: None Definition of positive and negative on screening test: RMI > 200	Age: Mean: 50.2 Range: 15-89 Menopausal status (n [%]): Pre: 121 (46%) Post: 143 (54%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Serum CA-125 performed for evaluation of pelvic mass Exclusion criteria: No suspected pelvic mass; CA-125 obtained for screening only; no histopathology	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: CA-125 Menopausal status Ultrasound score	 CA-125 Absolute value (capped at 500) Ultrasound score (U); criteria not described (0, 1, or 3 depending on the presence of particular features) Menopausal score (M) Postmenopausal (> 1 year amenorrhea) = 3 Premenopausal = 1 RMI1 = U x M x CA-125 (Jacobs, Oram, Fairbanks, et al., 1990 [#6820]); cutoff > 2000 	 RMI1 (n = 180 patients) Se = 70% Sp = 94% Can't calculate 2x2 (marginals not reported for this 180-patient subset for whom RMI1 was available). No stratification by age or menopausal status. 	Comments: Unable to determine 2x2 table from available information – reported that: "There was sufficient data to use the RMI of Jacobs, Oram, Fairbanks, et al., 1990 (#6820), in 180 patients: the Se was 0.70 and the Sp was 0.94." No singular solution or marginals were reported. Borderlines counted as malignant Quality assessment: Reference standard: + Verification bias: - Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: + Explicit validation method? + (this is validation study)

Study	Study Design	dy Design Patients Clinical Presentation		Items Included in Scoring System	Results	Comments/Quality Scoring
Gadducci, Capriello, Bartolini, et al., 1988 #6650	Geographical location: Pisa, Italy Dates: NR Size of population: 119 patients Diagnostic test study among referral series Reference standard: Histopathology; specimen obtained at laparotomy Reference standard applied to all test negatives?: Yes Statistical tests used: Se, Sp Blinding: No Definition of positive and negative on screening test: NA		Symptomatic (n [%]): NR Detected by exam (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	1) US score based on: Shape (rounded-0 patients; polycyclic – 2 patients; poorly defined – 4 patients) Ascites (absent – 0 patients; present – 4 patients); Outline (regular – 0 patients; poorly defined – 2 patients; thickened – 4 patients) Structure (anechoic or mildly echogenic – 0 patients; homogeneous echogenic – 1 patient; multilocular – 2 patients; anechoic with echogenic areas – 3 patients; echogenic with anechoic areas – 4 patients) Total score determined by summing points for each parameter (range 0-16 patients) T- < 10 T+ \ge 10 2) CA-125 solid phase sandwich radioimmunoassay (Centodor kit) T+ \ge 65 U/ml T- < 65 U/ml	CA-125 assay: T+ if either (or both) abnormal; T- if both normal T+ <u>33 5</u> T- <u>2 78</u> 80 Tot 35 83 118 <u>Lower</u> Upper <u>Value 95% CI 95% CI</u> Se 94.3% 86.6% 100.0% Sp 94.0% 88.9% 99.1% PPV 86.8% 76.1% 97.6% NPV 97.5% 94.1% 100.0%	 Blinding: - Definition of +/- on screening test: +

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Guerriero, Ajossa, Risalvato, et al., 1998 #3400	Geographical location: Cagliari, Italy Dates: Jan 1996-May 1997	Decation: Mean (SD): 41 (15) NR Morphologica Cagliari, Italy Range: 14-77 defined for be Detected by exam disorders Dates: Menopausal status (n [%]):	 B-mode TVUS; Morphological criteria defined for benign disorders Color Doppler imaging with PI and RI 	1) CDE and CA-125 \ge 65 U/ml (all patients – numbers are masses) T+ Dis+ Dis- Tot T+ 22 5 27 T- 11 140 151	Comments: Study described intra- observer variation for CDE, RI, and PI Quality assessment: Reference standard: +	
	Size of population: 192 adnexal masses in 178 women from among 240 eligible referred women Registry	Race/ethnicity (n [%]): NR Risk factors (n [%]):		calculated. If no Doppler waveforms were obtained, then the result was considered negative. 3) CA-125 (> 35 U/ml	Tot 33 145 178 Value 95% CI 95% CI Se 66.7% 50.6% 82.8% Sp 96.6% 93.6% 99.5% PPV 81.5% 66.8% 96.1% NPV 92.7% 88.6% 96.9%	Verification bias: + Test reliability/variability: + Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: +/-
	Consecutive Reference standard: Histopathology	NR Inclusion criteria: Consecutive women with adnexal mass	Additional data used for diagnosis: NR	or > 65 U/ml)	 CDE and CA-125 ≥ 65 U/ml (postmenopausal women only – numbers are masses) 	Explicit validation method?:
	Reference standard applied to all test negatives?: Yes	based on palpation or sonography Exclusion criteria :			Dis+ Dis- Tot T+ 17 0 17 T- 9 27 36 Tot 26 27 53	
	Statistical tests used: Se, Sp Blinding: NR	Pregnant			Lower Upper Value 95% CI 95% CI Se 65.4% 47.1% 83.7% Sp 100.0% 88.9% 100.0% PPV 100.0% 82.4% 100.0%	
	Definition of positive and negative on screening test: Yes				NPV 75.0% 60.9% 89.1% 3) CDE and CA-125 \geq 65 U/ml (premenopausal women only – numbers are masses)	
					Dis+ Dis- Tot T+ 5 5 10 T- 2 113 115 Tot 7 118 125	
					Lower Upper Value 95% Cl 95% Cl Se 71.4% 38.0% 100.0% Sp 95.8% 92.1% 99.4%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
				J - /	PPV 50.0% 19.0% 81.0%	<u>v</u>
					 CDE and CA-125 ≥ 35 U/ml (postmenopausal women only – numbers are masses) 	
					Dis+ Dis- Tot T+ 21 1 22 T- 5 26 31 Tot 26 27 53	
					LowerUpper 95% ClUpper 95% ClSe80.8%65.6%95.9%Sp96.3%89.2%100.0%PPV95.5%86.8%100.0%NPV83.9%70.9%96.8%	
					 B-mode and CA-125 ≥ 65 U/ml (postmenopausal women only – numbers are masses) 	
					Dis+ Dis- Tot T+ 17 0 17 T- 9 27 36 Tot 26 27 53	
					ValueLower 95% ClUpper 95% ClSe65.4%47.1%83.7%Sp100.0%88.9%100.0%PPV100.0%82.4%100.0%NPV75.0%60.9%89.1%	
					6) B-mode and CA-125 ≥ 35 U/ml (postmenopausal women only – numbers are masses)	
					Dis+ Dis- Tot T+ 21 1 22 T- 5 26 31 Tot 26 27 53	
					Lower Upper	

Study	Study Design	Patients	atients Clinical Presentation	Items Included in Res Scoring System	Results			Comments/Quality Scoring	
						Value	95% CI	95% CI	
					Se	80.8%	65.6%	95.9%	
					Sp	96.3%	89.2%	100.0%	
					PPV NPV	95.5% 83.9%	86.8% 70.9%	100.0% 96.8%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Guerriero, Alcazar, Coccia, et al., 2002 #2130	Geographical location: Cagliari, Florence, and Navarra, Italy Dates: Apr 1997-Jul 2000 Size of population: 826 masses in 789 women from a potential study population of 1020 women Registry Reference standard: Histopathology Reference standard applied to all test negatives?: Yes Statistical tests used: Se, Sp, PPV, NPV Blinding: None Definition of positive and negative on screening test: Yes	Age: Mean (SD): 40 (14) Range: 14-81 Menopausal status (n [%]): Pre: 617 (78%) Post: 172 (22%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: All women scheduled for surgery for the presence of a persistent adnexal mass Exclusion criteria: Anechoic unilocular or bilocular cystic mass with a thin regular wall without endocystic vegetation (n = 234)	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Scoring System 1) US morphology 2) Color Doppler US 3) CA-125	1) B-mode and CA-125 > 35 U/ml (postmenopausal women only – numbers are masses) T+ $\overrightarrow{73}$ $\overrightarrow{6}$ $\overrightarrow{79}$ T- 20 $\overrightarrow{74}$ 94 Tot 93 80 173 \underbrace{Value} 95% Cl 95% Cl Se 78.5% 70.1% 86.8% Sp 92.5% 86.7% 98.3% PPV 92.4% 86.6% 98.2% NPV 78.7% 70.4% 87.0% 2) Color Doppler and CA-125 > 35 U/ml (postmenopausal women only – numbers are masses) T+ $\overrightarrow{11}$ $\overrightarrow{3}$ 74 T- 22 $\overrightarrow{76}$ 98 Se 76.3% 67.7% 85.0% Se 76.3% 67.7% 85.0% Sp 96.2% 92.0% 100.0% PPV 95.9% 91.5% 100.0% NPV 77.6% 69.3% 85.8% 3) B-mode and CA-125 > 35 U/ml (all women – numbers are masses) T+ $\overrightarrow{113}$ $\overrightarrow{30}$ 143 T- $\overrightarrow{147}$ $\overrightarrow{679}$ 826	
					Lower Upper Value 95% CI 95% CI Se 76.9% 70.1% 83.7% Sp 95.6% 94.0% 97.1%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results				Comments/Quality Scoring
					PPV 79	9.0%	72.3%	85.7%	
					NPV 95	5.0%	93.4%	96.7%	
					4) Color D				
					U/ml (all wo	omen –	- numbers	are	
					masses)				
						Dis+	Dis-	Tot	
					T+	112	10	122	
					T-	35	669	704	
					Tot	147	679	826	
							Lower	Upper	
					V	/alue	95% CI	95% CI	
					Se 76	6.2%	69.3%	83.1%	
					Sp 98	8.5%	97.6%	99.4%	
						1.8%	86.9%	96.7%	
					NPV 95	5.0%	93.4%	96.6%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Jacobs, Oram, Fairbanks, et al., 1990	Geographical location: London, UK Dates:	Age: Mean: 51.8 Menopausal status (n [%]):	Symptomatic (n [%]): NR Detected by exam (n [%]):	RMI1 – clinical prediction rule developed from logistic regression model based on ultrasound, CA-125		Comments: Small data set relative to number of predictors examined; no validation; no a priori definition of positive
#6820	NR Size of population:	Pre: 61 Post: 82 > 1 year of	NR Detected by imaging	and menopausal status RMI1 = $U \times M \times CA-125$	T- <u>6 95</u> 101 Tot 41 98 139 Lower Upper	items Borderlines counted as malignant
	143 women	amenorrhea or age > 50 if status post hysterectomy	(n [%]): NR	1) Ultrasound score (U; transabdominal) – 1	Value 95% Cl 95% Cl Se 85.4% 74.5% 96.2%	Quality assessment: Reference standard: - (when
	retrospective or prospective series;	Race/ethnicity	Combination (n [%]): NR	point for each of the following: multilocular	Sp 96.9% 93.5% 100.0% PPV 92.1% 83.5% 100.0% NPV 92.1% 83.5% 100.0%	no specimen was sent for histopathology, the surgical
	diagnostic test study		Additional data used	cyst, evidence of solid areas, evidence of	NPV 94.1% 89.4% 98.7% 2) RMI1 with cutoff value of 250	diagnosis was assumed to be correct)
	Reference standard: Histopathological or	Risk factors (n [%]):	for diagnosis:	metastases, presence of ascites, and bilateral	(maximum specificity)	Verification bias: + Test reliability/variability: +/-
	operative report diagnosis	NR		lesions U = 0 for US score of 0	Dis+ Dis- Tot T+ 32 1 33 T- 9 97 106	(coefficient of variation < 10% for CA-125) Sample size: -
	Reference standard applied to all test negatives?:	Admitted for elective surgical investigation of an adnexal mass		=1 for US score of 1 = 3 for US score ≥ 2	Tot 41 98 139	Statistical tests: + Blinding: - (CA-125 only) Definition of +/- on screening
	No Statistical tests	Exclusion criteria:		 Serum CA-125 by RIA (Abbott Labs, Chicago) 	Lower Upper Value 95% CI 95% CI Se 78.0% 65.3% 90.7%	test: - Explicit validation method?: -
	used: Se, Sp, ROC curves,	None		4) Menopausal status	Sp99.0%97.0%100.0%PPV97.0%91.1%100.0%NPV91.5%86.2%96.8%	
	LR Blinding:			(M): 1 if premenopausal 3 if postmenopausal	3) RMI1 with cutoff value of 25 (maximum Se)	
	Clinical assessment blind only to CA-125 level				Dis+ Dis- Tot T+ 41 37 78	
	Definition of positive and negative on				T- 0 61 61 Tot 41 98 139	
	screening test: No a priori cutoff				Lower Upper Value 95% CI 95% CI	
					Se 100.0% 92.7% 100.0% Sp 62.2% 52.6% 71.8% PPV 52.6% 41.5% 63.6% NPV 100.0% 95.1% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
					Results were reported, but have not been abstracted, for the following combinations: RMI 1with cutoff values of 50, 75, 100, 150	
					Se Sp 50 95.1% 76.5% 75 92.7% 84.7% 100 85.4% 87.8% 150 85.4% 93.9%	
Lu, Van Gestel,	Geographical location:	Age: NR	Symptomatic (n [%]) : NR	developed using least	1) RMI1 with cutoff value of 75	Comments: Data from Table 2 (page
al., 2003	Leuven, Belgium	Menopausal status	Detected by exam	squares support vector machine (LS-SVM)	Dis+ Dis- Tot T+ 44 27 71	296) Models 2-7 parameters not
#1730	Dates: 1994-1999	(n [%]): NR	(n [%]) : NR	classifiers in a Bayesian evidence framework.	T- <u>10 79</u> 89 Tot 54 106 160	specified This paper written to
	1994-1997 (training) 1997-1999 (test)	Race/ethnicity	Detected by imaging	Model built on 265 patient training set;	Lower Upper	demonstrate feasibility of new modeling approach and
	Size of population: 525 women	(n [%]): NR	(n [%]): 525 (100%)	tested on 160-patient test set.	Value 95% CI 95% CI Se 81.5% 71.1% 91.8%	application to ovarian mass; does not provide model for use in clinical
	265 (training set) 160 (test set)	Risk factors (n [%]): NR	Combination (n [%]): NR	Candidate variables included 27	Sp 74.5% 66.2% 82.8% PPV 62.0% 50.7% 73.3%	decisionmaking
				demographic, serum	NPV 88.8% 82.2% 95.3% AUC = 0.8733 (± 0.0298 SE)	Quality assessment:
	Retrospective case series	Inclusion criteria: Women referred for US to single	Additional data used for diagnosis: NR	marker, color Doppler, B-mode US, US morphologic, and US	2) RMI1 with cutoff value of 100	Reference standard: + Verification bias: + Test reliability/variability: -
	Reference standard: Histopathologic diagnosis	ultrasonographer with persistent extrauterine pelvic mass which was		echogenicity variables. Variables were chosen using forward selection.	Dis+ Dis- Tot T+ 40 21 61 T- 14 85 99 Tot 54 106 160	Sample size: + Statistical tests: + Blinding: - Definition of +/- on screening
	Reference standard applied to all test	subsequently surgically removed		Six different models were built and tested	Lower Upper	test: - Explicit validation method?:
	negatives?: Yes	Exclusion criteria: No preoperative CA-		2) LR1- logistic	Value 95% CI 95% CI Se 74.1% 62.4% 85.8%	+
	Statistical tests used:	125 assay (n = 100)		regression 3) LS-SVM1 (Lin)	Sp 80.2% 72.6% 87.8% PPV 65.6% 53.7% 77.5% NPV 85.9% 79.0% 92.7%	
	Se, Sp, ROC curves			4) LS-SVM1 (RBF)	Results were reported, but have not	
	Blinding: None			5) LR2	been abstracted, for the following	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
	Definition of positiv	/e		6) LS-SVM2 (Lin)	combinations: Models 2-7 have Se, Sp, PPV and NPV	,
	and negative on screening test:			7) LS-SVM2 (RBF)	for 3 to 4 cutoff values each and AUC reported. Each performs better than RMI1.	
				8) RMI1 (Jacobs, Oram, Fairbanks, et al., 1990 [#6820])		

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Ma, Shen, and Lang, 2003	Geographical location: Beijing, China	ocation: Range: 30 - NR NR Beijing, China	Detected by exam	1) RMI2 (Tingulstad, Hagen, Skjeldestad, et al., 1996 [#3890]) – clinical prediction rule	1) RMI2 cutoff value 200 <u>Dis+ Dis-</u> Tot T+ <u>55</u> 12 67	Comments: Relatively poor quality of reporting
#1900	Dates: Jan 1998-Jun 1999	(n [%]): Pre: 89 (64%) Post: 51 (36%)	(n [%]): NR	developed from logistic regression model based on ultrasound (U), CA-	T- 8 65 73 Tot 63 77 140	Quality assessment: Reference standard: +/- Verification bias: +
	Size of population: 140 women	 > 1 year of amenorrhea or age > 50 if status post 	Detected by imaging (n [%]): NR	125, and menopausal status (M)	Lower Upper Value 95% Cl 95% Cl Se 87.3% 79.1% 95.5%	Test reliability/variability: - Sample size: - Statistical tests: +
	Single-institution retrospective case series	hysterectomy Race/ethnicity	Combination (n [%]): NR	RMI2 = U x M x CA-125 2) Ultrasound (U;	Sp84.4%76.3%92.5%PPV82.1%72.9%91.3%NPV89.0%81.9%96.2%	Blinding: - Definition of +/- on screening test: -
	Reference standard: Not stated explicitly,	(n [%]): NR	Additional data used for diagnosis:	transabdominal) scored 1 point for each of the following	2) RMI2 cutoff value 100	Explicit validation method?: + (this is a validation study of RMI2)
	but implied that all patients had pathological classification	Risk factors (n [%]): NR Inclusion criteria:	NR	characteristics: multilocular cyst, evidence of solid areas, evidence of metastases,	Dis+ Dis- Tot T+ 59 21 80 T- 4 56 60	
	Reference standard	"Ovarian neoplasm" patients over 30		presence of ascites, and bilateral lesions.	Tot 63 77 140 Lower Upper	
	applied to all test negatives?: Yes, presumably	years admitted to a single institution		U = 1 for total score of 0-1	Value 95% Cl 95% Cl Se 93.7% 87.7% 99.7% Sp 72.3% 62.3% 82.3%	
	Statistical tests used:	Exclusion criteria: NR		4 for total score ≥ 2 3) Serum CA-125	PPV 73.8% 64.1% 83.4% NPV 93.3% 87.0% 99.6%	
	Se, Sp, PPV Blinding:			 Menopausal status (M): 	Results were reported, but have not been abstracted, for the following combinations:	
	None Definition of positive			1 if premenopausal 4 if postmenopausal	RMI2 with cutoff of 50, 400, 1000	
	and negative on screening test: Used definitions of Tingulstad, Hagen, Skjeldestad, et al.,					
	1996 (#3890), but analyzed multiple cutoff values					

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Maggino, Gadducci, D'Addario, et al., 1994 #4500	Geographical location: Italy Dates: Mar 1991-Mar 1992 Size of population: 383 women 48 excluded for inadequate data 335 evaluable 45 benign cysts 290 surgical cases	Age: Mean: 61.9 Range: 40-91 Menopausal status (n [%]): Post: 290 (100%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR	Symptomatic (n [%]): 209 (72%) Detected by exam (n [%]): All patients Detected by imaging (n [%]): NR Combination (n [%]):	1) Gynecologic examination	1) Combined US (Gr III possibly malignant) or CA-125 (> 65 U/ml) as T+; else, T- Analysis limited to ovarian tumors $\begin{array}{c c} \hline Dis+ & Dis- & Tot\\ T+ & 100 & 36 & 136\\ T- & 6 & 98 & 104\\ Tot & 106 & 134 & 240\\ \hline Tot & 106 & 134 & 240\\ \hline \\ \hline \\ Se & 94.3\% & 89.9\% & 98.7\%\\ Sp & 73.1\% & 65.6\% & 80.6\%\\ \hline \end{array}$	-
	Case series	Inclusion criteria: Postmenopausal	Additional data used for diagnosis: NR	liquid content or solild homogeneous content; >3 thin septa; thick but	OP 73.1% 03.0% 80.0% PPV 73.5% 66.1% 80.9% NPV 94.2% 89.7% 98.7%	Quality assessment: Reference standard: +
	Reference standard:women with pelvic mass (intra- or extra adnexal)Histopathological diagnosis in 290 women; clinical and US followup in 45 patients with benign- appearing cystswomen with pelvic mass (intra- or extra adnexal)Exclusion criteria:Premenopause; previous malignant neoplasia (except	women with pelvic mass (intra- or extra- adnexal) Exclusion criteria: Premenopause; previous malignant		regular septa; absence of endocystic vegetation; absence of free peritoneal fluid; Malignant if none of above features observed 3) CA-125:	2) Combined US (Gr III possibly malignant) or CA-125 (> 35 U/ml) as T+; else, T- Analysis limited to ovarian tumors <u>Dis+ Dis-</u> Tot T+ <u>102 45</u> 147 T- <u>4 89</u> 93 Tot 106 134 240	Verification bias: - (45 women not verified, but were followup with US and clinical exam) Test reliability/variability: - Sample size: - Statistical tests: - (misguided statistical analysis) Blinding: -
	applied to all test negatives?: 45 women with US findings indicating benign cyst and CA- 125 < 35 U/ml not verified	previous bilateral adnexectomy; if > 55 years of age, previous hysterectomy for non- tumoral disease		 T- < 35 U/ml Borderline 35-65 U/ml T+ > 65 U/ml 4) Combination of US and CA-125 T+ if either individual test abnormal 	Value 95% CI 95% CI Se 96.2% 92.6% 99.9% Sp 66.4% 58.4% 74.4% PPV 69.4% 61.9% 76.8% NPV 95.7% 91.6% 99.8%	Definition of +/- on screening test: - Explicit validation method?:
	Statistical tests used: Se, Sp, PPV, NPV			T- if neither test abnormal	3) Combined US (Gr II-III possibly malignant or borderline) or CA-125 (> 65 U/ml) as T+; else, T-	
	Blinding: None				Analysis limited to ovarian tumors Dis+ Dis- Tot	
	Definition of positive and negative on screening test: Yes				T+ 106 77 183 T- 0 57 57 Tot 106 134 240	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
				<u> </u>	Lower Upper Value 95% Cl 95% Cl Se 100.0% 97.2% 100.0% Sp 42.5% 34.2% 50.9% PPV 57.9% 50.8% 65.1% NPV 100.0% 94.7% 100.0%	¥
					 4) Combined US (Gr II-III possibly malignant or borderline) or CA-125 (>35 U/ml) as T+; else, T- Analysis limited to ovarian tumors 	
					Dis+ Dis- Tot T+ 106 82 188 T- 0 52 52 Tot 106 134 240	
					Lower Upper Value 95% Cl 95% Cl Se 100.0% 97.2% 100.0% Sp 38.8% 30.6% 47.1% PPV 56.4% 49.3% 63.5% NPV 100.0% 94.2% 100.0%	
					5) CA-125 > 65	
					Dis+ Dis- Tot T+ 76 10 86 T- 30 124 154 Tot 106 134 240	
					Lower 95% ClUpper 95% ClSe71.7%63.1%80.3%Sp92.5%88.1%97.0%PPV88.4%81.6%95.1%NPV80.5%74.3%86.8%	
					6) US T+ Class III (possibly malignant) analysis limited to ovarian tumors (not ovarian tumors excluded)	1-
					Dis+ Dis- Tot T+ <mark>90 30</mark> 120	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results			Comments/Quality Scoring
					T- 1	6 104	120	
					Tot 10	6 134	240	
						Lower	Upper	
					Value	95% CI	95% CI	
					Se 84.9%	78.1%	91.7%	
					Sp 77.6%	70.6%	84.7%	
					PPV 75.0%	67.3%	82.7%	
					NPV 86.7%	80.6%	92.7%	
					Results were been abstract combinations No other comb following indivii US (Class II-II	ed, for the f nations, but dual tests: possibly ma	ollowing the	
					borderline as p CA-125 (> 35 l	,	ive)	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Mancuso, De Vivo, Triolo, et al., 2004	Iocation:Mean: 42.2Pain 68 (54%), Messina, ItalyRange: 18-82Menstrual dis (18%)	Symptomatic (n [%]): Pain 68 (54%) Menstrual disorder 22 (18%) Urinary/intestinal 5 (4%)	1) US (transvaginal) Positive if: solid structure or cystic but complex; irregular walls, endocystic vegetations,		Comments: 2x2 cell numbers do not result in exact figures for PPV as reported in Table 4	
#1610	Dates: NR Size of population: 125 women	Menopausal status (n [%]): Pre: 76 (61%) Post: 49 (39%)	Asymptomatic 30 (24%) Detected by exam (n [%]):		T- <u>1 101</u> 102 Tot 14 111 125 Lower Upper	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: -
	Case series Reference standard:	Race/ethnicity (n [%]): NR	NR Detected by imaging (n [%]):	35 U/ml 3) Combinations of US, age (> 50 years), CA-	Value 95% CI 95% CI Se 92.9% 79.4% 100.0% Sp 91.0% 85.7% 96.3% PPV 56.5% 36.3% 76.8% NPV 99.0% 97.1% 100.0%	Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening
	Histopathological diagnosis Reference standard	Risk factors (n [%]): Nulliparous: 62 (50%) Multiparous: 63		125, menopause (post)	2) Combination of CA-125 + age > 50	test: + Explicit validation method?: -
	applied to all test negatives?: Yes	(50%) Inclusion criteria: Women admitted for	Additional data used for diagnosis: NR		Dis+ Dis- Tot T+ 13 4 17 T- 1 107 108 Tot 14 111 125	
	Statistical tests used: Se, Sp, PPV, NPV	adnexal mass Exclusion criteria: None			Lower Upper Value 95% Cl 95% Cl Se 91.0% 76.0% 100.0% Sp 96.6% 93.2% 100.0%	
	Blinding: None Definition of positive				PPV 76.5% 56.3% 96.6% NPV 99.1% 97.3% 100.0% 3) Combination of US + menopause	
	and negative on screening test: CA-125 - >35 U/ml US, defined				Dis+ Dis- Tot T+ 14 13 27 T- 0 98 98 Tot 14 111 125	
					Lower Upper Value 95% Cl 95% Cl Se 100.0% 78.6% 100.0% Sp 88.7% 82.8% 94.6% PPV 51.9% 33.0% 70.7% NPV 100.0% 96.9% 100.0%	
					4) Combination of CA-125 + menopause	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
					Dis+ Dis- Tot T+ 14 4 18 T- 0 107 107 Tot 14 111 125	
					Lower Upper 95% CI 95% CI 95% CI 95% CI 95% CI 95% CI 96.6% 93.2% 9PV 77.8% 58.6% 97.0% NPV 100.0% 97.2% 100.0%	
					5) Combination of CA-125 + US Dis+ Dis- Tot	
					T+ 14 6 20 T- 0 105 105 Tot 14 111 125	
					Lower Upper 95% CI 95% CI Se 100.0% 78.6% 100.0% Sp 94.4% 90.1% 98.7% PPV 70.0% 49.9% 90.1% NPV 100.0% 97.1% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Manjunath, Pratap- kumar, Sujatha, et	Geographical location: Manipal, India	Age: NR Menopausal status	Symptomatic (n [%]): NR Detected by exam	1 point each for: so multilocular, solid areas,	Note: Borderline tumors not counted, so n = 148 (appropriate) Note: Results are given for 11 different	Quality assessment: Reference standard: + Verification bias: +
al., 2001 #2510	Dates: Jan 97-Aug 99	(n [%]): Pre: 84 (57%) Post: 64 (43%)	(n [%]): NR	intra-abdominal metastases	cutoff scores. The authors recommend cutoff of 200 for all 3 RMIs to minimize false positives.	Sample size: - Statistical tests: + Blinding: -
π2J10	Size of population: 152	Race/ethnicity (n [%]):	Detected by imaging 2) CA-125 ty (n [%]): 1) RMI1 (cur NR 3) Menopausal status	1) RMI1 (cutoff 200)	Definition of +/- on screening test: +/- (no a priori cutoff) Explicit validation method?:	
	Registry	NR	Combination (n [%]):	4) RMI1 (Jacobs, Oram,	Dis+ Dis- Tot T+ <u>68 5</u> 73	+ (validation of prior reports on the RMI)
	Reference standard: Pathology	Risk factors (n [%]): NR	NR Additional data used	Fairbanks, et al., 1990 [#6820]) RMI1 = U x M x CA-	T- <u>25 50</u> 75 Tot <mark>93 55</mark> 148	
	Reference standard applied to all test negatives?: Yes – applied to all in population regardless of RMI score	Inclusion criteria: Patients who underwent surgery for a pelvic mass Exclusion criteria: NR	for diagnosis: NR	125, where M = 1 or 3 (pre or post) and U = 0 (no points), 1 (one point) or 3 (2 or more points on ultrasound) 5) RMI2 (Tingulstad,	Lower Upper 95% Cl 95% Cl Se 73.0% 64.0% 82.0% Sp 91.0% 83.4% 98.6% PPV 93.2% 87.4% 98.9% NPV 66.7% 56.0% 77.3%	
	Statistical tests used: Chi-square, Se, Sp, PPV, NPV			Hagen, Skjeldestad, et al., 1996 [#3890]) RMI2 = U x M x CA-	2) RMI2 (cutoff 200) Dis+ Dis- Tot	
	Blinding: NR			125, where M = 1 or 4 (pre or post) and U = 1 (score 0 or 1) or 4 (score 2 or more)	T+ 71 10 81 T- 22 45 67 Tot 93 55 148	
	Definition of positive and negative on screening test: Ultrasound: 1 point each for: multilocular, solid areas, ascites,			6) RMI3 (Tingulstad et al 1999) RMI3 = U x M x CA- 125, where M = 1 or 3 (pre or post), U = 1 (score 0 or 1) or 3	Lower Upper Value 95% CI 95% CI Se 76.0% 67.3% 84.7% Sp 82.0% 71.8% 92.2% PPV 87.7% 80.5% 94.8% NPV 67.2% 55.9% 78.4%	
	bilateral, and intra- abdominal metastases Menopausal status: >			(score at least 2)	3) RMI3 (cutoff 125) Dis+ Dis- Tot	
	1 yr amenorrhea or age > 50				$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
					Lower Upper	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results			Comments/Quality Scoring
					Valu	e 95% CI	95% CI	
					Se 80.09	6 71.9%	88.1%	
					Sp 80.09	69.4%	90.6%	
					PPV 87.19	6 79.9%	94.2%	
					NPV 69.89	58.5%	81.2%	
					4) RMI3 (cutof	f 200)		
					Dis+	Dis-	Tot	
					T+	5 5	74	
					T- 2	24 50	74	
					Tot	3 55	148	
						Lower	Upper	
					Valu	95% CI	95% CI	
					Se 74.09	65.1%	82.9%	
					Sp 91.09	6 83.4%	98.6%	
					PPV 93.29	6 87.5%	99.0%	
					NPV 67.69	6 56.9%	78.2%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring Quality assessment: Reference standard: +
Mol, Boll, De Kanter, et al., 2001	Geographical location: Utrecht, the	Age: Mean: 46.6	Symptomatic (n [%]) : NR	1) Tailor 1997 ref 19 US, Doppler, age, AUC	1) Tailor et al., 1997 model sonography, color Doppler, age	
·	Netherlands	Range: 20-89	Detected by exam	0.81	Dis+DisTot	Verification bias: + Test reliability/variability: -
#5780	Dates: 1991-1998	Menopausal status (n [%]): Pre: 109 (64%) Post: 61 (36%)	(n [%]): NR Detected by imaging	2) Prompeler 1997 ref 22, AUC 0.73 US, menopausal status	T+ 27 77 104 T- 3 63 66 Tot 30 140 170	(this study is testing the models' reliability) Sample size: + Statistical tests: +
	Size of population: 170 women	Race/ethnicity (n [%]):	(n [%]) : NR	3) Jacobs 1990 ref 13 menopause, US, CA- 125, AUC 0.83	Lower Upper Value 95% CI 95% CI Se 90.0% 79.3% 100.0%	Blinding: - (NR) Definition of +/- on screening test: +
	Registry	NR	Combination (n [%]): NR	4) Jacobs 1993 ref 23	Sp 45.0% 36.8% 53.2% PPV 26.0% 17.5% 34.4%	Explicit validation method?: + (this is a validation study)
	Reference standard: Pathology	Risk factors (n [%]): NR	Additional data used for diagnosis:	menopause, US CA- 125, AUC 0.86	NPV 95.5% 90.4% 100.0%2) Prompeler 1997 ref 22, AUC 0.73	
	Reference standard applied to all test	Inclusion criteria: Surgery for an	NR	5)Tingulstad 1996 ref 12	U/S, menopausal status	
	negatives?: Yes	adnexal mass Exclusion criteria:		menopause, US, CA- 125, AUC 0.83	Dis+ Dis- Tot T+ 27 91 118	
	Statistical tests used:	NR		6) Timmerman 1999 ref 9	T- <u>3 49</u> 52 Tot <u>30 140</u> 170	
	ROC curves			menopause, US, Doppler, CA-125	Lower Upper Value 95% CI 95% CI	
	Blinding: NR			(neural network), AUC 0.84	Se 90.0% 79.3% 100.0% Sp 35.0% 27.1% 42.9%	
	Definition of positive and negative on			7) Timmerman 1999 ref 9	PPV 22.9% 15.3% 30.5% NPV 94.2% 87.9% 100.0%	
	screening test: Per the original reports of the models (cutoffs			Menopause, US, CA- 125 (neural network), AUC 0.85	3) Jacobs 1990 ref 13 menopause, U/S, CA-125, AUC 0.83	
	not specified here)			8) Timmerman 1999 ref 9 menopause, US, Doppler, CA-125	Dis+ Dis- Tot T+ 27 69 96 T- 3 71 74 Tot 30 140 170	
				(logistic regression), AUC 0.85	Lower Upper Value 95% CI 95% CI	
					Se 90.0% 79.3% 100.0% Sp 51.0% 42.7% 59.3% PPV 28.1% 19.1% 37.1% NPV 95.9% 91.5% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
					4) Jacobs 1993 ref 23 menopause, U/S CA-125, AUC 0.86	
					Dis+ Dis- Tot T+ 27 55 82 T- 3 85 88 Tot 30 140 170	
					Lower Upper 95% CI 95% CI 90.0% 79.3% 100.0% Sp 61.0% 52.9% 69.1% PPV 32.9% 22.8% 43.1% NPV 96.6% 92.8% 100.0%	
					5) Tingulstad 1996 ref 12 menopause, U/S, CA-125, AUC 0.83	
					Dis+ Dis- Tot T+ 27 69 96 T- 3 71 74 Tot 30 140 170	
					Lower Upper 95% CI 95% CI 90.0% 79.3% 100.0% Sp 51.0% 42.7% 59.3% PPV 28.1% 19.1% 37.1% NPV 95.9% 91.5% 100.0%	
					6) Timmerman 1999 ref 9 menopause, U/S, Doppler, CA-125 (neural network), AUC 0.84	
					Dis+ Dis- Tot T+ 27 56 83 T- 3 84 87 Tot 30 140 170	
					Lower Upper Value 95% CI 95% CI Se 90.0% 79.3% 100.0% Sp 60.0% 51.9% 68.1% PPV 32.5% 22.5% 42.6%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
				~ ~ ~	NPV 96.6% 92.7% 100.0%	*
					7) Timmerman 1999 ref 9 Menopause, U/S, CA-125 (neural network), AUC 0.85	
					Dis+ Dis- Tot T+ 27 76 103 T- 3 64 67 Tot 30 140 170	
					Lower Upper 95% CI 95% CI 90.0% 79.3% 100.0% Sp 46.0% 37.7% 54.3% PPV 26.2% 17.7% 34.7% NPV 95.5% 90.6% 100.0%	
					8) Timmerman 1999 ref 9 menopause, U/S, Doppler, CA-125 (logistic regression), AUC 0.85	
					Dis+ Dis- Tot T+ 27 62 89 T- 3 78 81 Tot 30 140 170	
					Lower Upper Value 95% CI 95% CI Se 90.0% 79.3% 100.0% Sp 56.0% 47.8% 64.2% PPV 30.3% 20.8% 39.9% NPV 96.3% 92.2% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Marca, Ditto, et al., 1999	Geographical location: Siena, Italy Dates:	Age: Mean NR Age reported as categorical variable	Symptomatic (n [%]): NR Detected by exam (n [%]):	 CA-125 Menopausal status age 50 if prior hysterectomy or > 1 yr 	1) RMI1 (cutoff 80): <u>Dis+</u> Dis- T+ <u>25</u> 19 44 T- <u>6</u> 74 80	Comments: 2 borderline tumors were treated as malignant, which is not exactly correct and may alter results
#2900	Jan 1995-Dec 1997 Size of population: 124 women Registry Reference standard: Pathology Reference standard applied to all test negatives?: Yes Statistical tests used: Sn,Sp, PPV, NPV, chi- square, ROC curves, Mann-Whitney U, McNemar's Blinding: NR Definition of positive and negative on screening test: Different cutoffs are reported for RMI1 and RMI2	Menopausal status (n [%]): Pre: 69 (56%) Post: 55 (44%) (amenorrhea > 1 yr or age > 50 if status post hysterectomy) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Age > 30, admitted for surgical evaluation of ovarian mass Exclusion criteria: Age < 30, no surgery	NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	amenorrhea 3) Ultrasound (U; 1 point each for multilocular, solid, bilateral, ascites, intra- abdominal mets) RMI1 (Jacobs, Oram, Fairbanks, et al., 1990 [#6820]) RMI1 = U x M x CA- 125, where U = 0 if score = 0, U = 1 if score = 1, U = 3 if score at least 2; M = 1 if premenopausal, M = 3 if postmenopausal RMI2 (Tingulstad, Hagen, Skjeldestad, et al., 1996 [#3890]) RMI2 = U x M x CA- 125, where U = 1 if score = 0 or 1, U = 4 if score at least 2; M = 1 if premenopausal, M = 4 if postmenopausal	Value 95% CI 95% CI Se 58.0% 40.6% 75.4% Sp 95.0% 90.6% 99.4% PPV 78.3% 61.4% 95.1% NPV 87.1% 80.6% 93.7% 3) RMI2 (cutoff 125): Dis+ Dis- Tot	RMI2 outperformed RMI1 at all cutoff values between 80 and 250 Quality assessment: Reference standard: + Verification bias: - (potentially there are patients who did not have surgery whose US findings were less concerning, and we don't have any knowledge of their pathology) Test reliability/variability: + Sample size: + Statistical tests: + Blinding: - Definition of +/- on screening test: + (tested different cutoffs) Explicit validation method?: + (this is a validation study)

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Resul	ts			Comments/Quality Scoring
					T+ T- Tot	Dis+ 23 8 31	Dis- 7 86 93	Tot 30 94 124	
					Se Sp PPV NPV	Value 74.0% 93.0% 76.7% 91.5%	Lower 95% CI 58.6% 87.8% 61.5% 85.8%	Upper 95% Cl 89.4% 98.2% 91.8% 97.1%	
					been a combii	s were replastracted nations: and RMI2 a	, for the f	•	

25, 50, 80, 100, 125, 150, 200, 250

		Presentation	Scoring System		Scoring
Geographical ocation: Cambridge, England Dates: an 2000-Dec 2001 Size of population: 00 Registry Reference standard: Pathology Reference standard upplied to all test segatives?: 'es Statistical tests used: Chi-square, Mann- Vhitney U Blinding: IR Definition of positive ind negative on creening test: RMI of Jacobs, Oram, Gairbanks, et al., 1990 #6820) - 4 cutoffs eseted: 100, 150, 200, 150	Age: Range: 30-NR Menopausal status (n [%]): Pre: 27 (27%) Post: 73 (73%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: 100 consecutive women with a pelvic mass who were admitted for laparotomy; age > 30 Exclusion criteria: NR	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]): 100 (100%) Combination (n [%]): NR Additional data used for diagnosis: NR	Scoring System 1) Menopausal status (M = 1 for pre, M = 3 for post); menopause defined as 1 year amenorrhea, or 50 years old for patients with prior hysterectomy 2) Ultrasound score (U): 1 point for each: multilocular, solid, bilateral, ascites, intra- abdominal metastases; U = 0 for score 0, U = 1 for score 1, U = 3 for score ≥ 2 3) CA-125 RMI1 (Jacobs, Oram, Fairbanks, et al., 1990 [#6820]) RMI1 = M x U x CA-125	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Scoring Comments: 16 borderline tumors were counted as malignant – not strictly true as these are less aggressive tumors which are not treated the same. May bias results. 72% had malignancy. This is a very high prevalence compared to the population that usually presents with a pelvic mass for surgery (usually would be < 10%). Think this may falsely elevate the estimated PPV of the test. Quality assessment: Reference standard: + Verification bias: - (possible bias since only patients who had surgery are reported here) Test reliability/variability: + Sample size: - Statistical tests: - Blinding: - Definition of +/- on screening test: + (several cutoffs tested) Explicit validation method?: + (this is a validation study)
				Lower Upper Value 95% CI 95% CI Se 90.0% 83.1% 96.9% Sp 89.0% 77.4% 100% PPV 95.6% 90.7% 100%	
	cation: cambridge, England fates: an 2000-Dec 2001 ize of population: 00 registry reference standard: tathology reference standard pplied to all test egatives?: res tatistical tests sed: chi-square, Mann- whitney U clinding: IR refinition of positive nd negative on creening test: MI of Jacobs, Oram, airbanks, et al., 1990 #6820) - 4 cutoffs ested: 100, 150, 200,	DetailRange: 30-NRDetailRange: 30-NRDetailMenopausal status (n [%]):Pates:Menopausal status (n [%]):Pre: 27 (27%) Post: 73 (73%)DotRace/ethnicity (n [%]):DotRace/ethnicity (n [%]):Reference standard: rathologyRisk factors (n [%]): NRReference standard: egatives?:Inclusion criteria: 100 consecutive women with a pelvic mass who were admitted for laparotomy; age > 30Sed: bil-square, Mann- Whitney UExclusion criteria: NRRefinition of positive nd negative on creening test: WI of Jacobs, Oram, airbanks, et al., 1990 #6820) - 4 cutoffs ested: 100, 150, 200,	Detected by exam (n [%]):Detected by exam (n [%]):Pates: an 2000-Dec 2001Menopausal status (n [%]):Detected by exam (n [%]):Post: 73 (73%)Pre: 27 (27%) Post: 73 (73%)Detected by imaging (n [%]):100Race/ethnicity (n [%]):Detected by imaging (n [%]):00Race/ethnicity (n [%]):Detected by imaging (n [%]):00Race/ethnicity (n [%]):Detected by imaging (n [%]):100 (100%)NRCombination (n [%]):Peference standard: athologyNRCombination (n [%]):Pilied to all test egatives?:Inclusion criteria: 100 consecutive women with a pelvic mass who were admitted for laparotomy; age > 30NRHinding: IRExclusion criteria: NRNRPefinition of positive nd negative on creening test: WI of Jacobs, Oram, airbanks, et al., 1990 (4820) - 4 cutoffs ested: 100, 150, 200,Na	becation: iambridge, England marbridge, England mates: an 2000-Dec 2001 Range: 30-NR NR (M = 1 for pre, M = 3 for post); menopause defined as 1 year amenorrhea, or 50 years old for patients with prior hysterectomy ize of population: 00 Pre: 27 (27%) Post: 73 (73%) Detected by exam (n [%]): Detected by imaging (n [%]): 00 Race/ethnicity (n [%]): NR 2) Ultrasound score (U): 1 point for each: mutillocular, solid, bilateral, ascites, intra- abdominal metastases; U = 0 for score 0, U = 1 for diagnosis: teference standard pplied to all test east: hil-sque, Mann- /hitmey U Inclusion criteria: 100 consecutive women with a pelvic mass who were admitted for laparotomy; age > 30 NR 3) CA-125 sed: hil-sque, Mann- /hitmey U Exclusion criteria: NR NR 3) CA-125 Refinition of positive nd negative on creening test: MI of Jacobs, Oram, airbanks, et al., 1990 #6820) - 4 cutoffs sted: 100, 150, 200, NR	coation: ambridge, England mates: an 2000-Dec 2001 Post: 73 (73%)NR(M = 1 for pre, M = 3 for post; menopause defined as 1 year amenorhea, or 50 or years old for patients with prior hysterectomyDis+Dis-Tot200Prec: 27 (27%) Post: 73 (73%)NRDetected by exam (n [%]): NRDetected by imaging (n [%]): 100 (100%)Detected by imaging (n [%]): 100 (100%)2) Ultrasound score (U): 1 point for each: multilocular, solid, bilateral, ascites, intra- abdominal metastases; U = 0 for score (U) = 1 for diagnosis: NRTotTotTotTotAdditional data used for diagnosis: NRInclusion criteria: 100 consecutive mass who were admitted for laparotomy; age > 30NRScore 2SeSeSeSeUser SeUser SeNRIndigo (RiferNRNRSitIndust (Rifer (R

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Resul	ts			Comments/Quality Scoring
					T .	Dis+	Dis-	Tot	
					T+ T-	62 10	3 25	65 35	
					Tot	72	23 28	100	
							Lower	Upper	
						Value	95% CI	95% CI	
					Se	86.0%	78.0%	94.0%	
					Sp	89.0%	77.4%	100.0%	
					PPV	95.4%	90.3%	100.0%	
					NPV	71.4%	56.5%	86.4%	
					been a	s were re bstracted nations:		it have not ollowing	

"AUC = 0.91"

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Roman, Muder- spach, Stein, et al., 1997	Geographical location: Los Angeles, CA Dates:	Age: NR Menopausal status (n [%]):	Symptomatic (n [%]): NR Detected by exam (n [%]):	 Pelvic exam; fixed, irregular or associated with ascites = suspicious 	 Pelvic exam, serum tumor marker, or US positive; postmenopausal women only; low malignant potential tumors counted as Disease + 	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: ? (references given for
#6160	Jul 1992-Mar 1994	Pre: 181 (80%) Post: 45 (20%)	NR	2) CA-125 > 35 U/ml	Dis+ Dis- Tot T+ 15 15 30	individual tests, not combinations)
	Size of population: 226 women (nonconsecutive)	Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	3) AFP > 10 ng/ml in non-pregnant patient	T- 0 13 13 Tot 15 28 43	Sample size: +/- (only 45 menopausal) Statistical tests: +
	Registry	NR Risk factors (n [%]):	Combination (n [%]): NR	 4) LDH > 350 U/I 5) TVUS; suspicious 	Lower Upper Value 95% CI 95% CI Se 100.0% 80.0% 100.0%	Blinding: - Definition of +/- on screening test: +
	Reference standard: Pathology	NR Inclusion criteria:	Additional data used for diagnosis:	masses are those which are cystic with one large or multiple nodules or	Sp46.4%28.0%64.9%PPV50.0%32.1%67.9%	Explicit validation method?: -
	Reference standard applied to all test negatives?:	Operative intervention for presumed adnexal mass	NR	cystic/solid, and solid masses not arising from the uterus	 Serum tumor markers and ultrasound, T+ if serum markers above threshold or US "suspicious" 	
	Statistical tests used: Chi-square, logistic regression	Exclusion criteria: Emergency surgery, clinical or radiographic		 Doppler; pulsatility index less than 1.0 or resistance index ≤ 0.4 are suspicious 	Dis+ Dis- Tot T+ 15 11 26 T- 1 18 19	
	Blinding: NR	evidence of metastatic disease		 HCG >15 mIU/ml in a non-pregnant patient 	Tot 16 29 45	
	Definition of positive and negative on screening test: See Scoring column				Lower Upper Value 95% CI 95% CI Se 93.8% 81.9% 100.0% Sp 62.1% 44.4% 79.7% PPV 57.7% 38.7% 76.7% NPV 94.7% 84.7% 100.0%	
					 Fitted LR model using tumor markers and ultrasound, cut off probability of malignancy = 0.50; postmenopausal women only Same 2x2 table as #2 above 	
					Results were reported, but have not been abstracted, for the following combinations: PE + US (Premenopausal and all)	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
				PE Tu	PE, tumor markers + US PE + tumor markers Tumor markers + US Postmenopausal women	
Schutter, Kenemans, Sohn, et al., 1994 #940	Geographical location: Amsterdam, The Netherlands Dates: Nov 1990-Dec 1992 Size of population: 276→ excluded 48 who did not meet inclusion criteria→ 228 Registry Reference standard: Pathology Reference standard applied to all test negatives?: Yes Statistical tests used: Se, Sp, PPV, NPV, chi-square, Fishers exact, ROC curves, logistic regression Blinding: NR Definition of positive and negative on screening test: Logistic regression model: Exam: benign (0) or malignant (1)	Age: NR Menopausal status (n [%]): Post: 228 (100%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Pelvic mass; age > 45; amenorrhea > 12 months; scheduled for surgery with biopsy or excision of mass; no history of BSO; no history of BSO; no history of malignancy Exclusion criteria: Age \geq 45; amenor- rhea < 12 months; additional malign- nancy; physical exam "indeterminate;" no pre-operative CA-125	NR Additional data used for diagnosis: NR	 Pelvic examination: abnormal if a mass distinguishable from the uterus was identified. Clinician was asked to characterize mass as benign (0) or malignant (1) TVUS; used Finkler scoring system (ref#3, Table 3). A score of 7 or more was considered positive for malignancy (1). Serum CA-125 >35 (1) is "malignant" 	1) Physical exam, TVUS, and CA-125 all positive defines malignancy T+ 19 3 T- 11 36 47 Tot 30 39 69 Value 95% CI 95% CI Se 62.0% 44.6% 79.4% Sp 92.0% 83.5% 100.0% PPV 86.4% 72.0% 100.0% NPV 76.6% 64.5% 88.7% 2) Physical exam and TVUS both positive defines malignancy T+ 0 10 10 10 10 10 10 10	Comments: Borderline tumors were excluded from 2x2 tables (included neither as benign nor malignant). No specific cutoff is giver or suggested using the new logistic regression model. Reported values for N, Si Sp, PPV, and NPV do not correspond precisely to 2x tables presented, presumably due to roundin error. Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: 7 (unclear for physical exam the other parameters used accepted/defined criteria) Sample size: + Statistical tests: + Blinding: - Definition of +/- on screeni test: + Explicit validation method?

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
	CA-125 ≤ 35 U/ml (0) or > 35 (1) Ultrasound score < 7 (0) or ≥ 7 (1)		resentation	Scoring System	Value95% CI95% CISe 64.0% 47.4% 80.6% Sp 89.0% 79.6% 98.4% PPV 80.0% 64.3% 95.7% NPV 76.0% 64.2% 87.8% 4)Logistic regression model Z = - $9.2378 + 2.2506(PE) + 1.6025(US) +$ $1.7293(CA-125)$.Probability ofmalignancy is $1/1+e \exp(-z)$."The ability to predict malignancy orbenignancy of the pelvic massappeared to be 81.5% ". No AUCgiven.Results were reported, but have notbeen abstracted, for the followingcombinations:	
					All possible combinations of ultrasound, CA-125, and exam findings.	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Schutter, Sohn, Kristen, et al., 1998 #730	Geographical location: The Netherlands Dates: Nov 1990-Dec 1992 Size of population: 155 (151 could be	Age: NR Menopausal status (n [%]): Post: 155 (100%) Race/ethnicity (n [%]):	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Detected by imaging (n [%]):	 Physical exam: malignant or benign Ultrasound: Finkler score* 7-10 positive, 1-6 negative CA-125: ≥ 35 positive 	1) PE/US/CA-125/CA-72-4: T+ Dis- Tot T- 32 92 124 Tot 59 92 151 Value 25% CI 95% CI	Comments: Borderline tumors not included (this is good) Quality assessment: Reference standard: + Verification bias: - (unclear how many negatives didn't have surgery)
	classified as malignant or benign; 4 borderlines not included in analysis)		NR	 4) CA72-4: ≥ 3 positive *Finkler score (Finkler et al 1988, ref #25) 	Se 46.0% 33.3% 58.7%	Test reliability/variability: + (US scoring system) Sample size: - Statistical tests: - Blinding: -
	Registry Reference standard: Histopathology	Inclusion criteria: Patients presenting with a pelvic mass who underwent surgery	Additional data used for diagnosis: NR	1-cyst/smooth borders 2-cyst/irregular borders 3-cyst/echoes and irregular borders 4-6-equivocal	2) PE/US: <u>Dis+ Dis-</u> Tot T+ <u>47 12</u> 59 T- 12 80 92	Definition of +/- on screening test: + Explicit validation method?:
	Reference standard applied to all test negatives?: Yes	Exclusion criteria: Storage problems making sera unusable		7-9-multiseptated or irregular cystic mass 10-pelvic mass with ascites	Tot 59 92 151 Lower Upper Value 95% CI 95% CI	
	Statistical tests used: Se, Sp, PPV, NPV, ROC curves, logistic regression				Sp87.0%80.1%93.9%PPV79.7%69.4%89.9%NPV87.0%80.1%93.8%	
	Blinding: NR Definition of positive				 Logistic regression model: 1/(1+e⁻²) where Z = - 5.6816+2.2677*(US)- 2.4928*(PE)+1.6057*(CA- 125)+1.5866*(CA72-4) 	
	and negative on screening test: See Scoring column for individual tests. See Results column				Dis+ Dis- Tot T+ 48 9 57 T- 11 83 94 Tot 59 92 151	
	for logistic regression equation				Lower Upper Value 95% CI 95% CI Se 81.4% 71.4% 91.3% Sp 90.2% 84.1% 96.3% PPV 84.2% 74.7% 93.7%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
					NPV 88.3% 81.8% 94.8%	
					4) US/CA-125/CA-72-4:	
					Dis+ Dis- Tot T+ 28 1 29	
					T- <u>31</u> 91 122	
					Tot 59 92 151	
					Lower Upper Value 95% CI 95% CI	
					Se 47.0% 34.3% 59.7% Sp 99.0% 97.0% 100.0%	
					PPV 96.6% 89.9% 100.0% NPV 74.6% 66.9% 82.3%	
					5) PE/US/CA-125:	
					Dis+ Dis- Tot	
					T+ 34 5 39 T- 25 87 112	
					Tot 59 92 151	
					Lower Upper Value 95% CI 95% CI	
					Se 57.6% 45.0% 70.2% Sp 94.6% 89.9% 99.2%	
					PPV 87.2% 76.7% 97.7% NPV 77.7% 70.0% 85.4%	
					Results were reported, but have no	
					been abstracted, for the following	it.
					combinations: PE/US/CA-72-4	
					CA-125/CA-72-4 PE/CA-125/CA-72-4	
					PE/CA-125	
					PE/CA-72-4 US/CA-125	
					US/CA-72-4	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Strigini, Gadducci, Del Bravo,	Geographical location: Pisa, Italy	Age: Median: 43 Range: 18-80	Symptomatic (n [%]): NR	1) Transvaginal ultrasound (TVUS)	1) TVUS or CA-125 /postmenopausal only	Comments: Definition of suspicious TVUS is fairly vague,
et al., 1996 #4000	Dates: Jan 1993-Jun 1994	Menopausal status (n [%]):	Detected by exam (n [%]): NR	Classified masses as probably benign or malignant.	Dis+ Dis- Tot T+ 12 3 15 T- 1 18 19	subjective – no previously published standard is used CA-125 > 65 U/ml also is
	Size of population: 109 total → 34 postmenopausal are reported here Registry Reference standard: Pathology Reference standard applied to all test	Post: 34 (31%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Surgery scheduled for an adnexal mass	Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Malignancy was defined as "solid portions with irregular structure, thick septae or papillae, irregular margins" 2) Doppler: pulsatility index < 1 was considered abnormal (reference #5 Kurjak). If no color flow was detected in the mass	Value Upper 95% CI Upper 95% CI Se 92.0% 77.3% 100.0% Sp 86.0% 71.2% 100.0% PPV 80.0% 59.8% 100.0% NPV 94.7% 84.7% 100.0% 2) TVUS and CA-125/postmenopausal only State State	not the usual cutoff, but a reference is given Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - (TVUS criteria vague) Sample size: - (only 34 postmenopausal women) Statistical tests: + Blinding: - Definition of +/- on screenin
	negatives?: Yes Statistical tests	Exclusion criteria: NR		the Doppler was considered negative (benign).	Dis+ Dis- Tot T+ 6 1 7 T- 7 20 27 Tot 13 21 34	test: +/- (TVUS criteria fairly vague) Explicit validation method?:
	used: Se, Sp Blinding: NR			3) CA-125 > 65 U/ml reference #11)	Lower Upper Value 95% CI 95% CI Se 46.0% 18.9% 73.1% Sp 95.0% 85.7% 100.0%	
	Definition of positive and negative on screening test: See Scoring column				PPV 85.7% 59.8% 100.0% NPV 74.1% 57.5% 90.6% 3) TVUS or Pl/postmenopausal only	
	<u> </u>				Dis+ Dis- Tot T+ 12 5 17 T- 1 16 17 Tot 13 21 34	
					Lower Upper Value 95% CI 95% CI Se 92.0% 77.3% 100.0% Sp 76.0% 57.7% 94.3% PPV 70.6% 48.9% 92.2% NPV 94.1% 82.9% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results Comments Scoring	/Quality
					4) TVUS and PI/postmenopausal only	
					$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	
					Lower Upper 95% Cl 95% Cl Se 69.0% 43.9% 94.1% Sp 95.0% 85.7% 100.0% PPV 90.0% 71.4% 100.0% NPV 83.3% 68.4% 98.2%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Tailor, Jurkovic, Bourne, et al., 1999 #2910	Geographical location: London, UK Dates: NR Size of population: 67 Registry Reference standard: Pathology Reference standard applied to all test negatives?: Yes Statistical tests used: ROC curves, logistic regression model using the network output gives probability of malignancy Blinding: NR Definition of positive and negative on screening test: Logistic regression model using the neural network output gives the probability of malignancy	Age: Mean: 39.6 Premenopausal (n = 45): mean age 38, range 20-52 Postmenopausal (n = 22): mean age 61, range 48-76 Menopausal status (n [%]): Pre (< 45): 45 (67%) Post (> 55): 22 (33%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Pelvic mass and scheduled for surgery Exclusion criteria: No histologic specimen obtained	Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	 Age Menopausal status Tumor diameter Tumor volume Locularity Presence of papillations Echogenicity Blood flow velocity waveforms Peak systolic velocity Time-average maximum velocity (TAMXV) Pulsatility index Resistance index Note: "best model" uses the following variables: age, maximum diameter, papillary projections, TAMXV 	1) Neural network "best model" (entire data set); ROC AUC = 0.9987: T+ <u>14</u> 0 T- <u>152</u> 53 Tot <u>15</u> 52 67 <u>Value 95% CI 95% CI</u> Se <u>93.3% 80.6% 100.0%</u> Sp 100.0% 94.2% 100.0% NPV 98.1% 94.5% 100.0% Training set n = 52 Test set n = 15 Data shown are for all cases, including training set	Comments: Borderlines classified as malignant (not strictly true) Very small sample size for modeling (n = 15 malignant cases in entire set) Quality assessment: Reference standard: - Verification bias: - (patients excluded who didn't have a pathology result [these could have been benign cases]) Test reliability/variability: - (don't know, other than smal validation set) Sample size: + Statistical tests: + Blinding: - Definition of +/- on screening test: + Explicit validation method?: + (authors used 15 patients for validation of the model found using the first 52)

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Bourne,	 Geographical location: Belgium and UK Dates: Aug 1994-Jul 1996 Size of population: 191 Prospective study of patients with a mass sent for U/S (consented prior to ultrasound and surgery) Reference standard: Pathology Reference standard applied to all test negatives?: Yes Statistical tests used: Multivariate logistic regression, ROC curves/AUC, Mann- Whitney U, student t, chi-square, Fisher exact Blinding: NR, but prospective Definition of positive and negative on screening test: 	Benign (n = 140): 40% postmenopausal Malignant (n = 51):	Additional data used for diagnosis: NR	 (A) RMI1: calculated per Jacobs, Oram, Fairbanks, et al., 1990 (#6820) using US, menopausal status, and CA-125 (B)Variables included in the final multivariable model: 1) Papillary structures in mass > 3 mm 2) Serum CA-125 3) Color score (subjective from 1-4 depending on amount of blood flow) 4) Menopausal score (can't find exact criteria - unclear if same as criteria used for RMI1) Multivariate model: Probability of malignancy = 1/(1-e-z) Where z=(2.6369 x color score) + (0.0225 x CA-125) + (7.1062 x papillations > 3 mm score) + (2.6423 x postmenopausal score) - 13.6796 (C) Morphologic Scoring system (Lerner, ref#18)-details not given on how it was calculated 	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Comments: 5 borderline tumors were counted as malignant Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: + Sample size: + Statistical tests: + Blinding: - (NR) Definition of +/- on screening test: + Explicit validation method?: +

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
				<u> </u>	PPV 81.1% 70.6% 91.7% NPV 95.0% 91.1% 98.9%	<u> </u>
					4) Morphologic Index of Lerner (ref #18), AUC = 0.840:	
					Dis+ Dis- Tot T+ 49 55 104 T- 2 85 87 Tot 51 140 191	
					Lower Upper Value 95% CI 95% CI Se 96.1% 90.8% 100.0% Sp 60.7% 52.6% 68.8% PPV 47.1% 37.5% 56.7% NPV 97.7% 94.6% 100.0%	
					Results were reported, but have not been abstracted, for the following combinations: RMI1 for cutoffs of 50, 75, 100, 150 (n = 173 patients who had CA-125 available AUC = 0.882) Timmerman model for training set (n = 116) and testing set (n = 57) but numbers NR for these subgroups	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Timmerman, Verrelst, Bourne, et al., 1999 #5940	 Geographical location: Leuven, Belgium Dates: Aug 1994-Aug 1996 Size of population: 173 Registry Reference standard: Pathology Reference standard applied to all test negatives?: Yes Statistical tests used: Logistic regression model, ROC curves/AUC Blinding: NR Definition of positive and negative on screening test: 	Risk factors (n [%]): NR Inclusion criteria: Adnexal mass; scheduled for surgery; had a CA- 125 Exclusion criteria: No CA-125	Symptomatic (n [%]): NR Detected by exam (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	 Neural Network 1 uses: menopause score (0 or 1), color score (1-4 subjective), papillations score (0 or 1), CA-125 Neural Network 2 uses: menopausal score (0 or 1), CA-125, ascites (0 or 1), unilocularity (0 or 1), papillations score (0 or 1), smooth walls score (0 or 1), bilaterality score (0 or 1), unilocular score (0 or 1), unilocular score (0 or 1) Logistic Regression 2 uses: menopausal score (0 or 1), CA-125, ascites (0 or 1), unilocularity (0 or 1), smoothe walls (0 or 1), papillations (0 or 1), bilaterality (0 or 1) z=0.5948 meno + 0.2025CA-125 + 0.5446ascites - 0.762unilocular - 1.1606smoothe + 1.5049papillations + 0.7633bilateral - 1.0889 RMI1 (Jacobs, Oram, Fairbanks, et al., 1990 [#6820]) uses: menopausal score, ultrasound score, CA- 125 	Dis+ Dis- Tot	Comments: 5 borderlines were counted as malignant Quality assessment: Reference standard: + Verification bias: - (only patients who had surgery are evaluated) Test reliability/variability: - Sample size: - Statistical tests: - Blinding: - (NR) Definition of +/- on screening test: + Explicit validation method?: +

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Resul	tS			Comments/Quality Scoring
					NPV	98.1%	95.6%	100.0%	
Tingulstad,	Geographical	Age:	Symptomatic (n [%]):	1) Ultrasound score (U)	1) RMI	1 cutoff 50	:		Comments:
•	location: Trondheim, Norway	NR	NR	Based on presence of multilocular cystic		Dis+	Dis-	Tot	Borderline tumors counted as malignant
et al., 1996	Detec	Menopausal status	Detected by exam	lesions, solid areas,	T+ T	49	22	71	Quality appagements
#3890	Dates: Feb 1992-Feb 1994	(n [%]): Pre (< 45): 82 (47%) Post (> 55): 91	(n [%]): NR	bilateral lesions, ascites, and intra- abdominal metastases	T- Tot	7 56	95 117	102 173	Quality assessment: Reference standard: + Verification bias: -
	Size of population: 173	(53%)	Detected by imaging (n [%]):	scored 1 point each: If score = 0, then U = 0		Value	Lower 95% CI	Upper 95% Cl	Test reliability/variability: + Sample size: +
	Devieter	Race/ethnicity	NR	If score = 1, then $U = 1$	Se	88.0%	79.5%	96.5%	Statistical tests: +
	Registry	(n [%]) : NR	Combination (n [%]):	If score \geq 2, the U = 3	Sp PPV	<mark>81.0%</mark> 69.0%	73.9% 58.3%	88.1% 79.8%	Blinding: - Definition of +/- on screening
	Reference standard:		NR	2) Menopause score	NPV	93.1%	38.3% 88.2%	79.8% 98.0%	test: +
	Pathology	Risk factors (n [%]):		(M):					Explicit validation method?:
	Reference standard	NR	Additional data used for diagnosis:	Premenopausal = 1 Postmenopausal = 3	2) RM	11 cutoff 10	0:		(not for RMI2; this is a validation study of RMI1)
	applied to all test	Inclusion criteria:	NR			Dis+	Dis-	Tot	validation olday of thinty
	negatives?:	Admitted for surgery			T+	44	9	53	
	Yes	for a pelvic mass		3) CA-125 in kU/L	T-	12	108	120	
	Statistical tests	Exclusion criteria:		RMI1 (Jacobs, Oram,	Tot	56	117	173	
	used:	NR		Fairbanks, et al., 1990			Lower	Upper	
	Se, Sp, chi-square, ROC curves			[#6820]) RMI1 = M x U x CA-125	_	Value	95% CI	95% CI	
					Se Sp	79.0% 92.0%	68.3% 87.1%	89.7% 96.9%	
	Blinding:			RMI2 (Tingulstad,	Sp PPV	83.0%	72.9%	90.9% 93.1%	
	NR			Hagen, Skjeldestad, et al., 1996 [#3890])	NPV	90.0%	84.6%	95.4%	
	Definition of positive			$RMI2 = M \times U \times CA-124$	2) DM	11 outoff OC			
	and negative on			as RMI1 except	3) RIVI	11 cutoff 20	10.		
	screening test: RMI1 = U x M x CA-			U = 1 if total is 0 or 1 4 if total \ge 2; M = 1 or 4		Dis+	Dis-	Tot	
	125, where $U = 0, 1, or$			4 II total ≥ 2 , $W = 1 \text{ of } 4$	<u>T</u> +	40	5	45	
	3; M = 1 or 3				T- Tot	16 56	112 117	128 173	
	RMI2 = U x M x CA-				101	00			
	125, where $U = 0, 1, or$					Value	Lower 95% CI	Upper 95% CI	
	4; M = 1 or 4				Se	71.0%	59.1%	82.9%	
					Sp	96.0%	92.4%	99.6%	
					PPV NPV	88.9% 87.5%	79.7% 81.8%	98.1% 93.2%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
					4) RMI2 cutoff 100:	
					Dis+ Dis- Tot T+ 47 21 68 T- 9 96 105 Tot 56 117 173	
					LowerUpperValue95% CI95% CISe84.0%74.4%93.6%Sp82.0%75.0%89.0%PPV69.1%58.1%80.1%NPV91.4%86.1%96.8%	
					5) RMI2 cutoff 200:	
					Dis+ Dis- Tot T+ 45 9 54 T- 11 108 119 Tot 56 117 173	
					Lower Upper Value 95% Cl 95% Cl Se 80.0% 69.5% 90.5% Sp 92.0% 87.1% 96.9% PPV 83.3% 73.4% 93.3% NPV 90.8% 85.6% 96.0%	
					Results were reported, but have no been abstracted, for the following combinations: RMI1 and RMI 2 at the following cutoffs: 25, 50, 80, 100, 125, 150, 25	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Tingulstad, Hagen,	Study Design Geographical location: Trondheim, Norway Dates: Feb 1995-Jan 1997 Size of population: 365 Registry Reference standard: Pathology Reference standard applied to all test negatives?: Statistical tests used: Chi-square, Mann- Whitney U, Se, Sp	Patients Age: NR Menopausal status (n [%]): Pre (< 45): 193 (53%) Post (> 55): 172 (47%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Age \geq 30 with pelvic masses, scheduled for surgery Exclusion criteria: NR			1) RMI2 cutoff 100: T+ $Dis+$ Dis- Tot T+ 17 229 246 Tot 75 290 365 Value 95% CI 95% CI Se $77.0\% 67.5\% 86.5\%$ Sp $79.0\% 74.3\% 83.7\%$ PPV 48.7% 39.8% 57.7% NPV 93.1% 89.9% 96.3% 2) RMI2 cutoff 150: T+ $Dis+$ Dis- Tot T+ 54 38 92 T- 21 252 273 Tot 75 290 365 Value 95% CI 95% CI	
	Blinding: NR				Se72.0%61.8%82.2%Sp87.0%83.1%90.9%PPV58.7%48.6%68.8%	
	Definition of positive and negative on screening test: RMI2 = M x U x CA-				NPV 92.3% 89.1% 95.5% 3) RMI2 cutoff 200: E <t< td=""><td></td></t<>	
	125, where U = 1 or 3; M = 1 or 3				Dis+ Dis- Tot T+ 53 23 76 T- 22 267 289 Tot 75 290 365	
					Value Lower 95% CI Upper 95% CI Se 71.0% 60.7% 81.3% PPV 69.7% 59.4% 80.1% NPV 92.4% 89.3% 95.4% 4) RMI2 cutoff 250: 250: 250:	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Resul	ts			Comments/Quality Scoring
					T+ T- Tot	Dis+ 53 23 75	Dis- 20 270 290	Tot 73 293 366	
					Se Sp PPV NPV	Value 70.0% 93.0% 72.6% 92.2%	Lower 95% CI 59.6% 90.1% 62.4% 89.1%	Upper 95% CI 80.4% 95.9% 82.8% 95.2%	
					been a combii RMI2 c	s were rep bstracted nations: sutoff 50 sutoff 300		it have not ollowing	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Torres, Derchain, Faundes, et al., 2002	Geographical location: São Paolo, Brazil	Age: NR Menopausal status	Symptomatic (n [%]): NR Detected by exam	1) Ultrasound score (0- 10) (Depriest et al 1993; Sassone et al., 1991) 0- unilocular simple	1) RMI (cutoff 150): Dis+ Dis- Tot T+ 53 19 72	Comments: 18 borderline tumors were treated as malignant (dubious)
#2170	Dates: Jan 1996-Mar 98	(n [%]) : NR	(n [%]) : NR	cysts w/regular fine wall or lesion suggesting dermoid cyst		The scoring system for ultrasound does not appear to be the same as that used
	Size of population: 158	Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR	1-multilocular cyst w/regular and smooth wall (< 3 mm) or thick (>	Lower Upper Value 95% CI 95% CI Se 79.0% 69.2% 88.8%	for the other RMI studies Quality assessment:
	Registry	Risk factors (n [%]):	Combination (n [%]):	3 mm) or solid homogeneous tumor	Sp 79.0% 70.6% 87.4% PPV 73.6% 63.4% 83.8%	Reference standard: + Verification bias: - (don't
	Reference standard: Pathology	NR	NR Additional data used	w/hyperechogenic and well-defined wall 2-Unilocular cyst or	NPV 83.7% 75.9% 91.5% AUC for RMI=0.90	know about patients who hac masses/cysts, but didn't qualify for study)
	Reference standard applied to all test negatives?: Yes	Pelvic mass apparently restricted to adnexal; admitted for surgery	for diagnosis: NR	multilocular cyst w/fine wall, with irregularity in the wall or septa (> 3 mm) 4-Multilocular cyst	2) RMI (cutoff 30): Dis+ Dis- Tot T+ 64 40 104 T- 3 51 54	(not sure authors did the ultrasound scoring the way other published reports did) Sample size: +
	Statistical tests used: Logistic regression, ROC curves	Exclusion criteria: Known distant metastasis		w/thick and irregular wall (irregularity in the wall or septa(> 3 mm), and/or irregular septa or cyst /papillary	Tot 67 91 158 Lower Upper Value 95% CI 95% CI	Statistical tests: + Blinding: - Definition of +/- on screening test: + Explicit validation method?:
	Blinding: NR			irregularity over 3 mm 5- Complex lesion w/irregularity in surface	Se 96.0% 91.3% 100.0% Sp 56.0% 45.8% 66.2% PPV 61.5% 52.2% 70.9%	(unless this is a validation study [not sure they used the same method as DePriest et
	Definition of positive and negative on screening test:			(< 3 mm) or badly- defined and irregular wall; or solid	NPV 94.4% 88.3% 100.0% 3) RMI (cutoff 100):	al (1993); Sassone et al., (1991) for ultrasound score])
	RMI = U x M x CA-125 Results reported for a cutoff of 150			heterogeneous lesion 10-Complex lesion w/irregularity in surface (< 3 mm) or badly defined and irregular	Dis+ Dis- Tot T+ 56 21 77 T- 11 70 81 Tot 67 91 158	
				wall; or solid heterogenous lesion +1 ascites +2 wall expansive involvement > 3 mm	Lower Upper Value 95% CI 95% CI Se 84.0% 75.2% 92.8% Sp 77.0% 68.4% 85.6% PPV 72.7% 62.8% 82.7%	
				2) Menopausal status (1 or 3)	NPV 86.4% 79.0% 93.9% 4) RMI (cutoff 200):	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Result	is			Comments/Quality Scoring
				3) CA-125					
					_	Dis+	Dis-	Tot	
					T+	49	13	62	
					Т-	18	78	96	
					Tot	67	91	158	
							Lower	Upper	
					_	Value	95% CI	95% CI	
					Se	73.0%	62.4%	83.6%	
					Sp	86.0%	78.9%	93.1%	
					PPV	79.0%	68.9%	89.2%	
					NPV	81.3%	73.4%	89.1%	
					been al		ported, bu , for the f	it have not ollowing	
					RMI cut	toff 500			

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
Twickler, Forte,	Geographical location:	Age: Mean (SD): 38.6	Symptomatic (n [%]) : NR	1) Age (years)	Ovarian Tumor Index AUC=0.91	Comments: 16 of 30 "malignant"
Santos- Ramos, et	Dallas, TX	(12.3) Range: 15-80	Detected by exam	2) Ovarian volume (ml)	1) Ovarian Tumor Index cutoff 45:	neoplasms are borderline tumors (dubious)
al., 1999	Dates: Feb 1993-Aug 1996	Menopausal status	(n [%]): 304 (100%)	 Morphology scale (1- 15) Sassone ref#3 	T+ 26 36 62	No validation set was tested
#3080	Size of population: 304 with masses on	(n [%]): NR	Detected by imaging (n [%]):	4) PI (-10 x PI)	T- 5 178 183 Tot 30 214 245	Quality assessment: Reference standard: - (no
	exam: 217 had surgery 27 had sonographic	Race/ethnicity (n [%]): NR	NR Combination (n [%]):	5) Vessel location: Peripheral -10 Central +10	Lower Upper Value 95% CI 95% CI Se 85.0% 72.2% 97.8%	followup on 60 patients) Verification bias: - (no followup on 60 patients)
	followup 60 had no followup	Risk factors (n [%]): NR	NR Additional data used	6) Intense echoes -10	Sp 83.0% 78.0% 88.0% PPV 41.9% 29.7% 54.2% NPV 97.3% 94.9% 99.6%	Test reliability/variability: - Sample size: + Statistical tests: +
	Prospective study of patients with pelvic masses detected by exam	Inclusion criteria: Patients with clinically suspected adnexal	for diagnosis: NR	Ovarian Tumor Index is the sum of the above scores	(likely rounding error in cell C)2) Ovarian Tumor Index cutoff 55:	Blinding: - (NR) Definition of +/- on screening test: + Explicit validation method?:
	Reference standard: Pathology or clinical	masses Exclusion criteria:			Dis+ Dis- Tot T+ 23 19 42 T- 7 195 202	
	followup Reference standard	NR			Tot 30 214 244	
	applied to all test negatives?: No – 60 had no				Lower Upper Value 95% CI 95% CI Se 78.0% 63.2% 92.8% Sp 91.0% 87.2% 94.8%	
	followup Statistical tests				PPV 54.8% 39.7% 69.8% NPV 96.5% 94.0% 99.1%	
	used: Mann-Whitney U, Fisher exact, linear				3) Ovarian Tumor Index cutoff 40:	
	logistic regression				Dis+ Dis- Tot T+ 28 54 82 T- 2 161 163	
	Blinding: NR				Tot 30 214 245	
	Definition of positive and negative on screening test:				Lower Upper Value 95% Cl 95% Cl Se 93.0% 83.9% 100.0% Sp 75.0% 69.2% 80.8%	
	Ovarian tumor index (see Scoring column for definition).				PPV 34.1% 23.9% 44.4% NPV 98.8% 97.1% 100.0%	

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results Comments/Quality Scoring
	Different cutoffs tested.				(likely rounding error)
Valentin, Hagen, Tingulstad, et al., 2001 #2340	Geographical location: Malmo, Sweden and Trondheim, Norway Dates: NR Size of population: 157 original, 21 excluded due to no surgery, no pathology, etc.→ 136 included Registry Reference standard: Pathology Reference standard applied to all test negatives?: Yes Statistical tests used: Se, Sp, ROC curves Blinding: NR Definition of positive and negative on screening test: Tailor cutoff 50% Timmerman cutoff 50%	Age: "Slightly older" than population of Tailor et al. (1997) Menopausal status (n [%]): NR Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Adnexal mass diagnosed clinically and scheduled for surgery Exclusion criteria: No surgery; no pathology from surgery available	Symptomatic (n [%]): NR Detected by exam (n [%]): 157 (100%) Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	 A) Tailor method, cutoff 50% (Tailor et al 1997): 1) Age 2) Menopausal status 3) Tumor diameter 4) Tumor volume 5) Locularity 6) Presence of papillations 7) Echogenicity 8) Blood flow velocity waveforms 9) Peak systolic velocity 10) Time-average maximum velocity 11) Pulsatility index 12) Resistance index B) Timmerman method (ref #5): 1) Papillary structures in mass > 3 mm 2) Serum CA-125 3) Color score (subjective from 1-4 	Dis+Dis-Tottwo previously published models – both performed worse than in the original reports. Patient population (numbers of different types tumors) were different than the original studies, possib accounting for the worse performance.Se69.0%53.7%84.3% 95.0%secounting for the worse performance.Sp88.0%81.6%94.4% 94.4%Borderline tumors classifi as malignantPPV66.7%51.3%82.1% 95.0%Borderline tumors classifi as malignant2) Timmerman model, cutoff 50%; AUC = 0.84:Ouality assessment: Reference standard: + Verification bias: - (some were excluded because the did not have surgery) Test reliability/variability: + Sample size: - Statistical tests: - Blinding: - Definition of +/- on screenti test: + Explicit validation method? +Value95% CI95% CISe62.0%44.3%YLower 11142Se62.0%44.3%YLower 111Se62.0%44.3%Sp79.0%68.0%NPV79.2%68.3%NPV79.2%68.3%NPV79.2%Results were reported, but have not been abstracted, for the following combinations: Tailor model cutoff 25% Timmerman model cutoff 25%

Study	Study Design	Patients	Clinical Presentation	Items Included in Scoring System	Results	Comments/Quality Scoring
				blood flow)		
				4) Menopausal score (exact criteria unclear)		

Evidence Table 5: Question 5: Among women with suspected benign masses on initial investigation, what are the sensitivity and specificity of monitoring with periodic CA-125 and/or interval ultrasound examinations for detecting malignant masses? How does the interval of testing/definition of change affect sensitivity and predictive value?

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Resul	ts			Comments/Quality Scoring
Castillo, Alcazar, and Jurado, 2004 #8040	Geographical location: Pamplona, Spain Dates: Jan 1995-Jun 2002 Size of population: 8794 total; 215 had simple unilocular cysts Screening study Reference standard: Surgery or followup at 3 and 9 months Reference standard applied to all test negatives?: Yes Test reliability established?: Same examiner to eliminate interobserver variability Statistical tests used: Chi-square Blinding: No Definition of positive and negative on screening test: Increase in cyst size by 1 cm or more	Age: Mean (SD): 59 (8.7) Menopausal status (n [%]): Post (> 55): 223 (100%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Postmenopausal (at least 1 year without menses and older than 45, or hysterectomy with symptoms and older than 45, or hysterectomy with symptoms and older than 50) Exclusion criteria: Previous history of malignancy; history of bilateral oophorectomy Loss to followup: 66 (30.6%) (no statistically significant differences in any parameters between those who completed study and those who were lost to followup) Of remaining 149, 34 underwent immediate surgery.	(n [%]): NR Additional data used for diagnosis: NR	Monitoring test: Ultrasound, CA-125 Interval of testing: 3 months, then every 6 months Definition of change: Progression: cyst increased in size at least 1 cm Regression: decrease at least 1 cm Resolution: cyst not detected in 2 consecutive exams	1) Can T+ T- Tot Se Sp PPV NPV	Dis+ 0 1 1 1 Value 0.0% 70.3% 0.0% 99.0%	ents follow Dis- 44 104 148 Lower 95% CI 0.0% 62.9% 0.0% 97.2%	red: Tot 44 105 149 Upper 95% CI 0.0% 77.6% 0.0% 100.0%	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: + Explicit validation method?: NA

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Resul	ts			Comments/Quality Scoring
	< 3 cm, no septations, solid areas, or papillary projections) less than 10 cm with CA-125 < 35, or patient choice, followed								
	Length of followup: Median 27 months								
	Type of followup: Repeat US and CA- 125								
	Followup interval: 3 months, then 6 months								
Goldstein, Subra- manyam,	Geographical location: New York, NY	Age: Range: 46-86	Symptomatic (n [%]): NR	Monitoring test: Ultrasound	1) Car	ncer in pati Dis+	ients follov Dis-	ved: Tot	Quality assessment: Reference standard: + Verification bias: +
Snyder, et al., 1989 #10490	Dates: NR, but 3-year time period	Menopausal status (n [%]): Post (> 55): 48 (100%)	Detected by exam (n [%]): NR	Interval of testing: 3-6 months Definition of change:	T+ T- Tot	0 0 0	2 14 16	2 14 16	Test reliability/variability: - Sample size: - Statistical tests: - Blinding: -
	Size of population: 48; 16 followed	Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR	NR	Se Sp	Value - 87.5%	Lower 95% CI - 71.3%	Upper 95% CI - 100.0%	Definition of +/- on screening test: - Explicit validation method?: NA
	Case series Reference standard: Surgery (26) or	Risk factors (n [%]): NR			PPV NPV	0.0% 100.0%	0.0% 78.6%	0.0% 100.0%	
	followup (16) Reference standard applied to all test	Inclusion criteria: Postmenopausal at least 12 months	Additional data used for diagnosis: NR						
	negatives?: Yes Test reliability established?: No	Exclusion criteria: NR Loss to followup: 6 (12.5%)							

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy Results	Comments/Quality Scoring
	Statistical tests used: None				¥
	Blinding: "Treatment rationale was not always available to the sonographers."				
	Definition of positive and negative on screening test: Unilateral, no septations or solid components, diameter ≤ 5 cm, no ascites				
	Length of followup: Mean 29 months (range 10-73 months)				
	Type of followup: Repeat transabdominal US				
	Followup interval: 3-6 months				

			Presentation						Scoring
Kupesic, et al., 1994 #4470 Ja #4470 Si So So So So So So So So So So So So So	Croatia Dates: Jan 1988-Dec 1992 Size of population: 5013 in initial screening population 404 had simple cysts; esults only reported or 88 with 2 nd scan Screening study Reference standard: Surgery or followup Reference standard applied to all test negatives?: Yes Fest reliability established?: Not eferenced Statistical tests	Age: NR for group with cyst Menopausal status (n [%]): Pre (< 45): 280 (69.3%) Peri (45-55): 0 Post (> 55): 124 (30.6%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: 40 years or older, absence of symptoms Exclusion criteria: NR Loss to followup: NR; apparently 0	Presentation Symptomatic (n [%]): 0 Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: NR	Monitoring test: Repeat ultrasound Interval of testing: 6 months Definition of change: Not explicitly defined	1) Cal benig T+ T- Tot Se Sp PPV NPV	Dis+ 1 0 1 Value 100.0% 80.2% 5.6%	followup a Dis- 17 69 86 Lower 95% CI 0.0% 71.8% 0.0% 95.7%	fter initial Tot 18 69 87 Upper <u>95% CI</u> 100.0% 88.6% 16.1% 100.0%	Scoring Comments: Incomplete details on other 316 subjects Short duration of followup Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: - Sample size: - Statistical tests: - Blinding: - Definition of +/- on screening test: + Explicit validation method?: NA
	S months								

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Resu	lts			Comments/Quality Scoring
	Repeat ultrasound								
	Followup interval: 6 months								
Levine, Gosink, Wolf, et al., 1992 #10320	Geographical location: Portland, OR Dates: Oct 1989-June 1990 Size of population: 184; 32 had simple cysts at initial evaluation, 31 developed over course of study Other: Cross-sectional, volunteer screening Reference standard: Followup Reference standard applied to all test negatives?: Yes Test reliability established?: Not discussed or referenced Statistical tests used: Chi-square, t-test Blinding: No Definition of positive and negative on screening test: Simple cyst –	Age: Mean (SD): 63.6 (8.1) Range: 50-85 Menopausal status (n [%]): Post (> 55): 184 (100%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Age ≥ 59, postmenopausal at least 1 year Exclusion criteria: NR Loss to followup: 49 of 63 women with cysts had ultrasound followup (22.2% loss to followup)	0 Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination	Monitoring test: Transabdominal/ transvaginal ultrasound Doppler and CA-125 if abnormal Interval of testing: 3 months Definition of change: Increased: diameter change ≥ 3 mm Decreased: diameter change ≤ 3 mm	1) Ca T+ T- Tot Se Sp PPV NPV	Dis+	Dis- 0 32 32 Lower 95% CI - 90.6% 90.6%	Tot 0 32 32 Upper 95% CI 100.0%	Comments: Results not presented clearly Inconsistent followup strategy Quality assessment: Reference standard: - Verification bias: - Test reliability/variability: - Sample size: - Statistical tests: - Blinding: - Definition of +/- on screening test: + Explicit validation method?: NA

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Results	Comments/Quality Scoring
	completely anechoic, unilocular, nonseptated					
	Length of followup: 2 years ("over half one year or more")					
	Type of followup: Transabdominal and transvaginal ultrasound					
	Followup interval: 3 months x 1 year, then every 6 months					
Maggino, Gadducci, D'Addario,	Geographical location: Padua, Pisa, Bari, Brescia,	Age: NR for subgroup of interest	Symptomatic (n [%]): NR	Monitoring test: Not systematic	1) Cancer during followup after initial benign:	Comments: No details on followup strategy
et al., 1994	and Milan, Italy	Menopausal status	Detected by exam	Interval of testing: NR	Dis+ Dis- Tot T+ 0 0 0	No details on length of followup
¥4500	Dates: Mar 1991-Mar 1992	(n [%]): Post (> 55): 45 (100%)	(n [%]): NR	Definition of change: NR	T- 0 45 45 Tot 0 45 45	Quality assessment: Reference standard: +
	Size of population: 335; 45 with benign cyst and CA-125 < 35	Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR		Lower Upper Value 95% CI 95% CI Se - - Sp 100.0% 93.3% 100.0%	Verification bias: + Test reliability/variability: + Sample size: - Statistical tests: -
	Case series		Combination		PPV	Blinding: -
	Reference standard: Surgery or followup	Risk factors (n [%]): NR	NR		NPV 100.0% 93.3% 100.0%	Definition of +/- on screening test: + Explicit validation method?:
	Reference standard applied to all test negatives?: Yes	Inclusion criteria: Pelvic mass, at least 1 year post- menopausal	Additional data used for diagnosis: NR			NA
	Test reliability established?: Yes	Exclusion criteria: Incomplete US data,				
	Statistical tests used: Se, Sp, PPV, NPV,	no CA-125, no histology for patients with surgery				
	Kappa	Loss to followup:				

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Results	Comments/Quality Scoring
		2/45 (4.4%)				
	Blinding: No					
	Definition of positive and negative on screening test: < 5 cm, thin wall, no echoes, ≤ 3 thin septa, no free fluid in pelvis					
	Length of followup: NR					
	Type of followup: NR					
	Followup interval: NR					
Menon, Talaat, Rosenthal,	Geographical location: United Kingdom	Age: NR	Symptomatic (n [%]): NR	Monitoring test: Pelvic ultrasound/serial CA-125	Among 17 patients with an equivocal scan who were triaged to followup in 4- 6 weeks:	with masses thought to be
et al., 2000 #2780	Dates: 1986-1989	Menopausal status (n [%]): All older than 45 (22,000/100%)	Detected by exam (n [%]): NR	Interval of testing: Depends on findings. If equivocal US, repeat	-9 had simple cysts, did not have surgery, and did not develop cancer (true negatives); -1 died of ovarian cancer before her	benign. The only categories in this paper are normal (doesn't differentiate those with probabl benign masses), equivocal
	Size of population: 22,000 screened; 741 with elevated CA- 125 had US; 97 scans were abnormal or equivocal Screening study	Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	every 6 weeks until normal or abnormal. If normal, repeat the CA- 125 every 3 months for a year. If US abnormal, refer to gynecologist for a decision.	repeat ultrasound (can't categorize); -1 died of pneumonia before a repeat ultrasound could be done (can't categorize); -5 had surgery with benign pathology	(can't classify as normal or abnormal) and abnormal. Not sure the "equivocal" category can be considered "masses thought to be benign," but that is the group we focused on to answer Question 4.
	Reference standard: Pathology and clinical followup	Inclusion criteria: Age > 45, CA-125 > 30 on screening Exclusion criteria:	Additional data used for diagnosis: NR	Definition of nl or abnl: Normal: volume < 8.8 ml or ovaries not visualized	found (true positive).	but the exact number lost to followup was not given. Authors didn't specify what happens if a patient with a normal scan subsequently
	Reference standard applied to all test negatives?: No	Premenopausal, CA- 125 < 30 Loss to followup:		Equivocal: volume < 8.8 with abnormal morphology		develops a rising CA-125. Quality assessment: Reference standard: +/-
	Test reliability established?: ?	NR		Abnormal: volume >		Verification bias: +/- (median followup was specified but not

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy Results	Comments/Quality Scoring
	Statistical tests used:			8.8 irrespective of morphology	all negatives got surgery) Test reliability/variability: Sample size: + Statistical tests: ?
	Blinding: No	-		Blinding: - Definition of +/- on screening	
	Definition of positive and negative on screening test: Yes				test: + Explicit validation method?: -
	Length of followup: Median 6.8 years				
	Type of followup: Annual questionnaires, Tumor Registry, pathology				
	Followup interval: If scan normal, repeat CA-125 every 3 months for a year. If scan equivocal, repeat every 6 weeks until it can be classified as normal or abnormal. If scan abnormal, refer to gynecologist – surgical intervention at the gynecologist's				
	discretion.				

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Results	Comments/Quality Scoring
Modesitt, Pavlik, Ueland, et al., 2003 #5560	Geographical location: Lexington, KY Dates: 1987-2002 Size of population: 15,106 screened with TVUS; 2763 women had 3259 unilocular ovarian cysts Screening study	Age: NR Menopausal status (n [%]): Post (> 55): 100% Race/ethnicity (n [%]): NR Risk factors (n [%]): 49% of patients with unilocular cysts were	Symptomatic (n [%]): 0 Detected by exam (n [%]): 0 Detected by imaging (n [%]): 2763 (100%) Combination (n [%]):	Monitoring test: TVUS Interval of testing: Repeat in 4-6 weeks with Doppler and CA- 125 if abnormality detected. A tumor score from 0-10 was assigned based on volume and structure at the second scan. If cyst still appears simple at second scan, repeat	2763 women had 3259 unilocular cysts. Of these, 2261 (69.4%) spontaneously resolved, 220 (6.8%) persisted, 726 (22.3%) developed changes such as septa or solid areas and were no longer considered simple, 12 (0.3%) had an ovary that couldn't be visualized on a subsequent scan, and 40 (1.2%) were removed during a subsequent surgery. Authors did not report how many patients had surgery. They did report that 10 patients in this "unilocular	Comments: Good evidence that simple ovarian cysts almost never represent cancer and can be followed. Could argue that 3 of the patients who developed cancer should be treated as "false negatives" but the cancers developed either after the original cyst had resolved or in the other ovary – did 2x2 tables for both interpretations.
	Reference standard: Clinical followup (mean 6.3 years) Reference standard applied to all test negatives?: Yes Test reliability established?: Yes Statistical tests	on hormone replacement therapy Inclusion criteria: At least 50 years old Exclusion criteria: Known ovarian tumor prior to screening, previous diagnosis of ovarian cancer, symptoms consistent	Additional data used for diagnosis: NR	TVUS every 3-6 months. Definition of change: Development of a septum or solid area, volume >10 cm ³ ,	cyst" population subsequently developed ovarian cancer: -7 of these had an additional abnormal area that developed on their TVUS besides the simple cyst (so presumably they are not "false negatives"-they were caught by screening eventually). -2 had the cyst in question resolve spontaneously, but were ultimately diagnosed with ovarian cancer (should these be considered false negatives – probably not). -1 was ultimately diagnosed with	followup) y Test reliability/variability: + Sample size: + Statistical tests: - (none) Blinding: Definition of +/- on screening
	Blinding:	with a pelvic mass Loss to followup: NR; mean followup			cancer in the opposite ovary (probably not a false negative).	
	Definition of positive and negative on screening test: Negative: unilocular simple cyst Positive: any septum, solid area, papillary projections, or volume > 10 cm ³ Length of followup:	6.3 years			They therefore claim a 0% false negative rate in unilocular cysts < 10 cm (none of these cysts subsequently turned into cancer). If all 3 in question above are treated as false negatives, the 2x2 table is below: ("by patient," not "by cyst") $\frac{\text{Dis+}}{\text{T-}} \frac{\text{Dis-}}{3} \frac{\text{Tot}}{2753} \frac{7}{2756}$	
	6.3 years Type of followup:				Tot 10 2753 2763	

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Resul	ts			Comments/Quality Scoring
							Lower	Upper	
	Followup interval:					Value	95% CI	95% CI	
					Se	70.0%	41.6%	98.4%	
					Sp	100.0%	99.9%	100.0%	
					PPV	100.0%	57.1%	100.0%	
					NPV	99.9%	99.8%	100.0%	
					2) On	a "by cyst"	basis, the	ere are no	
						egatives, s			
					who ha	d cancers	did so afte	er the cysts	
					in ques	tion resolv	/ed (or in t	he opposite	
					ovary):				
						Dis+	Dis-	Tot	
					T+	7	0	7	
					Т-	0	3252	3252	
					Tot	7	3252	3259	
							Lower	Linnor	
						Value	95% CI	Upper 95% CI	
					80	100.0%	57.1%	100.0%	
					Se				
					Sp	100.0%	99.9%	100.0%	
					PPV	100.0%	57.1%	100.0%	
					NPV	100.0%	99.9%	100.0%	

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Results	Comments/Quality Scoring
Schincaglia, Brondelli, Cicognani, et al., 1994 #4520	location: Bologna, Italy Dates: Aug 1988-Jun 1992 Size of population: -3541 screened -347 were asked to followup, and can be split into 2 groups: -249 were followed with additional scans but not deemed "abnormal" enough to refer for FNA/surgery	Age: NR Menopausal status (n [%]): Post (> 55): 3541 (100%) Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Inclusion criteria: Postmenopausal, no prior pelvic surgery or pelvic symptoms Exclusion criteria: Prior pelvic surgery, pelvic symptoms Loss to followup: Not stated, but followup listed as "at least one year" for negative screens and those managed conservatively	Symptomatic (n [%]): 0 Detected by exam (n [%]): 0 Detected by imaging (n [%]): All who qualified for followup (347) Combination (n [%]): NR Additional data used for diagnosis: NR	Monitoring test: Ultrasound Interval of testing: See below Definition of change: See below Volume of ovaries: < 9 negative < 9 with a cyst: followup US in 6 months. Increased volume → refer to level II 9-15: followup 3 and 6 months. Unchanged → refer to level II > 15 referral to level II Level II: Morphology assessment and biopsy if feasible Surgery if FNA not feasible, inadequate, positive, or patient refuses FNA	1) Of the 347 patients selected for followup initially, 283 were deemed appropriate for followup using repeat ultrasound at 3- to 6-month intervals without immediate referral for FNA/surgery. Of these 283, 34 subsequently had concerning US results and were referred for level II scan and possible FNA. The results of this group of 34 are not given separately. Of the 249 who had non- concerning followup scans, none developed cancer, with followup of "at least" 1 year. Therefore Specificity is 100% for patients with an initial abnormal but "probably benign" finding who had reassuring followup studies. Sensitivity within this group cannot be calculated with the information given. $\frac{Value}{95\%} \frac{Value}{95\%} \frac{98}{249}$ Tot 2 345 347 $\frac{Value}{95\%} \frac{Value}{95\%} \frac{95\%}{21} \frac{95\%}{20\%} \frac{100.0\%}{100.0\%}$ Sp PPV 2.0% 0.0% 100.0% NPV 100.0% 98.8% 100.0%	Comments: The category "probably benign" is not really defined here, so abstractor chose the patients who had something abnormal on their original screen. According to the authors, none of the patients who were not referred to level 2 developed ovarian cancer, but the followup time was fairly minimal compared to other large screening studies. Quality assessment: Reference standard: + Verification bias: - (followup not very long) Test reliability/variability: + Sample size: + Statistical tests: - Blinding: - (NR) Definition of +/- on screening test: + Explicit validation method?: -

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy	Results	Comments/Quality Scoring
	Blinding: NR					
	Definition of positive and negative on screening test: See under "Monitoring Strategy"					
	Length of followup: At least 1 year					
	Type of followup: Questionnaire for negative screens; others had followup studies as specified under "Monitoring Strategy"					
	Followup interval: Varied by ultrasound findings					
/alentin and Akrawi, 2002	Geographical location: Malmo, Sweden	Age: Median: 61 Range: 47-87	Symptomatic (n [%]): 84 (62.7%)	Monitoring test: TVUS	1) Change in US as positive test, cancer as disease:	Comments: Complete followup
¢8490	Dates: June 1991-Nov 2000	Menopausal status (n [%]): Post (> 55): 134	Detected by exam (n [%]): NR	Interval of testing: 3, 6, 12, then every 12 months	Dis+ Dis- Tot T+ 0 7 7 T- 0 127 127 Tot 0 134 134	Quality assessment: Reference standard: + Verification bias: + Test reliability/variability: -
	Size of population: 162; 134 agreed to followup (28 not followed older, had higher mortality)	(100%) Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR	Definition of change: Positive difference between largest diameter at most recent examination and at	Lower Upper Value 95% CI 95% CI Se	Sample size: - Statistical tests: + Blinding: - Definition of +/- on screening test: + (not defined, but
	Consecutive case- series	Risk factors (n [%]):	Combination (n [%]): NR	initial examination, or cyst "more complex"	Sp 94.8% 91.0% 98.5% PPV 0.0% 0.0% 0.0% NPV 100.0% 97.6% 100.0%	references provided) Explicit validation method?: NA
	Reference standard: Surgery or followup	Inclusion criteria: Cysts "judged to be benign," age ≥ 40,	Additional data used for diagnosis: NR	Morphology improved if cyst complexity decreased	4 additional patients were operated on for other causes	
	Reference standard applied to all test	menopausal for at least 1 year				

Study	Study Design	Patients	Clinical Presentation	Monitoring Strategy Results	Comments/Quality Scoring
	negatives ?: Yes				
		Exclusion criteria:			
	Test reliability established?: Yes	NR			
		Loss to followup:			
	Statistical tests	0% (mortality and			
	used:	surgical data			
	Sp, PPV, NPV	obtained from Swedish national			
	Blinding: No	registries)			
	Definition of positive				
	and negative on				
	screening test:				
	Referenced but not				
	explicitly described in				
	this paper				
	Length of followup:				
	Median 3 years (range				
	4 months-8 years)				
	Type of followup:				
	Transvaginal				
	ultrasound				
	Followup interval:				
	3, 6, 12 months, then				
	every 12 months				

Evidence Table 6: Question 6: Among women with adnexal masses, what are the morbidity and mortality from diagnostic surgery (laparoscopy or laparotomy)? At what point does the risk of surgery outweigh the risk of detecting malignancy?

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Canis, Mage,	Geographical location: Clermont-Ferrand,	Age: Mean (SD): 35.8 (12.6)	Symptomatic (n [%]): NR	1) Mortality: 0/757 (95% Cl, 0 to 0.6%)	Comments: Unclear whether some benign
Pouly, et al., 1994	France	Range: 8-84	Detected by exam (n [%]):	 Morbidity (total all complications): 8/727 (1.1%) 	cases excluded after surgery
#4610	Dates: NR	Menopausal status (n [%]):	NR	3) Specific complications:	Quality assessment: Size of population from which
	Size of population: 757	Pre (< 45): 671 (88.6%) Post (> 55): 86 (11.4%) 92 patients > 50	Detected by imaging (n [%]): NR	1 gastric laceration 1 acute abdomen 1 peritonitis (sigmoid laceration)	sample drawn: - Number of cases: + Patient selection: -
	Registry	Race/ethnicity (n [%]):	Combination (n [%]):	2 ovarian abscess 2 peritonitis (ruptured teratoma)	Application of reference standard: -
	Morbidity definitions: Not described	NR	NR	1 led to immediate re-operation 1 led to operation for CPP 12 mo later	
	Length of followup after surgery:	Risk factors (n [%]): NR	Additional data used for diagnosis: Ultrasound	1 abdominal wall endometrioma re-operated	
	Mean 42 months (range 3-153)	Loss to followup: 81/620 (13.1%)	Age CA-125	 Rate of conversion to laparotomy: Not described for non-malignant tumors 	
			"Recurrent cysts" < endometriomas, paraovarian and functional cysts, pseudoperitoneal cysts, and hydrosalpinges excluded; not clear if excluded before or after surgical diagnosis		

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Canis, Mashiach, Wattiez, et	Geographical location: Clermont-Ferrard, France		Symptomatic (n [%]): NR	 Mortality: NR Morbidity (total all complications): 	Comments: Clinical history prior to surgery not described
al., 2004	Dates: ?1992-1997	Menopausal status	Detected by exam (n [%]):	Sensitivity/specificity of frozen section: Low	described
ai., 2004	(specific dates not given)		NR	malignant potential = cancer, "unclear"	Quality assessment:
#7720		Pre (< 45): 99 (70.2%)		results on frozen = positive test	Size of population from which
	Size of population:	Post (> 55): 42 (29.8%)	Detected by imaging		sample drawn: +
	839 total, 141 with		(n [%]):	Dis+ Dis- Tot	Number of cases: -
	frozen section	Race/ethnicity (n [%]):	NR	T+ 47 4 51	Patient selection: Not described
	Single contor	NR	Combination (n [9/1);	T- 4 86 90	Application of reference standard: +
	Single center	Risk factors (n [%]):	Combination (n [%]): NR	Tot 51 90 141	
	Morbidity definitions:	NR	NR	Lower Upper	
	Sensitivity/specificity of		Additional data used for	Lower Upper Value 95% CI 95% CI	
	frozen section	Loss to followup:	diagnosis:	Se 92.2% 84.8% 99.5%	
		NR .	NR	Sp 95.6% 91.3% 99.8%	
	Length of followup			PPV 92.2% 84.8% 99.5%	
	after surgery:			NPV 95.6% 91.3% 99.8%	
	Up to 10 years (not				
	uniformly)			Specific complications: NR	
				4) Rate of conversion to laparotomy: NR	
Carley, Klingele,	Geographical location: Rochester, MN	Age: Mean (SD):	Symptomatic (n [%]): History not reported	1) Mortality: NR	Quality assessment: Size of population from which
Gebhart, et		Laparotomy: 46.4 (13.5)	history not reported	2) Morbidity (total all complications):	sample drawn: +
al., 2002	Dates: Dec 1995-Nov	Laparoscopy: 49.2 (15.9)	Detected by exam (n [%]):	Laparotomy: 2/44 (4.6%; 95% CI, 0.7,	Number of cases: -
,	2000		NR	16.7%)	Patient selection: -
#8500		Menopausal status			Application of reference standard: +
	Size of population:	(n [%]):	Detected by imaging	Specific complications:	
	106	NR	(n [%]):	Transfusion:	
	.		NR	Laparotomy: 1/44 (2.3%; 95% CI, 0 to	
	Single center	Race/ethnicity (n [%]):		13.5%)	
	Morbidity definitions:	NR	Combination (n [%]): NR	Laparoscopy (including conversions): 0/62 (0 to 8.6%)	
	-Febrile morbidity	Risk factors (n [%]):	NK	Febrile morbidity:	
	-Transfusion	NR	Additional data used for	Laparotomy: 1/44 (2.3%; 0 to 13.5%)	
	-Conversion		diagnosis:	Laparoscopy: 0/62 (0 to 8.6%)	
		Loss to followup:	Masses > 7 cm or with CA-		
	Length of followup	NR	125 > 35 not included in	4) Rate of conversion to laparotomy: 16%	
	after surgery:		analysis; malignant	,	
	Not specified		pathology excluded		

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Chapron,	Geographical location:	Age:	Symptomatic (n [%]):	1) Mortality:	Comments:
Dubuisson, and Capella-	Paris, France	Mean: Laparotomy 45.7	NR	Laparotomy: 0/65 (95% CI, 0 to 8.3%) Laparoscopy: 0/121 (0 to 4.5%)	Groups not comparable in terms of baseline assessment (those with
Allouc, 1997	Dates: Jan 1989-Dec	Laparoscopy 49.5	Detected by exam (n [%]):		higher suspicion of malignancy went
	1994	Damas	NR	2) Morbidity (total all complications):	to directly to laparotomy – and 21
#6150	Size of population:	Range: Laparotomy 18-72	Detected by imaging	Laparotomy: 10/65 (15.4%; 95% CI, 8.9 to 27.0%)	laparotomy patients were emergency surgery secondary to "considerable
	186	Laparoscopy 19-82	(n [%]):	Laparoscopy: 10/121 (8.3%; 4.6 to 15.0%)	hemoperitoneum")
		upu.coopy .c c	NR		Description of clinical pathway to
	Single center	Menopausal status		Specific complications:	surgery not described
		(n [%]):	Combination (n [%]):	Laparotomy:	19 of the "laparotomy" group
	Morbidity definitions:	Laparotomy	NR	Cystitis: 2/65	started as laparoscopy; data not
	-Conversion to	Pre (< 40): 18 (27.7%)	Additional data used for	Febrile morbidity: 2/65 Abdominal wall hematoma: 1/65	provided to summarize results by "intention to treat"
	laparotomy -Complications	Peri (40-50): 28 (43.1%) Post (> 50): 19 (29.2%)	diagnosis:	Abdominal wall abscess: 2/65	Reoperation for laparotomy group
	-complications	Laparoscopy	All patients underwent	Bowel obstruction: 1/65	not mentioned
	Length of followup	Pre (< 40): 21 (18.2%)	removal of adnexal	Evisceration: 2/65	Didn't include transfusion as
	after surgery:	Peri (40-50): 38 (31.4%)			specific com[placation (1/65 in
	NR	Post (> 50): 61 (50.4%)	Patients with "prophylactic" adnexal removal due to age,	Laparoscopy: Urinary tract infection: 1/121	laparotomy)
		Race/ethnicity (n [%]):	family history excluded	Febrile morbidity: 5/121	Quality assessment:
		NR	, ,	Bowel obstruction: 1/121	Size of population from which
				Evisceration: 2/121 (both re-operated)	sample drawn: - (referral base not
		Risk factors (n [%]): NR		Sigmoid injury: 1/121 (re-operated)	described) Number of cases: -
				Rate of conversion to laparotomy:	Patient selection: - (not described)
		Loss to followup: NR		19/140 (13.6%; 95% CI, 9.0 to 20.6%)	Application of reference standard: + (all patients underwent surgery)

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Chi, Abu- Rustum, Sonoda, et	Geographical location: New York, NY	Age: (all patients) Median: 54 Range: (15-88)	Symptomatic (n [%]): Pre-procedure history not reported	Results presented for diagnostic laparoscopy only	Comments: Gynecological oncology service Proportion of patients with adnexal
al., 2004 #7870	Dates: Jan 1991-Dec 2000	Menopausal status (n [%]):	Detected by exam (n [%]): NR	1) Mortality: 3/146 (2.5%; 95% Cl, 0.5 to 6.3%)	mass (as opposed to other malignancies) not reported
	Size of population: 1451 (146 with diagnostic laparoscopy) Single center	NR	Detected by imaging (n [%]): NR	 2) Morbidity (total all complications): 19/146 (13.0%; 95% Cl, 8.6 to 19.8%) 3) Specific complications: Grade 1: 14/146 (9.6%; 95% Cl, 5.8 to 	Quality assessment: Size of population from which sample drawn: + Number of cases: - Patient selection: -
	Morbidity definitions: -Grade 1: use of oral	Risk factors (n [%]) : NR	Combination (n [%]): NR	15.8%) Grade 2: 1/146 (0.7%; 0 to 4.3%) Grade 3: 4/146 (2.7%; 0.9 to 7.2%)	Application of reference standard: +
	medications, bedside interventions -Grade 2: IV medications, TPN, enteral nutrition, or blood transfusion -Grade 3: interventional radiology, endoscopy, intubation, or operation -Grade 4: Residual and lasting disability that requires major rehabilitation or organ resection -Grade 5: Death	Loss to followup: NR	Additional data used for diagnosis: NR	 Grade 4: 0/146 (0%; 0 to 3.76%) 4) Rate of conversion to laparotomy: 15/146 (10.3%; 95% CI, 6.4 to 16.6%) 5) Multivariate analysis: Complications significantly more likely with older age, history of radiation therapy, malignancy 	
	Length of followup after surgery: 30 days				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Childers,	Geographical location:	Age:	Symptomatic (n [%]):	1) Mortality:	Comments:
Nasseri, and Surwit, 1996	Tucson, AZ	Mean: 52 Range: 9-91	NR	0/138 (95% CI, 0 to 4.0%)	Selected population – gynecological oncology service,
	Dates: July 1991-Jan	C	Detected by exam (n [%]):	Morbidity (total all complications):	higher probability of malignancy
#6940	1995	Menopausal status (n [%]):	NR S S S	14/138 (10.1%; 95% CI, 6.2 to 16.7%)	No data on initial clinical presentation
	Size of population: 138	NR	Detected by imaging (n [%]):	 Specific complications: Enterotomy: 1/138 	Results not stratified by age or menopausal status
		Race/ethnicity (n [%]):	NR	Vena Cava injury: 1/138	
	Single center	NR		Bowel herniation: 1/138 (re-operated)	Quality assessment:
			Combination (n [%]):	Febrile morbidity: 2/138	Size of population from which
	Morbidity definitions:	Risk factors (n [%]):	NR	lleus: 3/138	sample drawn: - (no data on referral
	Complications	NR		Cardiac arrhythmia: 4/138	base)
			Additional data used for	Urinary retention: 2/138	Number of cases: - (< 200)
	Length of followup	Loss to followup:	diagnosis:		Patient selection: - (unclear how
	after surgery:	NR	"Suspicious adnexal mass",	Rate of conversion to laparotomy:	many patients did not undergo
	23-50 months (mean 37)		which on ultrasound did not	11/138 (8.0%; 95% CI, 4.5 to 14.1%)	laparoscopy)
	in patients with		meet all criteria:	All for either technical reasons, debulking, or	
	malignancy; not given for others		Size < 10 cm Unilateral	staging; none for complications	(all underwent pathology)
			Smooth borders	5) Malignancy	
			No excrescences No solid parts	19/138 (13.8%; 95% CI, 9.1 to 20.9%)	
			No fluid in cul-de-sac, and with no ascites, malignant		
			cells on paracentesis, or upper abdominal masses		

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Study Deckardt, Saks, and Graeff, 1994 #4310	Geographical location: Munich, Germany	Age: Laparotomy: Mean: 43.6 Range: 20-84 Laparoscopy: Mean: 40.1 Range: 18-74 Menopausal status (n [%]): Laparotomy: Pre (< 45): 73.7%	Clinical Presentation Symptomatic (n [%]): NR Detected by exam (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: Premenopausal: mass > 6 cm, persistent after 6 months, symptomatic; infertility; not a corpus luteum cyst by ultrasound Postmenopausal: any adnexal mass Patients randomized according to ward where they were admitted	 Mortality: Laparotomy: 0/76 (95% Cl, 0 to 7.1%) Laparoscopy: 0/116 (0 to 4.7%) Morbidity (total all complications): Laparotomy: 23/76 (30.3%; 21.8 to 42.3%) Laparoscopy: 13/116 (11.2%; 6.8 to 18.7%) Specific complications: Bladder injury: Laparotomy 1/76, laparoscopy 0/116 Incisional hernia: Laparotomy 3/76, laparoscopy 1/116 Umbilical hernia: Laparotomy 0/76, laparoscopy 1/116 UTI: Laparotomy 12/76, laparoscopy 2/116 Febrile morbidity: Laparotomy 3/76, laparoscopy 2/116 Bowel obstruction: Laparotomy 1/76, laparoscopy 2/116 Chemical peritonitis: Laparotomy 0/76, laparoscopy 1/116 Small bowel injury: Laparotomy 2/76, laparoscopy 1/116 Pulmonary embolus: Laparotomy 1/76, laparoscopy 0/116 Wound dehiscence: Laparotomy 2/76, laparoscopy 1/116 Rate of conversion to laparotomy: 4/116 (3.5%; 1.2 to 9.0%) 46% of laparotomy patients received prophylactic antibiotics, compared to 2.6% 	Comments: Randomization not well described; differences in baseline characteristics, types of procedure performed suggest some bias in treatment allocation
				 4/116 (3.5%; 1.2 to 9.0%) 5) 46% of laparotomy patients received prophylactic antibiotics, compared to 2.6% of laparoscopy patients 6) Laparoscopy patients significantly more likely to have cystectomy (60.0% vs 20.2%), 	
				 less likely to have oophorectomy (0.8% vs 20.2%), less likely to have bilateral salphingo-oophorectomy (4.0 vs 21.4%) 7) Reoperation 1/76 for laparotomy (assume 0/116 for laparoscopy?) 	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Dottino, Levine, Ripley, et	Geographical location: New York, NY	Age: Mean (SD): 52.2 (13.1)	Symptomatic (n [%]) : NR	1) Mortality: 0/160 (95% Cl, 0 to 3.4%)	Comments: Cases only performed by gynecological oncologists –
al., 1999 #6920	Dates: Apr 1992-Apr 1996	Menopausal status (n [%]): Pre (< 45): 75 (47%)	Detected by exam (n [%]): NR	2) Morbidity (total all complications): 12/160 (7.5%; 95% Cl, 4.3 to 12.9%)	suggests substantial prescreening in terms of likelihood of cancer, or anticipated difficulty of case
	Size of population: 160	Post (> 55): 85 (53%) Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	3) Specific complications: Vascular injury: 2/160 (1.3%; 95% CI, 0.9 to 4.8%)	
	Single center	White: 146 (91%) Other: 34 (9%)	Combination (n [%]):	Bleeding: 1/160 (0.6%; 0 to 3.9%) Intra-op bowel injury: 1/160 (0.6%; 0 to	sample drawn: - (no data on overall referral pool)
	Morbidity definitions: -Conversion to laparotomy	Risk factors (n [%]) : NR	NR Additional data used for	3.9%) Postop bowel obstruction: 3/160 (1.9%; 0.4 to 5.7%)	Number of cases: - (wide CIs) Patient selection: - (not much description of characteristics,
	-"Complications" -Reoperation -Misdiagnosis	Loss to followup: NR	diagnosis: All patients undergoing laparoscopic evaluation of	Postop febrile morbidity:4/160 (2.5%; 0.8 to 6.6%)	likelihood of bias) Application of reference standard: + (all got pathology)
	Length of followup after surgery: NR, but paper published		adnexal mass by gynecologic oncologist; excluded if mass above umbilicus, other indication for	 4) Rate of conversion to laparotomy: Total: 19/160 (11.9%; 95% CI, 7.8 to 18.1%) Secondary to complications: 5/160 (3.1%; 1.2 to 7.4%) 	
	Feb 1999, last patient enrolled Apr 1996		laparotomy, evidence of gross metastatic disease	5) Final diagnoses Benign: 139 (87%; 95% CI, 84 to 90%) Borderline: 8 (5%; 2.5 to 9.9%) Ovarian cancer: 9 (5%; 2.9 to 10.6%) 4 of 9 epithelial cancers postmenopause Non-gynecological cancer: 4 (3%; 0.8 to 6.6%)	
				6) Other:5 frozen sections reports changed from benign to borderline (3), malignant to benign (1), benign to cancer (1)	

Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Geographical location: Rome, Italy	Age: Mean (SD):	Symptomatic (n [%]): Laparoscopy: 35 (70%)	1) Mortality: 0	Comments: No malignancies
Dates: Jan 2003-Aug	Laparoscopy: 36.3 (12.1) Laparotomy: 37.5 (13.4)	Laparotomy: 38 (76%)	2) Morbidity (total all complications): Laparoscopy: 0/50 (0%: 95% Cl. 0 to	Small sample size
2003		Detected by exam (n [%]):	10.6%)	Quality assessment: Size of population from which
Size of population:	(n [%]):			sample drawn: +
100	Laparoscopy: 5 (10%) postmenopausal	Detected by imaging (n [%]):	3) Specific complications: Fever:	Number of cases: - Patient selection: +
Single center randomized trial	Laparotomy: 10 (20%) postmenopausal	NR	Laparoscopy: 0 Laparotomy: 2 (4%; 95% CI, 0.6 to 14.8%)	Application of reference standard: +
		Combination (n [%]):	, , , , , , , , , , , , , , , , , , , ,	
-lleus	Race/ethnicity (n [%]):	NR	Anemia: Laparoscopy : 0	
-Fever (temperature ≥ 38° C on 2 consecutive	Risk factors (n [%]):	Additional data used for diagnosis:	Laparotomy: 1 (2%; 0 to 12.0%)	
measurements at least 6	NR	Randomized trial Patients excluded for	4) Rate of conversion to laparotomy: 0	
-Anemia (hémoglobin < 8	•	BMI > 32 Cysts > 12 cm		
-Bowel/bladder/ureteral injuries	Ŭ	Hysterectomy required Postmenopausal and CA-		
Length of followup after surgery: 30 days		125 > 35		
	Geographical location: Rome, Italy Dates: Jan 2003-Aug 2003 Size of population: 100 Single center randomized trial Morbidity definitions: -Ileus -Fever (temperature ≥ 38° C on 2 consecutive measurements at least 6 hours apart) -Anemia (hemoglobin < 8 g/dl) -Bowel/bladder/ureteral injuries Length of followup after surgery:	Geographical location: Rome, Italy Age: Mean (SD): Laparoscopy: 36.3 (12.1) Dates: Jan 2003-Aug 2003 Menopausal status (n [%]): Laparoscopy: 5 (10%) postmenopausal Laparotomy: 10 (20%) postmenopausal Single center randomized trial Menopausal status (n [%]): Laparotomy: 10 (20%) postmenopausal Morbidity definitions: -Ileus -Fever (temperature ≥ 38° C on 2 consecutive measurements at least 6 hours apart) -Anemia (hemoglobin < 8 g/dl) Race/ethnicity (n [%]): NR -Anemia (hemoglobin < 8 g/dl) Risk factors (n [%]): 0 -Bowel/bladder/ureteral injuries NR	Geographical location: Rome, ItalyAge: Mean (SD): Laparoscopy: 36.3 (12.1) Laparoscopy: 37.5 (13.4)Symptomatic (n [%]): Laparoscopy: 35 (70%) Laparoscopy: 38 (76%)Dates: Jan 2003-Aug 2003Menopausal status (n [%]): Laparoscopy: 5 (10%) postmenopausal Laparotomy: 10 (20%) postmenopausalDetected by exam (n [%]): NRSingle center randomized trialRace/ethnicity (n [%]): NRDetected by imaging (n [%]): NRMorbidity definitions: -Fever (temperature ≥ 38° C on 2 consecutive measurements at least 6 hours apart)Race/ethnicity (n [%]): NRNRAdditional data used for diagnosis: 0Manomized trial Patients excluded for BMI > 32 Cysts > 12 cm Hysterectomy required Postmenopausal and CA- 125 > 35Length of followup after surgery:List factors (n [%]): NRSige component of the section of the s	Geographical location: Rome, Italy Age: Mean (SD): Laparoscopy: 36.3 (12.1) Symptomatic (n [%]): Laparoscopy: 35 (70%) 1) Mortality: 0 Dates: Jan 2003-Aug 2003 Menopausal status (n [%]): Laparotomy: 37.5 (13.4) Symptomatic (n [%]): Laparotomy: 38 (76%) 1) Mortality: 0 Size of population: 100 Menopausal status (n [%]): Laparoscopy: 5 (10%) postmenopausal Detected by exam (n [%]): NR 10.6%) Laparoscopy: 0/50 (0%; 95% CI, 0 to 10.6%) 3) Specific complications: Fever: Laparotomy: 3/50 (6.0%; 1.8 to 17.5%) Morbidity definitions: -lleus Race/ethnicity (n [%]): NR NR Anemia: Laparoscopy: 0 Japarotomy: 2 (4%; 95% CI, 0.6 to 14.8%) Morbidity definitions: -lleus Race/ethnicity (n [%]): NR NR Anemia: Laparoscopy: 0 Japarotomy: 1 (2%; 0 to 12.0%) NR NR Anemia: Laparotomy: 1 (2%; 0 to 12.0%) Japarotomy: 1 (2%; 0 to 12.0%) 4) Rate of conversion to laparotomy: 0 Morbidity definitions: -fleus 0 Cysts > 12 cm Hysterectomy required Postmenopausal and CA- 125 > 35 4) Rate of conversion to laparotomy: 0

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Havrilesky,	Geographical location:	Age:	Symptomatic (n [%]):	1) Mortality:	Comments:
Peterson, Dryden, et	Durham, NC	Median: 43 Range: 12-87	Clinical history NR	0 (95% CI, 0 to 1.2%)	Presurgical history not reported Risk of complications increased
al., 2003	Dates: NR	Menopausal status	Detected by exam (n [%]): NR	 Morbidity (total all complications): 33/396 (8.3%; 95% CI, 6.0 to 11.6%) 	with concurrent hysterectomyRisk of conversion increased with
#8180	Size of population:	(n [%]):			history of hysterectomy
	396	Pre (< 45): NR Peri (45-55): NR	Detected by imaging (n [%]):	 Specific complications: Incisional disruption/infection: 7 (1.8%; 95%) 	8/396 (2%) had cancer, 4 (1%) had borderline disease
	Single center	Post (> 55): 317 (37.2%)	NR	CI, 0.8 to 3.7%) Urinary retention: 3 (0.8%; 0.2 to 2.4%)	Quality assessment:
	Morbidity definitions: -Estimated blood loss ≥	Race/ethnicity (n [%]): White: 71.2%	Combination (n [%]): NR	Partial small bowel obstruction/prolonged ileus: 5 (1.3%; 0.5 to 3.1%)	Size of population from which sample drawn: +
	500 cc	Black: 26.2%		Urinary tract injury: 1 (0.25%; 0 to 1.6%)	Number of cases: +
	-Incision disruption/infection	Other: 2.4%	Additional data used for diagnosis:	Bowel injury: 2 (0.5%; 0.03 to 2.0%) Nerve injury: 1 (0.25%; 0 to 1.6%)	Patient selection: - Application of reference standard: +
	-Urinary retention -Small bowel obstruction -Urinary tract/GI/nerve	Risk factors (n [%]): NR	NR	Hemorrhage: 7 (1.8%; 0.8 to 3.7%) Re-exploration: 5 (1.3%; 0.5 to 3.1%)	
	-Subcutaneous emphysema	Loss to followup: NR		 Rate of conversion to laparotomy: 25% 	
	-Hemorrhage -Transfusion -Readmission			5) Undiagnosed cancer: 8/396 (2.0%)	
	-Re-exploration Length of followup				
	after surgery:				

NR

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Hidlebaugh,	Geographical location:	Age:	Symptomatic (n [%]):	1) Mortality:	Comments:
Vulga- ropulos,	Worcester, MA	Range: 14-83	NR	0 (95% Cl, 0 to 1.38%)	Selection criteria for laparoscopy vs. laparotomy not described
and Orr, 1997	Dates: Jan 1988-Dec 1995	Menopausal status (n [%]): Pre (< 45): NR	Detected by exam (n [%]): NR	2) Morbidity (total all complications): Laparoscopy: 5/199 (2.5%; 95% CI, 1.0 to 6.0%)	Potential differences in other risk factors for complications not described
#9490	Size of population: 405	Peri (45-55): NR Post (> 55): 82 (20.2%)	Detected by imaging (n [%]):	Laparotomy: 56/206 (27.2%; 21.8 to 34.0%)	Clinical history not described
			NR	Specific complications:	Quality assessment:
	Single center	Race/ethnicity (n [%]):		Intra-operative:	Size of population from which
		NR	Combination (n [%]):	Laparoscopy: 1/199 (0.5%; 95% CI, 0 to	sample drawn: +
	Morbidity definitions:		NR	3.2%)	Number of cases: +
	-Fever -Ilieus	Risk factors (n [%]): NR	Additional data used for	Laparotomy: 3/206 (1.5%; 0.3 to 4.5%)	Patient selection: - Application of reference standard:
	-Anemia/transfusion	NR	diagnosis:	Postoperative:	Application of reference standard.
	-Wound infection	Loss to followup:	NR	Laparoscopy: 2/199 (1.0%; 0.1 to 3.9%)	
	-Deep vein thrombosis -Reoperation	NR		Laparotomy: 33/206 (16.0%; 11.8 to 21.9%)	
	-Readmission			Late:	
				Laparoscopy: 2/199 (1.0%; 0.1 to 3.9%)	
	Length of followup after surgery:			Laparotomy: 18/206 (8.7%; 5.6 to 13.6%)	
	NR			Readmission:	
				Laparoscopy: 0/199 (0%; 0 to 2.4%) Laparotomy: 2/206 (1.0%; 0.1 to 3.8%)	
				4) Rate of conversion to laparotomy:	

10/199 (5.0%; 95% CI, 2.7 to 9.2%)

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Lok, Sahota, Rogers, et al., 2000	Geographical location: Hong Kong, China	Age: Mean (SD): 35.6 (9.8)	Symptomatic (n [%]): 389 (75.8%)	1) Mortality: 0/513 (95% Cl, 0 to 1.1%)	Comments: Preoperative history not described in detail
#8890	Dates: NR Size of population: 513 Single center Morbidity definitions: -Transfusion -Fever -Small bowel hernia -Pelvic hematoma -Urinary retention -Bowel/ureter/vascular injury -Reoperation Length of followup after surgery: NR	Menopausal status (n [%]): Pre (< 45): NR Peri (45-55): NR Post (> 55): 28 (5.5%) Race/ethnicity (n [%]): NR; presumably Asian Risk factors (n [%]): NR Loss to followup: NR	Detected by exam (n [%]): NR Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: "Concurrent problems necessitating other major laparoscopic procedures" excluded	 Morbidity (total all complications): 68/513 (13.3%; 95% Cl, 10.6 to 16.6%) Specific complications: Transfusion: 0 (95% Cl, 0 to 1.1%) Intra-operative: 16/513 (3.1%; 1.9 to 5.1%) Postoperative: 44 (8.6%; 6.5 to 11.4%) Febrile morbidity: 20/513 (3.9%; 2.5 to 6.0%) Reoperation: 7/513 (1.4%; 0.6 to 2.9%) Rate of conversion to laparotomy: 5 (0.97%; 95% Cl, 0.4 to 2.4%) Undiagnosed cancer: 2/513 (0.4%) 	Prevalence of malignancy 0.4% Criteria for selection for laparoscopic approach well described Quality assessment: Size of population from which sample drawn: + Number of cases: + Patient selection: + Application of reference standard: +
Mann and Reich, 1992	Geographical location: Kingston, PA	Mean: 58.7	Symptomatic (n [%]): 7 (15.9%)	1) Mortality: 0/44 (95% Cl, 0 to 11.9%)	Comments: 1/44 had cancer
#10330	Dates: NR	Range: 44-90 Menopausal status	Detected by exam (n [%]): NR	2) Morbidity (total all complications): 2/44 (4.6%; 95% CI, 0.7 to 16.7%)	Ascites, effusion only exclusion Quality assessment:
	Size of population: 44	(n [%]): Post (> 55): 44 (100%)	Detected by imaging (n [%]):	3) Specific complications: Readmission: 2/44 (4.6%; 95% CI, 0.7 to	Size of population from which sample drawn: - Number of cases: -
	Single center	Race/ethnicity (n [%]): NR	NR	16.7%)	Patient selection: + Application of reference standard: +
	Morbidity definitions: Readmission	Risk factors (n [%]) : NR	Combination (n [%]): 37 (84.0%); proportion detected by exam vs imaging	4) Rate of conversion to laparotomy: 2/44 (4.6%; 95% Cl, 0.7 to 16.7%)	
	Length of followup after surgery:	Loss to followup:	not reported	5) Undiagnosed cancer: 1/44 (2.3%)	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Marana, Muzii, Catalano, et al., 2004 #5450	Geographical location: Rome, Italy Dates: Jul 1990 - Dec 2001 Size of population: 683 Two centers (same surgeon) Morbidity definitions: -Complications -Recurrence Length of followup after surgery: Mean 30.2 months (minimum 6 months)	Age: Mean: 27.6 Range: 12-39 Menopausal status (n [%]): Pre (< 45): 100% Race/ethnicity (n [%]): NR Risk factors (n [%]): NR Loss to followup: NR	Symptomatic (n [%]): 416 (60.9%) Chronic pain: 147 (21.5%) Dysmenorrhea: 145 (21.2%) Infertility: 66 (9.7%) Menstrual irregularity: 57 (8.3%) Abdominal swelling: 1 (0.2%) Detected by exam (n [%]): 267 (39.1%) ("routine") Detected by imaging (n [%]): Not clear which of symptomatic ones were initially detected by imaging or exam Combination (n [%]): NR	 Mortality: 0/683 (95% Cl, 0 to 0.82%) Morbidity (total all complications): 6/683 (0.9%; 95% Cl, 0.4 to 2.0%) Specific complications: Retrouterine hematoma: 3/683 Febrile morbidity: 2/683 Ileus: 1/683 Umbilical hernia: 1/683 Transfusion: 1/683 Rate of conversion to laparotomy: 16/683 (2.3%; 95% Cl, 1.3 to 3.8%) patients with advanced endometriosis, 2 with large dermoids, one (0.15%) suspected malignancy (final pathology borderline) 8 patients total with final path not benign – 7 borderline, 1 focal invasive endometrioid cancer 	Comments: Fairly complete reporting of important clinical information Limited to premenopausal women Laparotomy 1/76, laparoscopy 0/116 Quality assessment: Size of population from which sample drawn: - (referral base not described) Number of cases: + Patient selection: + Application of reference standard: +
			Additional data used for diagnosis: No solid components, papillation, or septae; if mass < 7 cm, ultrasound repeated in 8-12 weeks; CA-125 not done Age < 40		

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Parker, Levine, Howard, et	Geographical location: Santa Monica, Irvine, and Los Angeles, CA;	Age: Mean: 65 Range: 47-81	Symptomatic (n [%]): NR	1) Mortality: 0/61(95% Cl, 0 to 7.4%)	Comments: Initial presentation not described "Presumptively benign" masses
al., 1994	Louisville, KY; Rochester, NY	Menopausal status	Detected by exam (n [%]): NR	 Morbidity (total all complications): 2/61 (3.3%; 95% CI, 0.4 to 12.3%) 	form series Only intra-operative complications
#910	Dates: NR	(n [%]): Post (> 55): 61 (100%)	Detected by imaging	3) Specific complications:	reported – length of followup after surgery not reported – assume very
	Size of population:	postmenopausal (> 45 ́ with 12 months of	(n [%]): NR	Bladder perforation: 1/61 Sigmoid injury: 1/61 (led to laparotomy)	short or not at all?
	61	amenorrhea, or FSH > 40 mIU/mL)	Combination (n [%]):	4) Rate of conversion to laparotomy:	Quality assessment: Size of population from which
	Multicenter	Race/ethnicity (n [%]):	NR	3/61 (4.9%; 95% CI, 1.4 to 14.5%)	sample drawn: - (referral base not described)
	Morbidity definitions: -Complications	NR	Additional data used for diagnosis:		Number of cases: - Patient selection: - (not described)
	-Conversion to laparotomy	Risk factors (n [%]): NR	Ultrasound done in all; masses < 10 cm, cystic, no irregularities, solid		Application of reference standard: + (laparotomy 1/76, laparoscopy
	Length of followup after surgery: NR	Loss to followup: NR	components, septae > 2 mm, no ascites = "presumptively benign"		0/116)
			Post menopause = > 45 years old with at least 12 months amenorrhea, if prior hysterecotomy = FSH > 40		
Parker and Proietto, 1997	Geographical location: Newcastle, Australia	Age: Mean: 34.4 Range: 12-82	Symptomatic (n [%]): NR	1) Mortality: 0/86 (95% Cl, 0 to 5.4%)	Quality assessment: Size of population from which sample drawn:
#9440	Dates: Jan 1993-Dec 1995	Menopausal status (n [%]):	Detected by exam (n [%]): NR	2) Morbidity (total all complications): 19/86 (22.1%; 95% CI, 15.1 to 32.7%)	Number of cases: Patient selection: Application of reference standard:
	Size of population: 86	NR	Detected by imaging (n [%]):	 Specific complications: Wound infection: 7/86 (8.1%; 95% CI, 4.0 to 	
	Single center	Race/ethnicity (n [%]): NR	NR	16.5%) Other infection: 5/86 (5.8%; 2.4 to 13.5%)	
	Morbidity definitions:	Risk factors (n [%]) : NR	Combination (n [%]): NR	Other wound: 2/86 (2.3%; 0.2 to 8.5%)	
	-Hernia -Pulmonary embolus	Loss to followup:	Additional data used for diagnosis:	 Aate of conversion to laparotomy: NA (all laparotomies) 	
	-Wound hematoma or	NR	NR	5) Undiagnosed cancer: 1/86 (1.2%)	

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
	other complication				
	Length of followup after surgery: NR				
Sadik, Onoglu, Gokdeniz, et	Geographical location: Matalyta, Turkey	Age: Mean (SD): 30.0 (9.7) Range: 13-68	Symptomatic (n [%]): NR	1) Mortality: 0/220	Comments: Data on masses converted to laparotomy not provided
al., 1999	Dates: NR	Menopausal status	Detected by exam (n [%]):	 Morbidity (total all complications): 2/220 (0.9%) 	Followup not described
#2880	Size of population: 220	(n [%]): Pre (< 45): 213 (96.8%) Post (> 55): 7 (3.2%)	Detected by imaging	3) Specific complications:Acute abdominal pain on postoperative day	Quality assessment: Size of population from which sample drawn: -
	Single center registry	Race/ethnicity (n [%]):	(n [%]): NR	5 – no cause at laparotomy Sigmoid perforation	Number of cases: + Patient selection: -
	Morbidity definitions:	NR	Combination (n [%]): NR	4) Rate of conversion to laparotomy:	Application of reference standard:
	-Hospital stay -"Complications"	Risk factors (n [%]):		Malignant masses "excluded from study"	
	Length of followup	NR	Additional data used for diagnosis:	5) 1 malignant dysgerminoma, 1 borderline	
	after surgery: NR	Loss to followup: NR	Cystic adnexal mass > 5, < 10 cm, no irregular solid	serous cystadoma	
		Other:	parts or septae > 2mm	6) 146 (67.3%) ruptured masses	
		66.9% no prior surgery	CA-125 < 35 No ascites, matted bowel No contraindication to surgery		

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Serur, Emeney, and Byrne,	Geographical location: Brooklyn, NY	Age: Range: 17-80 (Means not given for entire	Symptomatic (n [%]) : NR	1) Mortality: 0/100 (0%; 95% Cl, 0 to 5.44%)	Quality assessment: Size of population from which sample drawn: -
2001	Dates: Mar 1996-Nov 1998	group)	Detected by exam (n [%]) : NR	 Morbidity (total all complications): 10/100 (10%; 95% CI, 5.6 to 19.0%) 	Number of cases: + Patient selection: -
#8700	Size of population: 100 (19 converted to	Menopausal status (n [%]): Pre (< 45): 51 (51%)	Detected by imaging (n [%]):	3) Specific complications: NR	Application of reference standard: +
	laparotomy)	Post (> 55): 49 (49%)	NR	 Rate of conversion to laparotomy: 19/100 (19%; 95% CI, 12.8 to 38.6%) 	
	Single center	Race/ethnicity (n [%]): NR	Combination (n [%]): NR		
	Morbidity definitions: -Pneumothorax -Wound infection -Fever	Risk factors (n [%]): NR	Additional data used for diagnosis: NR		
	-Enterotomy -Pneumonia	Loss to followup: 1/100 (1%)			
	Length of followup after surgery: Variable: 6 weeks for all				
	All masses except patients with complex masses, ascites, and "elevated" CA-125				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Shalev, Eliyahu, Peleg, et al.,	Geographical location: Afula, Israel	Age: NR	Symptomatic (n [%]) : NR	1) Mortality: 0/55 (95% CI, 0 to 9.6%)	Comments: Preoperative history not reported
#10140	Dates: May 1988-June 1993	Menopausal status (n [%]): Post (> 55): 204 (100%)	Detected by exam (n [%]): NR	2) Morbidity (total all complications): 6/55 (10.9%; 95% CI, 5.2 to 22.9%)	Quality assessment: Size of population from which sample drawn: -
	Size of population: 204; 55 underwent laparoscopy	Race/ethnicity (n [%]): NR	Detected by imaging (n [%]): NR	 3) Specific complications: "Fever or pain" – not specified further 4) Data of conversion to longestations. 	Number of cases: - Patient selection: + Application of reference standard: -
	Single center Morbidity definitions:	Risk factors (n [%]): NR	Combination (n [%]): NR	4) Rate of conversion to laparotomy: 0/55 (95% Cl, 0 to 9.6%)	
	-Fever -Pain (prolonged hospitalization)	Loss to followup: NR	Additional data used for diagnosis: Inclusion: Simple or septate unilateral mass, CA-125 < 35		
	Length of followup after surgery: NR				
Somigliana, Ragni,	Geographical location: Milan, Italy	Age: Mean (SD): 32.2 (3.7)	Symptomatic (n [%]): NR	1) Mortality: NR	Quality assessment: Size of population from which
Benedetti, et al., 2003 #8140	Dates: Jan 2001-Dec 2002	Menopausal status (n [%]): Pre (< 45): 32 (100%)	Detected by exam (n [%]): NR	2) Morbidity (total all complications): Number of follicles after stimulation significantly lower in ovary where cyst removed (2.0 ± 1.5) compared to other	sample drawn: - Number of cases: - Patient selection: + Application of reference standard: -
<i>n</i> 0140	Size of population: 32	Race/ethnicity (n [%]):	Detected by imaging (n [%]): NR	ovary (4.2 ± 2.5) 3) Specific complications: NR	
	Single center				
	Morbidity definitions: Number of follicles in	Risk factors (n [%]): NR	Combination (n [%]): NR	4) Rate of conversion to laparotomy: NR	
	response to ovarian stimulation after removal of endometriotic cyst	Loss to followup: NR	Additional data used for diagnosis: NR		
	Length of followup after surgery: Mean 2.4 (± 1.7) years				

Study	Study Design	Patients	Clinical Presentation	Results Comments/Quality Scoring
Tangjit- gamol,	Geographical location: Bangkok, Thailand	Mean (SD): 45.9 (17.1)	Symptomatic (n [%]): NR	1) Mortality: NR Comments: Presurgical history not reported
Jesadapa- trakul,	Dates: Jan 1992-Dec	Range: 13-89	Detected by exam (n [%]):	 Morbidity (total all complications): Quality assessment:
Manusiri- vithaya, et	2002	Menopausal status (n [%]):	NR	"Defer" or greater = positive test, borderline = malignant Size of population from which sample drawn: +
al., 2004	Size of population:	NR	Detected by imaging	Number of cases: +
	212		(n [%]):	Dis+ Dis- Tot Patient selection: +
#1570		Race/ethnicity (n [%]):	NR	T+ 84 8 92 Application of reference standard: +
	Single center	NR		T- 8 112 120
	Morbidity definitions:	Risk factors (n [%]):	Combination (n [%]): NR	Tot 92 120 212
	Sensitivity/specificity of	NR		Lower Upper
	frozen section		Additional data used for	Value 95% CI 95% CI
		Loss to followup:	diagnosis:	Se 91.3% 85.5% 97.1%
	Length of followup	NA	NR	Sp 93.3% 88.9% 97.8%
	after surgery:			PPV 91.3% 85.5% 97.1%
	NR			NPV 93.3% 88.9% 97.8%
				"Defer" or greater = positive test, borderline = benign
				Dis+ Dis- Tot T+ 66 9 75 T- 10 127 137 Tot 76 136 212

Lower

95% CI

79.2%

89.2%

80.6%

88.3%

4) Rate of conversion to laparotomy: NR

Value

86.8%

93.4%

92.7%

3) Specific complications: NR

PPV 88.0%

Se Sp

NPV

Upper

95% CI

94.4%

97.6%

95.4%

97.1%

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Tarik and Fehmi, 2004	Geographical location: Ankara, Turkey	Mean (SD):	Symptomatic (n [%]): NR	1) Mortality: 0/3572 (95% CI, 0 to 0.13%)	Comments: Proportion with pre-op diagnosis of
#7770	Dates: 1996-2003	Diagnostic: 27.2 (4.6) Minor: 30.3 (3.2)	Detected by exam (n [%]): NR	2) Morbidity (total all complications): Diagnostic: 7/386 (1.8%; 95% CI, 0.8 to	adnexal mass not reported No malignancies Preprocedure history not reported
	Size of population:	Menopausal status		3.8%)	
	3572 (386 diagnostic laparoscopy, 1092 minor	(n [%]): NR	Detected by imaging (n [%]):	Minor: 15/1092 (1.4%; 0.8 to 2.3%)	Quality assessment: Size of population from which
	procedures)	Race/ethnicity (n [%]):	NR	 Specific complications: Vascular injury: 	sample drawn: + Number of cases: +
	Single center	NR	Combination (n [%]): NR	Diagnostic: 4/386 (1.0%; 95% CI, 0.3 to 2.8%)	Patient selection: - Application of reference standard: +
	Morbidity definitions:	Risk factors (n [%]):		Minor: 5/1092 (0.5%; 0.2 to 1.1%)	
	-Vascular injury -Urinary tract injury	NR	Additional data used for diagnosis:	Bowel injury:	
	-Bowel injury -Postoperative	Loss to followup: NR	NR	Diagnostic: 2/386 (0.5%; 0.03 to 2.0%) Minor:	
	complications			4) Rate of conversion to laparotomy: NR	
	Length of followup after surgery: NR				
van Herendael, Beretta,	Geographical location: Antwerp, Belgium and Varese, Italy	Age: Mean: 36 Range: 18-63	Symptomatic (n [%]) : NR	1) Mortality: 0/121 (95% CI, 0 to 4.5%)	Comments: Preoperative history not reported in detail
Slangen, et al., 1995	Dates: Jan 1989-Dec	Menopausal status	Detected by exam (n [%]) : NR	2) Morbidity (total all complications): 2/121 (1.7%; 95% CI, 0.1 to 6.4%)	Quality assessment:
#9830	1993	(n [%]) : NR	Detected by imaging	3) Specific complications:	Size of population from which sample drawn: -
	Size of population: 121	Race/ethnicity (n [%]):	(n [%]): NR	Anemia (no transfusion): 2/121 (1.7%; 95% CI, 0.1 to 6.4%)	Number of cases: - Patient selection: +
	Single center Two centers	NR Risk factors (n [%]):	Combination (n [%]): NR	4) Rate of conversion to laparotomy: 3/121 (2.5%; 95% CI, 0.6 to 7.5%)	Application of reference standard: +
	Marhidity definitions.	NR	Additional data waad far		
	Morbidity definitions: -Conversion -Anemia	Loss to followup: NR	Additional data used for diagnosis: NR		
	Length of followup after surgery: Median 20 months (range 1-60 months)				

Study	Study Design	Patients	Clinical Presentation	Results	Comments/Quality Scoring
Yuen, Yu, Yip, et al., 1997 #6930	Geographical location: Hong Kong Dates: Jul 1994-Sep 1995 Size of population: 110 Single center Morbidity definitions: -Complications -Cyst rupture rate Length of followup after surgery: 8 weeks	Age: Mean (SD): Laparotomy: 34.7 (8.8) Laparoscopy: 35.1 (10.3) Menopausal status (n [%]): Laparotomy Pre (< 45): 47 (94%) Post (> 55): 3 (6%) Laparoscopy Pre (< 45): 50 (96.2%) Post (> 55): 2 (3.8%) Race/ethnicity (n [%]): NR; presumably most Asian Risk factors (n [%]): NR Loss to followup: 4/110 (3.6%)	Symptomatic (n [%]): Laparotomy: 32 (64%) Laparoscopy: 28 (54%) Detected by exam (n [%]): Asymptomatic: Laparotomy 18 (36%) Laparoscopy 24 (46.1%) Detected by imaging (n [%]): NR Combination (n [%]): NR Additional data used for diagnosis: Cystic masses with no irregular solid parts, thick septae, ascites; except dermoid	 Mortality: Laparotomy: 0/50 (95% Cl, 0 to 10.6%) Laparoscopy: 0/52 (0 to 10.2%) Morbidity (total all complications): Total: Laparotomy: 14/50 (28%; 95% Cl, 18.5 to 43.1%) Laparoscopy: 4/52 (9.6%; 4.2 to 21.8%) Intraoperative Laparotomy: 1/50 (2.0%; 0 to 12.0%) Laparoscopy: 1/52 (1.9%; 0 to 11.6%) Postoperative: Laparotomy: 13/50 (26%; 16.8 to 41.0%) Laparoscopy 4/52 (7.8%; 2.9 to 19.3%) Specific complications: Laparotomy: Bladder injury: 1/50 Febrile morbidity: 10/50 UTI: 5/50 Urinary retention: 4/50 Wound infection: 1/50 Laparoscopy: Inf epigastric artery injury: 1/52 Febrile morbidity: 3/52 UTI: 2/52 Rate of conversion to laparotomy: 0/52 Cyst rupture rate Lapartomy: 9/30 (30%; 95% Cl, 18.4 to 50.3%) Laparoscopy: 9/33 (27.3%; 16.5 to 46.4%) 	Comments: Well-defined complications Size of population from which sample drawn: - Number of cases: + (a priori sample size calculation) Patient selection: + Application of reference standard: +

Evidence Table 7: Question 7: What are the estimated trade-offs resulting from various strategies for evaluation of the adnexal mass?

Study	Study Design	Study Outcomes	Sources for Model Probabilities	Sources for Model Outcomes	Results	Comments
Schapira, Matchar, and Young, 1993 #4870	Type of model: Decision tree Population modeled (age, range): Cohort of healthy 40- year old women. Life expectancy based on average life expectancy in the US for a 40-year old woman. Strategies compared: No screening to screening using CA 125 and TVS in combination	Life-expectancy No costs included	No data used for transition probabilities. One time screen assumed. Used NCI data to determine prevalence of disease in 40 year old population. Adjusted for % that would present with symptoms. National Halothane study used for estimate of laparotomy mortality Simplifying assumptions: Assume that survival time for early disease detected by screening or clinical symptoms is equivalent Morbidity and mortality rates for diagnostic laparotomy are the same for pts with and without the disease No benefit from identifying benign disease One-time screen	expectancy. 1988 NCHS figures used to estimate average life expectancy. Note European citations 31 and 32 for life expectancy for those with early and late stage cancer.	 CA125+TVS – 40.192 years No Screen – 40.191 years No screening preferred if post- operative mortality rate > 7.32% or specificity of the test is 98.35% Findings similar although LE gains not as great for women aged 65+. Specificity of test ≥ 99.25% in order for screening to be favored. 	Progression of ovarian cancer assumed to proceed in stepwise fashion through stages

Study	Study Design	Study Outcomes	Sources for Model Probabilities	Sources for Model Outcomes	Results	Comments
	Type of model: Stochastic simulation model Population modeled: (age, range): Age 50 to 75 Strategies compared: CA-125 screening	Years of life saved (undiscounted)	Assumes o log-normal distribution for each stage o correlation between duration of adjacent stages is high, lower for stages far apart o coefficient of variation constant across all stages Estimates and ranges for duration of stage obtained from 2 gynecologic oncologists Stage II: 9 months Stage III: 12 months	competing cause of death	Based on "best" estimates of mean duration and variation of duration, 3.4 ± 1 year of life saved per case by annual screening; range of 1-5 years Overall increase in life expectancy (cases and noncases) not reported Results sensitive to assumptions about duration of early stage cancer, frequency of screening	Model assumes stepwise progression through disease stage ("all tumors are assumed to pass through all four stages if there is no intervention" Source of estimates for natural history parameters obtained from only 2 gynecologic oncologists (no discussed in article, only evident from reference 11 (personal communications) Assumption regarding duration of disease and likelihood of detection doesn't necessarily reflect biology disease Model output of stage distribution in unscreened population not reported.

Study	Study Design	Study Outcomes	Probabilities	Sources for Model Outcomes	Results	Comments
			stage as clinically detected cases			
			Survival independent of age			
Tengs, Winer, Paddock, et al., 1998 #6010	Type of model: Markov model Population modeled (age, range): 30-year old woman testing for BRCA 1 and 2 Strategies compared: Testing for BRCA 1 and 2 with the following surgical options: Do nothing Mastectomy Mastectomy and oophorectomy Oophorectomy	Life years saved quality adjusted life years saved No costs included	Test accuracy provided by survey of companies marketing the tests SEER data for incidence – adjusted to account for the fact that data does not distinguish between those with genetic risk and those without. Literature used to estimate 92% risk reduction for breast cancer. Cancer experts for effectiveness of oophorectomy w/wout mastectomy Simplifying assumptions: "Operative mortality not included in the model as it would not havean appreciable effect."	survival	 Immediate mastectomy + oophorectomy offers greatest gains in survival when measured using LE Testing offers no benefit. Optimal intervention depends on pre-test probability of carrying mutation. When QALYs incorporated, depends on the test characteristics. If test is perfectly sens and spec then maximizes QALYs. If not perfectly sens and spec, then depends again on pre- test probability of mutation. 	Only considers prophylactic oophorectomy in setting of positive BRCA1/2 test; testing for early stage disease not considered Natural history of ovarian cancer not explicitly modeled

Study	Study Design	Study Outcomes	Sources for Model Probabilities	Sources for Model Outcomes	Results	Comments
Urban, Drescher, Etzioni and Colby 1997 #6140	Type of model: Stochastic simulation model Population modeled: (age, range): Age 50 to 80 Strategies compared: TVS and CA-125	Years of life saved	Age and stage based on SEER data Length of Stage 1 assumed to be independent of stage of disease at clinical diagnosis; Model assumes disease stages that correspond to FIGO staging with durations that are distributed log-normally with geometric means of 9, 4.5 12 and 3 months respectively, Stage 2 – $\frac{1}{2}$ of Stage I; Stage 3, 1.333 times the length of Stage I; Stage 4, .333 times the length of Stage 1. Used data from Skates and Singer to model natural history 0.001 probability of death each time laparotomy is performed.	Costs are based on a survey of labs, hospital clinics, and physician offices in Seattle, WA Note: used a 5% discount rate for the analysis	Multimodal strategy using CA 125 with a threshold for positivity of either elevation above 35U/ml or doubling since the previous screen, followed by TVS only if CA 125 is positive was found to be efficient. (Cost/year of life saved is \$64,000) Effectiveness and cost-effectiveness sensitive to assumptions about the behavior of early stage disease	Model assumes stepwise progression through disease stages; assumption based on opinion of clinicians (Skates and Singer 1991, above)

Abbreviations used in the Evidence Tables

2D	Two-dimensional				
3D	Three-dimensional				
AFP	Alpha-fetoprotein				
AHRQ	Agency for Healthcare Research and Quality				
AUC	Area under the curve				
BME	Bimanual examination				
BMI	Body mass index				
CA-19-9	Cancer antigen 19-9				
CA-72-4	Cancer antigen 72-4				
CA-125	Cancer antigen 125				
CEA	Carcinoembryonic antigen				
CI	Confidence interval				
CPP	Chronic pelvic pain				
CT	Computed tomography				
F-FDG	18-Fluorodeoxyglucose				
FNA	Fine needle aspiration				
FSH	Follicle-stimulating hormone				
GI	Gastrointestinal				
hCG	Human chorionic gonadotropin				
ICD-9	International Classification of Diseases, Ninth Revision				
LDH	Lactate dehydrogenase				
LMP	Low malignant potential				
MRI	Magnetic resonance imaging				
NIS	Nationwide Inpatient Sample				
NA	Not applicable				
NPV	Negative predictive value				
NR	Not reported				
OR	Odds ratio				
PE	Pelvic examination				
PET	Positron emission tomography				
PI	Pulsatility index				
PID	Pelvic inflammatory disease				
PPS	Papillary projection score				
PPV	Positive predictive value				
PSV	Peak systolic velocity				
RI	Resistance index				
RMI	Risk of Malignancy Index				
ROC	Receiver operating characteristic				
SD	Standard deviation				
Se	Sensitivity				
SEM	Standard error of the mean				
Sp	Specificity				
TAG-72	Tumor-associated glycoprotein 72				
TAMXV	Time-averaged maximum velocity				
	The averaged maximum versery				

TATI	Tumor-associated trypsin inhibitor
TVUS	Transvaginal ultrasound
US	Ultrasound
UTI	Urinary tract infection

References Cited in the Evidence Tables

Adonakis GL, Paraskevaidis E, Tsiga S, et al. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol 1996;65(2):221-5.

Alcazar JL, Castillo G. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Am J Obstet Gynecol 2005;192(3):807-12.

Alcazar JL, Errasti T, Zornoza A, et al. Transvaginal color Doppler ultrasonography and CA-125 in suspicious adnexal masses. Int J Gynaecol Obstet 1999;66(3):255-61.

Alcazar JL, Galan MJ, Garcia-Manero M, et al. Threedimensional sonographic morphologic assessment in complex adnexal masses: preliminary experience. J Ultrasound Med 2003;22(3):249-54.

Alcazar JL, Lopez-Garcia G. Transvaginal color Doppler assessment of venous flow in adnexal masses. Ultrasound Obstet Gynecol 2001;17(5):434-8.

Alcazar JL, Merce LT, Laparte C, et al. A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstet Gynecol 2003;188(3):685-92.

Anandakumar C, Chew S, Wong YC, et al. Role of transvaginal ultrasound color flow imaging and Doppler waveform analysis in differentiating between benign and malignant ovarian tumors. Ultrasound Obstet Gynecol 1996;7:280-4.

Andersen ES, Knudsen A, Rix P, et al. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol 2003;90(1):109-12.

Andolf E, Jorgensen C, Astedt B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol 1990;75(1):106-9.

Antonic J, Rakar S. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Anticancer Res 1995;15:1527-32.

Asif N, Sattar A, Dawood MM, et al. Pre-operative evaluation of ovarian mass: risk of malignancy index. J Coll Physicians Surg Pak 2004;14(3):128-31.

Aslam N, Banerjee S, Carr JV, et al. Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer. Obstet Gynecol 2000;96(1):75-80.

Aslam N, Tailor A, Lawton F, et al. Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG 2000;107(11):1347-53.

Balbi GC, Musone R, Menditto A, et al. Women with a pelvic mass: indicators of malignancy. Eur J Gynaecol Oncol 2001;22(6):459-62.

Benjapibal M, Sunsaneevitayakul P, Boriboonhirunsarn D, et al. Color Doppler ultrasonography for prediction of malignant ovarian tumors. J Med Assoc Thai 2002;85(6):709-15.

Benjapibal M, Sunsaneevitayakul P, Phatihattakorn C, et al. Sonographic morphological pattern in the pre-operative prediction of ovarian masses. J Med Assoc Thai 2003;86(4):332-7.

Berlanda N, Ferrari MM, Mezzopane R, et al. Impact of a multiparameter, ultrasound-based triage on surgical management of adnexal masses. Ultrasound Obstet Gynecol 2002;20(2):181-5.

Biagiotti R, Desii C, Vanzi E, et al. Predicting ovarian malignancy: application of artificial neural networks to transvaginal and color Doppler flow US. Radiology 1999;210(2):399-403.

Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol 1994;83(3):434-7.

Brown DL, Doubilet PM, Miller FH, et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 1998;208(1):103-10.

Buckshee K, Temsu I, Bhatla N, et al. Pelvic examination, transvaginal ultrasound and transvaginal color Doppler sonography as predictors of ovarian cancer. Int J Gynaecol Obstet 1998;61(1):51-7.

Buist MR, Golding RP, Burger CW, et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 1994;52(2):191-8.

Buy JN, Ghossain MA, Hugol D, et al. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. AJR Am J Roentgenol 1996;166(2):385-93.

Canis M, Mage G, Pouly JL, et al. Laparoscopic diagnosis of adnexal cystic masses: a 12-year experience with long-term follow-up. Obstet Gynecol 1994;83(5 Pt 1):707-12.

Canis M, Mashiach R, Wattiez A, et al. Frozen section in laparoscopic management of macroscopically suspicious ovarian masses. J Am Assoc Gynecol Laparosc 2004;11(3):365-9.

Canis M, Pouly JL, Wattiez A, et al. Laparoscopic management of adnexal masses suspicious at ultrasound. Obstet Gynecol 1997;89(5 Pt 1):679-83.

Carley ME, Klingele CJ, Gebhart JB, et al. Laparoscopy versus laparotomy in the management of benign unilateral adnexal masses. J Am Assoc Gynecol Laparosc 2002;9(3):321-6.

Carter JR, Lau M, Fowler JM, et al. Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. Am J Obstet Gynecol 1995;172(3):901-7.

Carter PG, Iles RK, Neven P, et al. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses. Gynecol Oncol 1993;51(3):368-71.

Caruso A, Caforio L, Testa AC, et al. Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol 1996;63(2):184-91.

Castillo G, Alcazar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004;92(3):965-9.

Chalas E, Welshinger M, Engellener W, et al. The clinical significance of thrombocytosis in women presenting with a pelvic mass. Am J Obstet Gynecol 1992;166(3):974-7.

Chapron C, Dubuisson JB, Capella-Allouc S. Salpingooophorectomy for adnexal masses. Place and results for operative laparoscopy. Eur J Obstet Gynecol Reprod Biol 1997;73(1):43-8.

Chen DX, Schwartz PE, Li FQ. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990;75(4):701-4.

Chen DX, Schwartz PE, Li XG, et al. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72(1):23-7.

Chi DS, Abu-Rustum NR, Sonoda Y, et al. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol 2004;191(4):1138-45.

Childers JM, Nasseri A, Surwit EA. Laparoscopic management of suspicious adnexal masses. Am J Obstet Gynecol 1996;175(6):1451-7; discussion 1457-9. Chou CY, Chang CH, Yao BL, et al. Color Doppler ultrasonography and serum CA 125 in the differentiation of benign and malignant ovarian tumors. J Clin Ultrasound 1994;22:491-6.

Cohen LS, Escobar PF, Scharm C, et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001;82(1):40-8.

Davies AP, Jacobs I, Woolas R, et al. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993;100(10):927-31.

Deckardt R, Saks M, Graeff H. Comparison of minimally invasive surgery and laparotomy in the treatment of adnexal masses. J Am Assoc Gynecol Laparosc 1994;1(4 Pt 1):333-8.

DePriest PD, Gallion HH, Pavlik EJ, et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997;65(3):408-14.

DePriest PD, Shenson D, Fried A, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51(1):7-11.

DePriest PD, van Nagell JR Jr, Gallion HH, et al. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol 1993;51(2):205-9.

DePriest PD, Varner E, Powell J. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol Oncol 1994;55:174-8.

Dottino PR, Levine DA, Ripley DL, et al. Laparoscopic management of adnexal masses in premenopausal and postmenopausal women. Obstet Gynecol 1999;93(2):223-8.

Dowd JR, Quinn MA, Rome R, et al. Women with a pelvic mass--when to perform an ultrasound. Aust N Z J Obstet Gynaecol 1993;33(4):404-7.

Einhorn N, Bast RC Jr, Knapp RC, et al. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986;67(3):414-6.

Ekerhovd E, Wienerroith H, Staudach A, et al. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol. 2001;184(2):48-54.

Fanfani F, Fagotti A, Ercoli A, et al. A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum Reprod 2004;19(10):2367-71.

Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002;223(3):780-8.

Ferdeghini M, Gadducci A, Prontera C, et al. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. Tumour Biol 1993;14(5):303-9.

Ferrazzi E, Zanetta G, Dordoni D, et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study.[erratum appears in Ultrasound Obstet Gynecol 1998 Jan;11(1):v Note: Lissoni G[corrected to Lissoni AA]]. Ultrasound Obstet Gynecol 1997;10(3):192-7.

Finkler NJ, Benacerraf B, Lavin PT, et al. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72(4):659-64.

Fleischer AC, Cullinan JA, Jones HW 3rd, et al. Correlation of histomorphology of ovarian masses with color Doppler sonography. Ultrasound Med Biol 1996;22(5):555-9.

Fleischer AC, Rodgers WH, Kepple DM, et al. Color Doppler sonography of benign and malignant ovarian masses. Radiographics 1992;12(5):879-85.

Franchi M, Beretta P, Ghezzi F, et al. Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography. Acta Obstet Gynecol Scand 1995;74(9):734-9.

Gadducci A, Baicchi U, Marrai R, et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996;60(2):197-202.

Gadducci A, Capriello P, Bartolini T, et al. The association of ultrasonography and CA-125 test in the preoperative evaluation of ovarian carcinoma. Eur J Gynaecol Oncol 1988;9(5):373-6.

Gadducci A, Ferdeghini M, Prontera C, et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992;44(2):147-54.

Gadducci A, Ferdeghini M, Rispoli G, et al. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest Suppl 1991;207(19-24).

Goldstein SR, Subramanyam B, Snyder JR, et al. The postmenopausal cystic adnexal mass: the potential role of ultrasound in conservative management. Obstet Gynecol 1989;73(1):8-10. Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77(3):454-9.

Granberg S, Norstrom A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990;37(2):224-9.

Granberg S, Norstrom A, Wikland M. Comparison ofendovaginal ultrasound and cytological evaluation of cystic ovarian tumors. J Ultrasound Med 1991;10:9-14.

Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test. Med J Aust 1995;162(8):408-10.

Guerriero S, Ajossa S, Garau N, et al. Ultrasonography and color Doppler-based triage for adnexal masses to provide the most appropriate surgical approach. Am J Obstet Gynecol 2005;192(2):401-6.

Guerriero S, Ajossa S, Risalvato A, et al. Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses. Ultrasound Obstet Gynecol 1998;11(4):277-82.

Guerriero S, Alcazar JL, Coccia ME, et al. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a multicenter European study. J Ultrasound Med 2002;21(10):1105-11.

Hata K, Hata T, Kitao M. Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy. Am J Obstet Gynecol 1995;172:1496-500.

Hata K, Hata T, Manabe A, et al. A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol 1992;80(6):922-6.

Havrilesky LJ, Peterson BL, Dryden DK, et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol 2003;102(2):243-51.

Herrmann UJ Jr, Locher GW, Goldhirsch A. Sonographic patterns of ovarian tumors: prediction of malignancy. Obstet Gynecol 1987;69(5):777-81.

Hidlebaugh DA, Vulgaropulos S, Orr RK. Treating adnexal masses. Operative laparoscopy vs. laparotomy. J Reprod Med 1997;42(9):551-8.

Hillaby K, Aslam N, Salim R, et al. The value of detection of normal ovarian tissue (the 'ovarian crescent sign') in the differential diagnosis of adnexal masses. Ultrasound Obstet Gynecol 2004;23(1):63-7. Hogdall EV, Hogdall CK, Tingulstad S, et al. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 2000;89(6):519-23.

Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging--multivariate analysis. Radiology 2000;214(1):39-46.

Huber S, Medl M, Baumann L, et al. Value of ultrasound and magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res 2002;22(4):2501-7.

Hurteau JA, Woolas RP, Jacobs IJ, et al. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 1995;76(9):1615-20.

Inoue M, Fujita M, Nakazawa A, et al. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol 1992;79(3):434-40.

Itakura T, Kikkawa F, Kajiyama H, et al. Doppler flow and arterial location in ovarian tumors. Int J Gynaecol Obstet 2003;83(3):277-83.

Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97(10):922-9.

Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988;1(8580):268-71.

Jain KA. Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings. Radiology 1994;191(1):63-7.

Jain KA, Friedman DL, Pettinger TW, et al. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. Radiology 1993;186(3):697-704.

Juhasz B, Kurjak A, Lampe L, et al. Tissue characterization by transvaginal colour doppler for the evaluation of gynaecological tumours. Acta Med Hung 1990;47:149-56.

Kawahara K, Yoshida Y, Kurokawa T, et al. Evaluation of positron emission tomography with tracer 18fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr 2004;28(4):505-16.

Kawai M, Kikkawa F, Ishikawa H. Differential diagnosis of ovarian tumors by transvaginal color -pulse Doppler sonography. Gynecol Oncol 1994;54:209-14.

Komatsu T, Konishi I, Mandai M, et al. Adnexal masses: transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure. Radiology 1996;198(1):109-15.

Kurjak A, Kupesic S. Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. Croat Med J 1999;40(3):413-20.

Kurjak A, Kupesic S, Sparac V, et al. Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet Gynecol 2000;16(4):365-71.

Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med 1992;11(12):631-8.

Kurjak A, Schulman H, Sosic A, et al. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol 1992;80(6):917-21.

Kurjak A, Shalan H, Kupesic S, et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994;13(4):295-301.

Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991;10(6):295-7.

Kurtz AB, Tsimikas JV, Tempany CM, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group. Radiology 1999;212(1):19-27.

Leeners B, Schild RL, Funk A, et al. Colour Doppler sonography improves the pre-operative diagnosis of ovarian tumours made using conventional transvaginal sonography. Eur J Obstet Gynecol Reprod Biol 1996;64(1):79-85.

Lerner JP, Timor-Tritsch IE, Federman A, et al. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170(1 Pt 1):81-5.

Levine D, Gosink BB, Wolf SI, et al. Simple adnexal cysts: the natural history in postmenopausal women.[see comment]. Radiology 1992;184(3):653-9.

Lin JY, Angel C, DuBeshter B, et al. Diagnoses after laparotomy for a mass in the pelvic area in women. Surg Gynecol Obstet 1993;176(4):333-8. Lin P, Wu C, Lee C, et al. Color Doppler Ultrasound in the Assessment of Ovarian Neoplasms. J Med Ultrasound 1993;1(4):172-6.

Lok IH, Sahota DS, Rogers MS, et al. Complications of laparoscopic surgery for benign ovarian cysts. J Am Assoc Gynecol Laparosc 2000;7(4):529-34.

Lu C, Van Gestel T, Suykens JA, et al. Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines. Artif Intell Med 2003;28(3):281-306.

Luxman D, Bergman A, Sagi J, et al. The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet Gynecol 1991;77(5):726-8.

Ma S, Shen K, Lang J. A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chin Med J 2003;116(3):396-9.

Maggino T, Gadducci A, D'Addario V, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54(2):117-23.

Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159(2):341-6.

Maly Z, Riss P, Deutinger J. Localization of blood vessels and qualitative assessment of blood flow in ovarian tumors. Obstet Gynecol 1995;85(1):33-6.

Mancuso A, De Vivo A, Triolo O, et al. The role of transvaginal ultrasonography and serum CA 125 assay combined with age and hormonal state in the differential diagnosis of pelvic masses. Eur J Gynaecol Oncol 2004;25(2):207-10.

Manjunath AP, Pratapkumar, Sujatha K, et al. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001;81(2):225-9.

Mann WJ, Reich H. Laparoscopic adnexectomy in postmenopausal women. J Reprod Med 1992;37(3):254-6.

Marana R, Muzii L, Catalano GF, et al. Laparoscopic excision of adnexal masses. J Am Assoc Gynecol Laparosc 2004;11(2):162-6.

Marchetti M, Zambon A, Lamaina V, et al. Ultrasound as a possible screening method in ovarian cancer.[erratum appears in Eur J Gynaecol Oncol. 2002;23(3):172 Note: Marchioro S [corrected to Marchiori S]]. Eur J Gynaecol Oncol 2002;23(2):123-6.

Marret H, Sauget S, Giraudeau B, et al. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med. 2004;23(12):1629-39; quiz 1641-42.

Matthes AC, Moreira de Andrade JM, Bighetti S. Selection of criteria for the treatment of ovarian cysts on the bases of ultrasound and cytology. Gynecol Obstet Invest 1996;42:244-8.

McIntosh MW, Drescher C, Karlan B, et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian cancer. Gynecol Oncol 2004;95:9-15.

Medl M, Kulenkampff KJ, Stiskal M, et al. Magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res 1995;15(3):1123-5.

Menon U, Talaat A, Rosenthal AN, et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 2000;107(2):165-9.

Merce LT, Caballero RA, Barco MJ, et al. B-mode, uteroovarian and intratumoural transvaginal colour Doppler ultrasonography for differential diagnosis of ovarian tumours. Eur J Obstet Gynecol Reprod Biol 1998;76(1):97-107.

Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003;102(3):594-9.

Mol BW, Boll D, De Kanter M, et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80(2):162-7.

Morgante G, la Marca A, Ditto A, et al. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999;106(6):524-7.

O'Connell GJ, Ryan E, Murphy KJ, et al. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 1987;70(6):930-2.

Obeidat BR, Amarin ZO, Latimer JA, et al. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet 2004;85(3):255-8.

Ong S, Duffy T, Murphy J. Transabdominal ultrasound and its correlation with clinical findings in gynaecology. Ir J Med Sci 1996;165(4):268-70.

Onsrud M, Shabana A, Austgulen R. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumour Biol 1996;17(2):90-6. Padilla LA, Radosevich DM, Milad MP. Accuracy of the pelvic examination in detecting adnexal masses. Obstet Gynecol 2000;96(4):593-8.

Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet 2005;88(1):84-8.

Padungsutt P, Thirapagawong C, Senapad S, et al. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy. Anticancer Res 2000;20(2B):1291-5.

Parker J, Proietto AM. Surgical treatment of adnexal cysts by laparotomy. Int J Gynaecol Obstet 1997;59(3):257-8.

Parker WH, Levine RL, Howard FM, et al. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg 1994;179(6):733-7.

Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988;159(4):873-6.

Prompeler HJ, Madjar H, Sauerbrei W. Classification of adnexal tumors by transvaginal color Doppler. Gynecol Oncol 1996;61(3):354-63.

Pyrgiotis E, Salamalekis E, Loghis C, et al. CA 125 in preoperative evaluation of pelvic masses. Eur J Gynaecol Oncol 1993;14(4):279-82.

Rehn M, Lohmann K, Rempen A. Transvaginal ultrasonography of pelvic masses: evaluation of B-mode technique and Doppler ultrasonography. Am J Obstet Gynecol 1996;175(1):97-104.

Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound 1997;25(5):217-25.

Reuter M, Steffens J., Schuppler U. Critical evaluation of the specificity of MRI and TVUs for differentiation of malignant from benign adnexal lesions. Eur Radiol 1998;8(39-44).

Roman LD, Muderspach LI, Burnett AF, et al. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med 1998;43(5):403-7.

Roman LD, Muderspach LI, Stein SM, et al. Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet Gynecol 1997;89(4):493-500.

Sadik S, Onoglu AS, Gokdeniz R, et al. Laparoscopic management of selected adnexal masses. J Am Assoc Gynecol Laparosc 1999;6(3):313-6.

Salem S, White LM, Lai J. Doppler sonography of adnexal masses: the predictive value of the pulsatility index in benign and malignant disease. AJR Am J Roentgenol 1994;163(5):1147-50.

Sassone AM, Timor-Tritsch IE, Artner A, et al. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78(1):70-6.

Sawicki W, Spiewankiewicz B, Cendrowski K, et al. Preoperative discrimination between malignant and benign adnexal masses with transvaginal ultrasonography and colour blood flow imaging. Eur J Gynaecol Oncol 2001;22(2):137-42.

Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening. A decision analysis model. Ann Intern Med 1993;118(11):838-43.

Schelling M, Braun M, Kuhn W, et al. Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 2000;77(1):78-86.

Schincaglia P, Brondelli L, Cicognani A, et al. A feasibility study of ovarian cancer screening: does fine-needle aspiration improve ultrasound specificity? Tumori 1994;80(3):181-7.

Schneider VL, Schneider A, Reed KL, et al. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses. Obstet Gynecol 1993;81(6):983-8.

Schutter EM, Davelaar EM, van Kamp GJ, et al. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol 2002;187(2):385-92.

Schutter EM, Kenemans P, Sohn C, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994;74(4):1398-406.

Schutter EM, Sohn C, Kristen P, et al. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol 1998;69(1):56-63.

Scoutt LM, McCarthy SM, Lange R, et al. MR evaluation of clinically suspected adnexal masses. J Comput Assist Tomogr 1994;18(4):609-18.

Sengoku K, Satoh T, Saitoh S, et al. Evaluation of transvaginal color Doppler sonography, transvaginal sonography and CA 125 for prediction of ovarian malignancy. Int J Gynaecol Obstet 1994;46(1):39-43.

Serur E, Emeney PL, Byrne DW. Laparoscopic management of adnexal masses. J Soc Laparoendosc Surg 2001;5(2):143-51.

Shabana A, Onsrud M. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma. Tumour Biol 1994;15(6):361-7.

Shalev E, Eliyahu S, Peleg D, et al. Laparoscopic management of adnexal cystic masses in postmenopausal women. Obstet Gynecol 1994;83(4):594-6.

Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol 2002;87(1):77-83.

Siegel BA, Dehdashti F, Mutch DG, et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44(5):700-7.

Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol 1991;44(4-5):365-80.

Smikle CB, Lunt CC, Hankins GD. Clinical predictors in the evaluation of a pelvic mass. Mil Med 1995;160(5):233-5.

Sohaib SA, Mills TD, Sahdev A, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol 2005;60(3):340-8.

Somigliana E, Ragni G, Benedetti F, et al. Does laparoscopic excision of endometriotic ovarian cysts significantly affect ovarian reserve? Insights from IVF cycles. Hum Reprod 2003;18(11):2450-3.

Soper JT, Hunter VJ, Daly L, et al. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 1990;75(2):249-54.

Stein SM, Laifer-Narin S, Johnson MB, et al. Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 1995;164(2):381-6.

Strigini FA, Gadducci A, Del Bravo B, et al. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Gynecol Oncol 1996;61(1):68-72.

Szpurek D, Moszyniki R, Sajdak S. Clinical value of the ultrasound Doppler index in determination of ovarian tumor malignancy. Eur J Gynaecol Oncol 2004;25(4):442-4.

Tailor A, Bourne TH, Campbell S, et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003;21(4):378-85.

Tailor A, Jurkovic D, Bourne TH, et al. Sonographic prediction of malignancy in adnexal masses using an artificial neural network. Br J Obstet Gynaecol 1999;106(1):21-30.

Takac I. Analysis of blood flow in adnexal tumors by using color Doppler imaging and pulsed spectral analysis. Ultrasound Med Biol 1998;24(8):1137-42.

Tangjitgamol S, Jesadapatrakul S, Manusirivithaya S, et al. Accuracy of frozen section in diagnosis of ovarian mass. Int J Gynecol Cancer 2004;14(2):212-9.

Tanir HM, Ozalp S, Yalcin OT, et al. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. Eur J Gynaecol Oncol 2003;24(3-4):271-4.

Tarik A, Fehmi C. Complications of gynaecological laparoscopy--a retrospective analysis of 3572 cases from a single institute. J Obstet Gynaecol 2004;24(7):813-6.

Tay SK, Chua EK. Correlation of serum, urinary and salivary CA 125 levels in patients with adnexal masses. Ann Acad Med Singapore 1994;23(3):311-4.

Tekay A, Jouppila P. Validity of pulsatility and resistance indices in classification of adnexal tumors with transvaginal color doppler ultrasound. Ultrasound Obstet Gynecol 1992;2:338-44.

Tengs TO, Winer EP, Paddock S, et al. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making 1998;18(4):365-75.

Tepper R, Lerner-Geva L, Altaras MM, et al. Transvaginal color flow imaging in the diagnosis of ovarian tumors. J Ultrasound Med 1995;14(10):731-4.

Tian J, Zhang J, Jiao L, et al. A prospective study of Tc-99m MIBI in the differential diagnosis of pelvic masses in female patients. Clin Nucl Med 2000;25(8):614-8.

Timmerman D, Bourne TH, Tailor A, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol 1999;181(1):57-65. Timmerman D, Verrelst H, Bourne TH, et al. Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. Ultrasound Obstet Gynecol 1999;13(1):17-25.

Timor-Tritsch LE, Lerner J, Monteagudo A, et al. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. Am J Obstet Gynecol 1993;168:909-13.

Tingulstad S, Hagen B, Skjeldestad FE, et al. The risk-ofmalignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93(3):448-52.

Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103(8):826-31.

Torres JC, Derchain SF, Faundes A, et al. Risk-ofmalignancy index in preoperative evaluation of clinically restricted ovarian cancer. Rev Paul Med 2002;120(3):72-6.

Troiano RN, Quedens-Case C, Taylor KJ. Correlation of findings on transvaginal sonography with serum CA 125 levels. AJR Am J Roentgenol 1997;168(6):1587-90.

Twickler DM, Forte TB, Santos-Ramos R, et al. The Ovarian Tumor Index predicts risk for malignancy. Cancer 1999;86(11):2280-90.

Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials 1997;18(3):251-70.

Valentin L. Gray scale sonography, subjective evaluation of the color Doppler image and measurement of blood flow velocity for distinguishing benign and malignant tumors of suspected adnexal origin. Eur J Obstet Gynecol Reprod Biol 1997;72(1):63-72.

Valentin L. Pattern recognition of pelvic masses by grayscale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 1999;14(5):338-47.

Valentin L. Comparison of Lerner score, Doppler ultrasound examination, and their combination for discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 2000;15(2):143-7.

Valentin L, Akrawi D. The natural history of adnexal cysts incidentally detected at transvaginal ultrasound examination in postmenopausal women. Ultrasound Obstet Gynecol 2002;20(2):174-80. Valentin L, Hagen B, Tingulstad S, et al. Comparison of 'pattern recognition' and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol 2001;18(4):357-65.

van Herendael B, Beretta P, Slangen T, et al. Management of adnexal masses by operative laparoscopy. J Am Assoc Gynecol Laparosc 1995;2(3):273-7.

van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77(3):350-6.

Vasilev SA, Schlaerth JB, Campeau J, et al. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988;71(5):751-6.

Vuento MH, Pirhonen JP, Makinen JI, et al. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995;76(7):1214-8.

Wakahara F, Kikkawa F, Nawa A, et al. Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors. Gynecol Obstet Invest 2001;52(3):147-52.

Weiner Z, Thaler I, Beck D, et al. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 1992;79(2):159-62.

Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59(1):111-6.

Wu CC, Lee CN, Chen T, et al. Factors contributing to the accuracy in diagnosing ovarian malignancy by color Doppler ultrasound. Obstet Gynecol 1994;84:605-8.

Yamashita Y, Hatanaka Y, Torashima M, et al. Characterization of sonographically indeterminate ovarian tumors with MR imaging. A logistic regression analysis. Acta Radiol 1997;38(4 Pt 1):572-7.

Yamashita Y, Torashima M, Hatanaka Y, et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology 1995;194(2):557-65.

Yuen PM, Yu KM, Yip SK, et al. A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 1997;177(1):109-14.

Zanetta G, Vergani P, Lissoni A. Color Doppler ultrasound in the preoperative assessment of adnexal masses. Acta Obstet Gynecol Scand 1994;73:637-41. Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999;73(1):56-61.

Zimmer Y, Tepper R, Akselrod S. An automatic approach for morphological analysis and malignancy evaluation of ovarian masses using B-scans. Ultrasound Med Biol 2003;29(11):1561-70.

Appendix E: Peer Reviewers

The Duke Evidence-based Practice Center is grateful to the following peer reviewers who read and commented on a draft version of this report:

Susan M. Ascher, MD; Department of Radiology, Georgetown University Hospital; Washington, DC

Andrew Berchuck, MD; Division of Gynecologic Oncology, Duke University Medical Center; Durham, NC

Michael L. Berman; Division of Gynecologic Oncology, UCI Medical Center; Orange, CA

Christie R. Eheman, MD; Centers for Disease Control and Prevention; Atlanta, GA

Barbara Goff, MD; University of Washington School of Medicine; Seattle, WA

Walter Kinney, MD; Department of Obstetrics and Gynecology, The Permanente Medical Group; Sacramento, CA

Ann Kolker; Ovarian Cancer National Alliance; Washington, DC

Herschel Lawson, MD; Center for Disease Control and Prevention; Atlanta, GA

Saralyn Mark, MD; Department of Health and Human Services; Washington, DC

Susan Meikle, MD, MSPH; Agency for Healthcare Research and Quality; Rockville, MD

Valerie McGuire, PhD; Department of Health Research and Policy, Stanford University; Stanford, CA

Edward E. Partridge, MD; Department of Obstetrics and Gynecology, University of Alabama; Birmingham, AL

Mona Saraiya, MD, MPH; Centers for Disease Control and Prevention; Atlanta, GA

George F. Sawaya, MD; Department of Obstetrics and Gynecology, UCSF; San Francisco, CA

Howard T. Sharp, MD; University of Utah Hospitals and Clinics; Salt Lake City, UT

Edward L. Trimble, MD, MPH; National Cancer Institute; Rockville, MD

John R. van Nagell Jr., MD; Department of Obstetrics and Gynecology, University of Kentucky Medical Center; Lexington, Kentucky

Nominations for peer reviewers were solicited from several sources, including the project's technical expert panel and interested federal agencies. The list of nominees was vetted and approved by the Agency for Healthcare Research and Quality (AHRQ).